Karyopharm Therapeutics Inc 8-K, filed Nov 3, 2026
Karyopharm Therapeutics Inc. (KPTI)
About this 8-K
Karyopharm Therapeutics Inc filed this 8-K on November 3, 2026, reporting on events of November 2, 2026.
Karyopharm Therapeutics Inc. and KPT Texas LLC filed Chapter 11 on November 2, 2026, seeking a $110 million DIP facility and an Ayrmid-led restructuring that would cancel existing equity. AI summary
Items reported
- Item 1.01: Entered into a material agreement
- Item 1.03: Bankruptcy or receivership
- Item 2.03: New debt or off-balance-sheet obligation
- Item 2.04: Debt obligation accelerated or increased
- Item 7.01: Regulation FD disclosure
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01. | Entry into a Material Definitive Agreement. |
The information set forth below in Item 1.03 and Item 2.03 of this Current Report on Form 8-K is incorporated herein by reference.
| Item 1.03. | Bankruptcy or Receivership. |
On November 2, 2026 (the “Petition Date”), Karyopharm Therapeutics Inc. (the “Company”) and its subsidiary, KPT Texas LLC (the “Subsidiary” and, together with the Company, the “Debtors”) filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of Texas, Houston Division (such court, the “Court” and such cases, the “Cases”). The Debtors have requested that the Cases be jointly administered under the caption In re Karyopharm Therapeutics Inc., et al. The Debtors will continue to operate their businesses as “debtors-in-possession” under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court. To ensure their ability to continue operating in the ordinary course of business, the Debtors have filed with the Court various “first day” motions requesting customary relief that will enable the Debtors to transition into Chapter 11 and minimize disruption to their ordinary course operations. In addition, the Debtors filed with the Court a motion seeking approval of the DIP Facility (as defined below).
The Debtors entered into a Restructuring Support Agreement (as defined below) with their existing lenders and noteholders holding, in the aggregate, 100% of the aggregate outstanding principal amount of the Company’s funded debt (consisting of the loans under the Credit and Guaranty Agreement (as defined below) and the 2028 Notes (as defined below) and 2029 Notes (as defined below), collectively, the “Funded Debt”) certain of the investors under the Company’s Revenue Interest Financing Agreement (as defined below), certain holders of the Company’s 0% Series A Convertible Perpetual Preferred Stock (the “Convertible Preferred Stock”), and Ayrmid Ltd. (“Ayrmid”), providing for Ayrmid to serve as the stalking horse bidder for a merger between Ayrmid and the reorganized Company (the “Merger”). Additionally, the Debtors filed with the Court a motion seeking approval of certain procedures relating to the marketing and auction (if necessary) of all or some of the Company’s assets, including proposed bidding procedures (the “Bidding Procedures”).
The Company has previously engaged Centerview Partners LLC (“Centerview”) to advise on its strategic options, including the process to sell its assets in connection with the Cases. Any sale would be subject to review and approval by the Court and compliance with the Bidding Procedures. The Company’s objective in the Cases is to maximize value for its stakeholders, which may be achieved through the sale of all or substantially all assets to the highest or otherwise best bidder or bidders, and/or through a reorganization with a Chapter 11 plan sponsor. In accordance with the Bidding Procedures, notice of the proposed Sale Transaction will be given to third parties and competing proposals and bids for the Company’s assets will be solicited, and the Debtors’ management of the process will be overseen by the Court.
Prior to the Petition Date, the Company, with the assistance of Centerview, conducted a marketing process for a sale of, or investment in, the Company. Centerview contacted numerous potential strategic and financial counterparties, several of which entered into confidentiality agreements and conducted due diligence. The process resulted in receipt of five non-binding indications of interest. After evaluating the proposals received, the Company determined, in consultation with its advisors, that the Ayrmid Transaction (as defined below), subject to a court-supervised market test under the Bidding Procedures, represented the best available path to maximize value for its stakeholders.
Chapter 11 Plan and Solicitation
On the Petition Date, the Debtors filed with the Court the proposed Joint Prepackaged Chapter 11 Plan of Reorganization of the Debtors (including all exhibits, attachments, annexes, and supplements thereto, as each may be amended, modified, or supplemented from time to time, the “Prepackaged Plan”) and a related disclosure statement (the “Disclosure Statement”). The Prepackaged Plan provides for the implementation of the Restructuring Transactions (as defined below), including the Merger. Under the Prepackaged Plan, the Company’s existing common stock, the Convertible Preferred Stock and the other existing equity interests in the Company will be cancelled, and the holders thereof will not receive any distribution on account of such shares and interests.
On November 2, 2026, prior to filing the Bankruptcy Petitions and in accordance with the Restructuring Support Agreement, the Debtors commenced solicitation of votes on the Prepackaged Plan with respect to the 1L Term Loan Claims, the 1.5L 2028 Notes Claims, the 2L 2029 Notes Claims and the RIFA Claims (each as defined in the Disclosure Statement) by distributing the Prepackaged Plan, the Disclosure Statement and related solicitation materials to holders of claims in Classes 3-6 (as defined in the Prepackaged Plan) that were entitled to vote on the Prepackaged Plan as of October 27, 2026 (the voting record date). The deadline for voting on the Prepackaged Plan is November 30, 2026. The Debtors have requested that the Court conditionally approve the Disclosure Statement and the solicitation procedures at the first day hearing scheduled for November 3, 2026, and schedule a hearing to consider final approval of the Disclosure Statement and confirmation of the Prepackaged Plan on or about January 11, 2027 (subject to availability of the Court). Confirmation of the Prepackaged Plan is subject to the approval of the Court, and there can be no assurance that the Prepackaged Plan will be confirmed or consummated on the terms or timeline described herein, or at all.
This Current Report on Form 8-K is not a solicitation of votes to accept or reject the Prepackaged Plan or an offer to sell or a solicitation of an offer to buy any securities. Any solicitation or offer will be made only pursuant to the Disclosure Statement and in compliance with applicable law.
Additional information about the Cases, including access to Court documents, is available online at https://cases.stretto.com/KPTI , a website administered by Stretto, Inc., a third-party bankruptcy claims and noticing agent proposed to be retained by the Debtors. The information on this website is not incorporated by reference herein and does not constitute part of this Current Report on Form 8-K.
Restructuring Support Agreement
On November 2, 2026, prior to the filing of the Bankruptcy Petitions, the Debtors entered into a restructuring support agreement (including all exhibits, attachments, annexes, and supplements thereto, as each may be amended, modified, or supplemented from time to time, the “Restructuring Support Agreement”) with certain holders of claims under the Credit and Guaranty Agreement (as defined below) (the “Consenting 1L Lenders”), certain holders of the Company’s 9.00% Convertible Senior Notes due 2028 (the “2028 Notes” and such holders, the “Consenting 2028 Noteholders”), certain holders of the Company’s 9.00% Convertible Senior Notes due 2029 (the “2029 Notes” and such holders, the “Consenting 2029 Noteholders” and, together with the Consenting 1L Lenders and the Consenting 2028 Noteholders, the “Consenting Funded Debt Parties”), certain holders of claims under the Revenue Interest Financing Agreement (as defined below) (the “Consenting Royalty Investors”), certain holders of the Convertible Preferred Stock (the “Consenting Preferred Shareholders” and, together with the Consenting Funded Debt Parties and the Consenting Royalty Investors, the “Consenting Stakeholders”) and Ayrmid.
The Restructuring Support Agreement provides for the restructuring of the Debtors (the “Restructuring Transactions”), to be implemented through the Cases pursuant to the Prepackaged Plan. The Restructuring Support Agreement provides for the Consenting Stakeholders’ and Ayrmid’s support for the Restructuring Transactions which include (i) the DIP Facility (as defined below) and the consensual use of cash collateral, (ii) a merger of the Debtors with Ayrmid or a sale of all or substantially all of the Debtors’ assets to Ayrmid or another party selected pursuant to Bidding Procedures (in each case, a “Sale Transaction”), to be effected through the Prepackaged Plan or, if applicable, pursuant to Section 363 of the Bankruptcy Code, and (iii) the treatment of claims against, and interests in, the Debtors under the Prepackaged Plan, including the cancellation of all existing equity interests in the Company without any distribution.
Ayrmid Transaction
The Restructuring Support Agreement incorporates a term sheet with Ayrmid (the “Ayrmid Term Sheet”) setting forth the principal terms of a proposed Sale Transaction (the “Ayrmid Transaction”), which would be memorialized pursuant to a merger agreement or other agreement (the “Merger Agreement”). Under the Ayrmid Term Sheet, on the effective date of the Prepackaged Plan, holders of claims in respect of the Company’s Funded Debt and the DIP Lenders (as defined below) would receive 100% of the common stock of the reorganized Company, which would be exchanged substantially concurrently for 55% of the common stock of NewCo (as defined in the Ayrmid Term Sheet), with Ayrmid’s existing stockholders receiving the remaining 45% of the common stock of NewCo, subject to certain adjustments. In connection with the Ayrmid Transaction, NewCo (or such other borrower identified in the relevant documentation) and the applicable guarantors will enter into a new senior secured term loan facility in an aggregate principal amount of up to $135 million, the proceeds of which would be used to repay up to $50 million of New Money DIP Loans, with remaining New Money DIP Loans together with any Roll-Up Loans (reconverted into prepetition first lien claims under the Credit and Guaranty Agreement) exchanged for equity in the reorganized Company and thereafter exchanged for common stock of NewCo. The Ayrmid Term Sheet also contemplates that holders of claims in respect of the Company’s Funded Debt would receive contingent value rights entitling them to payments tied to future net sales of XPOVIO® (selinexor) for patients with myelofibrosis.
Ayrmid has been selected as the stalking horse bidder, and the Ayrmid Transaction remains subject to higher or otherwise better bids pursuant to the Bidding Procedures, for which the Debtors have filed a motion seeking the Court’s approval, together with the designation of Ayrmid as the stalking horse bidder and certain bid protections for Ayrmid consisting of (i) a break-up fee equal to 3% of the Bid Protection Base (as defined in the Ayrmid Term Sheet), and (ii) reimbursement of Ayrmid’s reasonable and documented out-of-pocket fees and expenses, subject to an aggregate cap equal to 1% of the Bid Protection Base (collectively, the “Bid Protections”). The Bid Protections would be earned upon the Debtors’ selection of a bidder other than Ayrmid as the successful bidder and entitled to administrative expense priority. As the proposed stalking horse bidder, Ayrmid’s offer would serve as the minimum bid,
and if the Debtors select another bid as the successful bid, Ayrmid has agreed to serve as the back-up bidder and to keep its bid open until the earlier of the consummation of the transaction contemplated by such bid and the date that is 110 days after the Petition Date. The Ayrmid Transaction, and the designation of Ayrmid as the stalking horse bidder are subject to the approval of the Court, and the completion of the Ayrmid Transaction is subject to customary conditions, including the entry of an order of the Court approving the Ayrmid Transaction, the receipt of any required regulatory approvals, the performance by each party of its obligations, and the material accuracy of each party’s representations. Subject to conditions described in the Restructuring Support Agreement (including the Ayrmid Term Sheet) and the Prepackaged Plan, the Ayrmid Transaction is expected to close in the first quarter of 2027.
Ayrmid is majority-owned by funds managed by Highbridge Capital Management, LLC (“Highbridge”). Certain of these funds, together with other funds managed by Highbridge, are Consenting Stakeholders under the Restructuring Support Agreement and hold loans under the Credit and Guaranty Agreement, 2028 Notes and 2029 Notes. In light of that relationship, Highbridge recused itself from deliberations regarding the marketing and sale process and the evaluation of Ayrmid’s proposal, and the terms of the reorganization transaction were negotiated on behalf of the Debtors’ secured creditors by the other members of the ad hoc group and their advisors. The Debtors and their advisors did not share information regarding the marketing and sale process with Highbridge in its capacity as a member of the ad hoc group.
Support Commitments
The Restructuring Support Agreement contains customary representations, warranties, and covenants of the parties. Among other things, each Consenting Stakeholder has agreed, severally, to support the Restructuring Transactions and the DIP Facility, to vote its claims and interests (if entitled to vote) to accept the Prepackaged Plan, and not to support any alternative restructuring proposal unless it provides for payment in full at closing of at least $335.4 million, consisting of at least $316.6 million of cash and $18.75 million in cash or other non-cash consideration acceptable to the Consenting Royalty Investors (a “Qualifying Alternative Transaction”). Accordingly, the Debtors’ ability to pursue an alternative transaction with the support of the Consenting Stakeholders is subject to a substantial minimum cash consideration threshold. Further, under the Bidding Procedures, a bid must be a Qualifying Alternative Transaction and provide for payment of $13.8 million of cash or non-cash consideration relating to unsecured claims as well as payment of the Bid Protections, among other things, resulting in a minimum closing payment of $363.6 million for a bid to be successful. The Debtors have agreed, among other things, to implement the Restructuring Transactions, to pay the fees and expenses of the advisors to an ad hoc group of lenders and noteholders and of the Consenting Royalty Investors, and not to pursue any alternative restructuring proposal other than in accordance with the Bidding Procedures. Ayrmid has agreed, among other things, to use commercially reasonable efforts to consummate the Ayrmid Transaction in accordance with the Ayrmid Term Sheet and the Merger Agreement and to serve as a back-up bidder (if so designated) in the event the Debtors select another bid as the successful bid. The Restructuring Support Agreement does not require the Debtors or their boards of directors to take, or refrain from taking, any action that would be inconsistent with their fiduciary duties or applicable law, and permits the Debtors to consider and respond to alternative proposals, subject to notice obligations. Ayrmid’s consent rights with respect to the Prepackaged Plan and the Disclosure Statement cease upon the Debtors’ delivery of notice of a determination to pursue a Qualifying Alternative Transaction. Ayrmid is not entitled to receive information concerning other bids or bidders.
Milestones
The Restructuring Support Agreement requires the Debtors to satisfy specified milestones (the “Milestones”), including the entry of orders conditionally approving the Disclosure Statement, approving the DIP Facility on an interim basis and approving the Bidding Procedures within three calendar days after the Petition Date; the entry of an order approving the DIP Facility on a final basis within 35 days after the Petition Date; an auction, if necessary, within 60 days after the Petition Date; the entry of orders granting final approval of the Disclosure Statement, approving the Sale Transaction and confirming the Prepackaged Plan within 80 days after the Petition Date; and the occurrence of the effective date of the Prepackaged Plan within 110 days after the Petition Date. The Milestones may be extended or waived by the requisite Consenting Funded Debt Parties, except that certain Milestones may not be extended or waived without the prior written consent of Ayrmid.
Termination
The Restructuring Support Agreement contains customary termination provisions, including rights exercisable by the requisite Consenting Funded Debt Parties, by the Debtors, by the requisite Consenting Royalty Investors, and, solely as to itself, by Ayrmid, upon the occurrence of specified events, including material breach by another party, the denial of confirmation of the Prepackaged Plan, the conversion of the Cases or the appointment of a trustee or examiner, an event of default under the DIP Facility, the termination of or a material default under the Ayrmid Term Sheet or the Merger Agreement, certain Court or case-related events adverse to the terminating party, and the failure to satisfy a Milestone that requires Ayrmid’s consent to waive. The
Debtors may also terminate the Restructuring Support Agreement if the board of directors (or similar governing body) of any Debtor determines that proceeding with the Restructuring Transactions would be inconsistent with its fiduciary duties or applicable law or that it should pursue an alternative restructuring proposal. If the Debtors elect to proceed with a Qualifying Alternative Transaction and Ayrmid is not designated as the back-up bidder, the Debtors may terminate the Restructuring Support Agreement solely as to Ayrmid. The Restructuring Support Agreement terminates automatically upon the effective date of the Prepackaged Plan or the consummation of a Qualifying Alternative Transaction, in each case subject to the provisions that expressly survive termination, including obligations to pay the Bid Protections.
The foregoing description of the Restructuring Support Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Restructuring Support Agreement, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference. The representations, warranties, and covenants set forth in the Restructuring Support Agreement have been made only for purposes of the Restructuring Support Agreement and solely for the benefit of the parties thereto, and may be subject to limitations or qualifications agreed upon by the contracting parties and may not be relied on by any other person.
| Item 2.03. | Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
The Debtors, certain of the lenders under the Credit and Guaranty Agreement (as defined below) or their affiliates or managed or controlled funds (the “DIP Lenders”) and Wilmington Savings Fund Society, FSB (“Wilmington”), as administrative agent and collateral agent (in such capacities, the “DIP Agent”), will enter into a $110 million superpriority senior secured debtor-in-possession term loan facility term sheet (together with all annexes and exhibits thereto, the “DIP Term Sheet”), pursuant to which, and subject to the satisfaction of the applicable conditions precedent contained therein, including the entry by the Court of an interim order authorizing and approving the DIP Facility (as defined below) (the “Interim DIP Order”), the DIP Lenders will commit to provide the Company, as borrower, with a superpriority senior secured debtor-in-possession term loan facility in an aggregate principal amount of up to $110 million (the “DIP Facility”), comprised of (i) up to $55 million of first-out new money term loans (the “New Money DIP Loans”), which, subject to the satisfaction of certain conditions precedent to drawing set forth in the DIP Term Sheet, will be made available to the Debtors as follows: (a) an initial draw of up to $25 million upon entry of the Interim DIP Order and (b) a delayed draw of the remaining New Money DIP Loans upon entry by the Court of a final order authorizing and approving the DIP Facility (the “Final DIP Order”), and (ii) second-out term loans resulting from the conversion, on a cashless basis, of prepetition term loans under the Credit and Guaranty Agreement held by DIP Lenders that fund New Money DIP Loans (the “Roll-Up Loans”), equal to $1.00 of Roll-Up Loans for each $1.00 of New Money DIP Loans funded by the applicable DIP Lender. The Company’s obligations under the DIP Facility are guaranteed by the Subsidiary. The obligations under the DIP Facility will constitute superpriority administrative expense claims and will be secured by priming first-priority liens on substantially all of the Debtors’ assets (including the collateral securing the Credit and Guaranty Agreement, the Indentures and the Revenue Interest Financing Agreement, the liens on which will be primed by the DIP liens, and, subject to entry of the Final DIP Order, the proceeds of avoidance actions), subject to a carve-out and certain permitted prior liens.
The New Money DIP Loans will bear interest at a rate per annum equal to the Secured Overnight Financing Rate (“SOFR”) (subject to a 3.00% floor) plus 9.00%, and the Roll-Up Loans will bear interest at a rate per annum equal to SOFR (subject to a 3.00% floor) plus 12.25%, in each case payable quarterly in kind by capitalizing such interest and adding it to the outstanding principal amount of the applicable loans. The default interest rate under the DIP Facility is 2.00% per annum above the applicable interest rate. The Company will be required to pay an exit fee equal to (i) 4.00% of the aggregate commitments in respect of the New Money DIP Loans and (ii) 8.00% of the Roll-Up Loans, in each case payable upon any repayment or prepayment (including by acceleration) of the New Money DIP Loans or the Roll-Up Loans, respectively (other than, with respect to the Roll-Up Loans, a deemed reconversion of such Roll-Up Loans into allowed Prepetition First Lien Obligations (as defined in the DIP Term Sheet)), or any termination or reduction of the New Money DIP Commitments (other than a termination of New Money DIP Commitments resulting from the funding of New Money DIP Loans).
The DIP Facility matures on the earliest of (i) May 1, 2027, (ii) the effective date of the Prepackaged Plan, (iii) the consummation of a sale of all or substantially all of the Debtors’ assets under Sections 363 or 1129 of the Bankruptcy Code, (iv) the date that all DIP loans become due and payable, and (v) the dismissal of the Cases or their conversion to cases under Chapter 7 of the Bankruptcy Code. The New Money DIP Loans will be senior in right of payment to the Roll-Up Loans, and no obligations under the Indentures (as defined below) or the Revenue Interest Financing Agreement (as defined below) will be converted into the DIP Facility. In connection with the entry of the Final DIP Order, the Debtors, the DIP Agent and the DIP Lenders will enter into a definitive debtor-in-possession credit and guaranty agreement consistent with the DIP Term Sheet. The DIP Facility is expected to include conditions precedent, representations and warranties, affirmative and negative covenants and events of default set forth in the DIP Term Sheet or that are otherwise customary for financings of this type, including covenants requiring compliance with an approved budget (the “DIP Budget”), subject to permitted variances, and the achievement of certain milestones. Subject to the DIP Budget and permitted variances, proceeds of the New Money DIP Loans may be used for the Debtors’ working capital, capital expenditure and general corporate needs, including to fund the costs of the administration of the Cases, the sale process and the consummation of the Restructuring Transactions, and to pay professional fees and expenses.
The Debtors will use the cash collateral of their prepetition secured parties on a consensual basis in accordance with the DIP Budget. As adequate protection for any diminution in value of their interests in the prepetition collateral (including cash collateral) from and after the filing of the Bankruptcy Petitions, the lenders under the Credit and Guaranty Agreement, the holders of the 2028 Notes and the 2029 Notes and the investors under the Revenue Interest Financing Agreement, through their respective agents and trustees, are each expected to receive (i) replacement liens on the collateral securing the DIP Facility, including, upon entry of the Final DIP Order, the proceeds of avoidance actions, provided that the replacement liens granted to the collateral agent under the Revenue Interest Financing Agreement will attach only to such collateral that constitutes, or constitutes proceeds of, the prepetition collateral securing the Revenue Interest Financing Agreement, (ii) superpriority claims under Section 507(b) of the Bankruptcy Code, in each case junior to the liens and superpriority claims securing the DIP Facility and the carve-out and ranking among themselves as set forth in the Interim DIP Order and the Final DIP Order, (iii) current payment of the reasonable and documented fees and expenses of the administrative agent under the Credit and Guaranty Agreement and the advisors to the ad hoc group of lenders and noteholders and of the respective agents, trustees and advisors of the holders of the 2028 Notes and the 2029 Notes and the investors under the Revenue Interest Financing Agreement (subject, in the case of the investors under the Revenue Interest Financing Agreement, to a cap of $600,000) for legal counsel and monthly fees of $150,000 for the investment banker of such investors accruing from the Petition Date until the closing of the Ayrmid Transaction or a Qualifying Alternative Transaction and, solely upon consummation of a Qualifying Alternative Transaction, a deferred fee of $1 million (or $0.5 million if the transaction proceeds are insufficient to pay the Funded Debt in full in cash), in each case as it relates to the Cases, and (iv) financial and other reporting. Except as expressly set forth in the Interim DIP Order or the Final DIP Order, no prepetition secured party will receive or retain any payment on account of its Section 507(b) claims until the obligations under the DIP Facility have been paid in full in cash. Once approved by the Court, the DIP Facility, combined with cash generated from the Company’s ongoing operations, is expected to support the Company’s go-forward business during the Chapter 11 process and to meet its financial obligations arising subsequent to the Petition Date.
The foregoing description of the DIP Term Sheet does not purport to be complete and is qualified in its entirety by reference to the DIP Term Sheet, a copy of which is filed as Exhibit 10.2 hereto and incorporated by reference herein. The DIP Term Sheet remains subject to Court approval.
| Item 2.04. | Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. |
The filing of the Bankruptcy Petitions described in Item 1.03 above constituted an event of default that accelerated the Company’s obligations under the following debt instruments (the “Debt Instruments”):
| • | Credit and Guaranty Agreement, dated as of May 8, 2024, by and among the Company, as borrower, the guarantors party thereto from time to time, the lenders party thereto from time to time and Wilmington, as administrative agent and collateral agent as amended by that certain First Amendment and Waiver to Credit and Guaranty Agreement, dated October 7, 2025 and that certain Second Amendment to Credit and Guaranty Agreement, dated as of February 27, 2026 (as so amended, and as otherwise amended restated, supplemented, or otherwise modified from time to time, the “Credit and Guaranty Agreement”); |
| • | Indenture, dated as of October 10, 2025 (as amended, restated, supplemented or otherwise modified from time to time, the “2028 Indenture”), by and among the Company, the guarantors party thereto, and Wilmington, as trustee and collateral agent, governing the 2028 Notes; |
| • | Indenture, dated as of October 10, 2025 (as amended, restated, supplemented or otherwise modified from time to time, the “2029 Indenture” and, together with the 2028 Indenture, the “Indentures”), by and among the Company, the guarantors party thereto, and Wilmington, as trustee and collateral agent, governing the 2029 Notes; and |
| • | Revenue Interest Financing Agreement, dated as of September 14, 2019, by and among the Company, the investors party thereto, HealthCare Royalty Management, LLC, as investor representative, (“Investor Representative”) as amended by (i) that certain Omnibus Amendment to Transaction Documents, dated June 23, 2021, by and among the Company, Karyopharm Europe GmbH (“Karyopharm Europe”), Karyopharm Therapeutics (Bermuda) Ltd., certain Investors party thereto, the Investor Representative, and HCR Collateral Management, LLC as collateral agent (“HCR Collateral Management”); (ii) that certain Second Amendment to Revenue Interest Financing Agreement, dated August 1, 2023, by and among the Company, Karyopharm Europe, certain Investors party thereto, the Investor Representative, and HCR Collateral Management; (iii) that certain Second Omnibus Amendment to Transaction Documents, dated May 8, 2024, by and among the Company, Karyopharm Europe, certain Investors party thereto, the Investor Representative, HCR Collateral Management, and HCR Karyopharm SPV, LLC, as replacement collateral agent (“Royalty Collateral Agent”); (iv) that certain Third Amendment to Revenue Interest Financing Agreement, dated August 14, 2025, by and among the Company, certain Investors party thereto, the Investor Representative, HCR Collateral Management, and the Royalty Collateral Agent; (v) that certain Fourth Amendment to Revenue Interest Financing Agreement, dated August 27, 2025, by and among the Company, certain Investors party thereto, the Investor Representative, HCR Collateral Management and the Royalty Collateral Agent; and (vi) that certain Sixth Amendment to Revenue Interest Financing Agreement, dated October 7, 2025, by and among the Company, certain Investors party thereto, the Investor Representative, HCR Collateral Management, and the Royalty Collateral Agent (as so amended, and as otherwise amended, restated, supplemented or otherwise modified from time to time, the “Revenue Interest Financing Agreement”). |
The Credit and Guaranty Agreement and the Indentures provide that, upon the filing of the Bankruptcy Petitions, the outstanding principal amount of the loans and notes thereunder, consisting of approximately $129.0 million under the Credit and Guaranty Agreement, $15.6 million aggregate principal amount of 2028 Notes and $108.0 million aggregate principal amount of 2029 Notes, together with accrued and unpaid interest, fees and, with respect to the Credit and Guaranty Agreement, applicable premiums thereon, became immediately due and payable, and $113.5 million under the Revenue Interest Financing Agreement became due and payable in accordance with its terms. Any efforts to enforce such payment obligations under the Debt Instruments are automatically stayed as a result of the Bankruptcy Petitions, and the creditors’ rights of enforcement in respect of the Debt Instruments are subject to the applicable provisions of the Bankruptcy Code.
As previously disclosed, on September 10, 2026, the Company and its subsidiary guarantors entered into a Forbearance Agreement and Limited Waiver to Indentures (the “Forbearance Agreement”) with the lenders under the Credit and Guaranty Agreement, the holders of the 2028 Notes and the 2029 Notes, the Investor Representative, and the other parties thereto, and the applicable parties subsequently extended the Forbearance Period (as defined in the Forbearance Agreement) on October 13, 2026, to October 22, 2026 and further extended the Forbearance Period on October 22, 2026 to November 1, 2026. Under the terms of the Forbearance Agreement, the filing of the Bankruptcy Petitions terminated the Forbearance Period, as extended.
| Item 7.01. | Regulation FD Disclosure. |
Commencement of the Solicitation
On November 2, 2026, prior to filing the Bankruptcy Petitions, the Debtors commenced solicitation of votes on the Prepackaged Plan, including by distributing the Prepackaged Plan, Disclosure Statement and related solicitation materials to holders of claims in Classes 3-6 (as defined in the Prepackaged Plan) that were entitled to vote on the Prepackaged Plan as of the voting record date. A copy of the Disclosure Statement (including the Prepackaged Plan and certain other exhibits attached thereto) is furnished as Exhibit 99.1 hereto.
This Current Report on Form 8-K is not a solicitation of votes to accept or reject the Prepackaged Plan or an offer to sell or a solicitation of an offer to buy any securities. Any solicitation or offer will be made only pursuant to the Disclosure Statement and in compliance with applicable law.
Press Release
As previously disclosed, on November 2, 2026, the Company issued a press release announcing the filing of the Cases and entry into the Restructuring Support Agreement. A copy of the press release is attached as Exhibit 99.2 hereto and incorporated by reference herein.
| Item 8.01. | Other Events. |
As previously disclosed on August 31, 2026, the Company submitted a supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) seeking accelerated approval of XPOVIO® (selinexor) in combination with ruxolitinib for the treatment of patients with myelofibrosis. The FDA’s filing review period concluded on October 27, 2026 (“Day 60”). The Company did not receive a Refuse to File notification from the FDA by Day 60, indicating that the sNDA submission is sufficiently complete to permit a substantive review. The Company expects to receive a filing communication, or Day-74 Letter, from the FDA on or about November 10, 2026, which will include the Prescription Drug User Fee Act target action date and other pertinent information. The Company believes that the approval of selinexor in combination with ruxolitinib for myelofibrosis is the principal driver of the value of the Company’s business and of the contingent value rights to be issued to holders of claims in respect of the Company’s Funded Debt in connection with the Ayrmid Transaction under the Prepackaged Plan.
Cautionary Statements Regarding Trading in the Company’s Securities
The Company’s securityholders are cautioned that trading in the Company’s securities during the pendency of the Cases is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by the Company’s securityholders in the Cases. The Prepackaged Plan provides that holders of the Company’s common stock and the Convertible Preferred Stock will not receive any payment or other distribution on account of such securities. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities. In particular, the Company expects that its existing equity securities will have no value and that holders of such securities will experience a complete loss on their investment.
Cautionary Note Regarding Forward Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “potential,” “projects,” “target,” “will,” “would,” and “future” or similar expressions are intended to identify forward-looking statements. Such forward-looking statements include those regarding the Cases, the Company’s ability to consummate the transactions contemplated by the Restructuring Support Agreement, the Company’s ability to obtain Court approval of, and access to, the DIP Facility, the Company’s ability to continue operating in the ordinary course while the Cases are pending, the expected treatment of the Company’s securities in the Cases, anticipated communications from the FDA regarding the Company’s sNDA, the potential approval of selinexor in combination with ruxolitinib for myelofibrosis and the value of the Company’s business and the related contingent value rights, and other statements that are not historical fact. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in these forward-looking statements. These risks and uncertainties include, but are not limited to: (i) risks related to the consummation of the transactions contemplated by the Restructuring Support Agreement, including the ability to consummate the Ayrmid Transaction; (ii) potential adverse effects of the Cases on the Company’s liquidity and results of operations; (iii) the Company’s ability to obtain timely approval by the Court of the motions filed in the Cases, including with respect to the DIP Facility and the Bidding Procedures; (iv) objections to the transactions contemplated by the Restructuring Support Agreement and/or the Prepackaged Plan, the Bidding Procedures or other pleadings filed that could protract the Cases; (v) employee attrition and the Company’s ability to retain senior management and other key personnel due to the distractions and uncertainties; (vi) the Company’s ability to comply with the restrictions imposed by the terms and conditions of the Company’s financing arrangements, including the DIP Facility; (vii) the Company’s ability to maintain relationships with suppliers, vendors, collaboration and license partners, employees and other third parties and regulatory authorities as a result of the Cases; (viii) the effects of the Cases on the Company and on the interests of various constituents, including holders of the Company’s common stock and the Convertible Preferred Stock; (ix) the Court’s rulings in the Cases, including the approval of the terms and conditions of the transactions contemplated by the Restructuring
Support Agreement or the Prepackaged Plan, and the outcome of the Cases generally; (x) the length of time that the Company will operate under Chapter 11 protection and the continued availability of operating capital during the pendency of the Cases; (xi) risks associated with third party motions in the Cases, which may interfere with the Company’s ability to consummate the transactions contemplated by the Restructuring Support Agreement or the Prepackaged Plan or an alternative transaction; (xii) increased administrative and legal costs related to the Chapter 11 process; (xiii) exposure to potential litigation, including related to the transactions contemplated by the Restructuring Support Agreement or the Prepackaged Plan, and inherent risks involved in a bankruptcy process; (xiv) the occurrence of any event, change or other circumstances that could give rise to the right of the Company, the Consenting Stakeholders or Ayrmid to terminate the Restructuring Support Agreement; (xv) the possibility that the anticipated benefits of the transactions contemplated by the Restructuring Support Agreement or the Prepackaged Plan are not realized when expected or at all; (xvi) diversion of management’s attention from ongoing business operations and opportunities; (xvii) potential adverse reactions or changes to business or employee relationships, including those resulting from the bankruptcy proceedings of the Company or the announcement or completion of the transactions contemplated by the Restructuring Support Agreement or the Prepackaged Plan; (xviii) the expected delisting of the Company’s common stock from the Nasdaq Global Select Market; (xix) the content and timing of decisions made by the FDA and other regulatory authorities and institutional review boards; (xx) the value associated with selinexor in combination with ruxolitinib, if approved; and other risks and uncertainties, including those described in the section entitled “Risk Factors” in the Company’s most recent annual or quarterly report filed with the Securities and Exchange Commission (“SEC”) and in other filings the Company makes with the SEC from time to time. The forward-looking statements herein do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update the information contained in this Current Report on Form 8-K to reflect new events or circumstances, except as required by law.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits:
Exhibits 99.1 and 99.2 shall be deemed to be furnished, and not filed:
| * | Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish a copy of any omitted schedule or exhibit to the SEC upon request. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| KARYOPHARM THERAPEUTICS INC. | ||||||
| Date: November 2, 2026 | By: | /s/ Michael Mano | ||||
| Michael Mano | ||||||
| Executive Vice President, Chief Legal Officer and Secretary | ||||||
Exhibit 10.1
Certain portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
THIS RESTRUCTURING SUPPORT AGREEMENT IS NOT (NOR SHALL IT BE CONSTRUED TO BE) AN OFFER OR ACCEPTANCE WITH RESPECT TO ANY SECURITIES OR A SOLICITATION OF ACCEPTANCES OF A CHAPTER 11 PLAN WITHIN THE MEANING OF SECTION 1125 OF THE BANKRUPTCY CODE. ANY SUCH OFFER OR SOLICITATION WILL COMPLY WITH ALL APPLICABLE SECURITIES LAWS AND/OR PROVISIONS OF THE BANKRUPTCY CODE. NOTHING CONTAINED IN THIS RESTRUCTURING SUPPORT AGREEMENT SHALL BE AN ADMISSION OF FACT OR LIABILITY OR, UNTIL THE OCCURRENCE OF THE AGREEMENT EFFECTIVE DATE ON THE TERMS DESCRIBED HEREIN, DEEMED BINDING ON ANY OF THE PARTIES HERETO.
THIS RESTRUCTURING SUPPORT AGREEMENT IS THE PRODUCT OF SETTLEMENT DISCUSSIONS AMONG THE PARTIES HERETO. ACCORDINGLY, THIS RESTRUCTURING SUPPORT AGREEMENT IS PROTECTED BY RULE 408 OF THE FEDERAL RULES OF EVIDENCE AND ANY OTHER APPLICABLE STATUTES OR DOCTRINES PROTECTING THE USE OR DISCLOSURE OF CONFIDENTIAL SETTLEMENT DISCUSSIONS.
THIS RESTRUCTURING SUPPORT AGREEMENT (TOGETHER WITH THE EXHIBITS AND ANNEXES ATTACHED HERETO) DOES NOT PURPORT TO SUMMARIZE ALL OF THE TERMS, CONDITIONS, REPRESENTATIONS, WARRANTIES, AND OTHER PROVISIONS WITH RESPECT TO THE RESTRUCTURING TRANSACTIONS (AS DEFINED BELOW) THAT ARE DESCRIBED HEREIN, WHICH RESTRUCTURING TRANSACTIONS WILL BE SUBJECT TO THE COMPLETION AND EXECUTION OF DEFINITIVE DOCUMENTS INCORPORATING THE TERMS SET FORTH HEREIN, AND THE EFFECTIVENESS OF ANY RESTRUCTURING TRANSACTION SHALL BE SUBJECT TO THE TERMS AND CONDITIONS SET FORTH IN SUCH DEFINITIVE DOCUMENTS AND THE APPROVAL RIGHTS OF THE PARTIES SET FORTH HEREIN OR IN SUCH DEFINITIVE DOCUMENTS.
RESTRUCTURING SUPPORT AGREEMENT
This RESTRUCTURING SUPPORT AGREEMENT (as may be amended, supplemented, or otherwise modified from time to time in accordance with the terms hereof, including all exhibits, annexes, and schedules hereto in accordance with Section 16.02, this “Agreement”) is made and entered into as of November 2, 2026 (the “Execution Date”), by and among the following parties (each of the following described in sub-clauses (1) through (7) of this preamble, collectively, the “Parties”):1
| 1. | Karyopharm Therapeutics Inc., a corporation incorporated under the Laws of the State of Delaware (“Karyopharm”), and each of its affiliates listed on Exhibit A to this Agreement that have executed and delivered counterpart signature pages to this Agreement to each counsel to the Consenting Stakeholders (the Entities in this clause (1), collectively, the “Company Parties”); |
| 1 | Capitalized terms used but not defined in the preamble and recitals to this Agreement have the meanings ascribed to them in Section 1. |
| 2. | the undersigned holders or beneficial owners of, or investment advisors, sub-advisors, or managers of discretionary accounts that hold, Term Loan Claims that have executed and delivered counterpart signature pages to this Agreement, a Joinder, or a Transfer Agreement to counsel to the Company Parties (the “Consenting 1L Lenders”); |
| 3. | the undersigned holders or beneficial owners of, or investment advisors, sub-advisors, or managers of discretionary accounts that hold, 2028 Notes Claims that have executed and delivered counterpart signature pages to this Agreement, a Joinder, or a Transfer Agreement to counsel to the Company Parties (the “Consenting 2028 Noteholders”); |
| 4. | the undersigned holders or beneficial owners of, or investment advisors, sub-advisors, or managers of discretionary accounts that hold, 2029 Notes Claims that have executed and delivered counterpart signature pages to this Agreement, a Joinder, or a Transfer Agreement to counsel to the Company Parties (the “Consenting 2029 Noteholders,” and, together with the Consenting 1L Lenders and the Consenting 2028 Noteholders, the “Consenting Funded Debt Parties”); |
| 5. | the undersigned holders or beneficial owners of, or investment advisors, sub-advisors, or managers of discretionary accounts that hold, Royalty Claims that have executed and delivered counterpart signature pages to this Agreement, a Joinder, or a Transfer Agreement to counsel to the Company Parties (the “Consenting Royalty Investors”); |
| 6. | the undersigned holders or beneficial owners of, or investment advisors, sub-advisors, or managers of discretionary accounts that hold, shares of Convertible Preferred Stock that have executed and delivered counterpart signature pages to this Agreement, a Joinder, or a Transfer Agreement to counsel to the Company Parties (the “Consenting Preferred Shareholders,” and, together with the Consenting Funded Debt Parties and the Consenting Royalty Investors, the “Consenting Stakeholders”); and |
| 7. | Ayrmid Ltd., a private limited company incorporated under the Laws of England and Wales (“Ayrmid”). |
RECITALS
WHEREAS, the Company Parties, the Consenting Stakeholders, and Ayrmid have in good faith and at arm’s length negotiated or been apprised of certain restructuring and recapitalization transactions with respect to the Company Parties’ capital structure on the terms set forth in this Agreement and as specified in the Plan, attached hereto as Exhibit B, the Disclosure Statement, attached hereto as Exhibit C, the DIP Term Sheet, attached hereto as Exhibit D, and the Ayrmid Transaction Term Sheet, attached hereto as Exhibit E (the transactions described in or contemplated by this Agreement (including any Acceptable Alternative Transaction), the Plan, the Disclosure Statement, the DIP Term Sheet, and, as applicable, the Ayrmid Transaction Term Sheet, the “Restructuring Transactions”);
2
WHEREAS, as of the Execution Date, the Consenting Stakeholders hold, own, or control, in the aggregate, the following Company Claims/Interests:
(a) the Consenting 1L Lenders hold, own, or control $128,981,939 in aggregate outstanding principal amount of the Term Loans, representing 100% of the aggregate outstanding principal amount of the Term Loans;
(b) the Consenting 2028 Noteholders hold, own, or control $15,648,085 in aggregate outstanding principal amount of the 2028 Notes, representing 100% of the aggregate outstanding principal amount of the 2028 Notes;
(c) the Consenting 2029 Noteholders hold, own, or control $107,974,339 in aggregate outstanding principal amount of the 2029 Notes, representing 100% of the aggregate outstanding principal amount of the 2029 Notes;
(d) the Consenting Royalty Investors hold, own, or control $113,536,880 in aggregate outstanding amount of Royalty Claims, representing 100% of the aggregate outstanding amount of the Royalty Claims; and
(e) the Consenting Preferred Shareholders hold, own, or control 17,749 shares of Convertible Preferred Stock, representing 100% of the aggregate outstanding shares of the Convertible Preferred Stock.
WHEREAS, the Company Parties intend to implement the Restructuring Transactions, including through the commencement by the Debtors of voluntary cases under chapter 11 of the Bankruptcy Code in the Bankruptcy Court (the cases commenced, the “Chapter 11 Cases”);
WHEREAS, the Company Parties, through the marketing and sale process for their assets, have selected Ayrmid as the stalking horse bidder for such assets, and intend to enter into the Merger Agreement and to effectuate the Ayrmid Transaction through the Plan (subject to higher or better offers);
WHEREAS, certain of the Consenting Stakeholders have elected to commit to provide the DIP Facility, and the Company Parties and the Consenting Stakeholders have reached an agreement for the consensual use of cash collateral (as defined in the Bankruptcy Code);
WHEREAS, the Parties have agreed to take certain actions in support of the Restructuring Transactions on the terms and conditions set forth in this Agreement;
NOW, THEREFORE, in consideration of the covenants and agreements contained herein, and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Party, on a several but not joint basis, intending to be legally bound hereby, agrees as follows:
3
AGREEMENT
Section 1. Definitions and Interpretation.
1.01. Definitions. The following terms shall have the following definitions:
“2028 Indenture” means that certain Indenture, dated as of October 10, 2025, providing for the issuance of the 2028 Notes, as amended, restated, amended and restated, supplemented, or otherwise modified from time to time.
“2028 Notes” means those 9.00% convertible senior notes due 2028 under the 2028 Indenture.
“2028 Notes Claims” means any Claim on account of the 2028 Notes.
“2029 Indenture” means that certain Indenture, dated as of October 10, 2025, providing for the issuance of the 2029 Notes, as amended, restated, amended and restated, supplemented, or otherwise modified from time to time.
“2029 Notes” means those 9.00% convertible senior notes due 2029 under the 2029 Indenture.
“2029 Notes Claims” means any Claim on account of the 2029 Notes.
“Acceptable Alternative Transaction” means, to the extent consented to in writing by the Required Consenting Funded Debt Parties and the Required Consenting Royalty Investors, any Sale Transaction with an Entity other than Ayrmid that provides for net proceeds at closing of at least $335,384,812; provided that $18,750,000 of such amount allocable to the Royalty Claims held by the Consenting Royalty Investors (or their affiliates) may be satisfied with cash or non-cash consideration, in such form as is acceptable to such holders of Royalty Claims in their discretion, having a value of not less than such portion.
“Acceptable Alternative Transaction Notification” means delivery of written notice by the Debtors, with the consent of the Required Consenting Funded Debt Parties, to Ayrmid of a determination to pursue an Acceptable Alternative Transaction.
“Ad Hoc Group” means the ad hoc group of holders of Term Loan Claims, 2028 Notes Claims, and 2029 Notes Claims represented by the Ad Hoc Group Advisors.
“Ad Hoc Group Advisors” means, collectively, (a) Latham & Watkins LLP, as counsel, (b) Haynes and Boone, LLP, as local counsel, (c) Houlihan Lokey Capital, Inc., as investment banker and financial advisor, and (d) any other advisor retained by or on behalf of the Ad Hoc Group.
“Agent” means any administrative agent, collateral agent, or similar Entity under the Term Loans, the 2028 Notes, the 2029 Notes, and/or the Royalty Agreement, including any successors thereto.
4
“Agents/Trustees” means, collectively, each of the Agents and Trustees.
“Agreement” has the meaning set forth in the preamble to this Agreement and, for the avoidance of doubt, includes all the exhibits, annexes, and schedules hereto in accordance with Section 16.02.
“Agreement Effective Date” means the date on which the conditions to the effectiveness of this Agreement as set forth in Section 2 have been satisfied or waived in accordance with this Agreement.
“Agreement Effective Period” means the period from the Agreement Effective Date (or, in the case of any Consenting Stakeholder that becomes a Party hereto after the Agreement Effective Date, the date on which such Consenting Stakeholder executes and delivers a Transfer Agreement or a Joinder to counsel to the Company Parties in accordance with the terms hereof) to the Termination Date applicable to that Party.
“Alternative Restructuring Proposal” means any inquiry, proposal, offer, bid, term sheet, discussion, or agreement with respect to a sale, disposition, new-money investment, restructuring, reorganization, merger, amalgamation, acquisition, consolidation, dissolution, financing (including any debtor-in-possession financing, cash collateral usage, or exit financing), refinancing, debt incurrence, debt investment, equity investment, liquidation, tender offer, exchange offer, recapitalization, plan of reorganization or liquidation, share exchange, business combination, joint venture, partnership, or similar transaction, or series of related transactions, involving any one or more Company Parties or any of their respective subsidiaries, or the assets, liabilities, debt, equity, or other interests of any one or more of the Company Parties or any of their respective subsidiaries, other than the Restructuring Transactions, or any other transaction involving any one or more of the Company Parties that is an alternative to or inconsistent with the Restructuring Transactions; provided, that any transaction implemented pursuant to an amendment of this Agreement effected in accordance with Section 15 shall not constitute an Alternative Restructuring Proposal.
“Ayrmid” has the meaning set forth in the preamble to this Agreement.
“Ayrmid Advisors” means, collectively, (a) Paul Hastings LLP, as counsel to Ayrmid, (b) any local counsel to Ayrmid, and (c) any other financial advisor, investment banker, or other advisor retained by or on behalf of Ayrmid.
“Ayrmid Milestones” has the meaning set forth in Section 4.01 of this Agreement.
“Ayrmid Outside Date” means the date that is 110 days after the Petition Date.
“Ayrmid Termination Events” has the meaning set forth in Section 14.03 of this Agreement.
“Ayrmid Transaction” means that proposed reorganization incorporating the Sale Transaction with Ayrmid as counterparty, as detailed in the Ayrmid Transaction Term Sheet.
5
“Ayrmid Transaction Term Sheet” means that certain term sheet containing material terms of a proposed reorganization incorporating the Sale Transaction with Ayrmid as counterparty, attached hereto as Exhibit E.
“Bankruptcy Code” means title 11 of the United States Code, 11 U.S.C. §§ 101–1532, as amended.
“Bankruptcy Court” means the United States Bankruptcy Court for the Southern District of Texas.
“Bid Protections” means the break-up fee, expense reimbursement, and other bid protections set forth in the Ayrmid Transaction Term Sheet and/or the Merger Agreement, to the extent approved in the Bidding Procedures Order or other order entered by the Bankruptcy Court.
“Bidder Capacity” means, with respect to the Highbridge Funds and/or Ayrmid, acting in a capacity as, or as a direct or indirect participant in, a bidder or potential bidder for all or any portion of the Company Parties’ equity or assets, including pursuant to the Plan.
“Bidding Procedures Motion” means any motion filed by the Debtors seeking entry of the Bidding Procedures Order, together with all exhibits thereto and any declarations, affidavits, or other documents filed in connection with such motion.
“Bidding Procedures Order” means any order entered by the Bankruptcy Court on the docket of the Chapter 11 Cases approving the Debtors’ proposed procedures for conducting a sale and marketing process for their equity and/or assets.
“Business Day” means any day other than a Saturday, Sunday, or “legal holiday” (as defined in rule 9006(a) of the Federal Rules of Bankruptcy Procedure), or other day on which commercial banks are authorized to close under the Laws of, or are in fact closed in, the state of New York.
“Chapter 11 Cases” has the meaning set forth in the recitals to this Agreement.
“Claim” has the meaning ascribed to it in section 101(5) of the Bankruptcy Code.
“Company Claims/Interests” means any Claim against, or Equity Interest in, a Company Party, including the Term Loan Claims, the 2028 Notes Claims, the 2029 Notes Claims, the Royalty Claims, and the Convertible Preferred Stock.
“Company Parties” has the meaning set forth in the preamble to this Agreement.
“Company Party Termination Events” has the meaning set forth in Section 14.04 of this Agreement.
“Conditional Disclosure Statement Order” means the order entered by the Bankruptcy Court on the docket of the Chapter 11 Cases conditionally approving the Disclosure Statement and approving the Solicitation Materials.
6
“Confidentiality Agreement” means an executed confidentiality agreement, including with respect to the issuance of a “cleansing letter” or other public disclosure of material non-public information agreement, in connection with any proposed Restructuring Transactions.
“Confirmation Order” means the confirmation order with respect to the Plan.
“Consenting 1L Lenders” has the meaning set forth in the preamble to this Agreement.
“Consenting 2028 Noteholders” has the meaning set forth in the preamble to this Agreement.
“Consenting 2029 Noteholders” has the meaning set forth in the preamble to this Agreement.
“Consenting Funded Debt Parties” has the meaning set forth in the preamble to this Agreement.
“Consenting Funded Debt Party Termination Events” has the meaning set forth in Section 14.01 of this Agreement.
“Consenting Preferred Shareholders” has the meaning set forth in the preamble to this Agreement.
“Consenting Royalty Investor Termination Events” has the meaning set forth in Section 14.02 of this Agreement.
“Consenting Royalty Investors” has the meaning set forth in the preamble to this Agreement.
“Consenting Royalty Investors Advisors” means, collectively, Hogan Lovells Cadwalader US LLP, as counsel, and Stifel Financial Corp., as financial advisor.
“Consenting Stakeholders” has the meaning set forth in the preamble to this Agreement.
“Convertible Preferred Stock” means an aggregate of 20,000 shares of 0% Series A convertible perpetual preferred stock, par value $0.0001 per share, issued by Karyopharm under that certain Certificate of Designations of 0% Series A Convertible Perpetual Preferred Stock of Karyopharm Therapeutics Inc., dated as of September 17, 2026, in connection with the Fee Agreement.
“Debtors” means the Company Parties that commence the Chapter 11 Cases.
“Definitive Documents” means the documents listed in Section 3.01.
“DIP Agent” means the administrative agent and collateral agent under the DIP Facility, its successors, assigns, or any replacement agent appointed pursuant to the terms of the DIP Documents.
“DIP Budget” has the meaning set forth in the DIP Orders.
7
“DIP Documents” means, collectively, the DIP Term Sheet, the DIP Motion, the DIP Orders, any credit agreement governing the DIP Facility, and any other agreements, documents, and instruments delivered or entered into in connection therewith, including any guarantee agreements, pledge and collateral agreements, intercreditor agreements, and other security documents, as any of the foregoing may be amended, modified, or supplemented from time to time in accordance with the terms hereof and thereof.
“DIP Facility” means the superpriority senior secured DIP term loan facility to be provided on the terms set forth in the DIP Documents.
“DIP Lenders” has the meaning set forth in the DIP Term Sheet.
“DIP Motion” means any motion filed by the Company Parties seeking entry of the DIP Orders, together with all exhibits thereto and any declarations, affidavits, or other documents filed in connection with such motion.
“DIP Orders” means, together, the Interim DIP Order, the Final DIP Order, and any other order approving the DIP Facility.
“DIP Term Sheet” means that certain term sheet containing the material terms of the DIP Facility, attached hereto as Exhibit D.
“Disclosure Statement” means the disclosure statement with respect to the Plan and all exhibits, appendices, and schedules thereto, each as amended, supplemented, or otherwise modified from time to time in accordance with the terms thereof or hereof, as attached hereto as Exhibit C.
“Disclosure Statement Order” means the interim and final orders of the Bankruptcy Court entered on the docket of the Chapter 11 Cases approving the Disclosure Statement (including the Conditional Disclosure Statement Order) and, to the extent necessary, approving the related Solicitation Materials, which final order may be the Confirmation Order.
“Entity” has the meaning set forth in section 101(15) of the Bankruptcy Code.
“Equity Interests” means, collectively, the shares (or any class thereof), common stock, preferred stock, limited liability company interests, and any other equity, ownership, or profits interests of any Company Party, and options, warrants, rights, or other securities or agreements to acquire or subscribe for, or which are convertible into the shares (or any class thereof) of, common stock, preferred stock, limited liability company interests, or other equity, ownership, or profits interests of any Company Party (in each case whether or not arising under or in connection with any employment agreement); provided that 2028 Notes Claims and 2029 Notes Claims shall not constitute Equity Interests.
“Execution Date” has the meaning set forth in the preamble to this Agreement.
“Fee Agreement” means that certain letter agreement, Re: Fee Agreement Pursuant to Forbearance Agreement, dated as of September 10, 2026, entered into by and among Karyopharm and each of the Consenting Stakeholders party to the September 2026 Forbearance Agreement, as amended, restated, amended and restated, supplemented, or otherwise modified from time to time.
8
“Final DIP Order” means an order by the Bankruptcy Court entered on the docket of the Chapter 11 Cases approving the DIP Facility and related relief on a final basis.
“First Day Pleadings” means the first-day pleadings that the Company Parties, in consultation with the Required Consenting Funded Debt Parties, determine are necessary or desirable to file with the Bankruptcy Court.
“Funded Debt” means, collectively, the 2028 Notes, the 2029 Notes, and the Term Loans.
“Governmental Entity” means any “Governmental Unit” as defined in section 101(27) of the Bankruptcy Code and any applicable federal, state, local, or foreign government or any agency, bureau, board, commission, court or arbitral body, department, political subdivision, regulatory or administrative authority, tribunal, or other instrumentality thereof, or any self-regulatory organization.
“HCR Collateral Management” means HCR Collateral Management, LLC, as collateral agent under the Royalty Agreement.
“HCR Karyopharm SPV” means HCR Karyopharm SPV, LLC, as replacement collateral agent under the Royalty Agreement.
“Highbridge Funds” means, collectively, each holder of Company Claims/Interests whose Company Claims/Interests are beneficially owned or managed by Highbridge Capital Management, LLC or any of its affiliates, and each holder of Company Claims/Interests that is an affiliate of Ayrmid.
“Intercreditor Agreement” means that certain Amended and Restated Intercreditor Agreement, dated as of October 10, 2025, by and among Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent under the Term Loan Credit Agreement, Wilmington Savings Fund Society, FSB, in its capacity as collateral trustee under that certain Collateral Trust Agreement, dated as of October 10, 2025, and HCR Karyopharm SPV, LLC, as royalty collateral agent, as acknowledged by Karyopharm and the other grantors party thereto, as may be amended, restated, amended and restated, supplemented, or otherwise modified from time to time.
“Interim DIP Order” means an order by the Bankruptcy Court entered on the docket of the Chapter 11 Cases approving the DIP Facility and related relief on an interim basis.
“Joinder” means an executed form of the joinder providing, among other things, that a holder of Company Claims/Interests is bound by the terms of this Agreement and substantially in the form attached hereto as Exhibit G.
“Karyopharm Europe” means Karyopharm Europe GmbH.
“Law” means any federal, state, local, or foreign law (including, in each case, any common law), statute, code, ordinance, rule, regulation, decree, injunction, order, ruling, assessment, writ, or other legal requirement, or judgment, in each case, that is validly adopted, promulgated, issued, or entered by a Governmental Entity of competent jurisdiction (including the Bankruptcy Court).
9
“Lender Capacity” means, with respect to the Highbridge Funds, acting solely in their capacity as a holder of Company Claims/Interests and a member of the Ad Hoc Group.
“Merger Agreement” means an agreement to be entered into pursuant to the Ayrmid Transaction Term Sheet in order to effectuate the Ayrmid Transaction, including all exhibits and schedules thereto, as may be amended, modified, or supplemented in accordance with the terms thereof and this Agreement, a substantially final form of which shall be filed with the Plan Supplement.
“MF CVR Agreement” means the contingent value rights agreement providing for a synthetic royalty in the proceeds of XPOVIO® (selinexor) for patients with myelofibrosis, a substantially final form of which shall be filed with the Plan Supplement.
“Milestones” has the meaning set forth in Section 4.01.
“New Corporate Governance Documents” means, in the event of consummation of the Ayrmid Transaction, the documents providing for corporate governance of NewCo and/or the Reorganized Debtors, as applicable, including charters, bylaws, operating agreements, or other organizational documents or shareholders’ agreements, as applicable, which (a) shall be consistent with the terms of this Agreement and the consent rights contained herein and (b) shall be filed with the Plan Supplement.
“NewCo” means, in the event of consummation of the Ayrmid Transaction, the Entity that, upon consummation of the transactions pursuant to the Merger Agreement, shall directly or indirectly own the equity interests and assets of Reorganized Karyopharm and Ayrmid acquired in the Ayrmid Transaction or, if the Merger Agreement so provides, is the surviving Entity of the Ayrmid Transaction, in each case as identified in the Merger Agreement and the Plan.
“NewCo Term Loan Credit Agreement” means the credit agreement among NewCo and certain other Reorganized Debtors and affiliates, as applicable, and the lenders and administrative and collateral agents party thereto to effectuate the issuance of the exit term loans.
“NewCo Term Loan Documents” means the NewCo Term Loan Credit Agreement, any security agreement, and all other documentation governing the NewCo Term Loan Facility.
“NewCo Term Loan Facility” means the senior secured exit term loan facility in the amount of $135,000,000 in new money loans entered into by NewCo and certain other Reorganized Debtors as set forth in the Ayrmid Transaction Term Sheet and in the NewCo Term Loan Documents.
“NOL Motion” means the Debtors’ Emergency Motion for Entry of an Order (I) Approving Notification and Hearing Procedures for Certain Transfers of, and Declarations of Worthlessness with Respect to, Restricted Interests; and (II) Granting Related Relief to be filed in the Chapter 11 Cases.
10
“Parties” has the meaning set forth in the preamble to this Agreement.
“Permit” means any license, permit, registration, authorization, approval, certificate of authority, accreditation, qualification, or similar document or authority that has been issued or granted by any Governmental Entity, if applicable.
“Permitted Transfer” means each Transfer of any Company Claim/Interest that meets the requirements of Section 11 of this Agreement.
“Permitted Transferee” means each transferee of any Company Claims/Interests who meets the requirements of Section 11.01.
“Petition Date” means the first date any of the Company Parties commences a Chapter 11 Case with the Bankruptcy Court.
“Plan” means the joint chapter 11 plan filed by the Debtors under chapter 11 of the Bankruptcy Code that embodies the Restructuring Transactions, which shall be in form and substance reasonably acceptable to the Required Consenting Funded Debt Parties, the Company Parties and, to the extent set forth in Section 3.02, Ayrmid, attached hereto as Exhibit B.
“Plan Effective Date” means the occurrence of the effective date of the Plan according to its terms.
“Plan Supplement” means the compilation of documents, forms of documents, term sheets, agreements, schedules, or exhibits to the Plan (together with any amendments, supplements, or modifications thereto) that will be filed by the Debtors with the Bankruptcy Court, which shall be in form and substance reasonably acceptable to the Required Consenting Funded Debt Parties, the Company Parties and, to the extent set forth in Section 3.02, Ayrmid.
“Qualified Marketmaker” means an Entity that (a) holds itself out to the public, the syndicated loan market, the high yield bond market, or the applicable private markets as standing ready in the ordinary course of business to purchase from customers and sell to customers Company Claims/Interests (or enter with customers into long and short positions in Company Claims/Interests), in its capacity as a dealer or market maker in Company Claims/Interests and (b) is, in fact, regularly in the business of making a market in claims against issuers or borrowers (including term loans or debt or equity securities).
“Reorganized Debtors” means, collectively, Reorganized Karyopharm and each other Debtor, or any successor or assign thereto, by merger, consolidation, or otherwise (including NewCo), on and after the Plan Effective Date.
“Reorganized Karyopharm” means Karyopharm, as reorganized on the Plan Effective Date in accordance with the Plan.
“Required Consenting 1L Lenders” means, as of the relevant date and subject to Section 16.26, Consenting 1L Lenders holding at least 50.01% of the aggregate outstanding principal amount of the Term Loans that are held by the Consenting 1L Lenders; provided, that if as of such date there are two or more Consenting 1L Lenders, Required Consenting 1L Lenders shall include at least two unaffiliated Consenting 1L Lenders.
11
“Required Consenting 2028 Noteholders” means, as of the relevant date and subject to Section 16.26, Consenting 2028 Noteholders holding at least 50.01% of the aggregate outstanding principal amount of the 2028 Notes that are held by the Consenting 2028 Noteholders; provided, that if as of such date there are two or more Consenting 2028 Noteholders, Required Consenting 2028 Noteholders shall include at least two unaffiliated Consenting 2028 Noteholders.
“Required Consenting 2029 Noteholders” means, as of the relevant date and subject to Section 16.26, Consenting 2029 Noteholders holding at least 50.01% of the aggregate outstanding principal amount of the 2029 Notes that are held by the Consenting 2029 Noteholders; provided, that if as of such date there are two or more Consenting 2029 Noteholders, Required Consenting 2029 Noteholders shall include at least two unaffiliated Consenting 2029 Noteholders.
“Required Consenting Funded Debt Parties” means, as of the relevant date and subject to Section 16.26, each of the Required Consenting 1L Lenders, the Required Consenting 2028 Noteholders, and the Required Consenting 2029 Noteholders.
“Required Consenting Royalty Investors” means, as of the relevant date, the Consenting Royalty Investors holding at least 50.01% of the aggregate amount of the Royalty Claims owed to the Consenting Royalty Investors.
“Restructuring Fees and Expenses” means all reasonable and documented accrued and unpaid fees, costs, expenses, and disbursements of each of the Ad Hoc Group Advisors, in each case, incurred, as applicable to such advisor, in connection with the Restructuring Transactions, this Agreement, the September 2026 Forbearance Agreement, the Chapter 11 Cases, and the Definitive Documents, including all such fees (including any earned and payable restructuring, sale, success, or other transaction or similar fee), costs, expenses, and disbursements incurred in connection with the diligence, development, negotiation, preparation, and execution of, and any amendment, supplement, or modification to, this Agreement, the September 2026 Forbearance Agreement, and the Definitive Documents, the diligence, analysis, consummation, and administration of the transactions contemplated hereby and thereby, and the enforcement or preservation of any rights under this Agreement, the September 2026 Forbearance Agreement, or any Definitive Document, in each case whether incurred before, on, or after the Execution Date.
“Restructuring Transactions” has the meaning set forth in the recitals to this Agreement.
“Royalty Agreement” means that certain Revenue Interest Financing Agreement, dated September 14, 2019, by and among Karyopharm, the Royalty Investor Representative, and certain Royalty Investors, as amended by (i) that certain Omnibus Amendment to Transaction Documents, dated June 23, 2021, by and among Karyopharm, Karyopharm Europe, Karyopharm Therapeutics (Bermuda) Ltd., certain Royalty Investors party thereto, the Royalty Investor Representative, and HCR Collateral Management, (ii) that certain Second Amendment to Revenue Interest Financing Agreement, dated August 1, 2023, by and among Karyopharm, Karyopharm Europe, certain Royalty Investors party thereto, the Royalty Investor Representative, and HCR Collateral Management, (iii) that certain Second Omnibus Amendment to Transaction Documents, dated May
12
8, 2024, by and among Karyopharm, Karyopharm Europe, certain Royalty Investors party thereto, the Royalty Investor Representative, HCR Collateral Management, and HCR Karyopharm SPV, (iv) that certain Third Amendment to Revenue Interest Financing Agreement, dated August 14, 2025, by and among Karyopharm, certain Royalty Investors party thereto, the Royalty Investor Representative, HCR Collateral Management, and HCR Karyopharm SPV, (v) that certain Fourth Amendment to Revenue Interest Financing Agreement, dated August 27, 2025, by and among Karyopharm, certain Royalty Investors party thereto, the Royalty Investor Representative, HCR Collateral Management, and HCR Karyopharm SPV, (vi) that certain Sixth Amendment to Revenue Interest Financing Agreement, dated October 7, 2025, by and among Karyopharm, certain Royalty Investors party thereto, the Royalty Investor Representative, HCR Collateral Management, and HCR Karyopharm SPV, and as may be further amended, restated, amended and restated, supplemented, or otherwise modified from time to time.
“Royalty Claims” means any Claims on account of the Royalty Agreement.
“Royalty Investor Representative” means HealthCare Royalty Management, LLC, as investor representative under the Royalty Agreement.
“Royalty Investors” has the meaning set forth in the Royalty Agreement.
“Royalty Investors Fees” means, collectively, (a) reasonable and documented accrued and unpaid fees for the Consenting Royalty Investors’ legal counsel (subject only to objection if in excess of $600,000), and (b) with respect to the Consenting Royalty Investors’ financial advisor, (i) monthly fees of $150,000 solely to the extent accruing from the Petition Date until the closing of the Ayrmid Transaction or an Acceptable Alternative Transaction and (ii) solely in the event of the consummation of an Acceptable Alternative Transaction, (A) if transaction proceeds are sufficient to pay all Funded Debt outstanding in full and in cash, then a $1,000,000 deferred fee, or (B) if transaction proceeds are insufficient to pay all Funded Debt outstanding in full in cash, then a $500,000 deferred fee, in each case payable upon consummation of such Acceptable Alternative Transaction and solely from the proceeds thereof.
“Rules” means Rule 501(a)(1), (2), (3), and (7) of the Securities Act.
“Sale Order” means any order by the Bankruptcy Court entered on the docket of the Chapter 11 Cases approving a Sale Transaction, which order may be the Confirmation Order, if applicable.
“Sale Process Matter” means any matter relating to the marketing, solicitation, negotiation, evaluation, selection, approval, or consummation of a Sale Transaction or any Alternative Restructuring Proposal, including (a) the Bidding Procedures Motion, the Bidding Procedures Order, the Sale Order, the Merger Agreement, and any other asset purchase agreement with respect to the Company Parties’ assets, (b) bid deadlines, bid qualification and selection criteria, auction mechanics, minimum overbid increments, and stalking horse designation, (c) any bid protections, including break-up fees and expense reimbursement, (d) credit bidding, and (e) any sale-related Milestones or consent rights.
“Sale Transaction” means the sale of all or substantially all of the Debtors’ assets to, or a merger of the Debtors with, Ayrmid or another party selected by the Debtors with the consent of the Required Consenting Funded Debt Parties, each of which shall be effectuated pursuant to the Plan or section 363 of the Bankruptcy Code and included in the Restructuring Transactions.
13
“Securities Act” means the Securities Act of 1933, as amended.
“September 2026 Forbearance Agreement” means that certain Forbearance Agreement and Limited Waiver to Indentures, dated as of September 10, 2026, entered into by and among the Company Parties, certain of the Consenting Stakeholders, and the Agents/Trustees, as amended, restated, amended and restated, supplemented, or otherwise modified from time to time.
“Solicitation” means the solicitation of votes to accept or reject the Plan pursuant to sections 1125 and 1126 of the Bankruptcy Code in accordance with this Agreement and the Plan.
“Solicitation Materials” means all documents, ballots, forms, and other materials provided in connection with the Solicitation.
“Term Loan Claims” means any Claims on account of the Term Loans.
“Term Loan Credit Agreement” means that certain Credit and Guaranty Agreement, dated as of May 8, 2024, as amended by that certain First Amendment and Waiver to Credit and Guaranty Agreement, dated October 7, 2025, and that certain Second Amendment to Credit and Guaranty Agreement, dated as of February 27, 2026, and as otherwise amended, restated, amended and restated, supplemented, or otherwise modified from time to time.
“Term Loans” means the indebtedness under the Term Loan Credit Agreement.
“Termination Date” means the date on which termination of this Agreement as to a Party is effective in accordance with Sections 14.01, 14.02, 14.03, 14.04, 14.05, 14.06 or 15(b).
“Transfer” means to sell, resell, reallocate, use, pledge, loan, assign, transfer, hypothecate, participate, donate, tender or otherwise encumber or dispose of, directly or indirectly (including through derivatives, options, swaps, pledges, forward sales or other transactions), or to grant any proxy with respect to, deposit into any voting trust, or enter into any voting agreement with respect to, any Company Claims/Interests.
“Transfer Agreement” means an executed form of the transfer agreement providing, among other things, that a transferee of Company Claims/Interests is bound by the terms of this Agreement and substantially in the form attached hereto as Exhibit F.
“Trustee” means any indenture trustee, collateral trustee, or other trustee or similar Entity under the Term Loans, the 2028 Notes, the 2029 Notes, and/or the Royalty Agreement, including any successors thereto.
1.02. Interpretation. For purposes of this Agreement:
(a) in the appropriate context, each term, whether stated in the singular or the plural, shall include both the singular and the plural, and pronouns stated in the masculine, feminine, or neuter gender shall include the masculine, feminine, and neuter genders;
14
(b) capitalized terms defined only in the plural or singular form shall nonetheless have their defined meanings when used in the opposite form;
(c) unless otherwise specified and without limiting the applicable consent rights of the Consenting Stakeholders as set forth in this Agreement, any reference herein to a contract, lease, instrument, release, indenture, or other agreement or document being in a particular form or on particular terms and conditions means that such document shall be substantially in such form or substantially on such terms and conditions;
(d) unless otherwise specified, any reference herein to an existing document, schedule, or exhibit shall mean such document, schedule, or exhibit, as it may have been or may be amended, restated, supplemented, or otherwise modified from time to time; provided, that any capitalized terms herein which are defined with reference to another agreement are defined with reference to such other agreement as of the date of this Agreement, without giving effect to any termination of such other agreement or amendments to such capitalized terms in any such other agreement following the date hereof;
(e) unless otherwise specified, all references herein to “Sections” are references to Sections of this Agreement;
(f) the words “herein,” “hereof,” and “hereto” refer to this Agreement in its entirety rather than to any particular portion of this Agreement;
(g) captions and headings to Sections are inserted for convenience of reference only and are not intended to be a part of or to affect the interpretation of this Agreement;
(h) references to “shareholders,” “directors,” and/or “officers” shall also include “members” and/or “managers,” as applicable, as such terms are defined under the applicable limited liability company Laws;
(i) the use of “include” or “including” is without limitation, whether stated or not;
(j) the phrase “counsel to the Consenting Stakeholders” refers in this Agreement to each counsel identified pursuant to Section 16.10 other than counsel to the Company Parties or counsel to Ayrmid;
(k) the phrase “hold, own, or control” shall be deemed to be followed by the words “(including through beneficial ownership or as investment advisor, sub-advisor, or manager of discretionary accounts or funds for the account of a beneficial owner)”;
(l) to “beneficially own” or have “beneficial ownership” shall include having an interest in any Company Claims/Interests as a result of an open trade, total return swap, or other similar transaction; provided, that this clause (l) shall not apply for purposes of Section 11, and whether any Transfer has occurred shall be determined solely in accordance with Section 11; and
15
(m) to the extent any commitment, covenant, or other obligation of a Consenting Stakeholder under this Agreement requires or contemplates any action to be taken by an Agent/Trustee, such commitment, covenant, or obligation shall be construed to require only that such Consenting Stakeholder use commercially reasonable efforts to direct the applicable Agent/Trustee, or any of its brokers, sub-agents, nominees, or custodians, to take such action; provided, that no Consenting Stakeholder shall be required to provide any Agent/Trustee, or any other person, with any indemnity, security, prefunding, or similar monetary undertaking in connection with giving any such direction.
Section 2. Effectiveness of This Agreement. This Agreement shall become effective and binding upon each of the Parties on the date and time on which all of the following conditions have been satisfied or waived by the applicable Parties in accordance with this Agreement:
(a) each of the Company Parties shall have executed and delivered counterpart signature pages of this Agreement to counsel to each of the Parties;
(b) holders of at least 66.7% of the aggregate outstanding principal amount of the Term Loans shall have executed and delivered counterpart signature pages of this Agreement to counsel to the Company Parties;
(c) holders of at least 66.7% of the aggregate outstanding principal amount of the 2028 Notes shall have executed and delivered counterpart signature pages of this Agreement to counsel to the Company Parties;
(d) holders of at least 66.7% of the aggregate outstanding principal amount of the 2029 Notes shall have executed and delivered counterpart signature pages of this Agreement to counsel to the Company Parties;
(e) holders of at least 66.7% of the aggregate outstanding amount of the Royalty Claims shall have executed and delivered counterpart signature pages of this Agreement to counsel to the Company Parties;
(f) Ayrmid shall have executed and delivered its counterpart signature page of this Agreement to counsel to the Company Parties;
(g) the Company Parties shall have paid in full in cash all Restructuring Fees and Expenses incurred up to (and including) the Agreement Effective Date for which a reasonably detailed invoice has been received by the Company Parties no later than two (2) Business Days prior to the Agreement Effective Date; and
(h) counsel to the Company Parties shall have given notice to each counsel to the Consenting Stakeholders and counsel to Ayrmid in the manner set forth in Section 16.10 hereof (by email or otherwise) that the other conditions to the Agreement Effective Date set forth in this Section 2 have occurred.
Section 3. Definitive Documents.
3.01. The Definitive Documents governing the Restructuring Transactions (including all exhibits, schedules, amendments, modifications, supplements, appendices, annexes, instructions, and attachments thereto) shall include the following: (a) this Agreement; (b) the Plan; (c) the Confirmation Order; (d) the Disclosure Statement; (e) the Disclosure Statement Order; (f) the
16
Solicitation Materials; (g) the First Day Pleadings and all orders sought pursuant thereto; (h) the DIP Documents; (i) the Plan Supplement; (j) the Bidding Procedures Motion and the Bidding Procedures Order; (k) the Sale Order; (l) the Merger Agreement or any other asset purchase agreement with respect to the Company Parties’ assets; (m) the MF CVR Agreement; (n) the New Corporate Governance Documents; (o) the NewCo Term Loan Documents; (p) the restated Royalty Agreement; and (q) any and all other agreements, deeds, documentation, instruments, notices, filings, pleadings, motions, applications, briefs, objections, responses, declarations, affidavits, schedules, certificates, letters, memoranda, term sheets, stipulations, settlements, releases, and orders (and any amendments, modifications, or supplements to any of the foregoing) that are necessary or advisable (or that are executed or delivered) to implement, consummate, or document this Agreement, the Plan, and/or the Restructuring Transactions.
3.02. The Definitive Documents not executed or in a form attached to this Agreement as of the Execution Date remain subject to negotiation and completion. Upon completion, the Definitive Documents and every other document, deed, agreement, filing, notification, letter, or instrument related to this Agreement, the Plan, and/or the Restructuring Transactions shall, except as otherwise expressly provided herein, contain terms, conditions, representations, warranties, and covenants consistent with the terms of this Agreement, as they may be modified, amended, or supplemented in accordance with Section 15. Further, the Definitive Documents not executed or in a form attached to this Agreement as of the Execution Date (and any modifications, amendments, or supplements thereto) shall, except as provided herein, be in form and substance reasonably acceptable to the Company Parties and the Required Consenting Funded Debt Parties; provided, that, the Company Parties’ consent rights as to the form and substance of the NewCo Term Loan Documents shall be limited to such terms that directly concern the feasibility of the Plan; provided, further, that, the Bidding Procedures Motion and the Bidding Procedures Order (and any modifications, amendments, or supplements thereto) shall be in form and substance acceptable to the Required Consenting Funded Debt Parties and, solely with respect to the portions thereof concerning the Bid Protections, Ayrmid Outside Date, and the other terms on which Ayrmid may be required to serve as back-up bidder if such requirements are inconsistent with the terms hereof or of the Ayrmid Transaction Term Sheet, Ayrmid. Notwithstanding anything to the contrary herein, until an Acceptable Alternative Transaction Notification occurs, (a) the Plan, the Disclosure Statement, the Conditional Disclosure Statement Order, the Plan Supplement, the Confirmation Order, the Bidding Procedures Motion (solely to the extent materially inconsistent with the terms of this Agreement), the Bidding Procedures Order (solely to the extent materially inconsistent with the terms of this Agreement), the Merger Agreement, the MF CVR Agreement, the NewCo Term Loan Documents, the New Corporate Governance Documents and any modifications, amendments, or supplements to the foregoing shall be in form and substance reasonably acceptable to Ayrmid, and (b) each other Definitive Document shall, solely to the extent such Definitive Document relates to, describes, or affects Ayrmid, the Ayrmid Transaction, the Bid Protections, the Ayrmid Transaction Term Sheet or otherwise affects the rights or obligations of Ayrmid hereunder or thereunder, be in form and substance reasonably acceptable to Ayrmid. Notwithstanding anything to the contrary herein, neither the Consenting Stakeholders nor Ayrmid shall have consent rights with respect to any declarations filed by the Company Parties in the Chapter 11 Cases.
17
Section 4. Milestones.
4.01. On and after the Agreement Effective Date, the Company Parties shall implement the Restructuring Transactions in accordance with the following milestones (each, a “Milestone,” and, together, the “Milestones”), in each case, unless extended or waived in writing (email from counsel to the Ad Hoc Group shall suffice) by the Required Consenting Funded Debt Parties in their sole discretion or extended in accordance with Section 4.02; provided, that the Milestones set forth in Sections 4.01(b)(iii), 4.01(f) and, to the extent that the Debtors have not selected an Acceptable Alternative Transaction, 4.01(h) (the “Ayrmid Milestones”) may not be extended or waived without the prior written consent of Ayrmid (email from counsel to Ayrmid shall suffice), except as provided in Section 4.02; provided, further, that if any Milestone is not satisfied due to unavailability of the Bankruptcy Court, then such Milestone is so extended to the first day the Bankruptcy Court does have availability:
(a) no later than November 2, 2026, (i) the Petition Date shall have occurred, and (ii) the Debtors shall have filed the First Day Pleadings, the DIP Motion, the proposed Interim DIP Order, the Plan, the Disclosure Statement, the Solicitation Materials, and the proposed Bidding Procedures Order;
(b) no later than three (3) calendar days after the Petition Date, the Bankruptcy Court shall have entered on the docket of the Chapter 11 Cases (i) the Conditional Disclosure Statement Order, (ii) the Interim DIP Order, and (iii) the Bidding Procedures Order; provided, that with respect to the Bidding Procedures Order, this Milestone shall be deemed satisfied regardless of whether the Bidding Procedures Order includes approval of any break-up fee, expense reimbursement, or other bid protection identified in the Ayrmid Transaction Term Sheet;
(c) no later than thirty-five (35) days after the Petition Date, the Bankruptcy Court shall have entered on the docket for the Chapter 11 Cases the Final DIP Order;
(d) no later than sixty (60) days after the Petition Date, the Debtors shall have conducted an auction, if necessary, pursuant to the Bidding Procedures Order;
(e) no later than eighty (80) days after the Petition Date, the Bankruptcy Court shall have entered on the docket for the Chapter 11 Cases the Disclosure Statement Order;
(f) no later than eighty (80) days after the Petition Date, the Bankruptcy Court shall have entered on the docket for the Chapter 11 Cases the Sale Order (which may be the Confirmation Order);
(g) no later than eighty (80) days after the Petition Date, the Bankruptcy Court shall have entered on the docket for the Chapter 11 Cases the Confirmation Order; and
(h) no later than one hundred ten (110) days after the Petition Date, the Plan Effective Date shall have occurred.
18
4.02. If the Company Parties deliver an Acceptable Alternative Transaction Notification and the Acceptable Alternative Transaction is not consummated on or before one hundred ten (110) days after the Petition Date (or such other date as may be set forth in the Bidding Procedures Order), then, subject to the terms of the Bidding Procedures Order, if Ayrmid has been designated as the back-up bidder, then the applicable Milestones set forth in Section 4.01 shall, with the consent of the Required Consenting Funded Debt Parties and, with respect to the Ayrmid Milestones only, Ayrmid (each of which is not to be unreasonably withheld), be deemed extended to the extent reasonably necessary to effectuate the consummation of the Ayrmid Transaction.
Section 5. Commitments of the Consenting Stakeholders.
5.01. General Commitments.
(a) During the Agreement Effective Period but subject to Section 14, each Consenting Stakeholder agrees, subject to the limitations on the Highbridge Funds in Section 16.26 hereof, in respect of all of its Company Claims/Interests and on behalf of itself only, to:
(i) support the Restructuring Transactions and vote and use commercially reasonable efforts to exercise any powers or rights available to it (including in any board, shareholders’, or creditors’ meeting or in any process requiring voting or approval to which they are legally entitled to participate) in each case in favor of any matter requiring approval to the extent consistent with this Agreement and necessary to implement the Restructuring Transactions;
(ii) use commercially reasonable efforts to cooperate with and assist the Company Parties in obtaining additional support for the Restructuring Transactions from the Company Parties’ other stakeholders;
(iii) use commercially reasonable efforts to oppose any party taking any actions contemplated in Section 5.01(b);
(iv) use commercially reasonable efforts to give any notice, order, instruction, or direction to the applicable Agents/Trustees reasonably necessary to give effect to the Restructuring Transactions; provided, that such Consenting Stakeholder shall not be required to provide the applicable Agents/Trustees, or any other person, with any indemnities or similar monetary undertakings in connection with taking any such action or direction;
(v) subject to the terms of this Agreement and the Definitive Documents, negotiate in good faith any additional or alternative provisions or agreements to address any legal, financial, or structural impediment that may arise that would reasonably be expected to prevent, hinder, impede, or delay the consummation of the Restructuring Transactions or that are reasonably necessary to effectuate the consummation of the Restructuring Transactions;
(vi) negotiate in good faith and use commercially reasonable efforts to execute and implement the Definitive Documents that are consistent with this Agreement to which it is required to be a party; provided, that subject to the terms of this Agreement, no Consenting Stakeholder shall be obligated to (1) waive (to the extent such Consenting Stakeholder has the power or right to waive) any condition to the consummation of any part of the Restructuring Transactions set forth in any Definitive Document or (2) approve any Definitive Document that is not in form and substance reasonably acceptable to such Consenting Stakeholder if such Definitive Document is required to be in form and substance reasonably acceptable to such Consenting Stakeholder pursuant to this Agreement;
19
(vii) consent to, be deemed to have consented to, support, and not oppose the DIP Facility and entry of the DIP Orders, to the extent consistent with the terms of this Agreement;
(viii) use commercially reasonable efforts to notify the Company Parties in writing (email being sufficient) within two (2) Business Days (or as soon as reasonably practicable) after any Consenting Stakeholder receives notice or obtains actual knowledge of (i) any event or circumstance that would be reasonably expected to permit any Party to terminate, or result in the termination of, this Agreement, (ii) any matter or circumstance that is, or is reasonably likely to be, a material impediment to the implementation or consummation of the Restructuring Transactions, (iii) any breach of this Agreement (including any breach by a Consenting Stakeholder), (iv) any representation or statement made or deemed made by any Consenting Stakeholder under this Agreement that is or proves to have been materially incorrect or misleading in any respect when made or deemed made, (v) the commencement or threat of any material governmental or third-party complaint, litigation, investigation, or proceeding, including any proceeding challenging the validity of the Restructuring Transactions or any Definitive Document, and (vi) any enforcement or remedial action taken by any creditor of any Company Party, whether under any agreement governing the Funded Debt or otherwise; and
(ix) cooperate in good faith and use commercially reasonable efforts to structure and implement the Restructuring Transactions in a manner that optimizes the tax efficiency (including by way of the preservation or enhancement of favorable tax attributes) of the Restructuring Transactions for the Company Parties, the Consenting Stakeholders and Ayrmid, as reasonably determined by the Company Parties, the Required Consenting Funded Debt Parties and Ayrmid; provided, that in the event that the Debtors elect to proceed with an Acceptable Alternative Transaction, the Consenting Stakeholders shall not be required to optimize tax efficiency for Ayrmid, nor shall Ayrmid have reasonable determination rights with respect to such Acceptable Alternative Transaction.
(b) During the Agreement Effective Period but subject to Section 14, each Consenting Stakeholder agrees, in respect of all of its Company Claims/Interests and on behalf of itself only, that it shall not directly or indirectly:
(i) object to, delay, impede, or take any other action to interfere with acceptance, implementation, or consummation of the Restructuring Transactions;
(ii) propose, file, support, or vote in favor of any Alternative Restructuring Proposal that does not provide for payment in cash in full at closing of at least the amount set forth in the definition of “Acceptable Alternative Transaction”;
(iii) file any motion, pleading, or other document with the Bankruptcy Court or any other court (including any modifications or amendments thereof) that, in whole or in part, is not materially consistent with this Agreement or the Plan;
(iv) initiate, or have initiated on its behalf, any litigation or proceeding of any kind with respect to the Chapter 11 Cases, this Agreement, the Definitive Documents, or the other Restructuring Transactions contemplated herein against the Company Parties or the other Parties other than to enforce this Agreement or any Definitive Document or as otherwise permitted under this Agreement;
20
(v) exercise, or direct any other person to exercise, any right or remedy for the enforcement, collection, or recovery of any Claims against or Equity Interests in the Company Parties; or
(vi) object to, delay, impede, or take any other action to interfere with the Company Parties’ ownership and possession of their assets, wherever located, or interfere with the automatic stay arising under section 362 of the Bankruptcy Code.
(c) Notwithstanding anything to the contrary in this Agreement, if the Company Parties determine to pursue an Acceptable Alternative Transaction, then (i) each Consenting Stakeholder shall be bound by, and shall comply with its commitments under Sections 5.01 and 5.02 with respect to such Acceptable Alternative Transaction, the Plan and any other Definitive Documents implementing the same and (ii) the Ayrmid Transaction Term Sheet, the Merger Agreement, and any other document that would otherwise constitute a Definitive Document, to the extent it concerns the Ayrmid Transaction, shall in each case cease (unless and until Ayrmid is both designated as the back-up bidder and subsequently selected as the successful bidder) to (x) constitute part of the Restructuring Transactions or (y) be a Definitive Document; provided, that if such Acceptable Alternative Transaction would have a material, disproportionate, and adverse effect on the Company Claims/Interests held by any Consenting Stakeholder relative to the other Consenting Stakeholders holding Company Claims/Interests of the same class, the consent of each such affected Consenting Stakeholder shall also be required.
5.02. Commitments with Respect to Chapter 11 Cases.
(a) During the Agreement Effective Period but subject to Section 14, each Consenting Stakeholder that is entitled to vote to accept or reject the Plan pursuant to its terms agrees on behalf of itself only that it shall, subject to receipt by such Consenting Stakeholder, whether before or after the commencement of the Chapter 11 Cases, of the Solicitation Materials:
(i) vote (or, with respect to any unsettled trade purchases or open swap arrangements, give a direction to each applicable trade or swap counterparty to timely vote or cause to be voted) each of its impaired Company Claims/Interests to accept the Plan by delivering its duly executed and completed ballot accepting the Plan on a timely basis following the commencement of the solicitation of the Plan and its actual receipt of the Solicitation Materials and the ballot;
(ii) to the extent it is permitted to elect whether to opt out of or opt in to the releases set forth in the Plan, as applicable, (1) elect not to opt out of or (2) elect to opt in to, as applicable, the releases set forth in the Plan by timely delivering its duly executed and completed ballot(s) indicating such election;
(iii) not change, withdraw, amend, or revoke (or cause to be changed, withdrawn, amended, or revoked) any vote or election referred to in clauses (i) and (ii) above; and
21
(iv) support and not oppose the release, exculpation, injunction, and related provisions in the Plan.
(b) During the Agreement Effective Period but subject to Section 14, each Consenting Stakeholder, in respect of each of its Company Claims/Interests and on behalf of itself only, will support, and will not directly or indirectly object to, delay, impede, or take any other action to interfere with any motion or other pleading or document filed by a Company Party in the Bankruptcy Court that is consistent with this Agreement.
Section 6. Additional Provisions Regarding the Consenting Stakeholders’ Commitments. Notwithstanding anything contained in this Agreement, nothing in this Agreement shall: (a) affect the ability of any Consenting Stakeholder to consult with any other Consenting Stakeholder, the Company Parties, Ayrmid (subject to Section 16.26 hereof), or any other party in interest in the Chapter 11 Cases (including any official committee and the Office of the United States Trustee); (b) impair or waive the rights of any Consenting Stakeholder to assert or raise any objection permitted under this Agreement or any Definitive Document in connection with the Restructuring Transactions; (c) prevent any Consenting Stakeholder from enforcing this Agreement or any Definitive Document or asserting or contesting whether any matter, fact, or thing is a breach of, or is inconsistent with, this Agreement or any Definitive Document; (d) limit the rights of any Consenting Stakeholder in respect of the Chapter 11 Cases, including appearing as a party in interest in any matter to be adjudicated in order to be heard concerning any matter arising in the Chapter 11 Cases that is not inconsistent with this Agreement, in each case, so long as the exercise of any such right is not inconsistent with such Consenting Stakeholder’s obligations hereunder; (e) limit the ability of any Consenting Stakeholder to purchase, sell, or enter into any transactions regarding any Company Claims/Interests, subject to the terms of this Agreement and applicable Law; (f) except as and to the extent explicitly set forth in this Agreement, constitute a waiver or amendment of any term or provision of, or alter or diminish any right or obligation in, the Term Loan Credit Agreement, the 2028 Indenture, the 2029 Indenture, the Royalty Agreement or any related document; (g) except as and to the extent explicitly set forth in this Agreement, constitute a termination or release of any liens on, or security interests in, any of the assets or properties of the Company Parties that secure the obligations under the Term Loan Credit Agreement, the 2028 Indenture, the 2029 Indenture, the Royalty Agreement, or any related document; (h) except as and to the extent explicitly set forth herein or in any other Definitive Document, require any Consenting Stakeholder to incur, assume, become liable in respect of, or suffer to exist any expenses, liabilities, or other obligations, modify the economic consideration being provided to any Consenting Funded Debt Party under the Definitive Documents, or agree to or become bound by any commitments, undertakings, concessions, or other arrangements that could result in expenses, liabilities, or other obligations to such Consenting Stakeholder; (i) require any Consenting Stakeholder to take any action that is in violation of applicable Law or prevent any Consenting Stakeholder from taking any action that is required in order to comply with applicable Law; provided, that, if any Consenting Stakeholder proposes to take any action that is otherwise inconsistent with this Agreement or any other Definitive Document in order to comply with applicable Law, such Consenting Stakeholder shall provide, to the extent possible without violating applicable Law, at least five (5) Business Days’ advance written notice to the Parties; (j) prohibit any Consenting Stakeholder from taking any action that is not inconsistent with this Agreement; or (k) require any Consenting Stakeholder to fund or commit to fund any additional amounts (other than as expressly agreed in the DIP Term Sheet or in connection with an executed Definitive Document) without such Consenting Stakeholder’s written consent.
22
Section 7. Commitments of Ayrmid.
7.01. General Commitments.
(a) During the Agreement Effective Period, Ayrmid agrees that, subject to Section 14, it shall:
(i) support, and take all steps reasonably necessary and desirable to implement and consummate, the Ayrmid Transaction in accordance with this Agreement, including the Milestones, and the Definitive Documents (solely in connection with the Ayrmid Transaction);
(ii) use commercially reasonable efforts to cooperate with and assist the Company Parties in obtaining additional support for the Ayrmid Transaction from the Company Parties’ other stakeholders;
(iii) use commercially reasonable efforts to oppose and object to the efforts of any person or Entity seeking to object to, delay, impede, condition, or take any other action to interfere with the acceptance, implementation, or consummation of the Ayrmid Transaction (including, if applicable, in Ayrmid’s reasonable determination, by timely filing objections or written responses), to the extent such opposition or objection is reasonably necessary or desirable to facilitate implementation of the Ayrmid Transaction; provided, that nothing in this Section 7.01(a)(iii) shall limit or reduce Ayrmid’s obligations set forth in Section 7.02;
(iv) negotiate in good faith any additional or alternative provisions or agreements to address any legal, financial, or structural impediment that may arise that would reasonably be expected to prevent, hinder, impede, or delay the consummation of the Ayrmid Transaction or that are necessary to effectuate the consummation of the Ayrmid Transaction;
(v) negotiate in good faith and use commercially reasonable efforts to execute and implement the Definitive Documents (solely in connection with the Ayrmid Transaction) that are consistent with this Agreement to which it is required to be a party; provided, that, subject to the terms of this Agreement, Ayrmid shall not be obligated to (1) waive (to the extent Ayrmid has the power or right to waive) any condition to the consummation of any part of the Ayrmid Transaction set forth in any Definitive Document or (2) approve any Definitive Document that is not in form and substance reasonably acceptable to Ayrmid if such Definitive Document is required to be in form and substance reasonably acceptable to Ayrmid pursuant to this Agreement (solely in connection with the Ayrmid Transaction);
(vi) support, and not oppose, entry of the DIP Orders, to the extent consistent with the terms of this Agreement;
(vii) comply with those obligations set forth in the Ayrmid Transaction Term Sheet and the Merger Agreement (if applicable) and use commercially reasonable efforts to promptly consummate the Ayrmid Transaction, and cooperate in obtaining any approvals required by Governmental Entities (or other regulatory bodies) to facilitate the closing of the Ayrmid
23
Transaction; provided, that subject to the terms of this Agreement, Ayrmid shall not be obligated to (1) waive (to the extent Ayrmid has the power or right to waive) any condition to the consummation of any part of the Ayrmid Transaction set forth in any Definitive Document or (2) approve any Definitive Document that is not in form and substance reasonably acceptable to Ayrmid if such Definitive Document is required to be in form and substance reasonably acceptable to Ayrmid pursuant to this Agreement;
(viii) promptly notify counsel to the Company Parties and counsel to the Consenting Stakeholders (email being sufficient) within two (2) Business Days after Ayrmid receives notice or obtains actual knowledge of (1) any breach by Ayrmid of its obligations, representations, warranties, or covenants under this Agreement (including the Ayrmid Transaction Term Sheet) or the Merger Agreement (if applicable), and (2) the occurrence, or failure to occur, of any event of which Ayrmid is aware that would be likely to cause any condition precedent in the Merger Agreement (if applicable) or any other Definitive Document not to be satisfied or to become impossible to satisfy;
(ix) support all applicable releases, exculpations, injunctions, and discharges set forth in this Agreement, the Plan, and the other Definitive Documents;
(x) serve as the back-up bidder and commit to consummating the Ayrmid Transaction if, in accordance with the Bidding Procedures Order, the Debtors select an Acceptable Alternative Transaction as the successful bid; provided, that, such commitment shall be open and irrevocable and the Debtors may elect to proceed with the Ayrmid Transaction only until the Ayrmid Outside Date and following such date Ayrmid shall have no further obligations under this Agreement (except where such obligations expressly survive termination or have been agreed to by Ayrmid pursuant to a Definitive Document) or otherwise; and
(xi) maintain its good standing (or the equivalent concept) under the Laws of the jurisdiction in which it is incorporated or organized, and act in good faith with regard to the successful consummation of the Ayrmid Transaction consistent with this Agreement.
(b) During the Agreement Effective Period, Ayrmid agrees that, subject to Section 14, it shall not directly or indirectly:
(i) object to, delay, impede, or take any other action to interfere with acceptance, implementation, or consummation of the Restructuring Transactions;
(ii) file any motion, pleading, or other document with the Bankruptcy Court or any other court (including any modifications or amendments thereof) that, in whole or in part, is not materially consistent with this Agreement or the Plan;
(iii) initiate, or have initiated on its behalf, any litigation or proceeding of any kind with respect to the Chapter 11 Cases, this Agreement, the Definitive Documents, or the Restructuring Transactions contemplated herein against the Company Parties or the other Parties, other than in each case to enforce this Agreement or any Definitive Document or as otherwise permitted under this Agreement;
24
(iv) exercise, or direct any other person to exercise, any right or remedy for the enforcement, collection, or recovery of any Claims against or Equity Interests in the Company Parties;
(v) object to, delay, impede, or take any other action to interfere with the Company Parties’ ownership and possession of their assets, wherever located, or interfere with the automatic stay arising under section 362 of the Bankruptcy Code;
(vi) amend, modify, supplement, waive, or terminate the Ayrmid Transaction Term Sheet, or consent to any assignment thereof, in each case in any manner that is inconsistent with this Agreement or that would be materially adverse to the Consenting Stakeholders, without the prior written consent of the Required Consenting Funded Debt Parties;
(vii) seek, solicit, propose, file, support, consent to, vote for, or enter into or participate in any discussions, agreements, understandings, or other arrangements with any person or Entity regarding, or otherwise pursue or consummate, any Alternative Restructuring Proposal; provided that Ayrmid shall not object to, delay, impede, or take any other action to interfere with any Acceptable Alternative Transaction (except to the extent such Acceptable Alternative Transaction impairs or modifies Ayrmid’s Bid Protections);
(viii) object to, delay, impede, or take any other action to interfere with any motion, pleading, or other document filed by a Company Party or any Debtor in furtherance of the Restructuring Transactions that is not inconsistent with this Agreement, including the First Day Pleadings and any “second day” pleadings, the Bidding Procedures Motion, the Disclosure Statement, the Solicitation Materials, the Plan, the DIP Motion, and any other motion seeking approval of the DIP Facility or the use of cash collateral on the terms set forth in the DIP Documents;
(ix) commence, support, or join any litigation or adversary proceeding relating to the Chapter 11 Cases against any Consenting Stakeholder, or announce publicly, or inform any other party, of its intention not to support the Ayrmid Transaction; or
(x) take any action that is inconsistent in any material respect with, or that is intended to frustrate or impede approval, implementation, or consummation of, the Restructuring Transactions, this Agreement, or the Plan, subject to Section 16.27.
7.02. Commitments with Respect to Chapter 11 Cases.
(a) During the Agreement Effective Period, Ayrmid will support the Ayrmid Transaction, and will not directly or indirectly object to, delay, impede, or take any other action to interfere with any motion or other pleading or document filed by a Company Party in the Bankruptcy Court that is consistent with this Agreement.
(b) During the Agreement Effective Period, Ayrmid shall use commercially reasonable efforts to support the Debtors in obtaining entry of the Bidding Procedures Order, the Disclosure Statement Order, the Sale Order, and the Confirmation Order (solely in connection with the Ayrmid Transaction).
25
Section 8. Additional Provisions Regarding Ayrmid. Notwithstanding anything contained in this Agreement, subject to Section 16.26, nothing in this Agreement shall: (a) affect the ability of Ayrmid to consult with the Company Parties, any of the Consenting Stakeholders (subject to the Bidding Procedures Order), or any other party in interest in the Chapter 11 Cases (including any official committee and the Office of the United States Trustee); (b) impair or waive the rights of Ayrmid to assert or raise any objection permitted under this Agreement or any Definitive Document in connection with the Ayrmid Transaction; (c) prevent Ayrmid from enforcing this Agreement or any Definitive Document or contesting whether any matter, fact, or thing is a breach of, or is inconsistent with, this Agreement or any Definitive Document; (d) limit the rights of Ayrmid in respect of the Chapter 11 Cases, including appearing as a party in interest in any matter to be adjudicated in order to be heard concerning any matter arising in the Chapter 11 Cases that is not inconsistent with this Agreement, in each case, so long as the exercise of any such right is not inconsistent with Ayrmid’s obligations hereunder; (e) limit the ability of Ayrmid to purchase, sell, or enter into any transactions regarding any Company Claims/Interests, subject to the terms of this Agreement (including Section 16.26) and applicable Law; (f) except as and to the extent explicitly set forth herein or in any other Definitive Document, require Ayrmid to incur, assume, become liable in respect of, or suffer to exist any expenses, liabilities, or other obligations, modify the economic consideration being provided by Ayrmid under the Definitive Documents, or agree to or become bound by any commitments, undertakings, concessions, or other arrangements that could result in expenses, liabilities, or other obligations to Ayrmid; (g) require Ayrmid to take any action that is in violation of applicable Law or prevent Ayrmid from taking any action that is required in order to comply with applicable Law; provided, that, if Ayrmid proposes to take any action that is otherwise inconsistent with this Agreement or any other Definitive Document in order to comply with applicable Law, Ayrmid shall provide, to the extent possible without violating applicable Law, at least five (5) Business Days’ advance written notice to the Parties; (h) prohibit Ayrmid from taking any action that is not inconsistent with this Agreement; (i) require Ayrmid to fund or commit to fund any additional amounts without Ayrmid’s written consent; or (j) abridge or modify Ayrmid’s ability to preserve its rights as a bidder or back-up bidder or its rights to the Bid Protections.
Section 9. Commitments of the Company Parties.
9.01. Affirmative Commitments. During the Agreement Effective Period, the Company Parties agree that, subject to Section 14 and Section 16.26, each shall:
(a) support and take all steps reasonably necessary and desirable to consummate the Restructuring Transactions in accordance with this Agreement;
(b) to the extent any legal or structural impediment arises that would prevent, hinder, or delay the consummation of the Restructuring Transactions contemplated herein, take all steps reasonably necessary and desirable to address any such impediment;
(c) use commercially reasonable efforts to obtain any and all necessary Permits, third-party consents, and regulatory approvals for the Restructuring Transactions;
26
(d) negotiate in good faith and use commercially reasonable efforts to execute and deliver the Definitive Documents and any other required agreements to effectuate and consummate the Restructuring Transactions as contemplated by this Agreement;
(e) use commercially reasonable efforts to seek additional support for the Restructuring Transactions from their other material stakeholders to the extent reasonably prudent;
(f) subject to any applicable orders of the Bankruptcy Court, promptly pay in full in cash the Royalty Investors Fees and all Restructuring Fees and Expenses when incurred and invoiced in accordance with Section 16.21 and the applicable engagement letters or fee arrangements (including under any DIP Order), and continue to promptly pay such amounts as they come due;
(g) subject to Section 16.26, provide to the Ad Hoc Group Advisors, the Consenting Royalty Investors Advisors, and Ayrmid Advisors draft copies of (i) the First Day Pleadings and all orders sought pursuant thereto, (ii) the Bidding Procedures Motion and the Bidding Procedures Order, (iii) the Sale Order, (iv) the Plan, (v) the Plan Supplement, (vi) the Disclosure Statement, (vii) the Conditional Disclosure Statement Order and the Disclosure Statement Order, (viii) the Solicitation Materials, (ix) the DIP Motion and the DIP Orders, (x) the Confirmation Order, and (xi) all other material motions, pleadings, filings, applications, and proposed orders relating to the Restructuring Transactions or that any Company Party intends to file with the Bankruptcy Court, in each case at least three (3) calendar days prior to the date on which the applicable Company Party files or executes such document (or, if three (3) calendar days’ advance delivery is not reasonably practicable under the circumstances, as soon as reasonably practicable prior to such filing or execution), and consult in good faith with the Ad Hoc Group Advisors and Ayrmid Advisors regarding the form and substance of each of the foregoing in advance of such filing or execution;
(h) promptly, and in any event within two (2) Business Days after receipt or delivery of the same, deliver to the Ad Hoc Group Advisors and the Consenting Royalty Investors Advisors copies of all written expressions of interest, indications of interest, bids, term sheets, letters of intent, memoranda of understanding, definitive agreements, and similar documents received by, or delivered by, any Company Party or any of its investment bankers or financial advisors concerning any Alternative Restructuring Proposal or any sale, disposition, merger, recapitalization, or other restructuring transaction involving all or any material portion of the Company Parties’ businesses or assets, and notify the Ad Hoc Group Advisors of all persons or Entities to whom any marketing materials have been distributed; provided, that the Ad Hoc Group Advisors shall not share such materials with the Highbridge Funds, their advisors, Ayrmid, or any personnel or advisors of the Highbridge Funds that are, in each case, acting in a Bidder Capacity;
(i) notify the Ad Hoc Group Advisors, the Consenting Royalty Investors Advisors, and Ayrmid Advisors in writing (email being sufficient) within two (2) Business Days after any Company Party receives notice or obtains actual knowledge of (i) any event or circumstance that would permit any Party to terminate, or that would result in the termination of, this Agreement, (ii) any matter or circumstance that is, or is reasonably likely to be, a material impediment to the implementation or consummation of the Restructuring Transactions, (iii) any breach of this Agreement (including any breach by a Company Party), (iv) any representation or statement made
27
or deemed made by any Company Party under this Agreement that is or proves to have been materially incorrect or misleading in any respect when made or deemed made, (v) the commencement or threat of any material governmental or third-party complaint, litigation, investigation, or proceeding, including any proceeding challenging the validity of the Restructuring Transactions or any Definitive Document, and (vi) any enforcement or remedial action taken by any creditor of any Company Party, whether under any agreement governing the Funded Debt or otherwise; provided, that notification to the Ayrmid Advisors shall be subject to Section 16.26 and not be required for any information concerning other bids, bidders, or potential bidders, which such information shall not be disseminated to the Ayrmid Advisors;
(j) use commercially reasonable efforts to maintain the good standing and legal existence of each Company Party under the Laws of the state or other jurisdiction in which it is incorporated, organized, or formed, except as otherwise contemplated by the Restructuring Transactions or the Definitive Documents or as results from the Chapter 11 Cases;
(k) subject to the Bidding Procedures Order and the limitations provided in Section 16.26 hereof regarding any Sale Process Matter and so long as this Agreement has not been terminated as to Ayrmid, but in each case solely to the extent the same is provided or offered to any other bidder, (i) give Ayrmid and the Ayrmid Advisors reasonable access to their officers, employees, accountants, auditors, counsel, financial advisors and consultants, (ii) furnish to Ayrmid and the Ayrmid Advisors such financial, operating, and related data and other information as such persons reasonably request (provided that such information may also be shared with all other bidders), and (iii) instruct their employees, financial advisors, consultants and other representatives to use commercially reasonable efforts to cooperate with Ayrmid and the Ayrmid Advisors in respect of the aforementioned clauses (i) and (ii); provided, that the Company Parties shall not be required to afford such access to the extent that doing so would result in the loss of any privilege or violate any applicable Law; provided, further, that Ayrmid acknowledges and agrees that any such information pursuant to this Section 9.01(k) shall be treated as confidential information and be afforded protections pursuant to any applicable Confidentiality Agreement;
(l) use commercially reasonable efforts to permit employees or contractors of Ayrmid to advise and assist the Company Parties in their efforts to migrate all server data to cloud storage (in connection with NewCo operations) that are stored at the Wells Property prior to any exit from such premises in connection with the Chapter 11 Cases, provided that nothing herein shall obligate the Company Parties to provide information or data to Ayrmid that cannot otherwise be shared with other bidders;
(m) cooperate in good faith and use commercially reasonable efforts to structure and implement the Restructuring Transactions in a manner that optimizes the tax efficiency (including by way of the preservation or enhancement of favorable tax attributes) of the Restructuring Transactions for the Company Parties, the Consenting Stakeholders and Ayrmid, as reasonably determined by the Company Parties and the Required Consenting Funded Debt Parties; and
(n) cooperate with each Consenting Stakeholder, upon request, in determining whether such Consenting Stakeholder is a “Substantial Shareholder” within the meaning of the NOL Motion as and to the extent required for the Consenting Stakeholder to timely comply with any procedures set forth in the NOL Motion.
28
9.02. Negative Commitments. During the Agreement Effective Period, each of the Company Parties agrees that, subject to Section 14, it shall not directly or indirectly:
(a) object to, delay, impede, or take any other action to interfere with acceptance, implementation, or consummation of the Restructuring Transactions;
(b) take any action that is inconsistent in any material respect with, or that is intended to frustrate or impede approval, implementation, or consummation of, the Restructuring Transactions, this Agreement, or the Plan;
(c) modify or amend the Plan or any other Definitive Document, in whole or in part, in a manner that is not consistent with this Agreement in all material respects;
(d) file any motion, pleading, Definitive Document, or other document with the Bankruptcy Court or any other court (including any modifications or amendments thereof) that, in whole or in part, is not materially consistent with this Agreement or the Plan;
(e) terminate any engagement letter or fee arrangement relating to the Restructuring Fees and Expenses or the Royalty Investors Fees, except in the event of a breach by the applicable advisor or holder thereunder;
(f) withdraw or revoke the Plan, or announce publicly or inform any other party of its intention not to pursue the Plan or not to support the Restructuring Transactions, or delay the pursuit of confirmation of the Plan in a manner that is inconsistent with this Agreement, the Definitive Documents, or the Milestones;
(g) seek, solicit, encourage, propose, file, support, consent to, approve, vote for, or enter into or participate in any discussions, agreements, understandings, or other arrangements with any person or Entity regarding, or otherwise pursue or consummate, any Alternative Restructuring Proposal; provided, that, for the avoidance of doubt, actions taken by the Company Parties in accordance with the Bidding Procedures Order (which shall be in form and substance reasonably acceptable to the Required Consenting Funded Debt Parties and Ayrmid), including any such actions taken prior to entry of such order, shall not be a violation of this Section 9.02(g);
(h) sell, or file any motion or application seeking to sell, any material assets, other than in the ordinary course of business or in accordance with this Agreement or the Bidding Procedures Order;
(i) amend any of their corporate governance or organizational documents except as consented to by the Required Consenting Funded Debt Parties and Ayrmid, such consent not to be unreasonably withheld;
(j) other than as required by Law or regulation or consented to by the Required Consenting Funded Debt Parties and Ayrmid, (i) enter into or amend, establish, adopt, restate, supplement, or otherwise modify or accelerate (x) any deferred compensation, incentive, success, retention, bonus, or other compensatory arrangements, policies, programs, practices, plans, or agreements, including, without limitation, offer letters, employment agreements, consulting agreements, severance arrangements, or change in control arrangements, in the case of each of the
29
foregoing, with or for the benefit of their executive officers, other members of management and directors, or (y) any contracts, arrangements, or commitments that entitle any of their executive officers, other members of management and directors to indemnification from the Company Parties, or (ii) amend or terminate any existing compensation or benefit plans or arrangements (including employment agreements), unless otherwise expressly set forth as a line item in the DIP Budget;
(k) other than as required by Law or regulation or consented to by the Required Consenting Funded Debt Parties and Ayrmid, (i) enter into any settlement regarding any material Claims or Equity Interests, (ii) amend, supplement, modify, or terminate or enter into any material agreement that is inconsistent with this Agreement, (iii) knowingly allow any material agreement to expire if such expiration would frustrate or impede consummation of the Restructuring Transactions, or (iv) knowingly allow any material Permit, license, or regulatory approval to lapse, expire, terminate, or be revoked, suspended, or modified;
(l) (i) operate its business outside the ordinary course, other than the Restructuring Transactions or as contemplated by the DIP Budget, the DIP Documents, the First Day Pleadings or orders thereon, or consented to by the Required Consenting Funded Debt Parties and Ayrmid (in each case not to be unreasonably withheld), or (ii) other than as contemplated by this Agreement, transfer any material asset or right of the Company Parties (or their affiliates) or any material asset or right used in the business of the Company Parties (or their affiliates) to any person or Entity;
(m) other than as contemplated by this Agreement, engage in any material merger, consolidation, disposition, acquisition, investment, dividend, incurrence of indebtedness, or other similar transaction, or authorize or consummate any issuance or sale of equity interests of any Company Party, make any restricted payment, or make any payment with respect to the principal amount of any indebtedness, except as permitted by the DIP Documents, the First Day Pleadings, or the orders thereon;
(n) knowingly violate the terms of any Permits or regulatory approvals;
(o) commence, support, or join any litigation or adversary proceeding against any Consenting Stakeholder, any Agent, any Trustee and/or Ayrmid, other than to enforce this Agreement or any Definitive Document;
(p) prepare, commence, or support any avoidance action or other legal proceeding, or assist any third party in connection with any avoidance action or other legal proceeding, or file any motion, in each case seeking to avoid, disallow, subordinate, invalidate, limit, or recharacterize, or that otherwise challenges the amount, validity, allowance, character, enforceability, liens or encumbrances securing, or priority of, any Company Claims/Interests held by a Consenting Stakeholder, or consent to the standing of any such third party to bring such application, adversary proceeding, or cause of action;
(q) exercise, or direct any other person or Entity to exercise, any action with respect to any Company Claims/Interests that is inconsistent with the terms of this Agreement; or
30
(r) encourage any person or Entity, or facilitate any effort by any person or Entity, to do any of the foregoing.
Section 10. Additional Provisions Regarding Company Parties’ Commitments.
10.01. Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement shall require a Company Party, or the board of directors, board of managers, or similar governing body of such Company Party, after consulting with counsel, to take any action or to refrain from taking any action with respect to the Restructuring Transactions to the extent taking or failing to take such action would be inconsistent with applicable Law or its fiduciary obligations under applicable Law, and any such action or inaction pursuant to this Section 10.01 shall not be deemed to constitute a breach of this Agreement; provided, that, no such determination, action, or inaction shall limit, impair, or impede any Consenting Stakeholder’s right to terminate this Agreement in accordance with Section 14. The applicable Company Parties shall notify counsel to the other Parties in writing of any determination made in accordance with this Section 10.01 within forty-eight (48) hours following such determination. Notwithstanding anything to the contrary herein, each Consenting Stakeholder reserves its rights to challenge any action taken or not taken by any Company Party in the exercise of its fiduciary obligations.
10.02. Notwithstanding anything to the contrary in this Agreement (but subject to Section 10.01), each Company Party and its respective directors, officers, employees, investment bankers, attorneys, accountants, consultants, and other advisors or representatives shall have the rights to: (a) consider, respond to, and facilitate any Alternative Restructuring Proposal; (b) provide access to non-public information concerning any Company Party to any Entity or enter into Confidentiality Agreements or nondisclosure agreements with any Entity; (c) maintain or continue discussions or negotiations with respect to any Alternative Restructuring Proposal; (d) otherwise cooperate with, assist, participate in, or facilitate any inquiries, proposals, discussions, or negotiations with respect to any Alternative Restructuring Proposal; and (e) enter into or continue discussions or negotiations with holders of Claims against or Equity Interests in a Company Party (including any Consenting Stakeholder), any other party in interest in the Chapter 11 Cases (including any official committee and the Office of the United States Trustee), or any other Entity regarding the Restructuring Transactions or any Alternative Restructuring Proposal, in each case in a manner that is not otherwise inconsistent with the terms of this Agreement or the Restructuring Transactions. If any Company Party receives an Alternative Restructuring Proposal, then such Company Party shall: (x) within two (2) Business Days, provide the Ad Hoc Group Advisors with notice and a copy of such proposal, including all annexes, ancillary terms, and other components thereof (and, to the extent such proposal is not in writing, a detailed written summary thereof), including the identity of the person or group of persons involved; (y) provide the Ad Hoc Group Advisors with regular updates as to the status and progress of such Alternative Restructuring Proposal; and (z) promptly respond to reasonable information requests and questions from the Ad Hoc Group Advisors relating to such Alternative Restructuring Proposal; provided, that the Ad Hoc Group Advisors shall not share such materials or information with the Highbridge Funds, their advisors, Ayrmid, or any personnel or advisors of the Highbridge Funds that are, in each case, acting in a Bidder Capacity.
31
10.03. Nothing in this Agreement shall: (a) impair or waive the rights of any Party to assert or raise any objection permitted under this Agreement in connection with the Restructuring Transactions; or (b) prevent any Party from enforcing this Agreement or contesting whether any matter, fact, or thing is a breach of, or is inconsistent with, this Agreement.
Section 11. Transfer of Interests and Securities; Joinder.
11.01. Except as expressly provided herein, this Agreement shall not in any way restrict the right or ability of any Consenting Stakeholder to Transfer any Company Claims/Interests; provided, however, that, during the Agreement Effective Period, no Consenting Stakeholder shall Transfer any ownership (including any beneficial ownership as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) in any Company Claims/Interests to any affiliated or unaffiliated party, including any party in which it may hold a direct or indirect beneficial interest, unless:
(a) in the case of any Company Claims/Interests, the authorized transferee is either (i) a qualified institutional buyer as defined in Rule 144A of the Securities Act, (ii) a non-U.S. person in an offshore transaction as defined under Regulation S under the Securities Act, (iii) an institutional accredited investor (as defined in the Rules), (iv) a Consenting Stakeholder, or (v) an affiliate, affiliated fund, or affiliated entity with a common investment advisor of such Consenting Stakeholder;
(b) either (i) the transferee executes a Transfer Agreement and delivers an executed copy thereof to counsel to the Company Parties within five (5) Business Days following execution thereof or (ii) the transferee is a Consenting Stakeholder, or an affiliate, affiliated fund, or affiliated entity with a common investment advisor of a Consenting Stakeholder, and the transferee provides notice of such Transfer (including the amount and type of Company Claim/Interest so Transferred) to counsel to the Company Parties within five (5) Business Days following the closing of such Transfer; provided, that, upon any Transfer described in clause (ii) above, such transferee shall be deemed to become a Consenting Stakeholder; and
(c) such Transfer shall not violate the terms of any order entered by the Bankruptcy Court with respect to preservation of net operating losses.
11.02. Upon compliance with the requirements of Section 11.01, the transferor shall be deemed to relinquish its rights (and be released from its obligations) under this Agreement to the extent of the rights and obligations in respect of such transferred Company Claims/Interests. Any Transfer in violation of Section 11.01 shall be void ab initio.
11.03. This Agreement shall in no way be construed to preclude the Consenting Stakeholders from acquiring additional Company Claims/Interests; provided, however, that (a) such additional Company Claims/Interests shall automatically and immediately upon acquisition by a Consenting Stakeholder be deemed subject to the terms of this Agreement (regardless of when or whether notice of such acquisition is given to counsel to the Company Parties or counsel to the Consenting Stakeholders) and (b) such Consenting Stakeholder must provide notice of such acquisition (including the amount and type of Company Claim/Interest acquired) to counsel to the Company Parties within five (5) Business Days of such acquisition.
32
11.04. This Section 11 shall not impose any obligation on any Company Party or Ayrmid to issue any “cleansing letter” or otherwise publicly disclose information for the purpose of enabling a Consenting Stakeholder to Transfer any of its Company Claims/Interests. Notwithstanding anything to the contrary herein, to the extent a Company Party and another Party have entered into a Confidentiality Agreement, the terms of such Confidentiality Agreement shall continue to apply and remain in full force and effect according to its terms, and this Agreement does not amend, modify, or supersede any rights or obligations otherwise arising under such Confidentiality Agreements.
11.05. Notwithstanding Section 11.01, a Qualified Marketmaker that acquires any Company Claims/Interests with the purpose and intent of acting as a Qualified Marketmaker for such Company Claims/Interests shall not be required to execute and deliver a Transfer Agreement in respect of such Company Claims/Interests if (a) such Qualified Marketmaker subsequently transfers such Company Claims/Interests (by purchase, sale, assignment, participation, or otherwise) within ten (10) Business Days of its acquisition to a transferee that is an entity that is not an affiliate, affiliated fund, or affiliated entity with a common investment advisor; (b) the transferee otherwise is a Permitted Transferee under Section 11.01; and (c) the Transfer otherwise is a Permitted Transfer under Section 11. To the extent that a Consenting Stakeholder is acting in its capacity as a Qualified Marketmaker, it may Transfer (by purchase, sale, assignment, participation, or otherwise) any right, title, or interest in Company Claims/Interests that the Qualified Marketmaker acquires from a holder of the Company Claims/Interests who is not a Consenting Stakeholder without the requirement that the transferee be a Permitted Transferee.
11.06. Notwithstanding anything to the contrary in this Section 11, the restrictions on Transfer set forth in this Section 11 shall not apply to the grant of any liens or encumbrances on any claims and interests in favor of a bank or broker-dealer holding custody of such claims and interests in the ordinary course of business and which lien or encumbrance is released upon the Transfer of such claims and interests.
11.07. Any holder of Company Claims/Interests that is not a party to this Agreement as of the Agreement Effective Date may, at any time after the Agreement Effective Date, become a Consenting Stakeholder by executing and delivering a Joinder to counsel to the Company Parties pursuant to which such Entity shall be bound by the terms of this Agreement.
Section 12. Representations and Warranties of Consenting Stakeholders. Each Consenting Stakeholder severally, and not jointly, represents and warrants that, as of the date such Consenting Stakeholder executes and delivers this Agreement (or, in the case of any Consenting Stakeholder that becomes a Party after the Agreement Effective Date, as of the date such Consenting Stakeholder becomes a Party hereto):
(a) subject to customary exceptions contained in ordinary course fund financing arrangements, it is (or will be, following the closing of any currently open trades) the beneficial or record owner of the aggregate principal amount of the Company Claims/Interests, or is the nominee, investment manager, investment advisor, sub-advisor, or manager of discretionary accounts or funds that beneficially hold the Company Claims/Interests, or has investment or voting discretion with respect to, and the power and authority to bind the beneficial owners of, the principal amount of the Company Claims/Interests, in each case reflected in, and, having made reasonable inquiry, is not the beneficial or record owner of any Company Claims/Interests other than those reflected in, such Consenting Stakeholder’s signature page to this Agreement or a Transfer Agreement or a Joinder, as applicable (as may be updated pursuant to Section 11);
33
(b) it has the full power and authority to act on behalf of, vote and consent to matters concerning, such Company Claims/Interests;
(c) other than (i) with respect to any ordinary course pledge (1) in favor of a bank or broker-dealer at which such Consenting Stakeholder maintains an account, where such bank or broker-dealer holds a security interest in or other encumbrance over property in the account generally, or (2) to any holders of obligations owed, or securities issued, by such Consenting Stakeholder, including to any trustee for, or any other representative of, such holders, and (ii) pursuant to this Agreement, such Company Claims/Interests are free and clear of any pledge, lien, security interest, charge, claim, equity, option, proxy, voting restriction, right of first refusal, or other limitation on disposition, transfer, or encumbrance of any kind, that would adversely affect, in any material respect, such Consenting Stakeholder’s ability to perform any of its obligations under this Agreement at the time such obligations are required to be performed; and
(d) solely with respect to holders of Company Claims/Interests, (i) it is either (A) a qualified institutional buyer as defined in Rule 144A of the Securities Act, (B) not a U.S. person (as defined in Regulation S of the Securities Act), or (C) an institutional accredited investor (as defined in the Rules), and (ii) any securities acquired by the Consenting Stakeholder in connection with the Restructuring Transactions will have been acquired for investment and not with a view to distribution or resale in violation of the Securities Act.
Notwithstanding anything to the contrary in this Section 12, no Consenting Stakeholder shall be deemed to have breached any representation or warranty set forth in this Section 12 as a result of any swap agreement with respect to any Company Claims/Interests entered into in the ordinary course, so long as (i) such swap agreement is unwound or terminated, such Company Claims/Interests are returned or repurchased, or the applicable swap counterparty becomes a Consenting Stakeholder by executing and delivering a Joinder or Transfer Agreement, in each case sufficiently in advance of any voting or other deadline necessary for such Consenting Stakeholder to comply with its obligations hereunder, or (ii) the applicable swap counterparty acts in compliance with the commitments of the Consenting Stakeholders set forth in Section 5.
Section 13. Mutual Representations, Warranties, and Covenants. Each of the Parties severally, and not jointly, represents, warrants, and covenants to each other Party, as of the date such Party executes and delivers this Agreement (or, in the case of any Consenting Stakeholder that becomes a Party after the Agreement Effective Date, as of the date such Consenting Stakeholder becomes a Party hereto):
(a) it is validly existing and in good standing under the Laws of the jurisdiction of its organization, and this Agreement is a legal, valid, and binding obligation of such Party, enforceable against it in accordance with its terms, except as enforcement may be limited by applicable Laws relating to or limiting creditors’ rights generally or by equitable principles relating to enforceability;
34
(b) except as expressly provided in this Agreement, the Plan, and the Bankruptcy Code, no consent or approval is required by any other person or Entity in order for it to effectuate the Restructuring Transactions contemplated by, and perform its respective obligations under, this Agreement;
(c) the entry into and performance by it of, and the transactions contemplated by, this Agreement do not, and will not, conflict in any material respect with any Law or regulation applicable to it or with any of its articles of association, memorandum of association, or other organizational documents;
(d) except as expressly provided in this Agreement, it has (or will have, at the relevant time) all requisite corporate or other power and authority to enter into, execute, and deliver this Agreement and to effectuate the Restructuring Transactions contemplated by, and perform its respective obligations under, this Agreement; and
(e) except as expressly provided by this Agreement, it is not party to any restructuring or similar agreements or arrangements with the other Parties to this Agreement that have not been disclosed to all Parties to this Agreement.
Section 14. Termination Events.
14.01. Consenting Funded Debt Party Termination Events. This Agreement may be terminated as to all Parties by the Required Consenting Funded Debt Parties upon the occurrence of any of the following events (provided that such event does not arise as a direct or indirect result of the Company Parties terminating this Agreement pursuant to Section 14.04(a)(ii) in order to pursue an Alternative Restructuring Proposal); provided, further, that such termination is effective only upon the delivery to the Parties of a written notice in accordance with Section 16.10 hereof upon the occurrence of any of the following events:
(a) the breach in any material respect by a Company Party of any of the representations, warranties, or covenants of the Company Parties set forth in this Agreement that (i) is adverse to the Consenting Funded Debt Parties seeking termination and (ii) remains uncured for five (5) Business Days after the Required Consenting Funded Debt Parties transmit a written notice in accordance with Section 16.10 hereof detailing any such breach;
(b) the issuance by any Governmental Entity, including any regulatory authority or court of competent jurisdiction, of any final, non-appealable ruling or order that (i) enjoins the consummation of a material portion of the Restructuring Transactions and (ii) remains in effect for fifteen (15) Business Days after the Required Consenting Funded Debt Parties transmit a written notice in accordance with Section 16.10 hereof detailing any such issuance; provided, that this termination right may not be exercised by any Party that sought or requested such ruling or order in contravention of any obligation set out in this Agreement;
(c) the Bankruptcy Court enters an order denying confirmation of the Plan;
(d) the entry of an order by the Bankruptcy Court, or the filing of a motion or application by any Company Party or any of its affiliates seeking an order (without the prior written consent of the Required Consenting Funded Debt Parties in their sole discretion), (i) converting one or more of the Chapter 11 Cases of a Company Party to a case under chapter 7 of the Bankruptcy Code, (ii) appointing an examiner with expanded powers beyond those set forth in sections 1106(a)(3) and 1106(a)(4) of the Bankruptcy Code or a trustee in one or more of the Chapter 11 Cases of a Company Party, or (iii) rejecting this Agreement;
35
(e) the failure to meet a Milestone, where such Milestone has not been waived or extended in a manner consistent with this Agreement;
(f) this Agreement or any Definitive Document is entered into, amended, modified, or supplemented, without the prior written consent of the Required Consenting Funded Debt Parties, in a manner that is inconsistent with this Agreement or adversely affects, in any material respect, the rights or treatment of any Consenting Stakeholder, in each case where such entry, amendment, modification, or supplement has not been withdrawn or reversed within five (5) Business Days after written notice thereof; provided, that no modification, amendment, restatement, waiver, or supplement of this Agreement effected in accordance with Section 15 shall constitute a termination event under this Section 14.01(f);
(g) any Company Party or any of its affiliates files, amends, modifies, or files a pleading seeking approval of, or seeks authority to amend or modify, any Definitive Document, motion, or pleading in a manner that is inconsistent with this Agreement or the Bankruptcy Court enters an order approving any such Definitive Document, motion, or pleading, in each case where such filing has not been withdrawn, or such order stayed, reversed, or vacated, within five (5) Business Days following written notice thereof;
(h) any Company Party, without the prior written consent of the Required Consenting Funded Debt Parties, withdraws or revokes the Plan or the Disclosure Statement, or amends or modifies, or files a motion or pleading seeking to amend or modify, the Plan, the Disclosure Statement, or any Definitive Document in a manner that is inconsistent with this Agreement or materially adverse to any Consenting Funded Debt Party, and such amendment or modification has not been reversed, or such motion or pleading withdrawn, prior to the earlier of (i) five (5) Business Days after the Company Parties receive written notice thereof and (ii) entry of an order of the Bankruptcy Court approving such motion or pleading;
(i) any Company Party or any of its affiliates (i) publicly announces, or communicates to any Consenting Stakeholder or other holder of Company Claims/Interests, its intention not to support or pursue the Restructuring Transactions, (ii) suspends or revokes, or announces its intention to suspend or revoke, the Restructuring Transactions, (iii) solicits, executes, or enters into a definitive written agreement with respect to any Alternative Restructuring Proposal, or (iv) files, proposes, or otherwise supports any plan of reorganization or liquidation other than the Plan; provided, that, for the avoidance of doubt, actions taken by the Company Parties in accordance with this Agreement with respect to the Ayrmid Transaction and the Bidding Procedures Order shall not constitute a termination event under this Section 14.01(i);
(j) the failure of any Company Party to make any payment contemplated under this Agreement as and when due, including the Royalty Investors Fees or any Restructuring Fees and Expenses payable under Section 16.21;
36
(k) any Company Party, or any of their respective affiliates seeks, supports, joins in seeking, consents to, fails to oppose, or obtains an order, ruling, or other relief that (i) avoids, disallows, subordinates, invalidates, limits, or recharacterizes, in any respect, any Company Claims/Interests held by a Consenting Stakeholder or any liens or collateral securing the same, or (ii) imposes liability upon, enjoins, or restricts the rights of any holder of Company Claims/Interests in its capacity as such, in each case where such violation of this Section 14.01(k) has not been cured, or such order, ruling, or relief has not been stayed, reversed, or vacated, within two (2) Business Days following written notice thereof;
(l) the entry of an order by the Bankruptcy Court or any other court of competent jurisdiction avoiding, disallowing, subordinating, invalidating, limiting, or recharacterizing, in any respect, any Company Claims/Interests held by a Consenting Stakeholder or any liens or collateral securing the same, in each case where such order has not been stayed, reversed, or vacated, within two (2) Business Days following written notice thereof;
(m) the entry of an order by the Bankruptcy Court, or the filing of a motion or application by any Company Party seeking an order, terminating the Debtors’ exclusive right to file and/or solicit acceptances of a chapter 11 plan under section 1121 of the Bankruptcy Code or modifying the right of exclusivity (other than to extend the time to exercise such right), in each case where such filing has not been withdrawn, or such order stayed, reversed, or vacated, within five (5) Business Days following written notice thereof;
(n) after entry by the Bankruptcy Court of any of the DIP Orders, the Disclosure Statement Order, the Conditional Disclosure Statement Order, the Bidding Procedures Order, the Sale Order, or the Confirmation Order, any such order is reversed, dismissed, vacated, reconsidered, modified, or amended, or any Company Party files a motion, application, or other pleading seeking any of the foregoing, in each case in a manner materially inconsistent with this Agreement or materially adverse to any Consenting Funded Debt Party and without the prior written consent of the Required Consenting Funded Debt Parties, that remains uncured for a period of five (5) Business Days after written notice thereof;
(o) the Bankruptcy Court grants relief terminating, annulling, or modifying the automatic stay under section 362 of the Bankruptcy Code with regard to any asset or assets of the Company Parties having an aggregate fair market value in excess of $2 million, in each case without the prior written consent of the Required Consenting Funded Debt Parties in their sole discretion, in each case where such order has not been stayed, reversed, or vacated, within five (5) Business Days following written notice thereof;
(p) other than the Chapter 11 Cases, any Company Party, without the prior written consent of the Required Consenting Funded Debt Parties, voluntarily commences any restructuring, insolvency, winding up, liquidation, administration, or similar proceeding with respect to any Company Party or for a substantial part of any Company Party’s assets, except as contemplated by this Agreement;
(q) the commencement of an involuntary petition or proceeding seeking bankruptcy, winding up, dissolution, liquidation, administration, moratorium, reorganization, assignment for the benefit of creditors, or other similar relief in respect of any Company Party, its debts, or a substantial part of its assets, under any federal, state, or foreign bankruptcy, insolvency, administrative, receivership, or similar Law; provided, that such involuntary petition or proceeding is not dismissed, stayed, reversed, or vacated within ten (10) Business Days after the filing thereof, or any court order grants the relief sought in such involuntary petition or proceeding;
37
(r) the occurrence of an “Event of Default” under the DIP Term Sheet or any other DIP Document, or the acceleration of the obligations or termination of the commitments (other than a termination of commitments upon the funding of loans under the DIP Facility) under the DIP Facility, in each case that has not been cured or waived in accordance with the DIP Documents;
(s) the termination of the consensual use of cash collateral, or the entry of an order by the Bankruptcy Court terminating or modifying the Company Parties’ right to use cash collateral, in each case without the prior written consent of the Required Consenting Funded Debt Parties;
(t) (i) the Ayrmid Transaction Term Sheet or Merger Agreement (if applicable) is terminated or amended, modified, supplemented, waived, or assigned in a manner materially inconsistent with this Agreement or materially adverse to the Consenting Funded Debt Parties; (ii) the occurrence of any material breach or material default by any Company Party or Ayrmid under the Ayrmid Transaction Term Sheet or the Merger Agreement (if applicable), or of any event, condition, or circumstance that would permit any party thereto to terminate the Ayrmid Transaction Term Sheet or the Merger Agreement (if applicable) or that would cause any condition precedent to the closing of the Ayrmid Transaction not to be satisfied or to become incapable of satisfaction; or (iii) any Company Party or Ayrmid (if applicable) otherwise fails to consummate the Ayrmid Transaction in accordance with this Agreement and the Milestones; provided, that, with respect to the preceding clause (ii), if such breach or default is by Ayrmid or if such event, condition, or circumstance is attributable to Ayrmid, then this termination shall only be with respect to the Consenting Funded Debt Parties’ obligations to Ayrmid; provided, further, that none of the foregoing clauses (i) through (iii) shall constitute a termination event to the extent the applicable termination, amendment, modification, supplement, waiver, assignment, breach, default, event, condition, circumstance, or failure to consummate arises from or relates to the Debtors, with the consent of the Required Consenting Funded Debt Parties, determining to pursue an Acceptable Alternative Transaction;
(u) (a) this Agreement is terminated as to Ayrmid, Ayrmid withdraws from the sale process, or the Ayrmid Transaction has not been consummated by the Ayrmid Outside Date, and (b) within five (5) Business Days thereafter, (1) the Company Parties have not entered into a definitive agreement with respect to an Acceptable Alternative Transaction, and (2) the Consenting Funded Debt Parties (or the applicable Agents/Trustees on their behalf) have not submitted a credit bid for all or substantially all of the Company Parties’ assets; or
(v) the issuance, promulgation, or enactment by any Governmental Entity of any statute, regulation, ruling, or final order, or any change in Law, that in each case makes illegal or otherwise prevents or prohibits the consummation of a material portion of the Restructuring Transactions, and such statute, regulation, ruling, final order, or change in Law has not been reversed, stayed, or vacated within fifteen (15) Business Days thereafter.
38
14.02. Consenting Royalty Investor Termination Events. This Agreement may be terminated solely with respect to the Consenting Royalty Investors by the Required Consenting Royalty Investors (provided that such event does not arise as a direct or indirect result of the Company Parties terminating this Agreement pursuant to Section 14.04(a)(ii) in order to pursue an Alternative Restructuring Proposal); provided, that such termination is not with respect to any other Party and is effective only upon the delivery to the Company Parties of a written notice in accordance with Section 16.10 hereof upon the occurrence of any of the following events:
(a) the breach in any material respect by a Company Party of any of the representations, warranties, or covenants of the Company Parties set forth in this Agreement that (i) is materially adverse to the Consenting Royalty Investors seeking termination pursuant to this provision and (ii) remains uncured for five (5) Business Days after such terminating Consenting Royalty Investors transmit a written notice in accordance with Section 16.10 hereof detailing any such breach;
(b) the issuance by any Governmental Entity, including any regulatory authority or court of competent jurisdiction, of any final, non-appealable ruling or order that (i) enjoins the consummation of a material portion of the Restructuring Transactions and (ii) remains in effect for fifteen (15) Business Days after such terminating Consenting Royalty Investors transmit a written notice in accordance with Section 16.10 hereof detailing any such issuance; provided, that this termination right may not be exercised by any Party that sought or requested such ruling or order in contravention of any obligation set out in this Agreement;
(c) the Bankruptcy Court enters an order denying confirmation of the Plan;
(d) the entry of an order by the Bankruptcy Court, or the filing of a motion or application by any Company Party seeking an order (without the prior written consent of the Required Consenting Royalty Investors, not to be unreasonably withheld), (i) converting one or more of the Chapter 11 Cases of a Company Party to a case under chapter 7 of the Bankruptcy Code, (ii) appointing an examiner with expanded powers beyond those set forth in sections 1106(a)(3) and 1106(a)(4) of the Bankruptcy Code or a trustee in one or more of the Chapter 11 Cases of a Company Party, or (iii) rejecting this Agreement;
(e) the failure to meet a Milestone, where such Milestone has not been waived or extended in a manner consistent with this Agreement;
(f) this Agreement or any Definitive Document is entered into, amended, modified, or supplemented, without the prior written consent of the Required Consenting Royalty Investors, in a manner that is inconsistent with this Agreement and adversely affects, in any material respect, the rights or treatment of any Consenting Royalty Investor, in each case where such entry, amendment, modification or supplement has not been withdrawn or reversed within five (5) Business Days after written notice thereof; provided, that no modification, amendment, restatement, waiver, or supplement of this Agreement effected in accordance with Section 15 shall constitute a termination event under this Section 14.02(f);
39
(g) any Company Party or any of its affiliates files, amends, or modifies a pleading seeking approval of, or seeks authority to amend or modify, any Definitive Document, motion, or pleading in a manner that is materially inconsistent with this Agreement and materially adverse to any Consenting Royalty Investor or the Bankruptcy Court enters an order approving any such Definitive Document, motion, or pleading, in each case where such filing has not been withdrawn, or such order stayed, reversed, or vacated, within five (5) Business Days following written notice thereof;
(h) any Company Party, without the prior written consent of the Required Consenting Royalty Investors, withdraws or revokes the Plan or the Disclosure Statement, or amends or modifies, or files a motion or pleading seeking to amend or modify, the Plan, the Disclosure Statement, or any Definitive Document in a manner that is inconsistent with this Agreement and materially adverse to any Consenting Royalty Investor, and such amendment or modification has not been reversed, or such motion or pleading withdrawn, prior to the earlier of (i) five (5) Business Days after the Company Parties receive written notice thereof and (ii) entry of an order of the Bankruptcy Court approving such motion or pleading;
(i) any Company Party or any of its affiliates (i) publicly announces, or communicates to any Consenting Stakeholder or other holder of Company Claims/Interests, its intention not to support or pursue the Restructuring Transactions, (ii) suspends or revokes, or announces its intention to suspend or revoke, the Restructuring Transactions, (iii) solicits, executes, or enters into a definitive written agreement with respect to any Alternative Restructuring Proposal, or (iv) files, proposes, or otherwise supports any plan of reorganization or liquidation other than the Plan; provided, that, for the avoidance of doubt, actions taken by the Company Parties in accordance with this Agreement with respect to the Ayrmid Transaction and the Bidding Procedures Order shall not constitute a termination event under this Section 14.02(i);
(j) the failure of any Company Party to make any payment to the Consenting Royalty Investors or their advisors contemplated under this Agreement as and when due, including the Royalty Investors Fees payable under Section 16.21;
(k) any Company Party, or any of their respective affiliates seeks, supports, joins in seeking, consents to, fails to oppose, or obtains an order, ruling, or other relief that (i) avoids, disallows, subordinates, invalidates, limits, or recharacterizes, in any respect, any Company Claims/Interests held by a Consenting Royalty Investor or any liens or collateral securing the same, or (ii) imposes liability upon, enjoins, or restricts the rights of any holder of Company Claims/Interests in its capacity as such, in each case where such violation of this Section 14.02(k) has not been cured, or such order, ruling, or relief has not been stayed, reversed, or vacated, within two (2) Business Days following written notice thereof;
(l) the entry of an order by the Bankruptcy Court or any other court of competent jurisdiction avoiding, disallowing, subordinating, invalidating, limiting, or recharacterizing, in any respect, any Company Claims/Interests held by a Consenting Royalty Investor or any liens or collateral securing the same, in each case where such order has not been stayed, reversed, or vacated, within two (2) Business Days following written notice thereof;
(m) the entry of an order by the Bankruptcy Court, or the filing of a motion or application by any Company Party seeking an order, terminating the Debtors’ exclusive right to file and/or solicit acceptances of a chapter 11 plan under section 1121 of the Bankruptcy Code or modifying the right of exclusivity (other than to extend the time to exercise such right), in each case where such filing has not been withdrawn, or such order stayed, reversed, or vacated, within five (5) Business Days following written notice thereof;
40
(n) after entry by the Bankruptcy Court of any of the DIP Orders, the Disclosure Statement Order, the Conditional Disclosure Statement Order, the Bidding Procedures Order, the Sale Order, or the Confirmation Order, any such order is reversed, dismissed, vacated, reconsidered, modified, or amended, or any Company Party files a motion, application, or other pleading seeking any of the foregoing, in each case in a manner materially inconsistent with this Agreement and materially adverse to any Consenting Royalty Investor and without the prior written consent of the Required Consenting Royalty Investors, that remains uncured for a period of five (5) Business Days after written notice thereof;
(o) other than the Chapter 11 Cases, any Company Party, without the prior written consent of the Required Consenting Royalty Investors, voluntarily commences any restructuring, insolvency, winding up, liquidation, administration, or similar proceeding with respect to any Company Party or for a substantial part of any Company Party’s assets, except as contemplated by this Agreement;
(p) the commencement of an involuntary petition or proceeding seeking bankruptcy, winding up, dissolution, liquidation, administration, moratorium, reorganization, assignment for the benefit of creditors, or other similar relief in respect of any Company Party, its debts, or a substantial part of its assets, under any federal, state, or foreign bankruptcy, insolvency, administrative, receivership, or similar Law; provided, that such involuntary petition or proceeding is not dismissed, stayed, reversed, or vacated within ten (10) Business Days after the filing thereof, or any court order grants the relief sought in such involuntary petition or proceeding;
(q) (i) the Ayrmid Transaction Term Sheet or Merger Agreement (if applicable) is terminated or amended, modified, supplemented, waived, or assigned in a manner materially inconsistent with this Agreement and materially adverse to the Consenting Royalty Investors; (ii) the occurrence of any material breach or material default by any Company Party or Ayrmid under the Ayrmid Transaction Term Sheet or the Merger Agreement (if applicable), or of any event, condition, or circumstance that would permit any party thereto to terminate the Ayrmid Transaction Term Sheet or the Merger Agreement (if applicable) or that would cause any condition precedent to the closing of the Ayrmid Transaction not to be satisfied or to become incapable of satisfaction; or (iii) any Company Party or Ayrmid (if applicable) otherwise fails to consummate the Ayrmid Transaction in accordance with this Agreement and the Milestones; provided, that, with respect to the preceding clause (ii), if such breach or default is by Ayrmid or if such event, condition, or circumstance is attributable to Ayrmid, then this termination shall only be with respect to the Consenting Royalty Investors’ obligations to Ayrmid; provided, further, that none of the foregoing clauses (i) through (iii) shall constitute a termination event to the extent the applicable termination, amendment, modification, supplement, waiver, assignment, breach, default, event, condition, circumstance, or failure to consummate arises from or relates to the Debtors, with the consent of the Required Consenting Royalty Investors, determining to pursue an Acceptable Alternative Transaction;
41
(r) (a) this Agreement is terminated as to Ayrmid, Ayrmid withdraws from the sale process, or the Ayrmid Transaction has not been consummated by the Ayrmid Outside Date, and (b) within five (5) Business Days thereafter, (1) the Company Parties have not entered into a definitive agreement with respect to an Acceptable Alternative Transaction, and (2) the Consenting Funded Debt Parties (or the applicable Agents/Trustees on their behalf) have not submitted a credit bid for all or substantially all of the Company Parties’ assets; or
(s) the issuance, promulgation, or enactment by any Governmental Entity of any statute, regulation, ruling, or final order, or any change in Law, that in each case makes illegal or otherwise prevents or prohibits the consummation of a material portion of the Restructuring Transactions, and such statute, regulation, ruling, final order, or change in Law has not been reversed, stayed, or vacated within fifteen (15) Business Days thereafter.
14.03. Ayrmid Termination Events.
(a) This Agreement may be terminated solely with respect to Ayrmid by Ayrmid; provided, that such termination is not with respect to any other Party and is effective only upon the delivery to the Company Parties of a written notice in accordance with Section 16.10 hereof upon the occurrence of any of the following events:
(i) the breach in any material respect by a Company Party of any of the representations, warranties, or covenants of the Company Parties set forth in this Agreement that (A) is materially adverse to Ayrmid, and (B) remains uncured for five (5) Business Days after Ayrmid transmits a written notice in accordance with Section 16.10 hereof detailing any such breach; provided, that actions taken in accordance with the Bidding Procedures Order shall not constitute a breach or termination event for purposes of this Section 14.03(a)(i);
(ii) the breach in any material respect by one or more of the Consenting Funded Debt Parties of any provision set forth in this Agreement that is materially adverse to Ayrmid and that remains uncured for a period of five (5) Business Days after the receipt by such breaching Consenting Funded Debt Parties of notice of such breach; provided, that if the non-breaching Consenting Funded Debt Parties continue to hold, in the aggregate, at least 66.7% of each of (1) the aggregate outstanding principal amount of the Term Loans, (2) the aggregate outstanding principal amount of the 2028 Notes, and (3) the aggregate outstanding principal amount of the 2029 Notes, in each case that is held by the Consenting Funded Debt Parties, then any termination pursuant to this Section 14.03(a)(ii) shall be effective solely as to the breaching Consenting Funded Debt Parties, and this Agreement shall remain in full force and effect as to all other Parties;
(iii) the issuance by any Governmental Entity, including any regulatory authority or court of competent jurisdiction, of any final, non-appealable ruling or order that (A) enjoins the consummation of a material portion of the Restructuring Transactions and (B) remains in effect for fifteen (15) Business Days after Ayrmid transmits a written notice in accordance with Section 16.10 hereof detailing any such issuance; provided, that this termination right may not be exercised by Ayrmid if Ayrmid sought or requested such ruling or order in contravention of any obligation set out in this Agreement;
(iv) the Bankruptcy Court enters an order denying confirmation of the Plan;
42
(v) the entry of an order by the Bankruptcy Court, or the filing of a motion or application by any Company Party seeking an order (without the prior written consent of Ayrmid in its sole discretion), (A) converting one or more of the Chapter 11 Cases of a Company Party to a case under chapter 7 of the Bankruptcy Code, (B) appointing an examiner with expanded powers beyond those set forth in sections 1106(a)(3) and 1106(a)(4) of the Bankruptcy Code or a trustee in one or more of the Chapter 11 Cases of a Company Party, or (C) rejecting this Agreement;
(vi) the issuance, promulgation, or enactment by any Governmental Entity of any statute, regulation, ruling, or final order, or any change in Law, that in each case makes illegal or otherwise prevents or prohibits the consummation of a material portion of the Restructuring Transactions, and such statute, regulation, ruling, final order, or change in Law has not been reversed, stayed, or vacated within fifteen (15) Business Days thereafter;
(vii) the Debtors select an Acceptable Alternative Transaction as the successful bid and do not select Ayrmid as the back-up bidder;
(viii) this Agreement or any Definitive Document is entered into, amended, modified, or supplemented, without the prior written consent of Ayrmid, in a manner that is inconsistent with this Agreement or adversely affects, in any material respect, the rights of Ayrmid, in each case where such entry, amendment, modification, or supplement has not been withdrawn or reversed within five (5) Business Days after written notice thereof; provided, that no modification, amendment, restatement, waiver, or supplement of this Agreement effected in accordance with Section 15 shall constitute a termination event under this Section 14.03(a)(viii); provided, further, that actions taken in accordance with the Bidding Procedures Order shall not constitute a breach or termination event for purposes of this Section 14.03(a)(viii);
(ix) except in connection with an Acceptable Alternative Transaction in accordance with the Bidding Procedures Order, any Company Party, without the prior written consent of Ayrmid, withdraws or revokes the Plan or the Disclosure Statement, or amends or modifies, or files a motion or pleading seeking to amend or modify, the Plan, the Disclosure Statement, or any Definitive Document in a manner that is inconsistent with this Agreement or materially adverse to Ayrmid, and such amendment or modification has not been reversed, or such motion or pleading withdrawn, prior to the earlier of (A) five (5) Business Days after the Company Parties receive written notice thereof and (B) entry of an order of the Bankruptcy Court approving such motion or pleading;
(x) (A) except in connection with an Acceptable Alternative Transaction in accordance with the Bidding Procedures Order, the Ayrmid Transaction Term Sheet or Merger Agreement (if applicable) is terminated or amended, modified, supplemented, waived, or assigned in a manner inconsistent with this Agreement or materially adverse to Ayrmid; (B) the occurrence of any material breach or material default by any Company Party or the Consenting Funded Debt Parties under the Ayrmid Transaction Term Sheet or the Merger Agreement (if applicable), or of any event, condition, or circumstance that would permit any party thereto to terminate the Ayrmid Transaction Term Sheet or the Merger Agreement (if applicable) or that would cause any condition precedent to the closing of the Ayrmid Transaction to become incapable of satisfaction, in each case that has not been cured or waived within five (5) Business Days after written notice thereof; or (C) any Company Party or the Consenting Funded Debt Parties (as applicable) otherwise fail to consummate the Ayrmid Transaction in accordance with this Agreement; provided, that Ayrmid may not terminate this Agreement pursuant to the foregoing clause (B) or (C) with respect to any breach, default, or failure to consummate by the Consenting Funded Debt Parties if Ayrmid is then in breach of this Agreement or any Definitive Document;
43
(xi) the failure by the Company Parties to satisfy any Ayrmid Milestone by the applicable deadline (as such deadline may be extended or waived in accordance with Section 4.01), unless such failure results from a breach by Ayrmid of its obligations under this Agreement; provided, that, notwithstanding anything to the contrary in this Agreement, if the Bankruptcy Court shall not have entered the Bidding Procedures Order on or before four (4) calendar days after the Petition Date, such failure shall constitute a termination event under this Section 14.03(a)(xi); or
(xii) the Bankruptcy Court shall not have entered an order approving the Bid Protections, on the terms agreed herein, by the date that is thirty-five (35) days after the Petition Date; provided, that if such order is not timely entered due to availability of the Bankruptcy Court, then the deadline for entry of this order shall be extended to the first day the Bankruptcy Court does have availability.
14.04. Company Party Termination Events.
(a) Any Company Party may terminate this Agreement as to all Parties (except as otherwise provided herein) upon prior written notice to all Parties in accordance with Section 16.10 hereof upon the occurrence of any of the following events:
(i) the breach in any material respect by one or more of the Consenting Stakeholders of any provision set forth in this Agreement that remains uncured for a period of ten (10) Business Days after the receipt by such breaching Consenting Stakeholders of notice of such breach; provided, that if the non-breaching Consenting Funded Debt Parties continue to hold, in the aggregate, at least 66.7% of each of (1) the aggregate outstanding principal amount of the Term Loans, (2) the aggregate outstanding principal amount of the 2028 Notes, and (3) the aggregate outstanding principal amount of the 2029 Notes, in each case that is held by the Consenting Funded Debt Parties, then any termination pursuant to this Section 14.04(a)(i) shall be effective solely as to the breaching Consenting Stakeholders, and this Agreement shall remain in full force and effect as to all other Parties;
(ii) Any Company Party may terminate this Agreement as to its own obligations under this Agreement if the board of directors, board of managers, or such similar governing body of any Company Party determines, after consulting with counsel, (i) that proceeding with any of the Restructuring Transactions would be inconsistent with the exercise of its fiduciary duties or applicable Law or (ii) in the exercise of its fiduciary duties, to pursue an Alternative Restructuring Proposal; or
(iii) the issuance by any Governmental Entity, including any regulatory authority or court of competent jurisdiction, of any final, non-appealable ruling or order that (i) enjoins the consummation of a material portion of the Restructuring Transactions and (ii) remains in effect for fifteen (15) Business Days after such terminating Company Party transmits a written notice in accordance with Section 16.10 hereof detailing any such issuance;
44
provided, that this termination right shall not apply to or be exercised by any Company Party that sought or requested such ruling or order in contravention of any obligation or restriction set out in this Agreement.
(b) Any Company Party may terminate this Agreement as to its and the Consenting Stakeholders’ obligations to Ayrmid (i) if Ayrmid breaches in any material respect either this Agreement or the Merger Agreement (if applicable) and such breach remains uncured for five (5) Business Days after Ayrmid’s receipt of written notice thereof delivered in accordance with Section 16.10 hereof, or (ii) if the Debtors, with the consent of the Required Consenting Funded Debt Parties, elect to proceed with an Acceptable Alternative Transaction and Ayrmid is not selected as the back-up bidder; provided, however, that in each case, subject to the terms of this Agreement and the Definitive Documents, the Consenting Stakeholders will remain bound to this Agreement and retain their obligations to support this Agreement, the Restructuring Transactions, the Plan, and the consummation of the Acceptable Alternative Transaction.
14.05. Mutual Termination. This Agreement, and the obligations of all Parties hereunder, may be terminated by mutual written agreement among each Company Party, the Required Consenting Funded Debt Parties, and Ayrmid.
14.06. Automatic Termination. This Agreement shall terminate automatically without any further required action or notice immediately after the Plan Effective Date or the consummation of an Acceptable Alternative Transaction.
14.07. Effect of Termination.
(a) Upon the occurrence of a Termination Date as to a Party, this Agreement shall be of no further force and effect as to such Party and each Party subject to such termination shall be released from its commitments, undertakings, and agreements under or related to this Agreement and shall have the rights and remedies that it would have had, had it not entered into this Agreement, and shall be entitled to take all actions, whether with respect to the Restructuring Transactions or otherwise, that it would have been entitled to take had it not entered into this Agreement, including with respect to any and all Claims or causes of action. Upon the occurrence of a Termination Date prior to the Confirmation Order being entered by the Bankruptcy Court, any and all consents or ballots tendered by the Parties subject to such termination before a Termination Date shall be deemed, for all purposes, to be null and void from the first instance and shall not be considered or otherwise used in any manner by the Parties in connection with the Restructuring Transactions and this Agreement or otherwise; provided, however, that any Consenting Stakeholder withdrawing or changing its vote pursuant to this Section 14.07 shall promptly provide written notice of such withdrawal or change to each other Party to this Agreement and, if such withdrawal or change occurs on or after the Petition Date, file notice of such withdrawal or change with the Bankruptcy Court. If this Agreement may be terminated at a time when permission of the Bankruptcy Court is required for a Consenting Stakeholder to terminate, or cause the termination of, this Agreement, the Company Parties shall not oppose any attempt by such Consenting Stakeholder to terminate, or cause the termination of, this Agreement at such time so long as the respective Consenting Stakeholder has complied with the provisions of Section 14; provided, that the Company Parties’ rights to dispute whether the Consenting Stakeholder has complied with the provisions of Section 14 are preserved. Furthermore, if this Agreement is
45
terminated at a time when permission of the Bankruptcy Court is required for a Consenting Stakeholder to change, revoke or withdraw, or cause to change, revoke or withdraw, its vote to accept the Plan, the Company Parties shall not oppose any attempt by such Consenting Stakeholder to change, revoke or withdraw, or cause to change, revoke or withdraw, such vote at such time so long as such Consenting Stakeholder has complied with the provisions of Section 14; provided, that the Company Parties’ rights to dispute whether the Consenting Stakeholder has complied with the provisions of Section 14 are preserved. Nothing in this Agreement shall be construed as prohibiting a Company Party, Ayrmid, or any of the Consenting Stakeholders from contesting whether any such termination is in accordance with its terms or to seek enforcement of any rights under this Agreement that arose or existed before a Termination Date. Except as expressly provided in this Agreement, nothing herein is intended to, or does, in any manner waive, limit, impair, or restrict (a) any right of any Company Party or the ability of any Company Party to protect and preserve its rights (including rights under this Agreement), remedies, and interests, including its claims against any Consenting Stakeholder, (b) any right of any Consenting Stakeholder, or the ability of any Consenting Stakeholder, to protect and preserve its rights (including rights under this Agreement), remedies, and interests, including its claims against any Company Party or Consenting Stakeholder, and (c) any right of Ayrmid, or the ability of Ayrmid, to protect and preserve its rights (including rights under this Agreement), remedies, and interests, including its claims against any Company Party or any Consenting Stakeholder. No purported termination of this Agreement shall be effective under this Section 14.07 or otherwise if the Party seeking to terminate this Agreement is in material breach of this Agreement, except a termination pursuant to Section 14.04(a)(ii). Nothing in this Section 14.07 shall restrict any Company Party’s right to terminate this Agreement in accordance with Section 14.04(a)(ii).
(b) Upon the occurrence of a Termination Date with respect to Ayrmid or this entire Agreement for any reason (including pursuant to Section 14.01, Section 14.03, or Section 14.04), other than: (i) a termination by the Company Parties pursuant to Section 14.04(b); (ii) the automatic termination of this Agreement pursuant to Section 14.06 following consummation of the Ayrmid Transaction; (iii) any termination (by any Party, including pursuant to Section 14.01) arising from or attributable to (w) a material breach by Ayrmid of its obligations under this Agreement (including Section 7) or any Definitive Document, (x) any material failure by Ayrmid to cooperate in obtaining any approvals required by Governmental Entities (or other regulatory bodies) to facilitate the closing of the Sale Transaction, (y) any other event, condition, or circumstance attributable to Ayrmid, including any ruling or order sought or requested by Ayrmid that materially impedes the Parties’ ability to consummate the Ayrmid Transaction, or (z) Ayrmid withdrawing from the sale process, revoking or withdrawing its bid, or failing to consummate the Ayrmid Transaction by the Ayrmid Outside Date (except as a result of matters that were either directly or proximately caused by another Party); or (iv) any other termination to which Ayrmid has consented in writing, the Company Parties shall, jointly and severally, pay the break-up fee in the Bid Protections (to the extent approved by the Bankruptcy Court in the Bidding Procedures Order) to Ayrmid in full in cash within three (3) Business Days after the consummation of an Acceptable Alternative Transaction or a Sale Transaction with an Entity other than Ayrmid, and solely from the proceeds thereof. The Bid Protections, including the expense reimbursement, shall constitute allowed superpriority administrative expense claims against each of the Debtors under sections 503(b) and 507(a)(2) of the Bankruptcy Code. The obligations of the Company Parties under this Section 14.07 shall survive any termination of this Agreement.
46
Section 15. Amendments and Waivers.
(a) This Agreement may not be modified, amended, or supplemented, and no condition or requirement of this Agreement may be waived, in any manner except in accordance with this Section 15.
(b) This Agreement may be modified, amended, restated, amended and restated, or supplemented, or a condition or requirement of this Agreement may be waived, in a writing signed by: (i) in the case of a waiver, the Party against whom the waiver is to be effective (it being understood that the Required Consenting Funded Debt Parties may make any such waiver on behalf of all Consenting Funded Debt Parties); and (ii) in the case of a modification, amendment, restatement, or supplement, each Company Party and the Required Consenting Funded Debt Parties; provided, however, that if the proposed modification, amendment, restatement, waiver, or supplement has a (x) material, disproportionate, and adverse effect on any of the Company Claims/Interests held by a Consenting Stakeholder relative to the other Consenting Stakeholders or (y) material and adverse effect on Ayrmid, then the consent of each such affected Consenting Stakeholder or Ayrmid, as applicable, shall also be required to effectuate such modification, amendment, restatement, waiver, or supplement, and each such materially, disproportionately, and adversely affected Consenting Stakeholder shall be entitled to terminate this Agreement as to itself only for any breach of this Section 15(b); provided, that actions taken in accordance with the Bidding Procedures Order, including selection of an Acceptable Alternative Transaction, shall not constitute a modification, amendment, restatement, or supplement that has a material and adverse effect on Ayrmid; provided, further, that any proposed modification, amendment, restatement, waiver, or supplement that (a) materially modifies the Ayrmid Transaction Term Sheet relating to the treatment of the Royalty Obligations (as defined in the Ayrmid Transaction Term Sheet) or (b) materially and adversely modifies the adequate protection of the Consenting Royalty Investors provided in the DIP Term Sheet shall in each case require the reasonable consent of the Required Consenting Royalty Investors.
(c) Any proposed modification, amendment, restatement, waiver, or supplement that does not comply with this Section 15 shall be ineffective and void ab initio.
(d) The waiver by any Party of a breach of any provision of this Agreement shall not operate or be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach. No failure on the part of any Party to exercise, and no delay in exercising, any right, power, or remedy under this Agreement shall operate as a waiver of any such right, power, or remedy or any provision of this Agreement, nor shall any single or partial exercise of such right, power, or remedy by such Party preclude any other or further exercise of such right, power, or remedy or the exercise of any other right, power, or remedy. All remedies under this Agreement are cumulative and are not exclusive of any other remedies provided by Law.
47
Section 16. Miscellaneous.
16.01. Acknowledgement. Notwithstanding any other provision herein, this Agreement is not and shall not be deemed to be an offer with respect to any securities or solicitation of votes for the acceptance of a plan of reorganization for purposes of sections 1125 and 1126 of the Bankruptcy Code or otherwise. Any such offer or solicitation will be made only in compliance with all applicable securities Laws, provisions of the Bankruptcy Code, and/or other applicable Law.
16.02. Exhibits Incorporated by Reference; Conflicts. Each of the exhibits, annexes, signature pages, and schedules attached hereto is expressly incorporated herein and made a part of this Agreement, and all references to this Agreement shall include such exhibits, annexes, and schedules. In the event of any inconsistency between this Agreement (without reference to the exhibits, annexes, and schedules hereto) and the exhibits, annexes, and schedules hereto, this Agreement (without reference to the exhibits, annexes, and schedules hereto) shall govern. Notwithstanding the foregoing, in the event of any inconsistency between the Plan in the form attached hereto as Exhibit B and the Ayrmid Transaction Term Sheet, the Arymid Transaction Term Sheet shall govern, and the Parties shall modify the Plan to the extent necessary to resolve such inconsistency.
16.03. Further Assurances. Subject to the other terms of this Agreement, the Parties agree to execute and deliver such other instruments and perform such acts, in addition to the matters herein specified, as may be reasonably appropriate or necessary, or as may be required by order of the Bankruptcy Court, from time to time, to effectuate the Restructuring Transactions (but, with respect to Ayrmid, solely the Ayrmid Transaction), as applicable.
16.04. Complete Agreement. Except as otherwise explicitly provided herein, this Agreement constitutes the entire agreement among the Parties with respect to the subject matter hereof and supersedes all prior agreements, oral or written, among the Parties with respect thereto, other than any Confidentiality Agreement, the September 2026 Forbearance Agreement, and the Fee Agreement.
16.05. GOVERNING LAW; SUBMISSION TO JURISDICTION; SELECTION OF FORUM. THIS AGREEMENT IS TO BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN SUCH STATE, WITHOUT GIVING EFFECT TO THE CONFLICT OF LAWS PRINCIPLES THEREOF. All actions arising out of or relating to this Agreement shall be brought by the Parties in either a state or federal court of competent jurisdiction exclusively in the State of New York in the County of New York, Borough of Manhattan. Notwithstanding anything to the contrary herein, upon the commencement of the Chapter 11 Cases, each of the Parties hereby agrees that (a) the Bankruptcy Court shall have exclusive jurisdiction over all matters arising out of or in connection with this Agreement, and (b) it shall bring any action or proceeding in respect of any claim arising out of or related to this Agreement, to the extent possible, in the Bankruptcy Court, and solely in connection with claims arising under this Agreement: (i) irrevocably submits to the exclusive jurisdiction of the Bankruptcy Court; (ii) waives any objection to laying venue in any such action or proceeding in the Bankruptcy Court; and (iii) waives any objection that the Bankruptcy Court is an inconvenient forum or does not have jurisdiction over any Party hereto.
48
16.06. TRIAL BY JURY WAIVER. EACH PARTY HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.
16.07. Execution of Agreement. This Agreement may be executed and delivered in any number of counterparts and by way of electronic signature and delivery, and each such counterpart, when executed and delivered, shall be deemed an original, and all of which together shall constitute the same agreement. Except as expressly provided in this Agreement, each individual executing this Agreement on behalf of a Party has been duly authorized and empowered to execute and deliver this Agreement on behalf of said Party.
16.08. Rules of Construction. This Agreement is the product of negotiations among the Company Parties, the Consenting Stakeholders, and Ayrmid, and in the enforcement or interpretation hereof, is to be interpreted in a neutral manner, and any presumption with regard to interpretation for or against any Party by reason of that Party having drafted or caused to be drafted this Agreement, or any portion hereof, shall not be effective in regard to the interpretation hereof. The Company Parties, the Consenting Stakeholders, and Ayrmid were each represented by counsel during the negotiations and drafting of this Agreement and continue to be represented by counsel.
16.09. Successors and Assigns; Third Parties. This Agreement is intended to bind and inure to the benefit of the Parties and their respective successors and permitted assigns, as applicable. There are no third-party beneficiaries under this Agreement, and the rights or obligations of any Party under this Agreement may not be assigned, delegated, or transferred to any other person or entity except as provided by Section 11.
16.10. Notices. All notices hereunder shall be deemed given if in writing and delivered, by electronic mail, courier, or on the next Business Day after deposit prepaid with a national overnight express delivery service, to the following addresses (or at such other addresses as shall be specified by like notice):
(a) if to a Company Party, to:
Karyopharm Therapeutics Inc.
85 Wells Avenue
Suite 210
Newton, Massachusetts 02459
Attention: Chief Legal Officer
E-mail address: [***]
with copies to:
Sidley Austin LLP
787 Seventh Avenue
New York, New York 10019
49
Attention: Anthony R. Grossi and Maegan Quejada
E-mail addresses: [***] and [***]
(b) if to a Consenting Funded Debt Party, to the address or e-mail address set forth on such party’s signature page to this Agreement (or in the signature page to a Transfer Agreement or Joinder, as applicable), with a copy to:
Latham & Watkins LLP
1271 Avenue of the Americas
New York, New York 10020
Attention: David A. Hammerman and Keith A. Simon
E-mail addresses: [***] and [***]
Latham & Watkins LLP
330 North Wabash Avenue, Suite 2800
Chicago, Illinois 60611
Attention: Whit Morley
E-mail address: [***]
(c) if to the Consenting Royalty Investors, to the address or e-mail address set forth on such party’s signature page to this Agreement (or in the signature page to a Transfer Agreement or Joinder, as applicable), with a copy to:
Hogan Lovells Cadwalader US LLP
200 Liberty Street
New York, New York 10281
Attention: Douglas Mintz and Thomas Curtin
E-mail addresses: [***] and [***]
(d) if to a Consenting Preferred Shareholder, to the address or e-mail address set forth on such party’s signature page to this Agreement (or in the signature page to a Transfer Agreement or Joinder, as applicable), with a copy to:
Latham & Watkins LLP
1271 Avenue of the Americas
New York, New York 10020
Attention: David A. Hammerman and Keith A. Simon
E-mail addresses: [***] and [***]
(e) if to Ayrmid, to:
Ayrmid Ltd.
780 5th Avenue, Suite 200
Naples, Florida 34102
Attention: Rory Nealon
Email: [***]
with copies to:
50
Paul Hastings LLP
71 S. Wacker Drive, Forty-Fifth Floor
Chicago, IL 60606
Attention: Matt Warren and Geoff King
E-mail addresses: [***] and [***]
Paul Hastings LLP
1197 Peachtree Street N.E., Suite 200
Atlanta, GA 30361
Attention: Zach Cochran
E-mail address: [***]
Any notice given by delivery, mail, or courier shall be effective when received, and any notice given or delivered by electronic mail shall be effective when sent.
16.11. Independent Due Diligence and Decision Making. Each Consenting Stakeholder and Ayrmid hereby confirms that its decision to execute this Agreement has been based upon its independent investigation of the operations, businesses, financial and other conditions, and prospects of the Company Parties.
16.12. Enforceability of Agreement. Each of the Parties, to the extent enforceable, waives any right to assert that the exercise of termination rights under this Agreement is subject to the automatic stay provisions of the Bankruptcy Code, and expressly stipulates and consents hereunder to the prospective modification of the automatic stay provisions of the Bankruptcy Code for purposes of exercising termination rights under this Agreement, to the extent the Bankruptcy Court determines that such relief is required.
16.13. Reservation of Rights. If the Restructuring Transactions are not consummated, or if this Agreement is terminated for any reason, the Parties fully reserve any and all of their rights. Pursuant to Federal Rule of Evidence 408 and any other applicable rules of evidence, this Agreement and all negotiations relating hereto shall not be admissible into evidence in any proceeding other than a proceeding to enforce its terms or the payment of damages to which a Party may be entitled under this Agreement.
16.14. Specific Performance. It is understood and agreed by the Parties that money damages would be an insufficient remedy for any breach of this Agreement by any Party, and each non-breaching Party shall be entitled to specific performance and injunctive or other equitable relief (without the posting of any bond and without proof of actual damages) as a remedy for any such breach, including an order of the Bankruptcy Court or other court of competent jurisdiction requiring any Party to comply promptly with any of its obligations hereunder.
16.15. Several, Not Joint, Obligations; Relationship Among Parties. Notwithstanding anything to the contrary in this Agreement, the agreements, representations, warranties, duties, and obligations of the Parties under this Agreement are, in all respects, several and, for the avoidance of doubt, neither joint nor joint and several, such that no Consenting Stakeholder shall be liable or otherwise responsible for the agreements, representations, warranties, duties, or obligations of any
51
other Party, or for any breach or violation thereof. It is understood and agreed that no Consenting Stakeholder has, solely as a result of entering into or performing its obligations under this Agreement, any fiduciary duty, duty of trust or confidence in any form, or other duty or responsibility to any other Consenting Stakeholder, any Company Party, Ayrmid, or any of their respective creditors or other stakeholders, and, except as expressly provided in this Agreement, there are no agreements, commitments, or undertakings among or between them. No prior history, pattern, or practice of sharing confidences among or between any of the Consenting Stakeholders, the Company Parties, or Ayrmid shall in any way affect or negate this understanding and agreement. It is further understood and agreed that any Consenting Stakeholder may acquire or trade in any Company Claims/Interests or other debt or equity securities of the Company Parties without the consent of the Company Parties or any other Consenting Stakeholder, subject to applicable Law and the terms of this Agreement, and no Party shall have any responsibility for any such acquisition or trading by any other Party by virtue of this Agreement. Each Consenting Stakeholder shall be entitled to independently protect and enforce its rights under this Agreement, and it shall not be necessary for any other Consenting Stakeholder to be joined as an additional party in any proceeding for such purpose. No Consenting Stakeholder shall, as a result of its entering into or performing its obligations under this Agreement, be deemed to be part of a “group” (as that term is used in section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder) with any other Consenting Stakeholder.
16.16. Severability and Construction. If any provision of this Agreement shall be held by a court of competent jurisdiction to be illegal, invalid, or unenforceable, the remaining provisions shall remain in full force and effect if essential terms and conditions of this Agreement for each Party remain valid, binding, and enforceable.
16.17. Remedies Cumulative. All rights, powers, and remedies provided under this Agreement or otherwise available in respect hereof at Law or in equity shall be cumulative and not alternative, and the exercise of any right, power, or remedy thereof by any Party shall not preclude the simultaneous or later exercise of any other such right, power, or remedy by such Party.
16.18. Capacities of Consenting Stakeholders. Each Consenting Stakeholder has entered into this Agreement on account of all Company Claims/Interests that it holds (directly or through discretionary accounts that it manages or advises) and, except where otherwise specified in this Agreement, shall take or refrain from taking all actions that it is obligated to take or refrain from taking under this Agreement with respect to all such Company Claims/Interests.
16.19. Survival. Notwithstanding (i) any Transfer of any Company Claims/Interests in accordance with this Agreement or (ii) the termination of this Agreement in accordance with its terms, each of the following shall survive such Transfer and/or termination and shall continue in full force and effect for the benefit of the Parties in accordance with the terms hereof and thereof: (a) the agreements and obligations of the Parties in Section 14.07 and Section 16; (b) the Confidentiality Agreements; (c) the obligations of the Company Parties in respect of the Restructuring Fees and Expenses and the Royalty Investors Fees under Section 16.21, including with respect to all such amounts incurred up to and including the applicable Termination Date; (d) any claim for breach of this Agreement that occurred, and any right or remedy in respect thereof that arose or existed, prior to such Transfer or termination; (e) the September 2026 Forbearance Agreement and the Fee Agreement, in each case in accordance with Section 16.22; and (f) the obligations of the Company Parties in respect of the Bid Protections under Section 14.07.
52
16.20. Email Consents. Where a written consent, acceptance, approval, or waiver is required pursuant to or contemplated by this Agreement, such written consent, acceptance, approval, or waiver shall be deemed to have occurred if, by agreement between counsel to the Parties submitting and receiving such consent, acceptance, approval, or waiver, it is conveyed in writing (including electronic mail) between each such counsel without representations or warranties of any kind on behalf of such counsel.
16.21. Payment of Restructuring Fees and Expenses and Royalty Investors Fees.
(a) Whether or not the Restructuring Transactions are consummated, the Company Parties hereby agree, on a joint and several basis, to pay in cash the Restructuring Fees and Expenses as follows: (a) all Restructuring Fees and Expenses incurred up to (and including) the Agreement Effective Date for which a reasonably detailed invoice has been received by the Company Parties no later than two (2) Business Days prior to the Agreement Effective Date shall be paid in full in cash prior to the Agreement Effective Date; (b) after the Petition Date (to the extent permitted by order of the Bankruptcy Court), all Restructuring Fees and Expenses shall be paid in full in cash by the Company Parties on a regular and continuing basis promptly, and in any event within ten (10) Business Days, following receipt of a summary invoice (which may be redacted or limited to ensure the maintenance of all applicable legal privileges but shall otherwise comply with the requirements set forth in the applicable engagement letter); (c) upon termination of this Agreement as to any Party, all Restructuring Fees and Expenses incurred up to (and including) the applicable Termination Date shall be paid in full in cash promptly, and in any event within ten (10) Business Days, following receipt of a summary invoice; and (d) on the Plan Effective Date, all Restructuring Fees and Expenses incurred up to (and including) the Plan Effective Date shall be paid in full in cash against receipt of a summary invoice; provided, that in each case, such payment of Restructuring Fees and Expenses shall comply with any orders, procedures, or rules of the Bankruptcy Court and the Bankruptcy Code, as applicable; provided, further, that any earned and payable restructuring, sale, success, or other transaction or similar fee shall be paid from the proceeds of the DIP Facility or the Debtors’ cash on hand, and NewCo shall not be responsible therefor. The Consenting Funded Debt Parties and Ayrmid shall not be required to file any application with, or obtain the approval of, the Bankruptcy Court as a condition to the payment of Restructuring Fees and Expenses, and no recipient of Restructuring Fees and Expenses shall be required to file a fee application or comply with the U.S. Trustee guidelines in respect thereof. The Plan, the DIP Orders, and any other applicable order of the Bankruptcy Court shall contain provisions giving effect to the obligations under this Section 16.21.
(b) Whether or not the Restructuring Transactions are consummated, the Company Parties hereby agree, on a joint and several basis, to pay in cash the Royalty Investors Fees, subject to the terms set forth in the definition thereof, as follows: (a) after the Petition Date, pursuant to the terms of the DIP Orders; (b) upon termination of this Agreement as to any Party other than termination as to the Consenting Royalty Investors on account of a material breach of this Agreement by the Consenting Royalty Investors, all Royalty Investors Fees incurred up to (and including) the applicable Termination Date shall be paid in full in cash promptly, and in any event within ten (10) Business Days, following receipt of a summary invoice; and (c) on the Plan
53
Effective Date, all Royalty Investors Fees incurred up to (and including) the Plan Effective Date shall be paid in full in cash against receipt of a summary invoice; provided, that in each case, such payment of Royalty Investors Fees shall comply with any orders, procedures, or rules of the Bankruptcy Court and the Bankruptcy Code, as applicable. The advisors to the Consenting Royalty Investors shall not be required to file any application with, or obtain the approval of, the Bankruptcy Court as a condition to the payment of the Royalty Investors Fees, and no recipient of Royalty Investors Fees shall be required to file a fee application or comply with the U.S. Trustee guidelines in respect thereof. The Plan, the DIP Orders, and any other applicable order of the Bankruptcy Court shall contain provisions giving effect to the obligations under this Section 16.21.
16.22. September 2026 Forbearance Agreement. Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement shall (a) constitute an amendment, modification, waiver, or termination of any term or provision of, or alter or diminish any right, remedy, obligation, or protection under, the September 2026 Forbearance Agreement or the Fee Agreement, (b) constitute a waiver of, or a forbearance with respect to, any “Default” or “Event of Default” (as defined in or under the Term Loan Credit Agreement, the 2028 Indenture, the 2029 Indenture, or the Royalty Agreement, as applicable), whether or not forborne or waived under the September 2026 Forbearance Agreement, (c) extend, shorten, or otherwise modify the “Forbearance Period” under the September 2026 Forbearance Agreement or affect the occurrence of any “Forbearance Termination Event” thereunder, (d) affect any Consenting Stakeholder’s right (to the extent it is party to the September 2026 Forbearance Agreement) to terminate the September 2026 Forbearance Agreement, (e) impair or release any obligation of any Company Party to pay any fees, expenses, or other consideration payable under the September 2026 Forbearance Agreement or the Fee Agreement, or (f) constitute a termination or release of any liens on, or security interests in, any assets or properties of the Company Parties securing the obligations under the Term Loan Credit Agreement, the 2028 Indenture, the 2029 Indenture, or the Royalty Agreement. The September 2026 Forbearance Agreement and the Fee Agreement shall each remain in full force and effect in accordance with their respective terms, and in the event of any conflict between this Agreement and the September 2026 Forbearance Agreement or the Fee Agreement, the September 2026 Forbearance Agreement or the Fee Agreement, as applicable, shall govern and control.
16.23. Disclosure; Publicity. The Company Parties shall submit drafts to the Ad Hoc Group Advisors and Ayrmid Advisors of any press releases and public documents that constitute disclosure of the existence or terms of this Agreement or any amendment to the terms of this Agreement at least two (2) Business Days before making any such disclosure, and shall afford the Ad Hoc Group Advisors and Ayrmid Advisors a reasonable opportunity to comment on such documents and disclosures and shall incorporate any such reasonable comments in good faith; provided, that if delivery of such document at least two (2) Business Days in advance of such disclosure is impracticable under the circumstances, such document shall be delivered as soon as otherwise practicable. Except as required by Law (including any rules set by the Securities and Exchange Commission, stock exchange rules, or order from the Bankruptcy Court), no Party or its advisors shall use the name of any member of the Ad Hoc Group or Ayrmid in any public manner (including in any press release or public filing) with respect to this Agreement, the Restructuring Transactions, or any of the Definitive Documents without such member’s or Ayrmid’s, as applicable, prior written consent (which consent may be given by counsel). The Ad Hoc Group Advisors and Ayrmid Advisors shall submit drafts to the Company Parties of any press releases
54
and public documents that constitute disclosure of the existence or terms of this Agreement or any amendment to the terms of this Agreement at least two (2) Business Days before making any such disclosure, and shall afford the Company Parties a reasonable opportunity under the circumstances to comment on such documents and disclosures and shall incorporate any such reasonable comments in good faith. This Section 16.23 shall not apply to the disclosure of Ayrmid’s identity in any filing with the Bankruptcy Court, as determined by the Company Parties in their reasonable discretion.
16.24. Confidentiality and Redactions. No Party shall disclose to any Entity (including, for the avoidance of doubt, any other Consenting Stakeholder) the principal amount, number of shares, or percentage of any Company Claims/Interests held by any Consenting Stakeholder; provided, that: (a) a Party may disclose the foregoing information as may be required by applicable Law, including order, procedure, or rule of the Bankruptcy Court; (b) the Parties shall be permitted to disclose the foregoing information at any time to the legal, accounting, financial, and other advisors to the Company Parties, to the Ad Hoc Group Advisors and to the Ayrmid Advisors; and (c) the Company Parties shall be permitted to disclose at any time (i) the foregoing information on a confidential basis to their affiliates and (ii) the aggregate principal amount of, and aggregate percentage of, any class of Company Claims/Interests held by the Consenting Stakeholders collectively. The Consenting Stakeholders hereby consent to the disclosure of the execution, terms, and contents of this Agreement by the Company Parties in the Definitive Documents or as otherwise required by Law; provided, that (x) if any of the Company Parties determines that it is required to attach a copy of this Agreement, any Transfer Agreement, or any Joinder to any Definitive Document or any other filing or similar document relating to the Restructuring Transactions, it shall redact any reference to or concerning any specific Consenting Stakeholder’s holdings of Company Claims/Interests and the identity of such Consenting Stakeholder, to the extent permitted by applicable Law, and (y) if disclosure of additional identifying information of any Consenting Stakeholder is required by applicable Law, advance notice of the intent to disclose, if permitted by applicable Law, shall be given by the disclosing Party to each affected Consenting Stakeholder (which shall have the right to seek a protective order before such disclosure). The Company Parties further agree that such information shall be redacted from “closing sets” or other representations of the fully executed Agreement, any Transfer Agreement, or any Joinder, which redacted closing sets may be shared with the Consenting Stakeholders; provided, that the unredacted “closing sets” shall be provided to the Ad Hoc Group Advisors on a “professional eyes only” basis.
16.25. Identified Business Unit(s), Platform(s), and/or Trading Desk(s). For the avoidance of doubt, where a Consenting Stakeholder enters into or accedes to this Agreement through one or more identified business unit(s), platform(s), and/or trading desk(s) in respect of any Company Claims/Interests (as specified in the signature page to this Agreement, a Transfer Agreement, or a Joinder), the terms of this Agreement shall apply only to that identified business unit(s), platform(s), and/or trading desk(s) and not to any other business unit(s), platform(s), trading desk(s), and/or affiliate(s) within the legal Entity that has not signed or acceded to this Agreement (in accordance with the terms of this Agreement) separately in respect of any Company Claims/Interests or other debt or other instrument that it legally or beneficially owns, and, therefore, such Consenting Stakeholder shall not be required to procure compliance with this Agreement on behalf of such other business unit(s), platform(s), and/or trading desk(s) within that legal Entity.
55
16.26. Highbridge/Ayrmid Matters. Notwithstanding anything to the contrary in this Agreement or any Definitive Document, the Parties acknowledge and agree as follows:
(a) Subject to Section 16.26(c), unless and until Ayrmid irrevocably withdraws from the sale process in writing given in accordance with Section 16.10, the Highbridge Funds shall be walled off from, and shall recuse themselves from, all Ad Hoc Group discussions, negotiations, and positions regarding any Sale Process Matter. The terms of other bids shall not be shared with the Highbridge Funds or their advisors, and no information regarding any Sale Process Matter shared with the Ad Hoc Group shall be shared with Ayrmid or with any personnel or advisors of the Highbridge Funds acting in a Bidder Capacity.
(b) Except as set forth in the following proviso, and unless and until Ayrmid irrevocably withdraws from the sale process in writing given in accordance with Section 16.10, for purposes of determining whether any consent, approval, direction, or waiver with respect to a Sale Process Matter has been given or obtained by the Required Consenting Funded Debt Parties, the Required Consenting 1L Lenders, the Required Consenting 2028 Noteholders, or the Required Consenting 2029 Noteholders, as applicable, the Highbridge Funds and their Company Claims/Interests shall be excluded from both the numerator and the denominator of such determination, and any requirement that such group include at least two (2) unaffiliated holders shall be applied without regard to the Highbridge Funds; provided, that notwithstanding the foregoing restriction, in the event the vote of the Highbridge Funds is necessary to obtain requisite lender approval under the Term Loan Credit Agreement, the 2028 Indenture, the 2029 Indenture, or any other applicable document, appropriate protocols will be implemented at such time to permit the Highbridge Funds to make an informed vote without prejudice to the applicable Sale Process Matter.
(c) Ayrmid will receive diligence solely through the Company Parties and their advisors, and on the same terms as other bidders. Ayrmid shall be permitted to share such information with the Highbridge Funds. Any material information provided to Ayrmid that other bidders have not received will be made available to all qualified bidders. Information provided to the Highbridge Funds in their Lender Capacity (including forecasts, liquidity reporting, and diligence prepared for lenders, including pursuant to Section 9.01) will not be shared by the Highbridge Funds with the Ayrmid bidder team.
(d) Neither the Highbridge Funds nor Ayrmid will enter into any agreement, arrangement, or understanding with any other actual or potential bidder regarding bidding for or refraining from bidding on the Company Parties’ assets.
(e) The Highbridge Funds may participate in forbearance and debtor-in-possession financing discussions, negotiations, and structuring, including with respect to the September 2026 Forbearance Agreement, the DIP Facility, and the DIP Documents, to the same extent as any other lender in the Ad Hoc Group, except with respect to any Sale Process Matter.
56
(f) Notwithstanding anything to the contrary set forth herein, the Highbridge Funds shall be entitled to receive distributions on account of their secured debt claims on an equal pro rata basis with any similarly situated secured creditor on account of such claims, and the Highbridge Funds shall not be excluded from any protections, indemnifications, participation opportunities, or any other treatment afforded to such similarly situated secured creditors, including under Section 16.21.
16.27. Ayrmid Back-Up Bidder Rights and Obligations. Notwithstanding anything to the contrary in this Agreement or any Definitive Document, if the Debtors select an Acceptable Alternative Transaction as the successful bid and Ayrmid is selected as the back-up bidder (in accordance with the Bidding Procedures Order), then from the date of such selection until the earlier of (a) the Debtors’ determination (subject to the consent of the Required Consenting Funded Debt Parties) to proceed with the Ayrmid Transaction (upon which Ayrmid’s rights hereunder shall be reinstated) and (b) the Ayrmid Outside Date: (i) Ayrmid shall remain obligated to serve as the back-up bidder through the Ayrmid Outside Date; and (ii) Ayrmid shall have no consent or approval rights under this Agreement or with respect to any Definitive Document, and no Ayrmid Termination Event shall apply or be deemed to have occurred (other than Section 14.03(a)(xi) solely with respect to the Milestone set forth in Section 4.01(b)(iii)); provided that Ayrmid shall retain such rights solely to the extent necessary to prevent (1) any extension of its obligation to serve as a back-up bidder beyond the Ayrmid Outside Date or (2) any impairment of the Bid Protections or Ayrmid’s right to payment (including with respect to Milestones related to the Bid Protections) thereof under this Agreement and the Bidding Procedures Order.
16.28. Headings. The headings of the sections, paragraphs, and subsections of this Agreement are inserted for convenience of reference only and shall not affect the interpretation hereof or, for any purpose, be deemed a part of this Agreement.
IN WITNESS WHEREOF, the Parties hereto have executed this Agreement on the day and year first above written.
[Signature Pages Follow]
57
Company Party’s Signature Page to
the Restructuring Support Agreement
| KARYOPHARM THERAPEUTICS INC. |
| /s/ Richard Paulson |
| Name: Richard Paulson |
| Title: President and Chief Executive Officer |
| Address: Karyopharm Therapeutics Inc. 85 Wells Avenue, Suite 210 |
| Newton, Massachusetts 02459 |
E-mail address(es): [***]
Company Party’s Signature Page to
the Restructuring Support Agreement
| KPT TEXAS LLC |
| /s/ Michael Mano |
| Name: Michael Mano |
| Title: Executive Vice President, Chief Legal Officer and Secretary |
| Address: Karyopharm Therapeutics Inc. 85 Wells Avenue, Suite 210 |
| Newton, Massachusetts 02459 |
E-mail address(es): [***]
Consenting Stakeholder’s Signature Page to
the Restructuring Support Agreement
[***]
Ayrmid Signature Page to
the Restructuring Support Agreement
| AYRMID LTD. |
| /s/ Rory Peter Nealon |
| Name: Rory Peter Nealon |
| Title: Chief Financial Officer |
EXHIBIT A
Company Parties
| 1. | Karyopharm Therapeutics Inc. |
| 2. | KPT Texas LLC |
EXHIBIT B
Plan
[***]
EXHIBIT C
Disclosure Statement
[***]
EXHIBIT D
DIP Term Sheet
[***]
EXHIBIT E
Ayrmid Transaction Term Sheet
66
KARYOPHARM THERAPEUTICS INC., et al.
AYRMID TRANSACTION TERM SHEET
THIS TERM SHEET (“TERM SHEET”) SETS FORTH THE MATERIAL TERMS OF A PROPOSED REORGANIZATION OF KARYOPHARM THERAPEUTICS INC. (“KPTI”) AND ITS AFFILIATED DEBTOR-IN-POSSESSION (COLLECTIVELY, THE “DEBTORS”) IN THEIR JOINTLY ADMINISTERED BANKRUPTCY CASES (THE “CHAPTER 11 CASES”) TO BE FILED IN THE UNITED STATES BANKRUPTCY COURT FOR THE SOUTHERN DISTRICT OF TEXAS (THE “BANKRUPTCY COURT”).
THIS TERM SHEET IS NOT AN OFFER OR A SOLICITATION WITH RESPECT TO ANY SECURITIES OF THE DEBTORS, NOR IS IT A SOLICITATION OF THE ACCEPTANCE OR REJECTION OF A PLAN FOR PURPOSES OF SECTIONS 1125 AND 1126 OF THE BANKRUPTCY CODE. ANY SUCH OFFER OR SOLICITATION SHALL COMPLY WITH ALL APPLICABLE SECURITIES LAWS AND/OR PROVISIONS OF THE BANKRUPTCY CODE. THIS TERM SHEET AND THE TRANSACTIONS DESCRIBED HEREIN ARE SUBJECT IN ALL RESPECTS TO, AMONG OTHER THINGS, NEGOTIATION, EXECUTION AND DELIVERY OF DEFINITIVE DOCUMENTATION AND SATISFACTION OR WAIVER OF THE CONDITIONS PRECEDENT SET FORTH HEREIN AND THEREIN.
THIS TERM SHEET IS PRESENTED FOR DISCUSSION AND SETTLEMENT PURPOSES, AND IS ENTITLED TO PROTECTION FROM ANY USE OR DISCLOSURE TO ANY PERSON PURSUANT TO RULE 408 OF THE FEDERAL RULES OF EVIDENCE AND ANY OTHER RULE OF SIMILAR IMPORT. NO BINDING OBLIGATIONS WILL BE CREATED BY THIS TERM SHEET UNLESS AND UNTIL SIGNATURE PAGES TO THE RSA ARE EXECUTED AND DELIVERED BY ALL APPLICABLE PARTIES.
In connection with the restructuring and related funding transactions described in this Term Sheet, in each case solely to the extent implemented in connection with, and as part of, the Ayrmid Merger (as defined below) (and, for the avoidance of doubt, excluding any transaction that does not include the Ayrmid Merger) (collectively, the “Ayrmid Transaction”), reference is made to the following: (i) the obligations under that certain Indenture, dated as of October 10, 2025 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “2028 Indenture”), by and among KPTI, as issuer, the guarantors party thereto and Wilmington Savings Fund Society, FSB, as Trustee (the “2028 Trustee”), pursuant to which, among other things, KPTI issued 9.00% convertible senior notes due 2028 in an original principal amount of not less than $15,000,000 (the “2028 Notes,” and all obligations thereunder, the “2028 Notes Obligations,” and the holders thereof, the “2028 Noteholders”), (ii) the obligations under that certain Indenture, dated as of October 10, 2025 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “2029 Indenture”), by and among KPTI, as issuer, the guarantors party thereto and Wilmington Savings Fund Society, FSB, as Trustee (the “2029
67
Trustee”), pursuant to which, among other things, KPTI issued 9.00% convertible senior notes due 2029 in an aggregate original amount of not less than $103,502,450 (the “2029 Notes,” and all obligations thereunder, the “2029 Notes Obligations,” and the holders thereof, the “2029 Noteholders”), (iii) the obligations under that certain Credit and Guaranty Agreement, dated as of May 8, 2024 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “KPTI Credit Agreement”), by and among KPTI, as borrower, the guarantors thereunder, Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent (in such capacities, together with its successors and assigns in such capacities, the “KPTI Facility Agent”) and the lenders from time to time party thereto (the “KPTI Term Loan Lenders”) in an original principal amount of not less than $100,000,000 (the “KPTI Term Loan 1L Obligations”), (iv) the “Revenue Interests” (as defined in the KPTI RIFA) and all other obligations owing under that certain Revenue Interest Financing Agreement, dated September 14, 2019 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “KPTI RIFA”), by and among KPTI, as the company, Healthcare Royalty Partners III, L.P., Healthcare Royalty Partners IV, L.P., HCRx Investments Holdco, LLC, HCR Canary Fund, L.P., and HCR Molag Fund, L.P., as investors (together, with their successors and permitted assigns, the “KPTI RIFA Investors”), HealthCare Royalty Management, LLC, as investor representative (the “Investor Representative”), and HCR Karyopharm SPV, LLC, as collateral agent (the “Royalty Collateral Agent”), in the full amount owing thereunder (including the unpaid Hard Cap (as defined in the KPTI RIFA) and all other Obligations (as defined in the KPTI RIFA), the “KPTI RIFA Obligations”), (v) the obligations under that certain Loan and Security Agreement, dated as of December 12, 2022 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Ayrmid LSA”), by and among Gamida Cell Inc., as borrower (“Gamida (US)”), Gamida Cell Ltd., as guarantor (“Gamida (Israel)”), Ayrmid Ltd. (“Ayrmid”), as holdings, Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent, and the lenders party thereto from time to time, and (vi) that certain Restructuring Support Agreement, dated as of November 2, 2026 (the “RSA”), by and among the Debtors, the KPTI Term Loan Lenders party thereto, the 2028 Noteholders party thereto, the 2029 Noteholders party thereto, the Investor Representative, the holders of Existing Preferred Interests party thereto (the “Consenting Preferred Shareholders”), and Ayrmid (collectively, the “RSA Parties”). All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the RSA.
68
| Term |
Description | |
| Overview | ||
| Material Plan Terms | The Debtors will file a chapter 11 plan (the “Plan”) and disclosure statement providing for, or otherwise effectuating on the Effective Date, among other things, the following:
• 100% of the common equity of Reorganized KPTI2 (the “KPTI Plan Consideration”), which shall be allocated as follows:
a. 36.096% to 37.029% pro rata to the KPTI Term Loan Lenders in full and final satisfaction of their KPTI Term Loan 1L Obligations (the “1L Plan Consideration”);
b. 6.439% to 6.606% pro rata to the 2028 Noteholders in full and final satisfaction of their 2028 Notes Obligations (the “2028 Noteholder Plan Consideration”);
c. 33.259% to 34.119% pro rata to the 2029 Noteholders in full and final satisfaction of their 2029 Notes Obligations (the “2029 Noteholder Plan Consideration”);
d. 0% to 2.521% pro rata to the DIP Lenders in full and final satisfaction of their DIP Overage Claims (as defined below) (the “DIP Overage Plan Consideration”); and
e. 21.685% to 22.246% pro rata to the DIP Lenders in full and final satisfaction of their Roll-Up DIP Claims (as defined below) (the “Roll-Up Plan Consideration”).
• General Unsecured Claims shall be paid in full/otherwise rendered unimpaired.
• On the Effective Date, unless the Debtors select an Acceptable Alternative Transaction as the Successful Bid (as described below) in accordance with the Bidding Procedures Order, Reorganized KPTI and Ayrmid shall effect a business combination transaction directly or through one or more of their respective existing or newly-formed affiliates (the surviving parent entity of the combined business, “NewCo”) on the terms and conditions as agreed to by the Debtors, the Required Consenting Funded Debt Parties and Ayrmid (the “Ayrmid Merger”).
• The “Effective Date” of the Plan shall mean: (a) the first Business Day after the entry of the order confirming the Plan (the “Confirmation Order”) on which (i) no stay of the Confirmation Order is in effect and (ii) all conditions precedent to effectiveness of the Plan have been satisfied or waived in accordance with the Plan; or (b) such other date as may be mutually agreed to by the Debtors, the Required Consenting Funded Debt Parties and Ayrmid. | |
| Ayrmid Merger | If the Ayrmid Merger is consummated:
1. NewCo (or such other borrower identified in the relevant documentation) and the applicable guarantors will enter into an exit facility of up to $135,000,000 in new money (the “NewCo Facility,” and the commitments and loans thereunder, the “NewCo Facility Commitments” and the “NewCo Facility Loans,” respectively), the proceeds of which shall be available to be drawn in full on the | |
| 2 | “Reorganized KPTI” means KPTI, as reorganized on the Effective Date in accordance with the Plan. |
69
| Term |
Description | |
| Effective Date and used to refinance up to $50,000,000 of DIP Claims in cash (and, if the outstanding DIP Claims are equal to or less than $50,000,000, then in full), pay cure costs and other expenses of the Debtors under the Plan, and fund working capital needs, subject to the DIP Budget (as defined in the RSA).
2. Contemporaneously with, and as consideration for, the Ayrmid Merger:
a. the DIP Lenders, the 2028 Noteholders, the 2029 Noteholders and the KPTI Term Loan Lenders shall receive, in exchange for 100% of the common equity of Reorganized KPTI, and the organizational documents of NewCo and the documentation for the Ayrmid Merger shall provide, to the extent applicable, that the holders of the common equity of Reorganized KPTI shall receive, (i) their applicable pro rata share (based on each holder’s holdings of the common equity of Reorganized KPTI) of 55% of the issued and outstanding common equity of NewCo as of the Effective Date (subject to dilution solely by the Omisirge Contingent Equity and any applicable management incentive plan (the “MIP”)) and (ii) contingent payments pursuant to the terms and subject to the conditions of the MF CVR Agreement,3 which shall provide:
i. a synthetic royalty will be triggered upon FDA approval of any application or supplement submitted to the FDA by KPTI or NewCo (including, without limitation, the supplemental New Drug Application to the FDA submitted by KPTI on or about August 31, 2026) seeking accelerated approval of XPOVIO® (selinexor) for any use in the treatment of myelofibrosis;
ii. the synthetic royalty will commence on the first commercial sale of XPOVIO® (selinexor) for patients with myelofibrosis and will terminate on the earlier of (1) seven years after such first commercial sale and (2) generic entry into the market; and
iii. the synthetic royalty, to be based on net sales of XPOVIO® (selinexor) for patients with myelofibrosis, will be equal to: (1) 20.00% of such net sales if myelofibrosis is added to the label of approved uses for XPOVIO® (selinexor) on or prior to December 31, 2027 and (2) 15.00% of such net sales if approved at any time thereafter; |
| 3 | “MF CVRs” means the contingent value rights entitling the holders thereof to contingent payments in respect of a synthetic royalty in the proceeds of XPOVIO® (selinexor) for patients with myelofibrosis, pursuant to the terms and subject to the conditions of a contingent value rights agreement to be entered into with NewCo (the “MF CVR Agreement”). |
70
| Term |
Description | |
| b. the holders of equity interests in Ayrmid (the “Ayrmid Equity Holders”) shall receive (or otherwise retain) 45.00% of all issued and outstanding common equity of NewCo as of the Effective Date after giving effect to the Ayrmid Merger (which shall be subject to dilution by any applicable MIP but not subject to dilution by the Omisirge Contingent Equity) and the right to receive the Omisirge Contingent Equity, and the organizational documents of NewCo and the documentation for the Ayrmid Merger shall provide, to the extent applicable, that the Ayrmid Equity Holders shall receive:
i. up to an additional 6.50% of the issued and outstanding common equity of NewCo as of the Effective Date if global Omisirge net revenues for fiscal year 2028 exceed $70,000,000, with such amount of additional common equity increasing linearly from 0% at $70,000,000 of global Omisirge net revenue to 6.50% at $100,000,000 of global Omisirge net revenue, and
ii. up to an additional 2.00% of the issued and outstanding common equity of NewCo as of the Effective Date if global Omisirge net revenues for fiscal year 2028 exceed $100,000,000, with such amount of additional common equity increasing linearly from 0% at $100,000,000 of global Omisirge net revenue to 2.00% at $120,000,000 of global Omisirge net revenue.
3. In addition, on the Effective Date, the liens and obligations under the Ayrmid LSA will be addressed in a manner acceptable to the 2028 Noteholders, the 2029 Noteholders, the KPTI Term Loan Lenders and the Ayrmid LSA lenders; provided, that any liens and obligations with respect to the Ayrmid LSA (or any successor obligations thereto) shall be equitized into pre-Plan Effective Date Ayrmid or structurally subordinated in their entirety to claims against, and equity interests in, NewCo, in each case in a manner acceptable to the Required Consenting Funded Debt Parties in their sole discretion. | ||
| KPTI RIFA Obligations | Each KPTI RIFA Investor shall receive a pro rata share of revenue interests under a new royalty instrument (the “HCRx Royalty Agreement”) entered into by NewCo and each of its subsidiaries that owns or controls any selinexor assets, on the one hand, and the KPTI RIFA Investors (or their designee) and the Royalty Collateral Agent (or another collateral agent designated by the KPTI RIFA Investors), on the other hand, for payment of 3% of net revenues to NewCo from all selinexor products (including XPOVIO® (selinexor) in combination with ruxolitinib for myelofibrosis) over a period of five (5) years following the Effective Date, which such interest shall be unsecured (such revenue interests, the “KPTI RIFA Consideration”). The HCRx Royalty Agreement shall include a liquidated damages provision, which shall be set at a value equal to $18.75 million. | |
71
| Term |
Description | |
| HCRx may pursue an acquisition of KPTI’s interests in certain other royalty agreements in an amount up to $35 million, with any diligence to be conducted within the sale milestone process outlined herein; provided, however, that there shall be no obligation or requirement for the Debtors or NewCo to consummate such a sale; provided, further, that any such sale shall be subject to the consent of the Required Consenting Funded Debt Parties and the Debtors and, to the extent that the Debtors have not selected an Acceptable Alternative Transaction, Ayrmid.
The HCRx Royalty Agreement shall be in form and substance acceptable to the KPTI RIFA Investors, the Required Consenting Funded Debt Parties, and Ayrmid and the proposed treatment of the KPTI RIFA Obligations as outlined herein may not be amended, modified, or supplemented without the prior written consent of the KPTI RIFA Investors. | ||
| DIP Facility | The KPTI Term Loan Lenders (in such capacity, the “DIP Lenders”) will have provided KPTI with a debtor-in-possession financing facility (the “DIP Facility,” and the documents related thereto, interim and final orders approving the same, and ancillary documentation, the “DIP Facility Documents”) on the terms set forth in the term sheet annexed to the RSA (the “DIP Term Sheet”).
The DIP Facility shall provide for the “DIP Loans,” which shall consist of: (a) the new money term loans made available to the Debtors under the DIP Facility in an aggregate principal amount of up to $55,000,000, as more fully set forth in the DIP Facility Documents (the “DIP New Money Loans”); and (b) the junior loans under the DIP Facility deemed made upon the conversion, in accordance with the DIP Facility Documents, of KPTI Term Loan 1L Obligations into DIP Loans in an amount equal to $1.00 of KPTI Term Loan 1L Obligations for each $1.00 of DIP New Money Loans funded, as more fully set forth in the DIP Facility Documents (the “DIP Roll-Up Loans”). | |
| Executory Contracts and Unexpired Leases | Except as otherwise provided in the Plan, all executory contracts and unexpired leases not otherwise assumed or rejected will be deemed assumed in accordance with the provisions and requirements of the Bankruptcy Code, other than those that: (a) are identified by a schedule of rejected executory contracts and unexpired leases; (b) have previously expired or terminated pursuant to their own terms; (c) have been previously assumed or rejected by the Debtors; (d) are the subject of a motion to reject that is pending on the Effective Date; or (e) have an ordered or requested effective date of rejection that is after the Effective Date; provided that the employee and employment agreements relating to the severance and COBRA entitlements set forth on Annex A shall be assumed (subject to the limitations in amount on Annex A) notwithstanding anything to the contrary herein. | |
72
| Term |
Description | |
| Management Incentive Plan | On or after the Effective Date, NewCo shall implement the MIP on terms acceptable to Ayrmid and the Required Consenting Funded Debt Parties and approved by NewCo’s post-merger board. | |
| Indemnification Claims | All indemnification provisions in place as of the Effective Date (whether in the by-laws, certificates of incorporation or formation, limited liability company agreements, other organizational documents, board resolutions, indemnification agreements, employment contracts, or otherwise) for current and former directors, officers, managers, employees, attorneys, accountants, investment bankers, and other professionals of the Debtors, as applicable, shall be assumed by a newly-formed entity, which may be an Affiliate of NewCo (the “Indemnification Entity”), in scope acceptable to KPTI, Ayrmid, and the Required Consenting Funded Debt Parties and in scope no less favorable to such current and former directors, officers, managers, employees, attorneys, accountants, investment bankers, and other professionals of the Debtors than the indemnification provisions in place prior to the Effective Date. The obligations assumed by the Indemnification Entity shall include, for the avoidance of doubt, the obligation to fund and pay, as and when due, any self-insured retention, deductible, or similar amount required to be borne by the insureds under any of the D&O Liability Insurance Policies (including any runoff or tail policies) in connection with any claim thereunder against any such current or former director, officer, manager, employee, attorney, accountant, investment banker, or other professional of the Debtors. The obligations of the Indemnification Entity in respect of such indemnification provisions (including any such self-insured retention or deductible amounts) shall be supported by an intercompany promissory note in the principal amount of $2,500,000 issued by NewCo or an Affiliate of NewCo in favor of the Indemnification Entity on the Effective Date, on terms acceptable to KPTI, Ayrmid, and the Required Consenting Funded Debt Parties, and the Indemnification Entity shall not incur any indebtedness or other obligations other than the indemnification obligations assumed pursuant to the Plan. | |
| Treatment of Claims and Interests if the Ayrmid Merger Is Consummated | ||
| Unclassified Claims | ||
| Administrative, Priority Tax, and Other Priority Claims | On or as soon as practicable after the later to occur of (a) the Effective Date and (b) the date on which such claim becomes due in the ordinary course of business, each holder of an allowed Administrative Expense Claim or Priority Tax Claim shall receive, in full and final satisfaction, settlement, release, and discharge of, and in exchange for, such holder’s Administrative Expense Claim or Priority Tax Claim, (i) cash equal to the unpaid portion of such allowed Claim, (ii) such treatment as is consistent with the provisions of section 1129(a)(9) of the Bankruptcy Code, or (iii) such other treatment as may be agreed by the holder of such allowed Claim and the Debtors, and as is consistent with the DIP Budget or otherwise with the consent of the Required Consenting Funded Debt Parties. | |
73
| Term |
Description | |
| Not classified – non-voting. | ||
| DIP Claims | In full and final satisfaction, compromise, settlement, release, and discharge of all obligations owing to the DIP Lenders under the DIP Facility Documents (collectively, the “DIP Claims”), except to the extent that the DIP Agent or a DIP Lender agrees to less favorable treatment with respect to such DIP Lender’s DIP Claim, on the Effective Date, if the Ayrmid Merger is consummated, each DIP Lender shall receive:
(a) on account of its allowed DIP Claims in respect of the DIP New Money Loans:
i. its pro rata share of:
1. up to $50,000,000 of cash loan proceeds funded under the NewCo Facility; plus
2. any unrestricted cash (excluding, for the avoidance of doubt, proceeds of the NewCo Facility) on the balance sheet of the Debtors upon the consummation of the Ayrmid Transaction after funding: (A) the Carve-Out, (B) amounts allocated to the wind-down of Karyopharm Europe GmbH; and (C) amounts that the Debtors have reasonably estimated are necessary to pay allowed Administrative Expense Claims (including any amounts for professional advisors); and (D) amounts set forth in the DIP Budget allocated to allowed General Unsecured Claims that have not yet been paid (collectively, the purposes set forth in clauses (A) through (D), the “Reserved Purposes”); plus
3. after payment for the Reserved Purposes, any remaining unrestricted cash on the balance sheet of the Debtors;
ii. on account of the remainder (if any) of its allowed DIP Claims in respect of the DIP New Money Loans after application of the cash described in the foregoing clause (i) (such remainder, the “DIP Overage Claims”), its pro rata share of the DIP Overage Plan Consideration; and
(b) on account of its allowed DIP Claims in respect of the DIP Roll-Up Loans (the “Roll-Up DIP Claims”), its pro rata share of the Roll-Up Plan Consideration.
Nothing in this provision shall affect or dilute the 45.00% of NewCo equity received or otherwise retained by the Ayrmid Equity Holders. | |
74
| Term |
Description | |
| Not classified – non-voting. | ||
| Classes of Claims or Interests | ||
| Other Secured Claims | On or as soon as practicable after the Effective Date, in full and final satisfaction, compromise, settlement, release, and discharge of and in exchange for any secured claim that is not an Administrative Expense Claim, Priority Tax Claim or DIP Claim (an “Other Secured Claim”), the holder of such Other Secured Claim shall receive (a) payment in cash in an amount equal to such Other Secured Claim, (b) the collateral securing such Other Secured Claim, (c) reinstatement of its Other Secured Claim, or (d) such other treatment so as to render such Other Secured Claim unimpaired pursuant to section 1124 of the Bankruptcy Code.
Unimpaired – deemed to accept. | |
| Priority Non-Tax Claims | In full and final satisfaction, compromise, settlement, release, and discharge of each allowed Priority Non-Tax Claim, except to the extent that a holder of an allowed Priority Non-Tax Claim agrees to less favorable treatment, each holder of an allowed Priority Non-Tax Claim shall receive (a) cash in an amount equal to such allowed Claim or (b) such other treatment that will render such allowed Priority Non-Tax Claim unimpaired pursuant to section 1124 of the Bankruptcy Code.
Unimpaired – deemed to accept. | |
| KPTI Term Loan 1L Obligations | The KPTI Term Loan Lenders shall receive their pro rata share of the 1L Plan Consideration on account of all claims related to the KPTI Term Loan 1L Obligations.
Impaired – entitled to vote. | |
| 2028 Notes Obligations | The 2028 Noteholders shall receive their pro rata share of the 2028 Noteholder Plan Consideration on account of all claims related to the 2028 Notes Obligations.
Impaired – entitled to vote. | |
| 2029 Notes Obligations | The 2029 Noteholders shall receive their pro rata share of the 2029 Noteholder Plan Consideration on account of all claims related to the 2029 Notes Obligations.
Impaired – entitled to vote. | |
| KPTI RIFA Obligations | The KPTI RIFA Investors shall receive their pro rata share of the KPTI RIFA Consideration on account of all claims related to the KPTI RIFA Obligations, unless any of the KPTI RIFA Investors agree to less favorable treatment with respect to such KPTI RIFA Obligations. The KPTI RIFA Obligations may be classified separately from the 2028 Notes Obligations and the 2029 Notes Obligations. | |
75
| Term |
Description | |
| Impaired – entitled to vote. | ||
| General Unsecured Claims | In full and final satisfaction, compromise, settlement, release, and discharge of each allowed General Unsecured Claim, except to the extent that a holder of a General Unsecured Claim agrees to less favorable treatment, on the Effective Date, or as soon as practicable thereafter, the Debtors shall continue to pay or dispute each General Unsecured Claim in the ordinary course as if the Chapter 11 Cases had never been commenced.
Unimpaired – deemed to accept. | |
| Intercompany Claims | On the Effective Date, any and all Intercompany Claims shall, at the option of the Debtors with the consent of the Required Consenting Funded Debt Parties, be (a) extinguished, canceled and/or discharged on the Effective Date, (b) reinstated and otherwise survive the Debtors’ restructuring by virtue of such Intercompany Claims being left unimpaired, or (c) otherwise addressed such that holders of Intercompany Claims will not receive any distribution on account of such Intercompany Claims. To the extent any such Intercompany Claim is reinstated, or otherwise adjusted (including by contribution, distribution in exchange for new debt or equity, or otherwise), paid or continued as of the Effective Date, any such transaction may be effected on or after the Effective Date without any further action by the Bankruptcy Court, act or action under applicable law, regulation, order or rule or the vote, consent, authorization or approval of any Person.
Not entitled to vote. | |
| Existing Preferred Interests | On the Effective Date, each holder of an allowed Existing Preferred Interest shall receive no distribution on account of such interests, and all Existing Preferred Interests shall be canceled, released, and extinguished and will be of no further force or effect.
Not entitled to vote. | |
| Existing Common Stock Interests | On the Effective Date, each holder of an allowed Existing Common Stock Interest shall receive no distribution on account of such interests, and all Existing Common Stock Interests shall be canceled, released, and extinguished and will be of no further force or effect.
Not entitled to vote. | |
| Other Equity Interests | On the Effective Date, each holder of an allowed Other Equity Interest shall receive no distribution on account of such interests, and all Other Equity Interests shall be canceled, released, and extinguished and will be of no further force or effect. | |
76
| Term |
Description | |
| Not entitled to vote. | ||
| Existing Intercompany Equity Interests | On the Effective Date, each holder of an allowed Existing Intercompany Equity Interest shall receive no distribution on account of its Existing Intercompany Equity Interest, which shall, at the election of the Debtors with the consent of the Required Consenting Funded Debt Parties, be (a) extinguished, canceled or discharged on the Effective Date or (b) reinstated and otherwise survive the Debtors’ restructuring by virtue of such Existing Intercompany Equity Interest being left unimpaired.
Not entitled to vote. | |
| Other | ||
| Tax Structure | The Ayrmid Transaction contemplated by this Term Sheet will be structured in a manner reasonably acceptable to the Debtors, the Required Consenting Funded Debt Parties and Ayrmid and that, to the extent reasonably practicable: (a) minimizes any cash taxes payable as a result of the consummation of the Ayrmid Transaction; (b) maximizes the favorable tax attributes (including tax basis) of KPTI and NewCo and their respective subsidiaries going forward; and (c) otherwise achieves such tax-planning outcomes as reasonably requested by the Debtors, the Required Consenting Funded Debt Parties and Ayrmid. | |
| Transaction Expenses | Pursuant to the Plan, the Debtors shall pay, on or prior to the Effective Date, the fees, costs and expenses of: (a) to the extent approved by order of the Bankruptcy Court, Sidley Austin LLP, Centerview Partners LLC, FTI Consulting, Inc., Stretto, Inc., and Ernst & Young LLP, as counsel, investment banker, financial advisor, claims and noticing agent, and accountant, respectively, to KPTI; (b) Latham & Watkins LLP, Haynes and Boone LLP, and Houlihan Lokey Capital, Inc., as counsel, local counsel, and investment banker, respectively, to the Ad Hoc Group; and (c) Hogan Lovells Cadwalader US LLP (“HLC”) and Stifel Financial Corp. (“Stifel”), as counsel and investment banker, respectively, to the KPTI RIFA Investors; provided, with respect to clause (c), (i) amounts payable to HLC in excess of $600,000 shall be subject to objection, and (ii) with respect to Stifel, amounts payable shall include (x) monthly fees of $150,000 solely to the extent accruing from the Petition Date until the closing of the Ayrmid Transaction or an Acceptable Alternative Transaction and (y) solely in the event of the consummation of an Acceptable Alternative Transaction, (A) if transaction proceeds are sufficient to pay all Funded Debt outstanding in full and in cash, then a $1,000,000 deferred fee, or (B) if transaction proceeds are insufficient to pay all Funded Debt outstanding in full in cash, then a $500,000 deferred fee, in each case payable upon consummation of such Acceptable Alternative Transaction and solely from the proceeds thereof. | |
77
| Term |
Description | |
| NewCo Governance | The organizational documents of NewCo adopted on the Effective Date (and any other documents or agreements related thereto) shall be in form and substance as determined by the Required Consenting Funded Debt Parties and Ayrmid (the “NewCo Governance Documents”). | |
| Employee Compensation and Benefits – Plans | All employee policies, and all compensation and benefits plans, policies, and programs of the Debtors applicable to their respective employees, retirees, and nonemployee directors, including all savings plans, retirement plans, healthcare plans, disability plans, severance benefit plans, incentive plans, COBRA benefits and life and accidental death and dismemberment insurance plans that are assumed as executory contracts under the Plan pursuant to sections 365 and 1123 of the Bankruptcy Code shall be honored by NewCo in accordance with their respective terms, and NewCo shall abide by all applicable laws with respect to employee obligations; provided that such severance and COBRA benefits, for each eligible employee, retiree, and nonemployee director, shall not exceed the amounts scheduled on Annex A hereto. | |
| Employee Compensation and Benefits – Severance | From the Effective Date through the first (1st) anniversary of the Effective Date (the “Severance Protection Period”), NewCo: (a) shall not, and shall cause its subsidiaries not to, amend or terminate any KPTI Severance Plan in any manner adverse to any Covered Employee (except as otherwise provided herein); and (b) shall provide, or shall cause its applicable subsidiaries to provide, to each Covered Employee who experiences a Qualifying Termination, severance pay and benefits no less favorable than those that the KPTI Severance Plans provide for that Covered Employee upon that termination in the amounts for each such Covered Employee not to exceed the amounts scheduled on Annex A hereto. Subject to the foregoing limitations in amount, all KPTI Severance Plans will be deemed to be, and shall be treated as, executory contracts under the Plan and, on the Effective Date, shall be assumed pursuant to sections 365 and 1123 of the Bankruptcy Code.
“Covered Employee” means each individual employed by any Debtor immediately before the Effective Date, other than any individual who is then an “executive officer” of KPTI (as defined in Rule 3b-7 under the Securities Exchange Act of 1934) (the “Exchange Act”).
“KPTI Severance Plans” means each severance, separation pay, salary continuation, and termination pay or benefits plan, policy, program, guideline, and practice of the Debtors, whether written or unwritten, as in effect on the date of the RSA; provided, that any obligations owed to Covered Employees under the KPTI Severance Plans as of the Effective Date shall not exceed the amounts set forth on Annex A hereto. | |
78
| Term |
Description | |
| “Qualifying Termination” means a termination of a Covered Employee’s employment during the Severance Protection Period (a) by NewCo or any of its subsidiaries other than for cause (as defined in the applicable KPTI Severance Plan) or (b) by any Covered Employee for good reason, to the extent the applicable KPTI Severance Plan provides good reason rights or, for any Covered Employee without good reason rights under the applicable KPTI Severance Plan, following (i) a reduction in the Covered Employee’s base salary or base wage rate or (ii) a relocation of the Covered Employee’s primary work location by more than 35 miles, in each case without the Covered Employee’s written consent.
Severance pay and benefits under this provision exclude equity and equity-based awards, including any awards under any MIP. Nothing in this provision shall limit any notice or severance pay or benefits that applicable law requires, and nothing herein shall constitute an admission, or otherwise modify or limit any defenses, as to any amounts owed by NewCo to affected employees under the KPTI Severance Plans. Nothing herein shall affect NewCo’s ability to make changes to a Covered Employee’s division or direct supervisor, or similar changes to NewCo’s internal reporting lines.
The Plan and the Confirmation Order shall provide for the obligations in this provision, which shall bind NewCo and its successors and assigns. | ||
| Releases | The Plan shall provide for customary releases (including consensual third-party releases) and/or waivers, including standard carve-outs, and such other carve-outs acceptable to the Debtors, the Required Consenting Funded Debt Parties, the KPTI RIFA Investors, and Ayrmid in their sole discretion, among the Debtors, the RSA Parties, and their respective affiliates, in any capacity, and each of their respective current and former directors, officers, funds, affiliates, members, employees, partners, managers, agents, representatives, principals, consultants, and professional advisors (each in their capacity as such) (collectively, the “Released Parties”) of any and all claims, obligations (contractual or otherwise), suits, judgments, damages, rights, liabilities, or causes of action, whether known or unknown, foreseen or unforeseen, relating to any actions, transactions, events, or omissions on or before the Effective Date in any way relating to the Debtors, the Ayrmid Transaction, this Term Sheet and any related transactions. | |
| Exculpation | Customary exculpation provisions, including all Released Parties who are estate fiduciaries (including, without limitation, all current and former officers and directors of the Debtors), including standard carve-outs, and such other carve-outs acceptable to the Debtors, the Required Consenting Funded Debt Parties and Ayrmid in their applicable sole discretion. | |
79
| Term |
Description | |
| Break-Up Fee / Expense Reimbursement / Back-Up Bid | Subject to approval by the Bankruptcy Court (including, if applicable, through entry of an order approving the bidding procedures for the marketing process contemplated by the RSA (the “Bidding Procedures,” and such order, the “Bidding Procedures Order”)), in consideration of Ayrmid’s expenditure of time, effort, and resources in negotiating this Term Sheet, the RSA and the Restructuring Documents, and its commitment to serve as plan sponsor, upon the selection of a competing bid as the Successful Bid, Ayrmid shall earn and the Debtors shall be obligated to pay (a) a cash fee equal to 3.00% of $311,432,711 (the “Bid Protection Base” and, such fee, the “Break-Up Fee”); and (b) reasonable and documented out-of-pocket fees and expenses, including those of counsel, incurred in connection with negotiating and documenting this Term Sheet, the RSA and the Ayrmid Transaction but subject to an aggregate cap equal to 1.00% of the Bid Protection Base (the “Expense Reimbursement”), in each case, in accordance with the Bidding Procedures Order. The Break-Up Fee shall be payable in accordance with clause (y) of the final paragraph in this “Break-Up Fee / Expense Reimbursement / Back-Up Bid” section. Upon entry of the Bidding Procedures Order, the Break-Up Fee and Expense Reimbursement shall have administrative expense claim status pursuant to sections 105(a), 503(b), and 507(a)(2) of the Bankruptcy Code with priority over any and all administrative expenses of the kind specified in sections 503(b)(1) and 507(a) of the Bankruptcy Code, subject and subordinate to the DIP Claims and the Carve-Out.
If, in accordance with the Bidding Procedures Order and the RSA, the Debtors (with the consent of the Required Consenting Funded Debt Parties) select an Acceptable Alternative Transaction or an Alternative Restructuring Proposal as the successful bid (the “Successful Bid,” and the bidder thereunder, the “Successful Bidder”), whether the Successful Bid is selected at the conclusion of an auction conducted pursuant to the Bidding Procedures (an “Auction”) or, if no Auction is conducted, otherwise in accordance with the Bidding Procedures Order, Ayrmid shall, if the Debtors so designate in accordance with the Bidding Procedures Order, serve as the back-up bidder (in such capacity, the “Back-Up Bidder”) and shall keep its commitment to consummate the Ayrmid Transaction on the terms set forth in this Term Sheet and the Plan (as such terms may be improved by Ayrmid at the Auction) (the “Back-Up Bid”) open and irrevocable until the earlier of (i) the consummation of the transaction contemplated by the Successful Bid and (ii) the date that is 110 days after the Petition Date (the earlier of the dates described in clauses (i) and (ii), the “Back-Up Bid Termination Date”). |
80
| Term |
Description | |
| If the Successful Bidder fails to consummate the Successful Bid on or before the Back-Up Bid Termination Date (or the Successful Bidder’s definitive agreement with the Debtors is earlier terminated), the Debtors may, by written notice to Ayrmid delivered on or prior to the Back-Up Bid Termination Date, designate the Back-Up Bid as the Successful Bid, whereupon Ayrmid shall consummate the Ayrmid Transaction in accordance with this Term Sheet, the Plan, and the Restructuring Documents (as modified to reflect any improvements made by Ayrmid at the Auction) as promptly as practicable following satisfaction or waiver of the conditions precedent to the Effective Date, and the applicable milestones under the RSA and the DIP Term Sheet shall be deemed extended to the extent reasonably necessary to accommodate consummation of the Back-Up Bid.
Notwithstanding anything to the contrary in this Term Sheet or the RSA, if Ayrmid is designated as the Back-Up Bidder, (x) the RSA shall not terminate as to Ayrmid solely by reason of the Debtors’ selection of the Successful Bid, and Ayrmid’s obligations under the RSA with respect to the Back-Up Bid shall remain in full force and effect through the Back-Up Bid Termination Date; provided, however, that from and after the selection of the Successful Bid, (1) subject to the following clause (3), all obligations of the Debtors and the other RSA Parties owed to Ayrmid under the RSA and this Term Sheet shall be suspended and shall be of no force or effect, and the Debtors and the other RSA Parties shall be free to take any and all actions in furtherance of the Successful Bid without liability to Ayrmid; (2) Ayrmid shall have no right to terminate the RSA, and no termination event under the RSA in favor of Ayrmid shall be triggered, by reason of any action or inaction of the Debtors or the other RSA Parties in furtherance of the Successful Bid; and (3) the obligations described in clause (1) shall be reinstated and shall again be in full force and effect only if, and from and after the date on which, the Debtors designate the Back-Up Bid as the Successful Bid in accordance with the preceding paragraph, with the applicable milestones under the RSA and the DIP Term Sheet deemed extended as provided therein; and (y) the Break-Up Fee and the Expense Reimbursement, to the extent earned, shall be payable to Ayrmid within three (3) Business Days after the consummation of an Acceptable Alternative Transaction or Alternative Restructuring Proposal (subject in all cases to Ayrmid’s compliance with the terms of this Term Sheet and the RSA), in each case from the proceeds of the Acceptable Alternative Transaction or Alternative Restructuring Proposal (or as otherwise provided in the Bidding Procedures Order); provided, that, for the avoidance of doubt, the Break-Up Fee and the Expense Reimbursement shall constitute an allowed superpriority administrative claim when earned; provided, further, that such superpriority administrative claim shall be junior to the Carve-Out and all DIP Claims. Ayrmid’s commitment to serve as the Back-Up Bidder shall be without prejudice to its right to the Break-Up Fee and Expense Reimbursement if the Debtors select an Acceptable Alternative Transaction or an Alternative Restructuring Proposal. | ||
| Public to Private Filing | On the Effective Date and concurrently with the consummation of the Ayrmid Transaction, KPTI shall have completed the termination of registration of all securities under sections 13 and 15(d) of the Exchange Act and will continue as a private company. Unless otherwise consented by Ayrmid and the Required Consenting Funded Debt Parties, upon consummation of the Ayrmid Merger, the NewCo shall be a privately held entity. | |
81
| Term |
Description | |
| Conditions Precedent to the Effective Date | The occurrence of the Effective Date shall be subject to customary conditions precedent, including, without limitation, the following:
1. the RSA shall not have been terminated as to all parties thereto and shall remain in full force and effect;
2. the Confirmation Order shall have been entered and such order shall not have been reversed, stayed, vacated, or modified;
3. the Plan, Confirmation Order, and all schedules, documents, supplements and exhibits to the Plan, and any other Restructuring Documents, shall be consistent with the terms of the RSA and this Term Sheet and subject to the consent and approval rights set forth therein;
4. the Restructuring Documents shall have been executed and delivered and all conditions precedent to the effectiveness thereof shall have been satisfied or waived in accordance with the terms thereof;
5. the Ayrmid Merger shall have been consummated substantially contemporaneously with the occurrence of the Effective Date;
6. all reasonable professional fees and other amounts (including any earned and payable restructuring, sale, success, or other transaction or similar fee) required to be paid hereunder, under the RSA, the DIP Facility Documents, or any Restructuring Document, or in any order of the Bankruptcy Court related thereto shall have been paid or shall have been funded in an escrow account pending the approval of such fees and expenses by the Bankruptcy Court, as applicable; for avoidance of doubt, and unless Ayrmid otherwise consents in writing, NewCo shall not be responsible for, or otherwise obligated to pay, any of the foregoing fees and expenses; and
7. any and all requisite governmental, regulatory, and third-party approvals and consents required to implement the Plan or the Ayrmid Transaction shall have been obtained. | |
| Restructuring Documents | Any and all agreements, instruments, pleadings, orders, and other documents, including the MF CVR Agreement, Omisirge CVR Agreement, HCRx Royalty Agreement, NewCo Governance Documents, DIP Facility Documents, NewCo Facility Documents, Plan, disclosure statement, Confirmation Order and all related exhibits, schedules, supplements, appendices, annexes, and attachments thereto that are utilized to implement or effectuate, or that otherwise relate to, the Ayrmid Transaction or the RSA (collectively, the “Restructuring Documents”) shall be consistent in all respects with the RSA (including the documentation consent and approval rights therein) and this Term Sheet. | |
82
| Term |
Description | |
| Documentation | The parties shall negotiate the Restructuring Documents in good faith. Any and all documentation necessary to effectuate the Ayrmid Transaction (including, without limitation, the Restructuring Documents) shall be in form and substance consistent with this Term Sheet and the RSA and otherwise reasonably satisfactory to those parties who are party to such documentation or otherwise have consent rights specified in this Term Sheet or the RSA. | |
| Reservation of Rights | The submission of this Term Sheet to KPTI and the other RSA Parties is without prejudice to each RSA Party’s rights to negotiate the definitive documentation required to reflect the terms hereof pursuant to the terms of the RSA.
Nothing herein is an admission of any kind. If the Ayrmid Transaction is not consummated for any reason, all parties reserve any and all of their respective rights. | |
83
Annex A
KPTI Severance and COBRA Amounts
[***]
84
EXHIBIT F
Form of Transfer Agreement
[***]
85
EXHIBIT G
Form of Consenting Stakeholder Joinder
[***]
86
Exhibit 10.2
Certain portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
KARYOPHARM THERAPEUTICS INC., ET AL.
$110,000,000 SUPERPRIORITY SENIOR SECURED DEBTOR-IN-POSSESSION TERM LOAN FACILITY TERM SHEET
NOVEMBER 2, 2026
This term sheet (including all annexes and exhibits hereto, this “DIP Term Sheet”) sets forth the principal terms of a superpriority senior secured debtor-in-possession term loan credit facility (the “DIP Facility”; this DIP Term Sheet, the DIP Orders (as defined herein), the DIP Credit Agreement (as defined herein) and, if and to the extent required pursuant to the row titled “Documentation; DIP Term Sheet Controls” below, the other definitive financing documentation governing the DIP Facility, each of which shall be in form and substance acceptable to the Required DIP Lenders (as defined herein) and, with respect to the provisions which directly or indirectly apply to the rights and obligations of the DIP Agent (as defined herein) (collectively, the “DIP Agent Provisions”), the DIP Agent, collectively, the “DIP Documents”) to be entered into with the Debtors (as defined herein). The DIP Facility will be subject to the approval of the Bankruptcy Court (as defined herein) and consummated in cases to be commenced under chapter 11 (the “Chapter 11 Cases”) of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of Texas, Houston Division (the “Bankruptcy Court”), in accordance with (i) interim (a form of which is attached hereto as Exhibit A, the “Interim DIP Order”) and final orders (the “Final DIP Order” and, together with the Interim DIP Order, the “DIP Orders”) of the Bankruptcy Court authorizing the Debtors to enter into the DIP Facility, each of which shall be in form and substance acceptable to the Required DIP Lenders and, with respect to the DIP Agent Provisions, the DIP Agent, and (ii) the DIP Documents to be executed by the Debtors. In the event of any conflict between this DIP Term Sheet and the terms of the Interim DIP Order or the Final DIP Order, the terms of the applicable DIP Order shall govern.
Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Restructuring Support Agreement dated of even date herewith (the “RSA”), the Plan (as defined in the RSA), the DIP Orders, or that certain Credit and Guaranty Agreement, dated as of May 8, 2024 (as amended, restated, supplemented, waived or otherwise modified from time to time, the “Prepetition First Lien Credit Agreement” and, together with the other Credit Documents (as defined therein), the “Prepetition First Lien Documents” and the credit facility contemplated thereunder, the “Prepetition First Lien Facility”) by and among Karyopharm Therapeutics Inc. (the “Borrower”), each of the Borrower’s subsidiaries that are guarantors thereunder, the lenders party thereto from time to time (the “Prepetition First Lien Lenders”) and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent (in such respective capacities, the “Prepetition First Lien Agent”).
This DIP Term Sheet is being provided on a confidential basis, and the Borrower and Guarantors are not authorized to disclose this DIP Term Sheet to any person other than (i) their affiliates and their directors, officers, employees, accountants, attorneys and other professional advisors retained in connection with the transactions contemplated hereby, who shall agree to maintain its confidentiality, (ii) in a filing with the Bankruptcy Court in connection with the Chapter 11 Cases, (iii) the Office of the United States Trustee, (iv) Parties to the RSA, or (v) as may be required by applicable law.
THE TERMS AND CONDITIONS SET FORTH IN THIS DIP TERM SHEET DO NOT CONSTITUTE OR CREATE AN AGREEMENT, OBLIGATION OR COMMITMENT OF ANY KIND BY OR ON BEHALF OF ANY PARTY, UNLESS AND UNTIL EXECUTED BY EACH OF THE UNDERSIGNED PARTIES HERETO.
1
THIS DIP TERM SHEET IS NOT AN OFFER WITH RESPECT TO ANY SECURITIES OF THE BORROWER OR A SOLICITATION OF ACCEPTANCES OF ANY CHAPTER 11 PLAN WITHIN THE MEANING OF SECTION 1125 OF THE BANKRUPTCY CODE OR ANY OTHER PLAN OF REORGANIZATION OR SIMILAR PROCESS UNDER ANY APPLICABLE LAW. ANY SUCH OFFER OR SOLICITATION SHALL COMPLY WITH ALL APPLICABLE LAWS, INCLUDING SECURITIES LAWS AND/OR PROVISIONS OF THE BANKRUPTCY CODE, AS APPLICABLE.
THIS DIP TERM SHEET IS A SETTLEMENT PROPOSAL IN FURTHERANCE OF SETTLEMENT DISCUSSIONS AND IS ACCORDINGLY PROTECTED BY RULE 408 OF THE FEDERAL RULES OF EVIDENCE AND ANY OTHER APPLICABLE STATUTES OR DOCTRINES PROTECTING THE USE OR DISCLOSURE OF CONFIDENTIAL SETTLEMENT DISCUSSIONS.
THIS DIP TERM SHEET DOES NOT PURPORT TO SUMMARIZE ALL OF THE TERMS, CONDITIONS, REPRESENTATIONS, WARRANTIES, AND OTHER PROVISIONS WITH RESPECT TO THE DIP FACILITY, WHICH ARE SUBJECT IN ALL RESPECTS TO THE DIP DOCUMENTS.
2
| Term |
Description | |
| Borrower: | Karyopharm Therapeutics Inc., as a debtor-in-possession. | |
| Guarantors: | KPT Texas LLC, which shall be a debtor-in-possession, and any other subsidiary of the Borrower that is a debtor-in-possession under the Chapter 11 Cases (collectively the “Guarantors” and, together with the Borrower, the “Debtors”).
Each of the Guarantors jointly and severally hereby irrevocably and unconditionally guarantees to the DIP Agent for the ratable benefit of the DIP Secured Parties the due and punctual payment in full in cash of all DIP Obligations when the same shall become due, whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise. Each Guarantor agrees that its obligations hereunder are irrevocable, absolute, independent and unconditional and shall not be affected by any circumstance that constitutes a legal or equitable discharge of a guarantor or surety other than the indefeasible payment in full in cash of the DIP Obligations (subject to the terms of the RSA). | |
| DIP Agent: | Wilmington Savings Fund Society, FSB (“WSFS”), as administrative agent and collateral agent for the DIP Lenders (in such respective capacities, the “DIP Agent”). All DIP Loans and payments and administrative functions shall be handled through the DIP Agent. Until entry of the Final DIP Order and execution of the DIP Credit Agreement, in acting under this DIP Term Sheet, the DIP Agent shall be entitled to all of the rights, authority, privileges, protections, immunities, indemnities, reimbursements for expenses, limitations of liability and benefits afforded to WSFS as collateral agent or administrative agent, as applicable, under the Prepetition First Lien Credit Agreement, which provisions are incorporated herein by reference, mutatis mutandis, and shall survive the termination of its fee letter and the resignation or removal of the DIP Agent (collectively, the “Agency Provisions”); provided, that any references to a “Lender” or a “Credit Party” in the Prepetition First Lien Credit Agreement shall be deemed references to a DIP Lender and a Debtor, as applicable.
Notwithstanding any other terms or provisions in the DIP Documents, any actions (including any enforcement actions or the pursuit of remedies against the Debtors and/or the DIP Collateral) required or permitted to be taken by the DIP Lenders hereunder may be taken on their behalf by the DIP Agent. | |
| DIP Lenders: | The Prepetition First Lien Lenders and/or their respective affiliates or managed or controlled funds who elect to participate in the DIP Facility listed in Schedule 1 hereto (in such capacities, the “DIP Lenders” and, together with the DIP Agent, the “DIP Secured Parties”) in the amounts set forth on Schedule 1 hereto.
The obligation of any DIP Lender to fund any loan under the DIP Facility may be fulfilled on behalf of such DIP Lender by any of such DIP Lender’s affiliated or related funds or financing vehicles. | |
| Documentation; DIP Term Sheet Controls: | In connection with entry of the Final DIP Order, the Debtors, the DIP Agent, and the DIP Lenders shall execute and enter into a debtor-in-possession credit and guaranty agreement (the “DIP Credit Agreement”), which shall be (a) attached as an exhibit to the Final DIP Order, (b) consistent with this DIP Term Sheet (except as otherwise agreed by the Borrower and the Required DIP Lenders), and (c) in form and substance reasonably acceptable to the Debtors, the Required DIP Lenders, and the DIP Agent (with respect to any DIP Agent Provision). | |
3
| Term |
Description | |
| At the option of the Required DIP Lenders in their sole discretion, the Debtors shall execute other definitive financing documentation with respect to the DIP Facility, including, without limitation, guarantees and security documents, which shall be prepared by counsel to the Ad Hoc Group, in consultation with the counsel to the Debtors, based upon and giving due regard to the Prepetition First Lien Documents, in each case reasonably satisfactory in form and substance to the Required DIP Lenders, the DIP Agent (with respect to any DIP Agent Provision) and the Debtors, which shall contain the terms and conditions set forth in this DIP Term Sheet and such other terms as the Borrower, the DIP Agent (with respect to any DIP Agent Provision) and the Required DIP Lenders shall agree; provided, that such documentation (i) shall be consistent with and subject to the terms of this DIP Term Sheet unless otherwise agreed by the DIP Agent (with respect to any DIP Agent Provision) and the Required DIP Lenders and (ii) shall otherwise be on terms no less favorable to the DIP Secured Parties than the terms under this DIP Term Sheet unless otherwise agreed by the DIP Agent (with respect to any DIP Agent Provision) and the Required DIP Lenders.
The provisions of such definitive documentation shall, upon execution, supersede the provisions of this DIP Term Sheet solely to the extent of any direct conflict between such documentation and this DIP Term Sheet; provided, that prior to the execution of the DIP Credit Agreement, this DIP Term Sheet and the Interim DIP Order shall govern the DIP Facility. | ||
| Required DIP Lenders: | “Required DIP Lenders” shall mean, at any time, DIP Lenders holding a majority of the aggregate outstanding New Money DIP Loans and unfunded New Money DIP Commitments at such time. | |
| DIP Facility: | The DIP Facility shall be a superpriority senior secured term loan financing facility in an aggregate principal amount not to exceed $110,000,000, comprising (a) first-out new money term loans in an aggregate principal amount of up to $55,000,000 (the “New Money DIP Loans” and the commitments therefor, the “New Money DIP Commitments”; the New Money DIP Commitments of each DIP Lender are set forth on Schedule 1 hereto), available in the Initial Draw (as defined herein) upon entry of the Interim DIP Order and in one Delayed Draw (as defined herein) upon entry of the Final DIP Order, and (b) the Roll-Up Loans (as defined herein) (the New Money DIP Loans together with the Roll-Up Loans, the “DIP Loans”), in each case subject to the terms and conditions set forth in this DIP Term Sheet and the DIP Documents. The draw mechanics of the DIP Facility shall be on terms mutually agreed upon by the DIP Agent, the Required DIP Lenders and the Debtors, and in accordance with the DIP Budget1 (as defined herein); provided, that (x) until entry of the Final DIP Order and execution of the DIP Credit Agreement, the draw mechanics set forth in Section 2.1(c)(i) of the Prepetition First Lien Credit Agreement shall govern any draw of the DIP Facility, mutatis mutandis (however, (i) any references to conditions precedent shall be deemed references to the Interim Funding Conditions and (ii) references to the HCR Lender and the HCR Loans shall be disregarded), and (y) the DIP Agent shall maintain a register of the DIP Loans on the same terms and conditions as provided in Section 2.6(b) of the Prepetition First Lien Credit Agreement. | |
| 1 | As used herein, all references to the “DIP Budget” mean the “DIP Budget (subject to Permitted Variances)”. |
4
| Term |
Description | |
| New Money DIP Loans made by any DIP Lender under the DIP Facility may be made directly by such DIP Lender or “fronted” by a financial institution on terms reasonably acceptable to the Debtors, the relevant DIP Lender and such fronting financial institution. | ||
| Roll-Up: | Subject to and upon entry of the Interim DIP Order, and subject to the occurrence of the Closing Date (as defined herein), $25,000,000 in aggregate principal amount of Prepetition First Lien Term Loans in respect of such Prepetition First Lien Term Loans held by those DIP Lenders that fund New Money DIP Loans (or any of their respective designated affiliates or managed or controlled funds, as determined by the applicable DIP Lender) shall be automatically deemed “rolled up” and converted into a second-out tranche of term loans under the DIP Facility (such conversion, the “Interim Roll-Up” and such converted amounts, the “Interim Roll-Up Loans”), on a cashless basis, at a ratio of $1.00 of principal amount of Prepetition First Lien Term Loans held by each DIP Lender for every $1.00 of principal amount of New Money DIP Loans funded by such DIP Lender in the Initial Draw.
Subject to entry of the Final DIP Order and upon funding of the Delayed Draw, an additional $30,000,000 in aggregate principal amount of Prepetition First Lien Term Loans shall be automatically deemed “rolled up” and converted into a second-out tranche of term loans under the DIP Facility (such conversion, the “Final Roll-Up” and, together with the Interim Roll-Up, the “Roll-Up”; such converted amounts, the “Final Roll-Up Loans” and, together with the Interim Roll-Up Loans, the “Roll-Up Loans”), on a cashless basis, at a ratio of $1.00 of principal amount of Prepetition First Lien Term Loans of each DIP Lender for every $1.00 of the aggregate principal amount of New Money DIP Commitments of such DIP Lender funded by such DIP Lender in the Delayed Draw.
For the avoidance of doubt, no Prepetition 2028 Notes Obligations, Prepetition 2029 Notes Obligations or Prepetition Royalty Obligations shall be included in, refinanced, converted, “rolled up” or otherwise deemed satisfied in connection with the Roll-Up.
As used herein, (i) all obligations in respect of the New Money DIP Loans and the commitments therefor, together with all interest, fees, premiums, costs, expenses, indemnities and other amounts accrued or payable in respect thereof, are referred to as the “First-Out New Money DIP Obligations,” (ii) all obligations in respect of the Roll-Up Loans, together with all interest, fees, premiums, costs, expenses, indemnities and other amounts accrued or payable in respect thereof, are referred to as the “Second-Out Roll-Up DIP Obligations,” and (iii) the First-Out New Money DIP Obligations and the Second-Out Roll-Up DIP Obligations are referred to collectively as the “DIP Obligations.” Notwithstanding anything to the contrary herein, the First-Out New Money DIP Obligations shall be senior in right of payment to the Second-Out Roll-Up DIP Obligations, and all DIP Collateral and proceeds thereof shall be applied, after funding of the Carve-Out, first, to the First-Out New Money DIP Obligations until indefeasibly paid in full in cash (subject to the terms of the RSA), and second, to the Second-Out Roll- | |
5
| Term |
Description | |
| Up DIP Obligations. No payment or distribution shall be made on account of the Second-Out Roll-Up DIP Obligations (other than interest paid in kind in accordance with this DIP Term Sheet and the DIP Documents) unless and until the First-Out New Money DIP Obligations have been indefeasibly paid in full in cash (subject to the terms of the RSA). | ||
| Treatment Under Ayrmid Transaction: | Notwithstanding anything herein to the contrary, in the event of the consummation of the Ayrmid Transaction (as defined in the RSA), each holder of an allowed claim relating to the DIP Facility (a “DIP Claim”) consents to the treatment of its DIP Claim in accordance with the Ayrmid Transaction Term Sheet. Other than as set forth in the Ayrmid Transaction Term Sheet with respect to the Ayrmid Transaction, no holder of a DIP Claim shall be deemed to have waived its right to have its DIP Claim paid in full in cash in connection with any transaction (whether a Sale Transaction, chapter 11 plan, or otherwise) without the written consent of the Required DIP Lenders. | |
| Purpose: | The proceeds of the New Money DIP Loans shall be used to, among other things: (a) pay fees, interest, premiums, costs, and expenses associated with the DIP Facility, (b) provide for the ongoing working capital, capital expenditure, and general corporate needs of the Debtors during the pendency of the Chapter 11 Cases, (c) fund the Carve-Out (as defined herein), (d) make the adequate protection payments contemplated by the DIP Orders, and (e) fund the costs of the administration of the Chapter 11 Cases (including allowed administrative costs and expenses), the sale process, and the consummation of the Restructuring Transactions, in each case, subject to the DIP Budget; provided, that none of the foregoing shall limit the payment of Allowed Professional Fees (as defined in the Interim DIP Order attached as Exhibit A hereto) that benefit from the Carve-Out, as and when such Allowed Professional Fees are allowed by the Bankruptcy Court at any time (whether by interim order, procedural order or otherwise). | |
| Availability: | Upon the Bankruptcy Court’s entry of the Interim DIP Order, New Money DIP Loans in an aggregate principal amount not to exceed $25,000,000 (the “Interim DIP Amount”) shall be available to the Borrower and borrowed on the Closing Date (as defined herein) in a single draw (the “Initial Draw”), subject to compliance with the Interim Funding Conditions (as defined herein) and the other terms, conditions and covenants set forth in this DIP Term Sheet and the DIP Orders. The Interim Roll-Up Loans shall be incurred upon entry of the Interim DIP Order and shall be in addition to, and shall not be counted against, the Interim DIP Amount.
Upon the Bankruptcy Court’s entry of the Final DIP Order, the remaining New Money DIP Commitments (the “Delayed Draw Amount”) shall be available to the Borrower in a single draw (the “Delayed Draw”) of $30,000,000, subject to compliance with the Delayed Draw Conditions (as defined herein) and the other terms, conditions and covenants set forth in the DIP Documents. The Final Roll-Up Loans shall be incurred upon entry of the Final DIP Order and shall be in addition to, and shall not be counted against, the Delayed Draw Amount. | |
6
| Term |
Description | |
| Interim Funding Conditions: | The initial borrowing of New Money DIP Loans in the Interim DIP Amount under the DIP Facility shall be subject to the satisfaction or written waiver by the Required DIP Lenders of the following conditions precedent (collectively, the “Interim Funding Conditions”; the date of satisfaction of such conditions, the “Closing Date”):
i. this DIP Term Sheet shall have been executed and delivered by each Debtor, each DIP Lender and the DIP Agent, and each other DIP Document (other than the DIP Credit Agreement) shall be in form and substance consistent with this DIP Term Sheet and otherwise reasonably satisfactory to the DIP Agent and the Required DIP Lenders and shall have been executed and delivered by each Debtor party thereto;
ii. the Petition Date shall have occurred, and each Debtor shall be a debtor and a debtor-in-possession;
iii. all “first day orders” (other than the Interim DIP Order) entered by the Bankruptcy Court in the Chapter 11 Cases (including a cash management order) shall be satisfactory in form and substance to the Required DIP Lenders in their reasonable discretion;
iv. not later than three (3) calendar days following the Petition Date (subject to the availability of the Bankruptcy Court), (1) the DIP Agent shall have received a signed copy of the Interim DIP Order entered by the Bankruptcy Court: (a) authorizing and approving the making of the DIP Loans and the granting of the superpriority claims and liens contemplated by this DIP Term Sheet and the DIP Documents; (b) authorizing the Interim Roll-Up; (c) granting the DIP Agent, for the benefit of the DIP Secured Parties, valid and perfected liens on the DIP Collateral (consistent with the priorities set forth herein) to the extent and with the priority set forth in this DIP Term Sheet, subject only to the Carve-Out and the Permitted Prior Liens2; and (d) otherwise containing terms and conditions consistent with Exhibit A hereto and otherwise in form and substance acceptable to the Required DIP Lenders in their sole discretion and, with respect to any DIP Agent Provision, the DIP Agent in its sole discretion; and (2) such order shall be in full force and effect and shall not have been vacated, reversed, modified, amended, or stayed in any respect;
v. the Debtors shall be in compliance in all respects with the Interim DIP Order;
vi. no trustee or examiner with expanded powers (having powers beyond those set forth in Bankruptcy Code sections 1106(a)(3) and (4)) shall have been appointed with respect to the Debtors, any of their subsidiaries, or their respective properties; |
| 2 | The “Permitted Prior Liens” shall have the meaning ascribed in the DIP Orders. |
7
| Term |
Description | |
| vii. substantially concurrently with the Closing Date, subject to the Interim DIP Order, all fees and expenses, including reasonable and documented attorneys’ fees, of the DIP Secured Parties relating to the Chapter 11 Cases and the DIP Facility and all other fees required to be paid to the DIP Agent and the DIP Lenders on or before the Closing Date shall have been paid (or shall be paid with the proceeds of the Initial Draw) to the extent an invoice has been delivered to the Borrower at least twenty-four (24) hours in advance of the Closing Date;
viii. all governmental and third-party consents and approvals necessary in connection with the DIP Facility and the transactions contemplated thereby shall have been obtained;
ix. there shall exist no Default or Event of Default (each as defined herein) under the DIP Facility immediately before, or after giving effect to, the funding of the Initial Draw;
x. the representations and warranties of the Debtors set forth herein shall be true and correct in all material respects or, with respect to representations and warranties qualified by materiality, in all respects (other than any such representation and warranty that by its terms refers to a specified earlier date which shall be true and correct in all material respects or, with respect to representations and warranties qualified by materiality, in all respects, as of such earlier date) immediately before, and after giving effect to, the funding of the Initial Draw;
xi. since the RSA Effective Date (as defined in the RSA), there shall not have occurred any event, change, condition, or circumstance that has had, or that could reasonably be expected to have, a Material Adverse Effect (as defined herein), other than as a result of those events leading up to and following commencement of the Chapter 11 Cases;
xii. there shall exist no unstayed action, suit, investigation, litigation or proceeding pending or threatened in writing in any court or before any arbitrator or governmental instrumentality (other than the Chapter 11 Cases) that could reasonably be expected to have a Material Adverse Effect;
xiii. the DIP Agent shall have received (x) a notice (email from the chief executive officer, president, vice president or chief financial officer (each, an “Authorized Officer”) of the Borrower being sufficient) and (y) a duly executed letter of direction from the Borrower addressed to the DIP Agent directing the disbursement on the Closing Date of the proceeds of the DIP Loans made on such date substantially in the form of Exhibit B to the Prepetition First Lien Credit Agreement, in each case, in connection with such draw request no later than 11:00 a.m. (Prevailing Eastern Time) one (1) Business Day prior to the Closing Date (or such later time as the Required DIP Lenders and the DIP Agent may agree to); |
8
| Term |
Description | |
| xiv. the DIP Agent and the DIP Lenders shall have received a closing certificate, in form and substance reasonably satisfactory to the DIP Agent and the Required DIP Lenders (a “Closing Certificate”) duly executed by an Authorized Officer of the Borrower, appropriately completed, by which such Authorized Officer shall certify to the DIP Agent and the DIP Lenders that all of the Interim Funding Conditions have been satisfied;
xv. the DIP Secured Parties shall have received, and be satisfied with, the initial DIP Budget;
xvi. the Debtors shall have insurance (including, without limitation, commercial general liability and property insurance) with respect to the DIP Collateral, with financially sound and reputable insurance companies reasonably acceptable to the Required DIP Lenders, and in amounts as are generally carried in accordance with sound business practice by companies in similar businesses and circumstances as the Debtors;
xvii. the DIP Lenders shall have received a certificate, in form and substance reasonably satisfactory to the Required DIP Lenders, executed by an Authorized Officer of each Debtor on behalf of each such Debtor, certifying that attached to such certificate are true, correct and complete copies of (a) (x) the certificate of incorporation, certificate of limited partnership or articles of organization, as applicable, of such applicable Debtor and (y) the by-laws, operating agreement, limited liability company agreement or limited partnership agreement, as applicable, of such applicable Debtor, in each case, then in full force and effect (including all amendments thereto) (clauses (x) and (y), collectively, the “Organizational Documents”), (b) the resolutions then in full force and effect adopted by the board of directors (or comparable governing body) of such applicable Debtor authorizing and ratifying the execution, delivery and performance by such applicable Debtor of this DIP Term Sheet and the transactions contemplated hereby, (c) a certificate of good standing or certificate of fact and certificate of account status, as applicable, dated as of a recent date, from the secretary of state (or comptroller, as applicable) of the state under whose laws such applicable Debtor was incorporated or formed, and (d) an incumbency certificate evidencing the identity, authority and capacity of each Authorized Officer thereof authorized to execute this DIP Term Sheet, the DIP Documents and any other related document to which such Debtor is a party or is to be a party and specimen signatures thereof; and
xviii. the making of the DIP Loans shall not violate any requirement of law and shall not be enjoined, temporarily, preliminarily or permanently. | ||
| Delayed Draw Conditions: | Upon entry of the Final DIP Order, the availability of the Delayed Draw Amount under the DIP Facility shall be subject to the satisfaction, or written waiver by the Required DIP Lenders, of each of the following conditions precedent (collectively, the “Delayed Draw Conditions”): | |
9
| Term |
Description | |
| i. there shall exist no Default or Event of Default under the DIP Facility immediately before, or after giving effect to, the funding of the Delayed Draw;
ii. the representations and warranties of the Debtors set forth under the DIP Credit Agreement shall be true and correct in all material respects or, with respect to representations and warranties qualified by materiality, in all respects (other than any such representation and warranty that by its terms refers to a specified earlier date which shall be true and correct in all material respects or, with respect to representations and warranties qualified by materiality, in all respects, as of such earlier date) immediately before, and after giving effect to, the funding of the Delayed Draw;
iii. the making of the Delayed Draw shall not violate any requirement of law and shall not be enjoined, temporarily, preliminarily or permanently;
iv. since the RSA Effective Date, there shall not have occurred any event, change, condition, or circumstance that has had, or that could reasonably be expected to have, a Material Adverse Effect (as defined herein), other than as a result of those events leading up to and following commencement of the Chapter 11 Cases;
v. prior to or substantially concurrently with the making of the Delayed Draw, all fees and expenses, including reasonable and documented attorneys’ fees of the DIP Secured Parties shall have been paid in full (or shall be paid in connection with the Delayed Draw) to the extent an invoice has been delivered to the Borrower at least twenty-four (24) hours in advance;
vi. the DIP Agent shall have received a signed copy of the Final DIP Order entered by the Bankruptcy Court: (a) authorizing and approving the making of the DIP Loans and the granting of the superpriority claims and liens contemplated by this DIP Term Sheet and the DIP Documents; (b) authorizing the Final Roll-Up; (c) approving the DIP Credit Agreement in the form attached as an exhibit thereto (which shall be in form and substance acceptable to the Required DIP Lenders and, with respect to the DIP Agent Provisions, the DIP Agent); (d) granting the DIP Agent, for the benefit of the DIP Secured Parties, valid and perfected liens on the DIP Collateral (consistent with the priorities set forth herein) to the extent and with the priority set forth in this DIP Term Sheet, subject only to the Carve-Out and the Permitted Prior Liens; and (e) otherwise containing terms and conditions consistent with Exhibit A attached hereto and otherwise in form and substance acceptable to the Required DIP Lenders in their sole discretion (and the DIP Agent with respect to any DIP Agent Provision in its sole discretion);
vii. the Final DIP Order shall be in full force and effect and shall not have been vacated, reversed, modified, amended, or stayed in any respect, and the Debtors shall be in compliance in all respects with the Final DIP Order; |
10
| Term |
Description | |
| viii. receipt by the DIP Agent and the DIP Lenders of copies of the DIP Credit Agreement duly executed and delivered by the Debtors and, to the extent requested, the other DIP Documents, in each case in form and substance acceptable to the DIP Agent (with respect to any DIP Agent Provision), the Required DIP Lenders and the Debtors;
ix. the Debtors shall be in compliance with the Milestones;
x. after giving effect to the Delayed Draw, the total principal amount of New Money DIP Loans borrowed (without, for the avoidance of doubt, giving effect to any prepayments of the DIP Loans) shall not exceed the total New Money DIP Commitments;
xi. the DIP Agent shall have received (x) a notice (an email from an Authorized Officer of the Borrower being sufficient), and (y) a duly executed letter of direction from the Borrower addressed to the DIP Agent directing the disbursement on the Closing Date of the proceeds of the DIP Loans made on such date substantially in the form of Exhibit B to the Prepetition First Lien Credit Agreement, in each case, in connection with such draw request no later than 11:00 a.m. (Prevailing Eastern Time) one (1) Business Day prior to the requested funding date of the Delayed Draw (or such later time as the Required DIP Lenders may agree to); and
xii. the DIP Agent and the DIP Lenders shall have received a Closing Certificate duly executed by an Authorized Officer of the Borrower, appropriately completed, by which such Authorized Officer shall certify to the DIP Agent and the DIP Lenders that all of the Delayed Draw Conditions have been satisfied. | ||
| Interest Rates and Fees: | As set forth on Annex A hereto. | |
| Default Rate: | Upon the occurrence and during the continuance of any Event of Default, interest shall accrue on the principal amount of the outstanding New Money DIP Loans and any overdue amount (including overdue interest) at the applicable interest rate plus 2.00% per annum. | |
| Amortization: | None. | |
| Maturity: | The earliest of (a) May 1, 2027 (i.e., the date that is six (6) months following the Petition Date), (b) the Plan Effective Date, (c) the date of the closing of a sale of all or substantially all of the assets of the Debtors under section 363 or section 1129 of the Bankruptcy Code or otherwise, (d) the date all DIP Loans become due and payable hereunder or under the DIP Documents, whether by acceleration or otherwise, and (e) the date of the dismissal of any of the Chapter 11 Cases or the conversion of any of the Chapter 11 Cases to a case under chapter 7 of the Bankruptcy Code (such earliest date, the “Maturity Date”). | |
11
| Term |
Description | |
| All amounts owed hereunder in respect of the DIP Loans (including, without limitation, any accrued and unpaid interest thereon, any exit fee in respect thereof and all other DIP Obligations) shall be paid in full in cash upon the Maturity Date (except as otherwise agreed by the Required DIP Lenders). All payments of principal, interest, and fees hereunder in respect of the New Money DIP Loans shall be made to the DIP Lenders on a pro rata basis (in accordance with the respective outstanding principal amounts thereof). All payments of principal, interest, and fees hereunder in respect of the Roll-Up Loans shall be made to the DIP Lenders on a pro rata basis (in accordance with the respective outstanding principal amounts thereof). | ||
| Milestones: | The Debtors shall achieve the Milestones (as defined in the RSA), which Milestones are incorporated into this DIP Term Sheet as if they were set forth herein, as may be modified, extended or waived pursuant to the RSA. | |
| Collateral: | The DIP Obligations shall be secured by valid, binding, continuing, enforceable, non-avoidable and automatically and properly perfected security interests in and liens (the “DIP Liens”) on all real and personal property of each of the Debtors, whether now existing or hereafter arising and wherever located, tangible or intangible (the “DIP Collateral”), including, subject to entry of the Final DIP Order, the proceeds of any avoidance actions arising pursuant to chapter 5 of the Bankruptcy Code (the “Avoidance Action Proceeds”); provided, for the avoidance of doubt, that such DIP Liens shall be subject to the Carve-Out.
The DIP Liens shall consist of (a) pursuant to section 364(d)(1) of the Bankruptcy Code, a first priority, senior priming lien on all DIP Collateral that constitutes Prepetition Collateral (including Cash Collateral), senior to and priming the Prepetition 1L Liens, the Prepetition 2L Notes Liens, the Prepetition 2L Royalty Liens, and any adequate protection liens granted to the Prepetition Secured Parties, (b) pursuant to section 364(c)(2) of the Bankruptcy Code, a first priority lien on all other real and personal property of the Debtors not subject to a Permitted Prior Lien (or subject to a lien that becomes perfected subsequent to the Petition Date as permitted by section 546(b) of the Bankruptcy Code), and (c) pursuant to section 364(c)(3) of the Bankruptcy Code, a lien immediately junior to any Permitted Prior Liens on the real and personal property of the Debtors subject thereto, in each case subject and subordinate only to the Carve-Out and the Permitted Prior Liens. All of the DIP Liens shall be valid, binding, enforceable, non-avoidable and automatically and properly perfected upon entry of the applicable DIP Order, without the necessity of the execution or filing of any mortgages, security agreements, pledge agreements, financing statements, account control agreements or other agreements or instruments; provided, that the Debtors shall take all action reasonably requested by the DIP Agent (at the direction of the Required DIP Lenders) to maintain the validity, perfection, enforceability and priority of the DIP Liens and to enable the DIP Secured Parties to protect, exercise and enforce their rights in the DIP Collateral.
The relative priorities of the DIP Liens, the Prepetition 1L Liens, the Prepetition 2L Notes Liens, the Prepetition 2L Royalty Liens, and the adequate protection liens granted to the Prepetition Secured Parties are set forth on Annex C hereto (provided that (i) with respect to any obligations owed to the Prepetition Notes Secured Parties and the Prepetition Royalty Secured Parties (whether in the form of prepetition obligations, adequate protection obligations, or otherwise), any proceeds received by any such person shall be applied as between the Prepetition | |
12
| Term |
Description | |
| Notes Secured Parties and the Prepetition Royalty Secured Parties in accordance with Section 4.1 of the Intercreditor Agreement, mutatis mutandis and (ii) with respect to any obligations owed to the Prepetition Notes Secured Parties (whether in the form of prepetition obligations, adequate protection obligations, or otherwise), any proceeds received by any such person shall be applied as between the Prepetition 2028 Secured Parties and the Prepetition 2029 Secured Parties in accordance with Section 3.4 of the Collateral Trust Agreement, mutatis mutandis), and the DIP Orders shall be consistent therewith. | ||
| DIP Superpriority Claims: | All DIP Obligations at all times shall constitute allowed superpriority administrative expense claims, pursuant to section 364(c)(1) of the Bankruptcy Code, in the Chapter 11 Cases (the “DIP Superpriority Claims”), having priority over all administrative expenses of the kind specified in, or ordered pursuant to, sections 105, 326, 330, 331, 503(b), 506(c), 507(a), 507(b), or 726 or any other provisions of the Bankruptcy Code, subject only to the Carve-Out.
The relative priority of the DIP Superpriority Claims and the adequate protection claims granted to the Prepetition Secured Parties is set forth on Annex C hereto, and the DIP Orders shall be consistent therewith. | |
| Adequate Protection: | As adequate protection for any diminution in value of the Prepetition Secured Parties’ respective interests in the Prepetition Collateral (including the Cash Collateral) occurring from and after the Petition Date, whether or not resulting from the use, sale, or lease by the Debtors of the Prepetition Collateral (including Cash Collateral), the granting of the DIP Superpriority Claims, the granting of the DIP Liens, the subordination of the Prepetition 1L Liens, the Prepetition 2L Notes Liens, and the Prepetition 2L Royalty Liens thereto and to the Carve-Out, or the imposition or enforcement of the automatic stay of section 362(a) of the Bankruptcy Code, the Prepetition First Lien Agent, the Prepetition Notes Collateral Trustee and the Prepetition Royalty Collateral Agent, as applicable, shall receive, for the benefit of the Prepetition Secured Parties they respectively represent, the adequate protection granted to the Prepetition Secured Parties pursuant to the DIP Orders (which shall include, without limitation, (i) valid, perfected replacement security interests in and liens on all DIP Collateral, including, upon entry of the Final DIP Order, the Avoidance Action Proceeds, with the relative priorities set forth in the DIP Orders, (ii) superpriority claims as provided in section 507(b) of the Bankruptcy Code, with priority as provided therein and with the relative priorities set forth in the DIP Orders, (iii) current payment of the reasonable and documented fees, expenses and other disbursements of the Prepetition First Lien Agent and the Ad Hoc Group Advisors and of the respective agents, trustees and advisors of the Prepetition 2028 Secured Parties, the Prepetition 2029 Secured Parties, and the Prepetition Royalty Secured Parties (in the case of the Prepetition Royalty Secured Parties, (i) fees and expenses of counsel shall be subject to objection only if in excess of $600,000, and (ii) financial advisor fees to be limited to (x) monthly fees of $150,000 solely to the extent accruing from the Petition Date until the closing date of the Ayrmid Transaction or the Acceptable Alternative Transaction, as applicable, and (y) solely in the event of the consummation of an Acceptable Alternative Transaction (as defined in the RSA) that results in transaction proceeds, (A) if transaction proceeds are sufficient to pay all Funded Debt (as defined in the RSA) outstanding in full in and in cash, then a $1,000,000 deferred | |
13
| Term |
Description | |
| fee, or (B) if transaction proceeds are insufficient to pay all Funded Debt outstanding in full in cash, then a $500,000 deferred fee, in each case payable upon consummation of such Acceptable Alternative Transaction and, in each case, solely from the proceeds thereof), in each case as it relates to the Chapter 11 Cases, and (iv) financial and other reporting; provided, that any such financial and other reporting that relates to the Debtors’ sale and marketing process shall be provided only to the Ad Hoc Group Advisors and the Prepetition Royalty Secured Parties, and such information shall not be shared with any person acting in a Bidder Capacity (as defined in the RSA)); provided, further, that the Debtors shall not be required to provide any information where such provision would waive any privilege or violate applicable law. Except to the extent expressly set forth in the DIP Orders and subject to the terms of the RSA, none of the Prepetition Secured Parties shall receive or retain any payments, property or other amounts in respect of their respective section 507(b) claims unless and until all DIP Obligations (excluding contingent indemnification obligations for which no claim has been asserted) have been indefeasibly paid in full in cash.
The relative priority of the adequate protection liens and claims granted to the Prepetition Secured Parties, as among themselves and relative to the DIP Liens and the DIP Superpriority Claims, is set forth on Annex C hereto, and the DIP Orders shall be consistent therewith.
The Debtors’ use of Cash Collateral and other Prepetition Collateral is based on the consent (or deemed consent) of the DIP Lenders and Prepetition Secured Parties to such use. Nothing herein or in any DIP Order shall be deemed to constitute sufficient adequate protection in connection with any proposed non-consensual use of Cash Collateral and other Prepetition Collateral. | ||
| Carve-Out: | The DIP Orders shall include a carve-out as set forth in Section 30 of the Interim DIP Order attached hereto as Exhibit A (the “Carve-Out”). | |
| Mandatory Prepayments: | The Borrower may voluntarily, at any time, prepay any of the DIP Obligations and/or reduce the commitments under the DIP Facility at par plus accrued interest, without premium or penalty (but, for the avoidance of doubt, subject to the Exit Fee).
The following mandatory prepayments, subject to the DIP Orders, shall be required (and, in each case, shall be applied first, to the First-Out New Money DIP Obligations (including the Exit Fee in respect thereof) until indefeasibly paid in full in cash, and second, to the Second-Out Roll-Up DIP Obligations (including the Exit Fee in respect thereof)):
i. Asset Sales: Prepayments of the DIP Loans in an amount equal to 100% of the net cash proceeds of the sale or other disposition of any DIP Collateral, except for ordinary course sales (including, for the avoidance of doubt, sales of inventory) and de minimis sales and additional exceptions to be agreed;
ii. Insurance Proceeds: Prepayments of the DIP Loans in an amount equal to 100% of the net cash proceeds of insurance paid on account of any loss of any DIP Collateral, subject to exceptions to be agreed (including a right of the Debtors to reinvest such proceeds in assets used or useful in their business within 180 days after receipt); and | |
14
| Term |
Description | |
| iii. Incurrence of Indebtedness: Prepayments of the DIP Loans in an amount equal to 100% of the net cash proceeds of any indebtedness incurred by the Debtors or any of their respective subsidiaries after the Closing Date (other than any indebtedness otherwise permitted under the DIP Documents), payable no later than the date of receipt. | ||
| Representations and Warranties: | In order to induce the DIP Lenders to enter into this DIP Term Sheet and provide the New Money DIP Commitments and the DIP Loans hereunder, each Debtor represents and warrants to the DIP Agent and each DIP Lender that the statements set forth in Annex B are true and correct.
For the purposes of this DIP Term Sheet, “Material Adverse Effect” shall mean (a) a material adverse change in, or a material adverse effect on, the operations, business, properties, prospects or financial condition of the Debtors, taken as a whole, (b) a material impairment of the ability of the Debtors, taken as a whole, to perform their respective payment obligations hereunder or under any of the DIP Documents, (c) a material impairment of the rights and remedies of the DIP Agent or any DIP Lender hereunder or under any of the DIP Documents, or (d) a material impairment of the legality, validity, binding effect or enforceability against any Debtor of this DIP Term Sheet or any material DIP Document to which it is a party; provided, that none of the following shall constitute a Material Adverse Effect: the commencement, administration, or prosecution of the Chapter 11 Cases and the circumstances leading thereto. | |
| Affirmative Covenants: | The Debtors shall:
i. comply in all material respects with their respective covenants, commitments, agreements, and other obligations set forth in the RSA and the DIP Documents;
ii. without limitation of any other requirement hereunder or under any DIP Document, comply with the covenants set forth in Section 5.2, Section 5.4 (without regard to the proviso in such section), Section 5.6, Section 5.8, and Section 5.9 of the Prepetition First Lien Credit Agreement (in each case as modified as necessary to reflect the commencement of the Chapter 11 Cases and the Debtors’ financial condition), except for any such non-compliance as a result of the compliance by the Debtors with their express obligations set forth in this DIP Term Sheet, any DIP Document, the RSA or any other Definitive Document, or as results from the Chapter 11 Cases;
iii. timely deliver, or cause to be timely delivered, to the DIP Lenders the DIP Budget and Variance Reports, all in accordance with the provisions set forth herein and in the DIP Orders;
iv. (a) cooperate with, consult with, and provide to the DIP Agent and the DIP Lenders all such information as reasonably required or as reasonably requested by the DIP Agent or any DIP Lender, and (b) permit any authorized representatives designated by the DIP Agent or any DIP Lender to visit and inspect any of the properties of any | |
15
| Term |
Description | |
| Debtor and any of its respective subsidiaries, to inspect, copy and take copies of extracts from its and their financial and accounting records, and to discuss its and their affairs, finances and accounts with its and their officers, all upon reasonable prior notice and at such reasonable times during normal business hours, absent the continuance of an Event of Default, not more than once per calendar month;
v. comply with the DIP Budget (subject to the Permitted Variances) and with provisions of this DIP Term Sheet and the Interim DIP Order and/or the Final DIP Order (as applicable);
vi. within thirty (30) days after the Closing Date (or such later date as the Required DIP Lenders may agree), (1) provide to the DIP Lenders certificates of insurance demonstrating the Debtors’ compliance with clause (xvi) under the heading “Interim Funding Conditions” in this DIP Term Sheet and (2) provide that each of the Debtors’ policies of insurance shall (A) in the case of each liability insurance policy, name the DIP Agent and its successors and assigns, for the benefit of the DIP Secured Parties, as an additional insured thereunder as its interests may appear, (B) in the case of each casualty insurance policy, contain a lender loss payable clause or endorsement, reasonably satisfactory in form and substance to the Required DIP Lenders, that names the DIP Agent and its successors and assigns, for the benefit of the DIP Secured Parties, as the lender loss payee thereunder, and (C) in each case, provide for at least thirty (30) days’ (or ten (10) days’ in the case of nonpayment of premium) prior written notice to the DIP Agent of any modification or cancellation of such policy;
vii. subject to the RSA, provide draft copies of: (a) the First Day Pleadings and all orders sought pursuant thereto; (b) the Bidding Procedures Motion and the Bidding Procedures Order; (c) the Sale Order; (d) the Plan; (e) the Plan Supplement; (f) the Disclosure Statement; (g) the Conditional Disclosure Statement Order and the Disclosure Statement Order; (h) the Solicitation Materials; (i) the DIP Motion and the DIP Orders; (j) the Confirmation Order; and (k) all other material motions, pleadings, filings, applications, and proposed orders relating to the Restructuring Transactions or that any Debtor intends to file with the Bankruptcy Court, in each case at least three (3) calendar days prior to the date on which the applicable Debtor files or executes such document (or, if three (3) calendar days’ advance notice is not reasonably practicable under the circumstances, as soon as reasonably practicable prior to such filing or execution), and consult in good faith regarding the form and substance of each of the foregoing in advance of such filing or execution;
viii. comply with the schedule of Milestones (as defined in the RSA);
ix. timely file with the Bankruptcy Court a written objection to any motion filed with the Bankruptcy Court seeking the entry of an order (A) directing the appointment of an examiner with expanded powers or a trustee, (B) converting any of the Chapter 11 Cases to cases under chapter 7 of the Bankruptcy Code, (C) dismissing any of the Chapter 11 Cases, or (D) modifying (but not including any requests to extend) or terminating the Debtors’ exclusive right to file or solicit acceptances of a plan of reorganization; |
16
| Term |
Description | |
| x. not take any action that is inconsistent with, or is intended or is reasonably likely to interfere with or impede or delay consummation of, the Restructuring Transactions;
xi. not file or otherwise pursue a chapter 11 plan or any other Definitive Document that is inconsistent with the terms of this DIP Term Sheet or the Restructuring Transactions;
xii. take, or cause to be taken, all reasonably appropriate action, to do or cause to be done all things necessary, proper or advisable under applicable law, and to execute and deliver such documents and other papers, as may be required or reasonably requested by the DIP Agent (on behalf of the Required DIP Lenders) to carry out the provisions of this DIP Term Sheet, the Interim DIP Order or the Final DIP Order;
xiii. except to the extent contemplated by the DIP Budget or otherwise consented to by the Required DIP Lenders in writing, continue, and cause to be continued, the business of the Debtors, maintain, and cause to be maintained, the Debtors’ existence and material relationships, rights and privileges, and comply with all material agreements;
xiv. take, or cause to be taken, all appropriate action to remain the sole owner of the DIP Collateral, free of liens other than the Permitted Prior Liens, the DIP Liens, the adequate protection liens granted hereunder and under the DIP Orders, liens granted or incurred after the Petition Date in the ordinary course of business or other liens granted or imposed pursuant to an order of the Bankruptcy Court that is in form and substance reasonably acceptable to the Required DIP Lenders and the DIP Agent (collectively, “Permitted Liens”);
xv. take, or cause to be taken, all appropriate action to comply with all material applicable laws with respect to the DIP Collateral unless failure to comply could not reasonably be expected to result in a Material Adverse Effect;
xvi. subject to the DIP Budget, pay when due all material taxes imposed upon it or any of its properties or assets or in respect of any of its income, businesses or franchises, and all claims (including claims for labor, services, materials and supplies) for sums that have become due and payable, in each case prior to the time when any material penalty or fine shall be incurred with respect thereto or any lien on any of its assets may attach with respect thereto, except where (A) such tax or claim is being contested in good faith and adequate reserves have been established in accordance with GAAP, and in the case of a tax or claim that has or may become a lien against any of the DIP Collateral, such contest proceedings conclusively operate to stay the sale of any portion of the DIP Collateral to satisfy such tax or claim, or (B) to the extent payment and/or enforcement thereof is stayed as a result of the Chapter 11 Cases; |
17
| Term |
Description | |
| xvii. maintain its cash management system in a manner reasonably acceptable to the Required DIP Lenders (which shall be deemed satisfied if the cash management system is substantially the same as the cash management system in existence on the Petition Date, with such modifications as permitted under the cash management order, as entered); and
xviii. cause the Debtors’ senior management and legal and financial advisors to be available to conduct a telephonic conference (in the case of the Debtors’ senior management, during regular business hours) as reasonably requested by any DIP Lender, to discuss the DIP Budget, the Variance Report, the Chapter 11 Cases, the Restructuring Transactions, and the financial condition, performance and business affairs of the Debtors. | ||
| Negative Covenants: | Unless otherwise provided in the DIP Budget (subject to the Permitted Variances), no Debtor shall, without the express, prior written consent of the Required DIP Lenders, do, cause to be done, or agree to do or cause to be done, any of the following:
i. take any action prohibited by, or fail to take any action required by, the covenants, commitments, agreements, and other obligations of the Debtors set forth in the RSA (as may be amended, modified, or waived) or the DIP Documents;
ii. create, incur, assume or suffer to exist any lien, security interest or other encumbrance upon any of its property, assets, income or profits, whether now owned or hereafter acquired, except Permitted Liens which, other than the Permitted Prior Liens or other liens that are permitted to be senior to the DIP Liens by the Required DIP Lenders acting reasonably, are junior to the DIP Liens, the Prepetition 1L Liens, the Prepetition 2L Notes Liens and the Prepetition 2L Royalty Liens;
iii. convey, sell, lease, assign, transfer or otherwise dispose of (including through a transaction of merger or consolidation) any of its property, business or assets, whether now owned or hereafter acquired, other than (1) asset sales approved by an order of the Bankruptcy Court that is in form and substance acceptable to the Required DIP Lenders, or (2) in the ordinary course (including, for the avoidance of doubt, ordinary course sales of inventory);
iv. create, incur, assume or permit to exist any indebtedness for borrowed money (including any finance lease, purchase money indebtedness or sale-leaseback obligation), other than the DIP Obligations and the Prepetition Secured Obligations;
v. except as contemplated by the DIP Budget or the RSA, terminate, amend, modify, waive or compromise or not continue or extend any term or amount owed under a real property lease, material agreement, or other material vendor accommodation or arrangement without the consent of the Required DIP Lenders; | |
18
| Term |
Description | |
| vi. incur or make any expenditure, investment, loan or other payment, other than payments in respect of vesting programs in existence on the Petition Date or otherwise in accordance with the DIP Budget, subject to the Permitted Variances;
vii. incur or make any Restricted Payment (as defined herein) other than in accordance with the DIP Budget;
viii. create, or acquire any ownership interest in, any subsidiary (whether direct or indirect) other than those existing on the Petition Date or whose creation is necessary to effect the Restructuring Transactions (which subsidiaries shall, at the written request of the Required DIP Lenders, be joined hereto and to the DIP Documents as a Debtor pursuant to documentation reasonably acceptable to the DIP Agent and the Required DIP Lenders);
ix. create or permit to exist any other superpriority claim which is pari passu with or senior to the claims of the DIP Lenders under the DIP Facility, except for the Carve-Out;
x. modify or alter (A) in any material manner the nature and type of its business or the manner in which such business is conducted or (B) its organizational documents, except (1) as required by the Bankruptcy Code, (2) in a manner that is not materially adverse to the interests of the DIP Lenders (in their capacities as such) or (3) with the prior written consent of the Required DIP Lenders;
xi. pay prepetition indebtedness, except for (a) adequate protection payments in the form of interest payments in respect of the prepetition indebtedness as expressly provided for herein or in the DIP Budget or (b) payments consented to by the Required DIP Lenders (which may be through approval of the DIP Budget) and approved by an order of the Bankruptcy Court; or
xii. engage in any activities that would result in any of the Debtors becoming an “investment company” as defined in, or subject to regulation under, the Investment Company Act of 1940.
As used in this DIP Term Sheet, “Restricted Payment” means, with respect to any person (a) the declaration or payment of any dividend (whether in cash, securities or other property or assets) or distribution of cash or other property or assets in respect of equity interests of such person; (b) any payment (whether in cash, securities or other property or assets) on account of the purchase, redemption, defeasance, sinking fund or other retirement of the equity interests of such person or any other payment or distribution (whether in cash, securities or other property or assets) made in respect thereof, either directly or indirectly; (c) any payment or prepayment of principal or premium, if any, or interest, fees or other charges on or with respect to, and any redemption, purchase, retirement, defeasance (including in-substance or legal defeasance), sinking fund or similar payment and any claim for rescission with respect to any indebtedness (including any earn-out obligations or seller financing indebtedness); and (d) any payment made to redeem, purchase, repurchase or retire, or to obtain the surrender of, any outstanding warrants, options or other rights to acquire equity interests of such person now or hereafter outstanding. |
19
| Term |
Description | |
| Financial Covenants: | Until the indefeasible payment in full in cash of the DIP Obligations, the Debtors shall strictly perform in accordance with the DIP Budget; provided, that with respect to any Testing Period (as defined herein), (i) the Debtors’ aggregate actual cash receipts shall not be less than 80% of the projected amounts therefor set forth in the DIP Budget and (ii) the Debtors’ aggregate actual cash disbursements shall not be greater than 120% of the projected amounts therefor set forth in the DIP Budget (such variances, the “Permitted Variances”); provided, further, that (A) notwithstanding anything to the contrary in this DIP Term Sheet, the Allowed Professional Fees shall not be included in any calculations for purposes of testing compliance with the DIP Budget and any Permitted Variances and (B) none of the foregoing shall limit the payment of Allowed Professional Fees that benefit from the Carve-Out, as and when such Allowed Professional Fees are allowed by the Bankruptcy Court at any time (whether by interim order, procedural order or otherwise).
Compliance with the DIP Budget shall be tested on Wednesday of each second week (or, if such day is not a Business Day, the next succeeding Business Day) (each such date, a “Testing Date”) on a cumulative basis for the period commencing on the first day covered by the DIP Budget then in effect and ending as of the Sunday immediately preceding such Testing Date (each such period, a “Testing Period”), with the first such test to be conducted on November 18, 2026 for the period from the Petition Date to November 15, 2026. Compliance with the DIP Budget shall be tested based on the Variance Report required to be delivered pursuant to clause v under the heading “Reporting” in this DIP Term Sheet on the applicable Testing Date; provided that, if, as of any Testing Date, the Borrower has failed to deliver such Variance Report, the Borrower shall be deemed to be out of compliance with the DIP Budget for such Testing Date.
The Debtors shall maintain a minimum liquidity covenant requiring aggregate unrestricted cash and cash equivalents of the Debtors on a consolidated basis of not less than $10,000,000 at all times (for the avoidance of doubt, excluding the Plan Effective Date).
The Debtors shall not directly or indirectly incur or commit to incur any capital expenditures, other than capital expenditures that are contemplated by the DIP Budget (subject to Permitted Variances).
“DIP Budget” means a written budget setting forth on a line-item basis the Debtors’ projected cash receipts and cash disbursements on a weekly basis, including, without limitation, disbursements on account of the reasonable and documented fees and expenses of the DIP Secured Parties and the Ad Hoc Group Advisors, which initial budget is attached as Schedule 1 to the Interim DIP Order, and shall cover the period of at least thirteen (13) weeks following the Petition Date, and which budget shall be updated on a rolling thirteen-week (13-week) basis every four (4) weeks as provided in the DIP Orders. |
20
| Term |
Description | |
| Reporting: | The Borrower shall deliver to the DIP Agent, the DIP Lenders, the Ad Hoc Group Advisors, and the advisors to the Prepetition Royalty Secured Parties:
i. monthly unaudited consolidated financial statements of the Borrower and its subsidiaries within 30 days after the end of each fiscal month, certified by a financial officer of the Borrower;
ii. quarterly unaudited consolidated financial statements of the Borrower and its subsidiaries within 45 days of the end of each fiscal quarter of the fiscal year, certified by a financial officer of the Borrower;
iii. annual audited consolidated financial statements of the Borrower and its subsidiaries within 90 days of the year-end, certified with respect to such consolidated statements by the Borrower’s independent certified public accountants;
iv. 13-week cash flow forecasts, on a rolling 13-week basis, updated every four weeks and in form and substance reasonably acceptable to the Required DIP Lenders;
v. no later than Wednesday of each week, beginning on the second Wednesday following the Petition Date (or, if such day is not a Business Day, the next succeeding Business Day), a weekly line-by-line variance report (the “Variance Report”), which Variance Report shall (A) include line items consistent with the DIP Budget, including (without limitation) (1) “Total Receipts”, (2) “Total Operating Disbursements” (including payroll & benefits, bonuses, retention payments, rent, site payments, and accounts payable), (3) “Total Professional Fees” (on a professional-by-professional basis), and (4) “Net Cash Flow” and (B) compare actual cash receipts and disbursements of the Debtors with corresponding amounts provided for in the DIP Budget on a line-by-line basis for the prior week period and the Testing Period (or such shorter period as may have elapsed from the date hereof), including written descriptions in reasonable detail explaining any material positive or negative variances, and shall otherwise be in form and substance reasonably acceptable to the Required DIP Lenders;
vi. copies of all reports, analyses, presentations and other materials prepared by or for the Debtors’ investment bankers, financial advisors, consultants or other professionals in connection with any sale, financing, refinancing, capital raise or restructuring transaction involving the Debtors; provided, that any materials relating to the Debtors’ sale and marketing process shall not be provided—by any party or its advisors—to DIP Lenders acting in a Bidder Capacity;
vii. all other reports and notices required to be delivered hereunder or under the DIP Documents, and such other reports and notices as may be reasonably requested by the DIP Agent or the Required DIP Lenders; |
21
| Term |
Description | |
| viii. to the extent not otherwise delivered to the DIP Agent, the DIP Lenders, the Ad Hoc Group Advisors, and the advisors to the Prepetition Royalty Secured Parties, all of the financial information, reports, notices and other information delivered to, or required to be delivered to, the Prepetition First Lien Agent and/or the Prepetition First Lien Lenders pursuant to the Prepetition First Lien Documents (including, without limitation, pursuant to Sections 5.1 and 5.9(a) of the Prepetition First Lien Credit Agreement), when the same is (or is required to be) delivered to the Prepetition First Lien Agent and/or the Prepetition First Lien Lenders; and
ix. such other documents or information reasonably required by the DIP Documents; provided, that the Debtors shall not be required to provide information that would waive any privilege or violate applicable law.
In addition, the Debtors shall, and shall direct their officers, directors, employees, advisors and other representatives to:
i. provide to the DIP Agent, the DIP Lenders the Ad Hoc Group Advisors, and advisors to the Prepetition Royalty Secured Parties (1) reasonable access, during normal business hours and on reasonable advance notice and without disruption to the operation of the Debtors’ business, to the offices, properties, books and records, management, directors, employees, accountants, auditors, counsel and other advisors and representatives of the Debtors, (2) such other information regarding the Debtors’ assets, business, operations, liquidity, financial condition, tax matters, regulatory matters and intellectual property as is reasonably requested by the DIP Agent, any DIP Lender or the Ad Hoc Group Advisors, and (3) upon reasonable request, participation in periodic update calls with the Debtors’ management and advisors regarding the Debtors’ financial performance, liquidity and the progress of the Restructuring Transactions; provided, that any materials relating to the Debtors’ sale and marketing process shall not be provided—by any party or its advisors—to DIP Lenders acting in a Bidder Capacity;
ii. promptly respond to, and use reasonable best efforts to satisfy, all due diligence requests of the DIP Agent, the DIP Lenders, the Ad Hoc Group Advisors, and advisors to the Prepetition Royalty Secured Parties, including by establishing and maintaining an electronic data room to which the Ad Hoc Group Advisors are granted access, and cooperate with all business, financial, legal, tax, regulatory and intellectual property diligence reasonably requested in connection with the DIP Facility and the Restructuring Transactions; provided, that any materials relating to the Debtors’ sale and marketing process shall not be provided—by any party or its advisors—to DIP Lenders acting in a Bidder Capacity;
iii. irrevocably authorize, direct and cause the Debtors’ investment bankers, financial advisors, consultants and other professionals to (1) disclose fully and promptly to the DIP Agent, the DIP Lenders, the Ad Hoc Group Advisors, and advisors to the Prepetition Royalty Secured Parties all material developments concerning any sale, financing, refinancing, capital raise or restructuring transaction involving the Debtors, and (2) at a reasonable frequency requested by the Ad Hoc Group, consult with, and respond to the inquiries of, the DIP Agent, the DIP Lenders, the Ad Hoc Group Advisors, and advisors to the Prepetition Royalty Secured Parties concerning any and all matters relating to the affairs, finances, assets, business and operations of the Debtors and any aspect of any such transaction, including communications outside the presence of any representative of any Debtor; provided, that any materials relating to the Debtors’ sale and marketing process shall not be provided—by any party or its advisors—to DIP Lenders acting in a Bidder Capacity; and |
22
| Term |
Description | |
| iv. such other documents or information reasonably required by the DIP Documents; provided, that the Debtors shall not be required to provide information that would waive any privilege or violate applicable law. | ||
| Waivers: | The Final DIP Order shall provide a waiver of the equitable doctrine of “marshaling” with respect to the DIP Collateral and the Prepetition Collateral; provided, that such waiver shall only be effective with respect to the Prepetition Collateral until the Discharge of First Lien Obligations (as defined in the Intercreditor Agreement). The Final DIP Order shall provide (i) a waiver of the “equities of the case” exception to section 552(b) of the Bankruptcy Code with respect to the DIP Lenders and the Prepetition Secured Parties, and (ii) a waiver of the ability to surcharge the DIP Collateral and the Prepetition Collateral, including under section 506(c) of the Bankruptcy Code. | |
| Credit Bid: | The DIP Obligations may be credit bid in connection with the sale of any asset of the Debtors (in whole or in part), including, without limitation, sales occurring pursuant to section 363 of the Bankruptcy Code or included as part of any restructuring plan subject to confirmation under section 1129(b)(2)(A)(ii)–(iii) of the Bankruptcy Code. Any such credit bid shall be deemed a qualified bid, and the DIP Agent shall be deemed a qualified bidder, for all purposes of any bidding procedures or sale process. Nothing herein shall limit the right of the Prepetition Royalty Secured Parties to credit bid the Prepetition Royalty Obligations, subject to section 363(k) of the Bankruptcy Code and the Intercreditor Agreement. | |
| Events of Default: | “Events of Default” shall be limited to the following:
i. failure to pay principal or interest on the DIP Loans or any fees or any other amount due under the DIP Documents when due;
ii. (A) failure of any Debtor or any of their respective subsidiaries to pay when due any principal of or interest on or any other amount, including any payment in settlement, payable in respect of one or more items of Material Indebtedness (as defined in the Prepetition First Lien Credit Agreement) incurred on or after the Petition Date, in each case beyond the grace period, if any, provided therefor; or (B) breach or default by any Debtor or any of its subsidiaries with respect to any other term of (1) one or more items of such Material Indebtedness, or (2) any loan agreement, mortgage, indenture or other agreement relating to such item(s) of Material Indebtedness, in each case beyond the grace period, if any, provided therefor, if the effect of such breach or default is to cause, or to permit the holder or holders of that Material Indebtedness (or a trustee on behalf of such holder or holders), with or without the passage of time, to cause, that Material Indebtedness to become or be declared due and payable (or subject to a compulsory repurchase or other redemption) prior to its stated maturity or the stated maturity of any underlying obligation, as the case may be, unless in each case, payment or enforcement thereof is stayed as a result of the Chapter 11 Cases; | |
23
| Term |
Description | |
| iii. failure of any representation or warranty of any Debtor contained in this DIP Term Sheet or any DIP Document to be true and correct in all material respects when made (without duplication of any materiality qualifier contained therein);
iv. breach of any covenant hereunder or under the DIP Documents that, in the case of any affirmative covenant that is capable of being cured, has not been cured within five (5) Business Days;
v. any money judgment, writ or warrant of attachment or similar process involving (i) in any individual case an amount in excess of $2,500,000 or (ii) in the aggregate at any time an amount in excess of $5,000,000 (in either case to the extent not adequately covered by insurance as to which a solvent and unaffiliated insurance company has acknowledged coverage) shall be entered or filed against any Debtor or any of their subsidiaries or any of their respective assets and shall remain undischarged, unvacated, unbonded or unstayed for a period of sixty (60) days;
vi. any order, judgment or decree shall be entered against any Debtor or any of its subsidiaries decreeing the dissolution or split up of such Debtor or any of its subsidiaries and such order shall remain undischarged or unstayed for a period in excess of thirty (30) days;
vii. there shall occur one or more ERISA Events (as defined in the Prepetition First Lien Credit Agreement) that individually or in the aggregate results in or might reasonably be expected to result in liability of any Debtor or any of its subsidiaries or any of their respective ERISA Affiliates (as defined in the Prepetition First Lien Credit Agreement) in excess of $2,500,000 during the term of the DIP Facility; or there exists any fact or circumstance that reasonably could be expected to result in the imposition of a Lien or security interest under Section 430(k) of the Internal Revenue Code or ERISA (each as defined in the Prepetition First Lien Credit Agreement) or a violation of Section 436 of the Internal Revenue Code;
viii. a Change of Control (as defined in the Prepetition First Lien Credit Agreement) shall occur, excluding any Change of Control caused by the consummation of the Ayrmid Transaction or an Acceptable Alternative Transaction;
ix. at any time after the execution and delivery thereof (i) any DIP Document for any reason, other than the indefeasible payment in full in cash of all DIP Obligations, shall cease to be in full force and effect (other than in accordance with its terms) or shall be declared to be null and void or any Debtor shall repudiate its obligations thereunder, or (ii) any Debtor shall contest the validity or enforceability of any DIP Document in writing or deny in writing that it has any further liability, including with respect to future advances by DIP Lenders, under any DIP Document to which it is a party or shall contest the validity of or perfection of any lien in any DIP Collateral granted or purported to be granted pursuant to the DIP Documents; |
24
| Term |
Description | |
| x. the United States Food and Drug Administration (or any successor thereto) or any Debtor withdraws approval for selinexor with respect to its current approved indication for use with bortezomib and dexamethasone;
xi. noncompliance with the DIP Budget, subject to the Permitted Variances;
xii. the DIP Agent shall cease to have a valid and perfected security interest in and lien on any DIP Collateral with the priority provided for herein and in the DIP Orders (other than upon a release by reason of a transaction that is permitted hereunder or under the DIP Documents);
xiii. failure by any Debtor to comply in any material respect with the Interim DIP Order or Final DIP Order, as applicable;
xiv. the entry by a court of competent jurisdiction of an order amending, modifying, staying, revoking or reversing the Interim DIP Order or Final DIP Order, as applicable, without the express written consent of the Required DIP Lenders;
xv. subject to the terms of the RSA, any sale or other disposition of all or a material portion of the DIP Collateral securing the DIP Loans pursuant to section 363 of the Bankruptcy Code other than as permitted by the DIP Orders (or pursuant to a transaction that is permitted hereunder or under the DIP Documents) or the Debtors file any motion or pleading seeking authority for the foregoing;
xvi. the entry of an order dismissing any Chapter 11 Case or converting any Chapter 11 Case to a case under chapter 7 of the Bankruptcy Code, or the Debtors file any motion or pleading seeking authority for the foregoing;
xvii. the entry of an order appointing a chapter 11 trustee in any Chapter 11 Case or the Debtors file any motion or pleading seeking authority for the foregoing;
xviii. the entry of an order in any Chapter 11 Case appointing an examiner having expanded powers (beyond those set forth under sections 1106(a)(3) and (4) of the Bankruptcy Code) or the Debtors file any motion or pleading seeking authority for the foregoing;
xix. termination or expiration of the period of time during which only the Borrower and its co-debtors may file a plan pursuant to section 1121 of the Bankruptcy Code;
xx. failure to meet any Milestone (including, without limitation, failure of the Bankruptcy Court to enter, within thirty-five (35) calendar days following the Petition Date, the Final DIP Order);
xxi. other than the Carve-Out, the allowance of any claim or claims under section 506(c) of the Bankruptcy Code against or with respect to any of the DIP Collateral; |
25
| Term |
Description | |
| xxii. the existence of any claims or charges, or the entry of an order of the Bankruptcy Court authorizing any claims or charges, other than in respect of the DIP Facility and the Carve-Out or as otherwise permitted under the applicable DIP Documents, entitled to superpriority administrative expense claim status in any Chapter 11 Case pursuant to Section 364(c)(1) of the Bankruptcy Code pari passu with or senior to the DIP Superpriority Claims, or there shall arise or be granted by the Bankruptcy Court (i) any claim having priority over any or all administrative expenses of the kind specified in section 503(b) of the Bankruptcy Code or section 507(b) of the Bankruptcy Code (other than the Carve-Out) or (ii) any lien on the DIP Collateral having a priority senior to or pari passu with the DIP Liens, except, in each case, as expressly provided in the DIP Documents;
xxiii. any Debtor requests authorization, or supports any request for authorization, to obtain postpetition financing or other financial accommodations pursuant to section 364 of the Bankruptcy Code or otherwise, other than (x) from the DIP Lenders or (y) financing resulting in proceeds that are sufficient to, and are immediately applied to, indefeasibly pay the DIP Obligations, the Prepetition First Lien Obligations (as defined in the Interim DIP Order) and, following the entry of the Final DIP Order, the Prepetition Notes Obligations (as defined in the Interim DIP Order) in full in cash;
xxiv. any attempt by any Debtor to invalidate or otherwise impair the DIP Loans, the DIP Liens, the Prepetition First Lien Obligations, the Prepetition 1L Liens, the Prepetition 2028 Notes Obligations, the Prepetition 2029 Notes Obligations, or the Prepetition 2L Liens (in each case as defined in the Interim DIP Order);
xxv. the Debtors commence, join in, assist or otherwise participate as an adverse party in any suit or other proceeding against the DIP Agent, any of the DIP Lenders or any of the Prepetition Secured Parties to: (i) contest the validity or enforceability of any DIP Document, any Prepetition First Lien Document, any Prepetition 2028 Notes Document, or any Prepetition 2029 Notes Document; (ii) contest the validity, enforceability, extent, amount, perfection or priority of the DIP Liens, the DIP Superpriority Claims, the Prepetition First Lien Obligations, the Prepetition 1L Liens, the Prepetition 2028 Notes Obligations, the Prepetition 2029 Notes Obligations or the Prepetition 2L Liens held by the DIP Lenders, or (iii) assert or prosecute any claim or cause of action (including any action arising under chapter 5 of the Bankruptcy Code) against any DIP Secured Party or any Prepetition Secured Party;
xxvi. any breach by the Debtors under the RSA (subject to any applicable cure period);
xxvii. the RSA is terminated or otherwise fails to be in full force and effect;
xxviii.the entry of an Interim DIP Order or Final DIP Order in form or substance that is not acceptable to the Required DIP Lenders in their sole discretion;
xxix. (a) any Debtor files a pleading in any court seeking or supporting an order to revoke, reverse, stay, vacate, amend, supplement or otherwise modify any DIP Order or this DIP Term Sheet, in whole or in part, or (b) any material provision of the DIP Orders or DIP Term Sheet, or any other order of the Bankruptcy Court approving the Debtors’ use of Cash Collateral, shall for any reason cease to be valid and binding (without the prior written consent of the Required DIP Lenders); |
26
| Term |
Description | |
| xxx. subject to the terms of the RSA, the filing with the Bankruptcy Court of a motion seeking approval of a sale under section 363 of the Bankruptcy Code or a plan of reorganization or liquidation in any of the Chapter 11 Cases that, in either case, does not provide for indefeasible payment in full in cash to the DIP Lenders of DIP Loans and all other amounts outstanding under this DIP Term Sheet and the DIP Orders, on closing of such sale or the effective date of such plan;
xxxi. the granting of relief from the automatic stay by the Bankruptcy Court to any other creditor or party in interest in the Chapter 11 Cases with respect to any portion of the DIP Collateral;
xxxii. the Debtors, except as contemplated by the RSA, (A) file any motion or application, including in connection with a plan of reorganization, seeking authority to reject, assume, assume and assign, amend, supplement, or modify any material agreement or any Prepetition Royalty Document, or (B) amend, modify, supplement, extend, terminate, or otherwise enter into a modified arrangement with respect to any material agreement or any Prepetition Royalty Document, in each case, without the prior written consent of the Required DIP Lenders;
xxxiii. the cessation by the Debtors, taken as a whole, of conducting all or substantially all of their business operations; or
xxxiv. any Debtor shall make any payment of principal or interest or otherwise on account of any prepetition indebtedness or prepetition payables other than payments (A) in respect of accrued payroll and related expenses as of the commencement of the Chapter 11 Cases and (B) in respect of certain creditors, in each case, to the extent authorized by one or more “first day” orders acceptable in form and substance to the Required DIP Lenders and consistent with the DIP Budget.
As used in this DIP Term Sheet, the term “Default” means any condition or event that, after notice or lapse of time or both, would constitute an Event of Default. | ||
| Remedies: | Upon the occurrence of, and during the continuation of, an Event of Default, but subject to the DIP Orders, the DIP Agent (at the direction of the Required DIP Lenders) or the Required DIP Lenders may, by delivery of a DIP Termination Declaration (as defined in the DIP Orders), and subject to the terms of the DIP Orders, take any or all of the following actions without further order of or application to the Bankruptcy Court:
i. immediately terminate, reduce or restrict the Debtors’ use of any Cash Collateral (except to the extent such cash may be used in connection with the Carve-Out);
ii. terminate, reduce or restrict any undrawn New Money DIP Commitments, in whole or in part; | |
27
| Term |
Description | |
| iii. terminate the DIP Facility and the DIP Documents as to any future liability or obligation of the DIP Secured Parties (without affecting any of the DIP Liens or DIP Obligations, or the rights or remedies of the DIP Secured Parties in respect thereof); and
iv. declare all DIP Obligations to be immediately due and payable.
Following the expiration of the Remedies Notice Period (as defined in the DIP Orders, and as may be extended in accordance with the DIP Orders) and subject thereto, the DIP Agent (at the direction of the Required DIP Lenders) or the Required DIP Lenders may (in addition to any of the actions provided for above) take any or all of the following actions without further order of or application to the Bankruptcy Court:
i. freeze monies or balances in the Debtors’ accounts and sweep all funds contained in the Debtors’ deposit accounts;
ii. set-off any and all amounts in accounts maintained by the Debtors with the DIP Agent or the DIP Lenders against the DIP Obligations, or otherwise enforce any and all rights against the DIP Collateral in the possession of any of the applicable DIP Secured Parties, including, without limitation, disposition of the DIP Collateral solely for application towards the DIP Obligations;
iii. take any other actions or exercise any other rights or remedies permitted under the DIP Orders, this DIP Term Sheet, the DIP Documents or applicable law to effect the repayment of the DIP Obligations; and
iv. exercise rights and remedies subject to the terms of the DIP Orders, or applicable law (including, without limitation, direct any or all of the Debtors (or file a motion in the name of the Debtors)), (A) to enforce the terms and provisions of this DIP Term Sheet, (B) to collect accounts receivable, without setoff by any account debtor, including directing the Debtors to collect such accounts receivable, (C) to sell or otherwise dispose of any or all of the DIP Collateral on terms and conditions reasonably acceptable to the Required DIP Lenders pursuant to Sections 363, 365 and other applicable provisions of the Bankruptcy Code (and without limiting the foregoing, direct the Debtors (or file a motion in the name of the Debtors) to assume and assign any lease or executory contract included in the DIP Collateral to the DIP Lenders’ designees in accordance with and subject to Section 365 of the Bankruptcy Code), (D) credit bid any or all of the DIP Obligations, (E) enter into the premises of any Debtor in connection with the orderly sale or disposition of the DIP Collateral (including, without limitation, complete any work in process), (F) exercise such other rights and remedies to realize upon the DIP Collateral, and (G) take such action as is reasonably related to or is in furtherance of the foregoing; provided, that, subject to the DIP Orders, the Debtors shall take all action that is reasonably necessary to cooperate with the DIP Lenders in the exercise of their rights and remedies and facilitate the realization upon the DIP Collateral by the DIP Lenders. |
28
| Term |
Description | |
| Notwithstanding anything to the contrary herein, during any Remedies Notice Period, the Debtors may continue to use Cash Collateral solely to meet payroll obligations and pay expenses necessary to avoid immediate and irreparable harm to the Debtors’ estates (including to pay payroll, critical patient supply and product distribution costs, and the Carve-Out), in accordance with the DIP Budget (subject to the Permitted Variances), or that have otherwise been approved in advance in writing by the DIP Agent (at the direction of the Required DIP Lenders). | ||
| Assignments and Participations: | A DIP Lender may assign all or any part of its DIP Loans and commitments from time to time to any other person without any consent of or notice to the Debtors, but with the prior consent of the Required DIP Lenders (disregarding the assigning DIP Lender’s DIP Loans and unfunded New Money DIP Commitments) (not to be unreasonably withheld, conditioned or delayed); provided, that the Required DIP Lenders (disregarding the assigning DIP Lender’s DIP Loans and unfunded New Money DIP Commitments) shall be deemed to have consented to any such assignment unless they have objected to such assignment by written notice to the assigning DIP Lender within five (5) Business Days after having received notice thereof. Notwithstanding the foregoing, no consent of the Required DIP Lenders shall be required if the assignee is another DIP Lender or any affiliate or managed or controlled fund of a DIP Lender. The parties to each assignment shall execute and deliver to the DIP Agent an assignment agreement in a form substantially similar to the Assignment Agreement (as such term is defined in the Prepetition First Lien Credit Agreement) and reasonably acceptable to the DIP Agent, such other forms, certificates or other evidence, if any, that may be reasonably required by the DIP Agent, and with payment to the DIP Agent of a registration and processing fee of $3,500 (except that no such registration and processing fee shall be payable in the case of an assignee that is already a DIP Lender or is an affiliate or managed or controlled fund of a DIP Lender, which fee may be otherwise waived or reduced in the sole discretion of the DIP Agent). From and after the effective date specified in the assignment agreement, the assignee shall be a DIP Lender hereunder and the assigning DIP Lender shall be released from its obligations hereunder to the extent of the interest assigned. | |
| Expenses and Indemnification: | All reasonable, documented, out-of-pocket expenses and costs (limited to (i) reasonable legal fees and reasonable, documented, out-of-pocket expenses of one primary counsel and one local counsel in Texas for the DIP Agent, (ii) reasonable fees and reasonable, documented, out-of-pocket expenses of the Ad Hoc Group Advisors, and (iii) with respect to the Prepetition Royalty Secured Parties, (x) reasonable and documented fees and out-of-pocket expenses of counsel (subject to objection only if in excess of $600,000), (y) with respect to a financial advisor, monthly fees of $150,000 solely to the extent accruing from the Petition Date until the closing date of the Ayrmid Transaction or the Acceptable Alternative Transaction (each as defined in the RSA) and (z) solely in the event of the consummation of an Acceptable Alternative Transaction (as defined in the RSA) that results in transaction proceeds, (A) if transaction proceeds are sufficient to pay all Funded Debt (as defined in the RSA) outstanding in full in and in cash, then a $1,000,000 deferred fee, or (B) if transaction proceeds are insufficient to pay all Funded Debt outstanding in full in cash, then a $500,000 deferred fee, in each case payable upon consummation of such Acceptable Alternative Transaction and, in each case, solely from the proceeds thereof) | |
29
| Term |
Description | |
| incurred in connection with, whether before or after the commencement of, the Chapter 11 Cases and the negotiation and documentation of the DIP Facility are to be paid by the Borrower, in each case following written demand and, subject to the DIP Orders, without the requirement of Bankruptcy Court approval or the filing of any fee or retention application.
The Borrower will indemnify the DIP Secured Parties, and hold them harmless from and against all reasonable, documented, and out-of-pocket costs, expenses (including but not limited to reasonable legal fees and expenses) and liabilities arising out of or relating to the transactions contemplated hereby and any actual or proposed use of the proceeds of any loans made under the DIP Facility; provided, that no such person will be indemnified for costs, expenses or liabilities to the extent determined by a final, non-appealable judgment of a court of competent jurisdiction to have been incurred by reason of the gross negligence or willful misconduct of such person; provided, further, that no person will be indemnified for costs, expenses, or liabilities that do not involve an act or omission by any Debtor or any of its affiliates and arises solely from disputes among the DIP Secured Parties, other than claims against the DIP Agent, solely in its capacity as such, which shall remain subject to the immediately preceding proviso; provided, further, that no DIP Lender shall be indemnified for costs, expenses, or liabilities that result from a claim being brought by a Debtor against such person for a material breach of such person’s obligations under the DIP Documents if such Debtor has obtained a final and non-appealable judgment in its favor on such claim as determined by a court of competent jurisdiction. | ||
| Governing Law: | This DIP Term Sheet and the other DIP Documents shall be governed by, and construed in accordance with, the laws of the State of New York (except as governed by the Bankruptcy Code), without regard to the conflict of law principles thereof that would require the application of the law of any other jurisdiction. Each party hereto hereby waives all rights to a trial by jury and consents to the jurisdiction of the Bankruptcy Court. | |
| Amendments: | No provision of this DIP Term Sheet or any DIP Document may be amended, modified or waived other than by an instrument in writing signed by the Debtors and the Required DIP Lenders. Notwithstanding the foregoing (i) any amendment, modification or waiver that would (A) extend the Maturity Date of the DIP Loans, (B) waive, reduce or postpone any scheduled repayment (but not prepayment), (C) modify or waive any condition precedent to the funding of any DIP Loan, (D) reduce the rate of interest on any DIP Loan (other than a waiver of interest at the Default Rate), (E) waive or extend the time for payment of any such interest, fees, or premiums (other than a waiver of interest at the Default Rate), (F) reduce or forgive the principal amount of any DIP Loan, or increase the New Money DIP Commitment of any DIP Lender, (G) amend, modify, terminate or waive any provision under this heading “Amendments” or any other provision of this DIP Term Sheet that expressly provides that the consent of all DIP Lenders or any specific DIP Lenders is required, (H) amend the definition of Required DIP Lenders, (I) subordinate the DIP Liens to any other lien on or security interest in the DIP Collateral other than Permitted Prior Liens or (J) alter the ratable treatment of the DIP Obligations shall, in each case, require the consent of each DIP Lender directly and adversely affected thereby and (ii) any amendment, modification or waiver that would directly or indirectly affect the rights or obligations of the DIP Agent in any adverse manner shall require the consent of the DIP Agent. | |
30
| Term |
Description | |
| Counterparts and Electronic Transmission: | This DIP Term Sheet may be executed in any number of counterparts and by different parties hereto on separate counterparts, each of which when so executed and delivered shall be deemed an original, and all of which, when taken together, shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this DIP Term Sheet by facsimile, “PDF” or other electronic transmission shall be effective as delivery of a manually executed counterpart of this DIP Term Sheet. |
31
IN WITNESS WHEREOF, the parties hereto have executed this DIP Term Sheet as of the date first written above.
| DEBTORS:
| ||
| KARYOPHARM THERAPEUTICS INC., a Delaware corporation | ||
| By: |
| |
| Name: | ||
| Title: | ||
| KPT TEXAS LLC, a Texas limited liability company | ||
| By: |
| |
| Name: | ||
| Title: | ||
| DIP LENDERS: | ||
| [•], as a DIP Lender | ||
| By: |
| |
| Name: | ||
| Title: | ||
| DIP AGENT: | ||
| WILMINGTON SAVINGS FUND SOCIETY, FSB, as administrative agent and collateral agent for the DIP Lenders | ||
| By: |
| |
| Name: | ||
| Title: | ||
Schedule 1
New Money DIP Commitments
[***]
Annex A
Specific Terms of DIP Facility
| Interest Rate: | The interest rate applicable to the New Money DIP Loans will be SOFR (as defined herein) plus 900 bps, payable in kind quarterly on the last day of each March, June, September and December ending after the Closing Date (or, if such day is not a Business Day, the next succeeding Business Day) (each such date, an “Interest Payment Date”). The interest rate applicable to the Roll-Up Loans will be SOFR plus 1,225 bps, payable in kind quarterly on each Interest Payment Date. All interest and fees shall be calculated on the basis of a 360-day year for the actual number of days elapsed, and all accrued and unpaid interest in respect of any DIP Loans shall be paid in full in cash on the date on which the principal amount of such DIP Loans is paid.
“SOFR” means, for any date of determination, the greater of (i) the forward-looking term rate based on the secured overnight financing rate for a one-month tenor published by CME Group Benchmark Administration Limited (CBA) (or a successor administrator of SOFR selected by the DIP Agent) for the date that is two (2) Business Days prior to the Interest Payment Date immediately preceding such date of determination (or prior to the first Interest Payment Date, the Closing Date); provided, that if such rate is not published on such day, SOFR shall be such rate as published on the first preceding Business Day on which it was published; and (ii) 3.00%. | |
| Exit Fee: | 4.00% of the New Money DIP Loans (including interest paid in kind and added to the outstanding principal amount of the New Money DIP Loans) or New Money DIP Commitments, as applicable, payable upon any repayment or prepayment (including any acceleration thereof) or other satisfaction of the New Money DIP Loans or termination or reduction of the New Money DIP Commitments (other than a termination resulting from the funding of New Money DIP Loans).
8.00% of the Roll-Up Loans (including interest paid in kind and added to the outstanding principal amount of the Roll-Up Loans), payable upon any repayment or prepayment (including any acceleration thereof) or other satisfaction of the Roll-Up Loans (other than a deemed reconversion of Roll-Up Loans into allowed Prepetition First Lien Obligations, in which case there shall be no corresponding exit fee with respect to the Roll-Up Loans). | |
| DIP Agent Fee: | As set forth in the fee letter, dated as of October 30, 2026, between the Borrower and the DIP Agent, together with all amounts payable to or on behalf of the DIP Agent pursuant to the Agency Provisions. | |
Annex B
Representations and Warranties
A. Organization; Requisite Power and Authority; Qualification. Each Debtor and each of their respective subsidiaries (a) is duly organized, validly existing and in good standing (to the extent applicable) under the laws of its jurisdiction of organization, (b) subject to the Bankruptcy Court’s entry of the applicable DIP Order and any limitation under the Bankruptcy Code or other debtor relief Law, has all requisite power and authority to own and operate its properties, to carry on its business as now conducted and as proposed to be conducted, to enter into this DIP Term Sheet and the other DIP Documents to which it is a party and to carry out the transactions contemplated hereby and thereby, and (c) is qualified to do business and in good standing in every jurisdiction necessary to carry out its business and operations, except in jurisdictions where the failure to be so qualified or in good standing would not be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.
B. Due Authorization. The execution, delivery and performance of this DIP Term Sheet and the other DIP Documents have been duly authorized by all necessary action on the part of each Debtor that is a party thereto, in each case subject to the Bankruptcy Court’s entry of the DIP Orders.
C. No Conflict. The execution, delivery and performance by the Debtors of this DIP Term Sheet and the other DIP Documents to which they are parties and the consummation of the transactions contemplated hereby and thereby do not and will not (i) violate any provision of any material Law applicable to the Debtors or any of their subsidiaries, any of the Organizational Documents of the Debtors or any of their subsidiaries, or any order, judgment or decree of any court or other agency of government binding on the Debtors or any of their subsidiaries; (ii) conflict with, result in a breach of or constitute (with due notice or lapse of time or both) a default or give rise to any right of termination, amendment, cancellation or acceleration of any obligation or the loss of any material benefit or the triggering of any payment under any material agreement; (iii) result in or require the creation or imposition of any Lien upon any of the properties or assets of the Debtors or any of their subsidiaries (other than any liens created under any of the DIP Documents in favor of the DIP Agent, for the benefit of DIP Secured Parties); or (iv) require any approval of stockholders, members or partners or any approval or consent of any person under any material agreement except for such approvals or consents that have been obtained on or before the Closing Date and have been disclosed in writing to the DIP Lenders.
D. Governmental Consents. The execution, delivery and performance by the Debtors of this DIP Term Sheet and the other DIP Documents to which they are parties and the consummation of the transactions contemplated hereby and thereby do not and will not require any registration with, consent or approval of, or notice to, or other action to, with or by, any Governmental Entity except such that have been obtained or made and are in full force and effect.
E. Binding Obligation. The DIP Term Sheet and each other DIP Document has been duly executed and delivered by each Debtor that is a party thereto and is the legally valid and binding obligation of such Debtor, enforceable against such Debtor in accordance with its respective terms.
F. No Material Adverse Change. Since the RSA Effective Date, no event, circumstance or change has occurred that has caused or evidences, either in any case or in the aggregate, a Material Adverse Effect.
G. No Transfer. No transfer of property is being made by any Debtor and no obligation is being incurred by any Debtor in connection with the transactions contemplated by this DIP Term Sheet and the other DIP Documents with the intent to hinder, delay or defraud either present or future creditors of any Debtor.
H. No Indebtedness. Except for the Prepetition Secured Obligations and the DIP Obligations, the Debtors have no other indebtedness for borrowed money.
I. Adverse Proceedings, Etc. Other than the Chapter 11 Cases, there are no Adverse Proceedings (as defined in the Prepetition First Lien Credit Agreement) that (i) purport to affect or pertain to this DIP Term Sheet or any other DIP Document, or any of the transactions contemplated hereby and thereby or (ii) otherwise could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. None of the Debtors nor any of their subsidiaries (a) is in violation of any applicable law (including Environmental Laws (as defined in the Prepetition First Lien Credit Agreement)) that could, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, or (b) is subject to or in default with respect to any final judgments, writs, injunctions, decrees, rules or regulations of any court or any federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.
J. Payment of Taxes. All United States federal, state and all other material tax returns and reports of the Debtors and their subsidiaries required to be filed by any of them have been timely filed, and all taxes due and payable and all assessments, fees and other governmental charges upon the Debtors and their subsidiaries and upon their respective properties, assets, income, businesses and franchises that are due and payable have been paid when due and payable, other than any taxes the amount or validity of which are currently being contested in good faith by appropriate proceedings and with respect to which reserves in conformity with GAAP have been provided on the books of the applicable Debtor and/or its applicable subsidiary, or taxes the nonpayment for which is excused, permitted, or required by the Bankruptcy Code or stayed by the Chapter 11 Cases. With respect to the DIP Collateral, no Debtor is aware of any proposed material tax assessment against any Debtor with respect to United States federal, state or municipal taxes.
K. Properties. Each Debtor and each of their subsidiaries has (i) good, sufficient and legal title to (in the case of fee interests in real property), (ii) valid leasehold interests in (in the case of leasehold interests in real or personal property), (iii) valid licensed rights in (in the case of licensed interests in intellectual property), and (iv) good title to (in the case of all other personal property), all of their respective properties and assets, in each case except for minor defects in title that do not interfere with its ability to conduct its business as currently conducted or to utilize such properties and assets for their intended purposes and assets disposed of as otherwise permitted under clause (iii) under the heading “Negative Covenants” in this DIP Term Sheet. Except for Permitted Liens, all such properties and assets are free and clear of liens.
L. Environmental Matters. None of the Debtors nor any of their subsidiaries nor any of their respective Facilities (as defined in the Prepetition First Lien Credit Agreement) or operations are subject to any outstanding written order, consent decree or settlement agreement with any person relating to the violation of any Environmental Law, any Environmental Claim, or any Hazardous Materials Activity (in each case as defined in the Prepetition First Lien Credit Agreement) that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. None of the Debtors nor any of their subsidiaries has received any letter or request for information under Section 104 of the Comprehensive Environmental Response, Compensation, and Liability Act (42 U.S.C. § 9604) or any comparable state law. There are and, to each of the Debtors’ and their subsidiaries’ knowledge, have been, no conditions, occurrences, or Hazardous Materials Activities that would reasonably be expected to form the basis of an Environmental Claim against any Debtor or any of their subsidiaries that, individually or in the aggregate, would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. None of the Debtors nor any of their subsidiaries nor, to any Debtor’s knowledge, any predecessor of any Debtor or any of their subsidiaries has filed any notice under any Environmental Law indicating past or present treatment of Hazardous Materials (as defined in the Prepetition First Lien Credit Agreement) at any Facility in violation of applicable law, and none of the Debtors’ or any of their subsidiaries’ operations involves the generation, transportation, treatment, storage or disposal of hazardous waste, as defined under 40 C.F.R. Parts 260-270 or any state equivalent, except to the extent that such operations are undertaken in material compliance with law. Compliance with all current or reasonably foreseeable future requirements pursuant to or under Environmental Laws could not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect. No event or condition has occurred or is occurring with respect to any Debtor or any of their subsidiaries relating to the violation of any Environmental Law, any Release (as defined in the Prepetition First Lien Credit Agreement) of Hazardous Materials, or any Hazardous Materials Activity that individually or in the aggregate has had, or could reasonably be expected to have, a Material Adverse Effect.
M. No Defaults.
| 1. | No event shall have occurred and be continuing or would result from the consummation of the Initial Draw or the Delayed Draw (as applicable) that would constitute an Event of Default or a Default. |
| 2. | None of the Debtors nor any of their subsidiaries is in default in the performance, observance or fulfillment of any of the material obligations, covenants or conditions contained in any material agreement, and no condition exists that, with the giving of notice or the lapse of time or both, could constitute such a default, except where the consequences, direct or indirect, of such default or defaults, if any, individually or in the aggregate, would not reasonably be expected to |
| result in a Material Adverse Effect or liability of the Debtors or any of their subsidiaries in excess of $2,500,000, individually or $5,000,000 in the aggregate for all such defaults, in each case as modified as necessary to reflect the commencement and administration of the Chapter 11 Cases and the Debtors’ financial condition. |
N. Budget. Attached to the Interim DIP Order as Schedule 1 is a true and complete copy of the initial DIP Budget, which shall be updated from time to time in accordance with the procedures specified in the DIP Orders; provided, that the total amount of New Money DIP Loans provided pursuant to the DIP Budget shall not exceed the total amount of the New Money DIP Commitments authorized by the DIP Orders.
O. Governmental Regulation. No Debtor is required to be registered as an “investment company” under the Investment Company Act of 1940, as amended.
P. Federal Reserve Regulations; Exchange Act.
| 1. | None of the Debtors nor any of their subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying any Margin Stock (as defined in the Prepetition First Lien Credit Agreement). |
| 2. | No portion of the proceeds of the Initial Draw or Delayed Draw has been or will be used in any manner, whether directly or indirectly, that causes or could reasonably be expected to cause, the Initial Draw or Delayed Draw, as applicable, or the application of such proceeds to violate Regulation T, Regulation U or Regulation X of the Board of Governors or any other regulation thereof or to violate the Securities Exchange Act of 1934, as amended. |
Q. Employee Matters. None of the Debtors nor any of their subsidiaries is engaged in any unfair labor practice that would reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect or liability of any Debtor or any of their subsidiaries in excess of $2,500,000, individually, or $5,000,000, in the aggregate for all such practices, in each case during the term of the DIP Facility. There is (i) no unfair labor practice complaint pending against any Debtor or any of their subsidiaries, or to the best knowledge of the Debtors, threatened against any of them before the National Labor Relations Board and no grievance or arbitration proceeding arising out of or under any collective bargaining agreement that is so pending against any Debtor or any of their subsidiaries or to the best knowledge of the Debtors, threatened against any of them, (ii) no strike or work stoppage in existence or threatened involving any Debtor or any of their subsidiaries, and (iii) to the best knowledge of the Debtors, no union representation question existing with respect to the employees of any Debtor or any of their subsidiaries and, to the best knowledge of the Debtors, no union organization activity that is taking place, except (with respect to any matter specified in clauses (i), (ii) or (iii) above, either individually or in the aggregate) such as is not reasonably likely to have a Material Adverse Effect or result in liabilities in excess of $2,500,000, individually, or $5,000,000, in the aggregate for all such liabilities. No Debtor has incurred any liability or obligation under the Worker Adjustment and Retraining Notification Act or any similar federal or state law that remains unpaid or unsatisfied and would reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect or is in excess of $2,500,000, individually, or $5,000,000, in the aggregate for all such liabilities.
R. Employee Benefit Plans.
| 1. | Each Debtor, each of their subsidiaries and each of their respective ERISA Affiliates (as defined in the Prepetition First Lien Credit Agreement) are in compliance with all applicable provisions and requirements of ERISA (as defined in the Prepetition First Lien Credit Agreement) and the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”) and the regulations and published interpretations thereunder with respect to each Employee Benefit Plan (as defined in the Prepetition First Lien Credit Agreement), and have performed all their obligations under each Employee Benefit Plan. Each Employee Benefit Plan that is intended to qualify under Section 401(a) of the Internal Revenue Code has received a favorable determination letter from the Internal Revenue Service indicating that such Employee Benefit Plan is so qualified and nothing has occurred subsequent to the issuance of such determination letter that would cause such Employee Benefit Plan to lose its qualified status. |
| 2. | No liability to the PBGC (other than required premium payments), the Internal Revenue Service, any Employee Benefit Plan or any trust established under Title IV of ERISA has been or is expected to be incurred by any Debtor, any of their subsidiaries or any of their ERISA Affiliates. No ERISA Event (as defined in the Prepetition First Lien Credit Agreement) has occurred or is reasonably expected to occur. Except to the extent required under Section 4980B of the Internal Revenue Code or similar state laws, no Employee Benefit Plan provides health or welfare benefits (through the purchase of insurance or otherwise) for any retired or former employee of any Debtor, any of their subsidiaries or any of their respective ERISA Affiliates. |
| 3. | The present value of the aggregate benefit liabilities under each Pension Plan (as defined in the Prepetition First Lien Credit Agreement) sponsored, maintained or contributed to by any Debtor, any of their subsidiaries or any of their ERISA Affiliates (determined as of the end of the most recent plan year on the basis of the actuarial assumptions specified for funding purposes in the most recent actuarial valuation for such Pension Plan), did not exceed the aggregate current value of the assets of such Pension Plan. |
| 4. | As of the most recent valuation date for each Multiemployer Plan for which the actuarial report is available, the potential liability of any Debtor, their subsidiaries and their respective ERISA Affiliates for a complete withdrawal from such Multiemployer Plan (within the meaning of Section 4203 of ERISA), when aggregated with such potential liability for a complete withdrawal from all Multiemployer Plans, based on information available pursuant to Section 4221(e) of ERISA is zero. Each Debtor, each of their subsidiaries and each of their ERISA Affiliates have complied with the requirements of Section 515 of ERISA with respect to each Multiemployer Plan and are not in material “default” (as defined in Section 4219(c)(5) of ERISA) with respect to payments to a Multiemployer Plan. |
S. Compliance with Statutes, Etc. Each Debtor and each of their subsidiaries is in compliance in all material respects with all applicable law.
T. Disclosure. No representation or warranty of any Debtor contained in this DIP Term Sheet or any other DIP Document or in any other documents, certificates or written statements furnished to the DIP Agent or any DIP Lender by or on behalf of any Debtor or any of their subsidiaries (other than projections, pro forma financial information and information of a general economic or industry nature) for use in connection with the Restructuring Transactions contains, as of the date furnished, any known untrue statement of a material fact or omits to state a material fact (known to such Debtor, in the case of any document not furnished by it) necessary in order to make the statements contained herein or such documents, certificates or statements, when taken as a whole, not materially misleading in light of the circumstances in which the same were made. Any projections and pro forma financial information contained in such materials are based upon good faith estimates and assumptions believed by the Debtors to be reasonable at the time made, it being recognized by the DIP Lenders that such projections as to future events are not to be viewed as facts and that actual results during the period or periods covered by any such projections may differ from the projected results and such differences may be material. There are no facts known to any Debtor (other than matters of a general economic or industry nature) that, individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect and that have not been disclosed herein or in such other documents, certificates and statements furnished or publicly available to the DIP Lenders for use in connection with the transactions contemplated hereby.
U. Sanctions; Anti-Corruption and Anti-Bribery Laws; Anti-Terrorism and Anti-Money Laundering Laws; Etc.
| 1. | None of the Debtors, any of their subsidiaries, or any of their respective directors, officers or, to the knowledge of any Debtor, employees, agents, advisors, or affiliates is a Sanctioned Person (as defined in the Prepetition First Lien Credit Agreement). Each of the Debtors and each of their subsidiaries and their respective directors, officers and, to the knowledge of any Debtor, employees, agents, advisors and affiliates is in compliance with all and has not violated any (i) Sanctions, (ii) Anti-Corruption and Anti-Bribery Laws, or (iii) Anti-Terrorism and Anti-Money Laundering Laws (in each case, as defined in the Prepetition First Lien Credit Agreement). No part of the proceeds of the Initial Draw |
| or Delayed Draw has been or will be used, directly or indirectly, (A) for the purpose of financing any activities or business of or with any Sanctioned Person or in any Sanctioned Country (as defined in the Prepetition First Lien Credit Agreement), (B) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value to any person in violation of any Anti-Corruption and Anti-Bribery Laws, or (C) otherwise in any manner that would result in a violation of Sanctions, Anti-Terrorism and Anti-Money Laundering Laws, or Anti-Corruption and Anti-Bribery Laws by any person. |
| 2. | Each Debtor and each of their subsidiaries have established and currently maintain policies, procedures and controls that are reasonably designed (and otherwise comply with applicable law) to ensure that each of the Debtors, their subsidiaries, and their controlled affiliates, and each of their respective directors, officers, employees and agents, is and will continue to be in material compliance with all applicable current and future Sanctions, Anti-Terrorism and Anti-Money Laundering Laws, and Anti-Corruption and Anti-Bribery Laws. |
V. Healthcare and FDA Matters.
| 1. | All pre-clinical and clinical studies, tests and trials conducted by or on behalf of or sponsored by any Debtor or any of their subsidiaries, or in which any Debtor or any of their subsidiaries have participated with respect to their products and product candidates, were, and if still pending are, being conducted in all material respects in accordance with all applicable Healthcare Laws, Governmental Authorizations (in each case, as defined in the Prepetition First Lien Credit Agreement) and any applicable rules, regulations, and policies to which such studies, tests or trials are or were subject. Neither any Debtor nor any of their subsidiaries has received any written notices, correspondence or other communications from any Governmental Entity, institutional review board or other entity having authority over the conduct of such studies, tests, or trials requiring or threatening the termination, material modification, clinical hold or suspension of any such studies, tests or trials being conducted or proposed to be conducted by or on behalf of such Debtor or any of its subsidiaries, other than ordinary course communications with respect to modifications in connection with the design and implementation of such studies, tests or trials, and, to the knowledge of the Debtors, there are no reasonable grounds for the same. |
| 2. | Each of the Debtors and each of their subsidiaries has operated and currently is in compliance in all material respects with all applicable Healthcare Laws, including, without limitation, the statutes, rules and regulations enforced by the FDA, the U.S. Department of Health and Human Services Office of Inspector General, the Centers for Medicare |
| & Medicaid Services, the Office for Civil Rights, the Department of Justice or any other Governmental Entity having jurisdiction over the Debtors, their subsidiaries or any of their respective properties. Neither any Debtor nor any of their subsidiaries (i) has received any FDA Form-483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any other Governmental Entity alleging or asserting noncompliance in any material respect with any Healthcare Laws applicable to any Debtor or any of their subsidiaries, or (ii) is a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred or non-prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any Governmental Entity. None of the Debtors, their subsidiaries or any of their respective officers or directors or, to the knowledge of the Debtors, their independent contractors, has been excluded, suspended or debarred from participation in any U.S. federal healthcare program or human clinical research or, is subject to a governmental inquiry, investigation, proceeding, or other similar action that would reasonably be expected to result in debarment, suspension or exclusion. |
| 3. | The manufacture of the Debtors’ and their subsidiaries’ products and product candidates, whether by or on behalf of such Debtor or any of its subsidiaries, is being conducted in compliance in all material respects with all applicable Healthcare Laws. Since April 1, 2021, no manufacturing facility for the products and product candidates of the Debtors and their subsidiaries (whether a Facility or a contract manufacturing site for such products or product candidates) has been subject to any Governmental Entity shutdown. There have been no material recalls, field notifications, field corrections, market withdrawals or replacements, warnings, “dear doctor” letters, investigator notices, safety alerts or other comparable notice or action relating to an alleged lack of safety, efficacy, quality or regulatory compliance of the Debtors’ or their subsidiaries’ products (collectively, “Safety Notices”). To the knowledge of the Debtors, there are no facts that would be reasonably likely to result in (A) a material Safety Notice with respect to any Debtor’s or any of its subsidiaries’ products, (B) a material change in labeling of any Debtor’s or its subsidiaries’ products, or (C) a termination or suspension of marketing or testing of any of the Debtors’ or any of their subsidiaries’ products. |
| 4. | Each of the Debtors and each of their subsidiaries (i) possesses all Governmental Authorizations necessary to conduct the businesses now operated by it, and, subject to the entry of the DIP Orders, for the execution, delivery and performance by and enforcement against such Debtor of this DIP Term Sheet and the other DIP Documents and (ii) is in compliance in all material respects with the terms and conditions of |
| all such Governmental Authorizations. All such Governmental Authorizations are in full force and effect, and to the knowledge of the Debtors, no event has occurred which allows, or after notice or lapse of time would reasonably be expected to allow, revocation, termination, or material impairment of the rights of the holder of any material Governmental Authorization. None of the Debtors nor any of their subsidiaries has received notice of proceedings relating to the revocation or material adverse modification of any such material Governmental Authorizations and to the knowledge of the Debtors, no Governmental Entity granting any such material Governmental Authorization has taken any action to limit, suspend or revoke the same in any material respect. |
| 5. | All material reports, statements, documents, registrations, filings, or submissions required to be filed by any Debtor or any of their subsidiaries with any Governmental Entity have been so filed, properly maintained, and/or amended when required by applicable law, including all applicable Healthcare Laws. All such reports, statements, documents, registrations, submissions and filings were accurate, complete in all material respects and in material compliance with applicable law, including all applicable Healthcare Laws, when filed, or as amended or supplemented, and no material deficiencies have been asserted by any such Governmental Entity with respect to such reports and filings other than in the ordinary course of business. None of the Debtors has received any written notice that the FDA (i) has withdrawn, or intends to withdraw, the approval of any labeled indication of selinexor tablets or adversely modify, limit or restrict selinexor’s approved indications for use; or (ii) has identified any serious adverse events or other material events or material trends with respect to the safety or efficacy of selinexor that would reasonably be expected to lead to the material withdrawal, restriction, limitation or adverse modification of any labeled indication of selinexor. |
Annex C
Priorities
The following chart sets forth the relative priority of the liens and claims described in this DIP Term Sheet. Capitalized terms used in this Annex C and not defined in this DIP Term Sheet have the meanings given to them in the DIP Orders. In the event of any conflict between this chart and the DIP Orders, the terms of the applicable DIP Order shall govern. Liens and claims of the Prepetition Notes Secured Parties and the Prepetition Royalty Secured Parties listed at the same priority level shall rank pari passu with each other, and any proceeds thereof shall be applied as between them in accordance with Section 4.1 of the Intercreditor Agreement, mutatis mutandis and, with respect to the Prepetition Notes Secured Parties, in accordance with Section 3.4 of the Collateral Trust Agreement, mutatis mutandis. Nothing in this Annex C amends, alters or modifies the Intercreditor Agreement or the Collateral Trust Agreement, each of which shall remain in full force and effect in accordance with section 510(a) of the Bankruptcy Code.
| Priority |
Liens on Prepetition Non-Royalty Collateral (Including Cash Collateral) |
Liens on Prepetition Royalty Collateral |
Liens on Unencumbered Collateral |
Claims Against All Debtor Assets | ||||
| 1 | Carve-Out; Permitted Prior Liens | Carve-Out; Permitted Prior Liens | Carve-Out | Carve-Out | ||||
| 2 | DIP Liens | DIP Liens | DIP Liens | DIP Superpriority Claims | ||||
| 3 | First Lien Adequate Protection Liens | First Lien Adequate Protection Liens | First Lien Adequate Protection Liens | First Lien 507(b) Claims | ||||
| 4 | Prepetition 1L Liens | Prepetition 1L Liens | Notes Adequate Protection Liens;
Royalty Adequate Protection Liens |
Notes 507(b) Claims;
Royalty 507(b) Claims | ||||
| 5 | Notes Adequate Protection Liens | Notes Adequate Protection Liens;
Royalty Adequate Protection Liens |
None | All other administrative expense claims | ||||
| 6 | Prepetition 2L Notes Liens |
Prepetition 2L Notes Liens;
Prepetition 2L Royalty Liens |
None | None | ||||
| 7 | Royalty Adequate Protection Liens | None | None | None | ||||
Exhibit 99.1
Certain portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
IN THE UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF TEXAS
HOUSTON DIVISION
|
In re:
KARYOPHARM THERAPEUTICS INC., et al.,1
Debtors.
|
Chapter 11
Case No. 26-_____ (___)
(Joint Administration Requested) |
DISCLOSURE STATEMENT FOR
THE JOINT PREPACKAGED CHAPTER 11 PLAN OF
KARYOPHARM THERAPEUTICS INC. AND ITS DEBTOR AFFILIATE
| SIDLEY AUSTIN LLP Maegan Quejada (TX Bar No. 24105999) Chelsea McManus (TX Bar No. 24131499) 1000 Louisiana Street, Suite 5900 Houston, Texas 77002 Telephone: (713) 495-4500 Facsimile: (713) 495-7799 Email: mquejada@sidley.com cmcmanus@sidley.com
Proposed Counsel to the Debtors and Debtors in Possession |
SIDLEY AUSTIN LLP Stephen E. Hessler (pro hac vice pending) Anthony R. Grossi (pro hac vice pending) 787 Seventh Avenue New York, New York 10019 Telephone: (212) 839-5300 Facsimile: (212) 839-5599 Email: shessler@sidley.com agrossi@sidley.com
and
Ian C. Ferrell (pro hac vice pending) Daniela Rakowski (pro hac vice pending) One South Dearborn Chicago, Illinois 60603 Telephone: (312) 853-7000 Facsimile: (312) 853-7036 Email: iferrell@sidley.com drakowski@sidley.com |
| 1 | The Debtors in these chapter 11 cases, together with the last four digits of the Debtors’ federal tax identification numbers, are: Karyopharm Therapeutics Inc. (1704) and KPT Texas LLC (1815). The Debtors’ service address is 85 Wells Avenue, Suite 210, Newton, Massachusetts 02459. |
THIS IS A SOLICITATION OF VOTES TO ACCEPT OR REJECT THE PREPACKAGED PLAN IN ACCORDANCE WITH BANKRUPTCY CODE SECTION 1125 AND WITHIN THE MEANING OF BANKRUPTCY CODE SECTION 1126, 11 U.S.C. §§ 1125, 1126. THIS DISCLOSURE STATEMENT HAS NOT BEEN APPROVED BY THE BANKRUPTCY COURT. THE DEBTORS INTEND TO SUBMIT THIS DISCLOSURE STATEMENT TO THE BANKRUPTCY COURT FOR APPROVAL FOLLOWING COMMENCEMENT OF SOLICITATION AND THE DEBTORS’ FILING FOR RELIEF UNDER CHAPTER 11 OF THE BANKRUPTCY CODE. THE INFORMATION IN THIS DISCLOSURE STATEMENT IS SUBJECT TO CHANGE. THIS DISCLOSURE STATEMENT IS NOT AN OFFER TO SELL ANY SECURITIES AND IS NOT SOLICITING AN OFFER TO BUY ANY SECURITIES.
IMPORTANT INFORMATION ABOUT THIS DISCLOSURE STATEMENT
SOLICITATION OF VOTES ON THE JOINT PREPACKAGED CHAPTER 11 PLAN OF KARYOPHARM THERAPEUTICS INC. AND ITS DEBTOR AFFILIATE PURSUANT TO CHAPTER 11 OF THE BANKRUPTCY CODE FROM THE HOLDERS OF THE FOLLOWING OUTSTANDING CLAIMS:
| VOTING CLASS | NAME OF CLASS UNDER PREPACKAGED PLAN | |
| CLASS 3 | 1L TERM LOAN CLAIMS | |
| CLASS 4 | 1.5L 2028 NOTES CLAIMS | |
| CLASS 5 | 2L 2029 NOTES CLAIMS | |
| CLASS 6 | RIFA CLAIMS |
IF YOU HOLD A CLAIM IN CLASS 3, CLASS 4, CLASS 5, OR CLASS 6, YOU ARE RECEIVING THIS DOCUMENT AND THE ACCOMPANYING MATERIALS BECAUSE YOU ARE ENTITLED TO VOTE ON THE PREPACKAGED PLAN.
THE VOTING DEADLINE IS 4:00 P.M. (PREVAILING CENTRAL TIME) ON NOVEMBER 30, 2026.
FOR YOUR VOTE TO BE COUNTED, YOU MUST RETURN YOUR PROPERLY COMPLETED BALLOT TO THE CLAIMS AND BALLOTING AGENT, STRETTO, INC., SO THAT YOUR BALLOT IS ACTUALLY RECEIVED BY THE CLAIMS AND BALLOTING AGENT BEFORE THE VOTING DEADLINE.
THE BALLOTS CONTAIN DETAILED VOTING INSTRUCTIONS AND SET FORTH, AMONG OTHER THINGS, THE DEADLINES, PROCEDURES, AND INSTRUCTIONS FOR VOTING TO ACCEPT OR REJECT THE PREPACKAGED PLAN, AND THE APPLICABLE STANDARDS FOR TABULATING BALLOTS.
ii
IF YOU HAVE ANY QUESTIONS CONCERNING THIS DISCLOSURE STATEMENT OR THE VOTING PROCEDURES, PLEASE CONTACT THE CLAIMS AND BALLOTING AGENT, STRETTO, INC., BY TELEPHONE AT (866) 270-4922 (TOLL-FREE WITHIN THE UNITED STATES OR CANADA) OR +1 (949) 561-0471 (INTERNATIONAL). THE CLAIMS AND BALLOTING AGENT IS NOT AUTHORIZED TO PROVIDE, AND WILL NOT PROVIDE, LEGAL OR FINANCIAL ADVICE.
iii
This disclosure statement (as amended from time to time, the “Disclosure Statement”) provides information regarding the Joint Prepackaged Chapter 11 Plan of Karyopharm Therapeutics Inc. and its Debtor Affiliate (as may be amended, supplemented, or otherwise modified from time to time, the “Prepackaged Plan”),1 for which Karyopharm Therapeutics Inc. and its debtor affiliate, as debtors and debtors in possession (collectively, the “Debtors”), will seek confirmation by the United States Bankruptcy Court for the Southern District of Texas, Houston Division (the “Bankruptcy Court”). A copy of the Prepackaged Plan is attached hereto as Exhibit A and is incorporated herein by reference. The Debtors are providing the information in this Disclosure Statement to certain Holders of Claims for purposes of soliciting votes to accept or reject the Prepackaged Plan.
Pursuant to the Restructuring Support Agreement, the Prepackaged Plan is supported by the Debtors and certain Consenting Stakeholders that have executed the Restructuring Support Agreement, including Holders of 100% of the 1L Term Loan Claims, 100% of the 1.5L 2028 Notes Claims, 100% of the 2L 2029 Notes Claims, 100% of the RIFA Claims, and 100% of the Existing Preferred Interests.2
The consummation and effectiveness of the Prepackaged Plan are subject to certain material conditions precedent described herein and set forth in Article IX of the Prepackaged Plan. There is no assurance that the Bankruptcy Court will confirm the Prepackaged Plan or, if the Bankruptcy Court does confirm the Prepackaged Plan, that the conditions necessary for the Prepackaged Plan to become effective will be satisfied or, in the alternative, waived.
The Debtors urge each Holder of a Claim or Interest to consult with its own advisors with respect to any legal, financial, securities, tax, or business advice in reviewing this Disclosure Statement, the Prepackaged Plan, and each proposed transaction contemplated by the Prepackaged Plan.
The Debtors strongly encourage Holders of Claims in Class 3, Class 4, Class 5, and Class 6 to read this Disclosure Statement (including the Risk Factors described in Article VIII hereof) and the Prepackaged Plan in their entirety before voting to accept or reject the Prepackaged Plan. Assuming the requisite acceptances to the Prepackaged Plan are obtained, the Debtors will seek the Bankruptcy Court’s approval of the Prepackaged Plan at the Combined Hearing.
| 1 | Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Prepackaged Plan. The summary of the Prepackaged Plan provided herein is qualified in its entirety by reference to the Prepackaged Plan. In the case of any inconsistency between this Disclosure Statement and the Prepackaged Plan, the Prepackaged Plan will govern. |
| 2 | The members of the Ad Hoc Group and the Royalty Investors are also the holders of the Existing Preferred Interests issued on September 17, 2026 as consideration under the September Forbearance Agreement (as defined herein). |
iv
RECOMMENDATION BY THE DEBTORS
EACH DEBTOR’S BOARD OF DIRECTORS OR MANAGER, AS APPLICABLE, HAS APPROVED THE RESTRUCTURING TRANSACTIONS CONTEMPLATED BY THE PREPACKAGED PLAN AND DESCRIBED IN THIS DISCLOSURE STATEMENT, SUBJECT TO BANKRUPTCY COURT APPROVAL, AND EACH DEBTOR BELIEVES THAT THE COMPROMISES CONTEMPLATED UNDER THE PREPACKAGED PLAN ARE FAIR AND EQUITABLE, MAXIMIZE THE VALUE OF EACH OF THE DEBTORS’ ESTATES, AND PROVIDE THE BEST RECOVERY TO HOLDERS OF CLAIMS AND INTERESTS. EACH DEBTOR BELIEVES THAT THE PREPACKAGED PLAN AND RELATED TRANSACTIONS REPRESENT THE BEST ALTERNATIVE FOR ACCOMPLISHING THE DEBTORS’ OVERALL RESTRUCTURING OBJECTIVES. EACH OF THE DEBTORS THEREFORE STRONGLY RECOMMENDS THAT ALL HOLDERS OF CLAIMS WHOSE VOTES ARE BEING SOLICITED SUBMIT BALLOTS TO ACCEPT THE PREPACKAGED PLAN BY RETURNING THEIR BALLOTS SO AS TO BE ACTUALLY RECEIVED BY THE CLAIMS AND BALLOTING AGENT NO LATER THAN NOVEMBER 30, 2026, AT 4:00 P.M. (PREVAILING CENTRAL TIME) PURSUANT TO THE INSTRUCTIONS SET FORTH HEREIN AND ON THE BALLOTS.
HOLDERS OF ALLOWED GENERAL UNSECURED CLAIMS WILL NOT BE IMPAIRED BY THE PREPACKAGED PLAN AND, AS A RESULT, THE RIGHT TO RECEIVE PAYMENT IN FULL ON ACCOUNT OF EXISTING OBLIGATIONS TO SUCH HOLDERS IS NOT ALTERED BY THE PREPACKAGED PLAN. DURING THE CHAPTER 11 CASES, THE DEBTORS INTEND TO OPERATE THEIR BUSINESSES IN THE ORDINARY COURSE AND WILL SEEK AUTHORIZATION FROM THE BANKRUPTCY COURT TO MAKE PAYMENT IN FULL IN THE ORDINARY COURSE OF BUSINESS TO ALL TRADE CREDITORS, CUSTOMERS, AND EMPLOYEES OF ALL UNDISPUTED AMOUNTS DUE BEFORE AND DURING THE CHAPTER 11 CASES.
v
SPECIAL NOTICE REGARDING FEDERAL AND STATE SECURITIES LAWS
The Bankruptcy Court has not approved or disapproved this Disclosure Statement or the Prepackaged Plan, and the securities to be issued on or after the Effective Date will not have been the subject of a registration statement filed with the United States Securities and Exchange Commission (the “SEC”) under the United States Securities Act of 1933, as amended (the “Securities Act”) or any securities regulatory authority of any state under any state securities law (“Blue Sky Laws”). The Prepackaged Plan has not been approved or disapproved by the SEC or any state regulatory authority and neither the SEC nor any state regulatory authority has passed upon the accuracy or adequacy of the information contained in this Disclosure Statement or the Prepackaged Plan. Any representation to the contrary is a criminal offense.
Prior to the Petition Date, the Debtors commenced the solicitation of votes on the Prepackaged Plan (the “Solicitation”) with respect to the 1L Term Loan Claims, the 1.5L 2028 Notes Claims, the 2L 2029 Notes Claims, and the RIFA Claims pursuant to section 4(a)(2) of the Securities Act and Regulation S under the Securities Act and only from Holders of such Claims that are (i) located inside the United States and are (a) “qualified institutional buyers” (as defined in Rule 144A under the Securities Act) or (b) “accredited investors” (as defined in Rule 501(a) of Regulation D under the Securities Act), or (ii) located outside the United States and are not “U.S. persons” (as defined in Rule 902 of Regulation S under the Securities Act) (collectively, the “Eligible Holders”); provided, however, that all Holders of Allowed Claims and Interests will be entitled to receive applicable distributions under the Prepackaged Plan, as provided in the Prepackaged Plan.
After the Petition Date, the Debtors will rely on section 1145(a) of the Bankruptcy Code, or any other applicable exemption, to exempt from registration under the Securities Act and Blue Sky Laws the offer, issuance, and distribution of the Reorganized Parent Common Stock, the New Common Stock, the MF CVRs (to the extent constituting securities) and all other instruments to be entered into and/or issued in connection with or under the Prepackaged Plan (other than the New Common Stock to be issued to the equityholders of Ayrmid as Merger Consideration and the Omisirge Contingent Equity, which will be issued in reliance on section 4(a)(2) of the Securities Act and/or Regulation S under the Securities Act). Neither the Solicitation nor this Disclosure Statement constitutes an offer to sell or the solicitation of an offer to buy securities in any state or jurisdiction in which such offer or solicitation is not authorized.
No action has been taken, nor will be taken, in connection with the Prepackaged Plan in any jurisdiction that would permit a public offering of any securities (other than securities issued pursuant to section 1145 of the Bankruptcy Code) in any jurisdiction where such action for that purpose is required.
Except to the extent publicly available, this Disclosure Statement, the Prepackaged Plan, and the information set forth herein and therein are confidential and may contain material non-public information concerning the Debtors, their subsidiaries, and their respective debt and Securities. Each recipient hereby acknowledges that it (a) is aware that the federal securities laws of the United States prohibit any person who has material non-
vi
public information about a company, which is obtained from the company or its representatives, from purchasing or selling Securities of such company or from communicating the information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such Securities and (b) is familiar with the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the rules and regulations promulgated thereunder, and agrees that it will not use or communicate to any Person or Entity, under circumstances where it is reasonably likely that such Person or Entity is likely to use or cause any Person or Entity to use, any confidential information in contravention of the Exchange Act or any of its rules and regulations, including Rule 10b-5.
vii
DISCLAIMER
This Disclosure Statement contains summaries of certain provisions of the Prepackaged Plan and certain other documents and financial information that may be attached or incorporated by reference. The information included in this Disclosure Statement is provided solely for the purpose of providing adequate information to enable Holders of Claims or Interests who are entitled to vote on the Prepackaged Plan to make an informed decision in exercising their respective right to vote on the Prepackaged Plan and should not be relied upon for any purpose other than to determine whether and how to vote on the Prepackaged Plan. All Holders of Claims entitled to vote to accept or reject the Prepackaged Plan are advised and encouraged to read this Disclosure Statement and the Prepackaged Plan in their entirety before voting to accept or reject the Prepackaged Plan. The Debtors believe that these summaries are fair and accurate, and every effort has been made to provide adequate information to Holders of Claims or Interests on how various aspects of the Prepackaged Plan affect their respective Claims or Interests. The summaries of the financial information and the documents that are attached to, or incorporated by reference in, this Disclosure Statement are qualified in their entirety by reference to such information and documents. In the event of any inconsistency or discrepancy between a description in this Disclosure Statement, on the one hand, and the terms and provisions of the Prepackaged Plan or the financial information and documents incorporated in this Disclosure Statement by reference, on the other hand, the Prepackaged Plan or the financial information and documents, as applicable, shall govern for all purposes.
Except as otherwise provided in the Prepackaged Plan, by order of the Bankruptcy Court, or in accordance with applicable law, the Debtors are under no duty to update or supplement this Disclosure Statement. The Bankruptcy Court’s approval of this Disclosure Statement does not constitute a guarantee of the accuracy or completeness of the information contained herein or the Bankruptcy Court’s endorsement of the merits of the Prepackaged Plan. The statements and financial information contained in this Disclosure Statement have been made as of the date hereof unless otherwise specified. Holders of Claims or Interests reviewing this Disclosure Statement should not assume at the time of such review that there have been no changes in the facts set forth in this Disclosure Statement since the date of this Disclosure Statement. No Holder of a Claim or Interest should rely on any information, representations, or inducements that are not contained in or are inconsistent with the information contained in this Disclosure Statement, the documents attached to this Disclosure Statement, and the Prepackaged Plan. This Disclosure Statement does not constitute legal, business, financial, or tax advice. Any Person or Entity desiring any such advice should consult with their own advisors. Additionally, this Disclosure Statement has not been approved or disapproved by the Bankruptcy Court, the SEC, or any securities regulatory authority of any state under Blue Sky Laws. The Debtors are soliciting acceptances to the Prepackaged Plan prior to and after commencing any cases under chapter 11 of the Bankruptcy Code.
The financial information contained in or incorporated by reference into this Disclosure Statement has not been audited, except as specifically indicated otherwise. In the event the Reorganization Transaction is consummated, the Debtors’ management, in consultation with the Debtors’ advisors and Ayrmid, will prepare projections of the pro forma operating performance of the Reorganized Debtors following consummation of the Reorganization Transaction (the “Financial Projections”), which will be filed with the Plan Supplement. The Financial
viii
Projections, while presented with numerical specificity, necessarily will be based on a variety of estimates and assumptions that are inherently uncertain and may be beyond the control of the Debtors’ management, including assumptions regarding the regulatory and commercial prospects of XPOVIO® and Omisirge® and the integration of the businesses of the Company and Ayrmid. Important factors that may affect actual results and cause the management forecasts not to be achieved include, but are not limited to, risks and uncertainties relating to the Debtors’ businesses (including their ability to achieve strategic goals, objectives, and targets over applicable periods), industry performance, the regulatory environment, general business and economic conditions, and other factors. The Debtors caution that no representations can be made as to the accuracy of these projections or to their ultimate performance compared to the information contained in the forecasts or that the forecasted results will be achieved. Therefore, the Financial Projections may not be relied upon as a guarantee or other assurance that the actual results will occur and actual performance may be materially different than forecasted results.
Regarding contested matters, adversary proceedings, and other pending, threatened, or potential litigation or other actions, this Disclosure Statement does not constitute, and may not be construed as, an admission of fact, liability, stipulation, or waiver by the Debtors or any other party, but rather as a statement made in the context of settlement negotiations in accordance with Rule 408 of the Federal Rules of Evidence and any analogous state or foreign laws or rules. As such, this Disclosure Statement shall not be admissible in any non-bankruptcy proceeding involving the Debtors or any other party in interest, nor shall it be construed to be conclusive advice on the tax, securities, financial, or other effects of the Prepackaged Plan to Holders of Claims against, or Interests in, the Debtors or any other party in interest. Please refer to Article VIII of this Disclosure Statement, entitled “Risk Factors,” for a discussion of certain risk factors that Holders of Claims voting on the Prepackaged Plan should consider.
Except as otherwise expressly set forth herein, all information, representations, or statements contained herein have been provided by the Debtors. No person is authorized by the Debtors in connection with this Disclosure Statement, the Prepackaged Plan, or the Solicitation to give any information or to make any representation or statement regarding this Disclosure Statement, the Prepackaged Plan, or the Solicitation, in each case, other than as contained in this Disclosure Statement and the exhibits attached hereto or as otherwise incorporated herein by reference or referred to herein. If any such information, representation, or statement is given or made, it may not be relied upon as having been authorized by the Debtors.
This Disclosure Statement contains certain forward-looking statements, all of which are based on various estimates and assumptions. Such forward-looking statements are subject to inherent uncertainties and to a wide variety of significant business, economic, and competitive risks, including, but not limited to, those summarized herein. When used in this Disclosure Statement, the words “anticipate,” “believe,” “estimate,” “will,” “may,” “intend,” and “expect” and similar expressions generally identify forward-looking statements. Although the Debtors believe that their plans, intentions, and expectations reflected in the forward-looking statements are reasonable, they cannot be sure that they will be achieved. These statements are only predictions and are not guarantees of future performance or results. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by a forward-looking statement, including the risks set forth in Article VIII hereof. All forward-looking statements attributable to the Debtors or Persons or Entities acting on their behalf are expressly qualified in their entirety by the cautionary statements set forth in this Disclosure Statement. Forward-looking statements speak only as of the date on which they are made. Except as required by law, the Debtors expressly disclaim any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
ix
TABLE OF CONTENTS
| I. | INTRODUCTION | 1 | ||||
| II. | PRELIMINARY STATEMENT | 2 | ||||
| III. | QUESTIONS AND ANSWERS REGARDING THIS DISCLOSURE STATEMENT AND PREPACKAGED PLAN | 4 | ||||
| A. | What is chapter 11? | 4 | ||||
| B. | Why are the Debtors sending me this Disclosure Statement? | 5 | ||||
| C. | Why are votes being solicited prior to Bankruptcy Court approval of this Disclosure Statement? | 5 | ||||
| D. | Am I entitled to vote on the Prepackaged Plan? | 5 | ||||
| E. | What will I receive from the Debtors if the Prepackaged Plan is consummated? | 6 | ||||
| F. | What will I receive from the Debtors if I hold an Allowed Administrative Claim, DIP Claim, Professional Fee Claim, or a Priority Tax Claim? | 12 | ||||
| G. | Are any regulatory approvals required to consummate the Prepackaged Plan? | 16 | ||||
| H. | What happens to my recovery if the Prepackaged Plan is not confirmed or does not go effective? | 17 | ||||
| I. | If the Prepackaged Plan provides that I get a distribution, do I get it upon Confirmation or when the Prepackaged Plan goes effective, and what is meant by “Confirmation,” “Effective Date,” and “Consummation?” | 17 | ||||
| J. | What are the sources of Cash and other consideration required to fund the Prepackaged Plan? | 18 | ||||
| K. | Are there risks to owning the New Common Stock and the MF CVRs upon emergence from chapter 11? | 18 | ||||
| L. | Is there potential litigation related to the Prepackaged Plan? | 18 | ||||
| M. | Will the final amount of Allowed General Unsecured Claims affect the recovery of Holders of Allowed General Unsecured Claims under the Prepackaged Plan? | 19 | ||||
| N. | How will the preservation of the Causes of Action impact my recovery under the Prepackaged Plan? | 19 | ||||
| O. | Will there be releases and exculpation granted to parties in interest as part of the Prepackaged Plan? | 20 | ||||
| P. | What is the deadline to vote on the Prepackaged Plan? | 27 | ||||
| Q. | How do I vote to accept or reject the Prepackaged Plan? | 27 | ||||
| R. | Why is the Bankruptcy Court holding a Combined Hearing? | 27 | ||||
| S. | What is the purpose of the Combined Hearing? | 27 | ||||
| T. | What is the effect of the Prepackaged Plan on the Debtors’ ongoing businesses? | 28 | ||||
| U. | Will any party have significant influence over the corporate governance and operations of NewCo and the Reorganized Debtors? | 28 | ||||
x
| V. | Who do I contact if I have additional questions with respect to this Disclosure Statement or the Prepackaged Plan? | 29 | ||||||
| W. | Do the Debtors recommend voting in favor of the Prepackaged Plan? | 30 | ||||||
| X. | Who supports the Prepackaged Plan? | 30 | ||||||
| IV. |
THE RESTRUCTURING SUPPORT AGREEMENT AND PREPACKAGED PLAN |
30 | ||||||
| A. | Restructuring Support Agreement | 30 | ||||||
| B. | The DIP Facility | 31 | ||||||
| C. | The Prepackaged Plan | 31 | ||||||
| V. |
DEBTORS’ CORPORATE HISTORY, STRUCTURE, AND BUSINESS OVERVIEW |
51 | ||||||
| A. | Corporate History and Operations | 51 | ||||||
| B. | Business and Operations | 51 | ||||||
| C. | The Debtors’ Prepetition Capital Structure | 54 | ||||||
| VI. |
EVENTS LEADING TO THE CHAPTER 11 FILINGS |
58 | ||||||
| A. | The Company’s Operating Losses and Dependence on Clinical Milestones | 59 | ||||||
| B. | The Fall 2025 Transactions | 59 | ||||||
| C. | The February 2026 Forbearance Agreement and the March 2026 Private Placement | 61 | ||||||
| D. | Clinical and Regulatory Developments in 2026 | 62 | ||||||
| E. | 2026 Employee Retention Programs | 62 | ||||||
| F. | The September 2026 Forbearance Agreement and Fee Agreement | 63 | ||||||
| G. | Exploration of Strategic Alternatives and the Marketing and Sale Process | 66 | ||||||
| H. | The Restructuring Support Agreement and the Restructuring Transactions | 67 | ||||||
| VII. |
MATERIAL DEVELOPMENTS AND ANTICIPATED EVENTS OF THE CHAPTER 11 CASES |
69 | ||||||
| A. | First Day Relief | 69 | ||||||
| B. | Case Milestones | 69 | ||||||
| C. | The Bidding Procedures and the Continued Marketing and Sale Process | 70 | ||||||
| D. | Claims Process; No General Bar Date | 72 | ||||||
| VIII. |
RISK FACTORS |
72 | ||||||
| A. | Bankruptcy Law Considerations | 73 | ||||||
| B. | Risks Related to Recoveries Under the Prepackaged Plan | 79 | ||||||
| C. | Risks Related to the Merger and the Consideration to Be Issued in a Reorganization Transaction | 82 | ||||||
| D. | Risks Related to the Debtors’ and NewCo’s Businesses | 86 | ||||||
| E. | Disclosure Statement Disclaimer | 90 | ||||||
xi
| IX. |
SOLICITATION AND VOTING |
92 | ||||||
| A. | Holders of Claims Entitled to Vote on the Prepackaged Plan | 93 | ||||||
| B. | Voting Record Date | 93 | ||||||
| C. | Solicitation Package | 93 | ||||||
| D. | Voting on the Prepackaged Plan | 94 | ||||||
| E. | Non-Voting Classes; Opt-Out and Opt-In Forms | 94 | ||||||
| F. | Ballots Not Counted | 95 | ||||||
| X. |
CONFIRMATION OF THE PREPACKAGED PLAN |
95 | ||||||
| A. | The Combined Hearing | 95 | ||||||
| B. | Requirements for Confirmation of the Prepackaged Plan | 96 | ||||||
| C. | Best Interests of Creditors/Liquidation Analysis | 96 | ||||||
| D. | Feasibility | 97 | ||||||
| E. | Acceptance by Impaired Classes | 98 | ||||||
| F. | Confirmation Without Acceptance by All Impaired Classes | 98 | ||||||
| G. | Valuation of the Debtors | 99 | ||||||
| XI. |
CERTAIN SECURITIES LAW MATTERS |
100 | ||||||
| A. | Securities Issued Under Section 1145 | 100 | ||||||
| B. | Securities Issued Under Section 4(a)(2) and Regulation S | 101 | ||||||
| XII. |
CERTAIN U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PREPACKAGED PLAN |
102 | ||||||
| A. | Certain U.S. Federal Income Tax Consequences to the Debtors and the Reorganized Debtors/Post-Effective Date Debtors | 104 | ||||||
| B. | Certain U.S. Federal Income Tax Consequences to U.S. Holders of Certain Claims Entitled to Vote | 108 | ||||||
| C. | Certain U.S. Federal Income Tax Consequences to Non-U.S. Holders of Certain Claims | 111 | ||||||
| D. | Information Reporting and Back-Up Withholding | 114 | ||||||
| E. | Foreign Account Tax Compliance Act | 114 | ||||||
| XIII. |
RECOMMENDATION |
115 | ||||||
xii
EXHIBITS
EXHIBIT A Prepackaged Plan
EXHIBIT B Restructuring Support Agreement
EXHIBIT C Corporate Organization Chart
EXHIBIT D Liquidation Analysis
xiii
| I. | INTRODUCTION |
Karyopharm Therapeutics Inc. (“Parent” or “Karyopharm”) and its debtor affiliate, as debtors and debtors in possession (collectively, the “Debtors,” and together with any non-Debtor subsidiaries, the “Company”), submit this Disclosure Statement, pursuant to section 1125 of the Bankruptcy Code, to Holders of Claims against, and Interests in, the Debtors in connection with the solicitation of votes for acceptance of the Joint Prepackaged Chapter 11 Plan of Karyopharm Therapeutics Inc. and its Debtor Affiliate, dated November 2, 2026. A copy of the Prepackaged Plan is attached hereto as Exhibit A and incorporated herein by reference. The Prepackaged Plan constitutes a separate chapter 11 plan for each of the Debtors.
THE DEBTORS AND CERTAIN CONSENTING STAKEHOLDERS THAT HAVE EXECUTED THE RESTRUCTURING SUPPORT AGREEMENT, INCLUDING HOLDERS OF 100% OF THE 1L TERM LOAN CLAIMS, 100% OF THE 1.5L 2028 NOTES CLAIMS, 100% OF THE 2L 2029 NOTES CLAIMS, 100% OF THE RIFA CLAIMS, AND 100% OF THE EXISTING PREFERRED INTERESTS, BELIEVE THAT THE COMPROMISES CONTEMPLATED UNDER THE PREPACKAGED PLAN ARE FAIR AND EQUITABLE, MAXIMIZE THE VALUE OF THE DEBTORS’ ESTATES, AND PROVIDE THE BEST RECOVERY TO STAKEHOLDERS. AT THIS TIME, THE DEBTORS BELIEVE THE PREPACKAGED PLAN REPRESENTS THE BEST AVAILABLE OPTION FOR COMPLETING THE CHAPTER 11 CASES. THE DEBTORS STRONGLY RECOMMEND THAT YOU VOTE TO ACCEPT THE PREPACKAGED PLAN.
| II. | PRELIMINARY STATEMENT |
The Company is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Its lead product, XPOVIO® (selinexor) (“XPOVIO”), is a first-in-class, oral Selective Inhibitor of Nuclear Export compound approved by the U.S. Food and Drug Administration (the “FDA”) in two multiple myeloma indications and approved in more than 50 countries and territories, where it is commercialized through the Company’s licensing partners. The Company’s primary focus is on marketing XPOVIO in its currently approved indications and on developing and seeking regulatory approval of selinexor for the treatment of myelofibrosis, for which the Company submitted a supplemental New Drug Application to the FDA on August 31, 2026 seeking accelerated approval.
As described in greater detail in Article VI herein, the Company has incurred significant operating losses since its inception and has depended on periodic access to the capital markets, which in turn has depended on the progress of its clinical programs. When the Company’s two Phase 3 readouts in 2026 fell short of expectations and the Company faced increasing liquidity constraints, the Company’s secured creditors worked constructively with the Company—first to give the Company time to reach the trial readouts, and then to give it time to evaluate its alternatives in light of the results—through a series of payment deferrals, forbearances, and out-of-court transactions. Beginning in July 2025, the Company, with the assistance of Centerview Partners (“Centerview”), evaluated a range of strategic alternatives and, in July 2026, launched a formal marketing and sale process for all or a portion of the Company’s business (the “Marketing and Sale Process”). Although the Marketing and Sale Process generated multiple proposals, none were actionable before the Company exhausted its liquidity. The Marketing and Sale Process instead yielded the proposal of Ayrmid Ltd. (“Ayrmid”), the parent company of Gamida Cell Inc., a commercial-stage cell therapy company, to combine the two businesses, with the Company’s funded-debt creditors receiving a majority equity stake in the combined, better-capitalized commercial-stage oncology company together with a contingent interest in the myelofibrosis opportunity.
Following negotiations among the Company, Ayrmid, the Ad Hoc Group, and the Royalty Investors, the Debtors entered into a restructuring support agreement, dated as of November 2, 2026 (as may be amended, supplemented, or otherwise modified from time to time, the “Restructuring Support Agreement”), a copy of which is attached hereto as Exhibit B, with Ayrmid and the Consenting Stakeholders. As of the date of this Disclosure Statement, Holders of 100% of the 1L Term Loan Claims, 100% of the 1.5L 2028 Notes Claims, 100% of the 2L 2029 Notes Claims, 100% of the RIFA Claims, and 100% of the Existing Preferred Interests have executed the Restructuring Support Agreement.
2
In the event of a Reorganization Transaction, pursuant to the Prepackaged Plan, the Debtors will pursue a comprehensive restructuring of their balance sheet through the Reorganization Transaction, pursuant to which the Company’s business will be combined with Ayrmid’s business under an Entity serving as a holding company (“NewCo”). In such event, the Prepackaged Plan provides that:
| • | all claims under the 1L Term Loan Facility, the 1.5L 2028 Notes, and the 2L 2029 Notes (collectively, the “Funded Debt Claims”)—approximately $276 million in the aggregate—together with any Excess DIP Claims (as defined below), will be exchanged for 100% of the common stock of Reorganized Parent (the “Reorganized Parent Common Stock”), which will in turn be exchanged in the Merger for 55.0% of the New Common Stock of NewCo (subject to dilution by the Omisirge Contingent Equity and the Management Incentive Plan), together with contingent value rights entitling the holders thereof to a percentage of future net sales of XPOVIO in the myelofibrosis indication (the “MF CVRs”); |
| • | Ayrmid’s existing equityholders will receive the remaining 45.0% of the New Common Stock (which will not be diluted by the Omisirge Contingent Equity, but will be subject to dilution by the Management Incentive Plan), together with the Omisirge Contingent Equity, which is tied to the future revenues of Ayrmid’s Omisirge® product; |
| • | the claims under the $55 million new-money DIP Facility in respect of new-money loans will be repaid in Cash from (a) up to $50 million of the proceeds of the NewCo Facility, a new senior secured exit term loan facility of up to $135 million to be provided to NewCo by one or more third-party lenders, and (b) the Company’s unrestricted Cash on hand at closing in excess of the reserves provided for in the Prepackaged Plan, and the holders of any remaining new-money claims under the DIP Facility and of the loans under the 1L Term Loan Facility rolled up into the DIP Facility (collectively, the “Excess DIP Claims”) will receive Reorganized Parent Common Stock, which will be exchanged in the Merger as described above; |
| • | the claims under the RIFA will be exchanged for the rights and interests under the New Royalty Agreement, pursuant to which NewCo will pay the Royalty Investors an unsecured royalty equal to 3.0% of the net revenues received by NewCo from all products containing selinexor for the five (5) year period following the Effective Date, and the RIFA (including any change of control payment thereunder) will be canceled; the New Royalty Agreement will include a liquidated damages provision in the amount of $18,750,000, and the Royalty Investors may pursue the acquisition of the Debtors’ interests in certain other royalty agreements for aggregate consideration of up to $35,000,000, subject to the consents described in the Prepackaged Plan; |
| • | all General Unsecured Claims will be Unimpaired and paid in the ordinary course of business; and |
| • | all existing equity interests in Parent, including the Existing Preferred Interests, the Existing Common Stock Interests, and all warrants, options, restricted stock units, and performance stock units, will be canceled and will receive no distribution. |
At the same time, the Prepackaged Plan subjects the Company’s assets to a continued, court-supervised market test. The Debtors will continue the Marketing and Sale Process postpetition pursuant to bidding procedures (the “Bidding Procedures”) to be approved by the Bankruptcy Court, and if the Debtors receive a Qualified Bid that satisfies the Successful Bid Mandatory Conditions—which require, among other things, net proceeds at closing of not less
3
than $335,384,812 (of which $18,750,000, being the portion allocable to the RIFA Claims, may be satisfied with Cash or non-Cash consideration acceptable to the Holders of RIFA Claims), the payment in full in Cash (or other Unimpaired treatment) of all Allowed General Unsecured Claims, the payment in full in Cash of any Bid Protections, and the funding in Cash of the Wind-Down Budget—the Debtors may, with the consents required under the Restructuring Support Agreement, elect to pursue a sale of all or substantially all of their assets to the Successful Bidder (the “Sale Transaction”) in lieu of the Reorganization Transaction. The Debtors are soliciting votes on the Prepackaged Plan as a whole, and Holders of Claims entitled to vote are voting on both alternatives. The Debtors will announce which Restructuring Transaction will be pursued by filing a Sale Transaction Election Notice (if applicable) no later than the Sale Transaction Election Notice Deadline. Subject to the Debtors electing to pursue a Sale Transaction, the core terms of the Restructuring Support Agreement will be implemented through the Reorganization Transaction under the Prepackaged Plan (described more fully in Article IV.C of this Disclosure Statement, entitled “The Prepackaged Plan”).
Whether through the Reorganization Transaction or a Sale Transaction, consummation of the Prepackaged Plan will address the Company’s approximately $276 million of secured funded debt and the obligations under the RIFA and provide a path forward for the XPOVIO franchise—and for the patients who depend on it—that is not available to the Company on a stand-alone basis. In a Reorganization Transaction, the Funded Debt Claims will be exchanged for Reorganized Parent Common Stock which, immediately thereafter shall be exchanged for New Common Stock and the MF CVRs, and NewCo will emerge with no more than $135 million of funded debt under the NewCo Facility—a reduction of approximately $141 million in funded debt—and the obligations under the RIFA will be replaced by the unsecured royalty under the New Royalty Agreement. In a Sale Transaction, the Successful Bid Mandatory Conditions require net proceeds at closing of not less than $335,384,812—an amount sufficient to pay in full in Cash the Allowed DIP Claims, the Allowed 1L Term Loan Claims, and the Allowed 1.5L 2028 Notes Claims and to provide the agreed minimum recoveries on the Allowed 2L 2029 Notes Claims and the Allowed RIFA Claims (which, for the Holders of RIFA Claims, may consist of Cash or non-Cash consideration acceptable to them). In either case, the Debtors expect to continue to make XPOVIO available to patients, and to pay their trade creditors, employees, and other general unsecured creditors in full in the ordinary course of business. With a prepackaged chapter 11 plan and key stakeholder support in place pursuant to the Restructuring Support Agreement, the Debtors expect to either (a) emerge as part of a single, better-capitalized enterprise with committed financing sufficient to fund its business plan or (b) implement a value-maximizing Sale Transaction.
| III. | QUESTIONS AND ANSWERS REGARDING THIS DISCLOSURE STATEMENT AND PREPACKAGED PLAN |
| A. | What is chapter 11? |
Chapter 11 is the principal business reorganization chapter of the Bankruptcy Code. In addition to permitting debtor rehabilitation, chapter 11 promotes equality of treatment for creditors and similarly situated equity interest holders, subject to the priority of distributions prescribed by the Bankruptcy Code.
4
The commencement of a chapter 11 case creates an estate that comprises all of the legal and equitable interests of the debtor as of the date the chapter 11 case is commenced. The Bankruptcy Code provides that the debtor may continue to operate its business and remain in possession of its property as a “debtor in possession.”
Consummating a chapter 11 plan is the principal objective of a chapter 11 case. A bankruptcy court’s confirmation of a plan binds the debtor, any person acquiring property under the plan, any creditor or equity interest holder of the debtor, and any other entity as may be ordered by the bankruptcy court. Subject to certain limited exceptions, the order issued by a bankruptcy court confirming a plan provides for the treatment of the debtor’s liabilities in accordance with the terms of the confirmed plan.
| B. | Why are the Debtors sending me this Disclosure Statement? |
The Debtors are seeking to obtain Bankruptcy Court approval of the Prepackaged Plan. Before soliciting acceptances of the Prepackaged Plan, section 1125 of the Bankruptcy Code requires the Debtors to prepare a disclosure statement containing adequate information of a kind, and in sufficient detail, to enable a hypothetical reasonable investor to make an informed judgment regarding acceptance of the Prepackaged Plan and to share such disclosure statement with all holders of claims whose votes on the Prepackaged Plan are being solicited. This Disclosure Statement is being submitted in accordance with these requirements.
| C. | Why are votes being solicited prior to Bankruptcy Court approval of this Disclosure Statement? |
By sending this Disclosure Statement and soliciting the Prepackaged Plan prior to approval by the Bankruptcy Court, the Debtors are preparing to seek Confirmation of the Prepackaged Plan shortly after commencing the Chapter 11 Cases. The Voting Deadline is November 30, 2026, twenty-eight (28) days after the Petition Date. The Consenting Stakeholders, which hold 100% of the Claims in the Voting Classes, have agreed under the Restructuring Support Agreement to vote to accept the Prepackaged Plan, and the Debtors expect to receive their Ballots promptly following the commencement of the Solicitation. Following the Voting Deadline, the Debtors will file a final declaration of the Claims and Balloting Agent setting forth the final tabulation of votes. The Debtors will ask the Bankruptcy Court to approve this Disclosure Statement together with Confirmation of the Prepackaged Plan at the same hearing, which the Debtors have requested be held on January 11, 2027, all subject to the Bankruptcy Court’s approval and availability.
| D. | Am I entitled to vote on the Prepackaged Plan? |
Your ability to vote on, and your distribution under, the Prepackaged Plan, if any, depends on what type of Claim or Interest you hold and whether you held that Claim or Interest as of the Voting Record Date (i.e., as of October 27, 2026). Each category of Holders of Claims or Interests, as set forth in Article III of the Prepackaged Plan pursuant to section 1122(a) of the Bankruptcy Code, is referred to as a “Class.” Each Class’s respective voting status is set forth below:
5
| Class |
Type of Claim or Interest |
Impairment |
Entitled to Vote | |||
| Class 1 |
Other Secured Claims |
Unimpaired | No (Presumed to accept) | |||
| Class 2 |
Other Priority Claims |
Unimpaired | No (Presumed to accept) | |||
| Class 3 |
1L Term Loan Claims |
Impaired | Yes | |||
| Class 4 |
1.5L 2028 Notes Claims |
Impaired | Yes | |||
| Class 5 |
2L 2029 Notes Claims |
Impaired | Yes | |||
| Class 6 |
RIFA Claims |
Impaired | Yes | |||
| Class 7 |
General Unsecured Claims |
Unimpaired | No (Presumed to accept) | |||
| Class 8 |
Intercompany Claims |
Impaired / Unimpaired | No (Presumed to accept or deemed to reject) | |||
| Class 9 |
Existing Preferred Interests |
Impaired | No (Deemed to reject) | |||
| Class 10 |
Existing Common Stock Interests |
Impaired | No (Deemed to reject) | |||
| Class 11 |
Other Equity Interests |
Impaired | No (Deemed to reject) | |||
| Class 12 |
Intercompany Interests |
Impaired / Unimpaired | No (Presumed to accept or deemed reject) | |||
| E. | What will I receive from the Debtors if the Prepackaged Plan is consummated? |
The following chart provides a summary of the anticipated recovery to Holders of Claims or Interests under the Prepackaged Plan. Any estimates of Claims or Interests in this Disclosure Statement may vary from the final amounts allowed by the Bankruptcy Court. Your ability to receive distributions under the Prepackaged Plan depends upon the ability of the Debtors to obtain Confirmation and meet the conditions necessary to consummate the Prepackaged Plan. The estimated recoveries shown are illustrative and are based on the Allowed amounts of Claims set forth in the chart and, in the case of the Reorganization Transaction, the Debtors’ and their advisors’ estimates of the value of the consideration to be distributed under the Prepackaged Plan (including the New Common Stock, the MF CVRs, and the rights under the New Royalty Agreement), which are informed by the Marketing and Sale Process rather than by a separate valuation analysis (see Article X.G of this Disclosure Statement). Actual recoveries may vary materially depending on, among other things, which Restructuring Transaction is ultimately consummated pursuant to the Prepackaged Plan (i.e., the Reorganization Transaction or a Sale Transaction), the final Allowed amounts of Claims, and the other factors described in Article VIII of this Disclosure Statement, entitled “Risk Factors.”
6
THE PROJECTED RECOVERIES SET FORTH IN THE TABLE BELOW ARE ESTIMATES ONLY AND THEREFORE ARE SUBJECT TO CHANGE. FOR A COMPLETE DESCRIPTION OF THE DEBTORS’ CLASSIFICATION AND TREATMENT OF CLAIMS AND INTERESTS, REFERENCE SHOULD BE MADE TO THE ENTIRE PREPACKAGED PLAN.4
| SUMMARY OF EXPECTED RECOVERIES | ||||||||
| Class |
Claim/Interest |
Treatment of Claim/Interest |
Projected Allowed Amount of Claims |
Estimated % Recovery Under the Prepackaged Plan | ||||
| 1 | Other Secured Claims | The legal, equitable, and contractual rights of the Holders of Allowed Other Secured Claims are unaltered by the Prepackaged Plan. Each Holder of an Allowed Other Secured Claim shall receive, at the option of the applicable Debtor, with the consent of the Required Consenting Funded Debt Parties: (a) payment in full in Cash of its Allowed Other Secured Claim; (b) the collateral securing its Allowed Other Secured Claim; (c) Reinstatement of its Allowed Other Secured Claim; or (d) such other treatment that renders its Allowed Other Secured Claim Unimpaired in accordance with section 1124 of the Bankruptcy Code. | TBD | 100% | ||||
| 2 | Other Priority Claims | The legal, equitable, and contractual rights of the Holders of Allowed Other Priority Claims are unaltered by the Prepackaged Plan. Except to the extent that a Holder of an Allowed Other Priority Claim agrees to a lesser treatment, each Holder of an Allowed Other Priority Claim shall receive, at the option of the applicable Debtor with the consent of the Required Consenting Funded Debt Parties, (a) payment in full in Cash or (b) such other treatment that renders its Allowed Other Priority Claim Unimpaired in accordance with section 1124 of the Bankruptcy Code. | TBD | 100% | ||||
| 4 | The recoveries set forth below may change based upon changes in the amount of Claims that are Allowed as well as other factors related to the Debtors’ business operations and general economic conditions. |
7
| SUMMARY OF EXPECTED RECOVERIES | ||||||||
| Class |
Claim/Interest |
Treatment of Claim/Interest |
Projected Allowed Amount of Claims |
Estimated % Recovery Under the Prepackaged Plan | ||||
| 3 | 1L Term Loan Claims | In the event of a Reorganization Transaction, each Holder of an Allowed 1L Term Loan Claim shall receive, in full and final satisfaction of such Claim, its Pro Rata share of the 1L Equity Distribution (which shall be, subject to the Restructuring Transactions Memorandum, exchanged in the Merger, substantially concurrently with its issuance, for such Holder’s share of the Merger Consideration).
In the event of a Sale Transaction, each Holder of an Allowed 1L Term Loan Claim shall receive payment in full in Cash, including, for the avoidance of doubt, all principal amounts outstanding under the 1L Credit Agreement and any pre- and postpetition interest at the default rate, fees, redemption premium, expenses, costs, and other charges arising thereunder or related thereto, as applicable.
All distributions to Holders of Allowed 1L Term Loan Claims (in both a Reorganization Transaction and a Sale Transaction) shall be made in accordance with the Intercreditor Agreement. |
$128,981,938.62 5 | 100% | ||||
| 5 | The 1L Term Loan Claims shall be deemed Allowed in the aggregate principal amount of $128,981,938.62, plus all interest at the default rate, fees, redemption premiums, expenses, costs, and other charges due under the 1L Credit Agreement. As of the Petition Date, approximately $146 million is outstanding under the 1L Credit Agreement. |
8
| SUMMARY OF EXPECTED RECOVERIES | ||||||||
| Class |
Claim/Interest |
Treatment of Claim/Interest |
Projected Allowed Amount of Claims |
Estimated % Recovery Under the Prepackaged Plan | ||||
| 4 | 1.5L 2028 Notes Claims | In the event of a Reorganization Transaction, each Holder of an Allowed 1.5L 2028 Notes Claim shall receive, in full and final satisfaction of such Claim, its Pro Rata share of the 1.5L Equity Distribution (which shall be, subject to the Restructuring Transactions Memorandum, exchanged in the Merger, substantially concurrently with its issuance, for such Holder’s share of the Merger Consideration).
In the event of a Sale Transaction, each Holder of an Allowed 1.5L 2028 Notes Claim shall receive payment in full in Cash, including, for the avoidance of doubt, all principal amounts outstanding under the 1.5L 2028 Notes Indenture and any pre- and postpetition interest at the default rate, fees, redemption premium, expenses, costs, and other charges arising thereunder or related thereto, as applicable.
All distributions to Holders of Allowed 1.5L 2028 Notes Claims (in both a Reorganization Transaction and a Sale Transaction) shall be made in accordance with the Intercreditor Agreement and the Collateral Trust Agreement, as applicable. |
$15,648,085.006 | 100% | ||||
| 6 | The 1.5L 2028 Notes Claims shall be deemed Allowed in the aggregate principal amount of $15,648,085.00, plus all interest, fees, redemption premiums, expenses, costs, and other charges due under the 1.5L 2028 Notes Indenture. As of the Petition Date, approximately $16.4 million is outstanding under the 1.5L 2028 Notes, including accrued and unpaid interest. |
9
| SUMMARY OF EXPECTED RECOVERIES | ||||||||
| Class |
Claim/Interest |
Treatment of Claim/Interest |
Projected Allowed Amount of Claims |
Estimated % Recovery Under the Prepackaged Plan | ||||
| 5 | 2L 2029 Notes Claims | In the event of a Reorganization Transaction, each Holder of an Allowed 2L 2029 Notes Claim shall receive, in full and final satisfaction of such Claim, its Pro Rata share of the 2L Equity Distribution (which shall be, subject to the Restructuring Transactions Memorandum, exchanged in the Merger, substantially concurrently with its issuance, for such Holder’s share of the Merger Consideration).
In the event of a Sale Transaction, each Holder of an Allowed 2L 2029 Notes Claim shall receive either (x) payment in full in Cash, including, for the avoidance of doubt, all principal amounts outstanding under the 2L 2029 Notes Indenture and any pre- and postpetition interest at the default rate, fees, redemption premium, expenses, costs, and other charges arising thereunder or related thereto, as applicable, or, if the Successful Bid so provides, (y) payment in accordance with the Successful Bid Mandatory Conditions set forth in Article IV.B of the Prepackaged Plan.
All distributions to Holders of Allowed 2L 2029 Notes Claims (in both a Reorganization Transaction and a Sale Transaction) shall be made in accordance with the Intercreditor Agreement and the Collateral Trust Agreement, as applicable. |
$107,974,339.007 | 78.9%8 | ||||
| 7 | The 2L 2029 Notes Claims shall be deemed Allowed in the aggregate principal amount of $107,974,339.00, plus all interest, fees, redemption premiums, expenses, costs, and other charges due under the 2L 2029 Notes Indenture. As of the Petition Date, approximately $114 million is outstanding under the 2L 2029 Notes, including accrued and unpaid interest. |
| 8 | The estimated recovery shown is illustrative and reflects the recovery to a Holder of a 2L 2029 Notes Claim in a Reorganization Transaction. It is possible a Holder of a 2L 2029 Notes Claim may receive a greater recovery in a hypothetical Sale Transaction from a Qualified Bid that satisfies the Successful Bid Mandatory Conditions, with the ultimate recovery dependent on, among other things, the value of such Qualified Bid. |
10
| SUMMARY OF EXPECTED RECOVERIES | ||||||||
| Class |
Claim/Interest |
Treatment of Claim/Interest |
Projected Allowed Amount of Claims |
Estimated % Recovery Under the Prepackaged Plan | ||||
| 6 | RIFA Claims | In the event of a Reorganization Transaction, each Holder of an Allowed RIFA Claim shall receive, in full and final satisfaction of such Claim, its Pro Rata share of the rights and interests under the New Royalty Agreement.
In the event of a Sale Transaction, each Holder of an Allowed RIFA Claim shall receive, in full and final satisfaction of such Claim, its Pro Rata share of the consideration payable on account of the RIFA Claims under the Successful Bid, which may consist of Cash or non-Cash consideration in such form as is acceptable to the Holders of RIFA Claims in their discretion and shall have a value of not less than $18,750,000.
All distributions to Holders of Allowed RIFA Claims (in both a Reorganization Transaction and a Sale Transaction) shall be made in accordance with the Intercreditor Agreement. |
$113,536,880.009 | 16.5%10 | ||||
| 7 | General Unsecured Claims | The legal, equitable, and contractual rights of the Holders of Allowed General Unsecured Claims are unaltered by the Prepackaged Plan. Except to the extent that a Holder of an Allowed General Unsecured Claim agrees to different treatment, on and after the Effective Date, the Debtors shall continue to pay or dispute each General Unsecured Claim in the ordinary course of business as if the Chapter 11 Cases had never been commenced. | TBD | 100% | ||||
| 8 | Intercompany Claims | Each Allowed Intercompany Claim shall be, at the option of the applicable Debtor with the consent of the Required Consenting Funded Debt Parties, either: (a) Reinstated; (b) canceled, released, and extinguished, and will be of no further force or effect; or (c) otherwise addressed at the option of each applicable Debtor such that Holders of Intercompany Claims will not receive any distribution on account of such Intercompany Claims. | N/A | N/A | ||||
| 9 | The RIFA Claims shall be deemed Allowed in the aggregate amount of $113,536,880.00, plus all fees, expenses, costs, and other charges due under the RIFA as of the Petition Date. As of the Petition Date, the Company’s future royalty obligations under the RIFA totaled approximately $113.5 million. |
| 10 | The estimated recovery shown is illustrative and reflects the recovery to a Holder of a RIFA Claim in a Reorganization Transaction. It is possible a Holder of a RIFA Claim may receive a greater recovery in a hypothetical Sale Transaction from a Qualified Bid that satisfies the Successful Bid Mandatory Conditions, with the ultimate recovery dependent on, among other things, the value of such Qualified Bid. |
11
| SUMMARY OF EXPECTED RECOVERIES | ||||||||
| Class |
Claim/Interest |
Treatment of Claim/Interest |
Projected Allowed Amount of Claims |
Estimated % Recovery Under the Prepackaged Plan | ||||
| 9 | Existing Preferred Interests | All Existing Preferred Interests shall be canceled, released, and extinguished and will be of no further force or effect. | N/A | 0% | ||||
| 10 | Existing Common Stock Interests | All Existing Common Stock Interests shall be canceled, released, and extinguished and will be of no further force or effect. | N/A | 0% | ||||
| 11 | Other Equity Interests | Holders of Other Equity Interests will not receive any distribution on account of such Interests, which will be canceled, released, and extinguished as of the Effective Date, and will be of no further force or effect. | N/A | 0% | ||||
| 12 | Intercompany Interests | Each Intercompany Interest shall be, at the option of the applicable Debtor with the consent of the Required Consenting Funded Debt Parties, either: (a) Reinstated; (b) canceled, released, and extinguished, and will be of no further force or effect; or (c) otherwise addressed at the option of each applicable Debtor such that Holders of Intercompany Interests will not receive any distribution on account of such Intercompany Interests. | N/A | N/A | ||||
| F. | What will I receive from the Debtors if I hold an Allowed Administrative Claim, DIP Claim, Professional Fee Claim, or a Priority Tax Claim? |
In accordance with section 1123(a)(1) of the Bankruptcy Code, Administrative Claims, DIP Claims, Professional Fee Claims, Restructuring Expenses, and Priority Tax Claims have not been classified and, thus, are excluded from the Classes of Claims and Interests set forth in Article III of the Prepackaged Plan. Such Claims will be satisfied as set forth in Article II of the Prepackaged Plan, as summarized below.
12
| 1. | Administrative Claims. |
Subject to the provisions of sections 328, 330(a), and 331 of the Bankruptcy Code, unless otherwise agreed to by the Holder of an Allowed Administrative Claim and the Debtors or the Reorganized Debtors, as applicable, or otherwise provided for under the Prepackaged Plan or the Restructuring Support Agreement, each Holder of an Allowed Administrative Claim (other than Holders of Professional Fee Claims and Claims for fees and expenses pursuant to section 1930 of chapter 123 of title 28 of the United States Code) will receive in full and final satisfaction of its Allowed Administrative Claim an amount of Cash equal to the amount of such Allowed Administrative Claim in accordance with the following: (1) if an Administrative Claim is Allowed on or prior to the Effective Date, on the Effective Date or as soon as reasonably practicable thereafter (or, if not then due, when such Allowed Administrative Claim is due or as soon as reasonably practicable thereafter); (2) if such Administrative Claim is not Allowed as of the Effective Date, no later than thirty (30) days after the date on which an order allowing such Administrative Claim becomes a Final Order, or as soon as reasonably practicable thereafter; (3) if such Allowed Administrative Claim is based on liabilities incurred by the Debtors in the ordinary course of their business after the Petition Date, in accordance with the terms and conditions of the particular transaction giving rise to such Allowed Administrative Claim without any further action by the Holder of such Allowed Administrative Claim; (4) at such time and upon such terms as may be agreed upon by such Holder and the Debtors or the Reorganized Debtors, as applicable, and as is consistent with the DIP Budget or otherwise with the consent of the Required Consenting Funded Debt Parties; or (5) at such time and upon such terms as set forth in an order of the Bankruptcy Court.
| 2. | DIP Claims. |
On the Effective Date, except to the extent that a Holder of an Allowed DIP Claim agrees to less favorable treatment, in full and final satisfaction, settlement, release, and discharge of each Allowed DIP Claim, including, for the avoidance of doubt, all Claims in respect of the outstanding principal amount of DIP Loans and any accrued but unpaid interest thereon and any fees and expenses payable under the DIP Facility Documents, each Holder of an Allowed DIP Claim shall receive:
(a) in the event of the Reorganization Transaction, (i) on account of its Allowed DIP New Money Claims, payment in Cash of its Pro Rata share of (1) up to $50,000,000 of Cash loan proceeds funded under the NewCo Facility plus (2) any unrestricted Cash (excluding, for the avoidance of doubt, proceeds of the NewCo Facility) on the balance sheet of the Debtors upon the consummation of the Reorganization Transaction after funding (A) the Carve-Out, (B) the amounts to be deposited into the German RemainCo Winddown Account, (C) the amounts that the Debtors have reasonably estimated are necessary to pay Allowed Administrative Claims (including any amounts for Professionals and other professional advisors, including Professional Fee Claims in the amount of the Professional Fee Amount and the Restructuring Expenses), and (D) the amounts set forth in the DIP Budget allocated to Allowed General Unsecured Claims that have not yet been paid (collectively, the purposes in the foregoing clauses (A) through (D), the “Reserved Purposes”), plus (3) after payment of amounts for the Reserved
13
Purposes, any remaining unrestricted Cash on the balance sheet of the Debtors, (ii) on account of its Allowed Equitized DIP New Money Claims, its Pro Rata share of the DIP New Money Equity Distribution, and (iii) on account of its Allowed DIP Roll-Up Claims, its Pro Rata share of the DIP Roll-Up Equity Distribution; and
(b) in the event of a Sale Transaction, payment in full in Cash from the proceeds of the Sale Transaction on the Effective Date.
For the avoidance of doubt, the Holders of Allowed DIP Claims shall not be deemed to have waived their right to have the DIP Claims paid in full in Cash in connection with any transaction or chapter 11 plan other than the Reorganization Transaction.
| 3. | Professional Fee Claims. |
Professional Fee Claims will be satisfied as set forth in Article II.C of the Prepackaged Plan, as summarized herein.
| a. | Final Fee Applications and Payment of Professional Fee Claims. |
All requests for payment of Professional Fee Claims for services rendered and reimbursement of expenses incurred through and including the Confirmation Date must be Filed no later than forty-five (45) days after the Effective Date. The Bankruptcy Court shall determine the Allowed amounts of such Professional Fee Claims after notice and a hearing in accordance with the procedures established by the Bankruptcy Court. The Reorganized Debtors or the Post-Effective Date Debtors, as applicable, shall pay Professional Fee Claims in Cash in the amount the Bankruptcy Court allows, including from the Professional Fee Account, which the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, will establish in trust for the Professionals and fund with Cash equal to the Professional Fee Amount on the Effective Date.
| b. | Professional Fee Account. |
On the Effective Date, the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, shall establish and fund the Professional Fee Account with Cash equal to the Professional Fee Amount. The Professional Fee Account shall be funded from the proceeds of the DIP Facility or the Debtors’ Cash on hand, and NewCo shall not be responsible for any Professional Fee Claims (including any earned and payable restructuring, sale, success, or other transaction or similar fee). The Professional Fee Account shall be maintained solely for the Professionals. The amount of Allowed Professional Fee Claims shall be paid in Cash to the Professionals by the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, from the Professional Fee Account as soon as reasonably practicable after such Professional Fee Claims are Allowed. When such Allowed Professional Fee Claims have been paid in full, any remaining amount in the Professional Fee Account shall promptly be paid to the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, without any further action or order of the Bankruptcy Court.
14
| c. | Professional Fee Amount. |
Professionals shall reasonably estimate their unpaid Professional Fee Claims and other unpaid fees and expenses incurred in rendering services to the Debtors before and as of the Effective Date, and shall deliver such estimate to the Debtors no later than five (5) days before the Effective Date; provided that such estimate shall not be deemed to limit the amount of the fees and expenses that are the subject of each Professional’s final request for payment in the Chapter 11 Cases. If a Professional does not provide a timely estimate, the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, may estimate the unpaid and unbilled fees and expenses of such Professional.
| d. | Post-Confirmation Fees and Expenses. |
Except as otherwise specifically provided in the Prepackaged Plan, from and after the Confirmation Date, the Debtors shall, in the ordinary course of business and without any further notice to or action, order, or approval of the Bankruptcy Court, pay in Cash the reasonable and documented legal, professional, or other fees and expenses related to implementation of the Prepackaged Plan and Consummation incurred by the Debtors. Upon the Confirmation Date, any requirement that Professionals comply with sections 327 through 331, 363, and 1103 of the Bankruptcy Code in seeking retention or compensation for services rendered after such date shall terminate, and the Debtors may employ and pay any Professional in the ordinary course of business without any further notice to or action, order, or approval of the Bankruptcy Court.
| 4. | Priority Tax Claims. |
Except to the extent that a Holder of an Allowed Priority Tax Claim agrees to a less favorable treatment, in full and final satisfaction, settlement, release, and discharge of and in exchange for each Allowed Priority Tax Claim, each Holder of such Allowed Priority Tax Claim shall be treated in accordance with the terms set forth in section 1129(a)(9)(C) of the Bankruptcy Code.
| 5. | Payment of Restructuring Expenses. |
The Restructuring Expenses and the outstanding reasonable and documented fees and expenses of the Prepetition Agents incurred, or estimated to be incurred, up to and including the Effective Date (or, with respect to necessary post-Effective Date activities, after the Effective Date), shall be paid in full in Cash on the Effective Date (to the extent not previously paid during the course of the Chapter 11 Cases) in accordance with, and subject to, the terms of the Restructuring Support Agreement (including Section 16.21 thereof), any applicable engagement letter(s), and any DIP Orders, as applicable, without any requirement to File a fee application with the Bankruptcy Court, without the need for itemized time detail, and without any requirement for Bankruptcy Court review or approval; provided that any earned and payable restructuring, sale, success, or other transaction or similar fee included in the Restructuring Expenses shall be paid from the proceeds of the DIP Facility or the Debtors’ Cash on hand, and NewCo shall not be responsible therefor. All Restructuring Expenses to be paid on the Effective Date shall be estimated prior to and as of the Effective Date and such estimates shall be delivered to the Debtors at least five (5) calendar days before the anticipated Effective Date; provided that such estimates
15
shall not be considered an admission or limitation with respect to such Restructuring Expenses. On the Effective Date, or as soon as practicable thereafter, final invoices for all Restructuring Expenses incurred prior to and as of the Effective Date shall be submitted to the Debtors. In addition, the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, shall continue to pay pre- and post-Effective Date Restructuring Expenses related to implementation, consummation, and defense of the Prepackaged Plan, whether incurred before, on, or after the Effective Date, without any requirement for Bankruptcy Court review or approval.
| G. | Are any regulatory approvals required to consummate the Prepackaged Plan? |
The Debtors are evaluating any regulatory approvals that would be required to consummate the Prepackaged Plan, which may include, but are not limited to, the following. To the extent any such regulatory approvals or other authorizations, consents, rulings, or documents are necessary to implement and effectuate the Prepackaged Plan, it is a condition precedent to the Effective Date that they be obtained.
| 1. | Healthcare Regulatory Approvals. |
Consummation of the Prepackaged Plan is not expected to require the prior approval of the FDA or any other healthcare regulatory authority. Parent will remain the holder of the new drug application for XPOVIO® (selinexor) following the Effective Date, and neither the Reorganization Transaction nor the Sale Transaction (if structured as an equity sale) is expected to require a transfer of the Company’s FDA approvals. The Debtors will, however, be required to make certain post-closing notifications and filings with the FDA and with state boards of pharmacy and other state agencies that have issued wholesale distribution, manufacturing, or similar licenses to the Debtors, in order to reflect the change in the Debtors’ ultimate ownership. In the event of a Sale Transaction structured as an asset sale, the Purchaser will be required to obtain or transfer the applicable FDA approvals, state licenses, and other regulatory authorizations necessary to commercialize XPOVIO® (selinexor), and the Sale Transaction Documents are expected to address the allocation of responsibility for such transfers.
| 2. | Antitrust and Foreign Investment Approvals. |
Depending on the value of the transaction and the identity of the parties, the Merger may constitute a reportable transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in which case the Merger could not be consummated until the applicable waiting period under the HSR Act has expired or been terminated. The applicable waiting period is generally 30 days, except that it is 15 days for acquisitions of assets or voting securities of a debtor effected pursuant to section 363(b) of the Bankruptcy Code. The Debtors and Ayrmid are evaluating whether the Merger will require a filing under the HSR Act or any foreign merger control regime, including in Ireland and the European Union. In addition, because Ayrmid is a non-U.S. entity and the equityholders of Ayrmid include non-U.S. persons, the Debtors and Ayrmid are evaluating whether the Merger will require a filing with, or clearance from, the Committee on Foreign Investment in the United States (“CFIUS”). Any Sale Transaction may also be subject to premerger notification under the HSR Act and, to the extent the Purchaser is a foreign person, review by CFIUS, as well as other applicable federal, state, local, or foreign antitrust, competition, foreign investment, or sector-specific approvals. The applicability of any
16
such requirement will depend on, among other things, whether the Debtors pursue the Sale Transaction or the Reorganization Transaction, the size and structure of the applicable transaction, and the nature and ownership of the ultimate acquirer or investor. The Debtors, together with their advisors, intend to make any such filings and obtain any such approvals or clearances as may be required or they deem advisable prior to consummation of the Prepackaged Plan.
| 3. | Securities Law Matters. |
The Existing Common Stock Interests are currently listed on the Nasdaq Global Select Market under the symbol “KPTI,” and the Debtors expect that Nasdaq will suspend trading of the Existing Common Stock Interests and subsequently delist the securities from the Nasdaq Global Select Market. In the event of a Reorganization Transaction, the Existing Common Stock Interests will be canceled, and the Reorganized Debtors will take all actions reasonably necessary, to the extent permitted by applicable law, to delist the Existing Common Stock Interests from Nasdaq (to the extent not previously delisted), to terminate Parent’s registration under section 12 of the Exchange Act, to terminate Parent’s effective registration statements under the Securities Act, and to suspend Parent’s reporting obligations under section 15(d) of the Exchange Act. NewCo will emerge from the Chapter 11 Cases as a privately held company, the New Common Stock and the MF CVRs will not be listed on any securities exchange at the time of consummation of the Reorganization Transaction, and NewCo will not voluntarily report under the Exchange Act or any other reporting requirements promulgated by the SEC. See Article IV.C of this Disclosure Statement, entitled “The Prepackaged Plan,” and Article XI of this Disclosure Statement, entitled “Certain Securities Law Matters.”
| H. | What happens to my recovery if the Prepackaged Plan is not confirmed or does not go effective? |
In the event that the Prepackaged Plan is not confirmed or does not go effective, there is no assurance that the Debtors will be able to reorganize their businesses or consummate any sale transaction. It is possible that any alternative may provide Holders of Claims and Interests with less than they would have received pursuant to the Prepackaged Plan. For a more detailed description of the consequences of an extended chapter 11 case, see Article VIII.A of this Disclosure Statement, entitled “Bankruptcy Law Considerations.” For a more detailed description of a liquidation scenario, see Article X.C of this Disclosure Statement, entitled “Best Interests of Creditors/Liquidation Analysis,” and the Liquidation Analysis attached hereto as Exhibit D.
| I. | If the Prepackaged Plan provides that I get a distribution, do I get it upon Confirmation or when the Prepackaged Plan goes effective, and what is meant by “Confirmation,” “Effective Date,” and “Consummation?” |
“Confirmation” of the Prepackaged Plan refers to approval of the Prepackaged Plan by the Bankruptcy Court. Confirmation of the Prepackaged Plan does not guarantee that you will receive the distribution indicated under the Prepackaged Plan. After Confirmation of the Prepackaged Plan by the Bankruptcy Court, there are conditions that need to be satisfied or waived so that the Prepackaged Plan can go effective.
17
Initial distributions to Holders of Allowed Claims will only be made on the date the Prepackaged Plan becomes effective—the “Effective Date”—or as soon as reasonably practicable thereafter, as specified in the Prepackaged Plan.
“Consummation” of the Prepackaged Plan refers to the occurrence of the Effective Date. See Article IV.C of this Disclosure Statement, entitled “The Prepackaged Plan,” and Article X of this Disclosure Statement, entitled “Confirmation of the Prepackaged Plan,” for a discussion of the conditions precedent to Consummation of the Prepackaged Plan, which, in the event of a Reorganization Transaction, include the consummation of the Merger substantially concurrently with the Effective Date.
| J. | What are the sources of Cash and other consideration required to fund the Prepackaged Plan? |
The Debtors, the Reorganized Debtors, or Post-Effective Date Debtors, as applicable, shall fund distributions under the Prepackaged Plan with (a) the Debtors’ Cash on hand, (b) Cash generated from operations, (c) if the Reorganization Transaction is consummated, the Reorganized Parent Common Stock, the DIP Facility, and the NewCo Facility, and (d) if the Sale Transaction is consummated, the proceeds of the Sale Transaction.
| K. | Are there risks to owning the New Common Stock and the MF CVRs upon emergence from chapter 11? |
Yes. See Article VIII of this Disclosure Statement, entitled “Risk Factors,” including Article VIII.C, entitled “Risks Related to the Merger and the Consideration to Be Issued in a Reorganization Transaction.”
| L. | Is there potential litigation related to the Prepackaged Plan? |
Yes. Parties in interest may object to the approval of this Disclosure Statement and may object to Confirmation of the Prepackaged Plan as well, which objections potentially could give rise to litigation.
In the event that it becomes necessary to confirm the Prepackaged Plan over the rejection of certain Classes, the Debtors may seek confirmation of the Prepackaged Plan notwithstanding the dissent of such rejecting Classes. The Bankruptcy Court may confirm the Prepackaged Plan pursuant to the “cramdown” provisions of the Bankruptcy Code, which allow the Bankruptcy Court to confirm a plan that has been rejected by an impaired Class if it determines that the Prepackaged Plan satisfies section 1129(b) of the Bankruptcy Code. The Prepackaged Plan provides that section 1129(a)(10) of the Bankruptcy Code will be satisfied for purposes of Confirmation by acceptance of the Prepackaged Plan by one or more of the Classes entitled to vote. Because Classes 9, 10, and 11 are deemed to reject the Prepackaged Plan, the Debtors will seek nonconsensual Confirmation of the Prepackaged Plan with respect to such Classes. See Article X.F of this Disclosure Statement, entitled “Confirmation Without Acceptance by All Impaired Classes.”
18
| M. | Will the final amount of Allowed General Unsecured Claims affect the recovery of Holders of Allowed General Unsecured Claims under the Prepackaged Plan? |
No. The legal, equitable, and contractual rights of the Holders of Allowed General Unsecured Claims are unaltered by the Prepackaged Plan. Except to the extent that a Holder of an Allowed General Unsecured Claim agrees to different treatment, on and after the Effective Date, the Debtors shall continue to pay or dispute each General Unsecured Claim in the ordinary course of business as if the Chapter 11 Cases had never been commenced. In the event of a Sale Transaction, all Allowed General Unsecured Claims will be paid in full in Cash or otherwise rendered Unimpaired, as required by the Successful Bid Mandatory Conditions.
| N. | How will the preservation of the Causes of Action impact my recovery under the Prepackaged Plan? |
The Prepackaged Plan provides for the retention of all Causes of Action other than those that are expressly waived, relinquished, exculpated, released, compromised, or settled.
In accordance with section 1123(b) of the Bankruptcy Code, but subject to Article VIII of the Prepackaged Plan, each Reorganized Debtor or Post-Effective Date Debtor, as applicable, shall retain and may enforce all rights to commence and pursue, as appropriate, any and all Causes of Action of the Debtors, whether arising before or after the Petition Date, including any actions specifically enumerated in the Schedule of Retained Causes of Action, and the Reorganized Debtors’ and Post-Effective Date Debtors’ rights to commence, prosecute, or settle such Causes of Action shall be preserved notwithstanding the occurrence of the Effective Date, other than the Causes of Action released by the Debtors pursuant to the releases and exculpations contained in the Prepackaged Plan, including in Article VIII of the Prepackaged Plan, which shall be deemed released and waived by the Debtors and the Reorganized Debtors (or Post-Effective Date Debtors, as applicable) as of the Effective Date.
The Reorganized Debtors or Post-Effective Date Debtors, as applicable, may pursue such retained Causes of Action, as appropriate, in accordance with the best interests of the Reorganized Debtors or Post-Effective Date Debtors. No Entity (other than the Released Parties) may rely on the absence of a specific reference in the Prepackaged Plan, the Plan Supplement, or this Disclosure Statement to any Cause of Action against it as any indication that the Debtors or the Reorganized Debtors (or Post-Effective Date Debtors), as applicable, will not pursue any and all available Causes of Action of the Debtors against it. The Debtors and Reorganized Debtors (or Post-Effective Date Debtors, as applicable) expressly reserve all rights to prosecute any and all Causes of Action against any Entity, except as otherwise expressly provided in the Prepackaged Plan, including Article VIII of the Prepackaged Plan. Unless any Causes of Action of the Debtors against an Entity are expressly waived, relinquished, exculpated, released, compromised, or settled in the Prepackaged Plan or a Final Order, the Reorganized Debtors and Post-Effective Date Debtors expressly reserve all Causes of Action, for later adjudication, and, therefore, no preclusion doctrine, including the doctrines of res judicata, collateral estoppel, issue preclusion, claim preclusion, estoppel (judicial, equitable, or otherwise), or laches, shall apply to such Causes of Action upon, after, or as a consequence of the Confirmation or Consummation. For the avoidance of doubt, the Debtors and the Reorganized Debtors (or Post-
19
Effective Date Debtors, as applicable) do not reserve any Causes of Action that have been expressly released or exculpated pursuant to the Prepackaged Plan (including, for the avoidance of doubt, Claims and Causes of Action against the Consenting Stakeholders released pursuant to the releases by the Debtors provided in Article VIII.C of the Prepackaged Plan and the exculpation contained in Article VIII.E of the Prepackaged Plan).
The Reorganized Debtors and Post-Effective Date Debtors reserve and shall retain such Causes of Action of the Debtors notwithstanding the rejection or repudiation of any Executory Contract or Unexpired Lease during the Chapter 11 Cases or pursuant to the Prepackaged Plan. In accordance with section 1123(b)(3) of the Bankruptcy Code, any Causes of Action that a Debtor may hold against any Entity shall vest in the Reorganized Debtors or Post-Effective Date Debtors, except as otherwise expressly provided in the Prepackaged Plan, including Article VIII of the Prepackaged Plan. The applicable Reorganized Debtors or Post-Effective Date Debtors, through their authorized agents or representatives, shall retain and may exclusively enforce any and all such Causes of Action. The Reorganized Debtors or Post-Effective Date Debtors shall have the exclusive right, authority, and discretion to determine and to initiate, file, prosecute, enforce, abandon, settle, compromise, release, withdraw, or litigate to judgment any such Causes of Action and to decline to do any of the foregoing without the consent or approval of any third party or further notice to or action, order, or approval of the Bankruptcy Court.
| O. | Will there be releases and exculpation granted to parties in interest as part of the Prepackaged Plan? |
Yes. The Prepackaged Plan proposes to release the Released Parties and to exculpate the Exculpated Parties. The Debtors will also seek findings of fact and conclusions of law with regard to officers’ and directors’ performance of their duties as officers and directors of the Debtors. The Debtors’ releases, third-party releases, exculpation, and injunction provisions included in the Prepackaged Plan are an integral part of the Debtors’ overall restructuring efforts and were an essential element of the negotiations among the Debtors and the Consenting Stakeholders in obtaining their support for the Prepackaged Plan pursuant to the terms of the Restructuring Support Agreement.
The Released Parties and the Exculpated Parties have made substantial and valuable contributions to the Debtors’ restructuring through efforts to negotiate and implement the Prepackaged Plan, which will maximize and preserve the going-concern value of the Debtors for the benefit of all parties in interest. Accordingly, each of the Released Parties and the Exculpated Parties warrants the benefit of the release and exculpation provisions.
IMPORTANTLY, THE FOLLOWING PARTIES ARE INCLUDED IN THE DEFINITION OF “RELEASING PARTIES” AND WILL BE DEEMED TO HAVE EXPRESSLY, UNCONDITIONALLY, INDIVIDUALLY, AND COLLECTIVELY RELEASED AND DISCHARGED ALL CLAIMS AND CAUSES OF ACTION AGAINST THE DEBTORS AND THE RELEASED PARTIES: (A) EACH DEBTOR; (B) EACH REORGANIZED DEBTOR OR POST-EFFECTIVE DATE DEBTOR, AS APPLICABLE; (C) NEWCO; (D) THE PREPETITION AGENTS; (E) EACH CONSENTING STAKEHOLDER; (F) EACH CONSENTING ROYALTY INVESTOR; (G) EACH CONSENTING PREFERRED SHAREHOLDER; (H) THE DIP LENDERS; (I) THE DIP AGENT; (J) AYRMID; (K) ALL
20
HOLDERS OF CLAIMS OR INTERESTS THAT VOTE TO ACCEPT THE PREPACKAGED PLAN; (L) ALL HOLDERS OF CLAIMS OR INTERESTS THAT ARE DEEMED TO ACCEPT THE PREPACKAGED PLAN WHO DO NOT AFFIRMATIVELY OPT OUT OF THE RELEASES PROVIDED BY THE PREPACKAGED PLAN BY CHECKING THE BOX ON THE APPLICABLE NOTICE OF NON-VOTING STATUS INDICATING THAT THEY OPT NOT TO GRANT THE RELEASES PROVIDED IN THE PREPACKAGED PLAN; (M) ALL HOLDERS OF CLAIMS OR INTERESTS THAT ABSTAIN FROM VOTING ON THE PREPACKAGED PLAN AND WHO DO NOT AFFIRMATIVELY OPT OUT OF THE RELEASES PROVIDED BY THE PREPACKAGED PLAN BY CHECKING THE BOX ON THE APPLICABLE BALLOT INDICATING THAT THEY OPT NOT TO GRANT THE RELEASES PROVIDED IN THE PREPACKAGED PLAN; (N) ALL HOLDERS OF CLAIMS OR INTERESTS THAT VOTE TO REJECT THE PREPACKAGED PLAN AND WHO DO NOT AFFIRMATIVELY OPT OUT OF THE RELEASES PROVIDED BY THE PREPACKAGED PLAN BY CHECKING THE BOX ON THE APPLICABLE BALLOT OR NOTICE OF NON-VOTING STATUS, AS APPLICABLE, INDICATING THAT THEY OPT NOT TO GRANT THE RELEASES PROVIDED IN THE PREPACKAGED PLAN; (O) ALL HOLDERS OF CLAIMS OR INTERESTS THAT ARE DEEMED TO REJECT THE PREPACKAGED PLAN AND WHO AFFIRMATIVELY OPT IN TO THE RELEASES PROVIDED BY THE PREPACKAGED PLAN BY CHECKING THE BOX ON THE APPLICABLE NOTICE OF NON-VOTING STATUS INDICATING THAT THEY OPT TO GRANT THE RELEASES PROVIDED IN THE PREPACKAGED PLAN; (P) EACH CURRENT AND FORMER AFFILIATE OF EACH ENTITY IN THE FOREGOING CLAUSES (A) THROUGH (O); AND (Q) EACH RELATED PARTY OF EACH ENTITY IN CLAUSES (A) THROUGH (P).
Based on the foregoing, the Debtors believe that the releases and exculpations in the Prepackaged Plan are necessary and appropriate and meet the requisite legal standard promulgated by the United States Court of Appeals for the Fifth Circuit. Moreover, the Debtors will present evidence at the Combined Hearing to demonstrate the basis for and propriety of the release and exculpation provisions. The release, exculpation, and injunction provisions that are contained in the Prepackaged Plan are copied in pertinent part below.
| 1. | Release of Liens. |
Except as otherwise provided in the Prepackaged Plan, the Restructuring Support Agreement, the Confirmation Order, the Purchase Agreement, or in any contract, instrument, release, or other agreement or document amended or created pursuant to the Prepackaged Plan, on the Effective Date and concurrently with the applicable distributions made pursuant to the Prepackaged Plan and, in the case of a Secured Claim, satisfaction in full of the portion of the Secured Claim that is Allowed as of the Effective Date, except for Other Secured Claims that the Debtors elect to Reinstate in accordance with the Prepackaged Plan, all mortgages, deeds of trust, Liens, pledges, or other security interests against any property of the Estates shall be fully released and discharged, and all of the right, title, and interest of any holder of such mortgages, deeds of trust, Liens, pledges, or other security interests shall revert to the Reorganized Debtors or Post-Effective Date Debtors and their successors and assigns. Any Holder of such Secured Claim (and the applicable agents for such Holder) shall be authorized and directed, at the sole cost and expense of the
21
Reorganized Debtors or Post-Effective Date Debtors, to release any collateral or other property of any Debtor (including any Cash Collateral and possessory collateral) held by such Holder (and the applicable agents for such Holder), and to take such actions as may be reasonably requested by the Reorganized Debtors or Post-Effective Date Debtors to evidence the release of such Liens or security interests, including the execution, delivery, and filing or recording of such releases. The presentation or filing of the Confirmation Order to or with any federal, state, provincial, or local agency, records office, or department shall constitute good and sufficient evidence of, but shall not be required to effect, the termination of such Liens.
To the extent that any Holder of a Secured Claim that has been satisfied or discharged in full pursuant to the Prepackaged Plan, or any agent for such Holder, has filed or recorded publicly any Liens or security interests to secure such Holder’s Secured Claim, then as soon as practicable on or after the Effective Date, such Holder (or the agent for such Holder) shall take any and all steps requested by the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors that are necessary or desirable to record or effectuate the cancellation or extinguishment of such Liens or security interests, including the making of any applicable filings or recordings, and the Reorganized Debtors or Post-Effective Date Debtors shall be entitled to make any such filings or recordings on such Holder’s behalf.
| 2. | Releases by the Debtors. |
Notwithstanding anything contained in the Prepackaged Plan to the contrary, effective as of the Effective Date, pursuant to section 1123(b) of the Bankruptcy Code, for good and valuable consideration, including the obligations of the Debtors under the Prepackaged Plan and the contributions and services of the Released Parties in facilitating the implementation of the Restructuring Transactions, the adequacy of which is hereby confirmed, to the fullest extent allowed by applicable Law, each Released Party is hereby deemed conclusively, absolutely, unconditionally, irrevocably, and forever released, waived and discharged by each and all of the Debtors, their Estates, the Reorganized Debtors, the Post-Effective Date Debtors, the Post-Effective Date Plan Administrator, and any Person seeking to exercise the rights of the Debtors or their Estates, including any successors to the Debtors or any Estate representative appointed or selected pursuant to section 1123(b)(3) of the Bankruptcy Code, each of their respective current and former Affiliates, in each case on behalf of themselves and their Related Parties who may purport to assert any Claim or Cause of Action, directly or derivatively, by, through, for, or because of the foregoing Entities, from any and all Claims, Interests, and Causes of Action, and liabilities whatsoever, including any derivative claims, asserted by or assertable on behalf of any of the Debtors, their Estates, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, whether known or unknown, foreseen or unforeseen, asserted or unasserted, matured or unmatured, suspected or unsuspected, existing or hereinafter arising, contingent or non-contingent, liquidated or unliquidated, secured or unsecured, assertable, directly or derivatively, in Law (or any applicable rule, statute, regulation, treaty, right, duty or requirement), equity, contract, tort, or otherwise, that the Debtors, their Estates, the Reorganized Debtors, or the Post-Effective Date Debtors would have been legally entitled to assert in their own right (whether individually or collectively) or on behalf of the Holder of any Claim against, or Interest in, a Debtor or other Entity, or that any Holder of any Claim against, or Interest in, a Debtor or
22
other Entity could have asserted on behalf of the Debtors, based on or relating to (including the formulation, preparation, dissemination, negotiation, entry into, or filing of, as applicable), or in any manner arising from, in whole or in part, the Company-Related Matters, including the Prepetition Funded Debt Claims and the documents governing the same, the DIP Facility, the DIP Facility Documents, the DIP Orders, the ownership and/or operation of the Debtors by any Released Party or the distribution of any Cash or other property of the Debtors to any Released Party, the assertion or enforcement of rights and remedies against the Debtors, any Avoidance Actions (but excluding Avoidance Actions brought as counterclaims or defenses to Claims asserted against the Debtors), and any claim or Cause of Action seeking lender liability or challenging the validity, enforceability, priority, scope, extent, or perfection of, or seeking the recharacterization, subordination, disallowance, or avoidance of, any Claims or Liens held by any Released Party. Notwithstanding anything to the contrary in the foregoing, the releases set forth above do not release (1) any obligations arising on or after the Effective Date of any party or Entity under the Definitive Documents, or any document, instrument, or agreement (including those set forth in the Plan Supplement) executed to implement the Prepackaged Plan; or (2) any Causes of Action included in the Schedule of Retained Causes of Action; provided that in no event shall any Cause of Action included in the Schedule of Retained Causes of Action be asserted against any Consenting Stakeholder, the DIP Agent, any DIP Lender, any Prepetition Agent, or any Ad Hoc Group Advisor or Ayrmid Advisor, or any of their respective Related Parties, in each case in their capacities as such.
Entry of the Confirmation Order shall constitute the Bankruptcy Court’s approval, pursuant to Bankruptcy Rule 9019, of the Debtor Release, which includes by reference each of the related provisions and definitions contained in the Prepackaged Plan and, further, shall constitute the Bankruptcy Court’s finding that the Debtor Release is: (i) in exchange for good and valuable consideration provided by the Released Parties, including the Released Parties’ substantial contributions to facilitating the Restructuring Transactions and implementing the Prepackaged Plan; (ii) a good faith settlement and compromise of the Claims or Causes of Action released by the Debtor Release; (iii) in the best interests of the Debtors, their Estates, and all Holders of Claims and Interests; (iv) fair, equitable, and reasonable; (v) given and made after reasonable investigation by the Debtors and after due notice and opportunity for a hearing; and (vi) a bar to any of the Debtors, their Estates, the Reorganized Debtors, the Post-Effective Date Debtors, the Post-Effective Date Plan Administrator, or any Person seeking to exercise the rights of the Debtors or their Estates asserting any Claim or Cause of Action released pursuant to the Debtor Release.
| 3. | Releases by the Releasing Parties. |
Effective as of the Effective Date, in exchange for good and valuable consideration, the adequacy of which is hereby confirmed, to the fullest extent allowed by applicable Law, each of the Releasing Parties shall be deemed to have conclusively, absolutely, unconditionally, irrevocably, and forever, released, waived, and discharged each of the Released Parties from any and all Claims, Causes of Action, and liabilities whatsoever, including any derivative claims asserted by or assertable on behalf of any Releasing Party, whether known or unknown, foreseen or unforeseen, asserted or unasserted, matured or unmatured, suspected or unsuspected, existing or hereinafter arising, contingent or non-
23
contingent, liquidated or unliquidated, secured or unsecured, assertable, directly or derivatively, in Law (or any applicable rule, statute, regulation, treaty, right, duty or requirement), equity, contract, tort, or otherwise, that such Releasing Party would have been legally entitled to assert in its own right (whether individually or collectively) or on behalf of the Holder of any Claim against, or Interest in, a Released Party, or that any Holder of any Claim against, or Interest in, a Released Party could have asserted on behalf of the Releasing Party, or otherwise based on or relating to (including the formulation, preparation, dissemination, negotiation, entry into, or filing of, as applicable), or in any manner arising from, in whole or in part, the Company-Related Matters; provided that, with respect to Claims against the Debtors, Article VIII.D of the Prepackaged Plan shall only apply to Claims arising from any act or omission, transaction, agreement, event, or other occurrence taking place from and including the Petition Date through the Effective Date. Notwithstanding anything to the contrary in the foregoing, the releases set forth above do not release (a) any obligations arising on or after the Effective Date of any party or Entity under the Definitive Documents, or any document, instrument, or agreement (including those set forth in the Plan Supplement) executed to implement the Prepackaged Plan; or (b) any Causes of Action included in the Schedule of Retained Causes of Action.
Entry of the Confirmation Order shall constitute the Bankruptcy Court’s approval, pursuant to Bankruptcy Rule 9019, of the Third-Party Release, which includes by reference each of the related provisions and definitions contained in the Prepackaged Plan, and, further, shall constitute the Bankruptcy Court’s finding that the Third-Party Release is: (i) an integrated and global good faith compromise and settlement that is non-severable from the provisions of the Prepackaged Plan; (ii) consensual; (iii) essential to the confirmation of the Prepackaged Plan; (iv) given in exchange for the good and valuable consideration provided by the Released Parties, including the Released Parties’ contributions to facilitating the restructuring and implementing the Prepackaged Plan; (v) a good faith settlement and compromise of the Claims or Causes of Action released by the Third-Party Release; (vi) in the best interests of the Debtors and their Estates; (vii) fair, equitable, and reasonable; (viii) given and made after due notice and opportunity for a hearing; and (ix) a bar to any of the Releasing Parties asserting any Claim or Cause of Action released pursuant to the Third-Party Release.
| 4. | Exculpation. |
Effective as of the Effective Date, to the fullest extent permissible under applicable Law and without affecting or limiting either the Debtor Release or the Third-Party Release, and except as otherwise specifically provided in the Prepackaged Plan or the Confirmation Order, no Exculpated Party shall have or incur liability for, and each Exculpated Party hereby is exculpated from any Claim or Cause of Action arising during the period from the Petition Date to the Effective Date, whether direct or derivative, related to, any act or omission in connection with, relating to, or arising out of the negotiation, solicitation, confirmation, execution, or implementation (to the extent on or prior to the Effective Date) of, as applicable, the Company-Related Matters, but in all respects such Entities shall be entitled to reasonably rely on the advice of counsel with respect to their duties and responsibilities pursuant to the Definitive Documents. Notwithstanding anything to the contrary in the foregoing, an Exculpated Party shall be entitled to exculpation solely for
24
actions taken from the Petition Date through the Effective Date, and the exculpation set forth above does not exculpate (a) any obligations arising pursuant to or after the Effective Date of any party or Entity under the Prepackaged Plan, the Confirmation Order, or any document, instrument, or agreement (including those set forth in the Plan Supplement) executed to implement the Prepackaged Plan; or (b) any Causes of Action included in the Schedule of Retained Causes of Action.
The Exculpated Parties and other parties set forth above have, and upon confirmation of the Prepackaged Plan shall be deemed to have, participated in good faith and in compliance with the applicable Laws with regard to the solicitation of votes and distribution of consideration pursuant to the Prepackaged Plan and, therefore, are not, and on account of such distributions shall not be, liable at any time for the violation of any applicable Law, rule, or regulation governing the solicitation of acceptances or rejections of the Prepackaged Plan or such distributions made pursuant to the Prepackaged Plan.
Solely with respect to the exculpation provision, notwithstanding anything to the contrary in the Prepackaged Plan or Plan Supplement, each of the 1125(e) Exculpated Parties shall not incur liability for any Cause of Action or Claim related to any act or omission in connection with, relating to, or arising out of, in whole or in part, (a) the solicitation of acceptance or rejection of the Prepackaged Plan in good faith and in compliance with the applicable provisions of the Bankruptcy Code or (b) the participation, in good faith and in compliance with the applicable provisions of the Bankruptcy Code, in the offer, issuance, sale, or purchase of a security, offered or sold under the Prepackaged Plan. No Entity or Person may commence or pursue a Claim or Cause of Action of any kind against any of the Exculpated Parties or the 1125(e) Exculpated Parties that arose or arises from, in whole or in part, a Claim or Cause of Action subject to this paragraph, without the Bankruptcy Court specifically authorizing such Entity or Person to bring such Claim or Cause of Action against such Exculpated Party or 1125(e) Exculpated Party. The Bankruptcy Court will have sole and exclusive jurisdiction to adjudicate the underlying colorable Claim or Cause of Action.
| 5. | Injunction. |
Except as otherwise expressly provided in the Prepackaged Plan, or for obligations issued or required to be paid pursuant to the Prepackaged Plan or the Confirmation Order, all Entities who have held, hold, or may hold Claims and Causes of Action, and liabilities whatsoever, including any derivative claims, whether known or unknown, foreseen or unforeseen, matured or unmatured, suspected or unsuspected, existing or hereinafter arising, contingent or non-contingent, liquidated or unliquidated, secured or unsecured, assertable, directly or derivatively, in law (or any applicable rule, statute, regulation, treaty, right, duty or requirement), equity, contract, tort, or otherwise, asserted or assertable on behalf of any of the Debtors, their Estates, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, that have been released, settled, or are subject to exculpation are permanently enjoined, from and after the Effective Date, from taking any of the following actions against, as applicable, the Debtors, the Exculpated Parties, or the Released Parties: (a) commencing or continuing in any manner any action or other proceeding of any kind on account of or in connection with or with respect to any such Claims or Interests;
25
(b) enforcing, attaching, collecting, or recovering by any manner or means any judgment, award, decree, or order against such Entities on account of or in connection with or with respect to any such Claims or Interests; (c) creating, perfecting, or enforcing any encumbrance of any kind against such Entities, such property, or the property or the estates of such Entities on account of or in connection with or with respect to any such Claims or Interests; (d) asserting any right of setoff, subrogation, or recoupment of any kind, except to the extent such assertions are used as a defense to Claims or Causes of Action by the Debtors arising prior to the Effective Date, against any obligation due from such Entities or against the property of such Entities on account of or in connection with or with respect to any such Claims or Interests unless such Holder has Filed a motion requesting the right to perform such setoff on or before the Confirmation Date, and notwithstanding an indication of a claim or interest or otherwise that such Holder asserts, has, or intends to preserve any right of setoff pursuant to applicable law or otherwise; and (e) commencing or continuing in any manner any action or other proceeding of any kind on account of or in connection with or with respect to any such Claims or Interests released or settled pursuant to the Prepackaged Plan.
No Person or Entity may commence, continue, amend or pursue a Claim or Cause of Action, as applicable, of any kind against the Debtors, the Reorganized Debtors, the Post-Effective Date Debtors, the Exculpated Parties, or the Released Parties, as applicable, that relates to or is reasonably likely to relate to any act or omission in connection with, relating to, or arising out of a Claim or Cause of Action, as applicable, subject to Article VIII.C, Article VIII.D, Article VIII.E, and Article VIII.F of the Prepackaged Plan, without the Bankruptcy Court (a) first determining, after notice and a hearing, that such Claim or Cause of Action, as applicable, represents a colorable Claim of any kind, and (b) specifically authorizing such Person or Entity to bring such Claim or Cause of Action, as applicable, against any such Debtor, Reorganized Debtor, Post-Effective Date Debtor, Exculpated Party, or Released Party, as applicable. At such hearing, the Bankruptcy Court, inter alia, may, or shall if any Debtor, Reorganized Debtor, Post-Effective Date Debtor, Exculpated Party, Released Party, or other party in interest requests by motion (oral motion being sufficient), direct that such Person or Entity seeking to commence or pursue such Claim or Cause of Action file a proposed complaint with the Bankruptcy Court embodying such Claim or Cause of Action, such complaint satisfying the applicable Federal Rules of Civil Procedure or Bankruptcy Rules, including, but not limited to, rules 8 and 9 (as applicable) of the Federal Rules of Civil Procedure, which the Bankruptcy Court shall assess before making a determination of whether such Claim or Cause of Action represents a colorable Claim of any kind.
The Bankruptcy Court will have sole and exclusive jurisdiction to adjudicate the underlying colorable Claim or Cause of Action.
Upon entry of the Confirmation Order, all Holders of Claims and Interests and their respective current and former employees, agents, officers, directors, principals, and direct and indirect Affiliates shall be enjoined from taking any actions to interfere with the implementation or Consummation of the Prepackaged Plan. Each Holder of an Allowed Claim or Allowed Interest, as applicable, by accepting, or being eligible to accept, distributions under or Reinstatement of such Allowed Claim or Allowed Interest, as applicable, pursuant to the Prepackaged Plan, shall be deemed to have consented to the injunction provisions set forth in the Prepackaged Plan.
26
For more detail, see Article VIII of the Prepackaged Plan, entitled “Settlement, Release, Injunction, and Related Provisions,” which is incorporated herein by reference.
| P. | What is the deadline to vote on the Prepackaged Plan? |
The Voting Deadline is November 30, 2026, at 4:00 p.m. (prevailing Central Time), unless otherwise extended by the Bankruptcy Court or the Debtors.
| Q. | How do I vote to accept or reject the Prepackaged Plan? |
Detailed instructions regarding how to vote on the Prepackaged Plan are contained on the ballots distributed to Holders of Claims that are entitled to vote on the Prepackaged Plan (each, a “Ballot”). For your vote to be counted, your Ballot must be properly completed, executed, and delivered as directed, so that it is actually received by the Debtors’ proposed claims, noticing, and solicitation agent, Stretto, Inc. (the “Claims and Balloting Agent”), on or before the Voting Deadline, i.e., November 30, 2026, at 4:00 p.m. (prevailing Central Time). In light of the length of the solicitation period, Holders are strongly encouraged to submit their Ballots electronically through the Claims and Balloting Agent’s online portal (the “E-Portal”) at https://cases.stretto.com/KPTI or by electronic mail to the Claims and Balloting Agent in accordance with the instructions set forth on the Ballot. See Article IX of this Disclosure Statement, entitled “Solicitation and Voting,” for more information.
| R. | Why is the Bankruptcy Court holding a Combined Hearing? |
Section 1128(a) of the Bankruptcy Code requires the Bankruptcy Court to hold a hearing on confirmation of the Prepackaged Plan and recognizes that any party in interest may object to Confirmation of the Prepackaged Plan. Section 105(d)(2)(B)(vi) of the Bankruptcy Code, Section P of the Procedures for Complex Cases in the Southern District of Texas, and Bankruptcy Local Rule 3016-2 allow the Bankruptcy Court to combine the hearing on the adequacy of this Disclosure Statement and the hearing to confirm the Prepackaged Plan. The Debtors also intend to file with the Bankruptcy Court, in advance of the first day hearing, a preliminary declaration of the Claims and Balloting Agent setting forth the results of the Solicitation as of the Petition Date and, following the Voting Deadline, a final declaration setting forth the final tabulation of votes. All parties in interest will be served notice of the time, date, and location of the Combined Hearing once scheduled. The Combined Hearing may be adjourned from time to time without further notice.
| S. | What is the purpose of the Combined Hearing? |
The confirmation of a plan of reorganization by a bankruptcy court binds the debtor, any issuer of securities under a plan of reorganization, any person acquiring property under a plan of reorganization, any creditor or equity interest holder of a debtor, and any other person or entity as may be ordered by the bankruptcy court in accordance with the applicable provisions of the Bankruptcy Code. Subject to certain limited exceptions, the order issued by the bankruptcy court confirming a plan of reorganization discharges a debtor from any debt that arose before the confirmation of such plan of reorganization and provides for the treatment of such debt in accordance with the terms of the confirmed plan of reorganization. In addition, in the event of a Sale Transaction, the Debtors intend to seek approval of the Sale Transaction at the Combined Hearing, which may also serve as the Sale Hearing.
27
| T. | What is the effect of the Prepackaged Plan on the Debtors’ ongoing businesses? |
In the event of a Reorganization Transaction, the Debtors are reorganizing under chapter 11 of the Bankruptcy Code, and the occurrence of the Effective Date means that the Debtors will not be liquidated or forced to go out of business; rather, the Company’s business will be combined with Ayrmid’s business under NewCo with a deleveraged balance sheet. Following Confirmation, the Prepackaged Plan will be consummated on the Effective Date, which is the first Business Day after the Confirmation Date on which (a) no stay of the Confirmation Order is in effect and (b) all conditions to Consummation have been satisfied or waived (see Article IX of the Prepackaged Plan), including, in the event of a Reorganization Transaction, the consummation of the Merger substantially concurrently with the Effective Date. On or after the Effective Date, and unless otherwise provided in the Prepackaged Plan, the Reorganized Debtors may operate their businesses and, except as otherwise provided by the Prepackaged Plan, may use, acquire, or dispose of property and compromise or settle any Claims, Interests, or Causes of Action without supervision or approval by the Bankruptcy Court and free of any restrictions of the Bankruptcy Code or Bankruptcy Rules.
In the event of a Sale Transaction, all or substantially all of the Debtors’ assets will be sold to the Successful Bidder, which the Debtors expect would continue to commercialize XPOVIO, and the Debtors’ remaining affairs will be wound down in accordance with the Prepackaged Plan.
In either case, the Debtors expect to continue to operate in the ordinary course during the Chapter 11 Cases and to continue to make XPOVIO available to patients without interruption. Additionally, upon the Effective Date, all actions contemplated by the Prepackaged Plan will be deemed authorized and approved.
| U. | Will any party have significant influence over the corporate governance and operations of NewCo and the Reorganized Debtors? |
In the event of a Reorganization Transaction, as of the Effective Date, the terms of the then-sitting members of the boards of directors of the Debtors shall expire, and the initial boards of directors of the Reorganized Debtors (including NewCo), as well as the officers of each of the Reorganized Debtors (including NewCo), shall be appointed in accordance with the New Corporate Governance Documents. To the extent known, the identity and affiliation of any Person proposed to serve on the New Board, the Persons who will serve as officers of the Reorganized Debtors (including NewCo), and the identity and compensation of any insider that will be employed or retained by the Reorganized Debtors (including NewCo) will be disclosed in the Plan Supplement or prior to the Combined Hearing. In the event of a Sale Transaction structured as an asset sale, the Post-Effective Date Debtors will be administered by the Plan Administrator, as described in Article IV.C of this Disclosure Statement.
28
Assuming that the Effective Date occurs in a Reorganization Transaction, Holders of Funded Debt Claims will hold, in the aggregate, 55.0% of the New Common Stock (subject to dilution by the Omisirge Contingent Equity and the Management Incentive Plan) and the former equityholders of Ayrmid will hold the remaining 45.0% (which will not be diluted by the Omisirge Contingent Equity, but will be subject to dilution by the Management Incentive Plan). Consummation of the Prepackaged Plan may result in a small number of holders, including the former equityholders of Ayrmid and certain members of the Ad Hoc Group, each owning a significant percentage of the New Common Stock, and such holders may be in a position to control or significantly influence matters requiring approval by the holders of New Common Stock, including the election of directors and the approval of a change of control of NewCo. Ayrmid is majority-owned by certain funds managed by Highbridge Capital Management, LLC, which is also a member of the Ad Hoc Group; see Article VI.G of this Disclosure Statement. The New Corporate Governance Documents, which will be filed with the Plan Supplement, will govern the rights of holders of New Common Stock, including with respect to transfer restrictions, information rights, and board composition.
| V. | Who do I contact if I have additional questions with respect to this Disclosure Statement or the Prepackaged Plan? |
If you have any questions regarding this Disclosure Statement or the Prepackaged Plan, please contact the Claims and Balloting Agent, Stretto, Inc., via one of the following methods:
By regular mail, hand delivery, or overnight mail at:
Karyopharm Therapeutics Inc. Ballot Processing
c/o Stretto, Inc.,
410 Exchange, Suite 100,
Irvine, CA 92602
By electronic mail at:
TeamKaryopharm@stretto.com
(with “Karyopharm Solicitation Inquiry” in the subject line)
By telephone at:
(866) 270-4922 (toll-free within the United States or Canada); or
+1 (949) 561-0471 (international)
Copies of the Prepackaged Plan, this Disclosure Statement, and any other publicly filed documents in the Chapter 11 Cases are available upon written request to the Claims and Balloting Agent at the address above or by downloading the exhibits and documents from the Debtors’ restructuring website maintained by the Claims and Balloting Agent at https://cases.stretto.com/KPTI (free of charge) or via PACER at https://www.pacer.gov (for a fee).
29
| W. | Do the Debtors recommend voting in favor of the Prepackaged Plan? |
Yes. The Debtors believe that the Prepackaged Plan provides for a larger distribution to the Debtors’ creditors and equity holders than would otherwise result from any other available alternative. The Debtors believe that the Prepackaged Plan, which contemplates a significant deleveraging of the Debtors’ balance sheet, positions the XPOVIO franchise and myelofibrosis program within a larger, better-capitalized commercial platform, preserves the flexibility to pursue a superior Sale Transaction through the Bidding Procedures, and enables the Debtors to emerge from chapter 11 expeditiously, is in the best interest of all Holders of Claims or Interests, and that any other alternatives (to the extent they exist) fail to realize or recognize the value inherent under the Prepackaged Plan.
| X. | Who supports the Prepackaged Plan? |
The Prepackaged Plan is supported by the Debtors and certain Consenting Stakeholders that have executed the Restructuring Support Agreement, which includes Holders of 100% of the 1L Term Loan Claims, 100% of the 1.5L 2028 Notes Claims, 100% of the 2L 2029 Notes Claims, and 100% of the RIFA Claims; the Consenting Preferred Shareholders, which hold 100% of the Existing Preferred Interests; and Ayrmid.
| IV. | THE RESTRUCTURING SUPPORT AGREEMENT AND PREPACKAGED PLAN |
| A. | Restructuring Support Agreement. |
As more fully described in Article VI.G hereof, over the past year the Company and its Advisors (as defined herein) evaluated the strategic alternatives available to the Company and built consensus among the Ad Hoc Group, the Royalty Investors, and Ayrmid around the Restructuring Transactions. These efforts culminated in (a) commitments from the 1L Lenders (the “DIP Lenders”) to provide the DIP Facility; (b) agreement on the terms of the Reorganization Transaction, subject to the continued Marketing and Sale Process and the Debtors’ right to pursue a higher or otherwise better Sale Transaction; and (c) the support of the Consenting Stakeholders for the Restructuring Transactions, the Prepackaged Plan, and the commencement of the Chapter 11 Cases. That support is memorialized in the Restructuring Support Agreement, a copy of which is attached hereto as Exhibit B.
Pursuant to the Restructuring Support Agreement, the Consenting Stakeholders and Ayrmid have agreed to, among other things, as applicable:
| • | vote to accept the Prepackaged Plan (subject to the terms and conditions set forth therein); |
| • | support and provide the releases set forth in the Prepackaged Plan; |
| • | refrain from taking any action that would delay or impede consummation of the Restructuring Transactions or the Prepackaged Plan, and refrain from supporting any alternative transaction other than a Sale Transaction that satisfies the Successful Bid Mandatory Conditions; and |
| • | support and effectuate the Restructuring Transactions, including the Debtors’ entry into the DIP Facility and, in the case of Ayrmid, the Merger Agreement, in each case as contemplated by the Restructuring Support Agreement. |
30
The Prepackaged Plan represents a significant step in the Debtors’ year-long restructuring process. The Restructuring Support Agreement will allow the Debtors to proceed expeditiously through chapter 11 to a successful emergence or, if a Successful Bid is received, a value-maximizing Sale Transaction. The milestones under the Restructuring Support Agreement are set forth in Article VII.B hereof. Together, the Restructuring Support Agreement and the Prepackaged Plan provide a pathway toward a comprehensive restructuring of the Debtors’ prepetition funded debt, preserve the going-concern value of the XPOVIO franchise and the myelofibrosis program, and provide for an equitable distribution to the Debtors’ stakeholders, all while minimizing disruption to day-to-day operations and to the patients who depend on XPOVIO.
| B. | The DIP Facility. |
Pursuant to, and subject to the terms of, the Restructuring Support Agreement, the DIP Lenders have committed to provide the Debtors with a $55 million new-money, senior secured, superpriority debtor-in-possession term loan facility, together with a roll-up of a portion of the loans under the 1L Term Loan Facility (the “DIP Facility”), the proceeds of which will fund the administration of the Chapter 11 Cases, the continued operation of the Company’s business (including the continued supply of XPOVIO to patients and the orderly wind-down of the Company’s discontinued clinical programs), and the costs of consummating the Restructuring Transactions. Participation in the DIP Facility was offered ratably, on the same terms, to all 1L Lenders. On the Petition Date, the Debtors intend to file the DIP Motion seeking approval of the DIP Facility on an interim and final basis. The terms of the DIP Facility are summarized in the DIP Motion and set forth in the DIP Facility Documents.
On the Effective Date, in the event of a Reorganization Transaction, Allowed DIP New Money Claims will be repaid in Cash from up to $50,000,000 of the proceeds of the NewCo Facility and the Debtors’ unrestricted Cash on hand at closing in excess of the reserves provided for in the Prepackaged Plan, and the Holders of any Allowed Equitized DIP New Money Claims and Allowed DIP Roll-Up Claims will receive their Pro Rata shares of the DIP New Money Equity Distribution and the DIP Roll-Up Equity Distribution, respectively (which will be exchanged in the Merger for Merger Consideration). In the event of a Sale Transaction, the Allowed DIP Claims will be paid in full in Cash from the proceeds of the Sale Transaction on the Effective Date. See Article III.F of this Disclosure Statement.
| C. | The Prepackaged Plan. |
The Prepackaged Plan contemplates the following key terms, among others described herein and therein:
| 1. | General Settlement of Claims and Interests. |
As discussed in detail in this Disclosure Statement and as otherwise provided in the Prepackaged Plan, pursuant to section 1123 of the Bankruptcy Code and Bankruptcy Rule 9019, and in consideration for the classification, distributions, releases, and other benefits provided under the Prepackaged Plan, upon the Effective Date, the provisions of the Prepackaged Plan shall constitute a good faith compromise and settlement of all Claims, Interests, Causes of Action, and controversies released, settled, compromised, discharged, or otherwise resolved pursuant to the Prepackaged Plan, whether under any provision of chapter 5 of the Bankruptcy Code, on any equitable theory (including equitable subordination, equitable disallowance, or unjust enrichment) or otherwise.
31
The Prepackaged Plan shall be deemed a motion to approve the good faith compromise and settlement of all such Claims, Interests, Causes of Action, and controversies pursuant to Bankruptcy Rule 9019, and the entry of the Confirmation Order shall constitute the Bankruptcy Court’s approval of such compromise and settlement under section 1123 of the Bankruptcy Code and Bankruptcy Rule 9019, as well as a finding by the Bankruptcy Court that such settlement and compromise is fair, equitable, reasonable and in the best interests of the Debtors and their Estates. Subject to Article VI of the Prepackaged Plan, all distributions made to holders of Allowed Claims and Allowed Interests (as applicable) in any Class are intended to be and shall be final.
| 2. | Sale Transaction Election Deadline; Successful Bid. |
In accordance with the Restructuring Support Agreement, the Debtors intend to pursue Consummation of the Reorganization Transaction pursuant to the Prepackaged Plan; provided, however, that if a Successful Bid is received in accordance with the Bidding Procedures that satisfies the Successful Bid Mandatory Conditions (as defined below), the Debtors may, with the consent of the Required Consenting Funded Debt Parties (and, to the extent required under the Restructuring Support Agreement, the Required Consenting Royalty Investors), elect to pursue the Sale Transaction by Filing the Sale Transaction Election Notice by the Sale Transaction Election Notice Deadline. The marketing process for the Debtors’ assets, the submission and evaluation of Qualified Bids, any Auction, and the selection of any Successful Bid shall be conducted in accordance with the Restructuring Support Agreement, the Bidding Procedures, and the Bidding Procedures Order, and any Sale Transaction shall be implemented in accordance with the Restructuring Support Agreement, the Bidding Procedures, the Purchase Agreement, and the Confirmation Order or the Sale Order, as applicable.
The Debtors shall only designate a Qualified Bid as a Successful Bid if such Qualified Bid meets the requirements to be set forth in the Bidding Procedures and the following mandatory conditions (such conditions, the “Successful Bid Mandatory Conditions”):
| • | the Qualified Bid provides for net proceeds at closing of at least $335,384,812; provided that $18,750,000 of such amount allocable to the RIFA Claims may be satisfied with Cash or non-Cash consideration, in such form as is acceptable to the Holders of RIFA Claims in their discretion, having a value of not less than such portion; |
| • | the Qualified Bid provides for the payment in full in Cash of any Bid Protections payable in accordance with the Bidding Procedures Order; and |
| • | the Qualified Bid provides for the funding in Cash, at the closing of the Sale Transaction, of the Wind-Down Budget. |
32
The Debtors are authorized, subject to the entry of the Bidding Procedures Order or other order of the Bankruptcy Court approving the Bid Protections, to provide Bid Protections to Ayrmid in respect of the Reorganization Transaction in the amounts, on the terms, and subject to the conditions set forth in the Restructuring Support Agreement and the Bidding Procedures Order. The Bid Protections shall be earned upon the selection of a Successful Bid submitted by an Entity other than Ayrmid and shall constitute Allowed Administrative Claims pursuant to sections 105(a), 503(b), and 507(a)(2) of the Bankruptcy Code with priority over all other Administrative Claims of the kind specified in sections 503(b)(1) and 507(a) of the Bankruptcy Code, subject and subordinate to the DIP Claims and the Carve-Out, without further order of the Bankruptcy Court. The Bid Protections, to the extent earned, shall be payable in Cash within three (3) Business Days after the date on which an Acceptable Alternative Transaction or an Alternative Restructuring Proposal (each as defined in the Restructuring Support Agreement, and either of which may constitute the Sale Transaction) is consummated, whether pursuant to the Bidding Procedures Order, a chapter 11 plan (including the Prepackaged Plan), or otherwise, and shall be paid from the Cash proceeds of such Acceptable Alternative Transaction or Alternative Restructuring Proposal, as applicable (or as otherwise provided in the Bidding Procedures Order), in each case subject to (a) Ayrmid’s compliance with the terms of the Restructuring Support Agreement and (b) the exceptions set forth in Section 14.07(b) of the Restructuring Support Agreement (including where the termination of the Restructuring Support Agreement as to Ayrmid arises from or is attributable to Ayrmid’s breach of the Restructuring Support Agreement, Ayrmid’s withdrawal from the sale process, or Ayrmid’s failure to consummate the Reorganization Transaction (except, in the case of such a failure, as a result of matters directly or proximately caused by another party to the Restructuring Support Agreement)). Ayrmid’s agreement to serve as the Back-Up Bidder, if so designated, shall be without prejudice to its right to payment of the Bid Protections, to the extent earned, upon the consummation of an Acceptable Alternative Transaction or an Alternative Restructuring Proposal. For the avoidance of doubt, the failure to consummate an Acceptable Alternative Transaction or an Alternative Restructuring Proposal shall not affect the status of the Bid Protections, to the extent earned, as Administrative Claims.
If the Debtors File a Sale Transaction Election Notice and the Sale Transaction does not close on or before the Back-Up Bid Termination Date or the outside date set forth in the applicable Purchase Agreement (or such Purchase Agreement is otherwise terminated), then, subject to the terms of the Bidding Procedures Order and the Restructuring Support Agreement, the Debtors may (a) consummate a Sale Transaction with the Entity (if any) that submitted the next-highest or otherwise best Qualified Bid satisfying the Successful Bid Mandatory Conditions, or (b) if Ayrmid has been designated as the Back-Up Bidder by written notice to Ayrmid delivered on or prior to the conclusion of the auction, designate the Back-Up Bid as the Successful Bid, withdraw the Sale Transaction Election Notice, and consummate the Reorganization Transaction in accordance with the Prepackaged Plan and the Definitive Documents (as modified to reflect any improvements made by Ayrmid at the Auction), which Definitive Documents (including the Merger Agreement) shall be deemed reinstated and in full force and effect from and after the date of such designation (and not during the period between the selection of such Successful Bid and such designation), as promptly as practicable following the satisfaction or waiver of the conditions precedent set forth in Article IX.A of the Prepackaged Plan, in which case the applicable milestones under the Restructuring Support Agreement and the DIP Facility Documents shall, with the consent of the Required Consenting Funded Debt Parties (such consent not to be unreasonably withheld) and, solely with respect to the Ayrmid Milestones (as defined in the Restructuring Support Agreement), Ayrmid, be deemed extended to the extent reasonably necessary to accommodate the consummation of the Reorganization Transaction. The foregoing shall occur in each case without further solicitation of votes on the Prepackaged Plan and without the need for further order of the Bankruptcy Court other than the Confirmation Order; provided that the Confirmation Order shall provide that the Bankruptcy Court retains jurisdiction to resolve any dispute arising in connection therewith.
33
| 3. | Restructuring Transactions. |
On or before the Effective Date, the applicable Debtors or the Reorganized Debtors (and their respective officers, directors, members, or managers (as applicable)) shall enter into and shall take any actions as may be necessary or appropriate to effectuate the Restructuring Transactions, including as may be set forth in the Restructuring Transactions Memorandum, and may enter into and may take all actions as may be necessary or appropriate to effectuate any transaction described in, approved by, contemplated by, or necessary to effectuate the Prepackaged Plan and the Restructuring Support Agreement that are consistent with and pursuant and subject to the terms and conditions of the Prepackaged Plan and the Restructuring Support Agreement (and without the need for any approvals, authorizations, or consents except for those expressly required pursuant to the Prepackaged Plan), in each case in the most tax-efficient manner for the Debtors and the Consenting Stakeholders, as reasonably determined by the Debtors and the Required Consenting Funded Debt Parties (and, in the event of the Reorganization Transaction, Ayrmid). These actions to effectuate the Restructuring Transactions may include: (a) the execution and delivery of appropriate agreements or other documents of merger, amalgamation, consolidation, restructuring, conversion, disposition, transfer, arrangement, continuance, dissolution, sale, purchase, or liquidation containing terms that are consistent with the terms of the Prepackaged Plan and the Restructuring Support Agreement and that satisfy the applicable requirements of applicable Law and any other terms to which the applicable Entities may agree; (b) the execution and delivery of appropriate instruments of transfer, assignment, assumption, or delegation of any asset, property, right, liability, debt, or obligation on terms consistent with the terms of the Prepackaged Plan and the Restructuring Support Agreement and having other terms to which the applicable Entities may agree; (c) the filing of appropriate certificates or articles of incorporation, formation, organization, reincorporation, merger, consolidation, conversion, amalgamation, arrangement, continuance, or dissolution pursuant to applicable Law; (d) the issuance of the Reorganized Parent Common Stock and the New Common Stock, including the Omisirge Contingent Equity; (e) the execution and delivery of the MF CVR Agreement and any filing related thereto, and distribution of the MF CVRs pursuant to the MF CVR Agreement; (f) the execution and delivery of the New Royalty Agreement; (g) the execution and delivery of the New Corporate Governance Documents, and any certificates or articles of incorporation, bylaws, or such applicable formation documents (if any) of each Reorganized Debtor or Post-Effective Date Debtor, as applicable (including all actions to be taken, undertakings to be made, and obligations to be incurred and fees and expenses to be paid by the Debtors or the Reorganized Debtors or Post-Effective Date Debtors, as applicable); (h) the execution and delivery of the Purchase Agreement (if applicable), the Merger Agreement (if applicable) and the NewCo Facility Documents (if applicable), and any filing related thereto, and the incurrence of the obligations thereunder; (i) the winddown of the German RemainCo; and (j) all other actions that the applicable Entities determine to be necessary or appropriate, including making filings or recordings that may be required by applicable Law in connection with the Prepackaged Plan. All Holders of Claims and Interests receiving distributions pursuant to the Prepackaged Plan and all other necessary parties in interest, including any and all agents thereof, shall prepare, execute, and deliver any agreements or documents, including any subscription agreements, and take any other actions as the Debtors may determine are necessary or appropriate, subject to the consent rights set forth in the Restructuring Support Agreement, including by voting or exercising any powers or rights available to such Holder, including at any board, creditors’, or shareholders’ meeting, to effectuate the provisions and intent of the Prepackaged Plan.
34
The Confirmation Order shall, and shall be deemed to, pursuant to sections 363 and 1123 of the Bankruptcy Code, authorize, among other things, all actions as may be necessary or appropriate to effectuate any transaction described in, approved by, contemplated by, or necessary to effectuate the Prepackaged Plan, including as may be set forth in the Restructuring Transactions Memorandum.
| a. | Reorganization Transaction. |
If the Reorganization Transaction is to be consummated, on the Effective Date or as soon as reasonably practicable thereafter, the Reorganized Debtors, as applicable, shall issue or enter into all securities, notes, instruments, certificates, and other documents required to be issued or entered into pursuant to the Restructuring Transactions in accordance with the Restructuring Transactions Memorandum.
On the Effective Date, the New Board shall be established, and the Reorganized Debtors shall adopt their New Corporate Governance Documents. The Reorganized Debtors shall be authorized to adopt any other agreements, documents, and instruments and to take any other actions contemplated under the Prepackaged Plan as necessary to consummate the Prepackaged Plan. Cash payments to be made pursuant to the Prepackaged Plan will be made by the Debtors or the Reorganized Debtors, as applicable. The Debtors and the Reorganized Debtors will be entitled to transfer funds between and among themselves as they determine to be necessary or appropriate to enable the Debtors or the Reorganized Debtors, as applicable, to satisfy their obligations under the Prepackaged Plan. Except as set forth in the Prepackaged Plan, any changes in intercompany account balances resulting from such transfers will be accounted for and settled in accordance with the Debtors’ historical intercompany account settlement practices and will not violate the terms of the Prepackaged Plan.
From and after the Effective Date, the Reorganized Debtors, subject to any applicable limitations set forth in any post-Effective Date agreement, shall have the right and authority without further order of the Bankruptcy Court to raise additional capital and obtain additional financing, subject to the New Corporate Governance Documents and the NewCo Facility Documents, as the Governing Bodies of the applicable Reorganized Debtors deem appropriate.
| b. | Sale Transaction. |
In the event the Sale Transaction occurs, the Sale Transaction will be effectuated either by (a) one or more equity sale(s) under the Prepackaged Plan or (b) one or more asset sale(s) pursuant to section 363 of the Bankruptcy Code or the Prepackaged Plan, in each case, with such Sale Transaction Documents to be set forth in the Plan Supplement or Filed with the Bankruptcy Court.
35
| 4. | Continued Corporate Existence. |
Except as otherwise provided in the Prepackaged Plan, the Restructuring Transactions Memorandum, or any agreement, instrument, or other document incorporated in the Prepackaged Plan or the Plan Supplement, each Debtor shall continue to exist after the Effective Date as a separate corporate entity, limited liability company, partnership, or other form, as the case may be, with all the powers of a corporation, limited liability company, partnership, or other form, as the case may be, pursuant to the applicable Law in the jurisdiction in which each applicable Debtor is incorporated or formed and pursuant to the respective certificate of incorporation and bylaws (or other formation documents) in effect prior to the Effective Date, except to the extent such certificate of incorporation and bylaws (or other formation documents) are amended under the Prepackaged Plan or otherwise, in each case, consistent with the Prepackaged Plan, and to the extent such documents are amended in accordance therewith, such documents are deemed to be amended pursuant to the Prepackaged Plan and require no further action or approval (other than any requisite filings required under applicable state, provincial, or federal Law). After the Effective Date, the respective certificate(s) of incorporation and bylaws (or other formation documents) of one or more of the Reorganized Debtors or Post-Effective Date Debtors may be amended or modified on the terms therein without supervision or approval by the Bankruptcy Court and free of any restrictions of the Bankruptcy Code or Bankruptcy Rules. After the Effective Date, one or more of the Reorganized Debtors or the Post-Effective Date Debtors may be disposed of, dissolved, wound down, or liquidated without supervision or approval by the Bankruptcy Court and free of any restrictions of the Bankruptcy Code or Bankruptcy Rules.
| 5. | Vesting of Assets in the Reorganized Debtors or Post-Effective Date Debtors. |
Except as otherwise provided in the Confirmation Order, the Prepackaged Plan, the Restructuring Transactions Memorandum, or any agreement, instrument, or other document incorporated in, or entered into in connection with or pursuant to, the Prepackaged Plan or Plan Supplement, on the Effective Date, pursuant to sections 1141(b) and (c) of the Bankruptcy Code, all property in each Estate, all Causes of Action, and any property acquired by any of the Debtors pursuant to the Prepackaged Plan shall vest in each respective Reorganized Debtor or Post-Effective Date Debtor, as applicable, free and clear of all Liens, Claims, charges, or other encumbrances. On and after the Effective Date, except as otherwise provided in the Prepackaged Plan, each Reorganized Debtor or Post-Effective Date Debtor, as applicable, may operate its business and may use, acquire, or dispose of property and compromise or settle any Claims, Interests, or Causes of Action without supervision or approval by the Bankruptcy Court and free of any restrictions of the Bankruptcy Code or Bankruptcy Rules.
| 6. | Cancellation of Existing Securities and Agreements. |
Except for the purpose of evidencing a right to a distribution under the Prepackaged Plan and except as otherwise set forth in the Prepackaged Plan or the Plan Supplement (including the Restructuring Transactions Memorandum), on the Effective Date, all agreements, instruments, Securities, and other documents evidencing any Claim or Interest (other than Intercompany Interests that are not modified by the Prepackaged Plan) and any rights of any holder in respect thereof shall be deemed canceled and of no force or effect and the obligations of the Debtors
36
thereunder shall be deemed fully satisfied, released, and discharged; provided that for the avoidance of doubt, the foregoing shall not impact any Claims that are Unimpaired by the Prepackaged Plan. The holders of or parties to such canceled agreements, instruments, Securities, and other documentation shall have no rights arising from or related to such agreements, instruments, Securities, or other documentation or the cancellation thereof, except the rights provided for pursuant to the Prepackaged Plan.
| 7. | Cancellation of Certain Existing Security Interests. |
Upon the satisfaction or discharge in full pursuant to the Prepackaged Plan of an Allowed Secured Claim (including Allowed DIP Claims), or promptly thereafter, all mortgages, deeds of trust, Liens, pledges, or other security interests against any property of the Estates shall be fully released and discharged, and all of the right, title, and interest of any holder of such mortgages, deeds of trust, Liens, pledges, or other security interests shall revert to the Reorganized Debtors or Post-Effective Date Debtors and their successors and assigns. Any Holder of such Secured Claim (and the applicable agents for such Holder) shall be authorized and directed, at the sole cost and expense of the Reorganized Debtors or Post-Effective Date Debtors, to release any collateral or other property of any Debtor (including any Cash Collateral and possessory collateral) held by such Holder (and the applicable agents for such Holder), and to take such actions as may be reasonably requested by the Reorganized Debtors or Post-Effective Date Debtors to evidence the release of such Liens or security interests, including the execution, delivery, and filing or recording of such releases. The presentation or filing of the Confirmation Order to or with any federal, state, provincial, or local agency, records office, or department shall constitute good and sufficient evidence of, but shall not be required to effect, the termination of such Liens.
To the extent that any Holder of an Allowed Secured Claim (including Allowed DIP Claims) that has been satisfied or discharged in full pursuant to the Prepackaged Plan, or any agent for such Holder, has filed or recorded publicly any Liens or security interests to secure such Holder’s Allowed Secured Claim, then as soon as practicable on or after the Effective Date, such Holder (or the agent for such Holder) shall take any and all steps reasonably requested by the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors that are necessary or desirable to record or effectuate the cancellation or extinguishment of such Liens or security interests, including the making of any applicable filings or recordings, and the Reorganized Debtors or Post-Effective Date Debtors shall be entitled to make any such filings or recordings on such Holder’s behalf.
| 8. | Sources of Consideration for Prepackaged Plan Distributions. |
The Debtors, the Reorganized Debtors, or Post-Effective Date Debtors, as applicable, shall fund distributions under the Prepackaged Plan with (a) the Debtors’ Cash on hand, (b) Cash generated from operations, (c) if the Reorganization Transaction is consummated, the Reorganized Parent Common Stock, the DIP Facility, and the NewCo Facility, and (d) if the Sale Transaction is consummated, the proceeds of the Sale Transaction.
37
| 9. | New Common Stock. |
In connection with the Reorganization Transaction, the issuance of the Reorganized Parent Common Stock (comprising the Reorganized Parent Equity Distribution) pursuant to the Prepackaged Plan and the issuance of the New Common Stock (as part of the Merger Consideration) pursuant to the Merger Agreement shall be hereby authorized without the need for any further corporate or similar action and without any further action by the Holders of Claims or Interests. Reorganized Parent and NewCo, as applicable, shall be authorized to issue the number of shares, units or equity interests of Reorganized Parent Common Stock and New Common Stock, respectively, required to be issued under the Prepackaged Plan and the Merger Agreement and pursuant to their respective New Corporate Governance Documents. On the Effective Date, the Debtors or Reorganized Debtors, as applicable, shall issue or enter into all Securities, notes, instruments, certificates, and other documents required to be issued or entered into pursuant to the Prepackaged Plan. The New Corporate Governance Documents shall be effective as of the Effective Date and, as of such date, shall be deemed to be valid, binding, and enforceable in accordance with their respective terms. Subject to the agreement of the Required Consenting Funded Debt Parties and Ayrmid, NewCo may be a newly formed or an existing entity for the purposes of consummating the Merger, in either case to be determined on or prior to the Effective Date.
All of the shares, units, or equity interests (as the case may be based on how the New Common Stock is denominated) of New Common Stock issued or authorized to be issued pursuant to the Prepackaged Plan shall be duly authorized, validly issued, fully paid, and non-assessable. Each distribution and issuance referred to in Article VI of the Prepackaged Plan shall be governed by the terms and conditions set forth in the Prepackaged Plan applicable to such distribution or issuance and by the terms and conditions of the instruments evidencing or relating to such distribution or issuance, which terms and conditions shall bind each Entity receiving such distribution or issuance.
All of the shares, units, or equity interests (as the case may be based on how the New Common Stock is denominated) of New Common Stock issued or authorized to be issued pursuant to the Prepackaged Plan shall be duly authorized, validly issued, fully paid, and non-assessable. Each distribution and issuance referred to in Article VI of the Prepackaged Plan shall be governed by the terms and conditions set forth in the Prepackaged Plan applicable to such distribution or issuance and by the terms and conditions of the instruments evidencing or relating to such distribution or issuance, which terms and conditions shall bind each Entity receiving such distribution or issuance.
In the event of a Reorganization Transaction, the Reorganized Debtors (a) shall emerge from these Chapter 11 Cases as a private company on the Effective Date and the New Common Stock shall not be listed on any stock exchange or market and shall not be registered under the Exchange Act, (b) shall not be voluntarily subjected to any reporting requirements promulgated by the SEC, and (c) shall not be required to list the New Common Stock on any stock exchange or market.
38
On or prior to the Effective Date, the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors shall, as applicable, (a) take all actions necessary or appropriate to delist the Existing Common Stock Interests from Nasdaq and to deregister all securities of the Reorganized Debtors or Post-Effective Date Debtors, as applicable, under the Exchange Act as promptly as practicable in compliance with SEC rules (such that, in the event of the Reorganization Transaction, the termination of the registration of all securities of Parent under sections 12 and 15(d) of the Exchange Act shall have been completed and shall be effective on the Effective Date concurrently with the consummation of the Merger, to the extent permitted by applicable Law and SEC rules), (b) file a Form 25 with the SEC to delist the Existing Common Stock Interests from Nasdaq and to deregister the Existing Common Stock Interests from section 12(b) of the Exchange Act (unless Nasdaq has already filed a Form 25 with the SEC providing for such delisting and deregistration), (c) file post-effective amendments to terminate all of Parent’s currently effective registration statements under the Securities Act, (d) file a Form 15 notifying the SEC of the suspension of Parent’s duty to file reports under section 15(d) of the Exchange Act, and (e) take all actions reasonably necessary or appropriate to ensure (A) that the New Common Stock and the MF CVRs shall not be listed on a stock exchange or market and that the Reorganized Debtors shall not be required to list the New Common Stock or MF CVRs on a stock exchange or market, except, in each case, as otherwise may be required pursuant to the New Corporate Governance Documents or the MF CVR Agreement, as applicable, and (B) that the Reorganized Debtors or Post-Effective Date Debtors, as applicable, shall not be voluntarily subjected to any reporting requirements promulgated by the SEC.
| 10. | The Merger. |
Solely in the event of the Reorganization Transaction, on the Effective Date and immediately after the issuance of the Reorganized Parent Equity Distribution, the Merger shall be consummated in accordance with the Merger Agreement and the Restructuring Transactions Memorandum as a Restructuring Transaction pursuant to sections 1123(a)(5) and 1123(b)(3) of the Bankruptcy Code. In the Merger, NewCo shall issue the Merger Consideration on the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the Restructuring Transactions Memorandum. Each Holder of an Allowed Prepetition Funded Debt Claim, Allowed Equitized DIP New Money Claim, or Allowed DIP Roll-Up Claim shall be deemed to have received its share of the Reorganized Parent Equity Distribution and to have exchanged such Reorganized Parent Common Stock in the Merger for its share of the Merger Consideration, and the applicable Disbursing Agent shall deliver the New Common Stock and the MF CVRs constituting the Merger Consideration directly to or for the benefit of such Holders in accordance with Article VI of the Prepackaged Plan, without any requirement that certificates or book-entry positions evidencing the Reorganized Parent Common Stock be issued to or delivered by such Holders. For the avoidance of doubt, any New Common Stock or MF CVRs distributed on account of Allowed Equitized DIP New Money Claims and Allowed DIP Roll-Up Claims shall be allocated solely from the Merger Consideration otherwise distributable to the Holders of Allowed Prepetition Funded Debt Claims and shall not reduce or dilute the New Common Stock allocable to the equityholders of Ayrmid or the Omisirge Contingent Equity. On the Effective Date, the Liens and obligations under the Ayrmid Term Loan shall be addressed in the manner set forth in the Merger Agreement and the Restructuring Transactions Memorandum, which shall be acceptable to the Required Consenting Funded Debt Parties and Ayrmid and otherwise consistent with the Restructuring Support Agreement; provided that any Liens and obligations in respect of the Ayrmid Term Loan (or any successor obligations thereto) shall be equitized into pre-Effective Date Ayrmid or structurally subordinated in their entirety to the claims against, and the equity
39
interests in, NewCo, in each case in a manner acceptable to the Required Consenting Funded Debt Parties in their sole discretion, and no proceeds of the NewCo Facility shall be used to prepay the Ayrmid Term Loan. The Merger Agreement, the Merger, and the issuance of the Merger Consideration shall be deemed authorized and approved by the Confirmation Order without the need for any further corporate or similar action or any further action by Holders of Claims or Interests, and the Confirmation Order shall constitute all approvals and consents required under applicable non-bankruptcy Law for the consummation of the Merger. The Reorganization Transaction (including the Merger) shall be structured in a manner reasonably acceptable to the Debtors, the Required Consenting Funded Debt Parties, and Ayrmid that, to the extent reasonably practicable, (a) minimizes any cash taxes payable as a result of the consummation of the Reorganization Transaction, (b) maximizes the favorable tax attributes (including tax basis) of the Reorganized Debtors and NewCo and their respective subsidiaries going forward, and (c) otherwise achieves such tax-planning outcomes as are reasonably requested by the Debtors, the Required Consenting Funded Debt Parties and Ayrmid, in each case as set forth in the Restructuring Transactions Memorandum, which shall be Filed with the Plan Supplement. The Merger is a transaction contemplated by, and shall be deemed to be effectuated pursuant to, the Prepackaged Plan. Accordingly, and notwithstanding anything to the contrary in any Executory Contract or Unexpired Lease assumed pursuant to the Prepackaged Plan, or any other agreement, instrument, or document to which a Debtor is a party that is Reinstated or otherwise continues in effect after the Effective Date, the consummation of the Merger shall not constitute, give rise to, or be deemed to constitute or give rise to a default, breach, event of default, “change of control,” “fundamental change,” assignment, termination event, or any similar event, or entitle any counterparty to terminate, modify, accelerate, or exercise any other remedy under any such agreement, and any provision purporting to the contrary shall be unenforceable to the fullest extent permitted by sections 365, 541(c), and 1123 of the Bankruptcy Code.
| 11. | MF CVR Agreement; Omisirge Contingent Equity. |
Solely in the event of a Reorganization Transaction, on the Effective Date substantially concurrently with the consummation of the Merger, NewCo shall enter into the MF CVR Agreement and shall issue the MF CVRs to the Disbursing Agent for distribution as part of the Merger Consideration to the Holders of Allowed Prepetition Funded Debt Claims, Allowed Equitized DIP New Money Claims, and Allowed DIP Roll-Up Claims in accordance with Article II.B, Article III.B, and Article IV.J of the Prepackaged Plan. The MF CVRs shall not constitute equity interests in NewCo or confer any voting or governance rights.
Solely in the event of a Reorganization Transaction, the Merger Agreement (and, to the extent applicable, the New Corporate Governance Documents) shall provide for the issuance of the Omisirge Contingent Equity to the equityholders of Ayrmid as of immediately prior to the Merger if and to the extent specified in the Merger Agreement (and, to the extent applicable, the New Corporate Governance Documents). The issuance of the Omisirge Contingent Equity shall dilute solely the New Common Stock issued as Merger Consideration to the Holders of Allowed Prepetition Funded Debt Claims (and any other New Common Stock issued on account of Claims under the Prepackaged Plan), and shall not dilute New Common Stock issued in the Merger to the equityholders of Ayrmid as of immediately prior to the Merger.
40
The MF CVR Agreement and the provisions of the Merger Agreement and the New Corporate Governance Documents governing the Omisirge Contingent Equity shall be duly authorized without the need for any further corporate or similar action and without further action by the Debtors, the Reorganized Debtors, or the Holders of Claims or Interests. The MF CVR Agreement and the MF CVRs shall be effective as of the Effective Date and, as of such date, shall be deemed to be valid, binding, and enforceable obligations of NewCo in accordance with their respective terms.
| 12. | New Royalty Agreement. |
Solely in the event of a Reorganization Transaction, on the Effective Date, NewCo and each of its subsidiaries that owns or controls any selinexor assets shall enter into the New Royalty Agreement with the Holders of RIFA Claims (or their designee) and the Royalty Collateral Agent (or another collateral agent designated by the Holders of RIFA Claims), pursuant to which NewCo shall pay to the Holders of RIFA Claims (or their designee) an unsecured royalty equal to 3.0% of the net revenues received by NewCo from all products containing selinexor (including XPOVIO® (selinexor) in combination with ruxolitinib for patients with myelofibrosis) for the period of five (5) years following the Effective Date, on the terms and subject to the conditions set forth in the New Royalty Agreement and as more fully described in the Ayrmid Transaction Term Sheet. The obligations under the New Royalty Agreement shall be unsecured obligations of NewCo and its applicable subsidiaries and shall not be secured by any Lien on any assets of NewCo, the Reorganized Debtors, or their respective subsidiaries. The New Royalty Agreement shall include a liquidated damages provision in an amount equal to $18,750,000. Holders of RIFA Claims may pursue the acquisition of the Debtors’ interests in certain other royalty agreements for aggregate consideration of up to $35,000,000; provided, however, that there shall be no obligation or requirement for the Debtors or NewCo to consummate such a sale; provided, further, that any such sale shall be subject to the consent of the Debtors, the Required Consenting Funded Debt Parties, and, to the extent that the Debtors have not selected an Acceptable Alternative Transaction, Ayrmid. The New Royalty Agreement shall replace and supersede the RIFA in its entirety, and on the Effective Date the RIFA (including any change of control payment, premium, or similar amount thereunder) shall be canceled, released, and discharged in accordance with Article IV.F of the Prepackaged Plan. Entry into the New Royalty Agreement and the performance of NewCo’s obligations thereunder shall be authorized without the need for any further corporate or similar action and without any further action by the Debtors, the Reorganized Debtors, or the Holders of Claims or Interests.
| 13. | NewCo Facility. |
In connection with the Reorganization Transaction, on the Effective Date and immediately after the consummation of the Merger, entry into the NewCo Facility Documents by NewCo (or such other borrower identified in the NewCo Facility Documents) and the applicable guarantors, the incurrence of the obligations thereunder, and the granting of the related guarantees, Liens, and security interests shall be authorized without the need for any further corporate or similar action and without any further action by Holders of Claims or Interests. The proceeds of the NewCo Facility shall be available to be drawn in full on the Effective Date and shall be used to (a) refinance up to $50,000,000 of Allowed DIP New Money Claims in Cash in accordance with Article II.B of the Prepackaged Plan (and, if the Allowed DIP New Money Claims are equal to or less than
41
$50,000,000, to repay such Allowed DIP New Money Claims in full), (b) pay Cure amounts and other amounts payable by the Debtors or the Reorganized Debtors under the Prepackaged Plan, and (c) fund the working capital needs of NewCo and the Reorganized Debtors, in each case subject to the DIP Budget. Confirmation of the Prepackaged Plan shall be deemed authorization for the Debtors or the Reorganized Debtors, as applicable, to, without further notice to or order of the Bankruptcy Court, act or take action under applicable Law, regulation, order, or rule as may be necessary or appropriate to enter into, execute, deliver, and perform the NewCo Facility Documents, including the payment of all fees, indemnities, and expenses provided for therein.
On the Effective Date (or earlier, if provided in an order of the Bankruptcy Court), all Liens and security interests granted pursuant to, or in connection with, the NewCo Facility Documents and the related guarantees, (a) shall be deemed to be approved and shall, without the necessity of the execution, recordation, or filing of mortgages, security agreements, control agreements, pledge agreements, financing statements, or other similar documents, be valid, binding, fully perfected, fully enforceable Liens on, and security interests in, the collateral securing the NewCo Facility and the related guarantees, with the priorities established in respect thereof under the NewCo Facility Documents, applicable non-bankruptcy Law, the Prepackaged Plan, and the Confirmation Order; and (b) shall not be enjoined or subject to discharge, impairment, release, avoidance, recharacterization, or subordination (including equitable subordination) for any purposes whatsoever and shall not constitute preferential transfers, fraudulent conveyances, or other voidable transfers under the Bankruptcy Code or any applicable non-bankruptcy Law, the Prepackaged Plan, or the Confirmation Order.
The Reorganized Debtors, NewCo and the Persons granted Liens and security interests under the NewCo Facility Documents are authorized to make all filings and recordings and to obtain all governmental approvals and consents necessary to establish and perfect such Liens and security interests under the provisions of the applicable state, provincial, federal, or other Law (whether domestic or foreign) that would be applicable in the absence of the Prepackaged Plan and the Confirmation Order (it being understood that perfection shall occur automatically by virtue of entry of the Confirmation Order without the need for any filings or recordings) and will thereafter cooperate to make all other filings and recordings that otherwise would be necessary under applicable Law to give notice of such Liens and security interests to third parties.
| 14. | Corporate Action. |
Upon the Effective Date, all actions contemplated under the Prepackaged Plan, the Plan Supplement, and the Restructuring Transactions Memorandum shall be deemed authorized and approved in all respects, including: (a) the issuance and distribution of the Reorganized Parent Common Stock and the New Common Stock (including the Omisirge Contingent Equity, when and if issuable); (b) the entry into the NewCo Facility Documents; (c) the entry into the Merger Agreement, and the consummation of the Merger; (d) implementation of the Restructuring Transactions (including, in the event of a Sale Transaction, the Sale Transaction Documents); (e) entry into the MF CVR Agreement and issuance and distribution of the MF CVRs; (f) entry into the New Royalty Agreement; (g) all other actions contemplated under the Prepackaged Plan (whether to occur before, on, or after the Effective Date); (h) adoption of the New Corporate Governance Documents; (i) the rejection, assumption, or assumption and assignment, as applicable, of Executory Contracts and Unexpired Leases; and (j) all other acts or actions
42
contemplated or reasonably necessary or appropriate to promptly consummate the Restructuring Transactions contemplated by the Prepackaged Plan (whether to occur before, on, or after the Effective Date). All matters provided for in the Prepackaged Plan involving the corporate structure of the Debtors or the Reorganized Debtors, and any corporate, partnership, limited liability company, or other governance action required by the Debtors or the Reorganized Debtors, as applicable, in connection with the Prepackaged Plan shall be deemed to have occurred and shall be in effect, without any requirement of further action by the Security holders, members, directors, or officers of the Debtors or the Reorganized Debtors, as applicable. On or (as applicable) prior to the Effective Date, the appropriate officers of the Debtors or the Reorganized Debtors, as applicable, shall be authorized and (as applicable) directed to issue, execute, and deliver the agreements, documents, Securities, and instruments contemplated under the Prepackaged Plan (or necessary or desirable to effect the transactions contemplated under the Prepackaged Plan) in the name of and on behalf of the Reorganized Debtors (including NewCo), including, as applicable, the Reorganized Parent Common Stock, the New Common Stock, the NewCo Facility Documents, the Merger Agreement, the New Corporate Governance Documents, the MF CVRs, the MF CVR Agreement, and any and all other agreements, documents, Securities, and instruments relating to the foregoing. The authorizations and approvals contemplated by Article IV.M of the Prepackaged Plan shall be effective notwithstanding any requirements under non-bankruptcy Law.
| 15. | New Corporate Governance Documents. |
In the event of a Reorganization Transaction, on or immediately prior to the Effective Date, the New Corporate Governance Documents shall be automatically adopted by the applicable Reorganized Debtors and become effective. To the extent required under the Prepackaged Plan or applicable non-bankruptcy Law, each of the Reorganized Debtors will file its New Corporate Governance Documents with the applicable Secretaries of State or other applicable authorities in its respective state or country of organization if and to the extent required in accordance with the applicable Laws of the respective state or country of organization. The New Corporate Governance Documents will prohibit the issuance of non-voting equity Securities, to the extent required under section 1123(a)(6) of the Bankruptcy Code.
After the Effective Date, the Reorganized Debtors may amend and restate their respective New Corporate Governance Documents in accordance with the terms thereof, and the Reorganized Debtors may file such amended certificates or articles of incorporation, bylaws, or such other applicable formation documents, and other constituent documents as permitted by the Laws of the respective states, provinces, or countries of incorporation and the New Corporate Governance Documents.
| a. | Directors and Officers of the Reorganized Debtors. |
As of the Effective Date, the terms of the current members of the board of directors of the Debtors shall expire and the existing officers of the Debtors shall be automatically removed as officers, and the New Board and new officers of each of the Reorganized Debtors (including NewCo) shall be appointed. For subsequent terms, following the Effective Date, members of the New Board and new officers of each of the Reorganized Debtors (including NewCo) shall be appointed in accordance with the New Corporate Governance Documents and other constituent documents of each Reorganized Debtor (including NewCo).
43
Pursuant to section 1129(a)(5) of the Bankruptcy Code, to the extent known, the identity and affiliation of any Person proposed to serve on the New Board will be disclosed in the Plan Supplement or prior to the Combined Hearing, as well as those Persons that will serve as officers of the Reorganized Debtors (including NewCo) and, to the extent known, the identity and compensation of any insider (as such term is defined in section 101(31) of the Bankruptcy Code) that will be employed or retained by the Reorganized Debtors (including NewCo). Provisions regarding the removal, appointment, and replacement of members of the New Board, to the extent applicable, will be disclosed in the New Corporate Governance Documents.
| 16. | Effectuating Documents; Further Transactions. |
On and after the Effective Date, the Reorganized Debtors and Post-Effective Date Debtors, and their respective officers, directors, members, or managers (as applicable), are authorized to and may issue, execute, deliver, file, or record such contracts, Securities, instruments, releases, and other agreements or documents and take such actions as may be necessary or appropriate to effectuate, implement, and further evidence the terms and conditions of the Prepackaged Plan, and the Securities issued pursuant to the Prepackaged Plan in the name of and on behalf of the Reorganized Debtors, without the need for any approvals, authorizations, or consents except for those expressly required pursuant to the Prepackaged Plan.
| 17. | Treatment of Executory Contracts and Unexpired Leases. |
In the event of a Reorganization Transaction, on the Effective Date, except as otherwise provided in Articles V.E and V.F and elsewhere in the Prepackaged Plan, all Executory Contracts or Unexpired Leases not otherwise assumed or rejected will be deemed assumed by the applicable Reorganized Debtor (and shall remain in effect notwithstanding the consummation of the Merger) in accordance with the provisions and requirements of sections 365 and 1123 of the Bankruptcy Code, other than those that: (a) are identified on the Rejected Executory Contracts and Unexpired Leases Schedule; (b) have previously expired or terminated pursuant to their own terms; (c) have been previously assumed or rejected by the Debtors pursuant to a Final Order; (d) are the subject of a motion to reject that is pending on the Effective Date; or (e) have an ordered or requested effective date of rejection that is after the Effective Date.
In the event of a Sale Transaction, on the Effective Date, except as otherwise provided in Articles V.E and V.F and elsewhere in the Prepackaged Plan, all Executory Contracts or Unexpired Leases not otherwise assumed or rejected will be deemed rejected by the applicable Debtor or Post-Effective Date Debtor in accordance with the provisions and requirements of sections 365 and 1123 of the Bankruptcy Code, other than those that: (a) are identified on the Assumed Executory Contracts and Unexpired Leases Schedule; (b) have been previously assumed by the Debtors pursuant to a Final Order; (c) are the subject of a motion to assume that was Filed on or before the Confirmation Date; (d) are to be assumed by the Debtors or assumed by the Debtors and assigned to a third party, as applicable, in connection with any sale transaction, including the Sale Transaction; or (e) are a contract, instrument, release, indenture, or other agreement or document entered into in connection with the Prepackaged Plan.
44
Entry of the Confirmation Order shall constitute an order of the Bankruptcy Court approving the assumptions, assumptions and assignments, or rejections of Executory Contracts and Unexpired Leases as set forth in the Prepackaged Plan and the applicable schedule, and any provision in an assumed Executory Contract or Unexpired Lease (including any “change of control” or similar provision) that would be triggered by the Chapter 11 Cases, the assumption, or the Confirmation or Consummation of the Prepackaged Plan (including the Restructuring Transactions) shall be deemed modified such that the transactions contemplated by the Prepackaged Plan do not entitle the counterparty to terminate or modify such contract or lease or exercise default-related remedies. After the Petition Date and no later than twenty-one (21) calendar days before the Combined Hearing, the Debtors will serve notices of proposed assumption and proposed Cure amounts (if any) on the counterparties to the Executory Contracts and Unexpired Leases to be assumed, and the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, will pay any Cure amounts on the Effective Date or as soon as reasonably practicable thereafter (or, if a dispute is unresolved, as soon as reasonably practicable after resolution). Any objection by a counterparty to a proposed assumption or Cure amount must be Filed, served, and actually received by counsel to the Debtors no later than the date and time specified in the notice (which shall be not less than fourteen (14) days after such notice is served), and a counterparty that fails to object timely will be deemed to have assented to the assumption and Cure amount. The assumption of any Executory Contract or Unexpired Lease pursuant to the Prepackaged Plan shall result in the full release and satisfaction of any nonmonetary defaults arising from or triggered by the filing of the Chapter 11 Cases, including defaults of provisions restricting the change in control or ownership interest composition or any bankruptcy-related defaults, arising at any time prior to the effective date of assumption, and, in the event of a Reorganization Transaction, any default, change of control, assignment, or similar event that would otherwise arise from the consummation of the Merger or the other Restructuring Transactions. Unless otherwise provided by a Final Order of the Bankruptcy Court, all Proofs of Claim with respect to Claims arising from the rejection of Executory Contracts or Unexpired Leases must be Filed within thirty (30) days after the later of the date of entry of an order approving such rejection, the effective date of such rejection, and the Effective Date, and any such Claim not timely Filed will be automatically disallowed and forever barred. In the event of a Reorganization Transaction, all employee compensation and benefits plans, policies, and programs of the Debtors (including, subject to the limitations set forth in the Prepackaged Plan, the KPTI Severance Plans) will be assumed, and NewCo will provide COBRA continuation coverage through the eighteen-month anniversary of the Effective Date and, for one year following the Effective Date, severance pay and benefits to Covered Employees who experience a Qualifying Termination no less favorable than those provided under the KPTI Severance Plans, in each case up to the amounts scheduled on Annex A to the Ayrmid Transaction Term Sheet. See Article V of the Prepackaged Plan.
| 18. | Preservation of Causes of Action. |
In accordance with section 1123(b) of the Bankruptcy Code, but subject to Article VIII of the Prepackaged Plan, each Reorganized Debtor or Post-Effective Date Debtor, as applicable, shall retain and may enforce all rights to commence and pursue, as appropriate, any and all Causes of Action of the Debtors, whether arising before or after the Petition Date, including any actions specifically enumerated in the Schedule of Retained Causes of Action, and the Reorganized Debtors’ and Post-Effective Date Debtors’ rights to commence, prosecute, or settle such Causes of Action shall be preserved notwithstanding the occurrence of the Effective Date, other than the Causes of Action released by the Debtors pursuant to the releases and exculpations contained in the Prepackaged Plan, including in Article VIII of the Prepackaged Plan, which shall be deemed released and waived by the Debtors and the Reorganized Debtors (or Post-Effective Date Debtors, as applicable) as of the Effective Date.
45
The Reorganized Debtors or Post-Effective Date Debtors, as applicable, may pursue such retained Causes of Action, as appropriate, in accordance with the best interests of the Reorganized Debtors or Post-Effective Date Debtors. No Entity (other than the Released Parties) may rely on the absence of a specific reference in the Prepackaged Plan, the Plan Supplement, or this Disclosure Statement to any Cause of Action against it as any indication that the Debtors or the Reorganized Debtors (or Post-Effective Date Debtors), as applicable, will not pursue any and all available Causes of Action of the Debtors against it. The Debtors and Reorganized Debtors (or Post-Effective Date Debtors, as applicable) expressly reserve all rights to prosecute any and all Causes of Action against any Entity, except as otherwise expressly provided in the Prepackaged Plan, including Article VIII of the Prepackaged Plan. Unless any Causes of Action of the Debtors against an Entity are expressly waived, relinquished, exculpated, released, compromised, or settled in the Prepackaged Plan or a Final Order, the Reorganized Debtors and Post-Effective Date Debtors expressly reserve all Causes of Action, for later adjudication, and, therefore, no preclusion doctrine, including the doctrines of res judicata, collateral estoppel, issue preclusion, claim preclusion, estoppel (judicial, equitable, or otherwise), or laches, shall apply to such Causes of Action upon, after, or as a consequence of the Confirmation or Consummation. For the avoidance of doubt, the Debtors and the Reorganized Debtors (or Post-Effective Date Debtors, as applicable) do not reserve any Causes of Action that have been expressly released or exculpated pursuant to the Prepackaged Plan (including, for the avoidance of doubt, Claims and Causes of Action against the Consenting Stakeholders released pursuant to the releases by the Debtors provided in Article VIII.C of the Prepackaged Plan and the exculpation contained in Article VIII.E of the Prepackaged Plan).
The Reorganized Debtors and Post-Effective Date Debtors reserve and shall retain such Causes of Action of the Debtors notwithstanding the rejection or repudiation of any Executory Contract or Unexpired Lease during the Chapter 11 Cases or pursuant to the Prepackaged Plan. In accordance with section 1123(b)(3) of the Bankruptcy Code, any Causes of Action that a Debtor may hold against any Entity shall vest in the Reorganized Debtors or Post-Effective Date Debtors, except as otherwise expressly provided in the Prepackaged Plan, including Article VIII of the Prepackaged Plan. The applicable Reorganized Debtors or Post-Effective Date Debtors, through their authorized agents or representatives, shall retain and may exclusively enforce any and all such Causes of Action. The Reorganized Debtors or Post-Effective Date Debtors shall have the exclusive right, authority, and discretion to determine and to initiate, file, prosecute, enforce, abandon, settle, compromise, release, withdraw, or litigate to judgment any such Causes of Action and to decline to do any of the foregoing without the consent or approval of any third party or further notice to or action, order, or approval of the Bankruptcy Court.
46
| 19. | Certain Securities Law Matters. |
The offering, issuance (or entry into), and distribution of the New Common Stock and all other Securities entered into or issued in connection with the Prepackaged Plan (including, solely to the extent constituting securities as defined in and for purposes of the Securities Act, the MF CVRs), shall be exempt from, among other things, the registration requirements of section 5 of the Securities Act and any other applicable Law requiring registration prior to the offering, issuance, distribution, or sale of Securities to the maximum extent permitted by Law, in accordance with, and pursuant to, (a) section 1145 of the Bankruptcy Code, (b) section 4(a)(2) of the Securities Act or Regulation S under the Securities Act, or (c) any other available exemption from registration, as applicable.
Any Securities issued under section 1145 of the Bankruptcy Code (a) will not be “restricted securities” as defined in rule 144(a)(3) under the Securities Act and (b) will generally be freely tradable and transferable in the United States by a recipient thereof that (i) is not an “underwriter” as defined in section 1145(b)(1) of the Bankruptcy Code, (ii) is not an “affiliate” of the Debtors, NewCo, or the Reorganized Debtors as defined in Rule 144(a)(1) under the Securities Act, (iii) has not been such an “affiliate” within 90 days of the time of the transfer, and (iv) has not acquired such securities from an “affiliate” within one year of the time of transfer, subject in each case to compliance with applicable securities Laws and any rules and regulations of the SEC or state or local securities Laws, if any, applicable at the time of any future transfer of such Securities, and subject to any restrictions in the agreements, instruments or other documents governing such Securities or to which the holder of such Securities is a party.
To the extent issuance under section 1145(a) of the Bankruptcy Code is unavailable, the Merger Consideration (to the extent it consists of securities as defined in and for purposes of the Securities Act) will be issued without registration under the Securities Act in reliance upon the exemption set forth in section 4(a)(2) of the Securities Act or Regulation S under the Securities Act, and similar registration exemptions under state or local securities Laws, in each case to the maximum extent permitted thereunder. Any securities issued in reliance on section 4(a)(2) or Regulation S under the Securities Act will be “restricted securities” under the Securities Act or subject to resale restrictions and may be resold, exchanged, assigned or otherwise transferred only pursuant to registration, or an applicable exemption from registration under the Securities Act and other applicable Law and subject in each case to compliance with applicable securities Laws and any rules and regulations of the SEC or state or local securities Laws, if any, applicable at the time of any future transfer of such Securities, and subject to any restrictions in the agreements, instruments or other documents governing such Securities or to which the holder of such Securities is a party.
The issuance of the New Common Stock and any and all other Securities entered into or issued pursuant to the Prepackaged Plan shall not constitute an invitation or solicitation of an invitation or offer to sell or buy any securities in contravention of any applicable Law in any jurisdiction. No action has been taken, nor will be taken, in any jurisdiction that would permit a public offering of any securities (other than securities issued pursuant to section 1145 of the Bankruptcy Code) in any jurisdiction where such action for that purpose is required.
Notwithstanding anything to the contrary in the Prepackaged Plan, no Entity (including, for the avoidance of doubt, DTC and any transfer agent) shall be entitled to require a legal opinion regarding the validity of any transaction contemplated by the Prepackaged Plan, including, for the avoidance of doubt, whether the New Common Stock and MF CVRs are exempt from registration or eligible for DTC book-entry delivery, settlement, and depository services. DTC and any transfer agent shall be required to accept and conclusively rely upon the Prepackaged Plan and Confirmation Order in lieu of a legal opinion regarding whether the New Common Stock or MF CVRs are exempt from registration or eligible for DTC book-entry delivery, settlement and depository services.
47
| 20. | 1146 Exemption. |
To the fullest extent permitted by section 1146(a) of the Bankruptcy Code, any transfers (whether from a Debtor to a Reorganized Debtor, Post-Effective Date Debtor, or to any other Person) of property under or in connection with the Prepackaged Plan or pursuant to: (a) the issuance, distribution, transfer, or exchange of any debt, equity Security, or other interest in the Debtors, Reorganized Debtors or Post-Effective Date Debtors, including the Reorganized Parent Common Stock, the New Common Stock, and the MF CVRs; (b) the Restructuring Transactions; (c) the creation, modification, consolidation, termination, refinancing, or recording of any mortgage, deed of trust, or other security interest, or the securing of additional indebtedness by such or other means; (d) the making, assignment, or recording of any lease or sublease; (e) the grant of collateral as security for NewCo’s and the Reorganized Debtors’ obligations under and in connection with the NewCo Facility or any other debt instrument; or (f) the making, delivery, or recording of any deed or other instrument of transfer under, in furtherance of, or in connection with, the Prepackaged Plan, including any deeds, bills of sale, assignments, or other instrument of transfer executed in connection with any transaction arising out of, contemplated by, or in any way related to the Prepackaged Plan, shall not be subject to any document recording tax, stamp tax, conveyance fee, intangibles or similar tax, mortgage tax, real estate transfer tax, personal property transfer tax, sales or use tax, mortgage recording tax, Uniform Commercial Code filing or recording fee, regulatory filing or recording fee, or other similar tax or governmental assessment, and upon entry of the Confirmation Order, the appropriate state or local governmental officials or agents shall forgo the collection of any such tax or governmental assessment and accept for filing and recordation any of the foregoing instruments or other documents without the payment of any such tax, recordation fee, or governmental assessment. All filing or recording officers (or any other Person with authority over any of the foregoing), wherever located and by whomever appointed, shall comply with the requirements of section 1146(a) of the Bankruptcy Code, shall forgo the collection of any such tax or governmental assessment, and shall accept for filing and recordation any of the foregoing instruments or other documents without the payment of any such tax or governmental assessment.
| 21. | Additional Sale Transaction Provisions. |
Solely if the Sale Transaction occurs and is consummated, the following additional provisions shall apply:
| a. | Post-Effective Date Debtors. |
If the Sale Transaction is an asset sale, following the sale of certain assets of the Debtors under the Prepackaged Plan or the Sale Order(s), on and after the Effective Date, the Post-Effective Date Debtors shall continue in existence for purposes of (a) winding down the Debtors’ business and affairs as expeditiously as reasonably possible, (b) resolving Disputed Claims, (c) making distributions on account of Allowed Claims as provided under the Prepackaged Plan, (d) funding distributions, (e) enforcing and prosecuting claims, interests, rights, and privileges under the Causes of Action on the Schedule of Retained Causes of Action in an efficacious manner and only
48
to the extent the benefits of such enforcement or prosecution are reasonably believed to outweigh the costs associated therewith, (f) filing appropriate tax returns, (g) complying with their continuing obligations under the Purchase Agreement(s), if any, and (h) administering the Prepackaged Plan in an efficacious manner. In such case, the Post-Effective Date Debtors shall be deemed to be substituted as the party-in-lieu of the Debtors in all matters, including (i) motions, contested matters, and adversary proceedings pending in the Bankruptcy Court, and (ii) all matters pending in any courts, tribunals, forums, or administrative proceedings outside of the Bankruptcy Court, in each case without the need or requirement for a plan administrator to file motions or substitutions of parties or counsel in each such matter.
| b. | Post-Effective Date Plan Administrator. |
If the Sale Transaction is an asset sale and is consummated, on the Effective Date, the Post-Effective Date Plan Administrator shall be appointed with respect to each Post-Effective Date Debtor. The Post-Effective Date Plan Administrator shall be acceptable to the Debtors and the Required Consenting Funded Debt Parties and shall act for the Post-Effective Date Debtors in the same fiduciary capacity as applicable to a Governing Body, subject to the provisions of the Prepackaged Plan (and all certificates of formation, membership agreements, and related documents shall be deemed amended by the Prepackaged Plan to permit and authorize the same) and retain and have all the rights, powers, and duties necessary to carry out its responsibilities under the Prepackaged Plan on terms which shall be disclosed in the Plan Supplement.
| 22. | Director and Officer Liability Insurance. |
On or prior to the Effective Date, the Debtors shall place the D&O Liability Insurance Policies in effect as of the Petition Date into runoff (or purchase tail coverage providing substantially equivalent coverage) for a period of six (6) years following the Effective Date, at the Debtors’ expense, for the benefit of the Debtors’ current and former directors, officers, and managers with respect to conduct occurring prior to the Effective Date. Notwithstanding anything to the contrary in the Prepackaged Plan (including Article V.E of the Prepackaged Plan), after the Effective Date, none of the Reorganized Debtors (including NewCo) or the Post-Effective Date Debtors shall terminate, amend, or otherwise reduce the coverage under any such runoff or tail policies, and all directors, officers, and managers of the Debtors who served in such capacity at any time prior to the Effective Date shall be entitled to the full benefits of any such policy for the full term of such policy, to the extent set forth therein, regardless of whether such directors, officers, or managers remain in such positions after the Effective Date. NewCo and the Reorganized Debtors may obtain new D&O Liability Insurance Policies effective as of the Effective Date.
| 23. | Indemnification Obligations. |
All indemnification provisions in place as of the Effective Date (whether in the bylaws, certificates of incorporation or formation, limited liability company agreements, other organizational documents, board resolutions, indemnification agreements, employment contracts, or otherwise) for current and former directors, officers, managers, employees, attorneys, accountants, investment bankers, and other professionals of the Debtors, as applicable, shall be assumed by a newly-formed entity, which may be an Affiliate of NewCo (the “Indemnification
49
Entity”), in scope acceptable to the Debtors, Ayrmid, and the Required Consenting Funded Debt Parties and in scope no less favorable to such current and former directors, officers, managers, employees, attorneys, accountants, investment bankers, and other professionals of the Debtors than the indemnification provisions in place prior to the Effective Date. The obligations assumed by the Indemnification Entity shall include, for the avoidance of doubt, the obligation to fund and pay, as and when due, any self-insured retention, deductible, or similar amount required to be borne by the insureds under any of the D&O Liability Insurance Policies (including any runoff or tail policies described in Article IV.S of the Prepackaged Plan) in connection with any claim thereunder against any such current or former director, officer, manager, employee, attorney, accountant, investment banker, or other professional of the Debtors. The obligations of the Indemnification Entity in respect of such indemnification provisions (including any such self-insured retention or deductible amounts) shall be supported by an intercompany promissory note in the principal amount of $2,500,000 issued by NewCo or an Affiliate of NewCo in favor of the Indemnification Entity on the Effective Date, on terms acceptable to the Debtors, Ayrmid, and the Required Consenting Funded Debt Parties, and the Indemnification Entity shall not incur any indebtedness or other obligations other than the indemnification obligations assumed pursuant to Article IV.T of the Prepackaged Plan.
| 24. | Winddown of Karyopharm Europe GmbH. |
In the event of a Reorganization Transaction, on the Effective Date, the Debtors shall deposit a sufficient amount of Cash (in an amount agreed by the Debtors, the DIP Lenders, and the Required Consenting Funded Debt Parties) into a segregated account (the “German RemainCo Winddown Account”) in order to conduct an orderly winddown and dissolution of Karyopharm Europe GmbH (the “German RemainCo”) after the Effective Date.
| 25. | Management Incentive Plan. |
On or after the Effective Date, NewCo shall implement the Management Incentive Plan on terms acceptable to Ayrmid and the Required Consenting Funded Debt Parties and approved by the New Board, the terms of which, to the extent then available, shall be Filed with the Plan Supplement.
| 26. | Releases. |
The Prepackaged Plan contains certain releases (as described more fully in Article III.O of this Disclosure Statement, entitled “Will there be releases and exculpation granted to parties in interest as part of the Prepackaged Plan?”), including mutual releases among each of the following, solely in its capacity as such: (a) each Debtor; (b) the Post-Effective Date Plan Administrator or the Reorganized Debtors, as applicable; (c) NewCo; (d) the Prepetition Agents; (e) each Consenting Stakeholder; (f) each Consenting Royalty Investor; (g) each Consenting Preferred Shareholder; (h) the DIP Lenders; (i) the DIP Agent; (j) Ayrmid; (k) each current and former Affiliate of each Entity in the foregoing clauses (a) through (j); and (l) each Related Party of each Entity in clauses (a) through (k); provided that any Holder of a Claim or Interest that (x) affirmatively opts out of the releases provided by the Prepackaged Plan by checking the box on the applicable Ballot or Notice of Non-Voting Status indicating that it opts not to grant the releases provided in the Prepackaged Plan or (y) in the case of a Holder of a Claim or Interest in a Class that is deemed to reject the Prepackaged Plan, does not affirmatively opt in to the releases provided by the Prepackaged Plan by checking the box on the applicable Notice of Non-Voting Status indicating that it opts to grant the releases provided in the Prepackaged Plan, shall not be a “Released Party.”
50
| V. | DEBTORS’ CORPORATE HISTORY, STRUCTURE, AND BUSINESS OVERVIEW |
| A. | Corporate History and Operations. |
XPOVIO received its initial approval from the FDA in July 2019 and is currently approved in the United States in two multiple myeloma indications. The Company commercializes XPOVIO in the United States directly and, outside the United States, through its licensing partners.
Parent was incorporated in Delaware on December 22, 2008, and has its principal place of business in Newton, Massachusetts. The Company has one U.S. subsidiary, KPT Texas LLC, a Texas limited liability company, and one foreign non-Debtor subsidiary, Karyopharm Europe GmbH, organized in Germany. The Company is supported by approximately 192 employees who work remotely throughout the United States and overseas or at the Company’s headquarters in Massachusetts. In addition, the Company’s business operations are supported by 34 independent contractors. An illustrative chart of the Company’s corporate structure as of the Petition Date is attached hereto as Exhibit C.11
| B. | Business and Operations. |
The Company’s primary focus is on marketing XPOVIO in its currently-approved indications in multiple myeloma and on developing and seeking regulatory approval of selinexor in myelofibrosis. XPOVIO is currently approved and marketed in the United States for the following indications: (a) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and (b) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
The Company has historically financed its operations through a combination of proceeds from: (a) product revenue sales; (b) public and private placements of equity securities; (c) the issuance of convertible debt; (d) a term loan; (e) a deferred royalty obligation; (f) at-the-market offerings; and (g) business development activities. The Company’s prepetition capital structure and long-term obligations are described in greater detail in Article V.C of this Disclosure Statement. As of the Petition Date, the Company had $8.1 million of cash, cash equivalents, and investments.
| 11 | Karyopharm Europe GmbH is in the process of voluntary dissolution and winddown in accordance with local laws and regulations. |
51
As more fully detailed in Article VI of this Disclosure Statement, the Company has incurred significant operating losses since its inception and, because of disappointing trial results and delays in obtaining certain FDA approvals, the Company does not have sufficient liquidity to meet its debt obligations, support its continued operations, and maintain its research and development programs, including as the Company continues to develop and seek regulatory approval of selinexor for myelofibrosis. The Company’s continued operations are dependent on its ability to raise additional funding or enter into strategic alternatives and market XPOVIO in its currently approved indications.
| 1. | Cancer-Fighting Products. |
The Company’s novel approach targets the export of specific proteins from the nuclei of cancer cells using its Selective Inhibition of Nuclear Export (“SINE”) technology. The Company’s SINE compounds inhibit the nuclear export protein exportin 1 (“XPO1”) and represent a new class of drug candidates with a novel mechanism of action and the potential to treat a variety of diseases with high unmet medical need.
| a. | XPOVIO (selinexor). |
Selinexor, marketed as XPOVIO, is a first-in-class, oral SINE compound that functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. This reinitiates and amplifies their tumor suppressor function and is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. XPOVIO was also approved in the United States under the accelerated approval pathway for the treatment of relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”); however, in March 2026, at the FDA’s request and because completion of the required confirmatory trial was no longer feasible in light of the evolving treatment landscape, the Company agreed to withdraw that indication, and the withdrawal became effective on April 30, 2026. The withdrawal was not based on any safety concern and did not affect the multiple myeloma indications. XPOVIO has also been granted orphan drug designation by the FDA for myelofibrosis.
Outside the United States, XPOVIO (marketed as NEXPOVIO in Europe and certain other markets) was granted Conditional Marketing Authorization by the European Commission on March 29, 2021, and by the UK’s Medicines and Healthcare products Regulatory Agency on May 26, 2021, which authorizations were subsequently converted to full marketing authorizations in July 2022 and February 2023, respectively, and has since been approved in more than 50 countries and territories, where it is commercialized by the Company’s partners, including Menarini, Antengene, Neopharm, and FORUS. As set forth below, selinexor is also being evaluated in ongoing Phase 2 and Phase 3 clinical studies in patients with a variety of hematologic and solid tumor malignancies; in those settings, selinexor is an investigational medicine that has not been approved by the FDA or any other regulatory agency.
| b. | Eltanexor. |
Eltanexor (KPT-8602) is an investigational, second novel compound that, like selinexor, functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. By doing so, Eltanexor reinitiates and amplifies the proteins’ tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells.
52
In preclinical models, Eltanexor has a broad therapeutic window with reduced penetration of the blood brain barrier relative to selinexor and, therefore, has the potential to serve as a second-generation SINE compound for cancer indications. Following oral administration, animals treated with Eltanexor have shown a lower percentage of body weight loss and improved food consumption than animals similarly treated with selinexor. This allows more frequent dosing of Eltanexor, enabling a longer period of exposure at higher levels than is possible with selinexor. As a result, the Company believes that Eltanexor represents a second-generation SINE compound.
| 2. | Pipeline and Key Clinical Trials. |
| a. | Myelofibrosis. |
The Company has been focused on utilizing its innovative technologies to combat myelofibrosis, a rare blood cancer affecting roughly 20,000 U.S. patients in which the bone marrow becomes scarred, the spleen enlarges, and patients become anemic or symptomatic. The only currently approved drug class for myelofibrosis is JAK inhibitors, such as ruxolitinib. The Company has been conducting trials for myelofibrosis treatment that utilize selinexor in combination with ruxolitinib.
The Company’s pivotal myelofibrosis trial, SENTRY (XPORT-MF-034) (“SENTRY” or the “SENTRY Trial”), enrolled 353 patients who had not previously received a JAK inhibitor, randomized 2-to-1 to either once-weekly selinexor plus ruxolitinib or placebo plus ruxolitinib. SENTRY had two co-primary endpoints measured at week 24: (a) a reduction in spleen volume of at least 35% (“SVR35”); and (b) the average change in a patient-reported total symptom score.
On March 24, 2026, the Company announced topline results from SENTRY. The trial met its first co-primary endpoint, with 49.8% of patients in the combination arm achieving SVR35 at week 24 compared to 28.0% of patients receiving ruxolitinib alone (p<0.0001), but did not meet its second co-primary endpoint, as the improvement in total symptom score was comparable in both arms and the difference was not statistically significant. The Company also reported a promising, although not yet mature, overall survival signal in favor of the combination and a safety profile consistent with the known profiles of each agent. The SENTRY results were presented in a late-breaking oral presentation at the 2026 American Society of Clinical Oncology Annual Meeting on June 2, 2026, with simultaneous publication in the Journal of Clinical Oncology, and were subsequently presented at the 2026 European Hematology Association Congress.
Following engagement with the FDA, including Type B and Type C meetings, on August 31, 2026, the Company submitted a supplemental New Drug Application (the “sNDA”) to the FDA seeking accelerated approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis and requested Priority Review of the application, which, if granted, could result in a six-month review process. As of the date of this Disclosure Statement, the FDA’s 60-day filing review period for the sNDA has ended and the Company has not received a refuse-to-file letter. The Company expects to receive notice of the FDA’s decision on sNDA filing acceptance and, if accepted, the anticipated review timelines on or about November 10, 2026. If approved, selinexor plus ruxolitinib would be the first combination regimen approved for myelofibrosis. The Company is also evaluating selinexor as a monotherapy in the Phase 2 SENTRY-2 trial in myelofibrosis, with topline data from the 60 mg cohort expected to be reported at a medical congress in the second half of 2026.
53
| b. | Endometrial Cancer. |
XPORT-EC-042 (the “XPORT-EC-042 Trial”) was a global Phase 3 trial in 257 patients, testing weekly selinexor as a maintenance therapy after chemotherapy in women with TP53 wild-type advanced or recurrent endometrial cancer. Patients were randomized 1-to-1 against a placebo, with progression-free survival tested sequentially in two defined populations.
On July 30, 2026, the Company announced that XPORT-EC-042 did not meet its primary endpoint. In the modified intent-to-treat population of 236 patients, median progression-free survival was 12.75 months with selinexor compared to 7.43 months with placebo—a trend favoring selinexor that did not reach statistical significance. Following these results, the Company prioritized its investment toward its myelofibrosis and multiple myeloma programs, reduced its planned investment in endometrial cancer, and is continuing long-term follow-up of enrolled patients while winding down the trial.
| c. | Myeloma. |
XPORT-MM-031 (EMN29) is a Phase 3 trial conducted in collaboration with the European Myeloma Network evaluating an all-oral combination of selinexor, pomalidomide, and dexamethasone in previously treated multiple myeloma patients whose most recent therapy was an anti-CD38 antibody. Enrollment is complete and patients continue to be followed until the progression-free survival events required for the primary endpoint accrue. The Company expects to report topline data from this event-driven trial in the second half of 2026. As of the Petition Date, topline data have not yet been announced.
| C. | The Debtors’ Prepetition Capital Structure. |
As of the Petition Date, the Debtors have approximately $390 million in total funded debt obligations as set forth below:
| Funded Debt |
Maturity | Approximate Amount Outstanding as of November 1, 2026 |
||||||
| 1L Term Loan Facility |
May 2028 | $ | 146 million | |||||
| 1.5L 2028 Notes |
October 2028 | $ | 16 million | |||||
| 2L 2029 Notes |
May 2029 | $ | 114 million | |||||
| RIFA |
September 2035 | $ | 114 million | |||||
| Total Funded Debt |
$ | 390 million | ||||||
54
| 1. | Capital Structure Overview. |
The Company’s existing capital structure developed through a series of financing and restructuring transactions undertaken prior to the commencement of these Chapter 11 Cases. On October 16, 2018, the Company issued $150.0 million aggregate principal amount of 3.00% unsecured convertible senior notes due October 15, 2025 (the “2025 Notes”) in a private offering and, on October 29, 2018, the Company issued an additional $22.5 million aggregate principal amount of 2025 Notes on the same terms, for a total of $172.5 million aggregate principal amount of 2025 Notes. In September 2019, the Company entered into the RIFA (as defined below) with the Royalty Investors (as defined below), under which the Company received $75.0 million in exchange for a revenue interest in XPOVIO, and in June 2021 the Company entered into an omnibus amendment to the RIFA under which the Company received an additional $60.0 million. In May 2024, the Company completed a refinancing (the “May 2024 Refinancing”) in which it (a) entered into the 1L Credit Agreement (as defined below) providing for a $100.0 million senior secured term loan facility; (b) exchanged $148.0 million aggregate principal amount of 2025 Notes for approximately $116.0 million aggregate principal amount of new 6.00% second-lien convertible senior notes due 2029 (the “Original 2029 Notes”) and warrants to purchase common stock; and (c) amended the RIFA, including by making a $49.5 million cash payment to the Royalty Investors and delivering to the Royalty Investors a $15.0 million term loan under the 1L Credit Agreement and $5.0 million of Original 2029 Notes in reduction of the amounts owed under the RIFA.
In October 2025, as part of the Fall 2025 Transactions (as defined below) described in Article VI of this Disclosure Statement, the Company completed a series of exchange, new-money, and amendment transactions with its term loan lenders, the holders of its convertible notes, and the Royalty Investors (collectively, the “October 2025 Exchange Transactions”). Pursuant to the October 2025 Exchange Transactions: (a) the lenders under the 1L Credit Agreement funded an additional $12.5 million of term loans and waived certain then-existing defaults; (b) $101.0 million aggregate principal amount of Original 2029 Notes and those certain warrants to purchase common stock issued in the May 2024 Refinancing were exchanged for $103.5 million aggregate principal amount of new 9.00% second-lien convertible senior notes due 2029 issued under a new indenture and collateral trust arrangement and new warrants to purchase common stock, and the remaining $15.0 million of Original 2029 Notes was exchanged for common stock and pre-funded warrants to purchase common stock; (c) the Company issued $15.0 million aggregate principal amount of new 9.00% second-lien convertible senior notes due 2028 for cash; (d) $24.3 million aggregate principal amount of 2025 Notes—substantially all of the 2025 Notes then outstanding—was exchanged for common stock and warrants, and the remaining $0.3 million of 2025 Notes was repaid at maturity on October 15, 2025; and (e) the RIFA was further amended to, among other things, waive royalty payments on revenue recognized between April 1, 2025, and March 31, 2026. Following the October 2025 Exchange Transactions, no 2025 Notes or Original 2029 Notes remain outstanding, and all of the Company’s funded debt is secured by substantially all of the Company’s assets.
55
As of the Petition Date, the Company’s funded debt therefore consists of the 1L Term Loan Facility, the 1.5L 2028 Notes, the 2L 2029 Notes, and the obligations under the RIFA, each of which is described below. The relative lien priorities of, and the allocation of collateral proceeds among, the Company’s secured creditors are governed by (a) the Amended and Restated Intercreditor Agreement, dated as of October 10, 2025 (the “Intercreditor Agreement”), among WSFS (as defined below), as collateral agent under the 1L Credit Agreement, WSFS, as collateral trustee for the Secured Notes (as defined below), and HCR Karyopharm SPV, LLC, as the collateral agent under the RIFA, and acknowledged and agreed by the Company, and (b) the Collateral Trust Agreement, dated as of October 10, 2025 (the “Collateral Trust Agreement”), among the Company, WSFS, as trustee under each of the Indentures (as defined below), and WSFS, as collateral trustee, which, among other things, governs the sharing of collateral between the holders of the 1.5L 2028 Notes and the holders of the 2L 2029 Notes.
| a. | 1L Term Loan Facility. |
Parent is party to that certain Credit and Guaranty Agreement, dated as of May 8, 2024 (as amended by that certain First Amendment and Waiver to Credit and Guaranty Agreement, dated as of October 7, 2025 (the “First Amendment”), and that certain Second Amendment to Credit and Guaranty Agreement, dated as of February 27, 2026 (the “Second Amendment”), and as further amended, restated, supplemented, or otherwise modified from time to time, the “1L Credit Agreement”), by and among Parent, as borrower, the other Debtors, as guarantors, the lenders party thereto from time to time (the “1L Lenders”)12 and Wilmington Savings Fund Society, FSB (“WSFS”), as administrative agent and collateral agent, which provides for, subject to the terms and conditions set forth therein, an initial $100.0 million senior secured term loan facility (the “1L Term Loan Facility”).13 The 1L Term Loan Facility is secured by first-priority liens on substantially all of the Company’s assets. As of the Petition Date, approximately $146 million is outstanding under the 1L Term Loan Facility, including accrued and unpaid interest and applicable fees and premiums.
| b. | 1.5L 2028 Notes and 2L 2029 Notes. |
Parent, as issuer, is party to (a) that certain Indenture, dated as of October 10, 2025 (the “1.5L 2028 Notes Indenture”), by and among Parent, the other Debtors, as guarantors, and WSFS, as trustee, pursuant to which the Company issued $15.0 million aggregate principal amount of 9.00% Convertible Senior Notes due October 15, 2028 (the “1.5L 2028 Notes”), and (b) that certain Indenture, dated as of October 10, 2025 (the “2L 2029 Notes Indenture” and, together with the 1.5L 2028 Notes Indenture, the “Indentures”), by and among Parent, the other Debtors, as guarantors, and WSFS, as trustee, pursuant to which the Company issued approximately $103.5 million aggregate principal amount of 9.00% Convertible Senior Notes due May 13, 2029 (the “2L 2029 Notes” and, together with the 1.5L 2028 Notes, the “Secured Notes”). The Secured Notes bear interest at 9.00% per annum, which was payable in kind quarterly through March 31, 2026 and in cash quarterly thereafter, and are convertible at the option of the holders into shares of the Company’s common stock (or pre-funded warrants to purchase common stock) at initial conversion prices of $6.64 per share (1.5L 2028 Notes) and $22.50 per share (2L 2029 Notes), subject to customary adjustments and beneficial ownership limitations.
| 12 | The original 1L Lenders consisted of certain holders of the 2025 Notes and certain entities managed by HCRx, whose loans were subsequently assigned to an affiliate of KKR in connection with KKR’s acquisition of a majority interest in HCRx in July 2025. |
| 13 | The 1L Lenders funded an additional $12.5 million in October 2025 pursuant to the First Amendment. |
56
The Secured Notes are secured on a second-priority basis by liens on the same collateral that secures the 1L Term Loan Facility, held by WSFS, as collateral trustee, for the benefit of the holders of both series of Secured Notes pursuant to the Collateral Trust Agreement. Under the Collateral Trust Agreement, proceeds of the shared collateral are applied first to the 1.5L 2028 Notes until paid in full and thereafter to the 2L 2029 Notes (subject to the Intercreditor Agreement). Pursuant to the Intercreditor Agreement, the liens securing the Secured Notes are junior to the liens securing the 1L Term Loan Facility and pari passu with the liens securing the RIFA, subject to the waterfall set forth in the Intercreditor Agreement. As of the Petition Date, approximately $16 million is outstanding under the 1.5L 2028 Notes and approximately $114 million is outstanding under the 2L 2029 Notes, in each case including accrued and unpaid interest.
| c. | RIFA. |
Parent is party to that certain Revenue Interest Financing Agreement, dated as of September 14, 2019 (as amended by amendments dated June 23, 2021, August 1, 2023, May 8, 2024, August 14, 2025, August 27, 2025, and October 7, 2025, and as further amended, restated, supplemented, or otherwise modified from time to time, the “RIFA”), by and among Parent, the investors party thereto, HealthCare Royalty Management, LLC, as investor representative (together with the investors, the “Royalty Investors”), and HCR Karyopharm SPV, LLC, as collateral agent. The Royalty Investors’ interests were assigned to an affiliate of KKR & Co. Inc. (“KKR”) in connection with KKR’s acquisition of a majority interest in HealthCare Royalty Management, LLC (“HCRx”) in July 2025. Under the RIFA, the Company received a total of $135.0 million in exchange for the right to receive quarterly payments equal to a percentage (currently 8.0%) of the net revenues of XPOVIO and the Company’s other products, including worldwide net product sales and upfront, milestone, and royalty payments received from the Company’s partners.
Total aggregate payments to the Royalty Investors under the RIFA are capped at $263.3 million (the “Payment Cap”). The RIFA terminates on the earlier of the date on which the Royalty Investors have received payments totaling the Payment Cap and the legal maturity date of September 26, 2035, at which time any shortfall below a specified minimum return becomes payable. Upon a change of control or an event of default under the RIFA—including the Company’s failure to pay amounts due to the Royalty Investors, insolvency, or a payment default or acceleration under the Company’s other indebtedness—the Company is obligated to pay the Royalty Investors an amount equal to the Payment Cap less the aggregate payments previously made.
As of September 30, 2026, the Company had made $149.8 million in payments to the Royalty Investors under the RIFA. As of the Petition Date, approximately $114 million—the remaining amount payable up to the Payment Cap as of September 30, 2026—is currently due and payable in full under the RIFA.
The obligations under the RIFA are secured by liens on substantially all of the Company’s assets, which such liens are junior to the liens securing the 1L Term Loan Facility and share in the proceeds of the collateral with the Secured Notes in accordance with the waterfall set forth in the Intercreditor Agreement.
57
As of June 30, 2026, the Company had made $147.1 million in payments to the Royalty Investors under the RIFA.
| 2. | Equity Interests. |
Parent’s common stock is listed on the Nasdaq Global Select Market under the symbol “KPTI.” As of June 30, 2026, Parent had approximately 22,680,000 shares of common stock outstanding. As described in Article VI of this Disclosure Statement, in September 2026 Parent issued 20,000 shares of a newly created series of 0% series A convertible perpetual preferred stock (the “Convertible Preferred Stock”) to certain of its funded-debt creditors in satisfaction of the fees payable under the September 2026 forbearance arrangements. Parent also has outstanding several series of warrants and pre-funded warrants to purchase common stock issued in connection with the May 2024 Refinancing, the October 2025 Exchange Transactions, and the March 2026 Private Placement (each as defined below) (collectively, the “Warrants”) (the warrants to purchase 1,317,771 shares of common stock issued in the 2025 Private Placement and the warrants to purchase 4,421,518 shares of common stock issued in the March 2026 Private Placement expired in August 2026), as well as stock options, restricted stock units, and performance stock units issued under its equity incentive plans. Under the Prepackaged Plan, all existing equity interests in Parent, including the Convertible Preferred Stock, the common stock, and the Warrants, will be canceled and will receive no distribution.
| VI. | EVENTS LEADING TO THE CHAPTER 11 FILINGS |
The Company’s ability to fund its operations and service its funded debt has always depended on the success of its clinical programs and, in turn, on its access to the capital markets. When the Company’s two Phase 3 readouts in 2026 fell short of expectations, and the Company faced increased liquidity constraints, the Company’s secured creditors worked constructively with the Company—first to give the Company time to reach the trial readouts, and then to give it time to evaluate its alternatives in light of the results—through the payment deferrals, forbearances, and out-of-court transactions described below.
These efforts included: (a) the Fall 2025 Transactions (as defined below), which provided new capital, deferred near-term cash obligations, and equitized a substantial portion of the Company’s convertible notes; (b) the February 2026 forbearance and payment deferrals and the March 2026 Private Placement (as defined below), which together extended the Company’s runway through the readouts of the Company’s two Phase 3 trials; and (c) the September 2026 forbearance, which gave the Company additional time to advance its myelofibrosis program and to complete the Marketing and Sale Process (as defined below).
Although these efforts gave the Company the time it needed to reach its clinical readouts and to run the Marketing and Sale Process, no out-of-court alternative emerged that would address the Company’s liquidity constraints. The Marketing and Sale Process instead yielded Ayrmid’s proposal for the Reorganization Transaction, which, together with the Restructuring Support Agreement, contemplates effectuation through these Chapter 11 Cases. Accordingly, the Company determined that commencing these cases would maximize the value of its assets and operations for the benefit of its creditors and other stakeholders.
58
| A. | The Company’s Operating Losses and Dependence on Clinical Milestones. |
The Company has incurred significant operating losses since its inception. Although XPOVIO generates meaningful revenue—total revenue was $146.1 million in 2025, including approximately $114.9 million of U.S. XPOVIO net product revenue—the Company’s revenue has not been sufficient to fund its research and development programs, its commercial infrastructure, and the cash interest and amortization on its funded debt. For the six months ended June 30, 2026, the Company reported a loss from operations of approximately $49.3 million and interest expense of approximately $25.7 million, and as of June 30, 2026 it had an accumulated deficit of approximately $1.8 billion. The Company has accordingly depended on periodic access to the capital markets, which in turn has depended on the progress of its clinical programs. Entering 2026, the Company publicly described the year as a potentially transformative, catalyst-rich year, with topline data from the Phase 3 SENTRY trial in myelofibrosis expected in March 2026 and topline data from the Phase 3 XPORT-EC-042 trial in endometrial cancer expected in mid-2026, and disclosed that its existing liquidity—approximately $64 million of cash, cash equivalents, restricted cash, and investments as of December 31, 2025—was expected to fund operations only into the second quarter of 2026. The Company’s business therefore depended, in large part, on its ability to obtain and maintain regulatory approvals, and the outcome of those two trials and of the sNDA would largely determine both the Company’s access to capital and its ability to continue as a going concern.
| B. | The Fall 2025 Transactions. |
Entering the second half of 2025, the Company faced the October 15, 2025 maturity of the remaining $24.3 million of 2025 Notes, quarterly cash interest payments under the 1L Credit Agreement and the Original 2029 Notes and a quarterly royalty payment under the RIFA, each falling due in the third quarter of 2025, and a minimum liquidity covenant that left little margin for error, all while the Company awaited the topline readout of the SENTRY trial—the single most important value catalyst for the business. The Company, with the assistance of its advisors, including Sidley Austin LLP (“Sidley”) and Centerview (together with FTI Consulting, Inc. (“FTI”), which the Company retained in July 2026, the “Advisors”), determined that the most effective way to bridge to that readout was a negotiated series of transactions with its existing capital providers, together with a modest new equity raise (collectively, and together with the interim accommodations described below, the “Fall 2025 Transactions”), rather than a stand-alone capital raise on the terms then available in the market.
The Company first secured short-term accommodations while those transactions were negotiated. On August 14, 2025, the Company and the Royalty Investors entered into the Third Amendment to the RIFA, which deferred the quarterly royalty payment otherwise due on August 15, 2025 to August 29, 2025, and on August 27, 2025, the Company and the Royalty Investors entered into the Fourth Amendment to the RIFA, which further deferred that payment to September 30, 2025, the same date on which quarterly cash interest was due under the 1L Credit Agreement and the Original 2029 Notes. On September 30, 2025, while the October transactions were being finalized, the Company entered into a forbearance agreement (the “2025 Forbearance Agreement”) with the requisite lenders under the 1L Credit Agreement, the holders of 100% of the Original 2029 Notes, and the investor representative under the RIFA, pursuant to which those parties agreed to forbear, through October 15, 2025, from exercising rights and remedies with
59
respect to the anticipated defaults arising from the Company’s non-payment of the interest and royalty payments due on September 30, 2025 and any resulting cross-defaults, as well as any technical defaults arising from a delay in settling the contemplated note exchanges. The 2025 Forbearance Agreement did not waive any defaults, was conditioned on the continued forbearance of each creditor group, and was intended solely to permit the parties to sign and close the October transactions within the applicable grace periods.
On October 10, 2025 the Company closed the October 2025 Exchange Transactions described in Article V.C of this Disclosure Statement. Among other things, the October 2025 Exchange Transactions provided $27.5 million of new term loan and convertible note financing, temporarily reduced the Company’s minimum liquidity covenant by $15.0 million, converted the Company’s cash interest obligations under the 1L Term Loan Facility and the Secured Notes to payment-in-kind through mid-2026, waived royalty payments on revenue recognized between April 1, 2025, and March 31, 2026, equitized approximately $39.3 million of convertible notes, eliminated the Company’s October 2025 maturity and thereby extended the weighted-average maturity of the Company’s funded debt, and resolved, through the waivers granted in the First Amendment and the Sixth Amendment to the RIFA,14 the defaults that had been the subject of the 2025 Forbearance Agreement.
Concurrently with the October 2025 Exchange Transactions, the Company raised new equity capital through a private placement, pursuant to a securities purchase agreement dated October 7, 2025, of 1,489,917 shares of common stock and warrants to purchase 1,317,771 shares of common stock at an exercise price of $6.64 per share (which warrants expired in August 2026), for gross proceeds of approximately $8.8 million (the “2025 Private Placement”). The Company also entered into registration rights agreements with the participating investors and with its term loan lenders in respect of the shares and warrants issued in the Fall 2025 Transactions.
In the aggregate, the Fall 2025 Transactions provided the Company with what the Company estimated at the time to be approximately $100 million of new capital and near-term financial flexibility, eliminated the Company’s only remaining 2025 maturity, reduced the Company’s convertible note principal by approximately $39.3 million through equitization, and extended the Company’s projected cash runway into the second quarter of 2026—beyond the expected SENTRY readout.
Although the Fall 2025 Transactions achieved their purpose, they did not—and were not designed to—resolve the Company’s capital structure or its dependence on positive clinical results. With cash interest on the 1L Term Loan Facility and the Secured Notes scheduled to resume in 2026, the first $15.8 million principal installment under the 1L Term Loan Facility due on September 10, 2026, and the minimum liquidity covenant stepping back up to $25.0 million on October 10, 2026, the Company and its Advisors concluded in early 2026 that a further, more comprehensive solution would be required, but that it would be premature to determine that solution absent the SENTRY readout.
| 14 | To resolve a numbering discrepancy in the RIFA amendments, there is no Fifth Amendment to the RIFA. |
60
| C. | The February 2026 Forbearance Agreement and the March 2026 Private Placement. |
In its efforts to find a comprehensive solution, and to create a stable environment in which to pursue an equity capital raise and evaluate strategic alternatives, on February 27, 2026, the Company entered into a forbearance agreement (the “February Forbearance Agreement”) with the 1L Lenders, the holders of the 2L 2029 Notes and the 1.5L 2028 Notes, and the investor representative under the RIFA (collectively, the “Prepetition Secured Parties”), which became effective in March 2026. Under the February Forbearance Agreement, the Prepetition Secured Parties agreed not to exercise certain rights and remedies with respect to specified matters, including: (a) payment-related defaults through September 30, 2026, that would result from the Company’s non-payment of the interest due on June 30, 2026, on the Secured Notes; and (b) any defaults that would result from the requirement under the Indentures that the Company maintain minimum liquidity greater than the lesser of (i) $10.0 million plus 50% of the net cash proceeds received from certain debt and equity issuances (excluding proceeds applied to the Capital Raise Trigger (as defined below)) and (ii) $25.0 million through October 10, 2026, which effectively aligned the minimum liquidity covenant under the Indentures with the minimum liquidity covenant under the 1L Term Loan Facility. The February Forbearance Agreement did not constitute a waiver of any defaults or events of default, and the Prepetition Secured Parties reserved their rights and remedies, subject to the terms of the February Forbearance Agreement.
The effectiveness of the February Forbearance Agreement was conditioned upon, among other things, the consummation of a sale and issuance of the Company’s common stock, in one or more transactions, resulting in proceeds to the Company of not less than $25.0 million actually received in cash before June 10, 2026 (the “Capital Raise Trigger”). The Capital Raise Trigger was satisfied and the February Forbearance Agreement became effective in March 2026 upon receipt of the proceeds from the March 2026 Private Placement (as defined below).
Concurrently, the Company and the 1L Lenders entered into the Second Amendment, which became effective in March 2026 together with the February Forbearance Agreement and deferred the principal installment otherwise due under the 1L Term Loan Facility on June 10, 2026 to September 10, 2026 and provided for the interest otherwise payable in cash on June 30, 2026 to be paid in kind. Together with the March 2026 Private Placement (as defined below), these arrangements were intended to provide the Company with runway through the SENTRY readout and the submission of the sNDA, and to permit the Company and its Advisors to evaluate strategic alternatives in an orderly manner.
On March 24, 2026—the same day the Company announced the SENTRY topline results—the Company entered into a securities purchase agreement with RA Capital Healthcare Fund, L.P. pursuant to which the Company issued and sold in a private placement (the “March 2026 Private Placement”) 1,030,354 shares of common stock, pre-funded warrants to purchase up to 3,391,164 shares of common stock, and accompanying warrants to purchase 4,421,518 shares of common stock (which warrants expired in August 2026), for aggregate net proceeds of $26.9 million.
In addition, the Company has raised equity capital from time to time through at-the-market offerings under an open market sale agreement with Jefferies LLC, as agent, entered into in February 2023, pursuant to which the Company sold an aggregate of 2,994,441 shares of common stock during the six months ended June 30, 2026 for net proceeds of $19.8 million.
61
| D. | Clinical and Regulatory Developments in 2026. |
As described in Article V.B of this Disclosure Statement, the Company’s two Phase 3 readouts in 2026 produced mixed results. On March 24, 2026, the Company announced that SENTRY had met its spleen-volume co-primary endpoint but not its symptom-score co-primary endpoint. Although the SENTRY data ultimately supported a regulatory submission, the mixed result foreclosed the equity-market reception that a clean positive readout would have afforded and lengthened the path to approval, making the FDA’s willingness to accept an accelerated-approval filing on the basis of SVR35 a critical uncertainty. In March 2026, at the FDA’s request, the Company agreed to withdraw the accelerated approval of XPOVIO in DLBCL, which withdrawal became effective on April 30, 2026. On July 30, 2026, the Company announced that XPORT-EC-042 had not met its primary endpoint, eliminating the Company’s endometrial cancer opportunity and prompting the Company to reprioritize its investment toward myelofibrosis and multiple myeloma and to begin winding down the endometrial cancer program. The Company’s common stock declined approximately 68.47% following the XPORT-EC-042 announcement.
Following the SENTRY readout, the Company engaged with the FDA regarding a potential accelerated-approval pathway and, on August 31, 2026, submitted the sNDA seeking accelerated approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis and requested Priority Review. The FDA’s 60-day filing review period for the sNDA has ended, and the Company expects to receive notice of the FDA’s decision on sNDA filing acceptance and, if accepted, the anticipated review timelines on or about November 10, 2026. The Company’s ability to obtain approval of selinexor in myelofibrosis remains the principal driver of the value of the Company’s business and of the myelofibrosis-based contingent value rights to be issued to the Company’s funded-debt creditors under the Prepackaged Plan.
| E. | 2026 Employee Retention Programs. |
In the months preceding the Petition Date, to preserve the continuity of operations necessary to maintain the value of its business, the Company implemented a series of cash retention arrangements for employees whose continued service it determined to be critical (collectively, the “2026 Retention Programs”), each of which is described in the Employee Wages Motion (as defined below). On July 13, 2026, the Company’s Board of Directors, upon the recommendation of its Compensation Committee and after consultation with the Company’s Advisors, approved (a) a retention program for fifteen (15) employees, including critical members of the Company’s executive leadership team, under which awards totaling $8,875,000 were paid in a lump sum, replaced previously guaranteed amounts under the Company’s 2026 short-term incentive plan, and are subject to repayment if the recipient’s employment terminates in specified circumstances before the earliest of twelve months after payment, thirty days after a change in control, and thirty days after the Company’s emergence from these Chapter 11 Cases; and (b) a retention program for thirty-two (32) critical non-executive employees, with awards totaling $2,982,000 payable in four equal quarterly installments through June 30, 2027, subject to continued employment in good standing.
62
The Company’s Compensation Committee also approved (a) on July 22, 2026, a cash retention program for fifteen (15) medical science liaisons, nurse liaisons, and regional business directors, with awards totaling $922,000 payable in quarterly installments through June 30, 2027, and a one-time, performance-based supplement to the Company’s sales commission program for its hematology/oncology sales specialists with a maximum aggregate cost of approximately $1.7 million; and (b) on September 21, 2026, one-time cash retention awards of $40,000 to each of the Company’s four remaining regional business directors and $50,000 to each of two senior members of its finance organization, totaling $260,000, all of which were paid prior to the Petition Date. Prior to the Petition Date, the Company paid approximately $10.6 million under the 2026 Retention Programs; approximately $2.5 million in fixed installments remain payable, exclusive of up to approximately $1.2 million in performance-contingent payments. The purpose of the 2026 Retention Programs was to motivate key, in-demand talent and maintain business continuity during a period in which the Company expected several meaningful catalysts requiring the continued experience and expertise of the designated employees, and the Company is seeking authority in the Employee Wages Motion to continue to honor the 2026 Retention Programs in the ordinary course.
| F. | The September 2026 Forbearance Agreement and Fee Agreement. |
Notwithstanding the February Forbearance Agreement and the March 2026 Private Placement, by the summer of 2026 the Company’s liquidity was projected to fund operations only into September 2026. The Company did not make the cash interest payments due on the Secured Notes on June 30, 2026 (which, together with interest accrued on the overdue amount, would have become payable upon the expiration of the forbearance period under the February Forbearance Agreement on September 30, 2026), did not pay the $15.8 million principal installment due under the 1L Credit Agreement on September 10, 2026, did not pay the cash interest due on September 30, 2026 under the 1L Credit Agreement and the Indentures, and would not satisfy the $25.0 million minimum liquidity covenant that applies under the 1L Credit Agreement and the Indentures after October 10, 2026. These matters constituted, or, upon expiration of applicable grace periods, cures and conditions, would constitute, events of default under the 1L Credit Agreement and the Indentures and cross-defaults under the 1L Credit Agreement, the Indentures, and the RIFA (as detailed and defined in the September Forbearance Agreement, the “Specified Defaults”).
Therefore, on September 10, 2026, the Company entered into a forbearance agreement and limited waiver of indentures (the “September Forbearance Agreement” and, together with the February Forbearance Agreement, the “Forbearance Agreements”) with the Prepetition Secured Parties and WSFS, in its capacities as administrative agent and collateral agent under the 1L Credit Agreement and as trustee and collateral trustee under the Indentures, to provide the Company with additional time to continue to advance its myelofibrosis program following the August 31, 2026 submission of the sNDA, to continue the Marketing and Sale Process then underway, to further negotiate with its lenders, to pursue strategic alternatives, or to consummate an equity capital raise. Under the September Forbearance Agreement, the Prepetition Secured Parties agreed to forbear, during the relevant forbearance period, from exercising rights and remedies under the 1L Credit Agreement, the Indentures, and the RIFA solely with respect to the Specified Defaults.15
| 15 | The September Forbearance Agreement did not waive the Specified Defaults or extend the applicable payment deadlines, and the Prepetition Secured Parties reserved their rights and remedies with respect to those defaults. The September Forbearance Agreement provided limited waivers of certain mechanics under the Indentures for the payment of overdue interest, without waiving, deferring or extending the applicable payment obligations, and consents and waivers from the Prepetition Secured Parties to the Forbearance Consideration (as defined below). |
63
The September Forbearance Agreement provided that the forbearance period under the September Forbearance Agreement would end on the earliest of: (a) 11:59 p.m. (prevailing Eastern Time) on October 15, 2026, as such date may be extended by the parties specified in the September Forbearance Agreement; (b) a bankruptcy or insolvency-related default under any of the 1L Credit Agreement, the Indentures or the RIFA; (c) a material enforcement action by any creditor of the Company or its subsidiaries; (d) termination or expiration of any other forbearance or similar accommodations with respect to material indebtedness of the Company or any of its subsidiaries; and (e) delivery of a termination notice under the September Forbearance Agreement by any applicable requisite lender or noteholder group, or by the Royalty Investors, following specified events, as applicable, including the occurrence of any event of default other than the Specified Defaults, a breach of the September Forbearance Agreement, a material adverse effect, the Company’s consolidated liquidity falling below $10.0 million, or the FDA’s refusal to accept for filing the Company’s sNDA submitted for selinexor in combination with ruxolitinib for the treatment of patients with myelofibrosis or the Company’s withdrawal of the sNDA. Upon termination, all overdue amounts become immediately due and payable in cash and the Prepetition Secured Parties may exercise all rights and remedies, including acceleration.
On October 13, 2026, the Prepetition Secured Parties agreed to extend the scheduled expiration of the forbearance period from October 15, 2026, to October 22, 2026, and on October 22, 2026, further extended it to November 1, 2026, to permit the Company to continue the Marketing and Sale Process while negotiating and documenting the Restructuring Support Agreement, the Prepackaged Plan, and the DIP Facility. The forbearance period expired on November 1, 2026, and the Consenting Stakeholders have agreed, pursuant to the Restructuring Support Agreement, to support the Restructuring Transactions in lieu of exercising remedies.
In consideration for the September Forbearance Agreement, on September 10, 2026, the Company entered into a fee letter agreement with certain of the Prepetition Secured Parties (the “Fee Agreement”) pursuant to which the Company agreed to pay the applicable Prepetition Secured Parties fees in an aggregate amount of $20.0 million (the “Forbearance Consideration”), which the Company elected to pay in kind through the issuance, on September 17, 2026, of 20,000 shares of Convertible Preferred Stock having a liquidation preference of $1,000 per share and convertible into common stock at a conversion price of $1.62 per share, subject to a cap of 4,520,000 shares plus a 19.99% beneficial ownership cap, pending stockholder approval. The Convertible Preferred Stock does not bear regular dividends, is non-voting, and is subject to a one-time holder put right on and after the third anniversary of issuance.
64
| G. | Exploration of Strategic Alternatives and the Marketing and Sale Process. |
Beginning in July 2025, the Company, with the assistance of Centerview, evaluated a range of strategic alternatives, including incremental equity and debt financings, refinancing transactions, consensual equitization or liability management transactions, strategic partnerships and licensing transactions, and a sale of all or a portion of the business, and the Company and its Advisors engaged in regular discussions with the Ad Hoc Group and the Royalty Investors throughout that period.16 Following the SENTRY readout, and with the Company’s liquidity projected to fund operations only into September 2026, the Company determined that a formal marketing process would provide the greatest opportunity to canvass the market for actionable transactions that could maximize the value of the Company’s assets, whether through a sale, a strategic combination, or a recapitalization.
In July 2026, the Company, with the assistance of Centerview, launched the Marketing and Sale Process. Throughout the Marketing and Sale Process, Centerview contacted 27 potential acquirors, consisting of both strategic acquirers and financial sponsors, as well as 18 potential equity investors. Of the parties contacted, 17 executed confidentiality agreements and received access to a virtual data room containing over 5,500 documents containing significant diligence and other confidential information about the Company’s business. The Company’s management team, along with Centerview, engaged in 26 diligence sessions and other transaction-related conversations, including 10 management presentations with potential counterparties. Following multiple rounds of engagement, the Company sent an initial process letter to approximately 17 parties requesting that they provide an initial indication of interest (an “IOI”) by September 21, 2026 (the “Initial IOI Deadline”). By or shortly after the Initial IOI Deadline, the Company received five (5) non-binding IOIs for all or a portion of the Company’s business, structured variously as whole-company acquisitions, asset purchases, and recapitalization transactions. The Company and its Advisors evaluated each proposal on the basis of, among other things, (a) the structure of the proposed transaction, including whether such transaction was proposed to be consummated in court or out of court; (b) the form and amount of consideration offered, including any contingent consideration; (c) the assets to be acquired and the treatment of the Company’s licenses, contracts, and the RIFA; and (d) regulatory, financing, contingencies, and other considerations.
Following receipt of the IOIs, the Company and its Advisors actively engaged with each of the parties that submitted IOIs to clarify and improve their proposals, and conducted supplemental outreach to certain other parties that had demonstrated sufficient engagement in the Marketing and Sale Process such that continued dialogue regarding a potential transaction was warranted, which yielded revised IOIs from four (4) parties.
While the Marketing and Sale Process generated multiple proposals, the Debtors determined that the proposal received from Ayrmid represented the highest or otherwise best actionable proposal received in the Marketing and Sale Process. Although the Company’s secured creditors had not initially sought to acquire the Company or to convert their claims into equity, that transaction structure proved to provide the most effective mechanism by which to effectuate
| 16 | Prior to Centerview’s engagement in July 2025, the Company had previously marketed itself with the assistance of other advisors. |
65
Ayrmid’s proposal to combine the two businesses, with the Company’s funded-debt creditors receiving a majority equity stake in a combined, better-capitalized commercial-stage oncology company together with a contingent interest in the myelofibrosis opportunity. Following negotiations among the Company, Ayrmid, the Ad Hoc Group, and the Royalty Investors, the parties agreed on the terms of the Reorganization Transaction. The Company, in consultation with its Advisors and after considering all of the proposals received, determined that the Reorganization Transaction—subject to a continued, court-supervised market test—represented the highest or otherwise best path available to maximize value for all stakeholders and to preserve patient access to XPOVIO.
Ayrmid is majority-owned by certain funds managed by Highbridge Capital Management, LLC (“Highbridge”), which, through certain of its funds, also holds loans under the 1L Term Loan Facility, 1.5L 2028 Notes, and 2L 2029 Notes and is a member of the Ad Hoc Group. In light of that relationship, advisors to the Company, the Ad Hoc Group, and Ayrmid established procedures to ensure the integrity of the marketing process and, as part of those procedures, Highbridge recused itself from the Ad Hoc Group’s deliberations regarding the Marketing and Sale Process and the evaluation of Ayrmid’s proposal, and the terms of the Reorganization Transaction were negotiated on behalf of the Company’s secured creditors by the other members of the Ad Hoc Group and their advisors. The Company’s Board of Directors, advised by its independent professionals, evaluated Ayrmid’s proposal on the same basis as every other proposal received in the Marketing and Sale Process, and the Reorganization Transaction remains subject to the court-supervised market test described below. The Debtors believe these measures have preserved, and will continue to preserve, the integrity of the Marketing and Sale Process.17
Although the Company believes the Reorganization Transaction represents the highest or otherwise best actionable transaction available to it as of the Petition Date, the Company, in consultation with its Advisors, determined that continuing the Marketing and Sale Process under court supervision would provide a final opportunity to solicit higher or otherwise better bids. Accordingly, the Debtors will continue the Marketing and Sale Process postpetition pursuant to the Bidding Procedures, which the Debtors will request the Bankruptcy Court approve pursuant to the Bidding Procedures Motion (as defined herein), which will include a form asset purchase agreement and the Successful Bid Mandatory Conditions. Subject to the Restructuring Support Agreement, the Successful Bid Mandatory Conditions require, among other things, that any alternative bid provide for (a) net proceeds at closing of not less than $335,384,812, of which $18,750,000, being the portion allocable to the RIFA, may be satisfied in cash or in such other form of consideration as is acceptable to the Royalty Investors, which amount reflects the payment in full in cash of all claims under the DIP Facility, the 1L Term Loan Facility, and the 1.5L 2028 Notes and the agreed minimum recoveries on the 2L 2029 Notes and the RIFA; (b) the payment in full in cash or other unimpaired treatment of all general unsecured claims; (c) the payment of any Bankruptcy Court-approved Bid Protections; and (d) the funding in cash of a budget for the wind-down of the Debtors’ remaining estates. If the Marketing and Sale Process yields a qualified bid that satisfies the Successful Bid Mandatory Conditions and is selected as the highest or otherwise best bid, the Debtors may, with the consent of the Required Consenting Funded Debt Parties (and, to the extent required under the Restructuring Support Agreement, the Royalty
| 17 | Ayrmid is represented by independent counsel in its capacity as plan sponsor and participant in the Marketing and Sale Process. |
66
Investors), elect, by filing a notice of such election no later than December 28, 2026, to consummate the Sale Transaction with the successful bidder in lieu of the Reorganization Transaction (and, if the successful bidder fails to close, with the next-highest qualified bidder or, if Ayrmid has been designated as the back-up bidder, by reverting to the Reorganization Transaction), to be implemented through the Prepackaged Plan and the order confirming it or, if applicable, pursuant to a separate sale order under section 363 of the Bankruptcy Code. If no such bid is received, or the Debtors do not so elect, the Debtors will consummate the Reorganization Transaction pursuant to the Prepackaged Plan. In recognition of Ayrmid’s expenditure of time and resources in negotiating the Reorganization Transaction and its agreement to serve as plan sponsor and “stalking horse bidder” and, if so designated by the Debtors, as back-up bidder, the Debtors have agreed, subject to Bankruptcy Court approval at a hearing to be scheduled pursuant to the Bidding Procedures Motion (the “Bid Protections Hearing”), to provide Ayrmid with bid protections consisting of (a) a break-up fee equal to 3.0% of an agreed bid protection base of $311,432,711 (the “Bid Protection Base”) and (b) reimbursement of Ayrmid’s reasonable and documented out-of-pocket expenses incurred in connection with negotiating and documenting the Restructuring Support Agreement, the Prepackaged Plan, and the Reorganization Transaction, subject to a cap of 1.0% of the Bid Protection Base. The Bid Protections will be earned upon the selection of a Successful Bid submitted by a party other than Ayrmid, will constitute administrative expense claims once earned (junior to the claims under the DIP Facility and the Carve-Out), and will be payable, to the extent earned, within three (3) Business Days after the consummation of the Sale Transaction (or any other Acceptable Alternative Transaction or Alternative Restructuring Proposal (each as defined in the Restructuring Support Agreement)) from the proceeds thereof, subject to the terms of the Restructuring Support Agreement and the Bidding Procedures Order; no Bid Protections will be payable if Ayrmid’s back-up bid becomes the Successful Bid and the Reorganization Transaction is consummated. The Debtors’ entry into the Restructuring Support Agreement reflects the Debtors’ determination, in the exercise of their business judgment, that the Reorganization Transaction represents the highest or otherwise best transaction currently available to the Debtors and will be beneficial to the Debtors’ efforts to maximize the value of their estates.
| H. | The Restructuring Support Agreement and the Restructuring Transactions. |
The Restructuring Support Agreement and the Prepackaged Plan contemplate consummation of the Restructuring Transactions in accordance with the following key terms.
First, the Consenting Stakeholders support the Company’s entry into the $55 million new-money DIP Facility, which will fund the administration of these Chapter 11 Cases, the continued operation of the Company’s business (including the continued supply of XPOVIO to patients and the orderly wind-down of the Company’s discontinued clinical programs), and the costs of consummating the Restructuring Transactions. Participation in the DIP Facility was offered ratably, on the same terms, to all 1L Lenders.
Second, if the Reorganization Transaction is consummated, the Debtors’ capital structure will be reorganized in accordance with the following key terms, all as set forth in greater detail in the Prepackaged Plan: (a) the Debtors’ business will be combined with Ayrmid’s business under NewCo substantially concurrently with the effective date of the Prepackaged Plan pursuant to an agreement to be entered into with Ayrmid; (b) all claims under the 1L Term Loan Facility, the 1.5L 2028 Notes, and the 2L 2029 Notes (i.e., the Funded Debt Claims)—approximately
67
$276 million in the aggregate—together with any Excess DIP Claims, will be exchanged for 100% of the Reorganized Parent Common Stock, which will in turn be exchanged for 55.0% of the common stock of NewCo (subject to dilution by the Omisirge Contingent Equity described in clause (c) and the Management Incentive Plan), together with contingent value rights entitling the holders thereof to a percentage of future net sales of XPOVIO in the myelofibrosis indication (i.e., the MF CVRs); (c) Ayrmid’s existing equityholders will receive the remaining 45.0% of the common stock of NewCo (which will not be diluted by the Omisirge Contingent Equity, but will be subject to dilution by the Management Incentive Plan), together with additional contingent equity tied to the future revenues of Ayrmid’s Omisirge® product, which, if issued, will dilute only the New Common Stock issued to the Company’s creditors; (d) the new-money claims under the DIP Facility will be repaid in cash from (i) up to $50 million of the proceeds of loans under a new senior secured term loan facility of up to $135 million to be provided to NewCo by one or more third-party lenders (i.e., the NewCo Facility) and (ii) the Company’s unrestricted cash on hand at closing in excess of the reserves provided for in the Prepackaged Plan, and the holders of any Excess DIP Claims will receive Reorganized Parent Common Stock, which will be exchanged in the Merger as described in clause (b); (e) the claims under the RIFA will be exchanged for the rights and interests under the New Royalty Agreement, pursuant to which NewCo will pay the Royalty Investors an unsecured royalty equal to 3.0% of the net revenues received by NewCo from all products containing selinexor for the five (5) year period following the Effective Date, and the RIFA (including any change of control payment thereunder) will be canceled; the New Royalty Agreement will include a liquidated damages provision in the amount of $18,750,000, and the Royalty Investors may pursue the acquisition of the Debtors’ interests in certain other royalty agreements for aggregate consideration of up to $35,000,000, subject to the consents described in the Prepackaged Plan; (f) all general unsecured claims will be unimpaired and paid in the ordinary course of business; and (g) all existing equity interests in Parent, including the Convertible Preferred Stock, the common stock, the Warrants, and all options, restricted stock units, and performance stock units, will be canceled and will receive no distribution. In connection with the Merger, the liens and obligations under the Ayrmid Term Loan will be equitized into Ayrmid prior to the Merger or structurally subordinated in their entirety to the claims against, and the equity interests in, NewCo, in a manner acceptable to the Required Consenting Funded Debt Parties, and no proceeds of the NewCo Facility will be used to prepay that facility.
Third, if a Sale Transaction is consummated, the Successful Bid Mandatory Conditions require (except as otherwise agreed in accordance with the Restructuring Support Agreement) that: (a) all claims under the DIP Facility, the 1L Term Loan Facility, and the 1.5L 2028 Notes be paid in full in cash from the proceeds of the Sale Transaction at closing, and the claims under the 2L 2029 Notes and the RIFA receive the treatment required by the Successful Bid Mandatory Conditions (which, for the Royalty Investors, may consist of cash or other consideration acceptable to them); (b) all other allowed claims be paid in full in cash or otherwise rendered unimpaired; (c) the successful bidder fund a wind-down budget for the Debtors’ remaining estates; (d) if the Sale Transaction is structured as an asset sale, the Debtors’ remaining estates be administered and wound down by a plan administrator in accordance with the Prepackaged Plan; and (e) all existing equity interests in Parent be canceled and receive no distribution.
68
If the Reorganization Transaction is consummated, the Company’s approximately $276 million of secured funded debt and the obligations under the RIFA will, through the transaction steps contemplated thereby, be exchanged for New Common Stock and the MF CVRs and the rights under the New Royalty Agreement, and NewCo will emerge with no more than $135 million of funded debt under the NewCo Facility (other than the contingent obligations under the MF CVRs and the New Royalty Agreement)—a reduction of approximately $141 million in funded debt—and the Company’s commercial and development capabilities will be combined with those of Ayrmid in a single, better-capitalized enterprise with committed financing sufficient to fund its business plan. Whether through the Reorganization Transaction or a Sale Transaction, consummation of the Prepackaged Plan will eliminate or substantially reduce the Company’s secured funded debt and provide a path forward for the XPOVIO franchise—and for the patients who depend on it—that is not available to the Company on a stand-alone basis. The Debtors believe the Restructuring Transactions represent the best available path to a value-maximizing outcome for the Debtors, their estates, their creditors, and their patients.
| VII. | MATERIAL DEVELOPMENTS AND ANTICIPATED EVENTS OF THE CHAPTER 11 CASES |
| A. | First Day Relief. |
On the Petition Date, along with their voluntary petitions for relief under chapter 11 of the Bankruptcy Code (the “Petitions”), the Debtors intend to file several motions (the “First Day Motions”) designed to facilitate the administration of the Chapter 11 Cases and minimize disruption to the Debtors’ operations by, among other things, easing the strain on the Debtors’ relationships with employees, vendors, patients, and customers following the commencement of the Chapter 11 Cases. The First Day Motions, and all orders for relief granted in the Chapter 11 Cases, can be viewed free of charge at https://cases.stretto.com/KPTI.
| B. | Case Milestones. |
As part of the Restructuring Support Agreement, the Debtors agreed to the following case milestones (each as may be extended or waived in accordance with the Restructuring Support Agreement) to ensure that the Chapter 11 Cases proceed in a structured and expeditious manner toward Confirmation:18
| • | no later than November 2, 2026, (a) the Petition Date shall have occurred and (b) the Debtors shall have filed the First Day Pleadings, the DIP Motion, the proposed Interim DIP Order, the Prepackaged Plan, this Disclosure Statement, the Solicitation Materials, and the proposed Bidding Procedures Order; |
| • | no later than three (3) calendar days after the Petition Date, the Bankruptcy Court shall have entered the Solicitation Procedures Order (conditionally approving this Disclosure Statement), the Interim DIP Order, and the Bidding Procedures Order; |
| • | no later than thirty-five (35) calendar days after the Petition Date, the Bankruptcy Court shall have entered the Final DIP Order; |
| 18 | Notwithstanding the foregoing, the milestones may be extended subject to the consent requirements set forth in the Restructuring Support Agreement. |
69
| • | no later than sixty (60) calendar days after the Petition Date, the Debtors shall have conducted an Auction, if necessary, pursuant to the Bidding Procedures Order; |
| • | no later than eighty (80) calendar days after the Petition Date, the Bankruptcy Court shall have entered the order approving this Disclosure Statement and the Confirmation Order (and, if applicable, the Sale Order, which may be the Confirmation Order); and |
| • | no later than one hundred ten (110) calendar days after the Petition Date, the Effective Date shall have occurred. |
In connection with the foregoing, the Debtors have proposed the following schedule of dates and deadlines (the “Proposed Confirmation Schedule”), subject to the Bankruptcy Court’s approval and availability:
| Proposed Confirmation Schedule | ||
| Voting Record Date | October 27, 2026 | |
| Prepetition Solicitation Commencement Date | November 2, 2026 | |
| Anticipated Petition Date | November 2, 2026 | |
| Mailing of Combined Hearing Notice; Publication Notice; Mailing of Non-Voting Status Notice and Opt-Out Forms or Opt-In Forms | Within two (2) Business Days following entry of the Solicitation Procedures Order, or as soon as reasonably practicable thereafter | |
| Voting Deadline | November 30, 2026, at 4:00 p.m. (prevailing Central Time) | |
| Plan Supplement Filing Deadline | December 28, 2026 | |
| Sale Transaction Election Notice Deadline | December 28, 2026 | |
| Cure Notice Deadline | No later than twenty-one (21) calendar days before the Combined Hearing | |
| Opt-Out and Opt-In Deadline | 5:00 p.m. (prevailing Central Time) on January 4, 2027 | |
| Proposed Objection Deadline | 5:00 p.m. (prevailing Central Time) on January 4, 2027 | |
| Executory Contract and Unexpired Lease Assumption Objection Deadline | No less than fourteen (14) days after service of the applicable Cure Notice | |
| Combined Hearing | January 11, 2027 | |
| C. | The Bidding Procedures and the Continued Marketing and Sale Process. |
In accordance with the Restructuring Support Agreement, the Debtors intend to pursue Consummation of the Reorganization Transaction pursuant to the Prepackaged Plan. Notwithstanding the foregoing, the Debtors intend to continue the Marketing and Sale Process for all or substantially all of the Debtors’ assets postpetition pursuant to the Bidding Procedures and, if a Successful Bid is received in accordance with the Bidding Procedures, the Debtors may elect to pursue the Sale Transaction by filing the Sale Transaction Election Notice by the Sale Transaction Election Notice Deadline.
70
On the Petition Date, the Debtors intend to file the Bidding Procedures Motion seeking approval of the Bidding Procedures. As will be more fully described in the Bidding Procedures Motion, the Bidding Procedures contain provisions relating to, among other things, (a) participation requirements, (b) access to due diligence, (c) bid requirements, including the Successful Bid Mandatory Conditions, (d) designation of Qualified Bidders, (e) credit bids, (f) auction procedures (as applicable), and (g) the selection of any Successful Bid and back-up bid. Each Qualified Bid must provide for a purchase price sufficient to satisfy the Successful Bid Mandatory Conditions described in Article IV.C of this Disclosure Statement, including net proceeds at closing of not less than $335,384,812 (of which $18,750,000 allocable to the RIFA Claims may be satisfied with cash or non-cash consideration acceptable to the Holders of RIFA Claims), plus the amount of any Bid Protections payable and the funding of the Wind-Down Budget, and, if an Auction is held, each Overbid must exceed the prior highest or otherwise best bid by the minimum increment announced by the Debtors, which shall be not less than $2,000,000 for the initial Overbid. The Bidding Procedures Motion will also seek approval, at the Bid Protections Hearing (which the Debtors will request be scheduled for November 30, 2026, subject to the Bankruptcy Court’s availability), of the Bid Protections in favor of Ayrmid described in Article VI.G of this Disclosure Statement, consisting of a break-up fee equal to 3.0% of the Bid Protection Base and reimbursement of Ayrmid’s reasonable and documented out-of-pocket expenses, subject to a cap of 1.0% of the Bid Protection Base, which will be earned upon the selection of a Successful Bid submitted by a party other than Ayrmid and payable within three (3) Business Days after the consummation of the Sale Transaction (or any other Acceptable Alternative Transaction or Alternative Restructuring Proposal) from the proceeds thereof. Pursuant to the Restructuring Support Agreement, Ayrmid has agreed, if so designated by the Debtors, to serve as the back-up bidder (on the terms set forth in the Bidding Procedures Order) and to consummate the Reorganization Transaction contemplated by the Merger Agreement if the Debtors select an alternative bid as the Successful Bid and the transaction contemplated by such Successful Bid is not consummated, for the period set forth in the Restructuring Support Agreement.
In addition, the Bidding Procedures are expected to contain the following proposed dates and deadlines, subject to the Bankruptcy Court’s approval and availability:
| Date and Time (all in prevailing Central Time) |
Event or Deadline | |
| November 3, 2026 | Hearing to Approve Bidding Procedures | |
| November 13, 2026 | Deadline to File Cure Notice | |
| November 23, 2026 at 4:00 p.m. | Bid Protections Objection Deadline | |
| November 30, 2026 (subject to the Court’s availability) | Bid Protections Hearing | |
| December 16, 2026 | Bid Deadline | |
| December 18, 2026 | Determination of Qualified Bids | |
| December 21, 2026 | Auction (if applicable) | |
71
| Date and Time (all in prevailing Central Time) |
Event or Deadline | |
| One (1) business day following conclusion of the Auction | Deadline to File Post-Auction Notice | |
| January 4, 2027 | Sale Objection Deadline Adequate Assurance Objection Deadline | |
| January 11, 2027 | Sale Hearing | |
| D. | Claims Process; No General Bar Date. |
Because the Prepackaged Plan provides that all Allowed General Unsecured Claims will be Unimpaired and paid or disputed in the ordinary course of business as if the Chapter 11 Cases had not been commenced, the Debtors do not intend to seek the establishment of a general bar date for the filing of Proofs of Claim, and, pursuant to the Solicitation Procedures Motion, intend to seek an extension of the deadline to file Schedules and statements of financial affairs through and including January 29, 2027 and a waiver of that requirement upon Confirmation of the Prepackaged Plan on or before such date. As set forth in Article VII.A of the Prepackaged Plan, there is no requirement to file a Proof of Claim (or move the Bankruptcy Court for allowance) to have a Claim Allowed for purposes of the Prepackaged Plan, except with respect to Claims arising from the rejection of Executory Contracts or Unexpired Leases, which must be Filed within thirty (30) days after the later of the entry of an order approving such rejection, the effective date of such rejection, and the Effective Date, as set forth in Article V.B of the Prepackaged Plan, and Cure amounts, which are governed by Article V.C of the Prepackaged Plan. The Debtors reserve the right to seek to establish a bar date in the event that a Sale Transaction is pursued, in which case a separate order of the Bankruptcy Court will govern.
| VIII. | RISK FACTORS |
BEFORE TAKING ANY ACTION WITH RESPECT TO THE PREPACKAGED PLAN, HOLDERS OF CLAIMS AGAINST THE DEBTORS WHO ARE ENTITLED TO VOTE TO ACCEPT OR REJECT THE PREPACKAGED PLAN SHOULD READ AND CONSIDER CAREFULLY THE RISK FACTORS SET FORTH BELOW, AS WELL AS THE OTHER INFORMATION SET FORTH IN THIS DISCLOSURE STATEMENT, THE PREPACKAGED PLAN, AND THE DOCUMENTS DELIVERED TOGETHER HEREWITH, REFERRED TO, OR INCORPORATED BY REFERENCE INTO THIS DISCLOSURE STATEMENT, INCLUDING OTHER DOCUMENTS FILED WITH THE BANKRUPTCY COURT IN THE CHAPTER 11 CASES. THE RISK FACTORS SHOULD NOT BE REGARDED AS CONSTITUTING THE ONLY RISKS PRESENT IN CONNECTION WITH THE DEBTORS’ BUSINESSES OR THE RESTRUCTURING AND CONSUMMATION OF THE PREPACKAGED PLAN. EACH OF THE RISK FACTORS DISCUSSED IN THIS DISCLOSURE STATEMENT MAY APPLY EQUALLY TO THE DEBTORS, THE REORGANIZED DEBTORS AND THE POST-EFFECTIVE DATE DEBTORS, AS APPLICABLE AND AS CONTEXT REQUIRES.
72
Prior to voting on the Prepackaged Plan, Holders of Claims in Classes 3, 4, 5, and 6, as well as entities in non-voting Classes, should consider carefully the risk factors described below, as well as all of the information contained in this Disclosure Statement, including the Exhibits hereto. These risk factors should not, however, be regarded as constituting the only risks involved in connection with the Prepackaged Plan and its implementation. Holders of Claims should also review the risk factors described in Parent’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, each as filed with the SEC. See Article XII of this Disclosure Statement for a discussion of U.S. federal income tax law considerations.
| A. | Bankruptcy Law Considerations. |
The occurrence or non-occurrence of any or all of the following contingencies, and any others, could affect distributions available to Holders of Allowed Claims and Interests under the Prepackaged Plan but will not necessarily affect the validity of the vote of the Impaired Classes to accept or reject the Prepackaged Plan or necessarily require a re-solicitation of the votes of Holders of Claims in such Impaired Classes.
| 1. | There Is a Risk of Termination of the Restructuring Support Agreement. |
To the extent that events giving rise to termination of the Restructuring Support Agreement occur, the Restructuring Support Agreement may terminate prior to the Confirmation or Consummation of the Prepackaged Plan, which could result in the loss of support for the Prepackaged Plan by important stakeholder constituencies and could result in the loss of use of cash collateral by the Debtors under certain circumstances. Any such loss of support could adversely affect the Debtors’ ability to confirm and consummate the Prepackaged Plan. If the Prepackaged Plan is not consummated, there can be no assurance that the Chapter 11 Cases would not be converted to chapter 7 liquidation cases or that any new chapter 11 plan would be as favorable to Holders of Claims or Interests as the current Prepackaged Plan.
| 2. | The Bankruptcy Court May Not Approve the Debtors’ Use of Cash Collateral or Entry into the DIP Facility. |
Upon commencing the Chapter 11 Cases, the Debtors will ask the Bankruptcy Court to authorize the Debtors to enter into the DIP Facility and use Cash Collateral to fund the Chapter 11 Cases and to provide customary adequate protection to the Prepetition Secured Parties in accordance with the terms of the DIP Motion. Such access to postpetition financing and Cash Collateral will provide liquidity during the pendency of the Chapter 11 Cases. There can be no assurance that the Bankruptcy Court will approve the DIP Facility and/or such use of Cash Collateral on the terms requested.
Moreover, if the Chapter 11 Cases take longer than expected to conclude, the Debtors may exhaust their available Cash Collateral and postpetition financing. There is no assurance that the Debtors will be able to obtain an extension of the right to obtain further postpetition financing and/or use Cash Collateral, in which case the liquidity necessary for the orderly functioning of the Debtors’ businesses may be impaired materially.
73
| 3. | The Terms of the DIP Facility Documents Are Subject to Change Based on Negotiations and the Approval of the Bankruptcy Court. |
The terms of the DIP Facility Documents have not been finalized and are subject to change based on negotiations between the Debtors, the DIP Lenders, and the Prepetition Secured Parties and the approval of the Bankruptcy Court. As a result, the final terms of the DIP Facility Documents may differ from the terms described herein and in the DIP Motion.
| 4. | Parties in Interest May Object to the Prepackaged Plan’s Classification of Claims and Interests. |
There is no guarantee that the Bankruptcy Court will agree with the classification of Claims and Interests as proposed by the Prepackaged Plan. Section 1122 of the Bankruptcy Code provides that a chapter 11 plan may place a claim or an equity interest in a particular class only if that claim or interest is substantially similar to the other claims or interests in that class. As is described herein, the Debtors believe that the Prepackaged Plan’s classification of Claims and Interests complies with the requirements under the Bankruptcy Code. However, a holder of a Claim or Interest could challenge the Debtors’ classification. In such an event, the cost of the Chapter 11 Cases and the time needed to confirm the Prepackaged Plan may increase, and there can be no assurance that the Bankruptcy Court will agree with the Debtors’ classification. If the Bankruptcy Court concludes that the classifications of Claims and Interests under the Prepackaged Plan do not comply with the requirements of the Bankruptcy Code, the Debtors may need to modify the Prepackaged Plan (subject to the terms of the Restructuring Support Agreement). The Prepackaged Plan may not be confirmed if the Bankruptcy Court determines that the Debtors’ classification of Claims and Interests is not appropriate.
| 5. | The Conditions Precedent to the Effective Date of the Prepackaged Plan May Not Occur. |
As more fully set forth in Article IX of the Prepackaged Plan, the confirmation and Effective Date of the Prepackaged Plan are subject to a number of conditions precedent. If such conditions precedent are not waived or not met, the confirmation and Effective Date of the Prepackaged Plan will not take place. In the event that the Effective Date does not occur, the Debtors may seek confirmation of a new plan or be forced to pivot to a chapter 7 liquidation.
| 6. | The Bankruptcy Court May Find the Solicitation of Acceptances Inadequate. |
Usually, votes to accept or reject a plan of reorganization are solicited after the filing of a petition commencing a chapter 11 case. Nevertheless, a debtor may solicit votes prior to the commencement of a chapter 11 case in accordance with sections 1125(g) and 1126(b) of the Bankruptcy Code and Bankruptcy Rule 3018(b). Sections 1125(g) and 1126(b) of the Bankruptcy Code and Bankruptcy Rule 3018(b) require that:
| • | solicitation comply with applicable nonbankruptcy law; |
| • | the plan of reorganization be transmitted to substantially all creditors and other interest holders entitled to vote; and |
| • | the time prescribed for voting is not unreasonably short. |
74
In addition, Bankruptcy Rule 3018(b) provides that a holder of a claim or interest who has accepted or rejected a plan before the commencement of the case under the Bankruptcy Code will not be deemed to have accepted or rejected the plan if the court finds after notice and a hearing that the plan was not transmitted in accordance with reasonable solicitation procedures. Section 1126(b) of the Bankruptcy Code provides that a holder of a claim or interest that has accepted or rejected a plan before the commencement of a case under the Bankruptcy Code is deemed to have accepted or rejected the plan if (a) the solicitation of such acceptance or rejection was in compliance with applicable nonbankruptcy law, rule or regulation governing the adequacy of disclosure in connection with such solicitation or (b) there is no such law, rule, or regulation, and such acceptance or rejection was solicited after disclosure to such holder of adequate information (as defined by section 1125(a) of the Bankruptcy Code). While the Debtors believe that the requirements of sections 1125(g) and 1126(b) of the Bankruptcy Code and Bankruptcy Rule 3018(b) will be met, there can be no assurance that the Bankruptcy Court will reach the same conclusion.
The Bankruptcy Court could fail to finally approve this Disclosure Statement and determine that the votes in favor of the Prepackaged Plan could be disregarded. The Debtors would then be required to recommence the solicitation process, which could include re-filing a plan and disclosure statement.
| 7. | The Debtors May Fail to Satisfy the Vote Requirements. |
Pursuant to the Restructuring Support Agreement, the Consenting Stakeholders have agreed to vote to accept the Prepackaged Plan, and the Debtors expect to receive the requisite acceptances from each Voting Class on or before the Voting Deadline, which is November 30, 2026, twenty-eight (28) days after the Petition Date. If votes are received in number and amount sufficient to enable the Bankruptcy Court to confirm the Prepackaged Plan, the Debtors intend to seek, as promptly as practicable thereafter, confirmation of the Prepackaged Plan. In the event that sufficient votes are not received, the Debtors may need to seek to confirm an alternative chapter 11 plan or transaction, subject to the terms of the Restructuring Support Agreement. There can be no assurance that the terms of any such alternative chapter 11 plan or other transaction would be similar or as favorable to the Holders of Allowed Claims and Interests as those proposed in the Prepackaged Plan and the Debtors do not believe that any such transaction exists or is likely to exist that would be more beneficial to the Estates than the Prepackaged Plan.
| 8. | The Debtors May Not Be Able to Secure Confirmation of the Prepackaged Plan. |
Section 1129 of the Bankruptcy Code sets forth the requirements for confirmation of a chapter 11 plan, and requires, among other things, a finding by the Bankruptcy Court that: (a) such plan “does not unfairly discriminate” and is “fair and equitable” with respect to any non-accepting classes; (b) confirmation of such plan is not likely to be followed by a liquidation or a need for further financial reorganization unless such liquidation or reorganization is contemplated by the plan; and (c) the value of distributions to non-accepting holders of claims or equity interests within a particular class under such plan will not be less than the value of distributions such holders would receive if the debtors were liquidated under chapter 7 of the Bankruptcy Code.
75
There can be no assurance that the requisite acceptances to confirm the Prepackaged Plan will be received. Even if the requisite acceptances are received, there can be no assurance that the Bankruptcy Court will confirm the Prepackaged Plan. A non-accepting Holder of an Allowed Claim or Interest may object to Confirmation and assert that the Prepackaged Plan does not satisfy the requirements of the Bankruptcy Code or Bankruptcy Rules. Even if the Bankruptcy Court determines that this Disclosure Statement, the balloting procedures, and voting results are appropriate, the Bankruptcy Court could still decline to confirm the Prepackaged Plan if it finds that any of the statutory requirements for Confirmation are not met. If a chapter 11 plan of reorganization is not confirmed by the Bankruptcy Court, it is unclear whether the Debtors will be able to reorganize their business and what, if anything, Holders of Interests and Allowed Claims against them would ultimately receive.
The Debtors, subject to the terms and conditions of the Prepackaged Plan and the Restructuring Support Agreement, reserve the right to modify the terms and conditions of the Prepackaged Plan as necessary for Confirmation. Any such modifications could result in less favorable treatment of any non-accepting class of Claims or Interests, as well as any class junior to such non-accepting class, than the treatment currently provided in the Prepackaged Plan. Such a less favorable treatment could include a distribution of property with a lesser value than currently provided in the Prepackaged Plan or no distribution whatsoever under the Prepackaged Plan.
| 9. | The Debtors May Not Be Able to Secure Nonconsensual Confirmation Over Certain Impaired Non-Accepting Classes. |
In the event that any impaired class of claims or interests does not accept a chapter 11 plan, a bankruptcy court may nevertheless confirm a plan at the proponents’ request if at least one impaired class (as defined under section 1124 of the Bankruptcy Code) has accepted the plan (with such acceptance being determined without including the vote of any “insider” in such class), and, as to each impaired class that has not accepted the plan, the bankruptcy court determines that the plan “does not discriminate unfairly” and is “fair and equitable” with respect to the dissenting impaired class(es). The Debtors believe that the Prepackaged Plan satisfies these requirements, and the Debtors may request such nonconsensual Confirmation in accordance with subsection 1129(b) of the Bankruptcy Code. Nevertheless, there can be no assurance that the Bankruptcy Court will reach this conclusion. In addition, the pursuit of nonconsensual confirmation or Consummation of the Prepackaged Plan may result in, among other things, increased expenses relating to professional compensation.
| 10. | Even if the Restructuring Transactions Are Successful, the Debtors Will Face Continued Risk Upon Confirmation. |
Even if the Prepackaged Plan is consummated, the Reorganized Debtors will continue to face a number of risks, including certain risks that are beyond their control, such as further deterioration or other changes in economic conditions, changes in the pharmaceutical industry and the regulatory environment, the outcome of the FDA’s review of the sNDA, potential revaluing of their assets due to the Chapter 11 Cases, changes in demand for XPOVIO and Omisirge®, and increasing expenses. See Article VIII.D of this Disclosure Statement, entitled “Risks Related to the Debtors’ and NewCo’s Businesses.” Some of these concerns and effects typically become more acute when a case under the Bankruptcy Code continues for a protracted period without indication of how or when the case may be completed. As a result of these risks and others, there is no guarantee that the Prepackaged Plan will achieve the Debtors’ stated goals.
76
In addition, at the outset of the Chapter 11 Cases, the Bankruptcy Code provides the Debtors with the exclusive right to propose the Prepackaged Plan and prohibits creditors and others from proposing a plan. The Debtors will have retained the exclusive right to propose the Prepackaged Plan upon filing their Petitions. If the Bankruptcy Court terminates that right, however, or the exclusivity period expires, there could be a material adverse effect on the Debtors’ ability to achieve confirmation of the Prepackaged Plan in order to achieve the Debtors’ stated goals.
Furthermore, even if the Debtors’ debts are reduced and/or discharged through the Prepackaged Plan, the Debtors may need to raise additional funds through public or private debt or equity financing or other various means to fund the Debtors’ businesses after the completion of the proceedings related to the Chapter 11 Cases. Adequate funds may not be available when needed or may not be available on favorable terms.
| 11. | The Chapter 11 Cases May Be Converted to Cases Under Chapter 7 of the Bankruptcy Code. |
If the Bankruptcy Court finds that it would be in the best interest of creditors and/or the debtor in a chapter 11 case, the Bankruptcy Court may convert a chapter 11 bankruptcy case to a case under chapter 7 of the Bankruptcy Code. In such event, a chapter 7 trustee would be appointed or elected to liquidate the debtor’s assets for distribution in accordance with the priorities established by the Bankruptcy Code. The Debtors believe that liquidation under chapter 7 would result in significantly smaller distributions being made to creditors than those provided for in a chapter 11 plan because of (a) the likelihood that the assets would have to be sold or otherwise disposed of in a disorderly fashion over a short period of time, rather than reorganizing or selling the business as a going concern in a controlled manner, (b) additional administrative expenses involved in the appointment of a chapter 7 trustee, and (c) additional expenses and Claims, some of which would be entitled to priority, that would be generated during the liquidation, including Claims resulting from the rejection of Unexpired Leases and other Executory Contracts in connection with cessation of operations.
| 12. | The Debtors May Object to the Amount or Classification of a Claim. |
Except as otherwise provided in the Prepackaged Plan, the Debtors reserve the right to object to the amount or classification of any Claim under the Prepackaged Plan. The estimates set forth in this Disclosure Statement cannot be relied upon by any Holder of a Claim where such Claim is subject to an objection. Any Holder of a Claim that is subject to an objection thus may not receive its expected share of the estimated distributions described in this Disclosure Statement.
| 13. | Contingencies Could Affect Votes of Impaired Classes to Accept or Reject the Prepackaged Plan. |
The distributions available to Holders of Allowed Claims under the Prepackaged Plan can be affected by a variety of contingencies, including, without limitation, whether the Bankruptcy Court orders certain Allowed Claims to be subordinated to other Allowed Claims and whether the Reorganization Transaction or the Sale Transaction is consummated. The occurrence of any and all such contingencies, which could affect distributions available to Holders of Allowed Claims under the Prepackaged Plan, will not affect the validity of the vote taken by the Impaired Classes to accept or reject the Prepackaged Plan or require any sort of revote by the Impaired Classes.
77
The estimated Claims and creditor recoveries set forth in this Disclosure Statement are based on various assumptions, and the actual Allowed amounts of Claims may significantly differ from the estimates. Should one or more of the underlying assumptions ultimately prove to be incorrect, the actual Allowed amounts of Claims may vary from the estimated Claims contained in this Disclosure Statement. Moreover, the Debtors cannot determine with any certainty at this time, the number or amount of Claims that will ultimately be Allowed. Such differences may materially and adversely affect, among other things, the percentage recoveries to Holders of Allowed Claims under the Prepackaged Plan.
| 14. | Releases, Injunctions, and Exculpation Provisions May Not Be Approved. |
Article VIII of the Prepackaged Plan provides for certain releases, injunctions, and exculpations, including a release of liens and third-party releases that may otherwise be asserted against the Debtors, Reorganized Debtors, Post-Effective Date Debtors, or Released Parties, as applicable. The releases, injunctions, and exculpations provided in the Prepackaged Plan are subject to objection by parties in interest and may not be approved. If the releases are not approved, certain Released Parties may withdraw their support for the Prepackaged Plan.
The releases provided to the Released Parties and the exculpation provided to the Exculpated Parties are necessary to the success of the Debtors’ reorganization because the Released Parties and Exculpated Parties have made significant contributions to the Debtors’ reorganizational efforts that are important to the success of the Prepackaged Plan and have agreed to make further contributions, including by agreeing to massive reductions in the amounts of their claims against the Debtors’ estates and facilitating a critical source of post-emergence liquidity, but only if they receive the full benefit of the Prepackaged Plan’s release and exculpation provisions. The Prepackaged Plan’s release and exculpation provisions are an inextricable component of the Restructuring Support Agreement and Prepackaged Plan and the significant deleveraging and financial benefits that they embody.
| 15. | The Debtors Cannot Predict the Amount of Time Spent in Bankruptcy, and Time Spent in Bankruptcy Could Disrupt the Debtors’ Businesses. |
The Debtors estimate that the process of obtaining Confirmation and Consummation of the Prepackaged Plan by the Bankruptcy Court could last approximately 75 to 90 days from the Petition Date, but it could last considerably longer if, for example, Confirmation is contested or the conditions to Confirmation or Consummation, including obtaining any required regulatory approvals, are not satisfied or waived.
78
Although the Prepackaged Plan is designed to minimize the length of the bankruptcy proceedings, it is impossible to predict with certainty the amount of time that the Debtors may spend in bankruptcy, and the Debtors cannot be certain that the Prepackaged Plan will be confirmed. Even if confirmed on a timely basis, a bankruptcy proceeding to confirm the Prepackaged Plan could itself have an adverse effect on the Debtors’ businesses. There is a risk, due to uncertainty about the Debtors’ futures that, among other things:
| • | employees could be distracted from performance of their duties or more easily attracted to other career opportunities; and |
| • | suppliers, vendors, or other business partners could terminate their relationship with the Debtors or demand financial assurances or enhanced performance, any of which could impair the Debtors’ prospects. |
A lengthy bankruptcy proceeding also would involve additional expenses and divert the attention of management from the operation of the Debtors’ businesses.
The disruption that the bankruptcy process would have on the Debtors’ businesses could increase with the length of time it takes to complete the Chapter 11 Cases. If the Debtors are unable to obtain Confirmation of the Prepackaged Plan on a timely basis, because of a challenge to the Prepackaged Plan or otherwise, the Debtors may be forced to operate in bankruptcy for an extended period of time while they try to develop a different plan of reorganization that can be confirmed. A protracted bankruptcy case could increase both the probability and the magnitude of the adverse effects described above.
| 16. | Risk of Non-Occurrence of the Effective Date. |
Although the Debtors believe that the Effective Date may occur quickly after the Confirmation Date, there can be no assurance as to such timing or as to whether the Effective Date will, in fact, occur. As more fully set forth in Article IX of the Prepackaged Plan, the Effective Date of the Prepackaged Plan is subject to a number of conditions precedent, including obtaining any required regulatory approvals. If such conditions precedent are not met and not waived, the Effective Date will not take place.
| B. | Risks Related to Recoveries Under the Prepackaged Plan. |
| 1. | The Amounts of Allowed Claims May Adversely Affect the Recovery of Some Holders of Allowed Claims. |
The distributions available to Holders of Allowed Claims in Classes 3, 4, 5, and 6 under the Prepackaged Plan can be affected by a variety of contingencies, including, without limitation, the amount of Allowed Administrative Claims, DIP Claims, Priority Tax Claims, Other Secured Claims, and Other Priority Claims, and the amount of any Equitized DIP New Money Claims, which determines the allocation of the Reorganized Parent Equity Distribution among the Holders of DIP Claims and Classes 3, 4, and 5. The Debtors cannot determine with any certainty at this time the number or amount of such Claims that will ultimately be Allowed. Thus, the projected recoveries for Holders of Allowed Claims in Classes 3, 4, 5, and 6 disclosed in this Disclosure Statement are estimates only.
79
| 2. | The Restructuring Transaction Ultimately Consummated Has Not Been Determined, and Recoveries Differ Between the Reorganization Transaction and a Sale Transaction. |
The Prepackaged Plan provides for the Reorganization Transaction unless the Debtors, in accordance with the Bidding Procedures, elect to pursue a Sale Transaction by Filing a Sale Transaction Election Notice on or before the Sale Transaction Election Notice Deadline. The Debtors have not determined, and will not determine until after the occurrence of the Bid Deadline and the evaluation of any Qualified Bids received by such time, which Restructuring Transaction will be consummated. The form of consideration to be distributed to Holders of Allowed Claims in the Voting Classes differs materially between the two Restructuring Transactions (New Common Stock and MF CVRs in a Reorganization Transaction; Cash in a Sale Transaction), and the value ultimately realized by such Holders may differ materially depending on which Restructuring Transaction is consummated.
In addition, the Successful Bid Mandatory Conditions, including the requirement that a Successful Bid provide for net proceeds at closing of not less than $335,384,812 (of which $18,750,000 allocable to the RIFA Claims may be satisfied with Cash or non-Cash consideration acceptable to the Holders of RIFA Claims), may be modified or waived with the consent of the Required Consenting Funded Debt Parties (as defined in the Restructuring Support Agreement) and, to the extent required under the Restructuring Support Agreement, the Required Consenting Royalty Investors, in accordance with the Prepackaged Plan, the Restructuring Support Agreement, and the Bidding Procedures, and Ayrmid may itself be selected as the Successful Bidder or designated as the back-up bidder. Any such modification, or any modification of the Merger Agreement, the NewCo Facility Documents, the MF CVR Agreement, or the other Definitive Documents, will be made only in accordance with the Prepackaged Plan, the Restructuring Support Agreement, and section 1127 of the Bankruptcy Code, and the Debtors cannot predict whether any such modification would require the resolicitation of votes on the Prepackaged Plan.
| 3. | Any Valuation of Any Assets to Be Distributed Under the Prepackaged Plan Is Speculative, and Estimated Recoveries Are Not Intended to Represent Potential Market Values. |
Any valuation of any of the assets to be distributed under the Prepackaged Plan, including the New Common Stock, the MF CVRs, and the rights under the New Royalty Agreement, is necessarily speculative. Any estimate of the value of such assets depends on, among other things, the Financial Projections for the Reorganized Debtors on a combined basis, the results of the Marketing and Sale Process, assumptions regarding the achievement of synergies from the Merger, and assumptions regarding the regulatory and commercial prospects of XPOVIO® and Omisirge®, none of which can be assured. Accordingly, the ultimate value, if any, of these assets could materially affect, among other things, recoveries to the Holders of Allowed Claims in Classes 3, 4, 5, and 6.
The Debtors’ estimated recoveries to Holders of Allowed Claims are not intended to represent the market value of the New Common Stock, the MF CVRs, or the Debtors’ other Securities. The estimated recoveries are based on numerous assumptions (the realization of many of which will be beyond the control of the Debtors), including: (a) the consummation of the Merger and the successful integration of the businesses of the Company and Ayrmid; (b) an assumed date for the occurrence of the Effective Date; (c) NewCo’s ability to maintain adequate liquidity to fund operations and to service the NewCo Facility; (d) the assumption that capital and equity markets remain consistent with current conditions; and (e) the approval and commercial adoption of XPOVIO for the MF Indication.
80
| 4. | The Debtors Cannot Guarantee the Timing of Distributions. |
The timing of actual distributions to Holders of Allowed Claims may be affected by many factors that cannot be predicted, including the timing of the receipt of any required regulatory approvals and the satisfaction of the conditions to the Merger. Therefore, the Debtors cannot guarantee the timing of any recovery on an Allowed Claim.
| 5. | The Terms of the New Corporate Governance Documents, the NewCo Facility Documents, and the MF CVR Agreement Are Subject to Change Based on Negotiations and the Approval of the Bankruptcy Court. |
The terms of the New Corporate Governance Documents, the NewCo Facility Documents, the MF CVR Agreement, and the Merger Agreement have not been finalized and are subject to change based on negotiations among the Debtors, Ayrmid, and certain of the Consenting Stakeholders, subject to the terms and conditions of the Prepackaged Plan and the Restructuring Support Agreement (including the consent rights set forth therein). Holders of Claims that are not Consenting Stakeholders will not participate in these negotiations, and the results of such negotiations may affect the rights of holders of New Common Stock and MF CVRs following the Effective Date. As a result, the final terms of such documents may be less favorable to Holders of Claims than as described herein and in the Prepackaged Plan.
| 6. | Certain Tax Implications of the Debtors’ Bankruptcy. |
Holders of Allowed Claims should carefully review Article XII of this Disclosure Statement, entitled “Certain U.S. Federal Income Tax Consequences of the Prepackaged Plan,” to determine how the tax implications of the Prepackaged Plan and the Chapter 11 Cases may affect the Debtors, the Reorganized Debtors, and Holders of Claims, as well as certain tax implications of owning and disposing of the consideration to be received pursuant to the Prepackaged Plan.
| 7. | The Reorganized Debtors May Not Be Able to Achieve Their Projected Financial Results. |
The Financial Projections to be filed in the Plan Supplement represent the Debtors’ and Ayrmid’s management teams’ best estimate of the Reorganized Debtors’ future financial performance on a combined basis, which is necessarily based on certain assumptions regarding the anticipated future performance of the combined company’s operations, including the continued commercial performance of XPOVIO® and Omisirge®, the approval and commercialization of the MF Indication, the realization of anticipated synergies, and the United States and world economies in general, and the pharmaceutical industry in particular. While the Debtors believe that the Financial Projections will be reasonable, there can be no assurance that they will be realized. If the Reorganized Debtors do not achieve their projected financial results, the value of the New Common Stock may be negatively affected and NewCo may lack sufficient liquidity to continue operating as planned after the Effective Date or to make payments under the MF CVRs and the New Royalty Agreement. Moreover, the financial condition and results of operations of the Reorganized Debtors from and after the Effective Date will not be comparable to the financial condition or results of operations reflected in the Debtors’ historical financial statements.
81
| 8. | Financial Results May Be Volatile and May Not Reflect Historical Trends. |
During the Chapter 11 Cases, the Debtors expect that their financial results will continue to be volatile as asset impairments, asset dispositions, restructuring activities and expenses, contract terminations and rejections, and/or claims assessments significantly impact the Debtors’ consolidated financial statements. As a result, the Debtors’ historical financial performance likely will not be indicative of their financial performance after the Petition Date.
In addition, if the Reorganization Transaction is consummated, the amounts reported in NewCo’s subsequent consolidated financial statements may materially change relative to the Debtors’ historical consolidated financial statements, including as a result of the Merger, revisions to the Debtors’ operating plans, and the application of acquisition or “fresh start” accounting, in which case assets and liabilities may be recorded at fair value as of the applicable reporting date, which may differ materially from the recorded values of assets and liabilities on the Debtors’ consolidated balance sheets. The Financial Projections to be filed with the Plan Supplement may not reflect the impact of such accounting, which may have a material impact on the Financial Projections.
| C. | Risks Related to the Merger and the Consideration to Be Issued in a Reorganization Transaction. |
| 1. | The Merger May Not Be Consummated. |
Consummation of the Reorganization Transaction is conditioned on the consummation of the Merger substantially concurrently with the Effective Date. The Merger is subject to the satisfaction or waiver of a number of conditions set forth in the Merger Agreement, including the equitization or structural subordination of the Ayrmid Term Loan in a manner acceptable to the Required Consenting Funded Debt Parties, the receipt of any required regulatory approvals, the absence of a material adverse effect with respect to either party, and the execution and funding of the NewCo Facility. Many of these conditions are outside of the Debtors’ control. In addition, the Merger Agreement may be terminated by the parties thereto in certain circumstances. If the Merger is not consummated, the Reorganization Transaction cannot be consummated as currently contemplated, and the Debtors would be required to seek an alternative transaction, which may be less favorable to Holders of Claims than the Prepackaged Plan.
| 2. | The Combined Company Will Face Integration and Execution Risks. |
Following the Merger, NewCo will be required to integrate the businesses of the Company and Ayrmid, including their respective commercial organizations, supply chains, information technology systems, and corporate functions. The integration of two companies that have never operated together is complex, costly, and time-consuming, may divert management’s attention from the operation of the businesses, and may not result in the synergies and cost savings that are anticipated. In addition, Omisirge® is a cell therapy product with a manufacturing, logistics, and reimbursement profile that differs materially from that of XPOVIO®. Any failure to successfully integrate the businesses or to realize the anticipated benefits of the Merger could adversely affect the value of the New Common Stock.
82
| 3. | Holders of New Common Stock Will Be Subject to the Risks of Ayrmid’s Business. |
Holders of Funded Debt Claims that receive New Common Stock will hold an interest in a combined enterprise that includes Ayrmid and Gamida Cell Inc., and will therefore be exposed to the risks of Ayrmid’s business, including risks relating to the commercialization of Omisirge®, the manufacture of a complex cell therapy product through internal facilities and third-party contract manufacturers, reimbursement for cell therapy products, competition from other transplant and cellular therapy modalities, Ayrmid’s liabilities (including any contingent liabilities arising from the prior restructuring of Gamida Cell Ltd.), and Ayrmid’s ongoing clinical development programs. The Debtors have conducted due diligence with respect to Ayrmid’s business, but such diligence may not have identified all material risks, and the Debtors make no representation regarding the future performance of Ayrmid’s business.
| 4. | The Omisirge Contingent Equity and Any Management Incentive Plan Will Dilute Holders of New Common Stock. |
The Merger Agreement provides that the former equityholders of Ayrmid will be entitled to receive additional shares of New Common Stock representing up to 8.5% of the New Common Stock issued and outstanding on the Effective Date if global net revenues of Omisirge® for the fiscal year ending December 31, 2028 exceed specified thresholds. In addition, NewCo will implement the Management Incentive Plan on terms acceptable to Ayrmid and the Required Consenting Funded Debt Parties and approved by the New Board, providing for the issuance of equity awards to management and employees of NewCo. The issuance of the Omisirge Contingent Equity will dilute solely the New Common Stock issued as Merger Consideration to the Holders of Funded Debt Claims (and any other New Common Stock issued on account of Claims under the Prepackaged Plan), and will not dilute the New Common Stock issued to the former equityholders of Ayrmid, and any equity issued under the Management Incentive Plan will dilute the ownership percentage of all Holders of New Common Stock, including the Holders of Funded Debt Claims, and the amount and dilutive effect of any of the foregoing could be material. In the future, similar to all companies, additional equity financings or other equity issuances by NewCo could further dilute the New Common Stock.
| 5. | Holders of MF CVRs May Never Receive Any Payment. |
The MF CVRs represent a contingent right to receive Cash payments based on net sales of XPOVIO® for the MF Indication during the MF CVR Term. No payments will be made under the MF CVRs unless and until the FDA approves XPOVIO® (selinexor) in combination with ruxolitinib for the treatment of myelofibrosis and XPOVIO® is commercially sold for the MF Indication. As described in Article V.B of this Disclosure Statement, the SENTRY Trial did not meet its second co-primary endpoint, and the sNDA seeks accelerated approval based on the totality of the SENTRY Trial data. There can be no assurance that the FDA will accept the sNDA for filing, that the FDA will approve the sNDA on an accelerated basis or at all, that any approval will be granted on or before December 31, 2027 (in which case the payment rate under the MF
83
CVRs would be 15.0% rather than 20.0% of MF Net Sales), that any approval will not be subject to conditions, including a requirement to conduct additional confirmatory clinical trials, or that, if approved, XPOVIO® will achieve meaningful commercial adoption in the MF Indication. The MF CVR Term will terminate upon the first commercial sale in the United States of a generic version of XPOVIO®, which could occur earlier than anticipated as a result of patent challenges or otherwise. In addition, the obligations under the MF CVR Agreement will be unsecured obligations of NewCo that will be effectively subordinated to the NewCo Facility and any other secured indebtedness of NewCo to the extent of the value of the collateral securing such indebtedness, and NewCo’s ability to make payments under the MF CVRs will depend on its financial condition and compliance with the NewCo Facility Documents at the time such payments become due. The MF CVRs will be non-transferable except as expressly permitted by the MF CVR Agreement, will not be listed on any securities exchange, and will not confer any voting or governance rights. Holders of MF CVRs will have no ability to influence NewCo’s decisions regarding the development and commercialization of the MF Indication other than through the covenants set forth in the MF CVR Agreement.
| 6. | The New Common Stock Will Be Illiquid, and NewCo Will Be a Private Company. |
In the event of a Reorganization Transaction, NewCo will emerge from the Chapter 11 Cases as a privately held company, the New Common Stock will not be listed on any securities exchange, and NewCo will not be subject to the reporting requirements of the SEC. There is no existing market for the New Common Stock, and no assurance can be given that an active trading market will develop or, if developed, will be sustained. Holders of New Common Stock will have access to information regarding NewCo only to the extent provided in the New Corporate Governance Documents, which may be substantially less than the information currently available regarding Parent as an SEC-reporting company. In addition, the New Corporate Governance Documents may contain restrictions on the transfer of the New Common Stock, drag-along and tag-along rights, and other provisions customary for a privately held company. As a result, Holders of New Common Stock may be required to bear the economic risk of their investment for an indefinite period of time.
| 7. | Certain Holders of New Common Stock and MF CVRs May Be Restricted in Their Ability to Transfer or Sell Their Securities. |
To the extent that the New Common Stock and MF CVRs issued under the Prepackaged Plan are issued pursuant to section 1145(a)(1) of the Bankruptcy Code, such securities may be resold by the holders thereof without registration under the Securities Act unless such holder is an “underwriter” (as defined in section 1145(b) of the Bankruptcy Code) with respect to such securities; provided, however, such securities will not be freely tradeable if, at the time of transfer, the holder is an “affiliate” of NewCo or the Reorganized Debtors, as defined in Rule 144(a)(1) under the Securities Act, or had been such an “affiliate” within 90 days of such transfer. Such affiliate holders would only be permitted to sell such securities without registration if they are able to comply with an applicable exemption from registration, including Rule 144 under the Securities Act. Resales by Holders of Claims who receive New Common Stock or MF CVRs pursuant to the Prepackaged Plan that are deemed to be “underwriters” would not be exempted by section 1145 of the Bankruptcy Code from registration under the Securities Act or
84
applicable law. Holders who receive New Common Stock pursuant to the Prepackaged Plan that is issued in reliance upon section 4(a)(2) of the Securities Act or Regulation S promulgated thereunder will receive “restricted securities.” Such holders would only be permitted to sell such securities without registration if they are able to comply with an applicable exemption from registration, including Rule 144 under the Securities Act. The New Common Stock and MF CVRs will not be registered under the Securities Act or any state securities laws, and the Debtors make no representations regarding the right of any holder of New Common Stock or MF CVRs to freely resell such securities.
| 8. | A Small Number of Holders or Voting Blocks May Control NewCo. |
Consummation of the Prepackaged Plan may result in a small number of holders, including the former equityholders of Ayrmid and certain members of the Ad Hoc Group, each owning a significant percentage of the New Common Stock. These holders may be in a position to control the outcome of all actions requiring equity holder approval, including the election of directors, without the approval of other equity holders. This concentration of ownership could also facilitate or hinder a negotiated change of control of NewCo and, consequently, have an impact upon the value of the New Common Stock.
| 9. | New Common Stock Would Be Subordinated to NewCo’s Indebtedness. |
In any subsequent liquidation, dissolution, or winding up of NewCo, the New Common Stock would rank below all debt claims against NewCo and its subsidiaries, including the NewCo Facility, the obligations under the MF CVR Agreement, and the obligations under the New Royalty Agreement. As a result, holders of the New Common Stock will not be entitled to receive any payment or other distribution of assets upon the liquidation, dissolution, or winding up of NewCo until after all such debt obligations have been satisfied.
| 10. | NewCo Does Not Intend to Pay Dividends on the New Common Stock. |
NewCo does not anticipate paying any dividends on the New Common Stock as it expects to retain any future cash flows for debt reduction, payments under the MF CVRs and the New Royalty Agreement, and to support its operations and clinical development programs. In addition, covenants in the NewCo Facility Documents may restrict NewCo’s ability to pay cash dividends and may prohibit the payment of dividends and certain other payments. As a result, the success of an investment in the New Common Stock will depend entirely upon any future appreciation in the value of the New Common Stock. There is, however, no guarantee that the New Common Stock will appreciate in value or even maintain its initial value.
| 11. | The NewCo Facility May Not Be Available on the Terms Contemplated or at All. |
The Reorganization Transaction contemplates that NewCo will enter into the NewCo Facility in an aggregate principal amount of up to $135 million on the Effective Date. Although the Debtors have received nonbinding indications of interest to provide the NewCo Facility from prospective lenders, any commitment is subject to customary conditions, and as of the date hereof, the NewCo Facility has not been committed, and there can be no assurance that the NewCo Facility will be available on the terms contemplated, on terms acceptable to the Debtors and the Required Consenting Stakeholders, or at all. If the NewCo Facility is not available, the Debtors may be unable to consummate the Reorganization Transaction.
85
| 12. | NewCo May Not Be Able to Generate Sufficient Cash to Service Its Indebtedness. |
NewCo’s ability to make scheduled payments on, or to refinance, the NewCo Facility and its other obligations, including payments under the MF CVRs and the New Royalty Agreement, depends on NewCo’s financial condition and operating performance, which are subject to prevailing economic, industry, regulatory, and competitive conditions and to certain financial, business, legislative, regulatory, and other factors beyond NewCo’s control. NewCo may be unable to maintain a level of cash flow from operating activities sufficient to permit it to pay the principal, premium, if any, and interest and/or fees on its indebtedness.
| D. | Risks Related to the Debtors’ and NewCo’s Businesses. |
| 1. | The Debtors Will Be Subject to the Risks and Uncertainties Associated with the Chapter 11 Cases. |
For the duration of the Chapter 11 Cases, the Debtors’ ability to operate, develop, and execute a business plan, and continue as a going concern, will be subject to the risks and uncertainties associated with bankruptcy. These risks include the following: (a) ability to develop, confirm, and consummate the Restructuring Transactions specified in the Prepackaged Plan; (b) ability to obtain Bankruptcy Court approval with respect to motions Filed in the Chapter 11 Cases from time to time; (c) ability to maintain relationships with suppliers, vendors, service providers, customers, employees, and other third parties; (d) ability to maintain contracts that are critical to the Debtors’ operations; (e) ability of third parties to seek and obtain Bankruptcy Court approval to terminate contracts and other agreements with the Debtors; (f) ability to consummate the Merger or a value-maximizing Sale Transaction; (g) ability of third parties to seek and obtain Bankruptcy Court approval to terminate or shorten the exclusivity period for the Debtors to propose and confirm a chapter 11 plan, to appoint a chapter 11 trustee, or to convert the Chapter 11 Cases to chapter 7 proceedings; and (h) the actions and decisions of the Debtors’ creditors and other third parties who have interests in the Chapter 11 Cases that may be inconsistent with the Debtors’ plans.
These risks and uncertainties could affect the Debtors’ businesses and operations in various ways. For example, negative events associated with the Chapter 11 Cases could adversely affect the Debtors’ relationships with suppliers, service providers, customers, physicians, patients, payors, specialty distributors and pharmacies, contract manufacturers, clinical trial sites and investigators, licensing partners, employees, and other third parties, which in turn could adversely affect the Debtors’ operations and financial condition. Also, the Debtors will need the prior approval of the Bankruptcy Court for transactions outside the ordinary course of business, which may limit the Debtors’ ability to respond timely to certain events or take advantage of certain opportunities. Because of the risks and uncertainties associated with the Chapter 11 Cases, the Debtors cannot accurately predict or quantify the ultimate impact of events that occur during the Chapter 11 Cases that may be inconsistent with the Debtors’ plans.
86
| 2. | Operating in Bankruptcy for a Long Period of Time May Harm the Debtors’ Businesses. |
The Debtors’ future results will be dependent upon the successful confirmation and implementation of the Restructuring Transactions. A long period of operations under Bankruptcy Court protection could have a material adverse effect on the Debtors’ businesses, financial condition, results of operations, and liquidity. So long as the proceedings related to the Chapter 11 Cases continue, senior management will be required to spend a significant amount of time and effort dealing with the restructuring instead of focusing exclusively on business operations. A prolonged period of operating under Bankruptcy Court protection also may make it more difficult to retain management and other key personnel necessary to the success and growth of the Debtors’ businesses. In addition, the longer the proceedings related to the Chapter 11 Cases continue, the more likely it is that customers and suppliers will lose confidence in the Debtors’ ability to reorganize their businesses successfully and will seek to establish alternative commercial relationships.
So long as the proceedings related to the Chapter 11 Cases continue, the Debtors may be required to incur substantial costs for professional fees and other expenses associated with the administration of the Chapter 11 Cases. If the chapter 11 proceedings last longer than anticipated, the Debtors may require additional debtor-in-possession financing to fund the Debtors’ operations. If the Debtors are unable obtain such financing in those circumstances, the chances of successfully reorganizing the Debtors’ businesses may be seriously jeopardized, the likelihood that the Debtors will instead be required to liquidate or sell their assets may be increased, and, as a result, creditor recoveries may be significantly impaired.
| 3. | The Debtors Are Dependent on XPOVIO as Their Only Commercial Product. |
Substantially all of the Debtors’ revenue is derived from net product sales of XPOVIO® in the United States. Any event that adversely affects the sales of XPOVIO®—including increased competition from newer therapies for multiple myeloma such as bispecific antibodies, CAR-T cell therapies, and other novel agents, changes in treatment guidelines or clinical practice, adverse safety or efficacy data, supply interruptions, product recalls, pricing or reimbursement pressures, or the loss or impairment of the Company’s intellectual property protection—would have a material adverse effect on the Debtors’ and NewCo’s financial condition and results of operations, and could impair NewCo’s ability to service the NewCo Facility, to make payments under the MF CVRs and the New Royalty Agreement, and to fund its clinical development programs.
| 4. | The FDA May Not Approve the sNDA for the MF Indication, or May Not Do So on the Timeline Anticipated. |
The Debtors’ business plan and the value of the New Common Stock and the MF CVRs depend in significant part on the approval and successful commercialization of XPOVIO® for the MF Indication. The sNDA seeks accelerated approval based on the results of the SENTRY Trial, which met its SVR35 co-primary endpoint but did not meet its absolute total symptom score co-primary endpoint. The FDA may determine that the SENTRY Trial data do not support approval, may require additional clinical data or a confirmatory trial as a condition of accelerated
87
approval, may impose labeling restrictions that limit the commercial opportunity for the MF Indication, or may take longer than anticipated to complete its review. Any of these outcomes would adversely affect the value of the New Common Stock and the MF CVRs. In addition, even if approved, XPOVIO® will compete in the myelofibrosis market with established JAK inhibitors and other therapies, and may not achieve the level of adoption or pricing assumed in the Financial Projections.
| 5. | The Debtors Rely on Third Parties for the Manufacture, Distribution, and Clinical Development of Selinexor. |
The Debtors do not own or operate manufacturing facilities and rely on third-party contract manufacturers for the production of selinexor drug substance and XPOVIO® drug product, and on third-party logistics providers, specialty distributors, and specialty pharmacies for the distribution of XPOVIO®. The Debtors also rely on contract research organizations and clinical trial sites for the conduct of their clinical trials. The commencement of the Chapter 11 Cases may adversely affect the willingness of these third parties to continue to do business with the Debtors on customary terms, and any interruption in the supply or distribution of XPOVIO® or in the conduct of the Debtors’ clinical trials could have a material adverse effect on the Debtors’ business and on the value of the consideration to be distributed under the Prepackaged Plan.
| 6. | The Debtors’ Business Is Subject to Extensive Governmental Regulation and Pricing and Reimbursement Pressure. |
The Debtors’ operations are subject to extensive and evolving federal, state, and foreign laws and regulations governing, among other things, the development, approval, manufacture, labeling, marketing, promotion, distribution, pricing, and reimbursement of pharmaceutical products, including regulation by the FDA, the Centers for Medicare & Medicaid Services, the Office of Inspector General of the Department of Health and Human Services, and state regulatory authorities, as well as federal and state anti-kickback, false claims, physician payment transparency, and drug pricing laws. Failure to comply with these laws and regulations may result in the suspension or termination of operations and subject the Debtors to administrative, civil, and criminal penalties, which could have a material adverse effect on the recoveries set forth in the Prepackaged Plan. In addition, legislative and regulatory developments affecting drug pricing and reimbursement—including the Inflation Reduction Act of 2022 and its Medicare drug price negotiation and Part D redesign provisions, the 340B drug pricing program, and state drug pricing transparency and affordability laws—may adversely affect the net pricing and reimbursement of XPOVIO® and, following the Merger, Omisirge®.
| 7. | The Debtors’ Ability to Consummate the Prepackaged Plan Depends on Obtaining Any Required Regulatory Approvals. |
As described in Article III.G of this Disclosure Statement, the Merger or any Sale Transaction may require premerger notification under the HSR Act, review by CFIUS, or other antitrust, competition, or foreign investment approvals. There can be no assurance that such approvals, to the extent required, will be obtained on a timely basis or without the imposition of conditions that are unacceptable to the Debtors, Ayrmid, or a prospective Purchaser. Any delay in obtaining, or failure to obtain, such approvals could delay or prevent consummation of the Prepackaged Plan.
88
| 8. | The Debtors May Be Unable to Maintain Their Intellectual Property Protection. |
The Debtors’ commercial success depends on their ability to obtain and maintain patent and other intellectual property protection for selinexor and XPOVIO®, and to operate without infringing the intellectual property rights of others. The Debtors’ patents may be challenged, invalidated, circumvented, or held unenforceable, including in connection with the submission of abbreviated new drug applications by generic manufacturers seeking to market generic versions of XPOVIO® prior to the expiration of the Debtors’ patents. The entry of a generic version of XPOVIO® would materially and adversely affect NewCo’s revenue and would terminate the MF CVR Term.
| 9. | The Loss of Personnel Could Adversely Affect the Debtors’ Operations. |
The Debtors’ operations are dependent on a relatively small group of key management, regulatory, medical, and commercial personnel. The Debtors’ recent liquidity issues, the results of the XPORT-EC-042 Trial and the associated organizational changes, the pendency of the Chapter 11 Cases, and the uncertainty surrounding the Merger have created distractions and uncertainty for key management personnel and all employees. As a result, the Debtors have experienced and may continue to experience increased levels of employee attrition. Because competition for experienced pharmaceutical personnel is significant, the Debtors may be unable to find acceptable replacements with comparable skills and experience, and the loss of such personnel could adversely affect the Debtors’ ability to operate their businesses, to obtain approval of the sNDA, and to consummate and integrate the Merger.
| 10. | The Debtors Might Not Be Able to Satisfy Closing Conditions in Connection with a Sale Transaction. |
In the event of a Sale Transaction, it is possible that the Debtors might not be able to satisfy the conditions for closing the Sale Transaction or that counterparties in such Sale Transaction could exercise any relevant termination rights in accordance with the terms thereof. Further, it is possible that the Debtors might not receive any Qualified Bids that satisfy the Successful Bid Mandatory Conditions, or, in any case, might fail to reach an agreement on a Sale Transaction. If the Debtors File a Sale Transaction Election Notice and the Sale Transaction does not close, the Debtors may, subject to the terms of the Bidding Procedures Order, withdraw the Sale Transaction Election Notice and consummate the Reorganization Transaction, but there can be no assurance that the Merger and the NewCo Facility would remain available in such circumstances.
| 11. | A Sale Transaction Will Affect the Debtors’ Operations. |
In the event of a Sale Transaction, all or substantially all of the assets of the Debtors may be sold pursuant to sections 105, 363, and 365 of the Bankruptcy Code or the Prepackaged Plan. Any remaining assets of the Debtors will be wound down by the Post-Effective Date Plan Administrator in accordance with the Wind-Down Budget, and the Debtors will thereafter have no active ongoing operations.
89
| 12. | Certain Claims May Not Be Discharged and Could Have a Material Adverse Effect on the Debtors’ Financial Condition and Results of Operations. |
The Bankruptcy Code provides that the confirmation of a plan of reorganization discharges a debtor from substantially all debts arising prior to confirmation. With few exceptions, all Claims that arise prior to the Debtors’ filing of their Petitions or before confirmation of the plan of reorganization (a) would be subject to compromise and/or treatment under the plan of reorganization and/or (b) would be discharged in accordance with the terms of the plan of reorganization. Any Claims not ultimately discharged through a plan of reorganization could be asserted against the reorganized entity and may have an adverse effect on the Reorganized Debtors’ financial condition and results of operations. In addition, in the event of a Sale Transaction, the Debtors will not receive a discharge pursuant to section 1141(d)(3) of the Bankruptcy Code.
| E. | Disclosure Statement Disclaimer. |
| 1. | The Financial Information Contained in This Disclosure Statement Has Not Been Audited. |
In preparing this Disclosure Statement, the Debtors and their advisors relied on financial data derived from the Debtors’ books and records that was available at the time of such preparation. Although the Debtors have used their reasonable business judgment to ensure the accuracy of the financial information, and any conclusions or estimates drawn from that financial information, provided in this Disclosure Statement, and although the Debtors believe that the financial information herein fairly reflects the financial condition of the Debtors, the Debtors are unable to warrant that the financial information contained herein, or any conclusions or estimates drawn therefrom, is without inaccuracies.
| 2. | Information Contained in This Disclosure Statement Is for Soliciting Votes. |
The information contained in this Disclosure Statement is for the purpose of soliciting acceptances of the Prepackaged Plan and may not be relied upon for any other purpose.
| 3. | This Disclosure Statement Was Not Reviewed or Approved by the SEC. |
This Disclosure Statement was not filed with the SEC under the Securities Act or applicable state securities laws. Neither the SEC nor any state regulatory authority has passed upon the accuracy or adequacy of this Disclosure Statement or the exhibits or the statements contained in this Disclosure Statement.
| 4. | This Disclosure Statement May Contain Forward-Looking Statements. |
This Disclosure Statement may contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, as amended. Statements containing words such as “may,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “project,” “projections,” “business outlook,” “estimate,” or similar expressions constitute forward-looking statements and may include, without limitations, information regarding the Debtors’ expectations with respect to future events, including the FDA’s review of the sNDA, the
90
commercial prospects of XPOVIO® and Omisirge®, the consummation of the Merger, and the anticipated benefits thereof. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those risks described in this Article. Actual results or developments may differ materially from the expectations expressed or implied in the forward-looking statements, and the Debtors undertake no obligations to update any such statements.
Certain of the information contained in this Disclosure Statement is, by nature, forward-looking, and contains estimates and assumptions that might ultimately prove to be incorrect and projections that may be materially different from actual future experiences. Many of the assumptions underlying the projections are subject to significant uncertainties that are beyond the control of the Debtors, including the timing, confirmation, and consummation of the Prepackaged Plan, regulatory decisions, inflation, and other unanticipated market and economic conditions. There are uncertainties associated with any projections and estimates, and they should not be considered assurances or guarantees of the amount of funds or the amount of Claims in the various Classes that might be allowed. Some assumptions may not materialize, and unanticipated events and circumstances may affect the actual results. Projections are inherently subject to substantial and numerous uncertainties and to a wide variety of significant business, economic, and competitive risks, and the assumptions underlying the projections may be inaccurate in material respects. In addition, unanticipated events and circumstances occurring after the approval of this Disclosure Statement by the Bankruptcy Court may affect the actual financial results achieved by the Debtors. Such results may vary significantly from the forecasts and such variations may be material.
| 5. | No Legal or Tax Advice Is Provided to You by This Disclosure Statement. |
This Disclosure Statement is not legal advice to you. The contents of this Disclosure Statement should not be construed as legal, business or tax advice. Each Holder of a Claim or an Interest should consult his or her own legal counsel, accountant or other applicable advisor with regard to any legal, tax and other matters concerning his, her or its Claim or Interest. This Disclosure Statement may not be relied upon for any purpose other than to determine how to vote on the Prepackaged Plan or object to Confirmation of the Prepackaged Plan.
| 6. | No Admissions Made. |
The information and statements contained in this Disclosure Statement will neither (a) constitute an admission of any fact or liability by any entity (including, without limitation, the Debtors) nor (b) be deemed evidence of the tax or other legal effects of the Prepackaged Plan on the Debtors, Holders of Allowed Claims or Interests, or any other parties in interest.
| 7. | Failure to Identify Potential Objections. |
No reliance should be placed on the fact that a particular Cause of Action or potential objection to a particular Claim or Interest is, or is not, identified in this Disclosure Statement. The Reorganized Debtors, the Post-Effective Date Debtors, or the Post-Effective Date Plan Administrator, as applicable, may, pursuant to the Prepackaged Plan, object to applicable Claims or Interests after the Effective Date of the Prepackaged Plan irrespective of whether this Disclosure Statement identifies a particular Cause of Action or objection to a Claim.
91
| 8. | No Waiver of Right to Object or Right to Recover Transfers and Assets. |
The vote by a Holder of a Claim for or against the Prepackaged Plan does not constitute a waiver or release of any claims, causes of action or rights of the Debtors (or any entity, as the case may be) to object to that Holder’s Claim, or recover any preferential, fraudulent or other voidable transfer of assets, regardless of whether any claims or causes of action of the Debtors or their Estates are specifically or generally identified in this Disclosure Statement.
| 9. | Information Was Provided by the Debtors and Was Relied Upon by the Debtors’ Advisors. |
The Debtors’ advisors have relied upon information provided by the Debtors in connection with the preparation of this Disclosure Statement. Although the Debtors’ advisors have performed certain limited due diligence in connection with the preparation of this Disclosure Statement, they have not independently verified the information contained in this Disclosure Statement. Information regarding Ayrmid contained in this Disclosure Statement has been provided by Ayrmid and has not been independently verified by the Debtors or their advisors.
| 10. | Potential Exists for Inaccuracies, and the Debtors Have No Duty to Update. |
The statements contained in this Disclosure Statement are made by the Debtors as of the date of this Disclosure Statement, unless otherwise specified in this Disclosure Statement, and the delivery of this Disclosure Statement after the date of this Disclosure Statement does not imply that there has not been a change in the information set forth in this Disclosure Statement since that date. While the Debtors have used their reasonable business judgment to ensure the accuracy of all of the information provided in this Disclosure Statement and in the Prepackaged Plan, the Debtors nonetheless cannot, and do not, confirm the current accuracy of all statements appearing in this Disclosure Statement. Further, although the Debtors may subsequently update the information in this Disclosure Statement, the Debtors have no affirmative duty to do so unless ordered to do so by the Bankruptcy Court.
| 11. | No Representations Outside This Disclosure Statement Are Authorized. |
No representations concerning or relating to the Debtors, the Chapter 11 Cases, or the Prepackaged Plan are authorized by the Bankruptcy Court or the Bankruptcy Code, other than as set forth in this Disclosure Statement. Any representations or inducements made to secure your acceptance or rejection of the Prepackaged Plan that are other than as contained in, or included with, this Disclosure Statement should not be relied upon by you in arriving at your decision. You should promptly report unauthorized representations or inducements to counsel to the Debtors and the U.S. Trustee.
| IX. | SOLICITATION AND VOTING |
This Disclosure Statement is being distributed to the Holders of Claims in those Classes that are entitled to vote to accept or reject the Prepackaged Plan.
92
| A. | Holders of Claims Entitled to Vote on the Prepackaged Plan. |
Under the provisions of the Bankruptcy Code, not all Holders of claims against or interests in a debtor are entitled to vote on a chapter 11 plan. The table in Article III.D of this Disclosure Statement, entitled “Am I entitled to vote on the Prepackaged Plan?,” provides a summary of the status and voting rights of each Class (and, therefore, of each Holder within such Class absent an objection to the Holder’s Claim or Interest) under the Prepackaged Plan.
As shown in the table, the Debtors are soliciting votes to accept or reject the Prepackaged Plan only from Holders of Claims in Classes 3, 4, 5, and 6 (collectively, the “Voting Classes”). The Holders of Claims in the Voting Classes are Impaired under the Prepackaged Plan and may, in certain circumstances, receive a distribution under the Prepackaged Plan. Accordingly, Holders of Claims in the Voting Classes have the right to vote to accept or reject the Prepackaged Plan. Holders of Claims in the Voting Classes are voting to accept or reject the Prepackaged Plan in its entirety, and the Debtors’ election to pursue either Restructuring Transaction (including, if applicable, the withdrawal of a Sale Transaction Election Notice and consummation of the Reorganization Transaction) may be made without further solicitation of votes. Holders should therefore evaluate the Prepackaged Plan on the basis that either Restructuring Transaction may be consummated.
The Debtors are not soliciting votes from Holders of Claims or Interests in Classes 1, 2, 7, 8, 9, 10, 11, and 12. Holders of Claims in Classes 1, 2, and 7 are Unimpaired and are conclusively presumed to have accepted the Prepackaged Plan pursuant to section 1126(f) of the Bankruptcy Code (the “Presumed Accepting Classes”). Holders of Interests in Classes 9, 10, and 11 will not receive any distribution under the Prepackaged Plan and are deemed to have rejected the Prepackaged Plan pursuant to section 1126(g) of the Bankruptcy Code (the “Deemed Rejecting Classes”). Holders of Intercompany Claims and Intercompany Interests in Classes 8 and 12 are either Unimpaired and conclusively presumed to have accepted the Prepackaged Plan or Impaired and deemed to have rejected the Prepackaged Plan, and in either case are not entitled to vote.
| B. | Voting Record Date. |
The voting record date is October 27, 2026 (the “Voting Record Date”), which is the date for determining which Holders of Claims in Classes 3, 4, 5, and 6 are entitled to vote on the Prepackaged Plan.
| C. | Solicitation Package. |
Beginning on November 2, 2026 (the “Solicitation Commencement Date”), the Claims and Balloting Agent mailed or delivered (or caused to be mailed or delivered) to each Holder of a Claim in the Voting Classes as of the Voting Record Date a solicitation package (the “Solicitation Package”) containing: (a) this Disclosure Statement (with all exhibits hereto, including the Prepackaged Plan, the Restructuring Support Agreement, the Debtors’ corporate organizational chart, and the Liquidation Analysis); (b) the appropriate Ballot, together with voting instructions; and (c) a pre-addressed, pre-paid return envelope. The Solicitation Package may also be obtained free of charge from the Claims and Balloting Agent by (a) visiting https://cases.stretto.com/KPTI; (b) emailing the Claims and Balloting Agent at TeamKaryopharm@stretto.com (with “Karyopharm Solicitation Inquiry” in the subject line); or (c) calling (866) 270-4922 (toll-free within the United States or Canada) or +1 (949) 561-0471 (international).
93
| D. | Voting on the Prepackaged Plan. |
The deadline for voting on the Prepackaged Plan is November 30, 2026, at 4:00 p.m. (prevailing Central Time) (the “Voting Deadline”). In order to be counted as votes to accept or reject the Prepackaged Plan, all Ballots must be properly executed, completed, and delivered as directed, so that your Ballot is actually received by the Claims and Balloting Agent on or before the Voting Deadline. Ballots may be submitted electronically through the E-Portal or by electronic mail to the Claims and Balloting Agent in accordance with the instructions set forth on the Ballot, or returned by overnight courier or hand delivery to the address set forth on the Ballot. In light of the length of the solicitation period, Holders are strongly encouraged to submit their Ballots through the E-Portal or by electronic mail. Votes received via facsimile transmission or by electronic mail other than in accordance with the instructions set forth on the Ballot will not be counted. Each Ballot also includes instructions on how to opt out of the Third-Party Release set forth in Article VIII.D of the Prepackaged Plan by checking the box provided on the Ballot.
| 1. | Holders of Claims in Classes 3, 4, 5, and 6. |
Holders of 1L Term Loan Claims in Class 3, Holders of 1.5L 2028 Notes Claims in Class 4, Holders of 2L 2029 Notes Claims in Class 5, and Holders of RIFA Claims in Class 6 may vote on the Prepackaged Plan by completing and signing the Ballot for the applicable Class and returning it to the Claims and Balloting Agent on or before the Voting Deadline, by submitting the Ballot electronically through the E-Portal in accordance with the instructions set forth on the Ballot or by electronic mail, or, alternatively, by returning a hard copy Ballot by overnight courier or hand delivery to the address listed on the Ballot. Each Ballot has been coded to reflect the Class of Claims it represents. Accordingly, in voting to accept or reject the Prepackaged Plan, Holders must use only the coded Ballot sent to them in their Solicitation Package; no master ballots, nominee ballots, or pre-validated ballots will be used in connection with the Solicitation. The amount of each Holder’s Claim for voting purposes was determined as of the Voting Record Date by reference to the Debtors’ books and records and, in the case of Classes 4 and 5, the securities position report obtained from The Depository Trust Company (“DTC”) as of the Voting Record Date.
Only Eligible Holders of Claims in the Voting Classes may vote on the Prepackaged Plan; a Holder that is not an Eligible Holder may not use a Ballot or any other ballot to vote on the Prepackaged Plan. Each Ballot requires the Holder to certify that it is an Eligible Holder.
| E. | Non-Voting Classes; Opt-Out and Opt-In Forms. |
Holders of Claims and Interests in the Non-Voting Classes will not receive a Solicitation Package. Within two (2) Business Days after entry of the order approving the Solicitation Procedures Motion (the “Solicitation Procedures Order”), or as soon as reasonably practicable thereafter, the Claims and Balloting Agent will mail a notice of non-voting status (the “Non-Voting Status Notice”) to Holders of Claims and Interests in the Non-Voting Classes (other than Classes 8 and 12), together with (a) in the case of Holders of Claims in the Presumed Accepting Classes, a
94
form (the “Opt-Out Form”) by which such Holders may elect to opt out of the Third-Party Release, or (b) in the case of Holders of Interests in the Deemed Rejecting Classes, a form (the “Opt-In Form”) by which such Holders may elect to opt in to, and receive the benefit of, the Third-Party Release. The Non-Voting Status Notice and the Opt-Out Form or Opt-In Form, as applicable, (a) inform recipients of their status as Holders or potential Holders of Claims or Interests in the Non-Voting Classes, (b) provide the full text of the release, exculpation, and injunction provisions set forth in the Prepackaged Plan, (c) set forth the deadline by which Opt-Out Forms and Opt-In Forms must be actually received by the Claims and Balloting Agent, which is 5:00 p.m. (prevailing Central Time) on January 4, 2027, and (d) explain how the forms may be returned, including through the E-Portal. As described in Article III.O of this Disclosure Statement, a Holder of a Claim in a Presumed Accepting Class that does not timely opt out, and a Holder of an Interest in a Deemed Rejecting Class that timely opts in, will be a Releasing Party under the Prepackaged Plan.
| F. | Ballots Not Counted. |
The following Ballots will NOT be counted: (a) any Ballot that is illegible or contains insufficient information to permit the identification of the Holder of the Claim; (b) any Ballot that is not actually received by the Claims and Balloting Agent by the Voting Deadline (unless the Debtors determine otherwise or as permitted by the Bankruptcy Court, as applicable); (c) any Ballot that does not contain a signature (provided that signatures contained in electronic Ballots submitted via the E-Portal will be deemed to be immediately legally effective); (d) any Ballot that partially rejects and partially accepts the Prepackaged Plan; (e) any Ballot that does not contain an amount of claim denominated in U.S. currency; (f) any Ballot not marked to accept or reject the Prepackaged Plan or marked both to accept and reject the Prepackaged Plan; (g) any Ballot superseded by a later, timely submitted, valid, and properly executed Ballot; (h) any vote cast by a Person or Entity that did not hold a Claim in a Voting Class as of the Voting Record Date or that is not an Eligible Holder; and (i) any Ballot transmitted to the Claims and Balloting Agent by facsimile or by electronic mail other than in accordance with the instructions set forth on the Ballot.
| X. | CONFIRMATION OF THE PREPACKAGED PLAN |
| A. | The Combined Hearing. |
Under section 1128(a) of the Bankruptcy Code, the Bankruptcy Court, after notice, may hold a hearing to confirm a plan of reorganization. The Debtors will request, on the Petition Date, that the Bankruptcy Court set the Combined Hearing to approve the adequacy of the information provided in this Disclosure Statement and confirm the Prepackaged Plan. At the Combined Hearing, the Debtors will also request that the Bankruptcy Court approve the Solicitation as having been in compliance with section 1126(b) of the Bankruptcy Code and Bankruptcy Rule 3018(b) and direct that all acceptances received on or before the Voting Deadline, whether received before or after the Petition Date, be counted for purposes of Confirmation. The Combined Hearing may, however, be continued or adjourned from time to time without further notice to parties in interest other than an adjournment announced in open court or a notice of adjournment Filed with the Bankruptcy Court and served in accordance with the Bankruptcy Rules. Subject to section 1127 of the Bankruptcy Code and the Restructuring Support Agreement, the Prepackaged Plan may be modified, if necessary, prior to, during, or as a result of the Combined Hearing, without further notice to parties in interest.
95
Additionally, section 1128(b) of the Bankruptcy Code provides that a party in interest may object to Confirmation. The Debtors will request in the Solicitation Procedures Motion that the Bankruptcy Court set January 4, 2027, at 5:00 p.m. (prevailing Central Time) as the deadline to file objections to final approval of this Disclosure Statement and Confirmation of the Prepackaged Plan (the “Objection Deadline”). All such objections must (a) be in writing; (b) comply with the Bankruptcy Rules, the Bankruptcy Local Rules, and any other case management rules and orders of the Bankruptcy Court; (c) state the name and address of the objecting party and the amount and nature of the Claim or Interest beneficially owned by such entity; (d) state with particularity the legal and factual basis for such objections and, if practicable, a proposed modification to the Prepackaged Plan that would resolve such objections; and (e) be Filed with the Bankruptcy Court with proof of service thereof and served on (i) the Debtors; (ii) counsel to the Debtors; (iii) counsel to the Ad Hoc Group; (iv) counsel to Ayrmid; (v) counsel to the Consenting Royalty Investors; (vi) the U.S. Trustee; and (vii) counsel to any statutory committee, if appointed (collectively, the “Notice Parties”), so as to be actually received on or before the Objection Deadline.
| B. | Requirements for Confirmation of the Prepackaged Plan. |
Among the requirements for Confirmation of the Prepackaged Plan pursuant to section 1129 of the Bankruptcy Code are: (a) the Prepackaged Plan is accepted by all Impaired Classes of Claims or Interests, or if rejected by an Impaired Class, the Prepackaged Plan “does not discriminate unfairly” and is “fair and equitable” as to the rejecting Impaired Class; (b) the Prepackaged Plan is feasible; and (c) the Prepackaged Plan is in the “best interests” of Holders of Claims or Interests.
At the Combined Hearing, the Bankruptcy Court will determine whether the Prepackaged Plan satisfies all of the requirements of section 1129 of the Bankruptcy Code. The Debtors believe that: (a) the Prepackaged Plan satisfies, or will satisfy, all of the necessary statutory requirements of chapter 11 for plan confirmation; (b) the Debtors have complied, or will have complied, with all of the necessary requirements of chapter 11 for plan confirmation; and (c) the Prepackaged Plan has been proposed in good faith.
| C. | Best Interests of Creditors/Liquidation Analysis. |
Often referred to as the “best interests of creditors” test, section 1129(a)(7) of the Bankruptcy Code requires that each holder of a claim or interest in each impaired class either (a) accept the plan or (b) receive or retain under the plan property of a value, as of the effective date of the confirmed plan, that is not less than the amount such holder would receive if the debtor was liquidated under chapter 7 of the Bankruptcy Code.
Based on the Liquidation Analysis attached hereto as Exhibit D, the Debtors, with the assistance of their Advisors, believe that the Prepackaged Plan satisfies the best interests test and that each Holder of an Impaired Claim or Interest will receive value under the Prepackaged Plan on the Effective Date that is not less than the value such Holder would receive if the Debtors liquidated under chapter 7 of the Bankruptcy Code. The Debtors believe that the Liquidation Analysis and the conclusions set forth therein are fair and represent the Debtors’ best judgment regarding the results of a hypothetical liquidation of the Debtors under chapter 7 of the Bankruptcy Code.
96
The Liquidation Analysis represents an estimate of cash distributions and recovery percentages based on a hypothetical chapter 7 liquidation of the Debtors’ assets. It is, therefore, a hypothetical analysis based on certain assumptions discussed therein and in this Disclosure Statement. As such, asset values and claims discussed therein may differ materially from amounts referred to in the Prepackaged Plan and this Disclosure Statement. The Liquidation Analysis should be read in conjunction with the assumptions, qualifications, and explanations set forth in this Disclosure Statement and the Prepackaged Plan in their entirety, as well as the notes and assumptions set forth in the Liquidation Analysis.
The determination of the costs of, and proceeds from, the hypothetical liquidation of the Debtors’ assets in a chapter 7 case involves the use of estimates and assumptions that, although considered reasonable by the Debtors based on their business judgment and input from their advisors, are subject to significant business, economic, competitive uncertainties and contingencies beyond the control of the Debtors, their management and their advisors. The Liquidation Analysis was prepared for the sole purpose of generating a reasonable, good faith estimate of the proceeds that would be generated if the Debtors’ assets were liquidated in accordance with chapter 7 of the Bankruptcy Code. The Liquidation Analysis is not intended, and should not be used, for any other purpose.
| D. | Feasibility. |
Section 1129(a)(11) of the Bankruptcy Code requires that confirmation of a plan of reorganization is not likely to be followed by the liquidation, or the need for further financial reorganization of the debtor, or any successor to the debtor (unless such liquidation or reorganization is proposed in such plan of reorganization).
To determine whether the Prepackaged Plan meets this feasibility requirement, the Debtors, with the assistance of the Advisors, have analyzed their ability to meet their respective obligations under the Prepackaged Plan. As part of this analysis, the Debtors, in consultation with Ayrmid, will prepare the Financial Projections, which will be filed with the Plan Supplement. Creditors and other interested parties should review Article VIII of this Disclosure Statement, entitled “Risk Factors,” for a discussion of certain factors that may affect the future financial performance of the Reorganized Debtors or the Post-Effective Date Debtors, as applicable.
The Debtors believe that the Prepackaged Plan meets the feasibility requirement, as Confirmation is not likely to be followed by liquidation or the need for further financial reorganization of the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, or any successor under the Prepackaged Plan. In a Reorganization Transaction, NewCo will emerge with the NewCo Facility as its only funded debt (other than the contingent obligations under the MF CVRs and the New Royalty Agreement) and with committed financing sufficient to fund its business plan. In the event of a Sale Transaction, the Prepackaged Plan will be funded with the proceeds of the Sale Transaction and the Wind-Down Budget, and the Debtors’ remaining affairs will be wound down in accordance with the Prepackaged Plan.
97
| E. | Acceptance by Impaired Classes. |
The Bankruptcy Code requires, as a condition to confirmation, except as described in the following section, that each class of claims or equity interests impaired under a plan, accept the plan. A class that is not “impaired” under a plan is deemed to have accepted the plan and, therefore, solicitation of acceptances with respect to such a class is not required.19
Section 1126(c) of the Bankruptcy Code defines acceptance of a plan by a class of impaired claims as acceptance by holders of at least two-thirds in dollar amount and more than one-half in a number of allowed claims in that class, counting only those claims that have actually voted to accept or to reject the plan. Thus, a class of Claims will have voted to accept the Prepackaged Plan only if two-thirds in amount and a majority in number of the Allowed Claims in such class that vote on the Prepackaged Plan actually cast their ballots in favor of acceptance.
Section 1126(d) of the Bankruptcy Code defines acceptance of a plan by a class of impaired equity interests as acceptance by holders of at least two-thirds in amount of allowed interests in that class, counting only those interests that have actually voted to accept or to reject the plan. Thus, a Class of Interests will have voted to accept the Prepackaged Plan only if two-thirds in amount of the Allowed Interests in such class that vote on the Prepackaged Plan actually cast their ballots in favor of acceptance.
Pursuant to Article III.E of the Prepackaged Plan, if a Class contains Claims or Interests eligible to vote and no Holders of Claims or Interests eligible to vote in such Class vote to accept or reject the Prepackaged Plan, the Holders of such Claims or Interests in such Class shall be deemed to have accepted the Prepackaged Plan.
| F. | Confirmation Without Acceptance by All Impaired Classes. |
Section 1129(b) of the Bankruptcy Code allows a bankruptcy court to confirm a plan even if all impaired classes have not accepted it; provided that the plan has been accepted by at least one impaired class. Pursuant to section 1129(b) of the Bankruptcy Code, notwithstanding an impaired class’s rejection or deemed rejection of the plan, the plan will be confirmed, at the plan proponent’s request, in a procedure commonly known as a “cramdown” so long as the plan does not “discriminate unfairly” and is “fair and equitable” with respect to each class of claims or equity interests that is impaired under, and has not accepted, the plan.
Because Classes 9, 10, and 11 are deemed to reject the Prepackaged Plan, the Debtors will seek to confirm the Prepackaged Plan with respect to such Classes utilizing the “cramdown” provision of section 1129(b) of the Bankruptcy Code. To the extent that any other Impaired Class rejects the Prepackaged Plan or is deemed to have rejected the Prepackaged Plan, the Debtors may request Confirmation of the Prepackaged Plan, as it may be modified from time to time, under section 1129(b) of the Bankruptcy Code. The Debtors reserve the right to alter, amend, modify, revoke, or withdraw the Prepackaged Plan or any Plan Supplement document, including the right to amend or modify the Prepackaged Plan or any Plan Supplement document to satisfy the requirements of section 1129(b) of the Bankruptcy Code, in each case subject to the Restructuring Support Agreement.
| 19 | A class of claims is “impaired” within the meaning of section 1124 of the Bankruptcy Code unless the plan (a) leaves unaltered the legal, equitable and contractual rights to which the claim or equity interest entitles the holder of such claim or equity interest or (b) cures any default, reinstates the original terms of such obligation, compensates the holder for certain damages or losses, as applicable, and does not otherwise alter the legal, equitable, or contractual rights to which such claim or equity interest entitles the holder of such claim or equity interest. |
98
| 1. | No Unfair Discrimination. |
The “unfair discrimination” test applies to classes of claims or interests that are of equal priority and are receiving different treatment under a plan. The test does not require that the treatment be the same or equivalent, but that treatment be “fair.” In general, bankruptcy courts consider whether a plan discriminates unfairly in its treatment of classes of claims or interests of equal rank (e.g., classes of the same legal character). Bankruptcy courts will take into account a number of factors in determining whether a plan discriminates unfairly. A plan could treat two classes of unsecured creditors differently without unfairly discriminating against either class.
| 2. | Fair and Equitable Test. |
The “fair and equitable” test applies to classes of different priority and status (e.g., secured versus unsecured) and includes the general requirement that no class of claims receive more than 100 percent of the amount of the allowed claims in the class. As to the dissenting class, the test sets different standards depending upon the type of claims or equity interests in the class.
The Debtors submit that if the Debtors “cramdown” the Prepackaged Plan pursuant to section 1129(b) of the Bankruptcy Code, the Prepackaged Plan is structured so that it does not “discriminate unfairly” and satisfies the “fair and equitable” requirement. With respect to the unfair discrimination requirement, all Classes under the Prepackaged Plan are provided treatment that is substantially equivalent to the treatment that is provided to other Classes that have equal rank. With respect to the fair and equitable requirement, no Class under the Prepackaged Plan will receive more than 100 percent of the amount of Allowed Claims or Allowed Interests in that Class. The Debtors believe that the Prepackaged Plan and the treatment of all Classes of Claims or Interests under the Prepackaged Plan satisfy the foregoing requirements for nonconsensual Confirmation of the Prepackaged Plan.
| G. | Valuation of the Debtors. |
The Debtors do not intend to prepare or file a separate valuation analysis of the Reorganized Debtors or NewCo in connection with the Prepackaged Plan. The Reorganization Transaction is the product of the Marketing and Sale Process described in Article VI.G of this Disclosure Statement, and the Prepackaged Plan subjects the Debtors’ assets to a continued, court-supervised market test through the Bidding Procedures. Because the Debtors are continuing to engage with potential bidders pursuant to the Bidding Procedures and do not want to prejudice the competitive sale process, and because the Debtors believe that the Marketing and Sale Process and the Bidding Procedures, rather than a theoretical valuation analysis, provide the most reliable indication of the value of the Debtors’ assets and of the consideration to be distributed under the Prepackaged Plan, this Disclosure Statement does not include a valuation analysis. See 11 U.S.C. § 1125(b) (“The court may approve a disclosure statement without a valuation of the debtor or an appraisal of the debtor’s assets.”); In re Ditech Holding Corp., Case No. 19-10412
99
(JLG) (Bankr. S.D.N.Y. May 10, 2019) (ECF No. 544) (order authorizing delayed filing of valuation, liquidation, and recovery analysis until after the auction); In re LBI Media, Inc., Case No. 18-12655 (CSS) (Bankr. D. Del. Jan. 22, 2019) (ECF No. 360) (order approving disclosure statement without a valuation analysis and approving the filing of a valuation analysis at a later date, if necessary); In re Gastar Exploration Inc., Case No. 18-36057 (MI) (Bankr. S.D. Tex. Dec. 21, 2018) (ECF No. 282) (order approving disclosure statement that conducted valuation analysis through a comprehensive marketing process). The estimated recoveries set forth in Article III.E of this Disclosure Statement to Holders of Funded Debt Claims in a Reorganization Transaction are subject to the significant assumptions, qualifications, and limitations described herein.
| XI. | CERTAIN SECURITIES LAW MATTERS |
The Solicitation is being made before the Petition Date pursuant to section 4(a)(2) of the Securities Act and Regulation S under the Securities Act and only to Holders of Claims in the Voting Classes that are Eligible Holders. The Solicitation has been commenced prior to the Petition Date. Although the Voting Deadline will occur after the Petition Date, no Holder will be solicited after the Petition Date other than Holders that were solicited prior to the Petition Date in compliance with applicable nonbankruptcy law, as permitted by section 1125(g) of the Bankruptcy Code.
The offering, issuance, and distribution of any Securities pursuant to the Prepackaged Plan, including the Reorganized Parent Common Stock and, to the extent comprised of Securities, the Merger Consideration, will be made without registration under the Securities Act or any similar federal, state, or local law in reliance upon (a) in the case of the Reorganized Parent Common Stock and the Merger Consideration issued to Holders of Allowed Funded Debt Claims, section 1145 of the Bankruptcy Code (except with respect to an entity that is an “underwriter” as defined in subsection (b) of section 1145 of the Bankruptcy Code) or (b) in the case of the New Common Stock issued as Merger Consideration to the equityholders of Ayrmid and the Omisirge Contingent Equity, section 4(a)(2) of the Securities Act and/or Regulation S under the Securities Act and similar provisions of state or local securities laws. The following discussion of the issuance and transferability of the New Common Stock and the MF CVRs relates solely to matters arising under federal and state securities laws. The rights of holders of New Common Stock and MF CVRs, including the right to transfer such interests, will also be governed by the New Corporate Governance Documents and the MF CVR Agreement, as applicable.
In the event of a Sale Transaction, the Debtors do not expect to issue any Securities pursuant to the Prepackaged Plan, other than any Interests in the Post-Effective Date Debtors issued or transferred to the Purchaser in a Sale Transaction structured as an equity sale, which would be issued in reliance on section 1145 of the Bankruptcy Code, section 4(a)(2) of the Securities Act, Regulation S, or another available exemption from registration. The discussion in this Article XI accordingly applies principally to a Reorganization Transaction.
| A. | Securities Issued Under Section 1145. |
As discussed herein, the Prepackaged Plan provides for the offer, issuance, sale, and distribution of the Reorganized Parent Common Stock and, to the extent constituting Securities, the Merger Consideration to be received by Holders of Allowed Funded Debt Claims under section 1145 of the Bankruptcy Code.
100
Section 1145 of the Bankruptcy Code provides that section 5 of the Securities Act and any state law requirements for the issuance of a security do not apply to the offer or sale of stock, options, warrants, or other securities by a debtor (or an affiliate participating in a joint plan with the debtor, or a successor to the debtor under the plan) if (a) the offer or sale occurs under a plan of reorganization; (b) the recipients of the securities hold a Claim against, an interest in, or a Claim for administrative expense against, the debtor; and (c) the securities are issued in exchange for a Claim against or interest in a debtor or are issued principally in such exchange and partly for Cash and property. The Debtors believe that the issuance of the Reorganized Parent Common Stock and, to the extent constituting Securities, the Merger Consideration to be received by Holders of Allowed Funded Debt Claims satisfies the requirements of section 1145(a) of the Bankruptcy Code (except with respect to an underwriter as defined in section 1145(b)(1) of the Bankruptcy Code).
In addition, to the extent constituting Securities, the New Common Stock and MF CVRs issued under section 1145 of the Bankruptcy Code (a) will not be “restricted securities” as defined in rule 144(a)(3) under the Securities Act and (b) will generally be freely tradable and transferable in the United States by a recipient thereof that (i) is not an “underwriter” as defined in section 1145(b)(1) of the Bankruptcy Code, (ii) is not an “affiliate” of the Debtors, NewCo, or the Reorganized Debtors as defined in Rule 144(a)(1) under the Securities Act, (iii) has not been such an “affiliate” within 90 days of the time of the transfer, and (iv) has not acquired such securities from an “affiliate” within one year of the time of transfer, subject in each case to compliance with applicable securities Laws and any rules and regulations of the SEC or state or local securities Laws, if any, applicable at the time of any future transfer of such Securities, and subject to any restrictions in the New Corporate Governance Documents and MF CVR Agreement, as applicable.
Accordingly, no registration statement is expected to be filed under the Securities Act or any state securities laws with respect to the offer, issuance, sale, and distribution of the New Common Stock and the MF CVRs. The MF CVR Agreement will provide that the MF CVRs are non-transferable except as expressly permitted thereby, and the New Corporate Governance Documents may contain restrictions on the transfer of the New Common Stock. NewCo will be a privately held company, and the New Common Stock and the MF CVRs will not be listed on any securities exchange.
| B. | Securities Issued Under Section 4(a)(2) and Regulation S. |
The New Common Stock to be issued to the equityholders of Ayrmid as Merger Consideration and the Omisirge Contingent Equity (and, to the extent issuance under section 1145(a) of the Bankruptcy Code is unavailable and to the extent constituting Securities, the New Common Stock and the MF CVRs to be issued to the Holders of Allowed Funded Debt Claims) will be issued without registration under the Securities Act in reliance upon the exemption from registration provided under section 4(a)(2) of the Securities Act and/or Regulation S under the Securities Act. Section 4(a)(2) of the Securities Act provides that the registration requirements of section 5 of the Securities Act will not apply to the offer and sale of a Security in connection with transactions not involving any public offering. Regulation S provides that the registration requirements of section 5 of the Securities Act will not apply to certain transactions involving the
101
offer and sale of securities outside of the United States to any non U.S. person (within the meaning of Regulation S). Any Securities issued in reliance on section 4(a)(2) and/or Regulation S will be “restricted securities” under the Securities Act and may be resold, exchanged, assigned, or otherwise transferred only pursuant to registration or an applicable exemption from registration under the Securities Act and other applicable Law, and subject to any restrictions in the New Corporate Governance Documents and the MF CVR Agreement, as applicable.
| XII. | CERTAIN U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PREPACKAGED PLAN |
The following discussion summarizes certain U.S. federal income tax consequences of the implementation of the Prepackaged Plan to the Debtors and certain Holders of Allowed Claims. The following summary is based on the Internal Revenue Code of 1986, as amended (the “IRC”), Treasury Regulations promulgated thereunder, judicial decisions, administrative rules and pronouncements as in effect on the date hereof. Changes in such rules or new interpretations thereof may have retroactive effect and could significantly affect the U.S. federal income tax consequences described herein. This summary addresses certain U.S. federal income tax consequences only to Holders of Claims that are entitled to vote (i.e., Holders of Claims in Classes 3, 4, 5, and 6) and it does not address the U.S. federal income tax consequences to Holders of Claims or Interests that are not entitled to vote on the Prepackaged Plan. The U.S. federal income tax consequences of the Prepackaged Plan are complex and are subject to significant uncertainties.
This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular Holder of an Allowed Claim in light of such Holder’s particular facts and circumstances (such as the effects of section 451(b) of the IRC conforming the timing of certain income accruals to financial statements). In addition, this summary addresses only U.S. federal income taxes. Thus, the following discussion does not address foreign, state, or local tax consequences, or any estate, gift, or other non-income tax consequences, of the Prepackaged Plan, nor does it purport to address the U.S. federal income tax consequences of the Prepackaged Plan to Holders of Allowed Claims that are subject to special treatment under the IRC (such as Persons who are related to the Debtors within the meaning of the IRC, Holders liable for the alternative minimum tax, Holders whose functional currency is not the U.S. dollar, Holders that received their Claims as compensation, broker dealers, banks, mutual funds, insurance companies, financial institutions, small business investment companies, regulated investment companies, tax exempt organizations, governmental entities, pass-through entities such as partnerships or S corporations and investors therein, and Holders of Claims who are themselves in bankruptcy). Accordingly, this summary should not be relied upon for purposes of determining the specific tax consequences of the Prepackaged Plan with respect to a particular Holder of a Claim.
If a partnership (including any entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds an Allowed Claim, the tax treatment of a partner or other investor in such partnership will generally depend upon the status of the partner or investor and the activities of the partnership. If you are a partner or other investor in a partnership holding an Allowed Claim or Interest, you should consult your tax advisors.
102
For purposes of this discussion, a “U.S. Holder” is a beneficial owner of an Allowed Claim in Class 3, 4, 5, or 6 that is: (A) an individual citizen or resident of the United States for U.S. federal income tax purposes; (B) a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States, any state thereof or the District of Columbia; (C) an estate the income of which is subject to U.S. federal income taxation regardless of the source of such income; or (D) a trust (1) if a court within the United States is able to exercise primary jurisdiction over the trust’s administration and one or more United States persons have authority to control all substantial decisions of the trust or (2) that has a valid election in effect under applicable Treasury Regulations to be treated as a United States person (as defined in the IRC), and a “Non-U.S. Holder” is a beneficial owner of an Allowed Claim in Class 3, 4, 5, or 6 (other than an entity treated as a partnership for U.S. federal income tax purposes) that is not a U.S. Holder.
The following discussion assumes that the Prepackaged Plan will be implemented as described herein and does not address the tax consequences if the Prepackaged Plan is not carried out. Furthermore, this discussion assumes that Holders of Allowed Claims only hold the Claims in a single Class. For purposes of this discussion, it is assumed that the Claims in Classes 3, 4, 5, and 6 are treated as debt for U.S. federal income tax purposes. In addition, a substantial amount of time may elapse between the Confirmation Date and the receipt of a final distribution under the Prepackaged Plan. Events subsequent to the date of this Disclosure Statement, such as additional tax legislation, court decisions or administrative changes, could affect the U.S. federal income tax consequences of the Prepackaged Plan and the transactions contemplated thereunder.
This summary of the U.S. federal income tax consequences of the Prepackaged Plan is not binding on the Internal Revenue Service (“IRS”), and no ruling will be sought or has been sought from the IRS with respect to any of the tax aspects of the Prepackaged Plan, no opinion of counsel has been obtained or will be obtained by the Debtors with respect thereto, and no tax opinion is given by this Disclosure Statement. The U.S. federal income tax consequences of certain aspects of the Prepackaged Plan may therefore be uncertain due to the lack of applicable legal authority and may be subject to administrative or judicial interpretations that differ from the discussion below.
The following discussion is not exhaustive and the U.S. federal income tax consequences to each Holder of an Allowed Claim will differ and will depend on factors specific to each such Holder, including (A) whether the Holder’s Allowed Claim (or portion thereof) constitutes a claim for principal or interest; (B) the origin of the Holder’s Allowed Claim; (C) whether the Holder reports income using the accrual or cash basis method; (D) whether the Holder receives distributions under the Prepackaged Plan in more than one taxable year; (E) whether the Holder has previously included in income any accrued but unpaid interest with respect to an Allowed Claim; and (F) whether the Holder has previously taken a bad debt deduction with respect to an Allowed Claim or otherwise recognized a loss with respect to the Allowed Claim. The discussion is not a substitute for careful tax planning and professional tax advice based upon the individual circumstances of each Holder of an Allowed Claim. Accordingly, each Holder of an Allowed Claim is strongly urged to consult with its own tax advisor regarding the U.S. federal, state, local, and foreign income and other tax consequences of the Prepackaged Plan.
The tax consequences of the implementation of the Prepackaged Plan to the Debtors and the Holders of Claims will differ significantly depending on which of the Restructuring Transactions is consummated. Accordingly, this section provides a summary discussion of the potential consequences to the Debtors and the Holders of Claims in the event of either a Sale Transaction or a Reorganization Transaction.
103
Pursuant to the Prepackaged Plan and as part of the Reorganization Transaction, the Merger will be consummated in accordance with the Merger Agreement and the Restructuring Transactions Memorandum. Subject to the Restructuring Transactions Memorandum, in the Merger, holders of Reorganized Parent Common Stock will exchange such Reorganized Parent Common Stock for the New Common Stock and the MF CVRs, as more fully described in the Prepackaged Plan. The Debtors continue to analyze the tax consequences to the Debtors and holders of Reorganized Parent Common Stock of the Merger and the issuance of the New Common Stock, and intend to include a discussion of certain material U.S. federal income tax considerations relevant thereto in the Plan Supplement. In addition, the U.S. federal income tax treatment of the MF CVRs is highly uncertain due to lack of applicable legal authority. Holders of Claims are urged to consult their own tax advisors regarding the tax consequences of receiving, holding, and disposing of the MF CVRs.
| A. | Certain U.S. Federal Income Tax Consequences to the Debtors and the Reorganized Debtors/Post-Effective Date Debtors. |
| 1. | Potential Consequences to the Debtors as a Result of a Sale Transaction. |
If the Prepackaged Plan is effectuated through a Sale Transaction, the Sale Transaction is expected to be treated as a taxable disposition of assets for U.S. federal income tax purposes. As a result, the Debtors generally will recognize taxable gain or loss equal to the “amount realized” on the Sale Transaction, less the aggregate adjusted basis in the assets that are subject to the Sale Transaction. The amount realized on the Sale Transaction will generally be equal to the cash proceeds from the Sale Transaction (plus the amount of any liabilities assumed by the purchaser). The Company has significant amounts of tax basis in the assets that are the subject of the Sale Transaction and at this time it is unknown whether the Company will recognize a gain or a loss from the Sale Transaction.
In the event that the Sale Transaction results in a taxable loss, such loss may generate additional, or otherwise increase, the Debtors’ Tax Attributes (as defined below), which may be available to offset taxable income in future years. Subject to limitations on the use of NOLs discussed below, in the event that the Sale Transaction results in a taxable gain, the Debtors may be able to use their NOLs to offset such gain. Certain other tax attributes, including “carryforwards” under section 163(j) of the IRC, as discussed below, also may be available to offset the gain resulting from the Sale Transaction (any such other tax attributes, together with any NOLs, the “Tax Attributes”).
The Debtors estimate that, as of December 31, 2025, they had a substantial amount of Tax Attributes, including certain federal NOLs, federal tax credit carryforwards (consisting primarily of research credits and orphan drug credits), state NOLs, state research and development tax credits, section 163(j) carryforwards, and section 174 carryforwards. Further, the Debtors believe they may generate additional Tax Attributes in the 2026 tax year. In general, the Tax Attributes can be carried forward to future taxable years to reduce the Debtors’ taxable income, thereby reducing future aggregate tax obligations. However, the amount of any Tax Attributes, as well as the application of any limitations, remain subject to review and adjustment by the IRS. Therefore, the Debtors are currently unable to determine the amount of NOLs or other Tax Attributes that may be available following implementation of the Prepackaged Plan to offset any gain triggered by the Sale Transaction.
104
A corporation’s use of its NOL carryforwards is subject to various limitations in the IRC. For example, NOLs generated after December 31, 2017 generally can only be utilized to offset 80% of a corporation’s taxable income in a subsequent taxable year. In this regard, the Debtors’ NOL carryforwards generated after December 31, 2017 are subject to the 80% limitation. The Debtors’ NOL carryforwards generated before December 31, 2017 are generally available to be used prior to the restricted NOLs.
Another potential limitation on use of NOLs is section 382 of the IRC. If a corporation is treated as undergoing an ownership change under section 382 of the IRC, its annual use of its pre-ownership change NOLs is limited to a specified amount (the “Section 382 Limitation”), generally the product of (1) the fair market value of the stock of the corporation immediately before the “ownership change” (with certain adjustments) multiplied by (2) the “long term tax exempt rate” applicable to the month in which the ownership change occurs. Any unused portion of the Section 382 Limitation generally is available for use in subsequent years. The Section 382 Limitation is increased in the case of a corporation that has net unrealized built-in gains (“NUBIGs”), i.e., gains economically accrued but unrecognized at the time of the ownership change, in excess of a threshold amount (generally, fair market value of assets in excess of tax basis). Such a corporation can use NOLs in excess of its Section 382 Limitation to the extent that it realizes those NUBIGs for U.S. federal income tax purposes in the five years following the ownership change. Conversely, if a corporation has a net unrealized built-in loss (“NUBIL”) at the time of an ownership change, any built-in losses recognized (including amortization or depreciation deductions attributable to such built-in losses) during the five-year period following the ownership change (up to the amount of the original NUBIL) will be treated as pre-change losses subject to the Section 382 Limitation. In general, a NUBIG or NUBIL will be deemed to be zero unless it is greater than the lesser of (a) $10 million or (b) fifteen percent (15%) of the fair market value of the corporation’s assets (with certain adjustments) before the ownership change. The Debtors currently expect that they will have a NUBIG as of the Effective Date.
The Debtors’ tax advisors have concluded, based on an analysis of shifts in the ownership of the Debtors’ stock through September 10, 2026, that it is more likely than not that an ownership change occurred on October 10, 2025. As a result, the Tax Attributes generated on or before October 10, 2025 are subject to an annual limitation under section 382 of the IRC. While the Debtors intend to request relief through the NOL Motion to protect the Debtors against the possible loss or limitation of the Debtors’ Tax Attributes, it is possible that the Debtors may undergo an additional ownership change under section 382 of the IRC prior to the Sale Transaction, which may affect the Debtors’ ability to use their NOLs to offset any gain arising from the Sale Transaction.
Any Tax Attributes that remain unutilized following the Sale Transaction will be subject to reduction (but not “carryforwards” under section 163(j) of the IRC) and limitation similar to the manner described below for a Reorganization Transaction, but are not expected to have any meaningful value if the Post-Effective Date Debtors cease conducting any business operations.
105
| 2. Potential Consequences to the Debtors as a Result of a Reorganization Transaction. |
| a. | Cancellation of Debt and Reduction of Tax Attributes. |
In general, absent an exception, a taxpayer will realize and recognize cancellation of indebtedness income (“COD Income”) upon satisfaction of its outstanding indebtedness for total consideration less than the amount of such indebtedness. The amount of COD Income, in general, is the excess of (a) the adjusted issue price of the indebtedness satisfied over (b) the sum of (i) the amount of Cash paid, (ii) the issue price of any debt issued, and (iii) the fair market value of any other consideration (including equity of a debtor or a party related to such debtor) given, in each case, in satisfaction, or as part of the discharge, of such indebtedness at the time of the exchange. Under section 108 of the IRC, a taxpayer will not, however, be required to include COD Income in gross income if the taxpayer is under the jurisdiction of a court in a case under chapter 11 of the Bankruptcy Code and the discharge of debt occurs pursuant to that proceeding (the “Bankruptcy Exception”).
As a consequence of such COD Income exclusion under the Bankruptcy Exception, a taxpayer-debtor must reduce its tax attributes by the amount of COD Income that it excluded from gross income. Such reduction in tax attributes occurs only after the tax for the year of the debt discharge has been determined. In general, tax attributes will be reduced in the following order: (a) NOL carryforwards; (b) general business tax credit carryovers; (c) minimum tax credit carryovers; (d) capital loss carryovers; (e) tax basis in assets (but not below the amount of liabilities to which the debtor remains subject); (f) passive activity loss and credit carryovers; and (g) foreign tax credit carryovers. Alternatively, a debtor with COD Income may elect first to reduce the basis of its depreciable assets prior to reducing any other tax attributes, pursuant to section 108(b)(5) of the IRC. Any excess COD Income over the amount of available tax attributes will generally not give rise to U.S. federal income tax and will generally have no other U.S. federal income tax impact.
Depending on which of the Restructuring Transactions is consummated, the Debtors may realize COD Income. In the event that the Prepackaged Plan provides for certain Holders of Claims to receive non-Cash consideration, the amount of COD Income, and accordingly the amount of tax attributes required to be reduced, will depend, in part, on the fair market value of the non-Cash consideration received, which cannot be known with certainty at this time. As a result, the exact amount of any COD Income that will be realized by the Debtors, if any, will not be determinable until the consummation of the Prepackaged Plan.
| b. | Limitation of NOL Carryforwards and Other Tax Attributes. |
Following the Effective Date, unless either the section 382(l)(5) Exception or the section 382(l)(6) Exception (each as defined below) apply, the Debtors anticipate that any NOL carryforwards, tax credits, and certain other tax attributes (such as losses and deductions that have accrued economically but are unrecognized as of the date of the ownership change) of the Reorganized Debtors that are not reduced according to the COD Income rules described above and that are allocable to periods before the Effective Date (collectively, “Pre-Change Tax Attributes”) may be subject to limitation under sections 382 and 383 of the IRC as a result of an “ownership change” of the Reorganized Debtors by reason of the Restructuring Transactions.
106
Under sections 382 and 383 of the IRC, if a corporation undergoes an “ownership change,” the amount of its Pre-Change Tax Attributes that may be utilized to offset future taxable income generally is subject to an annual limitation. The rules of section 382 and 383 of the IRC are complex, but as a general matter, the Debtors anticipate that, if the Reorganization Transaction is consummated and such transaction results in an “ownership change” of the Debtors for these purposes, the Reorganized Debtors’ use of the Pre-Change Tax Attributes could be subject to limitation unless an exception to the general rules of section 382 of the IRC applies.
| a. | General Section 382 Annual Limitation. |
As discussed above, the Section 382 Limitation on the use of Pre-Change Tax Attributes in any “post-change year” will generally be equal to the product of (1) the fair market value of the stock of the corporation immediately before the “ownership change” (with certain adjustments) multiplied by (2) the “long term tax exempt rate” applicable to the month in which the ownership change occurs. The Section 382 Limitation may be increased during the five-year period following the ownership change to the extent that the Debtors have a NUBIG as of the Effective Date. Such limitations may apply regardless of whether the Prepackaged Plan is effectuated through either the Sale Transaction or the Reorganization Transaction. Any unused limitation may be carried forward, thereby increasing the annual limitation in the subsequent taxable year.
However, if a corporation that has undergone an ownership change does not continue its historic business or use a significant portion of its historic assets in a new business for at least two years after the ownership change, the Section 382 Limitation is generally reduced to zero, thereby precluding any utilization of the corporation’s Pre-Change Tax Attributes (absent any increases due to net unrealized built-in gain discussed above). As discussed below, however, special rules may apply in the case of a corporation which experiences an ownership change as the result of a bankruptcy proceeding.
| b. | Special Bankruptcy Exemptions. |
Certain exceptions to the foregoing annual limitation rules may apply in the case of a corporation that experiences an “ownership change” as a result of a chapter 11 bankruptcy proceeding. These exceptions are contained in sections 382(l)(5) and 382(l)(6) of the IRC (referred to herein as the “Section 382(l)(5) Exception” and “Section 382(l)(6) Exception,” respectively). The Section 382(l)(5) Exception applies when shareholders and/or “qualified creditors” of a debtor corporation in a chapter 11 proceeding receive, in respect of their claims or interests, at least 50 percent of the vote and value of the stock of the reorganized debtor (or a controlling corporation if also in a chapter 11 proceeding) pursuant to a confirmed chapter 11 plan. A qualified creditor is any beneficial owner of qualified indebtedness of the debtor corporation prior to the ownership change. Qualified indebtedness is debt held by a qualified creditor for at least eighteen months prior to the petition date or who has held “ordinary course indebtedness” that has been owned at all times by such qualified creditor. A creditor who does not become a direct or indirect “5-percent shareholder” (within the meaning of section 382(k) of the IRC) of a reorganized debtor may generally be treated as having continuously held its debt from the time it was originally acquired through the ownership change.
107
Under the Section 382(l)(5) Exception, a debtor’s Pre-Change Tax Attributes are not limited on an annual basis, but, instead, the Debtors’ NOL carryforwards are reduced by the amount of any interest deductions claimed during the three taxable years preceding the effective date of the ownership change, and during the part of the taxable year prior to and including the effective date of the ownership change, in respect of all debt converted into stock in the reorganization. If the Section 382(l)(5) Exception applies and the Reorganized Debtors undergo another “ownership change” within two years after the Effective Date, the Pre-Change Tax Attributes effectively would be eliminated in their entirety.
Where the Section 382(l)(5) Exception is not applicable to a corporation in bankruptcy (either because the debtor does not qualify for it or the debtor otherwise elects not to utilize the Section 382(l)(5) Exception), the Section 382(l)(6) Exception may apply. Under the Section 382(l)(6) Exception, the annual limitation will be calculated by reference to the lesser of the value of the debtor corporation’s new stock (with certain adjustments) immediately after the ownership change and the value of such debtor corporation’s assets (determined without regard to liabilities) immediately before the ownership change. This differs from the ordinary rule that requires the fair market value of a debtor corporation that undergoes an “ownership change” to be determined before the events giving rise to the change. The Section 382(l)(6) Exception also differs from the Section 382(l)(5) Exception in that the debtor corporation is not required to reduce its NOL carryforwards by the amount of interest deductions claimed within the prior three-year period, and the debtor may undergo an ownership change within two years without triggering the elimination of its Pre-Change Tax Attributes. The resulting limitation from a subsequent ownership change would be determined under the regular rules for ownership changes.
Because the Debtors may consummate either the Sale Transaction or the Reorganization Transaction, it is not possible to say at this time whether either the Section 382(l)(5) Exception or the Section 382(l)(6) Exception may apply and no assurances can be provided in this regard. As a result, the application of either the Section 382(l)(5) Exception or the Section 382(l)(6) Exception will not be determinable until the consummation of the Prepackaged Plan.
| B. | Certain U.S. Federal Income Tax Consequences to U.S. Holders of Certain Claims Entitled to Vote. |
The following discussion assumes that the Debtors will undertake the Restructuring Transactions as currently contemplated by the Prepackaged Plan. It is unclear whether a Holder that holds Claims in multiple Classes that are deemed exchanged will be considered to engage in separate exchanges with respect to each such Class of Claims. The following discussion assumes that a Holder of Claims in multiple Classes will be treated as separately engaging in the Restructuring Transactions with respect to each Class of Claims held.
The following discussion also assumes that the Claims that are treated as debt for U.S. federal income tax purposes do not constitute “securities” for U.S. federal income tax purposes. The term “security” is not defined in the IRC or in the Treasury Regulations and has not been clearly defined by judicial decisions. The determination of whether a particular debt
108
obligation constitutes a “security” depends on an overall evaluation of the nature of the debt, including whether the Holder of such debt obligation is subject to a material level of entrepreneurial risk and whether a continuing proprietary interest is intended or not. One of the most significant factors considered in determining whether a particular debt obligation is a security is its original term. In general, debt obligations issued with a weighted-average maturity at issuance of less than five (5) years do not constitute securities, whereas debt obligations with a weighted-average maturity at issuance of ten (10) years or more generally constitute securities. Generally, if a Claim does not constitute a security, the receipt of consideration in satisfaction for such Claim may be treated as a fully taxable transaction.
Holders of the Claims are urged to consult their own tax advisors regarding the tax consequences of the Restructuring Transactions to them, including with respect to the holding period of the Claims, the treatment of the Warrants and whether their Claim constitutes a security, in light of their own personal circumstances.
| 1. | U.S. Federal Income Tax Consequences to U.S. Holders of Claims in Class 3, 4, 5, or 6. |
This discussion assumes the Claims that are treated as debt for U.S. federal income tax purposes do not constitute “securities” for U.S. federal income tax purposes. Accordingly, upon the consummation of either Restructuring Transaction under the Prepackaged Plan, the Restructuring Transaction may be treated as a fully taxable transaction for each U.S. Holder of a Claim in Class 3, 4, 5, or 6, which the Debtors have treated as debt for U.S. federal income tax purposes. If the Restructuring Transaction is treated as a taxable exchange, each such Holder will generally recognize gain or loss under the Prepackaged Plan equal to the difference between the “amount realized” by such Holder and such Holder’s adjusted tax basis in its Claim (other than any amounts attributable to accrued but unpaid interest and possibly accrued original issue discount (“OID”)). The amount realized will include the amount of any Cash received from the Debtor, the fair market value of the Reorganized Parent Common Stock received (if any), less the amount (if any) allocable to accrued but unpaid interest, as discussed below under the heading “Accrued Interest and OID.”
To the extent a U.S. Holder of a Claim recognizes gain or loss as described above, the character of such gain or loss as capital gain or loss or as ordinary income or loss will be determined by a number of factors, including the tax status of the U.S. Holder, the nature of the Claim in such U.S. Holder’s hands, whether a Claim was purchased at a discount, and whether and to what extent the U.S. Holder previously has claimed a bad debt deduction with respect to a Claim. In general, any such gain or loss realized by a U.S. Holder should constitute capital gain or loss to such U.S. Holder, unless such Claim is not a capital asset in the hands of such U.S. Holder. If a Claim is a capital asset and it has been held for more than one year, the U.S. Holder will realize long-term capital gain or loss. The deductibility of capital losses is subject to limitations, as discussed below. To the extent that a portion of the consideration received in exchange for a Claim is allocable to accrued but unpaid interest, the U.S. Holder may recognize ordinary income. A U.S. Holder’s holding period for the Reorganized Parent Common Stock received on the Effective Date should begin on the day following the Effective Date.
109
| 2. | Certain U.S. Federal Income Tax Consequences of Ownership and Disposition of Reorganized Parent Common Stock to U.S. Holders. |
| a. | Sale, Redemption, or Other Taxable Disposition of Reorganized Parent Common Stock. |
Unless a non-recognition provision of the IRC applies, U.S. Holders generally will recognize capital gain or loss upon the sale, redemption, or other taxable disposition of the Reorganized Parent Common Stock (including the Merger). Such capital gain will be long-term capital gain if at the time of the sale, exchange, retirement, or other taxable disposition, the U.S. Holder held the Reorganized Parent Common Stock for more than one year. Long-term capital gains of a non-corporate taxpayer generally are taxed at preferential rates. The deductibility of capital losses may be subject to certain limitations as described below.
| 3. | Limitation on Use of Capital Losses. |
A U.S. Holder of a Claim who recognizes capital losses as a result of the distributions under the Prepackaged Plan will be subject to limits on the use of such capital losses. For a non-corporate U.S. Holder, capital losses may be used to offset capital gains (without regard to holding periods) to the extent of such capital gains and ordinary income to the extent of the lesser of (a) $3,000 ($1,500 for married individuals filing separate returns) or (b) the excess of the capital losses over the capital gains. A non-corporate U.S. Holder may carry over unused capital losses and apply them against future capital gains and a portion of their ordinary income for an unlimited number of years. For corporate U.S. Holders, capital losses may only be used to offset capital gains. A corporate U.S. Holder that has more capital losses than may be used in a tax year may carry back unused capital losses to the three years preceding the capital loss year or may carry forward unused capital losses for the five years following the capital loss year.
| 4. | Accrued Interest and OID. |
To the extent that any amount received by a U.S. Holder of an exchanged Claim in Class 3, 4, 5, or 6 is attributable to accrued but unpaid interest (or OID) on the debt instruments constituting the exchanged Claim, the receipt of such amount should be recognized by the U.S. Holder as ordinary interest income (to the extent not already included in income by the U.S. Holder). Conversely, a U.S. Holder of a Claim in Class 3, 4, 5, or 6 may be able to recognize a deductible loss to the extent that any accrued interest previously was recognized by the U.S. Holder but was not paid in full by the Debtors. The character of this loss is uncertain. The tax basis of any non-Cash consideration treated as received in satisfaction of accrued but unpaid interest or OID should equal the amount of such accrued but unpaid interest or OID. The holding period for such non-Cash consideration should begin on the day following the receipt of such consideration.
If the fair market value of the consideration is not sufficient to fully satisfy all principal and interest on a Claim in Class 3, 4, 5, or 6, the extent to which such consideration will be attributable to accrued but unpaid interest is unclear. While certain Treasury Regulations governing the payment ordering rules generally treat payments as allocated first to any accrued but unpaid interest and then to principal payments, certain legislative history indicates that an allocation of consideration as between principal and interest provided in a chapter 11 plan of
110
reorganization is binding for U.S. federal income tax purposes. Under the Prepackaged Plan, the aggregate consideration to be distributed to U.S. Holders of Claims in each Class will be allocated first to the principal amount of such Claims (as determined for U.S. federal income tax purposes), with any excess allocated to the remaining portion of such Claims, if any. However, the IRS could take the position that the consideration received by the U.S. Holder should be allocated in some way other than as provided in the Prepackaged Plan.
U.S. Holders are urged to consult their own tax advisors regarding the allocation of consideration received under the Prepackaged Plan, as well as the deductibility of accrued but unpaid interest and the character of any loss claimed with respect to accrued but unpaid interest previously included in gross income for U.S. federal income tax purposes.
| 5. | Market Discount. |
In general, a debt instrument is considered to have been acquired with “market discount” if it is acquired other than on original issue and if the U.S. Holder’s adjusted tax basis in the debt instrument is less than (a) in the case of a debt instrument issued without OID, the sum of all remaining payments to be made on the debt instrument, excluding “qualified stated interest” or (b) in the case of a debt instrument issued with OID, its “revised issue price,” in each of the cases of clauses (a)-(b), by at least a de minimis amount (equal to 0.25 percent of the sum of all remaining payments to be made on the debt instrument, excluding qualified stated interest, multiplied by the number of remaining whole years to maturity).
Any gain recognized by a U.S. Holder on the taxable disposition of a Claim in Class 3, 4, 5, or 6 pursuant to the Prepackaged Plan that had been acquired with market discount should be treated as ordinary income to the extent of the market discount that accrued thereon while the Claim was considered to be held by the U.S. Holder (unless the U.S. Holder elected to include market discount in income as it accrued).
U.S. Holders of Claims in Class 3, 4, 5, or 6 who acquired the debt instrument underlying their Claims with market discount are urged to consult with their own tax advisors as to the appropriate treatment of any such market discount and the timing of the recognition thereof.
| C. | Certain U.S. Federal Income Tax Consequences to Non-U.S. Holders of Certain Claims. |
The following discussion assumes that the Debtors will structure the Restructuring Transactions as currently contemplated by the Prepackaged Plan and includes only certain U.S. federal income tax consequences of the Restructuring Transactions to Non-U.S. Holders. The discussion does not include any non-U.S. tax considerations. The rules governing the U.S. federal income tax consequences to Non-U.S. Holders are complex, and each Non-U.S. Holder should consult its tax advisor regarding the U.S. federal, state, and local and the non-U.S. tax consequences of the consummation of the Prepackaged Plan to such Non-U.S. Holder.
111
| 1. | Gain Recognition. |
Whether a Non-U.S. Holder realizes gain or loss on the exchange and the amount of such gain or loss is generally determined in the same manner as set forth above in connection with U.S. Holders.
Any gain recognized by a Non-U.S. Holder of Claims in Classes 3, 4, 5, and 6 will not be subject to U.S. federal income tax, unless (a) such Non-U.S. Holder is engaged in a trade or business in the United States to which such gain is “effectively connected” for U.S. federal income tax purposes (and, if required, by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment or fixed base in the United States to which gain is attributable); or (b) if such Non-U.S. Holder is an individual, such Holder is present in the United States for 183 days or more during the taxable year of the disposition and certain other requirements are met.
Gain described in the first situation above generally will be subject to U.S. federal income tax on a net income basis at the regular rates. A Non-U.S. Holder that is a foreign corporation also may be subject to a branch profits tax at a rate of 30 percent (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items.
Gain described in the second situation above will be subject to U.S. federal income tax at a rate of 30 percent (or such lower rate specified by an applicable income tax treaty), which may be offset by certain U.S. source capital losses of the Non-U.S. Holder (even though the individual is not considered a resident of the United States), provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses.
Non-U.S. Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.
| 2. | Interest on Claims. |
Payments to a Non-U.S. Holder that are attributable to accrued but unpaid interest on its Claim in Class 3, 4, 5, or 6 generally will not be subject to U.S. federal income or withholding tax, provided that the withholding agent has received or receives, prior to payment, appropriate documentation (generally, IRS Form W-8BEN or W-8BEN-E) establishing that the Non-U.S. Holder is not a U.S. person, unless:
| (a) | the Non-U.S. Holder actually or constructively owns 10 percent or more of the total combined voting power of all classes of the applicable Debtor’s stock entitled to vote (after application of certain attribution rules); |
| (b) | the Non-U.S. Holder is a “controlled foreign corporation” that is a “related person” with respect to the Debtors as described in Section 881(c)(3)(C) of the IRC; |
| (c) | the Non-U.S. Holder is a bank receiving interest described in section 881(c)(3)(A) of the IRC; or |
112
| (d) | such interest is effectively connected with the conduct by the Non-U.S. Holder of a trade or business within the United States and, if required by an applicable income tax treaty, is attributable to a U.S. permanent establishment or fixed base of the Non-U.S. Holder (in which case, provided the Non-U.S. Holder provides a properly executed IRS Form W-8ECI (or successor form) to the withholding agent, the Non-U.S. Holder (x) generally will not be subject to withholding tax, but (y) will be subject to U.S. federal income tax in the same manner as a U.S. Holder (unless an applicable income tax treaty provides otherwise), and a Non-U.S. Holder that is a corporation for U.S. federal income tax purposes may also be subject to a branch profits tax with respect to such Non-U.S. Holder’s effectively connected earnings and profits that are attributable to the accrued but unpaid interest at a rate of 30 percent (or at a reduced rate or exemption from tax under an applicable income tax treaty)). |
A Non-U.S. Holder that does not qualify for exemption from withholding tax pursuant to clauses (a)–(d) above generally will be subject to withholding of U.S. federal income tax on such interest or imputed interest at a 30 percent rate (or at a reduced rate or exemption from tax under an applicable income tax treaty). To claim such treaty exemption, the Non-U.S. Holder must provide the applicable withholding agent with a properly executed IRS Form W-8BEN or W-8BEN-E (or other applicable documentation) claiming a reduction in or exemption from withholding tax under the benefit of an income tax treaty between the United States and the country in which the Non-U.S. Holder resides or is established. For purposes of providing a properly executed IRS Form W-8BEN or W-8BEN-E, special procedures are provided under applicable Treasury Regulations for payments through qualified foreign intermediaries or certain financial institutions that hold customers’ securities in the ordinary course of their trade or business.
The certifications described above must be provided to the applicable withholding agent prior to the payment of interest and must be updated periodically. Non-U.S. Holders that do not timely provide the applicable withholding agent with the required certification, but that qualify for a reduced rate under an applicable income tax treaty, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty.
| 3. | Sale, Redemption, or Other Taxable Disposition of Reorganized Parent Common Stock. |
A Non-U.S. Holder generally will not be subject to U.S. federal income tax with respect to any gain realized on the sale or other taxable disposition (including a cash redemption) of the Reorganized Parent Common Stock unless: (i) such Non-U.S. Holder is an individual who is present in the United States for 183 days or more in the taxable year of disposition or who is subject to special rules applicable to former citizens and residents of the United States; (ii) such gain is effectively connected with such Non-U.S. Holder’s conduct of a U.S. trade or business (and, if an income tax treaty applies, such gain is attributable to a permanent establishment maintained by such Non-U.S. Holder in the United States); or (iii) the Reorganized Parent is or has been during a specified testing period a “U.S. real property holding corporation”.
113
If the first exception applies, the Non-U.S. Holder generally will be subject to U.S. federal income tax at a rate of 30% (or at a reduced rate or exemption from tax under an applicable income tax treaty) on the amount by which such Non-U.S. Holder’s capital gains allocable to U.S. sources exceed capital losses allocable to U.S. sources during the taxable year of disposition of Reorganized Parent Common Stock. If the second exception applies, the Non-U.S. Holder generally will be subject to U.S. federal income tax with respect to such gain in the same manner as a U.S. Holder, and a Non-U.S. Holder that is a corporation for U.S. federal income tax purposes may also be subject to a branch profits tax with respect to earnings and profits effectively connected with a U.S. trade or business that are attributable to such gains at a rate of 30% (or at a reduced rate or exemption from tax under an applicable income tax treaty). If the third exception applies, the Non-U.S. Holder generally will be subject to U.S. federal income tax on any gain recognized upon the sale or other taxable disposition of the Reorganized Parent Common Stock at the rates applicable to U.S. persons, and such disposition generally will be subject to withholding at a rate of 15% of the amount realized, subject to applicable exceptions.
| D. | Information Reporting and Back-Up Withholding. |
The Debtors, the Reorganized Debtors, and applicable withholding agents will withhold all amounts required by law to be withheld from payments, whether in connection with distributions under the Prepackaged Plan or in connection with payments made on account of consideration received pursuant to the Prepackaged Plan. The Debtors, the Reorganized Debtors, and any applicable reporting agent will comply with all applicable information reporting requirements of the IRC. In general, information reporting requirements may apply to distributions or payments under the Prepackaged Plan. Additionally, under the backup withholding rules, a Holder may be subject to backup withholding (currently at a rate of 24 percent) with respect to distributions or payments made pursuant to the Prepackaged Plan unless such Holder (1) comes within certain exempt categories (which generally include corporations) and, when required, demonstrates that fact or (2) timely provides a correct taxpayer identification number and certifies under penalty of perjury that the taxpayer identification number is correct and that the Holder is not subject to backup withholding (generally in the form of a properly executed IRS Form W-9 for a U.S. Holder). Backup withholding is not an additional tax but an advance payment that may be refunded to the extent it results in an overpayment of tax, provided that the required information is timely provided to the IRS.
In addition, from an information reporting perspective, the Treasury Regulations generally require disclosure by a taxpayer on its U.S. federal income tax return of certain types of transactions in which the taxpayer participated, including certain transactions that result in the taxpayer claiming certain types of losses in excess of specified thresholds. Each Holder is urged to consult its tax advisor regarding these regulations and whether the transactions contemplated by the Prepackaged Plan would be subject to these regulations and require disclosure on such Holder’s tax returns.
| E. | Foreign Account Tax Compliance Act. |
Under sections 1471 to 1474 of the IRC (commonly referred to as the Foreign Account Tax Compliance Act (“FATCA”)), unless otherwise subject to an exception, foreign financial institutions and certain other foreign entities must report certain information with respect to their U.S. account holders and investors or be subject to 30% withholding on the receipt of “withholdable payments.” For this purpose, “withholdable payments” are generally U.S. source payments of fixed or determinable, annual or periodical income (including interest), and, subject to the paragraph immediately below, also include gross proceeds from the sale of any property of a type which can produce U.S.-source interest or dividends. FATCA withholding will apply even if the applicable payment would not otherwise be subject to U.S. federal nonresident withholding tax.
114
Withholding with respect to the gross proceeds of a disposition of any stock, debt instrument, or other property that can produce U.S.-source dividends or interest has been eliminated under proposed Treasury Regulations, which can be relied on until final regulations become effective.
THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PREPACKAGED PLAN ARE COMPLEX. THE FOREGOING SUMMARY DOES NOT DISCUSS ALL ASPECTS OF U.S. FEDERAL INCOME TAXATION THAT MAY BE RELEVANT TO A PARTICULAR HOLDER IN LIGHT OF SUCH HOLDER’S CIRCUMSTANCES AND INCOME TAX SITUATION. EACH HOLDER SHOULD CONSULT ITS TAX ADVISOR AS TO THE PARTICULAR TAX CONSEQUENCES TO IT OF THE TRANSACTIONS CONTEMPLATED BY THE PREPACKAGED PLAN, INCLUDING THE APPLICABILITY AND EFFECT OF ANY STATE, LOCAL, OR FOREIGN TAX LAWS AND OF ANY CHANGE IN APPLICABLE TAX LAWS.
| XIII. | RECOMMENDATION |
The Debtors believe the Prepackaged Plan is in the best interests of all stakeholders. Accordingly, the Debtors recommend that Holders of Claims in Classes 3, 4, 5, and 6 vote to accept the Prepackaged Plan and support Confirmation of the Prepackaged Plan.
[Remainder of page intentionally left blank.]
115
Dated: November 2, 2026
| Respectfully submitted, |
| /s/ Lori Macomber |
| Lori Macomber |
| Chief Financial Officer |
| Karyopharm Therapeutics Inc. and its Debtor affiliate |
EXHIBIT A
Prepackaged Plan
2
IN THE UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF TEXAS
HOUSTON DIVISION
| In re:
KARYOPHARM THERAPEUTICS INC., et al.,20
Debtors. |
Chapter 11
Case No. 26-_____ (___)
(Joint Administration Requested)
|
JOINT PREPACKAGED CHAPTER 11 PLAN OF
KARYOPHARM THERAPEUTICS INC. AND ITS DEBTOR AFFILIATE
| SIDLEY AUSTIN LLP Maegan Quejada (TX Bar No. 24105999) Chelsea McManus (TX Bar No. 24131499) 1000 Louisiana Street, Suite 5900 Houston, Texas 77002 Telephone: (713) 495-4500 Facsimile: (713) 495-7799 Email: mquejada@sidley.com cmcmanus@sidley.com
Proposed Counsel to the Debtors |
SIDLEY AUSTIN LLP Stephen E. Hessler (pro hac vice pending) Anthony R. Grossi (pro hac vice pending) 787 Seventh Avenue New York, New York 10019 Telephone: (212) 839-5300 Facsimile: (212) 839-5599 Email: shessler@sidley.com
and
Ian C. Ferrell (pro hac vice pending) Daniela Rakowski (pro hac vice pending) One South Dearborn Chicago, Illinois 60603 Telephone: (312) 853-7000 Facsimile: (312) 853-7036 Email: iferrell@sidley.com drakowski@sidley.com |
Dated: November 2, 2026
| 20 | The Debtors in these chapter 11 cases, together with the last four digits of the Debtors’ federal tax identification numbers, are: Karyopharm Therapeutics Inc. (1704); and KPT Texas LLC (1815). The Debtors’ service address is 85 Wells Avenue, Suite 210, Newton, Massachusetts 02459. |
3
TABLE OF CONTENTS
| Article I. Defined Terms, Rules Of Interpretation, Computation Of Time, And Governing Law |
1 | |||||
| A. |
Defined Terms |
1 | ||||
| B. |
Rules of Interpretation |
25 | ||||
| C. |
Computation of Time |
26 | ||||
| D. |
Governing Law |
26 | ||||
| E. |
Reference to Monetary Figures |
26 | ||||
| F. |
Reference to the Debtors or the Reorganized Debtors |
26 | ||||
| G. |
Nonconsolidated Prepackaged Plan |
26 | ||||
| H. |
Controlling Document |
27 | ||||
| I. |
Consultation, Information, Notice, and Consent Rights |
27 | ||||
| ARTICLE II. Administrative Claims, DIP CLAIMS, Priority Claims, And Restructuring Expenses |
28 | |||||
| A. |
Administrative Claims |
28 | ||||
| B. |
DIP Claims |
28 | ||||
| C. |
Professional Fee Claims |
29 | ||||
| D. |
Priority Tax Claims |
30 | ||||
| E. |
Payment of Restructuring Expenses |
30 | ||||
| ARTICLE III. Classification And Treatment Of Claims And Interests |
31 | |||||
| A. |
Classification of Claims and Interests |
31 | ||||
| B. |
Treatment of Claims and Interests |
32 | ||||
| C. |
Special Provision Governing Unimpaired Claims |
39 | ||||
| D. |
Elimination of Vacant Classes |
39 | ||||
| E. |
Voting Classes; Presumed Acceptance by Non-Voting Classes |
39 | ||||
| F. |
Intercompany Interests |
39 | ||||
| G. |
Confirmation Pursuant to Sections 1129(a)(10) and 1129(b) of the Bankruptcy Code |
39 | ||||
| H. |
Controversy Concerning Impairment |
40 | ||||
| I. |
Subordinated Claims |
40 | ||||
| ARTICLE IV. Means For Implementation Of The Plan |
40 | |||||
| A. |
General Settlement of Claims and Interests |
40 | ||||
| B. |
Sale Transaction Election Notice Deadline; Successful Bid |
41 | ||||
| C. |
Restructuring Transactions |
42 | ||||
| D. |
Continued Corporate Existence |
44 | ||||
i
| E. |
Vesting of Assets in the Reorganized Debtors or Post-Effective Date Debtors |
45 | ||||
| F. |
Cancellation of Existing Securities and Agreements |
45 | ||||
| G. |
Cancellation of Certain Existing Security Interests |
45 | ||||
| H. |
Sources of Consideration for Plan Distributions |
46 | ||||
| I. |
New Common Stock |
46 | ||||
| J. |
The Merger |
48 | ||||
| K. |
MF CVR Agreement; Omisirge Contingent Equity |
49 | ||||
| L. |
NewCo Facility |
49 | ||||
| M. |
Corporate Action |
50 | ||||
| N. |
New Corporate Governance Documents |
51 | ||||
| O. |
Preservation of Causes of Action |
52 | ||||
| P. |
Certain Securities Law Matters |
53 | ||||
| Q. |
1146 Exemption |
55 | ||||
| R. |
Additional Sale Transaction Provisions |
55 | ||||
| S. |
Director and Officer Liability Insurance |
56 | ||||
| T. |
Indemnification Obligations |
56 | ||||
| U. |
Winddown of Karyopharm Europe GmbH |
57 | ||||
| V. |
New Royalty Agreement |
57 | ||||
| W. |
Management Incentive Plan |
57 | ||||
| ARTICLE V. Treatment Of Executory Contracts And Unexpired Leases |
58 | |||||
| A. |
Assumption and Rejection of Executory Contracts and Unexpired Leases |
58 | ||||
| B. |
Claims Based on Rejection of Executory Contracts or Unexpired Leases |
59 | ||||
| C. |
Cure of Defaults for Assumed Executory Contracts and Unexpired Leases |
60 | ||||
| D. |
Preexisting Obligations to the Debtors Under Executory Contracts and Unexpired Leases |
61 | ||||
| E. |
Insurance Policies |
61 | ||||
| F. |
Employee Compensation and Benefits |
62 | ||||
| G. |
Reservation of Rights |
63 | ||||
| H. |
Nonoccurrence of Effective Date |
63 | ||||
| I. |
Contracts and Leases Entered Into After the Petition Date |
63 | ||||
| ARTICLE VI. Provisions Governing Distributions |
63 | |||||
| A. |
Distributions on Account of Claims Allowed as of the Effective Date |
63 | ||||
| B. |
Disbursing Agent |
64 | ||||
| C. |
Rights and Powers of Disbursing Agent |
64 | ||||
| D. |
Delivery of Distributions and Undeliverable or Unclaimed Distributions |
64 | ||||
ii
| E. |
Manner of Payment |
67 | ||||
| F. |
Compliance With Tax Requirements |
67 | ||||
| G. |
Allocations |
67 | ||||
| H. |
No Postpetition Interest on Claims |
68 | ||||
| I. |
Foreign Currency Exchange Rate |
68 | ||||
| J. |
Setoffs and Recoupment |
68 | ||||
| K. |
Claims Paid or Payable by Third Parties |
68 | ||||
| ARTICLE VII. Procedures For Resolving Contingent, Unliquidated, And Disputed Claims |
69 | |||||
| A. |
Disputed Claims Process |
69 | ||||
| B. |
Allowance of Claims |
70 | ||||
| C. |
Claims Administration Responsibilities |
71 | ||||
| D. |
Estimation of Claims and Interests |
71 | ||||
| E. |
Adjustment to Claims or Interests Without Objection |
71 | ||||
| F. |
Disallowance of Claims or Interests |
72 | ||||
| G. |
No Distributions Pending Allowance |
72 | ||||
| H. |
Distributions After Allowance |
72 | ||||
| I. |
No Interest |
72 | ||||
| J. |
Accrual of Dividends and Other Rights |
72 | ||||
| ARTICLE VIII. Settlement, Release, Injunction, And Related Provisions |
73 | |||||
| A. |
Discharge of Claims and Termination of Interests |
73 | ||||
| B. |
Release of Liens |
73 | ||||
| C. |
Releases by the Debtors |
74 | ||||
| D. |
Releases by the Releasing Parties |
75 | ||||
| E. |
Exculpation |
77 | ||||
| F. |
Injunction |
78 | ||||
| G. |
Protections Against Discriminatory Treatment |
79 | ||||
| H. |
Document Retention |
79 | ||||
| I. |
Reimbursement or Contribution |
79 | ||||
| ARTICLE IX. Conditions Precedent To Consummation Of The Plan |
80 | |||||
| A. |
Conditions Precedent to the Effective Date |
80 | ||||
| B. |
Waiver of Conditions |
83 | ||||
| C. |
Effect of Failure of Conditions |
83 | ||||
| D. |
Substantial Consummation |
83 | ||||
iii
| ARTICLE X. Modification, Revocation, Or Withdrawal Of The Plan |
84 | |||||
| A. |
Modification and Amendments |
84 | ||||
| B. |
Effect of Confirmation on Modifications |
84 | ||||
| C. |
Revocation or Withdrawal of Prepackaged Plan |
84 | ||||
| ARTICLE XI. Retention Of Jurisdiction |
85 | |||||
| ARTICLE XII. Miscellaneous Provisions |
88 | |||||
| A. |
Immediate Binding Effect |
88 | ||||
| B. |
Additional Documents |
88 | ||||
| C. |
Payment of Statutory Fees |
88 | ||||
| D. |
Statutory Committee and Cessation of Fee and Expense Payment |
88 | ||||
| E. |
Reservation of Rights |
89 | ||||
| F. |
Successors and Assigns |
89 | ||||
| G. |
Notices |
89 | ||||
| H. |
Term of Injunctions or Stays |
90 | ||||
| I. |
Entire Agreement |
90 | ||||
| J. |
Plan Supplement |
91 | ||||
| K. |
Severability of Prepackaged Plan Provisions |
91 | ||||
| L. |
Votes Solicited in Good Faith |
91 | ||||
| M. |
Closing of Chapter 11 Cases |
91 | ||||
| N. |
Waiver or Estoppel |
91 | ||||
| O. |
Creditor Default |
92 | ||||
| P. |
Deemed Acts |
92 | ||||
iv
INTRODUCTION
Karyopharm Therapeutics Inc. and its debtor affiliate, in the above-captioned chapter 11 cases (collectively, the “Debtors”), propose this joint prepackaged chapter 11 plan of reorganization (as modified, amended, or supplemented from time to time, the “Prepackaged Plan”) for the resolution of the outstanding claims against, and equity interests in, the Debtors. Although proposed jointly for administrative purposes, the Prepackaged Plan constitutes a separate chapter 11 plan for each Debtor. Holders of Claims against, or Interests in, the Debtors may refer to the Disclosure Statement for a discussion of the Debtors’ history, businesses, assets, results of operations, historical financial information, projections of future operations, risk factors, a summary and analysis of the Prepackaged Plan, the Restructuring Transactions, and certain related matters. The Debtors are the proponents of the Prepackaged Plan within the meaning of section 1129 of the Bankruptcy Code.
ALL HOLDERS OF CLAIMS ENTITLED TO VOTE ON THE PREPACKAGED PLAN ARE ENCOURAGED TO READ THE PREPACKAGED PLAN AND THE DISCLOSURE STATEMENT IN THEIR ENTIRETY BEFORE VOTING TO ACCEPT OR REJECT THE PREPACKAGED PLAN.
ARTICLE I.
DEFINED TERMS, RULES OF INTERPRETATION,
COMPUTATION OF TIME, AND GOVERNING LAW
| A. | Defined Terms. |
As used in the Prepackaged Plan, capitalized terms have the meanings set forth below.
1. “1125(e) Exculpated Parties” means, collectively, and in each case solely in its capacity as such and solely for purposes of section 1125(e) of the Bankruptcy Code: (a) the Debtors; (b) the Consenting Stakeholders; (c) Ayrmid; (d) the DIP Lenders; (e) the DIP Agent; (f) the Prepetition Agents; and (g) each Related Party of each Entity in the foregoing clauses (a) through (f).
2. “1L Agent” means Wilmington Savings Fund Society, FSB, in its capacity as administrative agent and collateral agent under the 1L Credit Agreement, and any successor thereto.
3. “1L Credit Agreement” means that certain Credit and Guaranty Agreement, dated as of May 8, 2024, by and among Parent, as borrower, the guarantors party thereto, the lenders party thereto from time to time, and the 1L Agent, as amended by that certain First Amendment and Waiver to Credit and Guaranty Agreement, dated as of October 7, 2025, that certain Second Amendment to Credit and Guaranty Agreement, dated as of February 27, 2026, and as may be further amended, restated, amended and restated, supplemented, or otherwise modified from time to time.
1
4. “1L Equity Distribution” means, subject to the Restructuring Transactions Memorandum, 36.096% to 37.029% (depending on the amount of Reorganized Parent Common Stock distributed to Holders of Allowed Equitized DIP New Money Claims) of the Reorganized Parent Common Stock issued and outstanding on the Effective Date.
5. “1L Loan Documents” means the “Loan Documents” as defined in the 1L Credit Agreement.
6. “1L Term Loan Claims” means any Claim for obligations arising under the 1L Credit Agreement and the other 1L Loan Documents, including Claims in respect of all principal amounts outstanding, interest, fees, redemption premiums, expenses, costs, and other charges arising thereunder or related thereto and all other Obligations (as defined in the 1L Credit Agreement), including postpetition interest, as applicable.
7. “1.5L 2028 Notes” means the 9.00% Convertible Senior Secured Notes due 2028 issued by Parent and outstanding under the 1.5L 2028 Notes Indenture.
8. “1.5L 2028 Notes Claims” means any Claim for obligations arising under the 1.5L 2028 Notes Indenture or the other 1.5L 2028 Notes Documents, including Claims in respect of all principal amounts outstanding, interest, fees, redemption premiums, expenses, costs, and other charges arising thereunder or related thereto and all other Obligations (as defined in the 1.5L 2028 Notes Indenture), including postpetition interest, as applicable.
9. “1.5L 2028 Notes Documents” means the “Transaction Documents” as defined in the 1.5L 2028 Notes Indenture.
10. “1.5L 2028 Notes Indenture” means that certain Indenture, dated as of October 10, 2025 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time), by and among Parent, as issuer, the guarantors party thereto, and the 1.5L 2028 Notes Trustee, governing the 1.5L 2028 Notes.
11. “1.5L 2028 Notes Trustee” means Wilmington Savings Fund Society, FSB, in its capacity as trustee under the 1.5L 2028 Notes Indenture, and any successor thereto.
12. “1.5L Equity Distribution” means, subject to the Restructuring Transactions Memorandum, 6.439% to 6.606% (depending on the amount of Reorganized Parent Common Stock distributed to Holders of Allowed Equitized DIP New Money Claims) of the Reorganized Parent Common Stock issued and outstanding on the Effective Date.
13. “2L 2029 Notes” means the 9.00% Convertible Senior Secured Notes due 2029 issued by Parent and outstanding under the 2L 2029 Notes Indenture.
14. “2L 2029 Notes Claims” means any Claim for obligations arising under the 2L 2029 Notes Indenture or the other 2L 2029 Notes Documents, including Claims in respect of all principal amounts outstanding, interest, fees, redemption premiums, expenses, costs, and other charges arising thereunder or related thereto and all other Obligations (as defined in the 2L 2029 Notes Indenture), including postpetition interest, as applicable.
15. “2L 2029 Notes Documents” means the “Transaction Documents” as defined in the 2L 2029 Notes Indenture.
2
16. “2L 2029 Notes Indenture” means that certain Indenture, dated as of October 10, 2025 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time), by and among Parent, as issuer, the guarantors party thereto, and the 2L 2029 Notes Trustee, governing the 2L 2029 Notes.
17. “2L 2029 Notes Trustee” means Wilmington Savings Fund Society, FSB, in its capacity as trustee under the 2L 2029 Notes Indenture, and any successor thereto.
18. “2L Collateral Trustee” means Wilmington Savings Fund Society, FSB, in its capacity as collateral trustee under the Collateral Trust Agreement, and any successor thereto.
19. “2L Equity Distribution” means, subject to the Restructuring Transactions Memorandum, 33.259% to 34.119% (depending on the amount of Reorganized Parent Common Stock distributed to Holders of Allowed Equitized DIP New Money Claims) of the Reorganized Parent Common Stock issued and outstanding on the Effective Date.
20. “Acceptable Alternative Transaction” has the meaning set forth in the Restructuring Support Agreement.
21. “Ad Hoc Group” means that certain ad hoc group of Holders of, or investment advisors, sub-advisors, or managers of discretionary accounts of funds that hold DIP Claims, 1L Term Loan Claims, 1.5L 2028 Notes Claims, or 2L 2029 Notes Claims represented by the Ad Hoc Group Advisors.
22. “Ad Hoc Group Advisors” means, collectively: (a) Latham & Watkins LLP, as counsel; (b) Haynes and Boone, LLP, as local counsel; (c) Houlihan Lokey Capital, Inc., as investment banker and financial advisor; and (d) any other advisor retained by or on behalf of the Ad Hoc Group.
23. “Administrative Claim” means a Claim for costs and expenses of administration of the Chapter 11 Cases pursuant to sections 327, 328, 330, 365, 503(b), 507(a), 507(b), or 1114(e)(2) of the Bankruptcy Code, including: (a) the actual and necessary costs and expenses of preserving the Estates and operating the businesses of the Debtors incurred on or after the Petition Date and through the Effective Date; (b) Allowed Professional Fee Claims; (c) all fees and charges assessed against the Estates under chapter 123 of the Judicial Code; (d) any Bid Protections, solely to the extent earned in accordance with Article IV.B hereof, the Restructuring Support Agreement, and the Bidding Procedures Order; and (e) Restructuring Expenses.
24. “Affiliate” has the meaning set forth in section 101(2) of the Bankruptcy Code as if the referenced Entity were a debtor in a case under the Bankruptcy Code.
25. “Allowed” means, with respect to any Claim, except as otherwise provided herein: (a) a Claim allowed pursuant to the Prepackaged Plan or a Final Order; (b) a Claim that is scheduled by the Debtors as not contingent, not unliquidated, and not disputed, and for which no Proof of Claim, as applicable, has been timely Filed; or (c) a Claim that is evidenced by a Proof of Claim or a request for payment of an Administrative Claim, as applicable, timely Filed (or for which Claim a Proof of Claim is not required under the Prepackaged Plan, the Bankruptcy Code, or a Final Order); provided that with respect to a Claim described in clauses (b) and (c) above,
3
such Claim shall be Allowed only if and to the extent that with respect to such Claim no objection to the allowance thereof is interposed within the applicable period of time fixed by the Prepackaged Plan, the Bankruptcy Code, the Bankruptcy Rules, or the Bankruptcy Court, or such an objection is so interposed and the Claim has been Allowed by a Final Order; provided further that the Reorganized Debtors or Post-Effective Date Debtors shall retain all claims and defenses with respect to Allowed Claims that are Reinstated or otherwise Unimpaired pursuant to the Prepackaged Plan. To the extent applicable, any Claim that has been or is hereafter listed in the Schedules as contingent, unliquidated, or disputed, and for which no contrary or superseding Proof of Claim is or has been timely Filed, or that is not or has not been Allowed by a Final Order, is not considered Allowed and shall be expunged without further action by the Debtors and without further notice to any party or action, approval, or order of the Bankruptcy Court. Unless expressly waived by the Prepackaged Plan, the Allowed amount of Claims or Interests shall be subject to and shall not exceed the limitations or maximum amounts permitted by the Bankruptcy Code, including sections 502 or 503 of the Bankruptcy Code, to the extent applicable. Notwithstanding anything to the contrary herein, no Claim of any Entity subject to section 502(d) of the Bankruptcy Code shall be deemed Allowed unless and until such Entity pays in full the amount that it owes the applicable Debtor or Reorganized Debtor.
26. “Alternative Restructuring Proposal” has the meaning set forth in the Restructuring Support Agreement.
27. “Assumed Executory Contracts and Unexpired Leases Schedule” means, in the event of a Sale Transaction, a schedule of Executory Contracts and Unexpired Leases to be assumed by the Debtors pursuant to the Prepackaged Plan, which shall be included in the Plan Supplement, as the same may be amended, modified, or supplemented from time to time.
28. “Auction” means the auction, if any, conducted by the Debtors in accordance with the Bidding Procedures if one or more Qualified Bids are received by the Bid Deadline.
29. “Avoidance Actions” means any and all actual or potential avoidance, recovery, subordination, or other Claims, Causes of Action, or remedies that may be brought by or on behalf of the Debtors or their Estates or other authorized parties in interest under the Bankruptcy Code or applicable non-bankruptcy Law, including Claims, Causes of Action, or remedies under sections 502, 510, 542, 544, 545, 547 through 553, and 724(a) of the Bankruptcy Code or under similar local, state, federal, or foreign statutes and common law, including fraudulent transfer Laws.
30. “Ayrmid” means Ayrmid Ltd., together with its Affiliates party to the Merger Agreement, party to any other agreement related to the Reorganization Transaction, or otherwise participating in the Restructuring Transactions, in each case in its capacity as such.
31. “Ayrmid Advisors” means (a) Paul Hastings LLP, as counsel to Ayrmid, (b) a single local counsel retained by Ayrmid, and (c) any other advisor retained by Ayrmid, as may be mutually agreed to by Ayrmid and the Debtors.
4
32. “Ayrmid Term Loan” means the indebtedness (including all principal, accrued and unpaid interest, fees, and other expenses) of Ayrmid and its subsidiaries outstanding under that certain Loan and Security Agreement, dated as of December 12, 2022, as amended by the First Amendment to Loan Agreement, dated as of March 13, 2025, and as further amended, amended and restated, supplemented, or otherwise modified from time to time prior to the date hereof.
33. “Ayrmid Transaction Term Sheet” has the meaning set forth in the Restructuring Support Agreement.
34. “Back-Up Bid” means, if Ayrmid is designated as the Back-Up Bidder, Ayrmid’s commitment to consummate the Reorganization Transaction on the terms set forth in the Restructuring Support Agreement, the Bidding Procedures Order, and the Prepackaged Plan (as such terms may be improved by Ayrmid at the Auction), which commitment shall remain open and irrevocable until the Back-Up Bid Termination Date in accordance with the Bidding Procedures Order.
35. “Back-Up Bid Termination Date” means the earlier of (a) the date on which the transaction contemplated by the Successful Bid is consummated and (b) the date that is 110 days after the Petition Date.
36. “Back-Up Bidder” means Ayrmid, if and to the extent designated by the Debtors as the back-up bidder in accordance with the Bidding Procedures Order following the selection of a Successful Bid submitted by an Entity other than Ayrmid.
37. “Bankruptcy Code” means title 11 of the United States Code, 11 U.S.C. §§ 101–1532, as amended from time to time.
38. “Bankruptcy Court” means the United States Bankruptcy Court for the Southern District of Texas.
39. “Bankruptcy Rules” means the Federal Rules of Bankruptcy Procedure promulgated under section 2075 of the Judicial Code and the general, local, and chambers rules of the Bankruptcy Court, each as amended from time to time.
40. “Bid Deadline” means the deadline for the submission of Qualified Bids under the Bidding Procedures Order.
41. “Bid Protections” means, subject to the Restructuring Support Agreement, any break-up fee, termination fee, expense reimbursement, or other bid protections approved by the Bankruptcy Court pursuant to the Bidding Procedures Order or any other order of the Bankruptcy Court, in the amounts and on the terms set forth therein.
42. “Bidding Procedures” means the procedures governing the marketing of the Debtors’ assets, the solicitation and evaluation of Qualified Bids, the conduct of any Auction, and the selection of any Successful Bid and the designation of any Back-Up Bidder in connection with the Sale Transaction, as approved in the Bidding Procedures Order and as may be amended from time to time in accordance with their terms.
43. “Bidding Procedures Motion” means the motion Filed by the Debtors seeking entry of the Bidding Procedures Order.
5
44. “Bidding Procedures Order” means the order (or, if applicable, the orders, collectively) entered by the Bankruptcy Court, inter alia, approving the Bidding Procedures, the Form APA, and the Bid Protections, and establishing the Bid Deadline, the date of any Auction, and related deadlines in accordance with such procedures, which order shall be consistent in all material respects with the Restructuring Support Agreement and the Prepackaged Plan.
45. “Business Day” means any day other than a Saturday, Sunday, or other day on which commercial banks are authorized to close under the Laws of, or are in fact closed in, the State of New York.
46. “Carve-Out” has the meaning set forth in the DIP Orders.
47. “Cash” or “$” means cash in legal tender of the United States of America and cash equivalents, including bank deposits, checks, and other similar items.
48. “Cash Collateral” has the meaning set forth in section 363(a) of the Bankruptcy Code.
49. “Cause of Action” or “Causes of Action” means any claims, interests, damages, remedies, causes of action, demands, rights, actions, controversies, proceedings, agreements, suits, obligations, liabilities, judgments, accounts, defenses, offsets, powers, privileges, licenses, Liens, indemnities, and guaranties, of any kind or character whatsoever, whether known or unknown, foreseen or unforeseen, existing or hereafter arising, contingent or non-contingent, liquidated or unliquidated, disputed or undisputed, secured or unsecured, assertable, directly or derivatively, matured or unmatured, suspected or unsuspected, whether arising before, on, or after the Petition Date, in contract, tort, law, equity, or otherwise. Causes of Action also include: (a) all rights of setoff, counterclaim, or recoupment and claims under contracts or for breaches of duties imposed by Law or in equity; (b) any claim based on or relating to, or in any manner arising from, in whole or in part, tort, breach of contract, breach of fiduciary duty, violation of state or federal Law or breach of any duty imposed by Law or in equity, including securities Laws, negligence, and gross negligence; (c) the right to object to or otherwise contest Claims or Interests; (d) claims pursuant to section 362 or chapter 5 of the Bankruptcy Code; (e) such claims and defenses as fraud, mistake, duress, and usury, and any other defenses set forth in section 558 of the Bankruptcy Code; and (f) any other Avoidance Action.
50. “Chapter 11 Cases” means (a) when used with reference to a particular Debtor, the case pending for that Debtor under chapter 11 of the Bankruptcy Code in the Bankruptcy Court and (b) when used with reference to all the Debtors, the procedurally consolidated chapter 11 cases pending for the Debtors in the Bankruptcy Court.
51. “Claim” means any claim, as defined in section 101(5) of the Bankruptcy Code, against any of the Debtors.
52. “Claims and Balloting Agent” means Stretto, Inc., the notice, claims, and solicitation agent retained by the Debtors in the Chapter 11 Cases.
53. “Claims Register” means the official register of Claims and Interests maintained by the Claims and Balloting Agent.
6
54. “Class” means a class of Claims or Interests as set forth in Article III of the Prepackaged Plan pursuant to section 1122(a) of the Bankruptcy Code.
55. “CM/ECF” means the Bankruptcy Court’s Case Management and Electronic Case Filing system.
56. “Collateral Trust Agreement” means that certain Collateral Trust Agreement, dated as of October 10, 2025, by and among Parent, the guarantors party thereto, the 1.5L 2028 Notes Trustee, the 2L 2029 Notes Trustee, and the 2L Collateral Trustee, as amended, restated, amended and restated, supplemented, or otherwise modified from time to time.
57. “Company Parties” means Parent and each of its direct and indirect subsidiaries.
58. “Company-Related Matters” means anything related to the Company Parties or the Debtors (including the management, ownership, or operation thereof), the purchase, sale, amendment, or rescission of any Claim against or Interest in the Debtors, the subject matter of, or the transactions or events giving rise to, any Claim or Interest that is treated in the Prepackaged Plan, the business or contractual arrangements between any Company Parties and any Released Party, the distribution of any Cash or other property of the Debtors to any Released Party, the assertion or enforcement of rights or remedies against the Debtors, the Company Parties’ in- or out-of-court restructuring efforts, the Company Parties’ intercompany transactions, the Chapter 11 Cases and any related adversary proceedings, the formulation, preparation, dissemination, solicitation, negotiation, entry into, or Filing of, as applicable, the Chapter 11 Cases, the Restructuring Support Agreement, the September 2026 Forbearance Agreement (and any other forbearance agreement with respect to prepetition Claims against the Debtors), the Forbearance Fee Agreement, the DIP Facility Documents, the Definitive Documents, the Disclosure Statement, the New Corporate Governance Documents, the Prepackaged Plan (including, for the avoidance of doubt, the Plan Supplement), or any Restructuring Transaction, contract, instrument, release, or other agreement or document created or entered into in connection with the foregoing (including, for the avoidance of doubt, any legal opinion requested by any Entity regarding any transaction, contract, instrument, document, or other agreement contemplated by the Prepackaged Plan or the reliance by any Released Party on the Prepackaged Plan or the Confirmation Order in lieu of such legal opinion), the pursuit of Confirmation, the pursuit of Consummation, the administration and implementation of the Prepackaged Plan, including the issuance or distribution of Securities pursuant to the Prepackaged Plan, or the distribution of property under the Prepackaged Plan or any other related agreement or upon any other related act, or omission, transaction, agreement, event, or other occurrence related or relating to any of the foregoing taking place on or before the Effective Date.
59. “Confirmation” means the Bankruptcy Court’s entry of the Confirmation Order on the docket of the Chapter 11 Cases.
60. “Confirmation Date” means the date upon which the Bankruptcy Court enters the Confirmation Order on the docket of the Chapter 11 Cases, within the meaning of Bankruptcy Rules 5003 and 9021.
7
61. “Confirmation Hearing” means the hearing to be held by the Bankruptcy Court on confirmation of the Prepackaged Plan and the adequacy of the Disclosure Statement, as such hearing may be continued from time to time.
62. “Confirmation Order” means the order of the Bankruptcy Court confirming the Prepackaged Plan pursuant to, inter alia, section 1129 of the Bankruptcy Code and approving the Disclosure Statement as containing, among other things, “adequate information” as required by section 1125 of the Bankruptcy Code.
63. “Consenting 2028 Noteholders” means the holders of 1.5L 2028 Notes Claims that have executed and delivered counterpart signature pages, transfer agreements, or joinders to the Restructuring Support Agreement.
64. “Consenting 2029 Noteholders” means the holders of 2L 2029 Notes Claims that have executed and delivered counterpart signature pages, transfer agreements, or joinders to the Restructuring Support Agreement.
65. “Consenting Funded Debt Parties” means, collectively, the Consenting Term Loan Lenders, the Consenting 2028 Noteholders, and the Consenting 2029 Noteholders.
66. “Consenting Preferred Shareholders” means the holders of Existing Preferred Interests that have executed and delivered counterpart signature pages, transfer agreements, or joinders to the Restructuring Support Agreement.
67. “Consenting Royalty Investors” means the holders of RIFA Claims that have executed and delivered counterpart signature pages, transfer agreements, or joinders to the Restructuring Support Agreement.
68. “Consenting Stakeholders” means, collectively, the Consenting Funded Debt Parties, the Consenting Royalty Investors, and the Consenting Preferred Shareholders.
69. “Consenting Term Loan Lenders” means the holders of 1L Term Loan Claims that have executed and delivered counterpart signature pages, transfer agreements, or joinders to the Restructuring Support Agreement.
70. “Consummation” means the occurrence of the Effective Date.
71. “Covered Employee” means each individual employed by any Debtor immediately before the Effective Date, other than any individual who is then an “executive officer” of Parent (as defined in Rule 3b-7 under the Exchange Act).
72. “Cure” means all amounts, including an amount of $0.00, required to cure any monetary defaults under any Executory Contract or Unexpired Lease (or such lesser amount as may be agreed upon by the parties under an Executory Contract or Unexpired Lease) that is to be assumed by the Debtors pursuant to sections 365 or 1123 of the Bankruptcy Code, other than a default that is not required to be cured pursuant to section 365(b)(2) of the Bankruptcy Code.
8
73. “D&O Liability Insurance Policies” means all insurance policies of any of the Debtors for directors’, managers’, and officers’ liability existing as of the Petition Date (including any “tail policy”) and all agreements, documents, or instruments relating thereto.
74. “Debtors” means, collectively, Karyopharm Therapeutics Inc. and KPT Texas LLC.
75. “Debtor Release” means the release set forth in Article VIII.C of the Prepackaged Plan.
76. “Definitive Documents” means (a) the Restructuring Support Agreement; (b) the Prepackaged Plan; (c) the Confirmation Order; (d) the Disclosure Statement; (e) the Disclosure Statement Order; (f) the Solicitation Materials; (g) the First Day Pleadings and all orders sought pursuant thereto; (h) the DIP Facility Documents; (i) the Plan Supplement; (j) the Bidding Procedures Motion and the Bidding Procedures Order; (k) the Sale Order; (l) the Merger Agreement or any Purchase Agreement or other asset purchase agreement with respect to the Debtors’ assets; (m) the New Corporate Governance Documents; (n) the NewCo Facility Documents; (o) the MF CVR Agreement; (p) the New Royalty Agreement; (q) the Plan Administrator Agreement; (r) the Wind-Down Budget; and (s) any and all other agreements, deeds, documentation, instruments, notices, filings, pleadings, motions, applications, briefs, objections, responses, declarations, affidavits, schedules, certificates, letters, memoranda, term sheets, stipulations, settlements, releases, and orders (and any amendments, modifications, or supplements to any of the foregoing) that are necessary or advisable (or that are executed or delivered) to implement, consummate, or document the Restructuring Support Agreement, the Prepackaged Plan, and/or the Restructuring Transactions (in each case, including all exhibits, schedules, amendments, modifications, supplements, appendices, annexes, instructions, and attachments thereto).
77. “DIP Agent” means the administrative agent, collateral agent, or similar Entity under the DIP Facility.
78. “DIP Budget” has the meaning set forth in the DIP Orders.
79. “DIP Claims” means any and all Claims arising under, derived from, or based upon the DIP Facility Documents, including Claims in respect of all principal amounts outstanding, interest, fees, redemption premiums, exit fees, expenses, costs, and other charges arising thereunder or related thereto, including postpetition interest, and all other DIP Obligations and Obligations (in each case as defined in the DIP Facility Documents), which DIP Claims shall have the priorities set forth in the DIP Facility Documents.
80. “DIP Credit Agreement” means the debtor-in-possession credit and guaranty agreement governing the DIP Facility, to be entered into in connection with entry of the Final DIP Order by and among Parent, as borrower, the Debtor guarantors party thereto, the DIP Agent, and the DIP Lenders, as may be amended, amended and restated, supplemented, or otherwise modified from time to time.
81. “DIP Facility” means the senior secured debtor-in-possession financing facility for the DIP Loans, entered into on the terms and conditions set forth in the DIP Facility Documents.
9
82. “DIP Facility Documents” means the DIP Facility Term Sheet, the DIP Credit Agreement, and any other documents governing the DIP Facility that are entered into in accordance with the DIP Facility Term Sheet (or DIP Credit Agreement, as applicable), and the DIP Orders, and any amendments, modifications, and supplements thereto, together with any related notes, certificates, agreements, security agreements, documents, and instruments (including any amendments, restatements, supplements, or modifications of any of the foregoing) related to or executed in connection therewith.
83. “DIP Facility Term Sheet” means the term sheet attached as Exhibit D to the Restructuring Support Agreement; provided that, following entry of the DIP Orders, the version attached to the applicable DIP Order, which may be the DIP Credit Agreement, shall control.
84. “DIP Lenders” means the lenders providing the DIP Facility under the DIP Facility Documents.
85. “DIP Loans” means the loans provided under the DIP Facility, which shall be treated in accordance with Article II.B of the Prepackaged Plan.
86. “DIP New Money Claims” means any DIP Claim in respect of the new money term loans advanced under the DIP Facility, including accrued but unpaid interest thereon (including interest paid in kind) and fees (including any exit fee) and expenses payable in respect thereof under the DIP Facility Documents, which shall be treated in accordance with Article II.B hereof.
87. “DIP New Money Equity Distribution” means, subject to the Restructuring Transactions Memorandum, 0% to 2.521% (depending on the amount of the Allowed Equitized DIP New Money Claims as of immediately prior to the effectiveness of the Prepackaged Plan) of the Reorganized Parent Common Stock issued and outstanding on the Effective Date, to be distributed Pro Rata to Holders of Allowed Equitized DIP New Money Claims in accordance with Article II.B hereof.
88. “DIP Orders” means, together, the Interim DIP Order, the Final DIP Order, and any other order approving the DIP Facility.
89. “DIP Roll-Up Claims” means any DIP Claim in respect of the loans deemed made under the DIP Facility upon the roll-up of 1L Term Loan Claims in accordance with the DIP Facility Documents, including accrued but unpaid interest thereon and fees and expenses payable in respect thereof under the DIP Facility Documents.
90. “DIP Roll-Up Equity Distribution” means, in the event of the Reorganization Transaction and subject to the Restructuring Transactions Memorandum, 21.685% to 22.246% (depending on the amount of Reorganized Parent Common Stock distributed to Holders of Allowed Equitized DIP New Money Claims) of the Reorganized Parent Common Stock issued and outstanding on the Effective Date.
91. “Disbursing Agent” means, as applicable, the Debtors, the Reorganized Debtors, the Post-Effective Date Debtors, the Post-Effective Date Plan Administrator, or such other Entity or Entities selected by the Debtors, the Reorganized Debtors, the Post-Effective Date Debtors, or the Post-Effective Date Plan Administrator, in each case, in consultation with the Required Consenting Funded Debt Parties, to make or facilitate distributions pursuant to the Prepackaged Plan.
10
92. “Disclosure Statement” means the disclosure statement for the Prepackaged Plan, including all exhibits and schedules thereto, to be approved by the Confirmation Order, a copy of which is attached to the Restructuring Support Agreement as Exhibit C.
93. “Disclosure Statement Order” means the order of the Bankruptcy Court approving the Disclosure Statement on a final basis and approving the Solicitation Materials, which order may be the Confirmation Order.
94. “Disputed” means, as to a Claim or an Interest, any Claim or Interest: (a) that is not Allowed; (b) that is not disallowed by the Prepackaged Plan, the Bankruptcy Code, or a Final Order, as applicable; (c) as to which a dispute is being adjudicated by a court of competent jurisdiction in accordance with non-bankruptcy Law; (d) that is Filed in the Bankruptcy Court and not withdrawn, as to which a timely objection or request for estimation has been Filed; or (e) with respect to which a party in interest has Filed a Proof of Claim or otherwise made a written request to a Debtor for payment, without any further notice to or action, order, or approval of the Bankruptcy Court.
95. “Distribution Date” means, except as otherwise set forth herein, the date or dates determined by the Debtors or the Reorganized Debtors, on or after the Effective Date, with the first such date occurring on or as soon as is reasonably practicable after the Effective Date, upon which the Disbursing Agent shall make distributions to Holders of Allowed Claims and Interests entitled to receive distributions under the Prepackaged Plan.
96. “Distribution Record Date” means the record date for purposes of making distributions under the Prepackaged Plan on account of Allowed Claims and Interests except with respect to public securities, which date shall be on or as soon as is reasonably practicable after the Effective Date.
97. “DTC” means the Depository Trust Company.
98. “Effective Date” means, as to the applicable Debtor, (a) the date that is the first Business Day after the Confirmation Date on which (i) no stay of the Confirmation Order is in effect and (ii) all conditions precedent to the occurrence of the Effective Date set forth in Article IX.A of the Prepackaged Plan have been satisfied or waived in accordance with Article IX.B of the Prepackaged Plan, or (b) such other date as may be mutually agreed to by the Debtors, the Required Consenting Funded Debt Parties, and, in the event of the Reorganization Transaction, Ayrmid. Any action to be taken on the Effective Date may be taken on or as soon as reasonably practicable thereafter.
99. “Entity” has the meaning set forth in section 101(15) of the Bankruptcy Code, including “person” (as defined in section 101(41) of the Bankruptcy Code) and “governmental unit” (as defined in section 101(27) of the Bankruptcy Code).
11
100. “Equitized DIP New Money Claims” means the portion of the Allowed DIP New Money Claims, if any, that exceeds the amount of such Allowed DIP New Money Claims repaid in Cash pursuant to clause (i) of Article II.B.1 hereof.
101. “Estate” means, as to each Debtor, the estate created for such Debtor in its Chapter 11 Case pursuant to section 541 of the Bankruptcy Code upon the commencement of such Debtor’s Chapter 11 Case.
102. “Exchange Act” means the Securities Exchange Act of 1934, 15 U.S.C. § 78a, et seq., as amended from time to time, and the rules and regulations promulgated thereunder.
103. “Exculpated Parties” means, collectively, and in each case in its capacity as such: (a) each of the Debtors; (b) each of the disinterested directors of the board of directors of Karyopharm Therapeutics Inc.; and (c) any statutory committee appointed in the Chapter 11 Cases and each of its respective members, solely in their respective capacities as such.
104. “Executory Contract” means a contract to which one or more of the Debtors is a party and that is subject to assumption or rejection under section 365 or 1123 of the Bankruptcy Code.
105. “Existing Common Stock Interests” means shares of the class of common stock of Parent, which as of the Petition Date are traded and quoted on the NASDAQ under the symbol “KPTI” and that exist immediately prior to the Effective Date, including shares issuable pursuant to (a) any restricted stock units of Parent that vest upon a “change of control” transaction and (b) the exercise in accordance with their terms prior to the Effective Date of any stock options or warrants issued by Parent.
106. “Existing Preferred Interests” means shares of any series of preferred stock of Parent that exist immediately prior to the Effective Date.
107. “Federal Judgment Rate” means the federal judgment rate in effect as of the Petition Date.
108. “File,” “Filed,” or “Filing” means file, filed, or filing with the Bankruptcy Court or its authorized designee in the Chapter 11 Cases.
109. “Final DIP Order” means any order approving the DIP Facility and authorizing the Debtors’ use of Cash Collateral on a final basis.
110. “Final Order” means, as applicable, an order or judgment of the Bankruptcy Court, or other court of competent jurisdiction with respect to the relevant subject matter, which has not been reversed, stayed, modified, or amended, including any order subject to appeal but for which no stay of such order has been entered, and as to which the time to appeal, seek certiorari, or move for a new trial, reargument, or rehearing has expired and as to which no appeal, petition for certiorari, or other proceeding for a new trial, reargument, or rehearing has been timely taken, or as to which any appeal that has been taken or any petition for certiorari that has been or may be Filed has been withdrawn with prejudice, resolved by the highest court to which the order or judgment was appealed or from which certiorari could be sought, or any request for new trial,
12
reargument, or rehearing has been denied, resulted in no stay pending appeal or modification of such order, or has otherwise been dismissed with prejudice; provided, that no order or judgment shall fail to be a “Final Order” solely because of the possibility that a motion under rules 59 or 60 of the Federal Rules of Civil Procedure or any analogous Bankruptcy Rule (or any analogous rules applicable in another court of competent jurisdiction) or sections 502(j) or 1144 of the Bankruptcy Code has been or may be Filed with respect to such order or judgment.
111. “First Day Pleadings” means the pleadings Filed by the Debtors on or about the Petition Date seeking ordinary and customary relief in the Chapter 11 Cases.
112. “Forbearance Fee Agreement” means that certain letter agreement, Re: Fee Agreement Pursuant to Forbearance Agreement, dated as of September 10, 2026, entered into by and among Parent and each of the Consenting Stakeholders party to the September 2026 Forbearance Agreement, as amended, restated, amended and restated, supplemented, or otherwise modified from time to time.
113. “Form APA” means the form of asset purchase agreement attached to the Bidding Procedures.
114. “General Unsecured Claim” means any Claim against any of the Debtors that is not (a) paid in full prior to the Effective Date pursuant to an order of the Bankruptcy Court; (b) an Administrative Claim; (c) a DIP Claim; (d) a Secured Claim; (e) an Other Secured Claim; (f) a Priority Tax Claim; (g) an Other Priority Claim; (h) a Prepetition Funded Debt Claim; (i) a RIFA Claim; (j) an Intercompany Claim; or (k) a Section 510(b) Claim.
115. “German RemainCo” has the meaning set forth in Article IV.U hereof.
116. “German RemainCo Winddown Account” has the meaning set forth in Article IV.U hereof.
117. “Governing Body” means, in each case in its capacity as such, the board of directors, board of managers, manager, general partner, special committee, or such similar governing body of any of the Debtors, the Reorganized Debtors, NewCo, or the Post-Effective Date Debtors, as applicable.
118. “Governmental Unit” has the meaning set forth in section 101(27) of the Bankruptcy Code.
119. “Holder” means an Entity holding a Claim against or an Interest in a Debtor, as applicable.
120. “Impaired” means with respect to a Class of Claims or Interests, a Class of Claims or Interests that is impaired within the meaning of section 1124 of the Bankruptcy Code.
121. “Indemnification Entity” has the meaning set forth in Article IV.T hereof.
122. “Intercompany Claim” means any Claim against a Debtor or an Affiliate of a Debtor held by another Debtor or an Affiliate of a Debtor.
13
123. “Intercompany Interest” means an Interest in a Debtor held by another Debtor.
124. “Intercreditor Agreement” means that certain Amended and Restated Intercreditor Agreement, dated as of October 10, 2025, by and among the 1L Agent, the 2L Collateral Trustee, and the Royalty Collateral Agent, as acknowledged by Parent and the other grantors party thereto, as may be amended, restated, amended and restated, supplemented, or otherwise modified from time to time.
125. “Interest” means any “equity security” (as such term is defined in section 101(16) of the Bankruptcy Code) in any of the Debtors, including all shares (or any class thereof), common stock, preferred stock, limited liability company interests, membership interests, and any other equity, ownership, or profits interests of any Debtor, and options, warrants, rights, stock appreciation rights, phantom units, incentives, restricted stock units, commitments, calls, redemption rights, repurchase rights, or other securities or arrangements, whether fully vested or vesting in the future, to acquire or subscribe for, or which are convertible into, or exercisable or exchangeable for the shares (or any class thereof) of, common stock, preferred stock, limited liability company interests, membership interests, or any other equity, ownership, or profits interests of any Debtor (in each case whether or not arising under or in connection with any employment agreement), excluding, for the avoidance of doubt, convertible debt securities; provided that 1.5L 2028 Notes Claims and 2L 2029 Notes Claims shall not constitute Interests.
126. “Interim DIP Order” means one or more orders entered on an interim basis approving the DIP Facility and the DIP Facility Documents and authorizing the Debtors’ use of Cash Collateral.
127. “Judicial Code” means title 28 of the United States Code, 28 U.S.C. §§ 1–4001, as amended from time to time.
128. “KPTI Severance Plans” means each severance, separation pay, salary continuation, and termination pay or benefits plan, policy, program, guideline, and practice of the Debtors, whether written or unwritten, as in effect on the date of the Restructuring Support Agreement; provided that any obligations owed to Covered Employees under the KPTI Severance Plans as of the Effective Date shall not exceed the amounts set forth on Annex A to the Ayrmid Transaction Term Sheet.
129. “Law” means any federal, state, local, or foreign law (including common law), statute, code, ordinance, rule, regulation, order, ruling, or judgment, in each case, that is validly adopted, promulgated, issued, or entered by a governmental authority of competent jurisdiction (including the Bankruptcy Court).
130. “Lien” has the meaning set forth in section 101(37) of the Bankruptcy Code.
131. “Management Incentive Plan” means the management incentive plan, if any, to be implemented by NewCo on or after the Effective Date on terms acceptable to Ayrmid and the Required Consenting Funded Debt Parties and approved by the New Board.
14
132. “Merger” means, subject to the Restructuring Transactions Memorandum, (a) the merger involving Reorganized Parent and Ayrmid, with Reorganized Parent (and, if NewCo is not Ayrmid, Ayrmid) surviving as wholly owned subsidiaries of NewCo, or (b) such other transactions detailed in the Restructuring Transactions Memorandum designed to combine the businesses or assets of Reorganized Parent and Ayrmid, in each case as set forth in the Merger Agreement and to be consummated on the Effective Date substantially concurrently with the issuance of the Reorganized Parent Equity Distribution as a Restructuring Transaction pursuant to the Merger Agreement and Article IV.J of the Prepackaged Plan.
133. “Merger Agreement” means that certain Agreement and Plan of Merger (or other agreement, instrument, or document providing for the combination of the businesses or assets of Reorganized Parent and Ayrmid), including all exhibits and schedules thereto, as may be amended, modified, or supplemented in accordance with the terms thereof and the Restructuring Support Agreement, a substantially final form of which shall be Filed with the Plan Supplement.
134. “Merger Consideration” means, subject to the Restructuring Transactions Memorandum, the consideration issued by NewCo in the Merger as set forth in the Merger Agreement to the Holders of Allowed Prepetition Funded Debt Claims, Allowed Equitized DIP New Money Claims, and Allowed DIP Roll-Up Claims, as the holders of the Reorganized Parent Common Stock immediately prior to the Merger, which consideration shall consist of (a) 55.0% of the New Common Stock issued and outstanding on the Effective Date after giving effect to the Merger, subject to dilution solely by any Omisirge Contingent Equity and the Management Incentive Plan, and (b) the MF CVRs issued by NewCo under the MF CVR Agreement.
135. “MF CVR Agreement” means that certain contingent value rights agreement, to be entered into on the Effective Date by and among NewCo and the initial holders of the MF CVRs issued thereunder, setting forth the terms and conditions of the MF CVRs, a substantially final form of which shall be Filed with the Plan Supplement.
136. “MF CVRs” means the contingent value rights to be issued by NewCo under the MF CVR Agreement and distributed to Holders of Allowed Prepetition Funded Debt Claims, Allowed Equitized DIP New Money Claims, and Allowed DIP Roll-Up Claims as part of the Merger Consideration, in each case on the terms and subject to the conditions set forth in the MF CVR Agreement.
137. “NASDAQ” means Nasdaq Stock Market, together with any successors thereto.
138. “New Board” means, in the event of the Reorganization Transaction, the boards of directors or members of the applicable Governing Bodies of NewCo, the Reorganized Parent or the other Reorganized Debtors, as applicable, as set forth in the Plan Supplement.
139. “NewCo” means, in the event of consummation of the Reorganization Transaction, and subject to the Restructuring Transactions Memorandum, the Entity that, upon consummation of the transactions pursuant to the Merger, shall directly or indirectly own 100% of the equity interests or assets of Reorganized Parent and Ayrmid as identified in the Merger Agreement and the Restructuring Transactions Memorandum.
140. “NewCo Facility” means, in the event of the Reorganization Transaction, the senior secured exit term loan facility in an aggregate principal amount of up to $135,000,000 in new money loans entered into by NewCo (or such other borrower identified in the NewCo Facility Documents) and certain other Reorganized Debtors, as applicable, and governed by the NewCo Facility Documents.
15
141. “NewCo Facility Documents” means the credit agreement among NewCo and certain other Reorganized Debtors and Affiliates, as applicable, and the lenders (which may include any Consenting Funded Debt Party, DIP Lender, or any of their respective Affiliates or managed or controlled funds) and administrative and collateral agents party thereto to effectuate the issuance of the exit term loans, any security agreement, and all other documentation governing the NewCo Facility, substantially final forms of which shall be Filed with the Plan Supplement.
142. “New Common Stock” means, in the event of the Reorganization Transaction, common equity interests of NewCo to be issued pursuant to the Prepackaged Plan, the Merger Agreement (including the Merger Consideration), and the Restructuring Transactions Memorandum or as otherwise permitted pursuant to the New Corporate Governance Documents.
143. “New Corporate Governance Documents” means, in the event of the Reorganization Transaction, the organizational and governance documents of NewCo or the Reorganized Debtors, as applicable, after giving effect to the Restructuring Transactions, including charters, bylaws, operating agreements, or other organizational documents or shareholders’ or investors’ agreements, as applicable, which shall be Filed with the Plan Supplement (provided that, with respect to the Reorganized Debtors other than NewCo, the New Corporate Governance Documents need only be Filed to the extent of any material amendments to the Prepetition Organizational Documents).
144. “New Royalty Agreement” means, in the event of the Reorganization Transaction, the new royalty agreement to be entered into on the Effective Date by and between NewCo, on the one hand, and the Holders of RIFA Claims (or their designee) and the Royalty Collateral Agent (or another collateral agent designated by the Holders of RIFA Claims), on the other hand, as described in Article IV.V hereof, a substantially final form of which shall be Filed with the Plan Supplement.
145. “Notice of Non-Voting Status” means the notice to be provided to Holders of Claims and Interests in Classes that are not entitled to vote to accept or reject the Prepackaged Plan, in the form approved by order of the Bankruptcy Court, which shall include, as applicable, the form by which such Holders may elect to opt out of, or opt in to, the releases set forth in Article VIII.D hereof.
146. “Omisirge Contingent Equity” means, in the event of the Reorganization Transaction, the additional New Common Stock issuable to the equityholders of Ayrmid pursuant to the Merger Agreement (and, to the extent applicable, the New Corporate Governance Documents or a separate contingent value rights or similar agreement entered into by NewCo on the Effective Date, a substantially final form of which, if applicable, shall be Filed with the Plan Supplement) as described in Article IV.K hereof.
147. “Other Equity Interests” means any and all Interests in the Debtors other than Existing Common Stock Interests, Existing Preferred Interests, or Intercompany Interests, including any and all outstanding and unexercised or unvested warrants, options, or rights to acquire Existing Common Stock Interests or other Interests in the Debtors existing immediately prior to the Effective Date and any Section 510(b) Claims.
16
148. “Other Priority Claim” means any Unsecured Claim, other than an Administrative Claim, a Priority Tax Claim, or a RIFA Claim, entitled to priority in right of payment under section 507(a) of the Bankruptcy Code.
149. “Other Secured Claim” means any Secured Claim other than a DIP Claim, Prepetition Funded Debt Claim, or RIFA Claim.
150. “Parent” means Karyopharm Therapeutics Inc.
151. “Person” has the meaning set forth in section 101(41) of the Bankruptcy Code.
152. “Petition Date” means the date on which the Debtors commenced the Chapter 11 Cases.
153. “Plan Administrator Agreement” means, in the event of a Sale Transaction that results in one or more Post-Effective Date Debtor(s), the agreement between the Post-Effective Date Plan Administrator and the Post-Effective Date Debtor(s) regarding the administration and wind-down of the Post-Effective Date Debtor(s)’ assets and other matters related to their applicable Estate(s), which shall be Filed as part of the Plan Supplement and shall be in form and substance acceptable to the Required Consenting Funded Debt Parties.
154. “Plan Distribution” means a payment or distribution of consideration to Holders of Allowed Claims and Allowed Interests under the Prepackaged Plan.
155. “Plan Supplement” means the compilation of documents and forms of documents, term sheets, agreements, schedules, and exhibits to the Prepackaged Plan (in each case, as may be altered, amended, modified, or supplemented up to and through the Effective Date in accordance with the terms hereof and the Restructuring Support Agreement, including the consent rights contained therein) to be Filed prior to the Confirmation Hearing to the extent available, and any additional documents Filed prior to the Effective Date as amendments to the Plan Supplement, including the following, as applicable: (a) the Schedule of Retained Causes of Action; (b) in the event of the Reorganization Transaction, (i) the New Corporate Governance Documents; (ii) to the extent known, the identities of the members of the New Board of NewCo and Reorganized Parent; (iii) the Rejected Executory Contracts and Unexpired Leases Schedule; (iv) the Merger Agreement; (v) the MF CVR Agreement; (vi) the NewCo Facility Documents; (vii) the New Royalty Agreement; (viii) the Restructuring Transactions Memorandum; and (ix) to the extent known, the identity and compensation of any insiders (as such term is defined in section 101(31) of the Bankruptcy Code) who will be employed or retained by the Reorganized Debtors (including NewCo); (c) in the event of a Sale Transaction, (i) the identity of the Post-Effective Date Plan Administrator; (ii) the Plan Administrator Agreement; (iii) the Assumed Executory Contracts and Unexpired Leases Schedule; and (iv) the Sale Transaction Documents; and (d) any and all other agreements, deeds, documentation, instruments, notices, schedules, certificates, term sheets, and other documents (and any amendments, modifications, or supplements to any of the foregoing) that are necessary or advisable to implement, consummate, or document the Prepackaged Plan or the Restructuring Transactions or that are contemplated by the Prepackaged Plan, together with all exhibits, attachments, schedules, agreements, documents, and instruments referred to in any of the foregoing, ancillary or otherwise.
17
156. “Post-Effective Date Debtors” means, in the event of a Sale Transaction, the Debtors after the Effective Date.
157. “Post-Effective Date Plan Administrator” means, in the event of a Sale Transaction, the Person or Entity selected by the Debtors, with the consent of the Required Consenting Funded Debt Parties, and identified in the Plan Supplement to be appointed on the Effective Date and who will serve as the plan administrator for the Post-Effective Date Debtors as set forth in Article IV.R.2 of the Prepackaged Plan.
158. “Prepackaged Plan” means this joint chapter 11 plan of reorganization, the Plan Supplement, and all exhibits and schedules annexed hereto or referenced herein, in each case, as may be amended, supplemented, or otherwise modified from time to time in accordance with the Bankruptcy Code, the Restructuring Support Agreement, and the terms hereof.
159. “Prepetition Agents” means, collectively, the 1L Agent, the 1.5L 2028 Notes Trustee, the 2L 2029 Notes Trustee, the 2L Collateral Trustee, and the Royalty Collateral Agent, each in its capacity as such.
160. “Prepetition Funded Debt Claims” means, collectively, the 1L Term Loan Claims, the 1.5L 2028 Notes Claims, and the 2L 2029 Notes Claims.
161. “Prepetition Organizational Documents” means the formation documents and governance documents for the Debtors as of the Petition Date.
162. “Priority Tax Claim” means any Claim of a Governmental Unit of the kind specified in sections 502(i) and 507(a)(8) of the Bankruptcy Code.
163. “Pro Rata” means the proportion that an Allowed Claim or an Allowed Interest in a particular Class bears to the aggregate amount of Allowed Claims or Allowed Interests in that Class, unless otherwise indicated.
164. “Professional” means an Entity: (a) employed pursuant to a Bankruptcy Court order in accordance with sections 327, 363, or 1103 of the Bankruptcy Code and to be compensated for services rendered prior to or on the Confirmation Date, pursuant to sections 327, 328, 329, 330, 331, and 363 of the Bankruptcy Code; or (b) awarded compensation and reimbursement by the Bankruptcy Court pursuant to section 503(b)(4) of the Bankruptcy Code.
165. “Professional Fee Account” means an account to be funded by the Debtors with Cash on the Effective Date in an amount equal to the Professional Fee Amount.
166. “Professional Fee Amount” means the aggregate amount of Professional Fee Claims and other unpaid fees and expenses that the Professionals estimate they have incurred or will incur in rendering services to the Debtors as set forth in Article II.C of the Prepackaged Plan.
18
167. “Professional Fee Claim” means a Claim by a Professional seeking an award by the Bankruptcy Court of compensation for services rendered or reimbursement of expenses incurred through and including the Confirmation Date under sections 330, 331, 503(b)(2), 503(b)(3), 503(b)(4), or 503(b)(5) of the Bankruptcy Code.
168. “Proof of Claim” means a proof of Claim Filed against any of the Debtors in the Chapter 11 Cases.
169. “Purchase Agreement” means, if any, the definitive purchase agreement(s) effectuating the Sale Transaction, including all exhibits and schedules thereto, and as may be amended, modified, or supplemented in accordance with the terms thereof, which shall be in form and substance consistent with the Bidding Procedures, the Successful Bid Mandatory Conditions, and the Restructuring Support Agreement.
170. “Purchaser” means one or more Entities that are the purchaser or purchasers under the Purchase Agreement(s), if any, together with any successors to and permitted assigns of such purchaser(s).
171. “Qualified Bid” means a bid that is determined by the Debtors to be a qualified bid in accordance with the Bidding Procedures, which shall satisfy the Successful Bid Mandatory Conditions.
172. “Qualifying Termination” means a termination of a Covered Employee’s employment during the Severance Protection Period (a) by NewCo or any of its subsidiaries other than for cause (as defined in the applicable KPTI Severance Plan) or (b) by any Covered Employee for good reason, to the extent the applicable KPTI Severance Plan provides good reason rights or, for any Covered Employee without good reason rights under the applicable KPTI Severance Plan, following (i) a reduction in the Covered Employee’s base salary or base wage rate or (ii) a relocation of the Covered Employee’s primary work location by more than 35 miles, in each case without the Covered Employee’s written consent.
173. “Reinstate,” “Reinstated,” or “Reinstatement” means with respect to Claims and Interests, that the Claim or Interest shall not be discharged hereunder and the holder’s legal, equitable, and contractual rights on account of such Claim or Interest shall remain unaltered by Consummation in accordance with section 1124(1) of the Bankruptcy Code.
174. “Rejected Executory Contracts and Unexpired Leases Schedule” means, in the event of the Reorganization Transaction, a schedule of Executory Contracts and Unexpired Leases to be rejected by the Debtors pursuant to the Prepackaged Plan, which schedule shall be included in the Plan Supplement, as the same may be amended, modified, or supplemented from time to time.
175. “Related Party” means, collectively, with respect to any Person, such Person’s current and former Affiliates, and such Person’s and its current and former Affiliates’ current and former directors, managers, officers, proxyholders, control persons, investment committee members, special committee members, members of any governing body, equity holders (regardless of whether such interests are held directly or indirectly), affiliated investment funds or investment vehicles, predecessors, participants, successors, assigns, subsidiaries, affiliates, managed accounts
19
or funds (including any beneficial holders for the account of whom such funds are managed), partners, limited partners, general partners, principals, members, management companies, fund advisors or managers, investment managers, investment advisors, employees, agents, fiduciaries, trustees, advisory board members, financial advisors, attorneys (including any other attorneys or professionals retained by any current or former director or manager in his or her capacity as director or manager of an Entity), accountants, investment bankers, consultants, representatives, heirs, executors, estates, and nominees, and other professionals and advisors, in each case solely in their capacities as such, together with their respective past and present directors, officers, stockholders, partners, members, employees, agents, attorneys, representatives, heirs, executors, and assigns, in each case solely in their capacities as such, and any Person claiming by or through any of them.
176. “Released Parties” means, collectively, and in each case in its capacity as such: (a) each Debtor; (b) the Post-Effective Date Plan Administrator or the Reorganized Debtors, as applicable; (c) NewCo; (d) the Prepetition Agents; (e) each Consenting Stakeholder; (f) each Consenting Royalty Investor; (g) each Consenting Preferred Shareholder; (h) the DIP Lenders; (i) the DIP Agent; (j) Ayrmid; (k) each current and former Affiliate of each Entity in the foregoing clauses (a) through (j); and (l) each Related Party of each Entity in clauses (a) through (k); provided that any Holder of a Claim or Interest that (x) affirmatively opts out of the releases provided by the Prepackaged Plan by checking the box on the applicable ballot or Notice of Non-Voting Status indicating that it opts not to grant the releases provided in the Prepackaged Plan or (y) in the case of a Holder of a Claim or Interest in a Class that is deemed to reject the Prepackaged Plan, does not affirmatively opt in to the releases provided by the Prepackaged Plan by checking the box on the applicable Notice of Non-Voting Status indicating that it opts to grant the releases provided in the Prepackaged Plan, shall not be a “Released Party.”
177. “Releasing Parties” means, collectively, and in each case in its capacity as such: (a) each Debtor; (b) each Reorganized Debtor or Post-Effective Date Debtor, as applicable; (c) NewCo; (d) the Prepetition Agents; (e) each Consenting Stakeholder; (f) each Consenting Royalty Investor; (g) each Consenting Preferred Shareholder; (h) the DIP Lenders; (i) the DIP Agent; (j) Ayrmid; (k) all Holders of Claims or Interests that vote to accept the Prepackaged Plan; (l) all Holders of Claims or Interests that are deemed to accept the Prepackaged Plan and who do not affirmatively opt out of the releases provided by the Prepackaged Plan by checking the box on the applicable Notice of Non-Voting Status indicating that they opt not to grant the releases provided in the Prepackaged Plan; (m) all Holders of Claims or Interests that abstain from voting on the Prepackaged Plan and who do not affirmatively opt out of the releases provided by the Prepackaged Plan by checking the box on the applicable ballot indicating that they opt not to grant the releases provided in the Prepackaged Plan; (n) all Holders of Claims or Interests that vote to reject the Prepackaged Plan and who do not affirmatively opt out of the releases provided by the Prepackaged Plan by checking the box on the applicable ballot or Notice of Non-Voting Status, as applicable, indicating that they opt not to grant the releases provided in the Prepackaged Plan; (o) all Holders of Claims or Interests that are deemed to reject the Prepackaged Plan and who affirmatively opt in to the releases provided by the Prepackaged Plan by checking the box on the applicable Notice of Non-Voting Status indicating that they opt to grant the releases provided in the Prepackaged Plan; (p) each current and former Affiliate of each Entity in the foregoing clauses (a) through (o); and (q) each Related Party of each Entity in clauses (a) through (p).
20
178. “Reorganization Transaction” means the Restructuring Transactions to be effectuated on the Effective Date pursuant to which, among other things, the Reorganized Parent Equity Distribution is issued to the Holders of Allowed Prepetition Funded Debt Claims, Allowed Equitized DIP New Money Claims, and Allowed DIP Roll-Up Claims and the Merger is consummated in accordance with Article IV.J hereof, unless the Debtors, with the consent of the Required Consenting Funded Debt Parties, elect to pursue the Sale Transaction in accordance with Article IV.B hereof and the Restructuring Support Agreement.
179. “Reorganized Debtors” means, in the event that the Reorganization Transaction is consummated, collectively, Reorganized Parent and each other Debtor, or any successor or assign thereto, by merger, consolidation, or otherwise (including NewCo), on and after the Effective Date.
180. “Reorganized Parent” means, in the event that the Reorganization Transaction is consummated, subject to the Restructuring Transactions Memorandum, Parent, as reorganized on the Effective Date in accordance with the Prepackaged Plan.
181. “Reorganized Parent Common Stock” means, in the event of the Reorganization Transaction, the common equity interests of Reorganized Parent to be issued to Holders of Allowed Prepetition Funded Debt Claims and, to the extent provided in Article II.B hereof, Holders of Allowed Equitized DIP New Money Claims and Allowed DIP Roll-Up Claims and exchanged in the Merger for Merger Consideration in accordance with Article IV.J hereof and the Restructuring Transactions Memorandum.
182. “Reorganized Parent Equity Distribution” means, in the event of the Reorganization Transaction and subject to the Restructuring Transactions Memorandum, collectively, the DIP New Money Equity Distribution, the DIP Roll-Up Equity Distribution, the 1L Equity Distribution, the 1.5L Equity Distribution, and the 2L Equity Distribution, which together constitute 100.0% of the Reorganized Parent Common Stock issued and outstanding on the Effective Date.
183. “Required Consenting Funded Debt Parties” has the meaning set forth in the Restructuring Support Agreement.
184. “Required Consenting Royalty Investors” has the meaning set forth in the Restructuring Support Agreement.
185. “Required DIP Lenders” has the meaning set forth in the DIP Facility Documents.
186. “Reserved Purposes” has the meaning set forth in Article II.B hereof.
187. “Restructuring Expenses” means all reasonable and documented out-of-pocket fees, costs, and expenses of the Ad Hoc Group Advisors, the Royalty Investor Advisors (in the case of the Royalty Investor Advisors, solely to the extent constituting Royalty Investors Fees (as defined in the Restructuring Support Agreement) and paid in accordance with the Restructuring Support Agreement and the DIP Orders), and the Ayrmid Advisors (in the case of the Ayrmid Advisors, solely if and to the extent the Bid Protections are earned and payable in accordance with Article IV.B hereof and the Bidding Procedures Order, and without duplication of any expense reimbursement payable as a Bid Protection) not previously paid by the Debtors, in each case, in connection with the negotiation, formulation, preparation, execution, delivery, implementation, consummation, and/or enforcement of the Restructuring Support Agreement, the Prepackaged Plan, the other Definitive Documents, the Restructuring Transactions, and the transactions contemplated hereby and thereby.
21
188. “Restructuring Support Agreement” means that certain Restructuring Support Agreement, dated as of November 2, 2026, by and among the Company Parties, the Consenting Stakeholders, and Ayrmid (together with all exhibits, supplements, annexes, appendices, schedules, and term sheets attached thereto, and as amended, restated, amended and restated, supplemented, or otherwise modified from time to time), a copy of which is attached to the Disclosure Statement as Exhibit B.
189. “Restructuring Transactions” means any transaction and any actions as may be necessary or appropriate to effect a restructuring of the Debtors’ respective businesses or a corporate restructuring of the overall corporate structure of the Debtors on the terms set forth in the Prepackaged Plan, the issuance of and entry into, as applicable, all securities, notes, instruments, agreements, certificates, and other documents required to be issued or executed pursuant to the Prepackaged Plan, one or more mergers, consolidations, amalgamations, arrangements, continuances, restructurings, conversions, elections, dissolutions, transfers, sales, purchases, liquidations, or other corporate transactions, as described in Article IV.C of the Prepackaged Plan, the Restructuring Support Agreement, and/or set forth in the Restructuring Transactions Memorandum.
190. “Restructuring Transactions Memorandum” means, in the event of the Reorganization Transaction, the memorandum setting forth the steps for, and the sequence of, implementing the Restructuring Transactions (including the Merger), which may include one or more stock transfers, sales, acquisitions, consolidations, combinations, conversions, elections, contributions, mergers, amalgamations, and/or other transactions involving Debtors and/or non-Debtor Entities, and any formula(s) for the issuance, exchange, or allocation of Securities in connection therewith, to be Filed with the Plan Supplement and which shall, to the extent reasonably practicable, structure the Restructuring Transactions in a manner that (a) minimizes any cash taxes payable as a result of the consummation of the Restructuring Transactions, (b) maximizes the favorable tax attributes (including tax basis) of the Reorganized Debtors and NewCo and their respective subsidiaries going forward, and (c) otherwise achieves such tax-planning outcomes as reasonably requested by the Debtors, the Required Consenting Funded Debt Parties, and Ayrmid.
191. “RIFA” means that certain Revenue Interest Financing Agreement, dated as of September 14, 2019, by and among Parent, the investors party thereto, and HealthCare Royalty Management, LLC, as investor representative, as amended by that certain Omnibus Amendment to Transaction Documents, dated as of June 23, 2021, that certain Second Amendment to Revenue Interest Financing Agreement, dated as of August 1, 2023, that certain Second Omnibus Amendment to Transaction Documents, dated as of May 8, 2024, that certain Third Amendment to Revenue Interest Financing Agreement, dated August 14, 2025, that certain Fourth Amendment to Revenue Interest Financing Agreement, dated August 27, 2025, that certain Sixth Amendment to Revenue Interest Financing Agreement, dated October 7, 2025, and as may be further amended, restated, amended and restated, supplemented, or otherwise modified from time to time.
22
192. “RIFA Claims” means any Claim arising under, derived from, or based upon the RIFA, including Claims in respect of any revenue interest payments, indemnities, fees, expenses, and other charges arising thereunder or related thereto, whether or not such Claims are secured.
193. “Royalty Collateral Agent” means HCR Karyopharm SPV, LLC, in its capacity as collateral agent under the RIFA, and any successor thereto.
194. “Royalty Investor Advisors” means Hogan Lovells Cadwalader US LLP and Stifel Financial Corp., as advisors to the Consenting Royalty Investors.
195. “Sale Hearing” means a hearing to consider the approval of any Sale Transaction, which may be combined with the Confirmation Hearing.
196. “Sale Order” means one or more Bankruptcy Court orders, which may be the Confirmation Order, approving the Debtors’ entry into one or more Purchase Agreement(s) in connection with the Sale Transaction, in each case, in form and substance consistent with the Bidding Procedures Order, the Successful Bid Mandatory Conditions, and the Restructuring Support Agreement and the consent rights contained therein.
197. “Sale Transaction” means the sale of all, substantially all, or a material portion of the assets of the Debtors’ Estates pursuant to section 363 of the Bankruptcy Code or the Prepackaged Plan in accordance with the Bidding Procedures and the Restructuring Support Agreement, which sale, in each case, may be pursuant to a credit bid of the Required Consenting Funded Debt Parties.
198. “Sale Transaction Documents” means the documents governing the Sale Transaction, including, without limitation, the Bidding Procedures, the Bidding Procedures Motion, the Bidding Procedures Order, the Purchase Agreement(s), and any Sale Order(s).
199. “Sale Transaction Election Notice” means a notice Filed in advance of the earlier of the Confirmation Hearing and the applicable Sale Hearing indicating that the Debtors have (a) received a Successful Bid in accordance with the Bidding Procedures and the Restructuring Support Agreement (and in each case the requirements set forth therein) and the Prepackaged Plan and (b) elected to pursue the Sale Transaction with the consent of the Required Consenting Funded Debt Parties (and, to the extent required under the Restructuring Support Agreement, the Required Consenting Royalty Investors).
200. “Sale Transaction Election Notice Deadline” means the date that is the deadline for the Debtors to File the Plan Supplement, as established by order of the Bankruptcy Court.
201. “Schedule of Retained Causes of Action” means the schedule of certain Causes of Action of the Debtors that are not released, waived, or transferred pursuant to the Prepackaged Plan, as the same may be amended, modified, or supplemented from time to time.
202. “Schedules” means, collectively, the schedules of assets and liabilities, schedules of Executory Contracts and Unexpired Leases, and statements of financial affairs (if any) Filed by the Debtors pursuant to section 521 of the Bankruptcy Code, including any amendments or supplements thereto.
23
203. “SEC” means the United States Securities and Exchange Commission.
204. “Section 510(b) Claims” means any Claim against a Debtor subject to subordination under section 510(b) of the Bankruptcy Code, whether by operation of Law or contract.
205. “Secured Claim” means a Claim that is secured by a Lien on property in which any of the Debtors’ Estates have an interest or that is subject to setoff under section 553 of the Bankruptcy Code, to the extent of the value of such Claim Holder’s interest in such Estate’s interest in such property or to the extent of the amount subject to setoff, as applicable, as determined pursuant to section 506(a) of the Bankruptcy Code or, in the case of setoff, pursuant to section 553 of the Bankruptcy Code.
206. “Securities Act” means the Securities Act of 1933, 15 U.S.C. §§ 77a–77aa, or any similar Law, each as amended from time to time, and the rules and regulations promulgated thereunder.
207. “Security” means any security, as defined in section 2(a)(1) of the Securities Act or section 101(49) of the Bankruptcy Code.
208. “September 2026 Forbearance Agreement” means that certain Forbearance Agreement and Limited Waiver to Indentures, dated as of September 10, 2026, entered into by and among the Company Parties, certain of the Consenting Stakeholders, and the Prepetition Agents, as amended, restated, amended and restated, supplemented, or otherwise modified from time to time.
209. “Severance Protection Period” has the meaning set forth in Article V.F hereof.
210. “Solicitation Materials” means the solicitation materials provided by the Claims and Balloting Agent to the parties entitled to vote to accept or reject the Prepackaged Plan.
211. “Successful Bid” means the bid selected by the Debtors as the highest or otherwise best bid satisfying the Successful Bid Mandatory Conditions and otherwise in accordance with the Bidding Procedures, the Bidding Procedures Order, and the Restructuring Support Agreement, whether at the conclusion of the Auction or, if no Auction is conducted, otherwise in accordance with the Bidding Procedures Order (which may be a bid submitted by Ayrmid); provided that the Debtors shall not select any Qualified Bid submitted by an Entity other than Ayrmid as the Successful Bid unless such Qualified Bid meets the Successful Bid Mandatory Conditions.
212. “Successful Bid Mandatory Conditions” has the meaning set forth in Article IV.B of the Prepackaged Plan.
213. “Third-Party Release” means the release set forth in Article VIII.D of the Prepackaged Plan.
214. “Unexpired Lease” means a lease to which one or more of the Debtors is a party that is subject to assumption or rejection under section 365 or 1123 of the Bankruptcy Code.
24
215. “Unimpaired” means with respect to a Class of Claims or Interests, a Class of Claims or Interests that is unimpaired within the meaning of section 1124 of the Bankruptcy Code.
216. “Unsecured Claim” means any Claim that is not a Secured Claim.
217. “Wind-Down Budget” means, in the event of a Sale Transaction, the budget for the wind-down of the Post-Effective Date Debtors and the administration of the Prepackaged Plan following the Effective Date (including the funding of the Professional Fee Account), which shall be in form and substance satisfactory to the Debtors and the Required Consenting Funded Debt Parties.
| B. | Rules of Interpretation. |
For purposes of the Prepackaged Plan: (1) in the appropriate context, each term, whether stated in the singular or the plural, shall include both the singular and the plural, and pronouns stated in the masculine, feminine, or neuter gender shall include the masculine, the feminine, and the neuter gender; (2) unless otherwise specified, any reference herein to a contract, lease, instrument, release, indenture, or other agreement or document being in a particular form or on particular terms and conditions means that the referenced document shall be substantially in that form or substantially on those terms and conditions; provided that nothing in this clause (2) shall affect any party’s consent rights over any of the Definitive Documents or any amendments thereto, as provided for in the Restructuring Support Agreement; (3) unless otherwise specified, any reference herein to an existing document, schedule, or exhibit, whether or not Filed, having been Filed or to be Filed shall mean that document, schedule, or exhibit, as it may thereafter be amended, modified, or supplemented in accordance with the Prepackaged Plan or Confirmation Order, as applicable; (4) any reference to an Entity as a Holder of a Claim or Interest includes that Entity’s successors and assigns; (5) unless otherwise specified, all references herein to “Articles” are references to Articles hereof or hereto; (6) unless otherwise specified, all references herein to exhibits are references to exhibits in the Plan Supplement; (7) unless otherwise specified, the words “herein,” “hereof,” and “hereto” refer to the Prepackaged Plan in its entirety rather than to a particular portion of the Prepackaged Plan; (8) subject to the provisions of any contract, certificate of incorporation, by-law, instrument, release, or other agreement or document entered into in connection with the Prepackaged Plan, the rights and obligations arising pursuant to the Prepackaged Plan shall be governed by, and construed and enforced in accordance with the applicable federal Law, including the Bankruptcy Code and Bankruptcy Rules; (9) captions and headings to Articles are inserted for convenience of reference only and are not intended to be a part of or to affect the interpretation of the Prepackaged Plan; (10) unless otherwise specified herein, the rules of construction set forth in section 102 of the Bankruptcy Code shall apply; (11) any term used in capitalized form herein that is not otherwise defined but that is used in the Bankruptcy Code or the Bankruptcy Rules shall have the meaning assigned to that term in the Bankruptcy Code or the Bankruptcy Rules, as the case may be; (12) all references to docket numbers of documents Filed in the Chapter 11 Cases are references to the docket numbers under the Bankruptcy Court’s CM/ECF system; (13) all references to statutes, regulations, orders, rules of courts, and the like shall mean as amended from time to time, and as applicable to the Chapter 11 Cases, unless otherwise stated; (14) the words “include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, and shall be deemed to be followed by the words “without limitation”; (15) references to “Proofs of Claim,” “Holders of Claims,” “Disputed
25
Claims,” and the like shall include “Proofs of Interest,” “Holders of Interests,” “Disputed Interests,” and the like, as applicable; (16) any immaterial effectuating provisions may be interpreted by the Reorganized Debtors in a manner that is consistent with the overall purpose and intent of the Prepackaged Plan all without further notice to or action, order, or approval of the Bankruptcy Court or any other Entity; and (17) all references herein to consent, acceptance, or approval may be conveyed by counsel for the respective parties that have such consent, acceptance, or approval rights, including by electronic mail.
| C. | Computation of Time. |
Unless otherwise specifically stated herein, the provisions of Bankruptcy Rule 9006(a) shall apply in computing any period of time prescribed or allowed herein. If the date on which a transaction may occur pursuant to the Prepackaged Plan shall occur on a day that is not a Business Day, then such transaction shall instead occur on the next succeeding Business Day. Any action to be taken on the Effective Date may be taken on or as soon as reasonably practicable after the Effective Date.
| D. | Governing Law. |
Unless a rule of law or procedure is supplied by federal Law (including the Bankruptcy Code and Bankruptcy Rules) or unless otherwise specifically stated, the Laws of the State of New York, without giving effect to the principles of conflict of laws (other than section 5-1401 and section 5-1402 of the New York General Obligations Law), shall govern the rights, obligations, construction, and implementation of the Prepackaged Plan, any agreements, documents, instruments, or contracts executed or entered into in connection with the Prepackaged Plan (except as otherwise set forth in those agreements, in which case the governing Law of such agreement shall control), and corporate governance matters; provided that corporate governance matters relating to the Debtors or the Reorganized Debtors, as applicable, not incorporated in New York shall be governed by the Laws of the state of incorporation or formation of the relevant Debtor or the Reorganized Debtors, as applicable.
| E. | Reference to Monetary Figures. |
All references in the Prepackaged Plan to monetary figures shall refer to currency of the United States of America, unless otherwise expressly provided herein.
| F. | Reference to the Debtors or the Reorganized Debtors. |
Except as otherwise specifically provided in the Prepackaged Plan to the contrary, references in the Prepackaged Plan to the Debtors or the Reorganized Debtors shall mean the Debtors and the Reorganized Debtors, as applicable, to the extent the context requires.
| G. | Nonconsolidated Prepackaged Plan. |
Although for purposes of administrative convenience and efficiency the Prepackaged Plan has been Filed as a joint plan for each of the Debtors and presents together Classes of Claims against and Interests in the Debtors, the Prepackaged Plan does not provide for the substantive consolidation of any of the Debtors.
26
| H. | Controlling Document. |
In the event of an inconsistency between the Prepackaged Plan and the Disclosure Statement, the terms of the Prepackaged Plan shall control in all respects. In the event of an inconsistency between the Prepackaged Plan and the Plan Supplement, the terms of the relevant provision in the Plan Supplement shall control (unless stated otherwise in such Plan Supplement document, in the Restructuring Support Agreement, or in the Confirmation Order). In the event of an inconsistency between the Confirmation Order and the Prepackaged Plan (including the Plan Supplement), the Confirmation Order shall control; provided that nothing in this Article I.H shall limit, impair, or override the consultation, information, notice, and consent rights set forth in Article I.I; provided further that solely with respect to any consultation, information, notice, or consent rights in the Prepackaged Plan, in the event of any inconsistency between the Prepackaged Plan and the Restructuring Support Agreement or any DIP Facility Document, the terms of the Restructuring Support Agreement or such DIP Facility Document shall control.
| I. | Consultation, Information, Notice, and Consent Rights. |
Notwithstanding anything herein to the contrary, any and all consultation, information, notice, and consent rights of the parties to the Restructuring Support Agreement set forth in the Restructuring Support Agreement (including the exhibits thereto), and of the DIP Lenders set forth in the DIP Facility Documents and the DIP Orders, with respect to the form and substance of the Prepackaged Plan, all exhibits to the Prepackaged Plan, and the Plan Supplement, and all other Definitive Documents (each of which shall be deemed a “Definitive Document” for all purposes of the Restructuring Support Agreement, whether or not expressly identified therein), including any amendments, restatements, supplements, or other modifications to such agreements and documents, and any consents, waivers, or other deviations under or from any such documents, shall be incorporated herein by this reference (including to the applicable definitions in Article I.A hereof) and fully enforceable as if stated in full herein.
The absence in the Prepackaged Plan of references to, or failure to reference, any and all consultation, information, notice, and consent rights referred to in the immediately preceding paragraph, including with respect to any amendments, restatements, supplements, or other modifications to, and any consents, waivers, or other deviations under or from, any such documents, as such rights relate to any document referenced in the Restructuring Support Agreement, the DIP Facility Documents, or the DIP Orders, or to any other Definitive Document, shall not impair, limit, modify, or negate such rights and obligations.
Solely with respect to any consultation, information, notice, or consent rights in the Prepackaged Plan, in the event of any inconsistency between the Prepackaged Plan or the Confirmation Order, on the one hand, and the Restructuring Support Agreement, the DIP Facility Documents, or the DIP Orders, on the other hand, the terms of the Restructuring Support Agreement, the DIP Facility Documents, or the DIP Orders, as applicable, shall control.
27
| XIV. | ADMINISTRATIVE CLAIMS, DIP CLAIMS, PRIORITY CLAIMS, AND RESTRUCTURING EXPENSES |
In accordance with section 1123(a)(1) of the Bankruptcy Code, Administrative Claims, DIP Claims, Professional Fee Claims, Restructuring Expenses, and Priority Tax Claims have not been classified and, thus, are excluded from the Classes of Claims and Interests set forth in Article III hereof.
| A. | Administrative Claims. |
Subject to the provisions of sections 328, 330(a), and 331 of the Bankruptcy Code, unless otherwise agreed to by the Holder of an Allowed Administrative Claim and the Debtors or the Reorganized Debtors, as applicable, or otherwise provided for under the Prepackaged Plan or the Restructuring Support Agreement, each Holder of an Allowed Administrative Claim (other than Holders of Professional Fee Claims and Claims for fees and expenses pursuant to section 1930 of chapter 123 of title 28 of the United States Code) will receive in full and final satisfaction of its Allowed Administrative Claim an amount of Cash equal to the amount of such Allowed Administrative Claim in accordance with the following: (1) if an Administrative Claim is Allowed on or prior to the Effective Date, on the Effective Date or as soon as reasonably practicable thereafter (or, if not then due, when such Allowed Administrative Claim is due or as soon as reasonably practicable thereafter); (2) if such Administrative Claim is not Allowed as of the Effective Date, no later than thirty (30) days after the date on which an order allowing such Administrative Claim becomes a Final Order, or as soon as reasonably practicable thereafter; (3) if such Allowed Administrative Claim is based on liabilities incurred by the Debtors in the ordinary course of their business after the Petition Date, in accordance with the terms and conditions of the particular transaction giving rise to such Allowed Administrative Claim without any further action by the Holder of such Allowed Administrative Claim; (4) at such time and upon such terms as may be agreed upon by such Holder and the Debtors or the Reorganized Debtors, as applicable, and as is consistent with the DIP Budget or otherwise with the consent of the Required Consenting Funded Debt Parties; or (5) at such time and upon such terms as set forth in an order of the Bankruptcy Court.
| B. | DIP Claims. |
On the Effective Date, except to the extent that a Holder of an Allowed DIP Claim agrees to less favorable treatment, in full and final satisfaction, settlement, release, and discharge of each Allowed DIP Claim, including, for the avoidance of doubt, all Claims in respect of the outstanding principal amount of DIP Loans and any accrued but unpaid interest thereon and any fees and expenses payable under the DIP Facility Documents, each Holder of an Allowed DIP Claim shall receive:
| 1. | in the event of the Reorganization Transaction, (i) on account of its Allowed DIP New Money Claims, payment in Cash of its Pro Rata share of (a) up to $50,000,000 of Cash loan proceeds funded under the NewCo Facility plus (b) any unrestricted Cash (excluding, for the avoidance of doubt, proceeds of the NewCo Facility) on the balance sheet of the Debtors upon the consummation of the Reorganization |
28
| Transaction after funding (1) the Carve-Out, (2) the amounts to be deposited into the German RemainCo Winddown Account, (3) the amounts that the Debtors have reasonably estimated are necessary to pay Allowed Administrative Claims (including any amounts for Professionals and other professional advisors, including Professional Fee Claims in the amount of the Professional Fee Amount and the Restructuring Expenses), and (4) the amounts set forth in the DIP Budget allocated to Allowed General Unsecured Claims that have not yet been paid (collectively, the purposes set forth in the foregoing clauses (1) through (4), the “Reserved Purposes”), plus (c) after payment of amounts for the Reserved Purposes, any remaining unrestricted Cash on the balance sheet of the Debtors, (ii) on account of its Allowed Equitized DIP New Money Claims, its Pro Rata share of the DIP New Money Equity Distribution, and (iii) on account of its Allowed DIP Roll-Up Claims, its Pro Rata share of the DIP Roll-Up Equity Distribution; and |
| 2. | in the event of a Sale Transaction, payment in full in Cash from the proceeds of the Sale Transaction on the Effective Date; |
provided that, for the avoidance of doubt, the Holders of Allowed DIP Claims shall not be deemed to have waived their right to have the DIP Claims paid in full in Cash in connection with any transaction or chapter 11 plan other than the Reorganization Transaction.
| C. | Professional Fee Claims. |
| 1. | Final Fee Applications and Payment of Professional Fee Claims. |
All requests for payment of Professional Fee Claims for services rendered and reimbursement of expenses incurred through and including the Confirmation Date must be Filed no later than forty-five (45) days after the Effective Date. The Bankruptcy Court shall determine the Allowed amounts of such Professional Fee Claims after notice and a hearing in accordance with the procedures established by the Bankruptcy Court. The Reorganized Debtors or the Post-Effective Date Debtors, as applicable, shall pay Professional Fee Claims in Cash in the amount the Bankruptcy Court allows, including from the Professional Fee Account, which the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, will establish in trust for the Professionals and fund with Cash equal to the Professional Fee Amount on the Effective Date.
| 2. | Professional Fee Account. |
On the Effective Date, the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, shall establish and fund the Professional Fee Account with Cash equal to the Professional Fee Amount. The Professional Fee Account shall be funded from the proceeds of the DIP Facility or the Debtors’ Cash on hand, and NewCo shall not be responsible for any Professional Fee Claims (including any earned and payable restructuring, sale, success, or other transaction or similar fee). The Professional Fee Account shall be maintained solely for the Professionals. The amount of Allowed Professional Fee Claims shall be paid in Cash to the Professionals by the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, from the Professional Fee Account as soon as reasonably practicable after such Professional Fee Claims are Allowed. When such Allowed Professional Fee Claims have been paid in full, any remaining amount in the Professional Fee Account shall promptly be paid to the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, without any further action or order of the Bankruptcy Court.
29
| 3. | Professional Fee Amount. |
Professionals shall reasonably estimate their unpaid Professional Fee Claims and other unpaid fees and expenses incurred in rendering services to the Debtors before and as of the Effective Date, and shall deliver such estimate to the Debtors no later than five (5) days before the Effective Date; provided that such estimate shall not be deemed to limit the amount of the fees and expenses that are the subject of each Professional’s final request for payment in the Chapter 11 Cases. If a Professional does not provide a timely estimate, the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, may estimate the unpaid and unbilled fees and expenses of such Professional.
| 4. | Post-Confirmation Fees and Expenses. |
Except as otherwise specifically provided in the Prepackaged Plan, from and after the Confirmation Date, the Debtors shall, in the ordinary course of business and without any further notice to or action, order, or approval of the Bankruptcy Court, pay in Cash the reasonable and documented legal, professional, or other fees and expenses related to implementation of the Prepackaged Plan and Consummation incurred by the Debtors. Upon the Confirmation Date, any requirement that Professionals comply with sections 327 through 331, 363, and 1103 of the Bankruptcy Code in seeking retention or compensation for services rendered after such date shall terminate, and the Debtors may employ and pay any Professional in the ordinary course of business without any further notice to or action, order, or approval of the Bankruptcy Court.
| D. | Priority Tax Claims. |
Except to the extent that a Holder of an Allowed Priority Tax Claim agrees to a less favorable treatment, in full and final satisfaction, settlement, release, and discharge of and in exchange for each Allowed Priority Tax Claim, each Holder of such Allowed Priority Tax Claim shall be treated in accordance with the terms set forth in section 1129(a)(9)(C) of the Bankruptcy Code.
| E. | Payment of Restructuring Expenses. |
The Restructuring Expenses and the outstanding reasonable and documented fees and expenses of the Prepetition Agents incurred, or estimated to be incurred, up to and including the Effective Date (or, with respect to necessary post-Effective Date activities, after the Effective Date), shall be paid in full in Cash on the Effective Date (to the extent not previously paid during the course of the Chapter 11 Cases) in accordance with, and subject to, the terms of the Restructuring Support Agreement (including Section 16.21 thereof), any applicable engagement letter(s), and any DIP Orders, as applicable, without any requirement to File a fee application with the Bankruptcy Court, without the need for itemized time detail, and without any requirement for Bankruptcy Court review or approval; provided that any earned and payable restructuring, sale, success, or other transaction or similar fee included in the Restructuring Expenses shall be paid from the proceeds of the DIP Facility or the Debtors’ Cash on hand, and NewCo shall not be
30
responsible therefor. All Restructuring Expenses to be paid on the Effective Date shall be estimated prior to and as of the Effective Date and such estimates shall be delivered to the Debtors at least five (5) calendar days before the anticipated Effective Date; provided that such estimates shall not be considered an admission or limitation with respect to such Restructuring Expenses. On the Effective Date, or as soon as practicable thereafter, final invoices for all Restructuring Expenses incurred prior to and as of the Effective Date shall be submitted to the Debtors. In addition, the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, shall continue to pay pre- and post-Effective Date Restructuring Expenses related to implementation, consummation, and defense of the Prepackaged Plan, whether incurred before, on, or after the Effective Date, without any requirement for Bankruptcy Court review or approval.
| XV. | CLASSIFICATION AND TREATMENT OF CLAIMS AND INTERESTS |
| A. | Classification of Claims and Interests. |
The Prepackaged Plan constitutes a separate chapter 11 plan proposed by each Debtor. Except for the Claims addressed in Article II hereof, all Claims and Interests are classified in the Classes set forth below in accordance with sections 1122 and 1123(a)(1) of the Bankruptcy Code. A Claim or an Interest, or any portion thereof, is classified in a particular Class only to the extent that any portion of such Claim or Interest fits within the description of that Class and is classified in other Classes to the extent that any portion of the Claim or Interest fits within the description of such other Classes. A Claim or an Interest also is classified in a particular Class for the purpose of receiving distributions under the Prepackaged Plan only to the extent that such Claim or Interest is an Allowed Claim or Allowed Interest in that Class and has not been paid, released, or otherwise satisfied prior to the Effective Date.
The classification of Claims against, and Interests in, the Debtors pursuant to the Prepackaged Plan is as follows:
| Class |
Type of Claim or Interest |
Impairment |
Entitled to Vote | |||
| Class 1 | Other Secured Claims | Unimpaired | No (Presumed to accept) | |||
| Class 2 | Other Priority Claims | Unimpaired | No (Presumed to accept) | |||
| Class 3 | 1L Term Loan Claims | Impaired | Yes | |||
| Class 4 | 1.5L 2028 Notes Claims | Impaired | Yes | |||
| Class 5 | 2L 2029 Notes Claims | Impaired | Yes | |||
| Class 6 | RIFA Claims | Impaired | Yes | |||
| Class 7 | General Unsecured Claims | Unimpaired | No (Presumed to accept) | |||
| Class 8 | Intercompany Claims | Impaired / Unimpaired | No (Presumed to accept or deemed to reject) | |||
| Class 9 | Existing Preferred Interests | Impaired | No (Deemed to reject) | |||
| Class 10 | Existing Common Stock Interests | Impaired | No (Deemed to reject) | |||
| Class 11 | Other Equity Interests | Impaired | No (Deemed to reject) | |||
| Class 12 | Intercompany Interests | Impaired / Unimpaired | No (Presumed to accept or deemed to reject) |
31
| B. | Treatment of Claims and Interests. |
Each Holder of an Allowed Claim or Allowed Interest, as applicable, shall receive under the Prepackaged Plan the treatment described below in full and final satisfaction, settlement, release, and discharge of and in exchange for such Holder’s Allowed Claim or Allowed Interest, except to the extent different treatment is agreed to by the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, and the Holder of such Allowed Claim or Allowed Interest, as applicable. Unless otherwise indicated, the Holder of an Allowed Claim or Allowed Interest, as applicable, shall receive such treatment on the Effective Date or as soon as reasonably practicable thereafter.
| 1. | Class 1 – Other Secured Claims |
| a. | Classification: Class 1 consists of all Other Secured Claims. |
| b. | Treatment: The legal, equitable, and contractual rights of the Holders of Allowed Other Secured Claims are unaltered by the Prepackaged Plan. Except to the extent that a Holder of an Allowed Other Secured Claim agrees to a less favorable treatment, each Holder of an Allowed Other Secured Claim shall receive, at the option of the applicable Debtor, with the consent of the Required Consenting Funded Debt Parties: |
| a. | payment in full in Cash of its Allowed Other Secured Claim; |
| b. | the collateral securing its Allowed Other Secured Claim; |
| c. | Reinstatement of its Allowed Other Secured Claim; or |
| d. | such other treatment that renders its Allowed Other Secured Claim Unimpaired in accordance with section 1124 of the Bankruptcy Code. |
| c. | Voting: Class 1 is Unimpaired under the Prepackaged Plan. Holders of Other Secured Claims are conclusively presumed to have accepted the Prepackaged Plan pursuant to section 1126(f) of the Bankruptcy Code. Therefore, such Holders are not entitled to vote to accept or reject the Prepackaged Plan. |
32
| 2. | Class 2 – Other Priority Claims |
| a. | Classification: Class 2 consists of all Other Priority Claims. |
| b. | Treatment: The legal, equitable, and contractual rights of the Holders of Allowed Other Priority Claims are unaltered by the Prepackaged Plan. Except to the extent that a Holder of an Allowed Other Priority Claim agrees to a less favorable treatment, each Holder of an Allowed Other Priority Claim shall receive, at the option of the applicable Debtor with the consent of the Required Consenting Funded Debt Parties, (i) payment in full in Cash or (ii) such other treatment that renders its Allowed Other Priority Claim Unimpaired in accordance with section 1124 of the Bankruptcy Code. |
| c. | Voting: Class 2 is Unimpaired under the Prepackaged Plan. Holders of Other Priority Claims are conclusively presumed to have accepted the Prepackaged Plan pursuant to section 1126(f) of the Bankruptcy Code. Therefore, such Holders are not entitled to vote to accept or reject the Prepackaged Plan. |
| 3. | Class 3 – 1L Term Loan Claims |
| a. | Classification: Class 3 consists of all 1L Term Loan Claims. |
| b. | Allowance: 1L Term Loan Claims shall be deemed Allowed in the aggregate principal amount of $128,981,938.62, plus all accrued and unpaid interest at the default rate, fees, redemption premiums, expenses, costs, and other charges due under the 1L Credit Agreement and the other 1L Loan Documents. |
| c. | Treatment: Except to the extent that a Holder of an Allowed 1L Term Loan Claim agrees to different treatment, |
| a. | in the event of the Reorganization Transaction, each Holder of an Allowed 1L Term Loan Claim shall receive, in full and final satisfaction of such Claim, its Pro Rata share of the 1L Equity Distribution (which shall be, subject to the Restructuring Transactions Memorandum, exchanged in the Merger, substantially concurrently with its issuance, for such Holder’s share of the Merger Consideration); |
| b. | in the event of a Sale Transaction, each Holder of an Allowed 1L Term Loan Claim shall receive payment in full in Cash, including, for the avoidance of doubt, all principal amounts outstanding under the 1L Credit Agreement and any pre- and postpetition interest at the default rate, fees, redemption premiums, expenses, costs, and other charges arising thereunder or related thereto, as applicable; |
33
provided that all distributions to Holders of Allowed 1L Term Loan Claims (in both the Reorganization Transaction and a Sale Transaction) shall be in accordance with the Intercreditor Agreement.
| d. | Voting: Class 3 is Impaired under the Prepackaged Plan. Holders of 1L Term Loan Claims are entitled to vote to accept or reject the Prepackaged Plan. |
| 4. | Class 4 – 1.5L 2028 Notes Claims |
| a. | Classification: Class 4 consists of all 1.5L 2028 Notes Claims. |
| b. | Allowance: 1.5L 2028 Notes Claims shall be deemed Allowed in the aggregate principal amount of $15,648,085.00, plus all accrued and unpaid interest at the default rate, fees, redemption premiums, expenses, costs, and other charges due under the 1.5L 2028 Notes Indenture and the other 1.5L 2028 Notes Documents. |
| c. | Treatment: Except to the extent that a Holder of an Allowed 1.5L 2028 Notes Claim agrees to different treatment, |
| a. | in the event of the Reorganization Transaction, each Holder of an Allowed 1.5L 2028 Notes Claim shall receive, in full and final satisfaction of such Claim, its Pro Rata share of the 1.5L Equity Distribution (which shall be, subject to the Restructuring Transactions Memorandum, exchanged in the Merger, substantially concurrently with its issuance, for such Holder’s share of the Merger Consideration); |
| b. | in the event of a Sale Transaction, each Holder of an Allowed 1.5L 2028 Notes Claim shall receive payment in full in Cash, including, for the avoidance of doubt, all principal amounts outstanding under the 1.5L 2028 Notes Indenture and any pre- and postpetition interest at the default rate, fees, redemption premiums, expenses, costs, and other charges arising thereunder or related thereto, as applicable; |
provided that all distributions to Holders of Allowed 1.5L 2028 Notes Claims (in both the Reorganization Transaction and a Sale Transaction) shall be in accordance with the Intercreditor Agreement and the Collateral Trust Agreement, as applicable.
| d. | Voting: Class 4 is Impaired under the Prepackaged Plan. Holders of 1.5L 2028 Notes Claims are entitled to vote to accept or reject the Prepackaged Plan. |
34
| 5. | Class 5 – 2L 2029 Notes Claims |
| a. | Classification: Class 5 consists of all 2L 2029 Notes Claims. |
| b. | Allowance: 2L 2029 Notes Claims shall be deemed Allowed in the aggregate principal amount of $107,974,339.00, plus all accrued and unpaid interest at the default rate, fees, redemption premiums, expenses, costs, and other charges due under the 2L 2029 Notes Indenture and the other 2L 2029 Notes Documents. |
| c. | Treatment: Except to the extent that a Holder of an Allowed 2L 2029 Notes Claim agrees to different treatment, |
| a. | in the event of the Reorganization Transaction, each Holder of an Allowed 2L 2029 Notes Claim shall receive, in full and final satisfaction of such Claim, its Pro Rata share of the 2L Equity Distribution (which shall be, subject to the Restructuring Transactions Memorandum, exchanged in the Merger, substantially concurrently with its issuance, for such Holder’s share of the Merger Consideration); |
| b. | in the event of a Sale Transaction, each Holder of an Allowed 2L 2029 Notes Claim shall receive either (x) payment in full in Cash, including, for the avoidance of doubt, all principal amounts outstanding under the 2L 2029 Notes Indenture and any pre- and postpetition interest at the default rate, fees, redemption premiums, expenses, costs, and other charges arising thereunder or related thereto, as applicable; or (y) if the Successful Bid so provides, payment in accordance with the Successful Bid Mandatory Conditions set forth in Article IV.B hereof; |
provided that all distributions to Holders of Allowed 2L 2029 Notes Claims (in both the Reorganization Transaction and a Sale Transaction) shall be in accordance with the Intercreditor Agreement and the Collateral Trust Agreement, as applicable.
| d. | Voting: Class 5 is Impaired under the Prepackaged Plan. Holders of 2L 2029 Notes Claims are entitled to vote to accept or reject the Prepackaged Plan. |
35
| 6. | Class 6 – RIFA Claims |
| a. | Classification: Class 6 consists of all RIFA Claims. |
| b. | Allowance: RIFA Claims shall be deemed Allowed in the aggregate amount of $113,536,880.00, plus all fees, expenses, costs, and other charges due under the RIFA as of the Petition Date. |
| c. | Treatment: Except to the extent that a Holder of an Allowed RIFA Claim agrees to different treatment, |
| a. | in the event of the Reorganization Transaction, each Holder of an Allowed RIFA Claim shall receive, in full and final satisfaction of such Claim, its Pro Rata share of the rights and interests under the New Royalty Agreement; |
| b. | in the event of a Sale Transaction, each Holder of an Allowed RIFA Claim shall receive, in full and final satisfaction of such Claim, its Pro Rata share of the consideration payable on account of the RIFA Claims under the Successful Bid, which may consist of Cash or non-Cash consideration in such form as is acceptable to the Holders of RIFA Claims in their discretion and shall have a value of not less than $18,750,000; |
provided that all distributions to Holders of Allowed RIFA Claims (in both the Reorganization Transaction and a Sale Transaction) shall be in accordance with the Intercreditor Agreement.
| d. | Voting: Class 6 is Impaired under the Prepackaged Plan. Holders of RIFA Claims are entitled to vote to accept or reject the Prepackaged Plan. |
| 7. | Class 7 – General Unsecured Claims |
| a. | Classification: Class 7 consists of all General Unsecured Claims. |
| b. | Treatment: The legal, equitable, and contractual rights of the Holders of Allowed General Unsecured Claims are unaltered by the Prepackaged Plan. Except to the extent that a Holder of an Allowed General Unsecured Claim agrees to different treatment, on and after the Effective Date, the Debtors shall continue to pay or dispute each General Unsecured Claim in the ordinary course of business as if the Chapter 11 Cases had never been commenced. |
| c. | Voting: Class 7 is Unimpaired under the Prepackaged Plan. Holders of General Unsecured Claims are conclusively presumed to have accepted the Prepackaged Plan pursuant to section 1126(f) of the Bankruptcy Code. Therefore, such Holders are not entitled to vote to accept or reject the Prepackaged Plan. |
36
| 8. | Class 8 – Intercompany Claims |
| a. | Classification: Class 8 consists of all Intercompany Claims. |
| b. | Treatment: Each Allowed Intercompany Claim shall be, at the option of the applicable Debtor with the consent of the Required Consenting Funded Debt Parties, either: |
| a. | Reinstated; |
| b. | canceled, released, and extinguished, and will be of no further force or effect; or |
| c. | otherwise addressed at the option of each applicable Debtor such that Holders of Intercompany Claims will not receive any distribution on account of such Intercompany Claims. |
| c. | Voting: Class 8 is either Unimpaired or Impaired under the Prepackaged Plan. Holders of Intercompany Claims are conclusively presumed to have accepted the Prepackaged Plan pursuant to section 1126(f) of the Bankruptcy Code or deemed to have rejected the Prepackaged Plan pursuant to section 1126(g) of the Bankruptcy Code. Class 8 is not entitled to vote to accept or reject the Prepackaged Plan. |
| 9. | Class 9 – Existing Preferred Interests |
| a. | Classification: Class 9 consists of all Existing Preferred Interests. |
| b. | Treatment: All Existing Preferred Interests shall be canceled, released, and extinguished and will be of no further force or effect. |
| c. | Voting: Class 9 is Impaired under the Prepackaged Plan. Holders of Existing Preferred Interests are conclusively deemed to have rejected the Prepackaged Plan pursuant to section 1126(g) of the Bankruptcy Code. Class 9 is not entitled to vote to accept or reject the Prepackaged Plan. |
37
| 10. | Class 10 – Existing Common Stock Interests |
| a. | Classification: Class 10 consists of all Existing Common Stock Interests. |
| b. | Treatment: All Existing Common Stock Interests shall be canceled, released, and extinguished and will be of no further force or effect. |
| c. | Voting: Class 10 is Impaired under the Prepackaged Plan. Holders of Existing Common Stock Interests are conclusively deemed to have rejected the Prepackaged Plan pursuant to section 1126(g) of the Bankruptcy Code. Class 10 is not entitled to vote to accept or reject the Prepackaged Plan. |
| 11. | Class 11 – Other Equity Interests |
| a. | Classification: Class 11 consists of all Other Equity Interests. |
| b. | Treatment: Holders of Other Equity Interests will not receive any distribution on account of such Interests, which will be canceled, released, and extinguished as of the Effective Date, and will be of no further force or effect. |
| c. | Voting: Class 11 is Impaired under the Prepackaged Plan. Holders of Other Equity Interests are conclusively deemed to have rejected the Prepackaged Plan pursuant to section 1126(g) of the Bankruptcy Code. Class 11 is not entitled to vote to accept or reject the Prepackaged Plan. |
| 12. | Class 12 – Intercompany Interests |
| a. | Classification: Class 12 consists of all Intercompany Interests. |
| b. | Treatment: Each Intercompany Interest shall be, at the option of the applicable Debtor with the consent of the Required Consenting Funded Debt Parties, either: |
| a. | Reinstated; |
| b. | canceled, released, and extinguished, and will be of no further force or effect; or |
| c. | otherwise addressed, in each case as and to the extent provided in the Restructuring Transactions Memorandum, such that Holders of Intercompany Interests will not receive any distribution on account of such Intercompany Interests. |
38
| c. | Voting: Class 12 is either Unimpaired or Impaired under the Prepackaged Plan. Holders of Intercompany Interests are conclusively presumed to have accepted the Prepackaged Plan pursuant to section 1126(f) of the Bankruptcy Code or deemed to have rejected the Prepackaged Plan pursuant to section 1126(g) of the Bankruptcy Code. Class 12 is not entitled to vote to accept or reject the Prepackaged Plan. |
| C. | Special Provision Governing Unimpaired Claims. |
Except as otherwise provided in the Prepackaged Plan, nothing under the Prepackaged Plan shall affect the Debtors’, the Reorganized Debtors’, or the Post-Effective Date Debtors’, as applicable, rights regarding any Unimpaired Claim, including all rights regarding legal and equitable defenses to or setoffs or recoupments against any such Unimpaired Claim. Unless otherwise Allowed, Claims that are Unimpaired shall remain Disputed Claims under the Prepackaged Plan.
| D. | Elimination of Vacant Classes. |
Any Class of Claims or Interests that does not have a Holder of an Allowed Claim or Allowed Interest or a Claim or Interest temporarily Allowed by the Bankruptcy Court in an amount greater than zero as of the date of the Confirmation Hearing shall be deemed eliminated from the Prepackaged Plan for purposes of voting to accept or reject the Prepackaged Plan and for purposes of determining acceptance or rejection of the Prepackaged Plan by such Class pursuant to section 1129(a)(8) of the Bankruptcy Code.
| E. | Voting Classes; Presumed Acceptance by Non-Voting Classes. |
If a Class contains Claims or Interests eligible to vote and no Holders of Claims or Interests eligible to vote in such Class vote to accept or reject the Prepackaged Plan, the Holders of such Claims or Interests in such Class shall be deemed to have accepted the Prepackaged Plan.
| F. | Intercompany Interests. |
To the extent Reinstated under the Prepackaged Plan or otherwise addressed in the Restructuring Transactions Memorandum, distributions on account of Intercompany Interests are not being received by Holders of such Intercompany Interests on account of their Intercompany Interests but for the purposes of administrative convenience and due to the importance of maintaining the prepetition corporate structure for the ultimate benefit of the holders of New Common Stock, and in exchange for the Debtors’, the Reorganized Debtors’, or the Post-Effective Date Debtors’, as applicable, agreement under the Prepackaged Plan to make certain distributions to the Holders of Allowed Claims.
| G. | Confirmation Pursuant to Sections 1129(a)(10) and 1129(b) of the Bankruptcy Code. |
Section 1129(a)(10) of the Bankruptcy Code shall be satisfied for purposes of Confirmation by acceptance of the Prepackaged Plan by one or more of the Classes entitled to vote pursuant to Article III.B of the Prepackaged Plan. The Debtors reserve the right, subject to the consent rights set forth in the Restructuring Support Agreement, to modify the Prepackaged Plan in accordance with Article X hereof and the Restructuring Support Agreement to the extent, if any, that Confirmation pursuant to section 1129(b) of the Bankruptcy Code requires modification, including by modifying the treatment applicable to a Class of Claims or Interests to render such Class of Claims or Interests Unimpaired to the extent permitted by the Bankruptcy Code and the Bankruptcy Rules.
39
| H. | Controversy Concerning Impairment. |
If a controversy arises as to whether any Claims or Interests, or any Class of Claims or Interests, are Impaired, the Bankruptcy Court shall, after notice and a hearing, determine such controversy on or before the Confirmation Date.
| I. | Subordinated Claims. |
The allowance, classification, and treatment of all Allowed Claims and Allowed Interests and the respective distributions and treatments under the Prepackaged Plan take into account and conform to the relative priority and rights of the Claims and Interests in each Class in connection with any contractual, legal, and equitable subordination rights relating thereto, whether arising under general principles of equitable subordination, section 510(b) of the Bankruptcy Code, or otherwise. Any such contractual, legal, or equitable subordination rights shall be settled, compromised, and released pursuant to the Prepackaged Plan.
| XVI. | MEANS FOR IMPLEMENTATION OF THE PLAN |
| A. | General Settlement of Claims and Interests. |
As discussed in detail in the Disclosure Statement and as otherwise provided herein, pursuant to section 1123 of the Bankruptcy Code and Bankruptcy Rule 9019, and in consideration for the classification, distributions, releases, and other benefits provided under the Prepackaged Plan, upon the Effective Date, the provisions of the Prepackaged Plan shall constitute a good faith compromise and settlement of all Claims, Interests, Causes of Action, and controversies released, settled, compromised, discharged, or otherwise resolved pursuant to the Prepackaged Plan, whether under any provision of chapter 5 of the Bankruptcy Code, on any equitable theory (including equitable subordination, equitable disallowance, or unjust enrichment) or otherwise.
The Prepackaged Plan shall be deemed a motion to approve the good faith compromise and settlement of all such Claims, Interests, Causes of Action, and controversies pursuant to Bankruptcy Rule 9019, and the entry of the Confirmation Order shall constitute the Bankruptcy Court’s approval of such compromise and settlement under section 1123 of the Bankruptcy Code and Bankruptcy Rule 9019, as well as a finding by the Bankruptcy Court that such settlement and compromise is fair, equitable, reasonable, and in the best interests of the Debtors and their Estates. Subject to Article VI hereof, all distributions made to Holders of Allowed Claims and Allowed Interests (as applicable) in any Class are intended to be and shall be final.
40
| B. | Sale Transaction Election Notice Deadline; Successful Bid. |
In accordance with the Restructuring Support Agreement, the Debtors intend to pursue Consummation of the Reorganization Transaction pursuant to the Prepackaged Plan; provided, however, that if a Successful Bid is received in accordance with the Bidding Procedures that satisfies the Successful Bid Mandatory Conditions (as defined below), the Debtors may, with the consent of the Required Consenting Funded Debt Parties (and, to the extent required under the Restructuring Support Agreement, the Required Consenting Royalty Investors), elect to pursue the Sale Transaction by Filing the Sale Transaction Election Notice by the Sale Transaction Election Notice Deadline. The marketing process for the Debtors’ assets, the submission and evaluation of Qualified Bids, any Auction, and the selection of any Successful Bid shall be conducted in accordance with the Restructuring Support Agreement, the Bidding Procedures, and the Bidding Procedures Order, and any Sale Transaction shall be implemented in accordance with the Restructuring Support Agreement, the Bidding Procedures, the Purchase Agreement, and the Confirmation Order or the Sale Order, as applicable.
Subject to the Restructuring Support Agreement, the Debtors shall only designate a Qualified Bid as a Successful Bid if such Qualified Bid meets the requirements to be set forth in the Bidding Procedures and the following mandatory conditions (such conditions, the “Successful Bid Mandatory Conditions”):
| 1. | the Qualified Bid provides for net proceeds at closing of at least $335,384,812; provided that $18,750,000 of such amount allocable to the RIFA Claims may be satisfied with Cash or non-Cash consideration, in such form as is acceptable to the Holders of RIFA Claims in their discretion, having a value of not less than such portion; |
218.
| 2. | the Qualified Bid provides for the payment in full in Cash of any Bid Protections payable in accordance with the Bidding Procedures Order; and |
| 3. | the Qualified Bid provides for the funding in Cash, at the closing of the Sale Transaction, of the Wind-Down Budget. |
The Debtors are authorized, subject to the entry of the Bidding Procedures Order, to provide Bid Protections to Ayrmid in respect of the Reorganization Transaction, in the amounts, on the terms, and subject to the conditions set forth in the Restructuring Support Agreement and the Bidding Procedures Order. The Bid Protections shall be earned upon the selection of a Successful Bid submitted by an Entity other than Ayrmid and, once earned, shall constitute Allowed Administrative Claims pursuant to sections 105(a), 503(b), and 507(a)(2) of the Bankruptcy Code with priority over all other Administrative Claims of the kind specified in sections 503(b)(1) and 507(a) of the Bankruptcy Code, subject and subordinate to the DIP Claims and the Carve-Out, without further order of the Bankruptcy Court. The Bid Protections, to the extent earned, shall be payable in Cash within three (3) Business Days after the date on which an Acceptable Alternative Transaction or an Alternative Restructuring Proposal (either of which may constitute the Sale Transaction) is consummated, whether pursuant to the Bidding Procedures Order, a chapter 11 plan (including the Prepackaged Plan), or otherwise, and shall be paid from the Cash proceeds of such Acceptable Alternative Transaction or Alternative Restructuring Proposal, as applicable (or as otherwise provided in the Bidding Procedures Order), in each case subject to (a) Ayrmid’s compliance with the terms of the Restructuring Support Agreement and (b) the exceptions set forth in Section 14.07(b) of the Restructuring Support Agreement (including where the termination of the Restructuring Support Agreement as to Ayrmid arises from or is
41
attributable to Ayrmid’s breach of the Restructuring Support Agreement, Ayrmid’s withdrawal from the sale process, or Ayrmid’s failure to consummate the Reorganization Transaction (except, in the case of such a failure, as a result of matters directly or proximately caused by another party to the Restructuring Support Agreement)). Ayrmid’s agreement to serve as the Back-Up Bidder, if so designated, shall be without prejudice to its right to payment of the Bid Protections, to the extent earned, upon the consummation of an Acceptable Alternative Transaction or an Alternative Restructuring Proposal. For the avoidance of doubt, the failure to consummate an Acceptable Alternative Transaction or an Alternative Restructuring Proposal shall not affect the status of the Bid Protections, to the extent earned, as Administrative Claims.
If the Debtors File a Sale Transaction Election Notice and the Sale Transaction does not close on or before the Back-Up Bid Termination Date or the outside date set forth in the applicable Purchase Agreement (or such Purchase Agreement is otherwise terminated), then, subject to the terms of the Bidding Procedures Order and the Restructuring Support Agreement, the Debtors may (a) consummate a Sale Transaction with the Entity (if any) that submitted the next-highest or otherwise best Qualified Bid satisfying the Successful Bid Mandatory Conditions, or (b) if Ayrmid has been designated as the Back-Up Bidder by written notice to Ayrmid delivered on or prior to the Back-Up Bid Termination Date, designate the Back-Up Bid as the Successful Bid, withdraw the Sale Transaction Election Notice, and consummate the Reorganization Transaction in accordance with the Prepackaged Plan and the Definitive Documents (as modified to reflect any improvements made by Ayrmid at the Auction), which Definitive Documents (including the Merger Agreement) shall be deemed reinstated and in full force and effect from and after the date of such designation (and not during the period between the selection of such Successful Bid and such designation), as promptly as practicable following the satisfaction or waiver of the conditions precedent set forth in Article IX.A hereof, in which case the applicable milestones under the Restructuring Support Agreement and the DIP Facility Documents shall, with the consent of the Required Consenting Funded Debt Parties (such consent not to be unreasonably withheld) and, solely with respect to the Ayrmid Milestones (as defined in the Restructuring Support Agreement), Ayrmid, be deemed extended to the extent reasonably necessary to accommodate the consummation of the Reorganization Transaction. The foregoing shall occur in each case without further solicitation of votes on the Prepackaged Plan and without the need for further order of the Bankruptcy Court other than the Confirmation Order; provided that the Confirmation Order shall provide that the Bankruptcy Court retains jurisdiction to resolve any dispute arising in connection therewith.
| C. | Restructuring Transactions. |
On or before the Effective Date, the applicable Debtors or the Reorganized Debtors (and their respective officers, directors, members, or managers (as applicable)) shall enter into and shall take any actions as may be necessary or appropriate to effectuate the Restructuring Transactions, including as may be set forth in the Restructuring Transactions Memorandum, and may enter into and may take all actions as may be necessary or appropriate to effectuate any transaction described in, approved by, contemplated by, or necessary to effectuate the Prepackaged Plan and the Restructuring Support Agreement that are consistent with and pursuant and subject to the terms and conditions of the Prepackaged Plan and the Restructuring Support Agreement (and without the need for any approvals, authorizations, or consents except for those expressly required pursuant to the Prepackaged Plan), in each case in the most tax-efficient manner for the Debtors and the
42
Consenting Stakeholders, as reasonably determined by the Debtors and the Required Consenting Funded Debt Parties (and, in the event of the Reorganization Transaction, Ayrmid). These actions to effectuate the Restructuring Transactions may include: (1) the execution and delivery of appropriate agreements or other documents of merger, amalgamation, consolidation, restructuring, conversion, disposition, transfer, arrangement, continuance, dissolution, sale, purchase, or liquidation containing terms that are consistent with the terms of the Prepackaged Plan and the Restructuring Support Agreement and that satisfy the applicable requirements of applicable Law and any other terms to which the applicable Entities may agree; (2) the execution and delivery of appropriate instruments of transfer, assignment, assumption, or delegation of any asset, property, right, liability, debt, or obligation on terms consistent with the terms of the Prepackaged Plan and the Restructuring Support Agreement and having other terms to which the applicable Entities may agree; (3) the filing of appropriate certificates or articles of incorporation, formation, organization, reincorporation, merger, consolidation, conversion, amalgamation, arrangement, continuance, or dissolution pursuant to applicable Law; (4) the issuance of the Reorganized Parent Common Stock and the New Common Stock, including the Omisirge Contingent Equity; (5) the execution and delivery of the MF CVR Agreement and any filing related thereto, and distribution of the MF CVRs pursuant to the MF CVR Agreement; (6) the execution and delivery of the New Royalty Agreement; (7) the execution and delivery of the New Corporate Governance Documents, and any certificates or articles of incorporation, bylaws, or such applicable formation documents (if any) of each Reorganized Debtor or Post-Effective Date Debtor, as applicable (including all actions to be taken, undertakings to be made, and obligations to be incurred and fees and expenses to be paid by the Debtors or the Reorganized Debtors or Post-Effective Date Debtors, as applicable); (8) the execution and delivery of the Purchase Agreement (if applicable), the Merger Agreement (if applicable) and the NewCo Facility Documents (if applicable), and any filing related thereto, and the incurrence of the obligations thereunder; (9) the winddown of the German RemainCo; and (10) all other actions that the applicable Entities determine to be necessary or appropriate, including making filings or recordings that may be required by applicable Law in connection with the Prepackaged Plan. All Holders of Claims and Interests receiving distributions pursuant to the Prepackaged Plan and all other necessary parties in interest, including any and all agents thereof, shall prepare, execute, and deliver any agreements or documents, including any subscription agreements, and take any other actions as the Debtors may determine are necessary or appropriate, subject to the consent rights set forth in the Restructuring Support Agreement, including by voting or exercising any powers or rights available to such Holder, including at any board, creditors’, or shareholders’ meeting, to effectuate the provisions and intent of the Prepackaged Plan.
The Confirmation Order shall, and shall be deemed to, pursuant to sections 363 and 1123 of the Bankruptcy Code, authorize, among other things, all actions as may be necessary or appropriate to effectuate any transaction described in, approved by, contemplated by, or necessary to effectuate the Prepackaged Plan, including as may be set forth in the Restructuring Transactions Memorandum.
| 1. | Reorganization Transaction. |
If the Reorganization Transaction is to be consummated, on the Effective Date or as soon as reasonably practicable thereafter, the Reorganized Debtors, as applicable, shall issue or enter into all securities, notes, instruments, certificates, and other documents required to be issued or entered into pursuant to the Restructuring Transactions in accordance with the Restructuring Transactions Memorandum.
43
On the Effective Date, the New Board shall be established, and the Reorganized Debtors shall adopt their New Corporate Governance Documents. The Reorganized Debtors shall be authorized to adopt any other agreements, documents, and instruments and to take any other actions contemplated under the Prepackaged Plan as necessary to consummate the Prepackaged Plan. Cash payments to be made pursuant to the Prepackaged Plan will be made by the Debtors or the Reorganized Debtors, as applicable. The Debtors and the Reorganized Debtors will be entitled to transfer funds between and among themselves as they determine to be necessary or appropriate to enable the Debtors or the Reorganized Debtors, as applicable, to satisfy their obligations under the Prepackaged Plan. Except as set forth herein, any changes in intercompany account balances resulting from such transfers will be accounted for and settled in accordance with the Debtors’ historical intercompany account settlement practices and will not violate the terms of the Prepackaged Plan.
From and after the Effective Date, the Reorganized Debtors, subject to any applicable limitations set forth in any post-Effective Date agreement, shall have the right and authority without further order of the Bankruptcy Court to raise additional capital and obtain additional financing, subject to the New Corporate Governance Documents and the NewCo Facility Documents, as the Governing Bodies of the applicable Reorganized Debtors deem appropriate.
| 2. | Sale Transaction. |
In the event the Sale Transaction occurs, the Sale Transaction will be effectuated either by (a) one or more equity sale(s) under the Prepackaged Plan or (b) one or more asset sale(s) pursuant to section 363 of the Bankruptcy Code or the Prepackaged Plan, in each case, with such Sale Transaction Documents to be set forth in the Plan Supplement or Filed with the Bankruptcy Court.
| D. | Continued Corporate Existence. |
Except as otherwise provided in the Prepackaged Plan, the Restructuring Transactions Memorandum, or any agreement, instrument, or other document incorporated in the Prepackaged Plan or the Plan Supplement, each Debtor shall continue to exist after the Effective Date as a separate corporate entity, limited liability company, partnership, or other form, as the case may be, with all the powers of a corporation, limited liability company, partnership, or other form, as the case may be, pursuant to the applicable Law in the jurisdiction in which each applicable Debtor is incorporated or formed and pursuant to the respective certificate of incorporation and bylaws (or other formation documents) in effect prior to the Effective Date, except to the extent such certificate of incorporation and bylaws (or other formation documents) are amended under the Prepackaged Plan or otherwise, in each case, consistent with the Prepackaged Plan, and to the extent such documents are amended in accordance therewith, such documents are deemed to be amended pursuant to the Prepackaged Plan and require no further action or approval (other than any requisite filings required under applicable state or federal Law). After the Effective Date, the respective certificate(s) of incorporation and bylaws (or other formation documents) of one or more of the Reorganized Debtors or Post-Effective Date Debtors may be amended or modified on the terms therein without supervision or approval by the Bankruptcy Court and free of any restrictions of the Bankruptcy Code or Bankruptcy Rules. After the Effective Date, one or more of the Reorganized Debtors or the Post-Effective Date Debtors may be disposed of, dissolved, wound down, or liquidated without supervision or approval by the Bankruptcy Court and free of any restrictions of the Bankruptcy Code or Bankruptcy Rules.
44
| E. | Vesting of Assets in the Reorganized Debtors or Post-Effective Date Debtors. |
Except as otherwise provided in the Confirmation Order, the Prepackaged Plan, the Restructuring Transactions Memorandum, or any agreement, instrument, or other document incorporated in, or entered into in connection with or pursuant to, the Prepackaged Plan or Plan Supplement, on the Effective Date, pursuant to sections 1141(b) and (c) of the Bankruptcy Code, all property in each Estate, all Causes of Action, and any property acquired by any of the Debtors pursuant to the Prepackaged Plan shall vest in each respective Reorganized Debtor or Post-Effective Date Debtor, as applicable, free and clear of all Liens, Claims, charges, or other encumbrances. On and after the Effective Date, except as otherwise provided in the Prepackaged Plan, each Reorganized Debtor or Post-Effective Date Debtor, as applicable, may operate its business and may use, acquire, or dispose of property and compromise or settle any Claims, Interests, or Causes of Action without supervision or approval by the Bankruptcy Court and free of any restrictions of the Bankruptcy Code or Bankruptcy Rules.
| F. | Cancellation of Existing Securities and Agreements. |
Except for the purpose of evidencing a right to a distribution under the Prepackaged Plan and except as otherwise set forth in the Prepackaged Plan or the Plan Supplement (including the Restructuring Transactions Memorandum), on the Effective Date, all agreements, instruments, Securities, and other documents evidencing any Claim or Interest (other than Intercompany Interests that are not modified by the Prepackaged Plan) and any rights of any holder in respect thereof shall be deemed canceled and of no force or effect and the obligations of the Debtors thereunder shall be deemed fully satisfied, released, and discharged; provided that for the avoidance of doubt, the foregoing shall not impact any Claims that are Unimpaired by the Prepackaged Plan. The holders of or parties to such canceled agreements, instruments, Securities, and other documentation shall have no rights arising from or related to such agreements, instruments, Securities, or other documentation or the cancellation thereof, except the rights provided for pursuant to the Prepackaged Plan.
| G. | Cancellation of Certain Existing Security Interests. |
Upon the satisfaction or discharge in full pursuant to the Prepackaged Plan of an Allowed Secured Claim (including Allowed DIP Claims), or promptly thereafter, all mortgages, deeds of trust, Liens, pledges, or other security interests against any property of the Estates shall be fully released and discharged, and all of the right, title, and interest of any holder of such mortgages, deeds of trust, Liens, pledges, or other security interests shall revert to the Reorganized Debtors or Post-Effective Date Debtors and their successors and assigns. Any Holder of such Secured Claim (and the applicable agents for such Holder) shall be authorized and directed, at the sole cost and expense of the Reorganized Debtors or Post-Effective Date Debtors, to release any collateral or other property of any Debtor (including any Cash Collateral and possessory collateral) held by such Holder (and the applicable agents for such Holder), and to take such actions as may be reasonably requested by the Reorganized Debtors or Post-Effective Date Debtors to evidence the release of such Liens or security interests, including the execution, delivery, and filing or recording of such releases. The presentation or filing of the Confirmation Order to or with any federal, state, or local agency, records office, or department shall constitute good and sufficient evidence of, but shall not be required to effect, the termination of such Liens.
45
To the extent that any Holder of an Allowed Secured Claim (including Allowed DIP Claims) that has been satisfied or discharged in full pursuant to the Prepackaged Plan, or any agent for such Holder, has filed or recorded publicly any Liens or security interests to secure such Holder’s Allowed Secured Claim, then as soon as practicable on or after the Effective Date, such Holder (or the agent for such Holder) shall take any and all steps reasonably requested by the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors that are necessary or desirable to record or effectuate the cancellation or extinguishment of such Liens or security interests, including the making of any applicable filings or recordings, and the Reorganized Debtors or Post-Effective Date Debtors shall be entitled to make any such filings or recordings on such Holder’s behalf.
| H. | Sources of Consideration for Plan Distributions. |
The Debtors, the Reorganized Debtors, or Post-Effective Date Debtors, as applicable, shall fund distributions under the Prepackaged Plan with (i) the Debtors’ Cash on hand, (ii) Cash generated from operations, (iii) if the Reorganization Transaction is consummated, the Reorganized Parent Common Stock, the DIP Facility, and the NewCo Facility, and (iv) if the Sale Transaction is consummated, the proceeds of the Sale Transaction.
| I. | New Common Stock. |
In connection with the Reorganization Transaction, the issuance of the Reorganized Parent Common Stock (comprising the Reorganized Parent Equity Distribution) pursuant to the Prepackaged Plan and the issuance of the New Common Stock (as part of the Merger Consideration) pursuant to the Merger Agreement shall be hereby authorized without the need for any further corporate or similar action and without any further action by the Holders of Claims or Interests. Reorganized Parent and NewCo, as applicable, shall be authorized to issue the number of shares, units, or equity interests of Reorganized Parent Common Stock and New Common Stock, respectively, required to be issued under the Prepackaged Plan and the Merger Agreement and pursuant to their respective New Corporate Governance Documents. On the Effective Date, the Debtors or Reorganized Debtors, as applicable, shall issue or enter into all Securities, notes, instruments, certificates, and other documents required to be issued or entered into pursuant to the Prepackaged Plan. The New Corporate Governance Documents shall be effective as of the Effective Date and, as of such date, shall be deemed to be valid, binding, and enforceable in accordance with their respective terms. Subject to the agreement of the Required Consenting Funded Debt Parties and Ayrmid, NewCo may be a newly formed or an existing entity for the purposes of consummating the Merger, in either case to be determined on or prior to the Effective Date.
46
All of the shares, units, or equity interests (as the case may be based on how the New Common Stock is denominated) of New Common Stock issued or authorized to be issued pursuant to the Prepackaged Plan shall be duly authorized, validly issued, fully paid, and non-assessable. Each distribution and issuance referred to in Article VI hereof shall be governed by the terms and conditions set forth in the Prepackaged Plan applicable to such distribution or issuance and by the terms and conditions of the instruments evidencing or relating to such distribution or issuance, which terms and conditions shall bind each Entity receiving such distribution or issuance.
In the event of the Reorganization Transaction, unless Ayrmid and the Required Consenting Funded Debt Parties otherwise consent in writing, the Reorganized Debtors and NewCo (1) shall be private companies on the Effective Date and the New Common Stock shall not be listed on any stock exchange or market and shall not be registered under the Exchange Act, (2) shall not be voluntarily subjected to any reporting requirements promulgated by the SEC, and (3) shall not be required to list the New Common Stock on any stock exchange or market. The Reorganized Debtors and NewCo shall use commercially reasonable efforts to ensure that, after giving effect to the distributions under the Prepackaged Plan, the Merger, and any Management Incentive Plan, neither Reorganized Parent nor NewCo has a class of equity securities held of record by 300 or more persons so as to avoid triggering the reinstatement of reporting obligations under section 15(d) of the Exchange Act.
On or prior to the Effective Date, the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors shall, as applicable, (i) take all actions necessary or appropriate to delist the Existing Common Stock Interests from Nasdaq and to deregister all securities of the Reorganized Debtors or Post-Effective Date Debtors, as applicable, under the Exchange Act as promptly as practicable in compliance with SEC rules (such that, in the event of the Reorganization Transaction, the termination of the registration of all securities of Parent under sections 12 and 15(d) of the Exchange Act shall have been completed and shall be effective on the Effective Date concurrently with the consummation of the Merger, to the extent permitted by applicable Law and SEC rules), (ii) file a Form 25 with the SEC to delist the Existing Common Stock Interests from Nasdaq and to deregister the Existing Common Stock Interests from section 12(b) of the Exchange Act (unless Nasdaq has already filed a Form 25 with the SEC providing for such delisting and deregistration), (iii) file post-effective amendments to terminate all of Parent’s currently effective registration statements under the Securities Act, (iv) file a Form 15 notifying the SEC of the suspension of Parent’s duty to file reports under section 15(d) of the Exchange Act, and (v) take all actions reasonably necessary or appropriate to ensure (A) that the New Common Stock and the MF CVRs shall not be listed on a stock exchange or market and that the Reorganized Debtors shall not be required to list the New Common Stock or MF CVRs on a stock exchange or market, except, in each case, as otherwise may be required pursuant to the New Corporate Governance Documents or the MF CVR Agreement, as applicable, and (B) that the Reorganized Debtors or Post-Effective Date Debtors, as applicable, shall not be voluntarily subjected to any reporting requirements promulgated by the SEC.
47
| J. | The Merger. |
Solely in the event of the Reorganization Transaction, on the Effective Date and immediately after the issuance of the Reorganized Parent Equity Distribution, the Merger shall be consummated in accordance with the Merger Agreement and the Restructuring Transactions Memorandum as a Restructuring Transaction pursuant to sections 1123(a)(5) and 1123(b)(3) of the Bankruptcy Code. In the Merger, NewCo shall issue the Merger Consideration on the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the Restructuring Transactions Memorandum. Each Holder of an Allowed Prepetition Funded Debt Claim, Allowed Equitized DIP New Money Claim, or Allowed DIP Roll-Up Claim shall be deemed to have received its share of the Reorganized Parent Equity Distribution and to have exchanged such Reorganized Parent Common Stock in the Merger for its share of the Merger Consideration, and the applicable Disbursing Agent shall deliver the New Common Stock and the MF CVRs constituting the Merger Consideration directly to or for the benefit of such Holders in accordance with Article VI hereof, without any requirement that certificates or book-entry positions evidencing the Reorganized Parent Common Stock be issued to or delivered by such Holders. For the avoidance of doubt, any New Common Stock or MF CVRs distributed on account of Allowed Equitized DIP New Money Claims and Allowed DIP Roll-Up Claims shall be allocated solely from the Merger Consideration otherwise distributable to the Holders of Allowed Prepetition Funded Debt Claims and shall not reduce or dilute the New Common Stock allocable to the equityholders of Ayrmid or the Omisirge Contingent Equity. On the Effective Date, the Liens and obligations under the Ayrmid Term Loan shall be addressed in the manner set forth in the Merger Agreement and the Restructuring Transactions Memorandum, which shall be acceptable to the Required Consenting Funded Debt Parties and Ayrmid and otherwise consistent with the Restructuring Support Agreement; provided that any Liens and obligations in respect of the Ayrmid Term Loan (or any successor obligations thereto) shall be equitized into pre-Effective Date Ayrmid or structurally subordinated in their entirety to the claims against, and the equity interests in, NewCo, in each case in a manner acceptable to the Required Consenting Funded Debt Parties in their sole discretion, and no proceeds of the NewCo Facility shall be used to prepay the Ayrmid Term Loan. The Merger Agreement, the Merger, and the issuance of the Merger Consideration shall be deemed authorized and approved by the Confirmation Order without the need for any further corporate or similar action or any further action by Holders of Claims or Interests, and the Confirmation Order shall constitute all approvals and consents required under applicable non-bankruptcy Law for the consummation of the Merger. The Reorganization Transaction (including the Merger) shall be structured in a manner reasonably acceptable to the Debtors, the Required Consenting Funded Debt Parties, and Ayrmid that, to the extent reasonably practicable, (a) minimizes any cash taxes payable as a result of the consummation of the Reorganization Transaction, (b) maximizes the favorable tax attributes (including tax basis) of the Reorganized Debtors and NewCo and their respective subsidiaries going forward, and (c) otherwise achieves such tax-planning outcomes as are reasonably requested by the Debtors, the Required Consenting Funded Debt Parties, and Ayrmid, in each case as set forth in the Restructuring Transactions Memorandum, which shall be Filed with the Plan Supplement. The Merger is a transaction contemplated by, and shall be deemed to be effectuated pursuant to, the Prepackaged Plan. Accordingly, and notwithstanding anything to the contrary in any Executory Contract or Unexpired Lease assumed pursuant to the Prepackaged Plan, or any other agreement, instrument, or document to which a Debtor is a party that is Reinstated or otherwise continues in effect after the Effective Date, the consummation of the Merger shall not constitute, give rise to, or be deemed to constitute or give rise to a default, breach, event of default, “change of control,” “fundamental change,” assignment, termination event, or any similar event, or entitle any counterparty to terminate, modify, accelerate, or exercise any other remedy under any such agreement, and any provision purporting to the contrary shall be unenforceable to the fullest extent permitted by sections 365, 541(c), and 1123 of the Bankruptcy Code.
48
| K. | MF CVR Agreement; Omisirge Contingent Equity. |
Solely in the event of the Reorganization Transaction, on the Effective Date substantially concurrently with the consummation of the Merger, NewCo shall enter into the MF CVR Agreement and shall issue the MF CVRs to the Disbursing Agent for distribution as part of the Merger Consideration to the Holders of Allowed Prepetition Funded Debt Claims, Allowed Equitized DIP New Money Claims, and Allowed DIP Roll-Up Claims in accordance with Article II.B, Article III.B, and Article IV.J hereof. The MF CVRs shall not constitute equity interests in NewCo or confer any voting or governance rights.
Solely in the event of the Reorganization Transaction, the Merger Agreement (and, to the extent applicable, the New Corporate Governance Documents) shall provide for the issuance of the Omisirge Contingent Equity to the equityholders of Ayrmid as of immediately prior to the Merger if and to the extent specified in the Merger Agreement (and, to the extent applicable, the New Corporate Governance Documents). The issuance of the Omisirge Contingent Equity shall dilute solely the New Common Stock issued as Merger Consideration to the Holders of Allowed Prepetition Funded Debt Claims (and any other New Common Stock issued on account of Claims under the Prepackaged Plan), and shall not dilute New Common Stock issued in the Merger to the equityholders of Ayrmid as of immediately prior to the Merger.
The MF CVR Agreement and the provisions of the Merger Agreement and the New Corporate Governance Documents governing the Omisirge Contingent Equity shall be duly authorized without the need for any further corporate or similar action and without further action by the Debtors, the Reorganized Debtors, or the Holders of Claims or Interests. The MF CVR Agreement and the MF CVRs shall be effective as of the Effective Date and, as of such date, shall be deemed to be valid, binding, and enforceable obligations of NewCo in accordance with their respective terms.
| L. | NewCo Facility. |
In connection with the Reorganization Transaction, on the Effective Date and immediately after the consummation of the Merger, entry into the NewCo Facility Documents by NewCo (or such other borrower identified in the NewCo Facility Documents) and the applicable guarantors, the incurrence of the obligations thereunder, and the granting of the related guarantees, Liens, and security interests shall be authorized without the need for any further corporate or similar action and without any further action by Holders of Claims or Interests. The proceeds of the NewCo Facility shall be available to be drawn in full on the Effective Date and shall be used to (a) refinance up to $50,000,000 of Allowed DIP New Money Claims in Cash in accordance with Article II.B hereof (and, if the Allowed DIP New Money Claims are equal to or less than $50,000,000, to repay such Allowed DIP New Money Claims in full), (b) pay Cure amounts and other amounts payable by the Debtors or the Reorganized Debtors under the Prepackaged Plan, and (c) fund the working capital needs of NewCo and the Reorganized Debtors, in each case subject to the DIP Budget. Confirmation of the Prepackaged Plan shall be deemed authorization for the Debtors or the Reorganized Debtors, as applicable, to, without further notice to or order of the Bankruptcy Court, act or take action under applicable Law, regulation, order, or rule as may be necessary or appropriate to enter into, execute, deliver, and perform the NewCo Facility Documents, including the payment of all fees, indemnities, and expenses provided for therein.
49
On the Effective Date (or earlier, if provided in an order of the Bankruptcy Court), all Liens and security interests granted pursuant to, or in connection with, the NewCo Facility Documents and the related guarantees (1) shall be deemed to be approved and shall, without the necessity of the execution, recordation, or filing of mortgages, security agreements, control agreements, pledge agreements, financing statements, or other similar documents, be valid, binding, fully perfected, fully enforceable Liens on, and security interests in, the collateral securing the NewCo Facility and the related guarantees, with the priorities established in respect thereof under the NewCo Facility Documents, applicable non-bankruptcy Law, the Prepackaged Plan, and the Confirmation Order; and (2) shall not be enjoined or subject to discharge, impairment, release, avoidance, recharacterization, or subordination (including equitable subordination) for any purposes whatsoever and shall not constitute preferential transfers, fraudulent conveyances, or other voidable transfers under the Bankruptcy Code or any applicable non-bankruptcy Law, the Prepackaged Plan, or the Confirmation Order.
The Reorganized Debtors, NewCo, and the Persons granted Liens and security interests under the NewCo Facility Documents are authorized to make all filings and recordings and to obtain all governmental approvals and consents necessary to establish and perfect such Liens and security interests under the provisions of the applicable state, provincial, federal, or other Law (whether domestic or foreign) that would be applicable in the absence of the Prepackaged Plan and the Confirmation Order (it being understood that perfection shall occur automatically by virtue of entry of the Confirmation Order without the need for any filings or recordings) and will thereafter cooperate to make all other filings and recordings that otherwise would be necessary under applicable Law to give notice of such Liens and security interests to third parties.
| M. | Corporate Action. |
Upon the Effective Date, all actions contemplated under the Prepackaged Plan, the Plan Supplement, and the Restructuring Transactions Memorandum shall be deemed authorized and approved in all respects, including: (1) the issuance and distribution of the Reorganized Parent Common Stock and the New Common Stock (including the Omisirge Contingent Equity, when and if issuable); (2) the entry into the NewCo Facility Documents; (3) the entry into the Merger Agreement and the consummation of the Merger; (4) implementation of the Restructuring Transactions (including, in the event of a Sale Transaction, the Sale Transaction Documents); (5) entry into the MF CVR Agreement and issuance and distribution of the MF CVRs; (6) entry into the New Royalty Agreement; (7) all other actions contemplated under the Prepackaged Plan (whether to occur before, on, or after the Effective Date); (8) adoption of the New Corporate Governance Documents; (9) the rejection, assumption, or assumption and assignment, as applicable, of Executory Contracts and Unexpired Leases; and (10) all other acts or actions contemplated or reasonably necessary or appropriate to promptly consummate the Restructuring Transactions contemplated by the Prepackaged Plan (whether to occur before, on, or after the Effective Date). All matters provided for in the Prepackaged Plan involving the corporate structure of the Debtors or the Reorganized Debtors, and any corporate, partnership, limited liability company, or other governance action required by the Debtors or the Reorganized Debtors, as applicable, in connection with the Prepackaged Plan shall be deemed to have occurred and shall
50
be in effect, without any requirement of further action by the Security holders, members, directors, or officers of the Debtors or the Reorganized Debtors, as applicable. On or (as applicable) prior to the Effective Date, the appropriate officers of the Debtors or the Reorganized Debtors, as applicable, shall be authorized and (as applicable) directed to issue, execute, and deliver the agreements, documents, Securities, and instruments contemplated under the Prepackaged Plan (or necessary or desirable to effect the transactions contemplated under the Prepackaged Plan) in the name of and on behalf of the Reorganized Debtors (including NewCo), including, as applicable, the Reorganized Parent Common Stock, the New Common Stock, the NewCo Facility Documents, the Merger Agreement, the New Corporate Governance Documents, the MF CVRs, the MF CVR Agreement, and any and all other agreements, documents, Securities, and instruments relating to the foregoing. The authorizations and approvals contemplated by this Article IV.M shall be effective notwithstanding any requirements under non-bankruptcy Law.
| N. | New Corporate Governance Documents. |
In the event of the Reorganization Transaction, on or immediately prior to the Effective Date, the New Corporate Governance Documents shall be automatically adopted by the applicable Reorganized Debtors and become effective. To the extent required under the Prepackaged Plan or applicable non-bankruptcy Law, each of the Reorganized Debtors will file its New Corporate Governance Documents with the applicable Secretaries of State or other applicable authorities in its respective state or country of organization if and to the extent required in accordance with the applicable Laws of the respective state or country of organization. The New Corporate Governance Documents will prohibit the issuance of non-voting equity Securities, to the extent required under section 1123(a)(6) of the Bankruptcy Code.
After the Effective Date, the Reorganized Debtors may amend and restate their respective New Corporate Governance Documents in accordance with the terms thereof, and the Reorganized Debtors may file such amended certificates or articles of incorporation, bylaws, or such other applicable formation documents, and other constituent documents as permitted by the Laws of the respective states, provinces, or countries of incorporation and the New Corporate Governance Documents.
| 1. | Directors and Officers of the Reorganized Debtors. |
As of the Effective Date, the terms of the current members of the board of directors of the Debtors shall expire and the existing officers of the Debtors shall be automatically removed as officers, and the New Board and new officers of each of the Reorganized Debtors (including NewCo) shall be appointed. For subsequent terms, following the Effective Date, members of the New Board and new officers of each of the Reorganized Debtors (including NewCo) shall be appointed in accordance with the New Corporate Governance Documents and other constituent documents of each Reorganized Debtor (including NewCo).
Pursuant to section 1129(a)(5) of the Bankruptcy Code, to the extent known, the identity and affiliation of any Person proposed to serve on the New Board will be disclosed in the Plan Supplement or prior to the Confirmation Hearing, as well as those Persons that will serve as officers of the Reorganized Debtors (including NewCo) and, to the extent known, the identity and compensation of any insider (as such term is defined in section 101(31) of the Bankruptcy Code) that will be employed or retained by the Reorganized Debtors (including NewCo). Provisions regarding the removal, appointment, and replacement of members of the New Board, to the extent applicable, will be disclosed in the New Corporate Governance Documents.
51
| 2. | Effectuating Documents; Further Transactions. |
On and after the Effective Date, the Reorganized Debtors and Post-Effective Date Debtors, and their respective officers, directors, members, or managers (as applicable), are authorized to and may issue, execute, deliver, file, or record such contracts, Securities, instruments, releases, and other agreements or documents and take such actions as may be necessary or appropriate to effectuate, implement, and further evidence the terms and conditions of the Prepackaged Plan, and the Securities issued pursuant to the Prepackaged Plan in the name of and on behalf of the Reorganized Debtors, without the need for any approvals, authorizations, or consents except for those expressly required pursuant to the Prepackaged Plan.
| O. | Preservation of Causes of Action. |
In accordance with section 1123(b) of the Bankruptcy Code, but subject to Article VIII hereof, each Reorganized Debtor or Post-Effective Date Debtor, as applicable, shall retain and may enforce all rights to commence and pursue, as appropriate, any and all Causes of Action of the Debtors, whether arising before or after the Petition Date, including any actions specifically enumerated in the Schedule of Retained Causes of Action, and the Reorganized Debtors’ and Post-Effective Date Debtors’ rights to commence, prosecute, or settle such Causes of Action shall be preserved notwithstanding the occurrence of the Effective Date, other than the Causes of Action released by the Debtors pursuant to the releases and exculpations contained in the Prepackaged Plan, including in Article VIII hereof, which shall be deemed released and waived by the Debtors and the Reorganized Debtors (or Post-Effective Date Debtors, as applicable) as of the Effective Date.
The Reorganized Debtors or Post-Effective Date Debtors, as applicable, may pursue such retained Causes of Action, as appropriate, in accordance with the best interests of the Reorganized Debtors or Post-Effective Date Debtors. No Entity (other than the Released Parties) may rely on the absence of a specific reference in the Prepackaged Plan, the Plan Supplement, or the Disclosure Statement to any Cause of Action against it as any indication that the Debtors or the Reorganized Debtors (or Post-Effective Date Debtors), as applicable, will not pursue any and all available Causes of Action of the Debtors against it. The Debtors and Reorganized Debtors (or Post-Effective Date Debtors, as applicable) expressly reserve all rights to prosecute any and all Causes of Action against any Entity, except as otherwise expressly provided in the Prepackaged Plan, including Article VIII hereof. Unless any Causes of Action of the Debtors against an Entity are expressly waived, relinquished, exculpated, released, compromised, or settled in the Prepackaged Plan or a Final Order, the Reorganized Debtors and Post-Effective Date Debtors expressly reserve all Causes of Action, for later adjudication, and, therefore, no preclusion doctrine, including the doctrines of res judicata, collateral estoppel, issue preclusion, claim preclusion, estoppel (judicial, equitable, or otherwise), or laches, shall apply to such Causes of Action upon, after, or as a consequence of the Confirmation or Consummation. For the avoidance of doubt, the Debtors and the Reorganized Debtors (or Post-Effective Date Debtors, as applicable) do not reserve any Causes of Action that have been expressly released or exculpated pursuant to the Prepackaged Plan (including, for the avoidance of doubt, Claims and Causes of Action against the Consenting Stakeholders released pursuant to the releases by the Debtors provided in Article VIII.C hereof and the exculpation contained in Article VIII.E hereof).
52
The Reorganized Debtors and Post-Effective Date Debtors reserve and shall retain such Causes of Action of the Debtors notwithstanding the rejection or repudiation of any Executory Contract or Unexpired Lease during the Chapter 11 Cases or pursuant to the Prepackaged Plan. In accordance with section 1123(b)(3) of the Bankruptcy Code, any Causes of Action that a Debtor may hold against any Entity shall vest in the Reorganized Debtors or Post-Effective Date Debtors, except as otherwise expressly provided in the Prepackaged Plan, including Article VIII hereof. The applicable Reorganized Debtors or Post-Effective Date Debtors, through their authorized agents or representatives, shall retain and may exclusively enforce any and all such Causes of Action. The Reorganized Debtors or Post-Effective Date Debtors shall have the exclusive right, authority, and discretion to determine and to initiate, file, prosecute, enforce, abandon, settle, compromise, release, withdraw, or litigate to judgment any such Causes of Action and to decline to do any of the foregoing without the consent or approval of any third party or further notice to or action, order, or approval of the Bankruptcy Court.
| P. | Certain Securities Law Matters. |
No registration statement shall be filed under the Securities Act, or pursuant to any state securities Laws, with respect to the offer, issuance, and distribution of the New Common Stock or the MF CVRs under the Prepackaged Plan, the Merger Agreement, the Restructuring Transactions Memorandum, the Confirmation Order, and the MF CVR Agreement.
The offering, issuance (or entry into), and distribution of the New Common Stock and all other Securities entered into or issued in connection with the Prepackaged Plan (including, solely to the extent constituting securities as defined in and for purposes of the Securities Act, the MF CVRs) shall be exempt from, among other things, the registration requirements of section 5 of the Securities Act and any other applicable Law requiring registration prior to the offering, issuance, distribution, or sale of Securities to the maximum extent permitted by Law, in accordance with, and pursuant to, (i) section 1145 of the Bankruptcy Code, (ii) section 4(a)(2) of the Securities Act or Regulation S under the Securities Act, or (iii) any other available exemption from registration, as applicable.
Any Securities issued under section 1145 of the Bankruptcy Code (1) will not be “restricted securities” as defined in Rule 144(a)(3) under the Securities Act and (2) will be freely tradable and transferable in the United States by a recipient thereof that (i) is an entity that is not an “underwriter” as defined in section 1145(b)(1) of the Bankruptcy Code, (ii) is not an “affiliate” of the Debtors or the Reorganized Debtors as defined in Rule 144(a)(1) under the Securities Act, (iii) has not been such an “affiliate” within 90 days of the time of the transfer, and (iv) has not acquired such securities from an “affiliate” within one year of the time of transfer, subject in each case to compliance with applicable securities Laws and any rules and regulations of the SEC or state or local securities Laws, if any, applicable at the time of any future transfer of such Securities, and subject to any restrictions in the agreements, instruments, or other documents governing such Securities or to which the holder of such Securities is a party.
53
To the extent issuance under section 1145(a) of the Bankruptcy Code is unavailable, the Merger Consideration (to the extent it consists of securities as defined in and for purposes of the Securities Act) will be issued without registration under the Securities Act in reliance upon the exemption set forth in section 4(a)(2) of the Securities Act or Regulation S under the Securities Act, and similar registration exemptions under state or local securities Laws, in each case to the maximum extent permitted thereunder. Any securities issued in reliance on section 4(a)(2) or Regulation S under the Securities Act will be “restricted securities” under the Securities Act or subject to resale restrictions and may be resold, exchanged, assigned, or otherwise transferred only pursuant to registration or an applicable exemption from registration under the Securities Act and other applicable Law and subject in each case to compliance with applicable securities Laws and any rules and regulations of the SEC or state or local securities Laws, if any, applicable at the time of any future transfer of such Securities, and subject to any restrictions in the agreements, instruments or other documents governing such Securities or to which the holder of such Securities is a party.
The issuance of the New Common Stock and any and all other Securities entered into or issued pursuant to the Prepackaged Plan shall not constitute an invitation or solicitation of an invitation or offer to sell or buy any securities in contravention of any applicable Law in any jurisdiction. No action has been taken, nor will be taken, in any jurisdiction that would permit a public offering of any securities (other than securities issued pursuant to section 1145 of the Bankruptcy Code) in any jurisdiction where such action for that purpose is required.
The Reorganized Debtors and NewCo need not provide any further evidence other than the Prepackaged Plan and the Confirmation Order with respect to the treatment of the New Common Stock or the MF CVRs under applicable securities Laws.
Notwithstanding anything to the contrary in the Prepackaged Plan, no Entity (including, for the avoidance of doubt, DTC and any transfer agent) shall be entitled to require a legal opinion regarding the validity of any transaction contemplated by the Prepackaged Plan, including, for the avoidance of doubt, whether the New Common Stock and MF CVRs are exempt from registration or eligible for DTC book-entry delivery, settlement, and depository services. DTC and any transfer agent shall be required to accept and conclusively rely upon the Prepackaged Plan and Confirmation Order in lieu of a legal opinion regarding whether the New Common Stock or MF CVRs are exempt from registration or eligible for DTC book-entry delivery, settlement, and depository services.
Notwithstanding any policies, practices, or procedures of DTC, DTC and any participants and intermediaries shall fully cooperate and take all actions to facilitate any and all transactions necessary or appropriate for implementation of the Prepackaged Plan or otherwise contemplated thereby, including any and all distributions pursuant to the Prepackaged Plan.
54
| Q. | 1146 Exemption. |
To the fullest extent permitted by section 1146(a) of the Bankruptcy Code, any transfers (whether from a Debtor to a Reorganized Debtor, Post-Effective Date Debtor, or to any other Person) of property under or in connection with the Prepackaged Plan or pursuant to: (1) the issuance, distribution, transfer, or exchange of any debt, equity Security, or other interest in the
Debtors, Reorganized Debtors or Post-Effective Date Debtors, including the Reorganized Parent Common Stock, the New Common Stock, and the MF CVRs; (2) the Restructuring Transactions; (3) the creation, modification, consolidation, termination, refinancing, or recording of any mortgage, deed of trust, or other security interest, or the securing of additional indebtedness by such or other means; (4) the making, assignment, or recording of any lease or sublease; (5) the grant of collateral as security for NewCo’s and the Reorganized Debtors’ obligations under and in connection with the NewCo Facility or any other debt instrument; or (6) the making, delivery, or recording of any deed or other instrument of transfer under, in furtherance of, or in connection with, the Prepackaged Plan, including any deeds, bills of sale, assignments, or other instrument of transfer executed in connection with any transaction arising out of, contemplated by, or in any way related to the Prepackaged Plan, shall not be subject to any document recording tax, stamp tax, conveyance fee, intangibles or similar tax, mortgage tax, real estate transfer tax, personal property transfer tax, sales or use tax, mortgage recording tax, Uniform Commercial Code filing or recording fee, regulatory filing or recording fee, or other similar tax or governmental assessment, and upon entry of the Confirmation Order, the appropriate state or local governmental officials or agents shall forgo the collection of any such tax or governmental assessment and accept for filing and recordation any of the foregoing instruments or other documents without the payment of any such tax, recordation fee, or governmental assessment. All filing or recording officers (or any other Person with authority over any of the foregoing), wherever located and by whomever appointed, shall comply with the requirements of section 1146(a) of the Bankruptcy Code, shall forgo the collection of any such tax or governmental assessment, and shall accept for filing and recordation any of the foregoing instruments or other documents without the payment of any such tax or governmental assessment.
| R. | Additional Sale Transaction Provisions. |
Solely if the Sale Transaction occurs and is consummated, the following additional provisions shall apply:
| 1. | Post-Effective Date Debtors. |
If the Sale Transaction is an asset sale, following the sale of certain assets of the Debtors under the Prepackaged Plan or the Sale Order(s), on and after the Effective Date, the Post-Effective Date Debtors shall continue in existence for purposes of (a) winding down the Debtors’ business and affairs as expeditiously as reasonably possible, (b) resolving Disputed Claims, (c) making distributions on account of Allowed Claims as provided hereunder, (d) funding distributions, (e) enforcing and prosecuting claims, interests, rights, and privileges under the Causes of Action on the Schedule of Retained Causes of Action in an efficacious manner and only to the extent the benefits of such enforcement or prosecution are reasonably believed to outweigh the costs associated therewith, (f) filing appropriate tax returns, (g) complying with their continuing obligations under the Purchase Agreement(s), if any, and (h) administering the Prepackaged Plan in an efficacious manner. In such case, the Post-Effective Date Debtors shall be deemed to be substituted as the party-in-lieu of the Debtors in all matters, including (i) motions, contested matters, and adversary proceedings pending in the Bankruptcy Court, and (ii) all matters pending in any courts, tribunals, forums, or administrative proceedings outside of the Bankruptcy Court, in each case without the need or requirement for a plan administrator to file motions or substitutions of parties or counsel in each such matter.
55
| 2. | Post-Effective Date Plan Administrator. |
If the Sale Transaction is an asset sale and is consummated, on the Effective Date, the Post-Effective Date Plan Administrator shall be appointed with respect to each Post-Effective Date Debtor. The Post-Effective Date Plan Administrator shall be acceptable to the Debtors and the Required Consenting Funded Debt Parties and shall act for the Post-Effective Date Debtors in the same fiduciary capacity as applicable to a Governing Body, subject to the provisions hereof (and all certificates of formation, membership agreements, and related documents shall be deemed amended by the Prepackaged Plan to permit and authorize the same) and retain and have all the rights, powers, and duties necessary to carry out its responsibilities under the Prepackaged Plan on terms which shall be disclosed in the Plan Supplement.
| S. | Director and Officer Liability Insurance. |
On or prior to the Effective Date, the Debtors shall place the D&O Liability Insurance Policies in effect as of the Petition Date into runoff (or purchase tail coverage providing substantially equivalent coverage) for a period of six (6) years following the Effective Date, at the Debtors’ expense, for the benefit of the Debtors’ current and former directors, officers, and managers with respect to conduct occurring prior to the Effective Date. Notwithstanding anything to the contrary in the Prepackaged Plan (including Article V.E hereof), after the Effective Date, none of the Reorganized Debtors (including NewCo) or the Post-Effective Date Debtors shall terminate, amend, or otherwise reduce the coverage under any such runoff or tail policies, and all directors, officers, and managers of the Debtors who served in such capacity at any time prior to the Effective Date shall be entitled to the full benefits of any such policy for the full term of such policy, to the extent set forth therein, regardless of whether such directors, officers, or managers remain in such positions after the Effective Date. NewCo and the Reorganized Debtors may obtain new D&O Liability Insurance Policies effective as of the Effective Date.
| T. | Indemnification Obligations. |
All indemnification provisions in place as of the Effective Date (whether in the bylaws, certificates of incorporation or formation, limited liability company agreements, other organizational documents, board resolutions, indemnification agreements, employment contracts, or otherwise) for current and former directors, officers, managers, employees, attorneys, accountants, investment bankers, and other professionals of the Debtors, as applicable, shall be assumed by a newly-formed entity, which may be an Affiliate of NewCo (the “Indemnification Entity”), in scope acceptable to the Debtors, Ayrmid, and the Required Consenting Funded Debt Parties and in scope no less favorable to such current and former directors, officers, managers, employees, attorneys, accountants, investment bankers, and other professionals of the Debtors than the indemnification provisions in place prior to the Effective Date. The obligations assumed by the Indemnification Entity shall include, for the avoidance of doubt, the obligation to fund and pay, as and when due, any self-insured retention, deductible, or similar amount required to be borne by the insureds under any of the D&O Liability Insurance Policies (including any runoff or tail policies described in Article IV.S hereof) in connection with any claim thereunder against any such current or former director, officer, manager, employee, attorney, accountant, investment banker, or other professional of the Debtors. The obligations of the Indemnification Entity in respect of such indemnification provisions (including any such self-insured retention or
56
deductible amounts) shall be supported by an intercompany promissory note in the principal amount of $2,500,000 issued by NewCo or an Affiliate of NewCo in favor of the Indemnification Entity on the Effective Date, on terms acceptable to the Debtors, Ayrmid, and the Required Consenting Funded Debt Parties, and the Indemnification Entity shall not incur any indebtedness or other obligations other than the indemnification obligations assumed pursuant to this Article IV.T.
| U. | Winddown of Karyopharm Europe GmbH. |
In the event of the Reorganization Transaction, on the Effective Date, the Debtors shall deposit a sufficient amount of Cash (in an amount agreed by the Debtors, the DIP Lenders, and the Required Consenting Funded Debt Parties) into a segregated account (the “German RemainCo Winddown Account”) in order to conduct an orderly winddown and dissolution of Karyopharm Europe GmbH (the “German RemainCo”) after the Effective Date.
| V. | New Royalty Agreement. |
Solely in the event of the Reorganization Transaction, on the Effective Date, NewCo and each of its subsidiaries that owns or controls any selinexor assets shall enter into the New Royalty Agreement with the Holders of RIFA Claims (or their designee) and the Royalty Collateral Agent (or another collateral agent designated by the Holders of RIFA Claims), pursuant to which NewCo shall pay to the Holders of RIFA Claims (or their designee) an unsecured royalty equal to 3.0% of the net revenues received by NewCo from all products containing selinexor (including XPOVIO® (selinexor) in combination with ruxolitinib for patients with myelofibrosis) for the period of five (5) years following the Effective Date, on the terms and subject to the conditions set forth in the New Royalty Agreement and as more fully described in the Ayrmid Transaction Term Sheet. The obligations under the New Royalty Agreement shall be unsecured obligations of NewCo and its applicable subsidiaries and shall not be secured by any Lien on any assets of NewCo, the Reorganized Debtors, or their respective subsidiaries. The New Royalty Agreement shall include a liquidated damages provision in an amount equal to $18,750,000. Holders of RIFA Claims may pursue the acquisition of the Debtors’ interests in certain other royalty agreements for aggregate consideration of up to $35,000,000; provided, however, that there shall be no obligation or requirement for the Debtors or NewCo to consummate such a sale; provided, further, that any such sale shall be subject to the consent of the Debtors, the Required Consenting Funded Debt Parties, and, to the extent that the Debtors have not selected an Acceptable Alternative Transaction, Ayrmid. The New Royalty Agreement shall replace and supersede the RIFA in its entirety, and on the Effective Date the RIFA (including any change of control payment, premium, or similar amount thereunder) shall be canceled, released, and discharged in accordance with Article IV.F hereof. Entry into the New Royalty Agreement and the performance of NewCo’s obligations thereunder shall be authorized without the need for any further corporate or similar action and without any further action by the Debtors, the Reorganized Debtors, or the Holders of Claims or Interests.
| W. | Management Incentive Plan. |
On or after the Effective Date, NewCo shall implement the Management Incentive Plan on terms acceptable to Ayrmid and the Required Consenting Funded Debt Parties and approved by the New Board, the terms of which, to the extent then available, shall be Filed with the Plan Supplement.
57
| XVII. | TREATMENT OF EXECUTORY CONTRACTS AND UNEXPIRED LEASES |
| A. | Assumption and Rejection of Executory Contracts and Unexpired Leases. |
| 1. | Reorganization Transaction. |
In the event of the Reorganization Transaction, on the Effective Date, except as otherwise provided in Articles V.E and V.F and elsewhere herein, all Executory Contracts or Unexpired Leases not otherwise assumed or rejected will be deemed assumed by the applicable Reorganized Debtor (and shall remain in effect notwithstanding the consummation of the Merger) in accordance with the provisions and requirements of sections 365 and 1123 of the Bankruptcy Code, other than those that: (a) are identified on the Rejected Executory Contracts and Unexpired Leases Schedule; (b) have previously expired or terminated pursuant to their own terms; (c) have been previously assumed or rejected by the Debtors pursuant to a Final Order; (d) are the subject of a motion to reject that is pending on the Effective Date; or (e) have an ordered or requested effective date of rejection that is after the Effective Date.
| 2. | Sale Transaction. |
In the event of a Sale Transaction, on the Effective Date, except as otherwise provided in Articles V.E and V.F and elsewhere herein, all Executory Contracts or Unexpired Leases not otherwise assumed or rejected will be deemed rejected by the applicable Debtor or Post-Effective Date Debtor in accordance with the provisions and requirements of sections 365 and 1123 of the Bankruptcy Code, other than those that: (a) are identified on the Assumed Executory Contracts and Unexpired Leases Schedule; (b) have been previously assumed by the Debtors pursuant to a Final Order; (c) are the subject of a motion to assume that was Filed on or before the Confirmation Date; (d) are to be assumed by the Debtors or assumed by the Debtors and assigned to a third party, as applicable, in connection with any sale transaction, including the Sale Transaction; or (e) are a contract, instrument, release, indenture, or other agreement or document entered into in connection with the Prepackaged Plan.
| 3. | General Provisions. |
Entry of the Confirmation Order shall constitute an order of the Bankruptcy Court approving the assumptions, assumptions and assignments, or rejections of the Executory Contracts or Unexpired Leases as set forth in the Prepackaged Plan, the Rejected Executory Contracts and Unexpired Leases Schedule (or the Assumed Executory Contracts and Unexpired Leases Schedule in the case of a Sale Transaction), pursuant to sections 365(a) and 1123 of the Bankruptcy Code. Except as otherwise specifically set forth herein, assumptions or rejections of Executory Contracts and Unexpired Leases pursuant to the Prepackaged Plan are effective as of the Effective Date. Each Executory Contract or Unexpired Lease assumed pursuant to the Prepackaged Plan or by Bankruptcy Court order but not assigned to a third party before the Effective Date shall re-vest in and be fully enforceable by the applicable contracting Reorganized Debtor or Post-Effective Date Debtor in accordance with its terms, except as such terms may have been modified by the provisions of the Prepackaged Plan or any order of the Bankruptcy Court authorizing and providing for its assumption. Any motions to assume Executory Contracts or Unexpired Leases pending on the Effective Date shall be subject to approval by a Final Order on or after the Effective Date but may be withdrawn, settled, or otherwise prosecuted by the Reorganized Debtors or Post-Effective Date Debtors, as applicable.
58
To the maximum extent permitted by Law, to the extent any provision in any Executory Contract or Unexpired Lease assumed or assumed and assigned pursuant to the Prepackaged Plan or any prior order of the Bankruptcy Court (including any “change of control” or similar provision) prohibits, restricts, or conditions, or purports to prohibit, restrict, or condition, or is modified, breached, or terminated, or deemed modified, breached, or terminated by, or triggers any right or contingent right to any payment or benefit (either alone or in conjunction with any other action or event) as a result of: (i) the commencement of the Chapter 11 Cases or the insolvency or financial condition of any Debtor at any time before the closing of its respective Chapter 11 Case; (ii) any Debtor’s, Reorganized Debtor’s, or Post-Effective Date Debtor’s assumption or assumption and assignment of such Executory Contract or Unexpired Lease; or (iii) the Confirmation or Consummation of the Prepackaged Plan (including the Restructuring Transactions), then such provision shall be deemed modified such that the transactions contemplated by the Prepackaged Plan shall not entitle the non-Debtor party thereto to modify or terminate such Executory Contract or Unexpired Lease or to exercise any other default-related rights or remedies with respect thereto, and any required consent under any such Executory Contract or Unexpired Lease shall be deemed satisfied by the Confirmation of the Prepackaged Plan. Notwithstanding anything to the contrary in the Prepackaged Plan, the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, reserve the right to alter, amend, modify, or supplement the Assumed Executory Contracts and Unexpired Leases Schedule and the Rejected Executory Contracts and Unexpired Leases Schedule at any time up to forty-five (45) days after the Effective Date, so long as such alteration, amendment, modification, or supplement is consistent with the Restructuring Support Agreement.
| B. | Claims Based on Rejection of Executory Contracts or Unexpired Leases. |
Unless otherwise provided by a Final Order of the Bankruptcy Court, all Proofs of Claim with respect to Claims arising from the rejection of Executory Contracts or Unexpired Leases, pursuant to the Prepackaged Plan or the Confirmation Order, if any, must be Filed with the Bankruptcy Court within thirty (30) days after the later of (1) the date of entry of an order of the Bankruptcy Court (including the Confirmation Order) approving such rejection, (2) the effective date of such rejection, or (3) the Effective Date. Any Claims arising from the rejection of an Executory Contract or Unexpired Lease not Filed with the Bankruptcy Court within such time will be automatically disallowed, forever barred from assertion, and shall not be enforceable against the Debtors, the Reorganized Debtors, the Post-Effective Date Debtors, the Estates, or their property without the need for any objection by the Reorganized Debtors or the Post-Effective Date Debtors or further notice to, or action, order, or approval of the Bankruptcy Court or any other Entity, and any Claim arising out of the rejection of the Executory Contract or Unexpired Lease shall be deemed fully satisfied, released, and discharged, notwithstanding anything in the Proof of Claim to the contrary. All Allowed Claims arising from the rejection of the Debtors’ Executory Contracts or Unexpired Leases shall be classified as General Unsecured Claims and shall be treated in accordance with Article III.B.7 of the Prepackaged Plan.
59
| C. | Cure of Defaults for Assumed Executory Contracts and Unexpired Leases. |
Any monetary amounts by which any Executory Contract or Unexpired Lease to be assumed under the Prepackaged Plan is in default shall be satisfied, under section 365(b)(1) of the Bankruptcy Code, by the Debtors, Reorganized Debtors, or Post-Effective Date Debtors, as applicable, upon assumption thereof.
After the Petition Date and no later than 21 calendar days before the Confirmation Hearing the Debtors shall serve notices of proposed assumption on the counterparties to the Executory Contracts and Unexpired Leases to be assumed reflecting the Debtors’ intention to assume the contract, and setting forth the proposed Cure amount (if any) or otherwise indicating that the Cure amount shall be asserted against the Debtors or Reorganized Debtors, as applicable, in the ordinary course of business. Each such notice shall include a description of the procedures for resolving disputes related to the proposed assumption of applicable Executory Contracts and Unexpired Leases. In the event that any Executory Contract or Unexpired Lease is to be assumed after the provision of initial notices of proposed assumptions described above, a notice of proposed assumption with respect to such Executory Contract or Unexpired Lease will be sent promptly to the counterparty thereof. If a counterparty to any Executory Contract or Unexpired Lease that the Debtors or Reorganized Debtors, as applicable, intend to assume does not receive such a notice, the proposed Cure amount for such Executory Contract or Unexpired Lease shall be deemed to be asserted against the Debtors or the Reorganized Debtors, as applicable, in the ordinary course of business.
Unless otherwise agreed in writing by the parties to the applicable Executory Contract or Unexpired Lease, any objection by a counterparty to an Executory Contract or Unexpired Lease to a proposed assumption or related Cure amount must be Filed, served, and actually received by counsel to the Debtors no later than the date and time specified in the notice (which shall be not less than fourteen (14) days after such notice is served). The Debtors or the Reorganized Debtors or Post-Effective Date Debtors, as applicable, may reconcile and settle, subject to the consent rights set forth in the Restructuring Support Agreement, in the ordinary course of the Debtors’ business any dispute (following a timely Filed objection) regarding any Cure or any other matter pertaining to assumption without any further notice to or action, order, or approval of the Bankruptcy Court.
Any counterparty to an Executory Contract or Unexpired Lease that fails to object timely to the proposed assumption or Cure amount (including any request for an additional or different cure amount) will be deemed to have assented to such assumption or Cure amount and any untimely request for an additional or different Cure amount shall be disallowed and forever barred, estopped, and enjoined from assertion, and shall not be enforceable against any Reorganized Debtor or Post-Effective Date Debtor, without the need for any objection by the applicable Reorganized Debtors or Post-Effective Date Debtors or any other party in interest or any further notice to or action, order, or approval of the Bankruptcy Court.
60
The Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, shall pay the Cure amounts, if any, on the Effective Date or as soon as reasonably practicable thereafter, in the ordinary course of business, or on such other terms as the parties to such Executory Contracts or Unexpired Leases may agree; provided that if a dispute regarding assumption or Cure is unresolved as of the Effective Date, or any applicable objection period remains pending, then payment of the applicable Cure amount shall occur as soon as reasonably practicable after such dispute is resolved. Any Cure shall be deemed fully satisfied, released, and discharged upon payment of the Cure.
The assumption of any Executory Contract or Unexpired Lease pursuant to the Prepackaged Plan, in connection with the Sale Transaction or Reorganization Transaction, shall result in the full release and satisfaction of any nonmonetary defaults arising from or triggered by the filing of the Chapter 11 Cases, including defaults of provisions restricting the change in control or ownership interest composition or any bankruptcy-related defaults, arising at any time prior to the effective date of assumption, and, in the event of the Reorganization Transaction, any default, change of control, assignment, or similar event that would otherwise arise from the consummation of the Merger or the other Restructuring Transactions. Any and all Proofs of Claim based upon Executory Contracts or Unexpired Leases that have been assumed in the Chapter 11 Cases, including pursuant to the Confirmation Order, shall be deemed disallowed and expunged as of the later of (1) the date of entry of an order of the Bankruptcy Court (including the Confirmation Order) approving such assumption, (2) the effective date of such assumption, or (3) the Effective Date, without the need for any objection thereto or any further notice to or action, order, or approval of the Bankruptcy Court.
| D. | Preexisting Obligations to the Debtors Under Executory Contracts and Unexpired Leases. |
Rejection of any Executory Contract or Unexpired Lease pursuant to the Prepackaged Plan, in connection with the Reorganization Transaction or Sale Transaction, or otherwise shall not constitute a termination of preexisting obligations owed to the Debtors, the Reorganized Debtors, or Post-Effective Date Debtors, as applicable, under such Executory Contracts or Unexpired Leases. In particular, notwithstanding any non-bankruptcy Law to the contrary, the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, expressly reserve and do not waive any right to receive, or any continuing obligation of a counterparty to provide, warranties or continued maintenance obligations with respect to goods previously purchased by the Debtors pursuant to rejected Executory Contracts or Unexpired Leases.
| E. | Insurance Policies. |
Each of the Debtors’ insurance policies and any agreements, documents, or instruments relating thereto, shall be treated as Executory Contracts hereunder. Unless otherwise provided in the Prepackaged Plan or the Restructuring Support Agreement, on the Effective Date, in connection with all contemplated transactions under the Prepackaged Plan, (1) the Debtors shall be deemed to have assumed all insurance policies and any agreements, documents, and instruments relating to coverage of all insured Claims, excluding all D&O Liability Insurance Policies (other than any runoff or tail policies described in Article IV.S hereof), which shall be rejected, and (2) such insurance policies and any agreements, documents, or instruments relating thereto, shall revest in the applicable Reorganized Debtors or Post-Effective Date Debtors.
61
Nothing in the Prepackaged Plan, the Restructuring Support Agreement, the Plan Supplement, the Disclosure Statement, the Confirmation Order, or any other Final Order (including any other provision that purports to be preemptory or supervening), (1) alters, modifies, or otherwise amends the terms and conditions of (or the coverage provided by) any of such insurance policies assumed pursuant to the Prepackaged Plan or (2) alters or modifies the duty, if any, that the insurers or third party administrators have to pay claims covered by such insurance policies and their right to seek payment or reimbursement from the Debtors (or the Purchaser, solely to the extent assumed and assigned to the Purchaser under the Purchase Agreement) or draw on any collateral or security therefor. For the avoidance of doubt, insurers and third-party administrators shall not need to nor be required to file or serve a cure objection or a request, application, claim, Proof of Claim, or motion for payment and shall not be subject to any claims bar date or similar deadline governing cure amounts or Claims.
| F. | Employee Compensation and Benefits. |
All employee policies, and all compensation and benefits plans, policies, and programs of the Debtors applicable to their respective employees, retirees, and nonemployee directors, including all savings plans, retirement plans, healthcare plans, disability plans, severance benefit plans, incentive plans, COBRA benefits, and life and accidental death and dismemberment insurance plans that are assumed as Executory Contracts under the Prepackaged Plan pursuant to sections 365 and 1123 of the Bankruptcy Code (including, for the avoidance of doubt, the KPTI Severance Plans and the severance and change-of-control payments set forth on Annex A to the Ayrmid Transaction Term Sheet) shall be honored by NewCo in accordance with their respective terms, and NewCo shall abide by all applicable Laws with respect to employee obligations; provided that such severance and COBRA benefits, for each eligible employee, retiree, and nonemployee director, shall not exceed the amounts scheduled on Annex A to the Ayrmid Transaction Term Sheet.
From the Effective Date through the first (1st) anniversary of the Effective Date (the “Severance Protection Period”), NewCo (a) shall not, and shall cause its subsidiaries (including the Reorganized Debtors) not to, amend or terminate any KPTI Severance Plan in any manner adverse to any Covered Employee (except as otherwise provided in this Article V.F); and (b) shall provide, or shall cause its applicable subsidiaries to provide, to each Covered Employee who experiences a Qualifying Termination, severance pay and benefits no less favorable than those that the KPTI Severance Plans provide for such Covered Employee upon such termination, in each case up to the amounts for each such Covered Employee scheduled on Annex A to the Ayrmid Transaction Term Sheet. Subject to the foregoing limitations in amount, all KPTI Severance Plans shall be deemed to be, and shall be treated as, Executory Contracts under the Prepackaged Plan and, on the Effective Date, shall be assumed pursuant to sections 365 and 1123 of the Bankruptcy Code. Nothing herein shall affect NewCo’s ability to modify a Covered Employee’s division, direct supervisor, or similar changes to NewCo’s internal reporting lines.
62
Severance pay and benefits under this Article V.F exclude equity and equity-based awards, including any awards under any management incentive program. Nothing in this Article V.F shall limit any notice or severance pay or benefits required by applicable Law and nothing herein shall constitute an admission, or otherwise modify or limit any defenses, as to any amounts owed by NewCo and its Affiliates to affected employees under the KPTI Severance Plans. The obligations set forth in this Article V.F shall be binding on NewCo and its successors and assigns.
| G. | Reservation of Rights. |
Nothing contained in the Prepackaged Plan, the Restructuring Support Agreement, the Purchase Agreement, the Plan Supplement, or any other Definitive Document shall constitute an admission by the Debtors or any other party that any contract or lease is in fact an Executory Contract or Unexpired Lease or that any Reorganized Debtor or Post-Effective Date Debtor has any liability thereunder. If there is a dispute regarding whether a contract or lease is or was executory or unexpired at the time of assumption or rejection, the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, shall have forty-five (45) days following entry of a Final Order resolving such dispute to alter their treatment of such contract or lease.
| H. | Nonoccurrence of Effective Date. |
In the event that the Effective Date does not occur, the Bankruptcy Court shall retain jurisdiction with respect to any request to extend the deadline for assuming or rejecting Unexpired Leases pursuant to section 365(d)(4) of the Bankruptcy Code.
| I. | Contracts and Leases Entered Into After the Petition Date. |
Contracts and leases entered into after the Petition Date by any Debtor, including any Executory Contracts and Unexpired Leases assumed by such Debtor, will be performed by the applicable Debtor, Reorganized Debtor, or Post-Effective Date Debtor in the ordinary course of its business. Accordingly, such contracts and leases (including any assumed Executory Contracts and Unexpired Leases) will survive and remain unaffected by entry of the Confirmation Order.
| XVIII. | PROVISIONS GOVERNING DISTRIBUTIONS |
| A. | Distributions on Account of Claims Allowed as of the Effective Date. |
Except as otherwise provided herein, in a Final Order, or as otherwise agreed to by the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as the case may be, and the Holder of the applicable Allowed Claim, on the first Distribution Date, the applicable Reorganized Debtors or Post-Effective Date Debtors shall make initial distributions under the Prepackaged Plan on account of Claims Allowed on or before the Effective Date, subject to the right of the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, to object to Claims; provided that (1) Allowed Administrative Claims with respect to liabilities incurred by the Debtors in the ordinary course of business during the Chapter 11 Cases or assumed by the Debtors prior to the Effective Date shall be paid or performed in the ordinary course of business in accordance with the terms and conditions of any controlling agreements, course of dealing, course of business, or industry practice, (2) Allowed Priority Tax Claims shall be paid in accordance with Article II.D of the Prepackaged Plan, and (3) Allowed General Unsecured Claims shall be paid in accordance with Article III.B.7 of the Prepackaged Plan. To the extent any Allowed Priority Tax Claim is not due and owing on the Effective Date, such Claim shall be paid in full in Cash in accordance with the terms of any agreement between the Debtors and the Holder of such Claim or as may be due and payable under applicable non-bankruptcy Law or in the ordinary course of business.
63
| B. | Disbursing Agent. |
The Debtors, the Reorganized Debtors, the Post-Effective Date Debtors, or the Post-Effective Date Plan Administrator, as applicable, shall have the authority to enter into agreements with one or more Disbursing Agents to facilitate the distributions required hereunder. All distributions under the Prepackaged Plan shall be made by the Disbursing Agent. The Disbursing Agent shall not be required to give any bond or surety or other security for the performance of its duties unless otherwise ordered by the Bankruptcy Court. Additionally, in the event that the Disbursing Agent is so otherwise ordered, all costs and expenses of procuring any such bond or surety shall be borne by the Reorganized Debtors or the Post-Effective Date Debtors, as applicable.
| C. | Rights and Powers of Disbursing Agent. |
| 1. | Powers of the Disbursing Agent. |
The Disbursing Agent shall be empowered to: (a) effect all actions and execute all agreements, instruments, and other documents necessary to perform its duties under the Prepackaged Plan; (b) make all distributions contemplated hereby; (c) employ professionals to represent it with respect to its responsibilities; and (d) exercise such other powers as may be vested in the Disbursing Agent by order of the Bankruptcy Court, pursuant to the Prepackaged Plan, or as deemed by the Disbursing Agent to be necessary and proper to implement the provisions hereof.
| 2. | Expenses Incurred On or After the Effective Date. |
Except as otherwise ordered by the Bankruptcy Court, the amount of any reasonable fees and expenses incurred by the Disbursing Agent on or after the Effective Date (including taxes), and any reasonable compensation and expense reimbursement claims (including reasonable attorney fees and expenses), made by the Disbursing Agent shall be paid in Cash by the Reorganized Debtors or Post-Effective Date Debtors, as applicable.
| D. | Delivery of Distributions and Undeliverable or Unclaimed Distributions. |
| 1. | Record Date for Distribution. |
On the Distribution Record Date, the Claims Register shall be closed and any party responsible for making distributions shall instead be authorized and entitled to recognize only those record holders listed on the Claims Register as of the close of business on the Distribution Record Date. If a Claim is transferred twenty (20) or fewer days before the Distribution Record Date, the Disbursing Agent shall make distributions to the transferee only to the extent practical and, in any event, only if the relevant transfer form contains an unconditional and explicit certification and waiver of any objection to the transfer by the transferor.
64
| 2. | Delivery of Distributions in General. |
Except as otherwise provided herein, the Disbursing Agent shall make distributions to Holders of Allowed Claims and Allowed Interests (as applicable) as of the Distribution Record Date at the address for each such Holder as indicated on the Debtors’ records as of the date of any such distribution; provided that the manner of such distributions shall be determined at the discretion of the Reorganized Debtors or Post-Effective Date Debtors.
| 3. | Minimum Distributions. |
No fractional shares of New Common Stock or Reorganized Parent Common Stock, and no fractional MF CVRs, shall be distributed and no Cash shall be distributed in lieu of such fractional amounts. When any distribution pursuant to the Prepackaged Plan on account of an Allowed Claim or Allowed Interest (if applicable) would otherwise result in the issuance of a number of shares of New Common Stock or Reorganized Parent Common Stock that is not a whole number, the actual distribution of such shares shall be rounded to the next lower whole number with no further payment therefor. The total number of authorized shares of New Common Stock and Reorganized Parent Common Stock to be distributed to the Holders of Allowed Claims hereunder shall be adjusted as necessary to account for the foregoing rounding.
None of the Reorganized Debtors, the Post-Effective Date Debtors, or the Disbursing Agent shall have any obligation to make a Cash distribution that is less than two hundred fifty dollars ($250) to any Holder of an Allowed Claim.
| 4. | Undeliverable Distributions and Unclaimed Property. |
In the event that any distribution to any Holder of Allowed Claims or Allowed Interests (as applicable) is returned as undeliverable, no distribution to such Holder shall be made unless and until the Disbursing Agent has determined the then-current address of such Holder, at which time all currently-due, missed distributions shall be made to such Holder without interest. Undeliverable distributions shall remain in the possession of the Reorganized Debtors or Post-Effective Date Debtors, as applicable, until such time as a distribution becomes deliverable, or such distribution reverts to the Reorganized Debtors or Post-Effective Date Debtors, as applicable, or is canceled pursuant to this Article VI, and shall not be supplemented with any interest, dividends, or other accruals of any kind.
Any distribution under the Prepackaged Plan that is an unclaimed distribution or remains undeliverable (as reasonably deemed unclaimed or undeliverable by the Reorganized Debtors, the Post-Effective Date Debtors, or the Disbursing Agent) for a period of ninety (90) days after distribution shall be deemed unclaimed property under section 347(b) of the Bankruptcy Code and such unclaimed distribution or undeliverable distribution shall revest in the applicable Reorganized Debtor or Post-Effective Date Debtor automatically (and without need for a further order by the Bankruptcy Court, notwithstanding any applicable federal or state escheat, abandoned, or unclaimed property Laws to the contrary) and, to the extent such unclaimed distribution is comprised of New Common Stock or MF CVRs, then such New Common Stock or MF CVRs shall be canceled. Upon such revesting, the Claim of the Holder or its successors with respect to such property shall be canceled, released, discharged, and forever barred notwithstanding any applicable federal or state escheat, abandoned, or unclaimed property Laws, or any provisions in any document governing the distribution that is an unclaimed distribution, to the contrary, and the Claim of any Holder of Claims and Interests to such property or Interest in property shall be discharged and forever barred. The Disbursing Agent shall adjust the distributions of the New Common Stock or the MF CVRs to reflect any such cancellation; however, for the avoidance of doubt, additional Securities shall not be issued to other Holders of Claims due to any such cancellations.
65
| 5. | Surrender of Canceled Instruments or Securities. |
On the Effective Date or as soon as reasonably practicable thereafter, each holder of a certificate or instrument evidencing a Claim or an Interest that has been canceled in accordance with Article IV.F hereof shall be deemed to have surrendered such certificate or instrument to the Disbursing Agent. Such surrendered certificate or instrument shall be canceled solely with respect to the Debtors, and such cancellation shall not alter the obligations or rights of any non-Debtor third parties vis-à-vis one another with respect to such certificate or instrument, including with respect to any indenture or agreement that governs the rights of the Holder of a Claim or Interest, which shall continue in effect for purposes of allowing holders to receive distributions under the Prepackaged Plan, charging liens, priority of payment, and indemnification rights. Notwithstanding anything to the contrary herein, this paragraph shall not apply to certificates or instruments evidencing Claims that are Reinstated under the Prepackaged Plan.
| 6. | Delivery of Distributions on Prepetition Funded Debt Claims. |
Except as otherwise reasonably requested by the applicable Prepetition Agent, all distributions to Holders of Allowed Prepetition Funded Debt Claims shall be deemed completed when made to the applicable Prepetition Agent. The applicable Prepetition Agent shall hold or direct such distributions for the benefit of the Holders of the applicable Allowed Prepetition Funded Debt Claims. As soon as practicable in accordance with the requirements set forth in this Article VI, the applicable Prepetition Agent shall arrange to deliver such distributions to or on behalf of its holders, subject to such Prepetition Agent’s charging lien. The 1.5L 2028 Notes Trustee and the 2L 2029 Notes Trustee may transfer or direct the transfer of such distributions directly through the facilities of DTC (whether by means of book-entry exchange, free delivery, or otherwise) and will be entitled to recognize and deal for all purposes under the Prepackaged Plan with Holders of Allowed 1.5L 2028 Notes Claims and Allowed 2L 2029 Notes Claims, to the extent consistent with the customary practices of DTC. If a Prepetition Agent is unable to make, or consents to the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, making such distributions, the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, with such Prepetition Agent’s cooperation, shall make such distributions to the extent practicable to do so; provided that until such distributions are made, such Prepetition Agent’s charging lien shall attach to the property to be distributed in the same manner as if such distributions were made through such Prepetition Agent. No Prepetition Agent shall have any duties or responsibilities relating to any form of distribution that is not DTC eligible and the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, shall seek the cooperation of DTC so that any distribution on account of an Allowed 1.5L 2028 Notes Claim or Allowed 2L 2029 Notes Claim that is held in the name of, or by a nominee of, DTC, shall be made through the facilities of DTC on the Effective Date or as soon as practicable thereafter.
66
| E. | Manner of Payment. |
| 1. | All distributions of the New Common Stock and the MF CVRs to the holders of the applicable Allowed Claims under the Prepackaged Plan shall be made by the Disbursing Agent on behalf of the Debtors or the Reorganized Debtors, as applicable. |
| 2. | The MF CVRs shall be distributed in accordance with the MF CVR Agreement. |
| 3. | All distributions of Cash to the holders of the applicable Allowed Claims under the Prepackaged Plan shall be made by the Disbursing Agent on behalf of the applicable Debtor, Reorganized Debtor, or Post-Effective Date Debtor. |
| 4. | At the option of the Disbursing Agent, any Cash payment to be made hereunder may be made by check or wire transfer or as otherwise required or provided in applicable agreements. |
| F. | Compliance With Tax Requirements. |
In connection with the Prepackaged Plan, the Restructuring Transactions Memorandum, and all distributions under the Prepackaged Plan, to the extent applicable, the Debtors, the Reorganized Debtors, the Post-Effective Date Debtors, the Disbursing Agent, and any applicable withholding agent shall comply with all tax withholding and reporting requirements imposed on them by any Governmental Unit, and all distributions made pursuant to the Prepackaged Plan shall be subject to such withholding and reporting requirements. Notwithstanding any provision in the Prepackaged Plan to the contrary, such parties shall (i) be authorized to take all actions necessary or appropriate to comply with such withholding and reporting requirements, including liquidating a portion of the distribution to be made under the Prepackaged Plan to generate sufficient funds to pay applicable withholding taxes, withholding distributions pending receipt of information necessary to facilitate such distributions, or establishing any other mechanisms they believe are reasonable and appropriate and (ii) in furtherance of the foregoing, allow distributees a meaningful opportunity to provide any tax forms or other documents permitted by applicable Law to minimize any otherwise applicable withholding. The Debtors, the Reorganized Debtors, and the Post-Effective Date Debtors reserve the right to allocate all distributions made under the Prepackaged Plan in compliance with all applicable wage garnishments, alimony, child support, and similar spousal awards, Liens, and encumbrances.
| G. | Allocations. |
Distributions in respect of Allowed Claims shall be allocated first to the principal amount of such Claims (as determined for federal income tax purposes) and then, to the extent the consideration exceeds the principal amount of the Claims, to any portion of such Claims for accrued but unpaid interest.
67
| H. | No Postpetition Interest on Claims. |
Unless otherwise specifically provided for in the Prepackaged Plan, the Restructuring Support Agreement, the DIP Orders and the other DIP Facility Documents, the Confirmation Order, any other order of the Bankruptcy Court, or required by applicable bankruptcy and non-bankruptcy Law, postpetition interest shall not accrue or be paid on any prepetition Claims, and no Holder of a Claim shall be entitled to interest accruing on or after the Petition Date on such Claim.
| I. | Foreign Currency Exchange Rate. |
Except as otherwise provided in a Bankruptcy Court order, as of the Effective Date, any Claim asserted in currency other than U.S. dollars shall be automatically deemed converted to the equivalent U.S. dollar value using the exchange rate for the applicable currency as published in The Wall Street Journal (National Edition), on the Effective Date.
| J. | Setoffs and Recoupment. |
Except as expressly provided in the Prepackaged Plan, and except with respect to an Allowed Claim held by a Consenting Stakeholder, each Reorganized Debtor or Post-Effective Date Debtor, as applicable, may, pursuant to section 553 of the Bankruptcy Code, set off or recoup against any Plan Distributions to be made on account of any Allowed Claim, any and all claims, rights, and Causes of Action that such Reorganized Debtor or Post-Effective Date Debtor, as applicable, may hold against the Holder of such Allowed Claim to the extent such setoff or recoupment is either (1) agreed in amount among the relevant Reorganized Debtor(s) or Post-Effective Date Debtor(s), as applicable, and the Holder of the Allowed Claim or (2) otherwise adjudicated by the Bankruptcy Court or another court of competent jurisdiction; provided that neither the failure to effectuate a setoff or recoupment nor the allowance of any Claim hereunder shall constitute a waiver or release by a Reorganized Debtor or Post-Effective Date Debtor, as applicable, or its successor of any and all claims, rights, and Causes of Action that such Reorganized Debtor or its successor may possess against the applicable holder. In no event shall any Holder of a Claim be entitled to recoup such Claim against any claim, right, or Cause of Action of the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, unless such holder actually has performed such recoupment and provided notice thereof in writing to the Debtors in accordance with Article XII.G hereof on or before the Effective Date, notwithstanding any indication in any Proof of Claim or otherwise that such holder asserts, has, or intends to preserve any right of recoupment.
| K. | Claims Paid or Payable by Third Parties. |
| 1. | Claims Paid by Third Parties/Insurers. |
The Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, shall reduce in full a Claim, and such Claim shall be disallowed without a Claims objection having to be Filed and without any further notice to or action, order, or approval of the Bankruptcy Court, to the extent that the Holder of such Claim receives payment in full on account of such Claim from a party that is not a Debtor, a Reorganized Debtor, or a Post-Effective Date Debtor. Subject to the last sentence of this paragraph, to the extent a Holder of a Claim receives a distribution on account of such Claim and receives payment from a party that is not a Debtor, a Reorganized Debtor, or a Post-Effective Date Debtor on account of such Claim, such holder shall, within fourteen (14) days of receipt thereof, repay or return the distribution to the applicable Reorganized Debtor or Post-
68
Effective Date Debtor, to the extent the holder’s total recovery on account of such Claim from the third party and under the Prepackaged Plan exceeds the amount of such Claim as of the date of any such distribution under the Prepackaged Plan. The failure of such holder to timely repay or return such distribution shall result in the holder owing the applicable Reorganized Debtor or Post-Effective Date Debtor annualized interest at the Federal Judgment Rate on such amount owed for each Business Day after the fourteen (14) day grace period specified above until the amount is repaid.
| 2. | Claims Payable by Third Parties. |
No distributions under the Prepackaged Plan shall be made on account of an Allowed Claim that is payable pursuant to one of the Debtors’ insurance policies until the Holder of such Allowed Claim has exhausted all remedies with respect to such insurance policy. To the extent that one or more of the Debtors’ insurers agrees to satisfy in full or in part a Claim (if and to the extent adjudicated by a court of competent jurisdiction), then immediately upon such insurers’ agreement, the applicable portion of such Claim may be expunged without a Claims objection having to be Filed and without any further notice to or action, order, or approval of the Bankruptcy Court.
| 3. | Applicability of Insurance Policies. |
Except as otherwise provided in the Prepackaged Plan, distributions to Holders of Allowed Claims shall be in accordance with the provisions of any applicable insurance policy. Nothing contained in the Prepackaged Plan shall constitute or be deemed a waiver of any Cause of Action that the Debtors or any Entity may hold against any other Entity, including insurers under any policies of insurance, nor shall anything contained herein constitute or be deemed a waiver by such insurers of any defenses, including coverage defenses, held by such insurers.
| XIX. | PROCEDURES FOR RESOLVING CONTINGENT, UNLIQUIDATED, AND DISPUTED CLAIMS |
| A. | Disputed Claims Process. |
In light of the Unimpaired status of all Allowed General Unsecured Claims under the Prepackaged Plan, there is no requirement to File a Proof of Claim (or move the Bankruptcy Court for allowance) to have a Claim Allowed for the purposes of the Prepackaged Plan, except as provided in Article V.B of the Prepackaged Plan or Article V.C with respect to a Cure amount, and the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, shall determine, adjudicate, and resolve any disputes over the validity and amounts of such Claims in the ordinary course of business as if the Chapter 11 Cases had not been commenced (and no approval or authority from the Bankruptcy Court shall be required) except that (unless expressly waived pursuant to the Prepackaged Plan) the Allowed amount of such Claims shall be subject to the limitations or maximum amounts permitted by the Bankruptcy Code, including sections 502 and 503 of the Bankruptcy Code, to the extent applicable; provided that the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, reserve the right to seek to set a future bar date that may require a Proof of Claim to be Filed in the event that a Sale Transaction is pursued (in which case a separate order of the Bankruptcy Court will govern).
69
On and after the Effective Date, except as otherwise provided in the Prepackaged Plan, all Allowed Claims shall be satisfied in the ordinary course of business by the Reorganized Debtors or the Post-Effective Date Debtors, as applicable. The Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, shall have the exclusive authority to (1) determine, without the need for notice to or action, order, or approval of the Bankruptcy Court, that a claim subject to any Proof of Claim that is Filed is Allowed and (2) File, settle, compromise, withdraw, or litigate to judgment any objections to Claims as permitted under the Prepackaged Plan. If the Debtors, Reorganized Debtors, or Post-Effective Date Debtors dispute any Claim, such dispute shall be determined, resolved, or adjudicated, as the case may be, in the manner as if the Chapter 11 Cases had not been commenced and shall survive the Effective Date as if the Chapter 11 Cases had not been commenced; provided that the Debtors, Reorganized Debtors, or Post-Effective Date Debtors may elect, at their sole option, to object to any Claim (other than Claims expressly Allowed by the Prepackaged Plan) and to have the validity or amount of any Claim adjudicated by the Bankruptcy Court; provided further that Holders of Claims may elect to resolve the validity or amount of any Claim in the Bankruptcy Court. All Proofs of Claim Filed in the Chapter 11 Cases shall be deemed objected to and Disputed without further action by the Debtors. Upon the Effective Date, all Proofs of Claim Filed against the Debtors, regardless of the time of Filing, and including Proofs of Claim Filed after the Effective Date, shall be deemed withdrawn and expunged, except as otherwise provided herein. Notwithstanding anything in the Prepackaged Plan to the contrary, disputes regarding the amount of any Cure pursuant to section 365 of the Bankruptcy Code and Claims that the Debtors seek to have determined by the Bankruptcy Court shall in all cases be determined by the Bankruptcy Court. Except as otherwise provided herein, all Proofs of Claim Filed after the Effective Date shall be disallowed and forever barred, estopped, and enjoined from assertion, and shall not be enforceable against any Reorganized Debtor or Post-Effective Date Debtor, as applicable, without the need for any objection by the Reorganized Debtors or Post-Effective Date Debtors, as applicable, or any further notice to or action, order, or approval of the Bankruptcy Court.
| B. | Allowance of Claims. |
After the Effective Date, except as otherwise expressly set forth herein, each of the Reorganized Debtors or Post-Effective Date Debtors, as applicable, shall have and retain any and all rights and defenses such Debtor had with respect to any Claim or Interest immediately prior to the Effective Date. The Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, may, with the consent of the Required Consenting Funded Debt Parties, affirmatively determine to deem Unimpaired Claims Allowed to the same extent such Claims would be allowed under applicable non-bankruptcy Law, without further notice or order from the Bankruptcy Court.
70
| C. | Claims Administration Responsibilities. |
Except as otherwise specifically provided in the Prepackaged Plan, after the Effective Date, the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, with the consent of the Required Consenting Funded Debt Parties, shall have the exclusive authority: (1) to File, withdraw, or litigate to judgment objections to Claims or Interests; (2) to settle or compromise any Disputed Claim without any further notice to or action, order, or approval by the Bankruptcy Court; and (3) to administer and adjust the Claims Register to reflect any such settlements or compromises without any further notice to or action, order, or approval by the Bankruptcy Court. For the avoidance of doubt, except as otherwise provided herein, from and after the Effective Date, each Reorganized Debtor or Post-Effective Date Debtor, as applicable, shall have and retain any and all rights and defenses such Debtor had immediately prior to the Effective Date with respect to any Disputed Claim or Interest, including the Causes of Action retained pursuant to Article IV.O of the Prepackaged Plan.
Any objections to Proofs of Claim (other than Proofs of Claim with respect to Administrative Claims) shall be served and Filed (a) on or before the date that is one hundred eighty (180) days following the later of (i) the Effective Date and (ii) the date that a Proof of Claim is Filed or amended or a Claim is otherwise asserted or amended in writing by or on behalf of a Holder of a Claim, or (b) such later date as ordered by the Bankruptcy Court.
| D. | Estimation of Claims and Interests. |
Before, on, or after the Effective Date, the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, may, with the consent of the Required Consenting Funded Debt Parties, at any time request that the Bankruptcy Court estimate any Disputed Claim or Interest that is contingent or unliquidated pursuant to section 502(c) of the Bankruptcy Code for any reason, regardless of whether any party in interest previously has objected to such Claim or Interest or whether the Bankruptcy Court has ruled on any such objection, and the Bankruptcy Court shall retain jurisdiction to estimate any such Claim or Interest, including during the litigation of any objection to any Claim or Interest or during the appeal relating to such objection. Notwithstanding any provision otherwise in the Prepackaged Plan, a Claim that has been expunged from the Claims Register, but that either is subject to appeal or has not been the subject of a Final Order, shall be deemed to be estimated at zero dollars, unless otherwise ordered by the Bankruptcy Court. In the event that the Bankruptcy Court estimates any contingent or unliquidated Claim or Interest, that estimated amount shall constitute a maximum limitation on such Claim or Interest for all purposes under the Prepackaged Plan (including for purposes of distributions), and the relevant Reorganized Debtor or Post-Effective Date Debtor, as applicable, may elect to pursue any supplemental proceedings to object to any ultimate distribution on such Claim or Interest.
| E. | Adjustment to Claims or Interests Without Objection. |
Any duplicate Claim or Interest or any Claim or Interest that has been paid, satisfied, amended, or superseded may be adjusted or expunged on the Claims Register by the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, without the Reorganized Debtors or Post-Effective Date Debtors, as applicable, having to File an application, motion, complaint, objection, or any other legal proceeding seeking to object to such Claim or Interest and without any further notice to or action, order, or approval of the Bankruptcy Court.
71
| F. | Disallowance of Claims or Interests. |
Except as otherwise expressly set forth herein, all Claims and Interests of any Entity from which property is sought by the Debtors under sections 542, 543, 550, or 553 of the Bankruptcy Code or that the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors allege is a transferee of a transfer that is avoidable under sections 522(f), 522(h), 544, 545, 547, 548, 549, or 724(a) of the Bankruptcy Code shall be disallowed if: (1) the Entity, on the one hand, and the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, on the other hand, agree or the Bankruptcy Court has determined by Final Order that such Entity or transferee is liable to turn over any property or monies under any of the aforementioned sections of the Bankruptcy Code; and (2) such Entity or transferee has failed to turn over such property by the date set forth in such agreement or Final Order. No payment or distribution shall be made on account of such Claim or Interest unless the transferee has paid or turned over such property.
| G. | No Distributions Pending Allowance. |
Notwithstanding any other provision of the Prepackaged Plan, if any portion of a Claim or Interest is a Disputed Claim or Interest, as applicable, no payment or distribution provided hereunder shall be made on account of such Claim or Interest unless and until such Disputed Claim or Interest becomes an Allowed Claim or Interest; provided that if only the Allowed amount of an otherwise valid Claim or Interest is Disputed, such Claim or Interest shall be deemed Allowed in the amount not Disputed and payment or distribution shall be made on account of such undisputed amount.
| H. | Distributions After Allowance. |
To the extent that a Disputed Claim or Interest ultimately becomes an Allowed Claim or Interest, distributions (if any) shall be made to the Holder of such Allowed Claim or Interest in accordance with the provisions of the Prepackaged Plan. As soon as reasonably practicable after the date that the order or judgment of the Bankruptcy Court allowing any Disputed Claim or Interest becomes a Final Order, the Disbursing Agent shall provide to the Holder of such Claim or Interest the distribution (if any) to which such Holder is entitled under the Prepackaged Plan as of the Effective Date, without any interest to be paid on account of such Claim or Interest.
| I. | No Interest. |
Unless otherwise specifically provided for in the Prepackaged Plan, the Restructuring Support Agreement, the DIP Orders and the other DIP Facility Documents, the Confirmation Order, any other order of the Bankruptcy Court, or required by applicable bankruptcy and non-bankruptcy Law, postpetition interest shall not accrue or be paid on Claims, and no Holder of a Claim shall be entitled to interest accruing on or after the Petition Date on any Claim or right. Additionally, and without limiting the foregoing, interest shall not accrue or be paid on any Disputed Claim with respect to the period from the Effective Date to the date a final distribution is made on account of such Disputed Claim, if and when such Disputed Claim becomes an Allowed Claim.
| J. | Accrual of Dividends and Other Rights. |
For purposes of determining the accrual of distributions or other rights after the Effective Date, the New Common Stock and MF CVRs shall be deemed distributed as of the Effective Date regardless of the date on which they are actually distributed; provided, however, that the relevant Reorganized Debtors shall not pay any such distributions or distribute such other rights, if any, until after distribution of the applicable New Common Stock or MF CVRs actually takes place.
72
| XX. | SETTLEMENT, RELEASE, INJUNCTION, AND RELATED PROVISIONS |
| A. | Discharge of Claims and Termination of Interests. |
Pursuant to and to the fullest extent permitted by section 1141(d) of the Bankruptcy Code, and except as otherwise specifically provided in the Definitive Documents, the Prepackaged Plan, or in any contract, instrument, or other agreement or document created or entered into pursuant to the Prepackaged Plan, the distributions, rights, and treatment that are provided in the Prepackaged Plan shall be in complete satisfaction, discharge, and release, effective as of the Effective Date, of Claims (including any Intercompany Claims resolved or compromised after the Effective Date by the Reorganized Debtors or Post-Effective Date Debtors, as applicable), Interests, and Causes of Action of any nature whatsoever, including any interest accrued on Claims or Interests from and after the Petition Date, whether known or unknown, against, liabilities of, Liens on, obligations of, rights against, and interests in, the Debtors or any of their assets or properties, regardless of whether any property shall have been distributed or retained pursuant to the Prepackaged Plan on account of such Claims and Interests, including demands, liabilities, and Causes of Action that arose before the Effective Date, any liability (including withdrawal liability) to the extent such Claims or Interests relate to services performed by employees of the Debtors prior to the Effective Date and that arise from a termination of employment, any contingent or non-contingent liability on account of representations or warranties issued on or before the Effective Date, and all debts of the kind specified in sections 502(g), 502(h), or 502(i) of the Bankruptcy Code, in each case whether or not: (1) a Proof of Claim based upon such debt or right is Filed or deemed Filed pursuant to section 501 of the Bankruptcy Code; (2) a Claim or Interest based upon such debt, right, or interest is Allowed pursuant to section 502 of the Bankruptcy Code; or (3) the Holder of such a Claim or Interest has accepted the Prepackaged Plan. The Confirmation Order shall be a judicial determination of the discharge of all Claims (other than the Reinstated Claims) and Interests (other than the Intercompany Interests that are Reinstated) subject to the occurrence of the Effective Date; provided that, in the event of a Sale Transaction, the Debtors shall not receive a discharge pursuant to section 1141(d)(3) of the Bankruptcy Code.
| B. | Release of Liens. |
Except as otherwise provided in the Prepackaged Plan, the Restructuring Support Agreement, the Confirmation Order, the Purchase Agreement, or in any contract, instrument, release, or other agreement or document amended or created pursuant to the Prepackaged Plan, on the Effective Date and concurrently with the applicable distributions made pursuant to the Prepackaged Plan and, in the case of a Secured Claim, satisfaction in full of the portion of the Secured Claim that is Allowed as of the Effective Date, except for Other Secured Claims that the Debtors elect to Reinstate in accordance with the Prepackaged Plan, all mortgages, deeds of trust, Liens, pledges, or other security interests against any property of the Estates shall be fully released and discharged, and all of the right, title, and interest of any holder of such mortgages, deeds of trust, Liens, pledges, or other security interests shall revert to the Reorganized Debtors or Post-Effective Date Debtors and
73
their successors and assigns. Any Holder of such Secured Claim (and the applicable agents for such Holder) shall be authorized and directed, at the sole cost and expense of the Reorganized Debtors or Post-Effective Date Debtors, to release any collateral or other property of any Debtor (including any Cash Collateral and possessory collateral) held by such Holder (and the applicable agents for such Holder), and to take such actions as may be reasonably requested by the Reorganized Debtors or Post-Effective Date Debtors to evidence the release of such Liens or security interests, including the execution, delivery, and filing or recording of such releases. The presentation or filing of the Confirmation Order to or with any federal, state, provincial, or local agency, records office, or department shall constitute good and sufficient evidence of, but shall not be required to effect, the termination of such Liens.
To the extent that any Holder of a Secured Claim that has been satisfied or discharged in full pursuant to the Prepackaged Plan, or any agent for such Holder, has filed or recorded publicly any Liens or security interests to secure such Holder’s Secured Claim, then as soon as practicable on or after the Effective Date, such Holder (or the agent for such Holder) shall take any and all steps requested by the Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors that are necessary or desirable to record or effectuate the cancellation or extinguishment of such Liens or security interests, including the making of any applicable filings or recordings, and the Reorganized Debtors or Post-Effective Date Debtors shall be entitled to make any such filings or recordings on such Holder’s behalf.
| C. | Releases by the Debtors. |
Notwithstanding anything contained in the Prepackaged Plan to the contrary, effective as of the Effective Date, pursuant to section 1123(b) of the Bankruptcy Code, for good and valuable consideration, including the obligations of the Debtors under the Prepackaged Plan and the contributions and services of the Released Parties in facilitating the implementation of the Restructuring Transactions, the adequacy of which is hereby confirmed, to the fullest extent allowed by applicable Law, each Released Party is hereby deemed conclusively, absolutely, unconditionally, irrevocably, and forever released, waived and discharged by each and all of the Debtors, their Estates, the Reorganized Debtors, the Post-Effective Date Debtors, the Post-Effective Date Plan Administrator, and any Person seeking to exercise the rights of the Debtors or their Estates, including any successors to the Debtors or any Estate representative appointed or selected pursuant to section 1123(b)(3) of the Bankruptcy Code, each of their respective current and former Affiliates, in each case on behalf of themselves and their Related Parties who may purport to assert any Claim or Cause of Action, directly or derivatively, by, through, for, or because of the foregoing Entities, from any and all Claims, Interests, and Causes of Action, and liabilities whatsoever, including any derivative claims, asserted by or assertable on behalf of any of the Debtors, their Estates, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, whether known or unknown, foreseen or unforeseen, asserted or unasserted, matured or unmatured, suspected or unsuspected, existing or hereinafter arising, contingent or non-contingent, liquidated or unliquidated, secured or unsecured, assertable, directly or derivatively, in Law (or any applicable rule, statute, regulation, treaty, right, duty or requirement), equity, contract, tort, or otherwise, that the Debtors, their Estates, the Reorganized Debtors, or the Post-Effective Date Debtors would have been legally entitled to assert in their own right (whether
74
individually or collectively) or on behalf of the Holder of any Claim against, or Interest in, a Debtor or other Entity, or that any Holder of any Claim against, or Interest in, a Debtor or other Entity could have asserted on behalf of the Debtors, based on or relating to (including the formulation, preparation, dissemination, negotiation, entry into, or filing of, as applicable), or in any manner arising from, in whole or in part, the Company-Related Matters, including the Prepetition Funded Debt Claims and the documents governing the same, the DIP Facility, the DIP Facility Documents, the DIP Orders, the ownership and/or operation of the Debtors by any Released Party or the distribution of any Cash or other property of the Debtors to any Released Party, the assertion or enforcement of rights and remedies against the Debtors, any Avoidance Actions (but excluding Avoidance Actions brought as counterclaims or defenses to Claims asserted against the Debtors), and any claim or Cause of Action seeking lender liability or challenging the validity, enforceability, priority, scope, extent, or perfection of, or seeking the recharacterization, subordination, disallowance, or avoidance of, any Claims or Liens held by any Released Party. Notwithstanding anything to the contrary in the foregoing, the releases set forth above do not release (1) any obligations arising on or after the Effective Date of any party or Entity under the Definitive Documents, or any document, instrument, or agreement (including those set forth in the Plan Supplement) executed to implement the Prepackaged Plan; or (2) any Causes of Action included in the Schedule of Retained Causes of Action; provided that in no event shall any Cause of Action included in the Schedule of Retained Causes of Action be asserted against any Consenting Stakeholder, the DIP Agent, any DIP Lender, any Prepetition Agent, or any Ad Hoc Group Advisor or Ayrmid Advisor, or any of their respective Related Parties, in each case in their capacities as such.
Entry of the Confirmation Order shall constitute the Bankruptcy Court’s approval, pursuant to Bankruptcy Rule 9019, of the Debtor Release, which includes by reference each of the related provisions and definitions contained in the Prepackaged Plan and, further, shall constitute the Bankruptcy Court’s finding that the Debtor Release is: (i) in exchange for good and valuable consideration provided by the Released Parties, including the Released Parties’ substantial contributions to facilitating the Restructuring Transactions and implementing the Prepackaged Plan; (ii) a good faith settlement and compromise of the Claims or Causes of Action released by the Debtor Release; (iii) in the best interests of the Debtors, their Estates, and all Holders of Claims and Interests; (iv) fair, equitable, and reasonable; (v) given and made after reasonable investigation by the Debtors and after due notice and opportunity for a hearing; and (vi) a bar to any of the Debtors, their Estates, the Reorganized Debtors, the Post-Effective Date Debtors, the Post-Effective Date Plan Administrator, or any Person seeking to exercise the rights of the Debtors or their Estates asserting any Claim or Cause of Action released pursuant to the Debtor Release.
| D. | Releases by the Releasing Parties. |
Effective as of the Effective Date, in exchange for good and valuable consideration, the adequacy of which is hereby confirmed, to the fullest extent allowed by applicable Law, each of the Releasing Parties shall be deemed to have conclusively, absolutely, unconditionally, irrevocably, and forever, released, waived, and discharged each of the Released Parties from any and all Claims, Causes of Action, and liabilities whatsoever, including any derivative claims asserted by or assertable on behalf of any Releasing Party,
75
whether known or unknown, foreseen or unforeseen, asserted or unasserted, matured or unmatured, suspected or unsuspected, existing or hereinafter arising, contingent or non-contingent, liquidated or unliquidated, secured or unsecured, assertable, directly or derivatively, in Law (or any applicable rule, statute, regulation, treaty, right, duty or requirement), equity, contract, tort, or otherwise, that such Releasing Party would have been legally entitled to assert in its own right (whether individually or collectively) or on behalf of the Holder of any Claim against, or Interest in, a Released Party, or that any Holder of any Claim against, or Interest in, a Released Party could have asserted on behalf of the Releasing Party, or otherwise based on or relating to (including the formulation, preparation, dissemination, negotiation, entry into, or filing of, as applicable), or in any manner arising from, in whole or in part, the Company-Related Matters; provided that, with respect to Claims against the Debtors, this Article VIII.D shall only apply to Claims arising from any act or omission, transaction, agreement, event, or other occurrence taking place from and including the Petition Date through the Effective Date. Notwithstanding anything to the contrary in the foregoing, the releases set forth above do not release (1) any obligations arising on or after the Effective Date of any party or Entity under the Definitive Documents, or any document, instrument, or agreement (including those set forth in the Plan Supplement) executed to implement the Prepackaged Plan; or (2) any Causes of Action included in the Schedule of Retained Causes of Action.
Entry of the Confirmation Order shall constitute the Bankruptcy Court’s approval, pursuant to Bankruptcy Rule 9019, of the Third-Party Release, which includes by reference each of the related provisions and definitions contained in the Prepackaged Plan, and, further, shall constitute the Bankruptcy Court’s finding that the Third-Party Release is: (i) an integrated and global good faith compromise and settlement that is non-severable from the provisions of the Prepackaged Plan; (ii) consensual; (iii) essential to the confirmation of the Prepackaged Plan; (iv) given in exchange for the good and valuable consideration provided by the Released Parties, including the Released Parties’ contributions to facilitating the restructuring and implementing the Prepackaged Plan; (v) a good faith settlement and compromise of the Claims or Causes of Action released by the Third-Party Release; (vi) in the best interests of the Debtors and their Estates; (vii) fair, equitable, and reasonable; (viii) given and made after due notice and opportunity for a hearing; and (ix) a bar to any of the Releasing Parties asserting any Claim or Cause of Action released pursuant to the Third-Party Release.
Each of the Releasing Parties in each of the Debtor Release and the Third-Party Release contained above expressly acknowledges that although ordinarily a general release may not extend to Claims that the Releasing Party does not know or suspect to exist in its favor, which, if known by it, may have materially affected its settlement with the party released, it has carefully considered and taken into account in determining to enter into the above releases the possible existence of such unknown losses or claims. Without limiting the generality of the foregoing, each Releasing Party expressly waives any and all rights conferred upon it by any statute or rule of Law that provides that a release does not extend to claims that the claimant does not know or suspect to exist in its favor at the time of providing the release, which, if known by it, may have materially affected its settlement with the released party.
76
| E. | Exculpation. |
Effective as of the Effective Date, to the fullest extent permissible under applicable Law and without affecting or limiting either the Debtor Release or the Third-Party Release, and except as otherwise specifically provided in the Prepackaged Plan or the Confirmation Order, no Exculpated Party shall have or incur liability for, and each Exculpated Party hereby is exculpated from any Claim or Cause of Action arising during the period from the Petition Date to the Effective Date, whether direct or derivative, related to, any act or omission in connection with, relating to, or arising out of the negotiation, solicitation, confirmation, execution, or implementation (to the extent on or prior to the Effective Date) of, as applicable, the Company-Related Matters, but in all respects such Entities shall be entitled to reasonably rely on the advice of counsel with respect to their duties and responsibilities pursuant to the Definitive Documents. Notwithstanding anything to the contrary in the foregoing, an Exculpated Party shall be entitled to exculpation solely for actions taken from the Petition Date through the Effective Date, and the exculpation set forth above does not exculpate (a) any obligations arising pursuant to or after the Effective Date of any party or Entity under the Prepackaged Plan, the Confirmation Order, or any document, instrument, or agreement (including those set forth in the Plan Supplement) executed to implement the Prepackaged Plan; or (b) any Causes of Action included in the Schedule of Retained Causes of Action.
The Exculpated Parties and other parties set forth above have, and upon confirmation of the Prepackaged Plan shall be deemed to have, participated in good faith and in compliance with the applicable Laws with regard to the solicitation of votes and distribution of consideration pursuant to the Prepackaged Plan and, therefore, are not, and on account of such distributions shall not be, liable at any time for the violation of any applicable Law, rule, or regulation governing the solicitation of acceptances or rejections of the Prepackaged Plan or such distributions made pursuant to the Prepackaged Plan.
Solely with respect to the exculpation provision, notwithstanding anything to the contrary in the Prepackaged Plan or Plan Supplement, each of the 1125(e) Exculpated Parties shall not incur liability for any Cause of Action or Claim related to any act or omission in connection with, relating to, or arising out of, in whole or in part, (a) the solicitation of acceptance or rejection of the Prepackaged Plan in good faith and in compliance with the applicable provisions of the Bankruptcy Code or (b) the participation, in good faith and in compliance with the applicable provisions of the Bankruptcy Code, in the offer, issuance, sale, or purchase of a security, offered or sold under the Prepackaged Plan. No Entity or Person may commence or pursue a Claim or Cause of Action of any kind against any of the Exculpated Parties or the 1125(e) Exculpated Parties that arose or arises from, in whole or in part, a Claim or Cause of Action subject to this paragraph, without the Bankruptcy Court specifically authorizing such Entity or Person to bring such Claim or Cause of Action against such Exculpated Party or 1125(e) Exculpated Party. The Bankruptcy Court will have sole and exclusive jurisdiction to adjudicate the underlying colorable Claim or Cause of Action.
77
| F. | Injunction. |
Except as otherwise expressly provided in the Prepackaged Plan, or for obligations issued or required to be paid pursuant to the Prepackaged Plan or the Confirmation Order, all Entities who have held, hold, or may hold Claims and Causes of Action, and liabilities whatsoever, including any derivative claims, whether known or unknown, foreseen or unforeseen, matured or unmatured, suspected or unsuspected, existing or hereinafter arising, contingent or non-contingent, liquidated or unliquidated, secured or unsecured, assertable, directly or derivatively, in law (or any applicable rule, statute, regulation, treaty, right, duty or requirement), equity, contract, tort, or otherwise, asserted or assertable on behalf of any of the Debtors, their Estates, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, that have been released, settled, or are subject to exculpation are permanently enjoined, from and after the Effective Date, from taking any of the following actions against, as applicable, the Debtors, the Exculpated Parties, or the Released Parties: (1) commencing or continuing in any manner any action or other proceeding of any kind on account of or in connection with or with respect to any such Claims or Interests; (2) enforcing, attaching, collecting, or recovering by any manner or means any judgment, award, decree, or order against such Entities on account of or in connection with or with respect to any such Claims or Interests; (3) creating, perfecting, or enforcing any encumbrance of any kind against such Entities, such property, or the property or the estates of such Entities on account of or in connection with or with respect to any such Claims or Interests; (4) asserting any right of setoff, subrogation, or recoupment of any kind, except to the extent such assertions are used as a defense to Claims or Causes of Action by the Debtors arising prior to the Effective Date, against any obligation due from such Entities or against the property of such Entities on account of or in connection with or with respect to any such Claims or Interests unless such Holder has Filed a motion requesting the right to perform such setoff on or before the Confirmation Date, and notwithstanding an indication of a claim or interest or otherwise that such Holder asserts, has, or intends to preserve any right of setoff pursuant to applicable law or otherwise; and (5) commencing or continuing in any manner any action or other proceeding of any kind on account of or in connection with or with respect to any such Claims or Interests released or settled pursuant to the Prepackaged Plan.
No Person or Entity may commence, continue, amend or pursue a Claim or Cause of Action, as applicable, of any kind against the Debtors, the Reorganized Debtors, the Post-Effective Date Debtors, the Exculpated Parties, or the Released Parties, as applicable, that relates to or is reasonably likely to relate to any act or omission in connection with, relating to, or arising out of a Claim or Cause of Action, as applicable, subject to Article VIII.C, Article VIII.D, Article VIII.E, and Article VIII.F hereof, without the Bankruptcy Court (i) first determining, after notice and a hearing, that such Claim or Cause of Action, as applicable, represents a colorable Claim of any kind, and (ii) specifically authorizing such Person or Entity to bring such Claim or Cause of Action, as applicable, against any such Debtor, Reorganized Debtor, Post-Effective Date Debtor, Exculpated Party, or Released Party, as applicable. At such hearing, the Bankruptcy Court, inter alia, may, or shall if any Debtor, Reorganized Debtor, Post-Effective Date Debtor, Exculpated Party, Released Party, or other party in interest requests by motion (oral motion being sufficient), direct that such Person or Entity seeking to commence or pursue such Claim or Cause of Action file a proposed complaint with the Bankruptcy Court embodying such Claim or Cause of Action, such complaint satisfying the applicable Federal Rules of Civil Procedure or Bankruptcy Rules, including, but not limited to, rules 8 and 9 (as applicable) of the Federal Rules of Civil Procedure, which the Bankruptcy Court shall assess before making a determination of whether such Claim or Cause of Action represents a colorable Claim of any kind.
78
The Bankruptcy Court will have sole and exclusive jurisdiction to adjudicate the underlying colorable Claim or Cause of Action.
Upon entry of the Confirmation Order, all Holders of Claims and Interests and their respective current and former employees, agents, officers, directors, principals, and direct and indirect Affiliates shall be enjoined from taking any actions to interfere with the implementation or Consummation of the Prepackaged Plan. Each Holder of an Allowed Claim or Allowed Interest, as applicable, by accepting, or being eligible to accept, distributions under or Reinstatement of such Allowed Claim or Allowed Interest, as applicable, pursuant to the Prepackaged Plan, shall be deemed to have consented to the injunction provisions set forth herein.
| G. | Protections Against Discriminatory Treatment. |
Consistent with section 525 of the Bankruptcy Code and the Supremacy Clause of the U.S. Constitution, all Entities, including Governmental Units, shall not discriminate against the Reorganized Debtors or Post-Effective Date Debtors, as applicable, or deny, revoke, suspend, or refuse to renew a license, permit, charter, franchise, or other similar grant to, condition such a grant to, discriminate with respect to such a grant against, the Reorganized Debtors or Post-Effective Date Debtors, as applicable, or another Entity with whom the Reorganized Debtors or Post-Effective Date Debtors, as applicable, have been associated, solely because each Debtor has been a debtor under chapter 11 of the Bankruptcy Code, has been insolvent before the commencement of the Chapter 11 Cases (or during the Chapter 11 Cases but before the Debtors are granted or denied a discharge), or has not paid a debt that is dischargeable in the Chapter 11 Cases.
| H. | Document Retention. |
On and after the Effective Date, the Reorganized Debtors or Post-Effective Date Debtors, as applicable, may maintain documents in accordance with their standard document retention policy, as may be altered, amended, modified, or supplemented by the Reorganized Debtors or Post-Effective Date Debtors, as applicable.
| I. | Reimbursement or Contribution. |
If the Bankruptcy Court disallows a Claim for reimbursement or contribution of an Entity pursuant to section 502(e)(1)(B) of the Bankruptcy Code, then to the extent that such Claim is contingent as of the time of allowance or disallowance, such Claim shall be forever disallowed and expunged notwithstanding section 502(j) of the Bankruptcy Code, unless prior to the Confirmation Date: (1) such Claim has been adjudicated as non-contingent or (2) the relevant Holder of a Claim has Filed a non-contingent Proof of Claim on account of such Claim and a Final Order has been entered prior to the Confirmation Date determining such Claim as no longer contingent.
79
| XXI. | CONDITIONS PRECEDENT TO CONSUMMATION OF THE PLAN |
| A. | Conditions Precedent to the Effective Date. |
It shall be a condition to the Effective Date that the following conditions shall have been satisfied or waived pursuant to the provisions of Article IX.B hereof:
| a. | the Bankruptcy Court shall have entered the Confirmation Order (which shall include final approval of the Disclosure Statement), which shall be a Final Order, in form and substance consistent in all respects with the Restructuring Support Agreement (including any consent rights thereunder), and which shall: |
| a. | authorize the Debtors to take all actions necessary or appropriate to enter into, implement, and consummate the contracts, instruments, releases, leases, indentures, and other agreements or documents created in connection with the Prepackaged Plan; |
| b. | decree that the provisions in the Confirmation Order and the Prepackaged Plan are nonseverable and mutually dependent; |
| c. | authorize the Debtors, as applicable or necessary, to: (a) implement the Restructuring Transactions; (b) distribute the New Common Stock and MF CVRs (solely to the extent the MF CVRs constitute securities as defined in and for purposes of the Securities Act) pursuant to the exemption from registration under the Securities Act provided by section 1145 of the Bankruptcy Code, section 4(a)(2) of the Securities Act, or Regulation S under the Securities Act, as applicable; (c) make all distributions and issuances as required under the Prepackaged Plan, including Cash, the New Common Stock, and MF CVRs; and (d) enter into any agreements, transactions, and sales of property as set forth in the Plan Supplement, in each case, in a manner consistent with the terms of the Restructuring Support Agreement and subject to the consent rights set forth therein; |
| d. | authorize the implementation of the Prepackaged Plan in accordance with its terms; and |
| e. | provide that, pursuant to section 1146 of the Bankruptcy Code, the assignment or surrender of any lease or sublease, and the delivery of any deed or other instrument or transfer order, in furtherance of, or in connection with the Prepackaged Plan, including any deeds, bills of sale, or assignments executed in connection with any disposition or transfer of assets contemplated under the Prepackaged Plan, shall not be subject to any stamp, real estate transfer, mortgage recording, or other similar tax; |
80
| b. | the Debtors shall have obtained all authorizations, consents, regulatory approvals, rulings, or documents that are necessary to implement and effectuate the Prepackaged Plan, each of which shall not be subject to unfulfilled conditions and shall be in full force and effect, and all applicable waiting periods shall have expired or been terminated; |
| c. | the final version of each of the Prepackaged Plan, the Definitive Documents, and all documents contained in any supplement to the Prepackaged Plan, including the Plan Supplement and any exhibits, schedules, amendments, modifications, or supplements thereto or other documents contained therein shall have been executed or Filed, as applicable, in form and substance consistent in all respects with the Restructuring Support Agreement, the DIP Orders, and the Prepackaged Plan, and comply with the applicable consent rights set forth in the Restructuring Support Agreement or the Prepackaged Plan for such documents, and shall not have been modified in a manner inconsistent with the Restructuring Support Agreement or the DIP Orders, and shall remain in full force and effect; |
| d. | the Restructuring Support Agreement shall not have been terminated as to the Debtors, the Required Consenting Funded Debt Parties or, in the event of the Reorganization Transaction, Ayrmid, shall be in full force and effect, and the Debtors and the other parties thereto shall be in compliance therewith; |
| e. | the DIP Facility and the DIP Orders shall not have been terminated in accordance with their respective terms and shall be in full force and effect; and there shall not have occurred and be continuing any event, act, or omission that, but for the expiration of time, would permit the Required Consenting Funded Debt Parties to terminate the Restructuring Support Agreement or the Required DIP Lenders to (or to instruct the DIP Agent to) terminate the DIP Facility in accordance with their respective terms; |
| f. | all Professional Fee Amounts that require the approval of the Bankruptcy Court shall have been paid in full or amounts sufficient to pay such fees and expenses after the Effective Date shall have been funded into the Professional Fee Account pending the approval of such fees and expenses by the Bankruptcy Court; |
| g. | all outstanding Restructuring Expenses and all outstanding reasonable and documented fees and expenses of the Prepetition Agents, including estimated fees and expenses through the Effective Date, shall have been paid in full in Cash, and all other fees, costs, and expenses required to be paid under the Restructuring Support Agreement, the DIP Facility Documents, and the other Definitive Documents shall have been paid in full in Cash in accordance therewith; |
81
| h. | in the case of a Sale Transaction, an Acceptable Alternative Transaction, or any other Alternative Restructuring Proposal, all Bid Protections earned and payable in accordance with Article IV.B hereof, the Restructuring Support Agreement, and the Bidding Procedures Order shall have been paid in full in Cash or otherwise satisfied in accordance with Article IV.B hereof; |
| i. | in the event of the Reorganization Transaction: (i) the Liens and obligations under the Ayrmid Term Loan shall have been equitized into pre-Effective Date Ayrmid, structurally subordinated, or otherwise addressed in accordance with Article IV.J hereof; (ii) the Merger Agreement shall be in full force and effect, all conditions to the consummation of the Merger thereunder shall have been satisfied or waived in accordance with its terms (other than those conditions that by their nature are to be satisfied at the closing of the Merger), and the Merger shall be consummated substantially concurrently with the Effective Date; (iii) the NewCo Facility Documents shall have been executed and delivered, all conditions precedent to the effectiveness thereof shall have been satisfied or waived in accordance with their terms, and the NewCo Facility shall have been funded; (iv) the MF CVR Agreement shall have been executed and delivered; and (v) the New Royalty Agreement shall have been executed and delivered; |
| j. | no court of competent jurisdiction or other competent governmental or regulatory authority shall have issued a final and non-appealable order making illegal or otherwise restricting, preventing or prohibiting the consummation of the Prepackaged Plan or the Restructuring Transactions; |
| k. | in the event of the Sale Transaction, the conditions to effectiveness of the Purchase Agreement(s) shall have been duly satisfied or waived; |
| l. | in the event of the Reorganization Transaction, the Reorganized Parent Common Stock (comprising the Reorganized Parent Equity Distribution) and the Merger Consideration (including the New Common Stock and the MF CVRs) shall have been issued in accordance with the Prepackaged Plan and the Merger Agreement; |
82
| m. | in the event of the Reorganization Transaction, the Debtors shall have funded the German RemainCo Winddown Account in accordance with Article IV.U hereof; and |
| n. | the Debtors shall have implemented the Restructuring Transactions and all transactions contemplated in the Prepackaged Plan in a manner consistent with the Restructuring Support Agreement (and subject to, and in accordance with, the consent rights set forth therein). |
Notwithstanding when a condition precedent to the Effective Date occurs, for purposes of the Prepackaged Plan, such condition precedent shall be deemed to have occurred simultaneously upon the completion of the conditions precedent to the Effective Date; provided that, to the extent a condition precedent (a “Prerequisite Condition”) may be required to occur prior to another condition precedent (a “Subsequent Condition”), then, for purposes of the Prepackaged Plan, the Prerequisite Condition shall be deemed to have occurred immediately prior to the Subsequent Condition, regardless of when such Prerequisite Condition or Subsequent Condition shall have occurred.
| B. | Waiver of Conditions. |
Except as otherwise specified in the Prepackaged Plan or the Restructuring Support Agreement, any one or more of the conditions to Consummation (or component thereof) set forth in this Article IX (other than entry of the Confirmation Order) may be waived in writing by the Debtors with the prior written consent of the Required Consenting Funded Debt Parties, and otherwise subject to the consent rights set forth in the Restructuring Support Agreement, without notice, leave, or order of the Bankruptcy Court or any formal action other than proceedings to confirm or consummate the Prepackaged Plan; provided that the condition precedent set forth in Article IX.A(g) may not be waived without the prior written consent of each affected Ad Hoc Group Advisor or Royalty Investor Advisor, as applicable.
| C. | Effect of Failure of Conditions. |
If Consummation does not occur as to any Debtor, the Prepackaged Plan shall be null and void in all respects as to such Debtor and nothing contained in the Prepackaged Plan, the Disclosure Statement, or the Restructuring Support Agreement as to such Debtor shall: (1) constitute a waiver or release of any Claims by the Debtors, any Holders of Claims or Interests, or any other Entity; (2) prejudice in any manner the rights of the Debtors, any Holders of Claims or Interests, or any other Entity; or (3) constitute an admission, acknowledgment, offer, or undertaking by the Debtors, any Holders of Claims or Interests, or any other Entity.
| D. | Substantial Consummation. |
“Substantial Consummation” of the Prepackaged Plan, as defined in 11 U.S.C. § 1101(2), shall be deemed to occur on the Effective Date.
83
| XXII. | MODIFICATION, REVOCATION, OR WITHDRAWAL OF THE PLAN |
| A. | Modification and Amendments. |
Except as otherwise specifically provided in the Prepackaged Plan and subject to the consent rights set forth in the Restructuring Support Agreement, the DIP Facility Documents, and the DIP Orders, the Debtors reserve the right to modify the Prepackaged Plan, whether such modification is material or immaterial, and seek Confirmation consistent with the Bankruptcy Code and, as appropriate, not resolicit votes on such modified Prepackaged Plan. Subject to those restrictions on modifications set forth in the Prepackaged Plan, the Restructuring Support Agreement, the DIP Facility Documents, and the DIP Orders, the requirements of section 1127 of the Bankruptcy Code, Bankruptcy Rule 3019, and, to the extent applicable, sections 1122, 1123, and 1125 of the Bankruptcy Code, each of the Debtors expressly reserves its respective rights to revoke or withdraw, or to alter, amend, or modify the Prepackaged Plan with respect to such Debtor, one or more times, after Confirmation, and, to the extent necessary, may initiate proceedings in the Bankruptcy Court to so alter, amend, or modify the Prepackaged Plan, or remedy any defect or omission, or reconcile any inconsistencies in the Prepackaged Plan, the Disclosure Statement, or the Confirmation Order, in such manner as may be necessary to carry out the purposes and intent of the Prepackaged Plan.
| B. | Effect of Confirmation on Modifications. |
Entry of the Confirmation Order shall mean that all modifications or amendments to the Prepackaged Plan since the solicitation thereof are approved pursuant to section 1127(a) of the Bankruptcy Code and do not require additional disclosure or resolicitation under Bankruptcy Rule 3019.
| C. | Revocation or Withdrawal of Prepackaged Plan. |
To the extent permitted by the Restructuring Support Agreement, the Debtors reserve the right to revoke or withdraw the Prepackaged Plan prior to the Confirmation Date and to File subsequent plans of reorganization. If the Debtors revoke or withdraw the Prepackaged Plan, or if Confirmation or Consummation does not occur, then: (1) the Prepackaged Plan shall be null and void in all respects; (2) any settlement or compromise embodied in the Prepackaged Plan (including the fixing or limiting to an amount certain of any Claim or Interest or Class of Claims or Interests), assumption or rejection of Executory Contracts or Unexpired Leases effected under the Prepackaged Plan, and any document or agreement executed pursuant to the Prepackaged Plan, shall be deemed null and void; and (3) nothing contained in the Prepackaged Plan shall: (a) constitute a waiver or release of any Claims or Interests; (b) prejudice in any manner the rights of the Debtors or any other Entity; or (c) constitute an admission, acknowledgment, offer, or undertaking of any sort by the Debtors or any other Entity.
84
| XXIII. | RETENTION OF JURISDICTION |
Notwithstanding the entry of the Confirmation Order and the occurrence of the Effective Date, on and after the Effective Date, the Bankruptcy Court shall retain exclusive jurisdiction over all matters arising out of, or relating to, the Chapter 11 Cases and the Prepackaged Plan pursuant to sections 105(a) and 1142 of the Bankruptcy Code, and to the fullest extent permissible by 28 U.S.C. § 1334 to hear, and by 28 U.S.C. § 157 to determine, all proceedings in respect thereof, including, without limitation, for the following purposes:
| a. | allow, disallow, determine, liquidate, classify, estimate, or establish the priority, secured or unsecured status, or amount of any Claim or Interest, and resolve any and all objections to the secured or unsecured status, priority, amount, or allowance of Claims or Interests; |
| b. | decide and resolve all matters related to the granting and denying, in whole or in part, any applications for allowance of compensation or reimbursement of expenses to Professionals authorized pursuant to the Bankruptcy Code or the Prepackaged Plan; |
| c. | resolve any matters related to: (i) the assumption, assumption and assignment, or rejection of any Executory Contract or Unexpired Lease to which a Debtor is party or with respect to which a Debtor may be liable and to hear, determine, and, if necessary, liquidate, any Claims arising therefrom, including Cures pursuant to section 365 of the Bankruptcy Code; (ii) any potential contractual obligation under any Executory Contract or Unexpired Lease that is assumed; (iii) the Reorganized Debtors or Post-Effective Date Debtors amending, modifying, or supplementing, after the Effective Date, pursuant to Article V hereof, the list of Executory Contracts and Unexpired Leases to be assumed or rejected or otherwise; and (iv) any dispute regarding whether a contract or lease is or was executory or expired; |
| d. | resolve disputes concerning Disputed Claims and consider the allowance, classification, priority, compromise, estimation, secured or unsecured status, amount or payment of any Claim, including any Administrative Claims, including any dispute over the application to any Claim of any limitation on its allowance set forth in sections 502 or 503 of the Bankruptcy Code or asserted under non-bankruptcy Law pursuant to section 502(b)(1) of the Bankruptcy Code; |
| e. | ensure that distributions to Holders of Allowed Claims and Allowed Interests (as applicable) are accomplished pursuant to the provisions of the Prepackaged Plan, including with respect to the MF CVRs pursuant to the MF CVR Agreement; |
| f. | adjudicate, decide, or resolve any motions, adversary proceedings, contested or litigated matters, and any other matters, and grant or deny any applications involving a Debtor that may be pending on the Effective Date; |
85
| g. | adjudicate, decide, or resolve any and all matters related to section 1141 of the Bankruptcy Code; |
| h. | enter and implement such orders as may be necessary to execute, implement, or consummate the provisions of the Prepackaged Plan and all contracts, instruments, releases, indentures, and other agreements or documents created or entered into in connection with the Prepackaged Plan or the Disclosure Statement, including the Restructuring Support Agreement; |
| i. | enter and enforce any order for the sale of property pursuant to sections 363, 1123, or 1146(a) of the Bankruptcy Code; |
| j. | resolve any cases, controversies, suits, disputes, or Causes of Action that may arise in connection with the Consummation, interpretation, or enforcement of the Prepackaged Plan or any Entity’s obligations incurred in connection with the Prepackaged Plan; |
| k. | issue injunctions, enter and implement other orders, or take such other actions as may be necessary to restrain interference by any Entity with Consummation or enforcement of the Prepackaged Plan; |
| l. | resolve any cases, controversies, suits, disputes, or Causes of Action with respect to the releases, injunctions, exculpations, and other provisions contained in Article VIII hereof and enter such orders as may be necessary or appropriate to implement such releases, injunctions, and other provisions; |
| m. | resolve any cases, controversies, suits, disputes, or Causes of Action with respect to the repayment or return of distributions and the recovery of additional amounts owed by the Holder of a Claim or Interest for amounts not timely repaid pursuant to Article VII.F hereof; |
| n. | enter and implement such orders as are necessary if the Confirmation Order is for any reason modified, stayed, reversed, revoked, or vacated; |
| o. | determine any other matters that may arise in connection with or relate to the Prepackaged Plan, the Plan Supplement, the Disclosure Statement, the Confirmation Order, or any contract, instrument, release, indenture, or other agreement or document created in connection with the Prepackaged Plan or the Disclosure Statement, including the Restructuring Support Agreement; |
86
| p. | enter an order concluding or closing the Chapter 11 Cases; |
| q. | adjudicate any and all disputes arising from or relating to distributions under the Prepackaged Plan; |
| r. | consider any modifications of the Prepackaged Plan in accordance with section 1127 of the Bankruptcy Code, to cure any defect or omission, or to reconcile any inconsistency in any Bankruptcy Court order, including the Confirmation Order; |
| s. | determine requests for the payment of Claims and Interests entitled to priority pursuant to section 507 of the Bankruptcy Code; |
| t. | hear and determine disputes arising in connection with the interpretation, implementation, or enforcement of the Prepackaged Plan or the Confirmation Order, including disputes arising under agreements, documents, or instruments executed in connection with the Prepackaged Plan; |
| u. | hear and determine matters concerning state, local, and federal taxes in accordance with sections 346, 505, and 1146 of the Bankruptcy Code; |
| v. | recover all assets of the Debtors and property of the Debtors’ Estates, wherever located; |
| w. | hear and determine all disputes involving the existence, nature, scope, or enforcement of any exculpations, discharges, injunctions, and releases granted in the Prepackaged Plan, including under Article VIII hereof; |
| x. | enforce all orders previously entered by the Bankruptcy Court; and |
| y. | hear any other matter not inconsistent with the Bankruptcy Code. |
As of the Effective Date, notwithstanding anything in this Article XI to the contrary, the New Corporate Governance Documents, the New Common Stock, the MF CVR Agreement, the NewCo Facility, the New Royalty Agreement, and any documents related thereto shall be governed by the jurisdictional provisions therein and the Bankruptcy Court shall not retain jurisdiction with respect thereto.
87
| XXIV. | MISCELLANEOUS PROVISIONS |
| A. | Immediate Binding Effect. |
Subject to Article IX.A hereof and notwithstanding Bankruptcy Rules 3020(e), 6004(h), or 7062 or otherwise, upon the occurrence of the Effective Date, the terms of the Prepackaged Plan (including, for the avoidance of doubt, the documents and instruments contained in the Plan Supplement) shall be immediately effective and enforceable and deemed binding upon the Debtors, the Reorganized Debtors, the Post-Effective Date Debtors, any and all Holders of Claims or Interests (irrespective of whether such Holders of Claims or Interests have, or are deemed to have, accepted the Prepackaged Plan), all Entities that are parties to or are subject to the settlements, compromises, releases, discharges, and injunctions described in the Prepackaged Plan, each Entity acquiring property under the Prepackaged Plan, and any and all non-Debtor parties to Executory Contracts and Unexpired Leases with the Debtors.
| B. | Additional Documents. |
On or before the Effective Date, and consistent in all respects with the terms of the Restructuring Support Agreement, the Debtors may File with the Bankruptcy Court such agreements and other documents as may be necessary to effectuate and further evidence the terms and conditions of the Prepackaged Plan and the Restructuring Support Agreement. The Debtors, the Reorganized Debtors, or the Post-Effective Date Debtors, as applicable, and all holders of Claims or Interests receiving distributions pursuant to the Prepackaged Plan and all other parties in interest shall, from time to time, prepare, execute, and deliver any agreements or documents and take any other actions as may be necessary or appropriate to effectuate the provisions and intent of the Prepackaged Plan.
| C. | Payment of Statutory Fees. |
All fees payable pursuant to section 1930(a) of the Judicial Code shall be paid by each of the Reorganized Debtors or the Post-Effective Date Debtors, as applicable (or the Disbursing Agent on behalf of each of the Reorganized Debtors or the Post-Effective Date Debtors, as applicable) for each quarter (including any fraction thereof) until the earlier of entry of a final decree closing the Chapter 11 Cases or an order of dismissal or conversion.
| D. | Statutory Committee and Cessation of Fee and Expense Payment. |
On the Confirmation Date, any statutory committee appointed in the Chapter 11 Cases shall dissolve and members thereof shall be released and discharged from all rights and duties from or related to the Chapter 11 Cases. The Reorganized Debtors or the Post-Effective Date Debtors, as applicable, shall no longer be responsible for paying any fees or expenses incurred by the members of or advisors to any statutory committees after the Confirmation Date.
88
| E. | Reservation of Rights. |
Except as expressly set forth in the Prepackaged Plan, the Prepackaged Plan shall have no force or effect unless the Bankruptcy Court shall enter the Confirmation Order, and the Confirmation Order shall have no force or effect if the Effective Date does not occur. None of the Filing of the Prepackaged Plan, any statement or provision contained in the Prepackaged Plan, or the taking of any action by any Debtor with respect to the Prepackaged Plan, the Disclosure Statement, or the Plan Supplement shall be or shall be deemed to be an admission or waiver of any rights of any Debtor with respect to the Holders of Claims or Interests prior to the Effective Date.
| F. | Successors and Assigns. |
The rights, benefits, and obligations of any Entity named or referred to in the Prepackaged Plan shall be binding on, and shall inure to the benefit of any heir, executor, administrator, successor or assign, Affiliate, officer, manager, director, agent, representative, attorney, beneficiary, or guardian, if any, of each Entity.
| G. | Notices. |
All notices, requests, and demands to or upon the Debtors to be effective shall be in writing (including by facsimile transmission) and, unless otherwise expressly provided herein, shall be deemed to have been duly given or made when actually delivered or, in the case of notice by facsimile transmission, when received and telephonically confirmed, addressed as follows:
Debtors
Karyopharm Therapeutics Inc.
85 Wells Avenue, Suite 210
Newton, Massachusetts 02459
Attention: Michael Mano, Executive Vice President, Chief Legal Officer
michael.mano@karyopharm.com
| Counsel to the Debtors | Counsel to the Ad Hoc Group | |
| Sidley Austin LLP 787 Seventh Avenue New York, New York 10019 Attention: Anthony Grossi
and
Sidley Austin LLP |
Latham & Watkins LLP
and
Latham & Watkins LLP 330 North Wabash Avenue, Suite 2800 Chicago, IL 60611 Attention: Whit Morley whit.morley@lw.com |
89
| Counsel to Ayrmid | Counsel to the Consenting Royalty Investors | |
| Paul Hastings LLP
and
Paul Hastings LLP |
Hogan Lovells Cadwalader US LLP 200 Liberty Street New York, NY 10281 Attention: Douglas Mintz and Thomas Curtin douglas.mintz@hlc.com thomas.curtin@hlc.com |
After the Effective Date, the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, have the authority to send a notice to Entities that provides that to continue to receive documents pursuant to Bankruptcy Rule 2002, such Entity must file a renewed request to receive documents pursuant to Bankruptcy Rule 2002. After the Effective Date, the Reorganized Debtors or the Post-Effective Date Debtors, as applicable, are authorized to limit the list of Entities receiving documents pursuant to Bankruptcy Rule 2002 to those Entities who have Filed such renewed requests.
| H. | Term of Injunctions or Stays. |
Unless otherwise provided in the Prepackaged Plan or in the Confirmation Order, all injunctions or stays in effect in the Chapter 11 Cases pursuant to sections 105 or 362 of the Bankruptcy Code or any order of the Bankruptcy Court, and extant on the Confirmation Date (excluding any injunctions or stays contained in the Prepackaged Plan or the Confirmation Order) shall remain in full force and effect until the Effective Date. All injunctions or stays contained in the Prepackaged Plan or the Confirmation Order shall remain in full force and effect in accordance with their terms.
| I. | Entire Agreement. |
Except as otherwise indicated, and without limiting the effectiveness of the Restructuring Support Agreement, the Prepackaged Plan (including, for the avoidance of doubt, the documents and instruments in the Plan Supplement) supersedes all previous and contemporaneous negotiations, promises, covenants, agreements, understandings, and representations on such subjects, all of which have become merged and integrated into the Prepackaged Plan.
90
| J. | Plan Supplement. |
All exhibits and documents included in the Plan Supplement are incorporated into and are a part of the Prepackaged Plan as if set forth in full in the Prepackaged Plan. After the exhibits and documents are Filed, copies of such exhibits and documents shall be available upon written request to the Debtors’ counsel at the address above or by downloading such exhibits and documents from the Debtors’ restructuring website at https://cases.stretto.com/KPTI or the Bankruptcy Court’s website at www.txs.uscourts.gov/bankruptcy. To the extent any exhibit or document is inconsistent with the terms of the Prepackaged Plan, unless otherwise ordered by the Bankruptcy Court, the non-exhibit or non-document portion of the Prepackaged Plan shall control.
| K. | Severability of Prepackaged Plan Provisions. |
If, prior to Confirmation, any term or provision of the Prepackaged Plan is held by the Bankruptcy Court to be invalid, void, or unenforceable, the Bankruptcy Court shall have the power to alter and interpret such term or provision to make it valid or enforceable to the maximum extent practicable, consistent with the original purpose of the term or provision held to be invalid, void, or unenforceable, and such term or provision shall then be applicable as altered or interpreted. Notwithstanding any such holding, alteration, or interpretation, the remainder of the terms and provisions of the Prepackaged Plan will remain in full force and effect and will in no way be affected, impaired, or invalidated by such holding, alteration, or interpretation. The Confirmation Order shall constitute a judicial determination and shall provide that each term and provision of the Prepackaged Plan, as it may have been altered or interpreted in accordance with the foregoing, is: (1) valid and enforceable pursuant to its terms; (2) integral to the Prepackaged Plan and may not be deleted or modified without the Debtors’, Reorganized Debtors’, or Post-Effective Date Debtors’ consent, as applicable; and (3) nonseverable and mutually dependent.
| L. | Votes Solicited in Good Faith. |
Upon entry of the Confirmation Order, the Debtors will be deemed to have solicited votes on the Prepackaged Plan in good faith and in compliance with section 1125(g) of the Bankruptcy Code, and pursuant to section 1125(e) of the Bankruptcy Code, the Debtors and each of their respective Affiliates, agents, representatives, members, principals, stockholders, officers, directors, employees, advisors, and attorneys will be deemed to have participated in good faith and in compliance with the Bankruptcy Code in the offer, issuance, sale, and purchase of Securities offered and sold under the Prepackaged Plan and any previous plan, and, therefore, none of such parties or individuals, the Reorganized Debtors, or the Post-Effective Date Debtors will have any liability for the violation of any applicable Law, rule, or regulation governing the solicitation of votes on the Prepackaged Plan or the offer, issuance, sale, or purchase of the Securities offered and sold under the Prepackaged Plan and any previous plan.
| M. | Closing of Chapter 11 Cases. |
The Reorganized Debtors or the Post-Effective Date Debtors, as applicable, shall, promptly after the full administration of the Chapter 11 Cases, File with the Bankruptcy Court all documents required by Bankruptcy Rule 3022 and any applicable order of the Bankruptcy Court to close the Chapter 11 Cases.
| N. | Waiver or Estoppel. |
Each Holder of a Claim or an Interest shall be deemed to have waived any right to assert any argument, including the right to argue that its Claim or Interest should be Allowed in a certain amount, in a certain priority, secured or not subordinated by virtue of an agreement made with the Debtors or their counsel, or any other Entity, if such agreement was not disclosed in the Prepackaged Plan, the Disclosure Statement, or papers Filed with the Bankruptcy Court prior to the Confirmation Date.
91
| O. | Creditor Default. |
An act or omission by a Holder of a Claim or an Interest (other than the Consenting Stakeholders) in contravention of the provisions of the Prepackaged Plan shall be deemed an event of default under the Prepackaged Plan. Upon an event of default, the Reorganized Debtors or Post-Effective Date Debtors may seek to hold the defaulting party in contempt of the Confirmation Order and shall be entitled to reasonable attorneys’ fees and costs of the Reorganized Debtors or Post-Effective Date Debtors in remedying such default. Upon the finding of such a default by a creditor, the Bankruptcy Court may: (a) designate a party to appear, sign, or accept the documents required under the Prepackaged Plan on behalf of the defaulting party, in accordance with Bankruptcy Rule 7070; (b) enforce the Prepackaged Plan by order of specific performance; (c) award judgment against such defaulting creditor in favor of the Reorganized Debtors or Post-Effective Date Debtors in an amount, including interest, to compensate the Reorganized Debtors or Post-Effective Date Debtors for the damages caused by such default; and (d) make such other order as may be equitable that does not materially alter the terms of the Prepackaged Plan.
| P. | Deemed Acts. |
Subject to and conditioned on the occurrence of the Effective Date, whenever an act or event is expressed under the Prepackaged Plan to have been deemed done or to have occurred, it shall be deemed to have been done or to have occurred without any further act by any party, by virtue of the Prepackaged Plan and the Confirmation Order.
92
| Dated: November 2, 2026 | KARYOPHARM THERAPEUTICS INC. KPT TEXAS LLC | |||||
| /s/ Lori Macomber | ||||||
| Lori Macomber | ||||||
| Authorized Signatory/CFO | ||||||
EXHIBIT B
Restructuring Support Agreement
[***]
EXHIBIT C
Corporate Organization Chart
[***]
EXHIBIT D
Liquidation Analysis
[***]
Exhibit 99.2
Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
– The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis –
– Ayrmid will Serve as Lead Bidder in Court-Supervised Sale Process to Maximize Business Value for all Stakeholders –
– The Company Receives a Commitment of $55 Million in Additional Financing and Ongoing Operations Are Expected to be Uninterrupted During Sale Process –
NEWTON, Mass., November 2, 2026 – Karyopharm Therapeutics Inc. (Nasdaq: KPTI) (“Karyopharm” or the “Company”), a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced today it has entered into a Restructuring Support Agreement with its existing lenders and noteholders and other key stakeholders, which provides for a merger between Ayrmid Ltd. (“Ayrmid”) and a reorganized Karyopharm (the “Transaction”). During this process, Karyopharm remains focused on its commitment to advancing its multiple myeloma and myelofibrosis programs and improving the lives of the patients Karyopharm serves and will continue to operate in the ordinary course of business.
To implement the Transaction, Karyopharm has filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. The Company anticipates completing the Transaction through a Chapter 11 plan, and the Company will seek Court approval of bidding procedures, which will allow other parties to submit competing proposals and bids for the Company’s assets. The Transaction is expected to close in the first quarter of 2027, subject to the conditions described in the Chapter 11 plan.
“Following a comprehensive review of available alternatives, we believe this process provides a clear framework to pursue a value maximizing transaction for our stakeholders while continuing our important work of advancing therapies for patients with multiple myeloma and myelofibrosis,” said Richard Paulson, President and Chief Executive Officer at Karyopharm. “We are pleased to have signed an agreement with Ayrmid, a company committed to advancing meaningful therapies for patients with hematological disorders. Ayrmid’s proposal underscores the strategic interest in our programs and establishes a strong foundation as we move through this process designed to maximize value. Throughout, we will remain focused on supporting our employees, maintaining continuity across the business, and advancing our mission to improve the lives of patients.”
“We see a strong strategic fit between Ayrmid and Karyopharm, with complementary portfolios, established commercial capabilities and a shared commitment to addressing significant unmet needs in hematology,” said Dr. Joe Wiley, Chairman and CEO of Ayrmid. “We see considerable potential in Karyopharm’s marketed products, development pipeline and experienced team, and believe that, together, we can build a broader, stronger commercial-stage hematology business with meaningful opportunities for future growth. Subject to the successful completion of the transaction, we look forward to working with the Karyopharm team to realize that potential and continue delivering important therapies to patients in need.”
In connection with this process, Karyopharm has secured commitments for up to $55 million in debtor-in-possession (“DIP”) financing from its existing secured lenders. Once approved by the Court, this DIP financing, combined with cash generated from the Company’s ongoing operations, is expected to support the go-forward business during the Chapter 11 process and to meet its financial obligations arising subsequent to the filing date.
Karyopharm is prepared to move through this process quickly and efficiently without any disruption to either its ordinary course operations or the partnerships essential to supporting Karyopharm’s patients and advancing its programs.
1
Parties interested in participating in Karyopharm’s sale process should contact Centerview Partners at centerview@karyopharm.com.
Additional Information
Additional information about Karyopharm’s restructuring process is available at https://cases.stretto.com/KPTI, or by contacting Stretto, the Company’s noticing and claims agent, at (866) 270-4922 (toll-free) and (949) 561-0471 (international).
Karyopharm is advised in this matter by Sidley Austin LLP as legal counsel, Centerview Partners LLC as investment banker and FTI Consulting Inc. as financial and communications advisor.
An ad hoc group of term lenders and noteholders is advised in this matter by Latham & Watkins LLP and Haynes and Boone LLP as legal counsel and Houlihan Lokey Capital, Inc. as investment banker and financial advisor.
Ayrmid is advised in this matter by Paul Hastings LLP as legal counsel.
About Karyopharm Therapeutics
Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company’s lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor’s potential in hematologic cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercialization infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm.
About Ayrmid
Ayrmid, Ltd., the parent company of Gamida Cell Inc., is a commercial-stage biotechnology company focused on delivering differentiated therapies that address significant unmet needs in haematology. With established commercial infrastructure in the United States and an international distribution network serving markets outside the US, Ayrmid has built a platform to support the commercialisation of specialised therapies globally. Ayrmid currently has two FDA-approved products, Omisirge® (omidubicel-onlv) and APHEXDA® (motixafortide). Omisirge® (omidubicel-onlv) is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy approved to treat adults and pediatric patients 12 years and older with hematologic malignancies, and adults and pediatric patients 6 years and older with severe aplastic anemia (SAA) (please see the current full Prescribing Information here). APHEXDA® (motixafortide) is a CXCR4 antagonist approved to mobilize hematopoietic stem cells in adult patients with multiple myeloma (please see the current full Prescribing Information here). For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, X, Facebook or Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the voluntary petitions under Chapter 11 (the “Cases”), Karyopharm’s expectations with respect to its ability to consummate the transactions contemplated by the Restructuring Support Agreement, obtain Court approval of, and access to, the DIP Facility, and continue operating in the ordinary course while the Cases are pending, the timing of the Transaction closing, the ability of the Company to meet its financial obligations,
2
and other statements that are not historical fact. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in these forward-looking statements. These risks and uncertainties include, but are not limited to: (i) risks related to the consummation of the transactions contemplated by the Restructuring Support Agreement; (ii) potential adverse effects of the Cases on the Company’s liquidity and results of operations; (iii) the Company’s ability to obtain timely approval by the Court of the motions filed in the Cases, including with respect to the DIP Facility and the bidding procedures; (iv) objections to the transactions contemplated by the Restructuring Support Agreement and/or the Chapter 11 Plan of Reorganization (the “Plan”), the bidding procedures or other pleadings filed that could protract the Cases; (v) employee attrition and the Company’s ability to retain senior management and other key personnel due to the distractions and uncertainties; (vi) the Company’s ability to comply with the restrictions imposed by the terms and conditions of the Company’s financing arrangements, including the DIP Facility; (vii) the Company’s ability to maintain relationships with suppliers, vendors, collaboration and license partners, employees and other third parties and regulatory authorities as a result of the Cases; (viii) the effects of the Cases on the Company and on the interests of various constituents, including holders of the Company’s common stock and the Convertible Preferred Stock; (ix) the Court’s rulings in the Cases, including the approval of the terms and conditions of the transactions contemplated by the Restructuring Support Agreement or the Plan, and the outcome of the Cases generally; (x) the length of time that the Company will operate under Chapter 11 protection and the continued availability of operating capital during the pendency of the Cases; (xi) risks associated with third party motions in the Cases, which may interfere with the Company’s ability to consummate the transactions contemplated by the Restructuring Support Agreement Plan or an alternative transaction; (xii) increased administrative and legal costs related to the Chapter 11 process; (xiii) exposure to potential litigation, including related to the transactions contemplated by the Restructuring Support Agreement or the Plan, and inherent risks involved in a bankruptcy process; (xiv) the occurrence of any event, change or other circumstances that could give rise to the right of any parties to the Restructuring Support Agreement to terminate the Restructuring Support Agreement; (xv) the possibility that the anticipated benefits of the transactions contemplated by the Restructuring Support Agreement or the Plan are not realized when expected or at all; (xvi) diversion of management’s attention from ongoing business operations and opportunities; (xvii) potential adverse reactions or changes to business or employee relationships, including those resulting from the bankruptcy proceedings of the Company or the announcement or completion of the transactions contemplated by the Restructuring Support Agreement or the Plan; (xviii) the expected delisting of the Company’s common stock from the Nasdaq Global Select Market; and (xix) other risks and uncertainties, including those described in the section entitled “Risk Factors” in the Company’s most recent annual or quarterly report filed with the Securities and Exchange Commission (“SEC”) and in other filings the Company makes with the SEC from time to time. The forward-looking statements herein do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact
Brendan Strong
Senior Vice President, Investor Relations
617.762.2661
Brendan.Strong@karyopharm.com
Media Contact
Rachel Chesley / Misha Ross
KaryopharmComms@fticonsulting.com
3